file_path,num_pages,extracted_text,extracted_tables,extracted_images
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_22122021/Supplemental-Index-12-22-21.pdf,17.0,"Section 1 - 125742/0/0
Section 2 - 125742/0/0
Section 5.3.1 - 125742/0/0
December 20, 2021 8:32 AM License Action Recommendation Documents for Submissions and FDA Communication Page 1
***FOR OFFICIAL USE ONLY*** Exclude Inspection Related
Order: FDA/Appl, Then Date Ascending
***THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION***
STN: L 125742/0
Applicant: BioNTech Manufacturing GmbH #2229
Product: COVID-19 Vaccine, mRNA
Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.
Date Elec Post Description FDA Recd Date Login ID
13-MAY-2021 Y Letter. Acknowledgement Letter - Rolling Review ( DICKERSON, DAVID )
18-MAY-2021 Y Telecon. Information Request - IR RE datasets. ( SMITH, MICHAEL )
20-MAY-2021 Y Telecon. Information Request - Four facility questions from DMPQ and a
request for a t-con on 5/25/21 or 5/26/21 to discuss production schedules and
the shutdown activities planned for the Puurs, Belgium site. ( SMITH,
MICHAEL )
03-JUN-2021 Y Meeting Summary. First Committee Meeting - First Committee Meeting
Summary ( NAIK, RAMACHANDRA )
08-JUN-2021 Y Telecon. Information Request - Three clinical questions. ( SMITH,
MICHAEL )
09-JUN-2021 Y Telecon. Information Request - IR for PREA dates for deferred pediatric
studies. ( SMITH, MICHAEL )
17-JUN-2021 Y Memo. Other - Permission to release License number to applicant prior to
approval. ( JONECKIS, CHRISTOPHER )
25-JUN-2021 Y Telecon. Information Request - IR from DBSQC regarding the lot release
protocol (LRP) template and samples & reagents. ( SMITH, MICHAEL )
25-JUN-2021 Y Telecon. Information Request - IR regarding the document titled ¿bnt162-
01-interim3-report-body¿. ( SMITH, MICHAEL )
29-JUN-2021 Y Meeting Summary. Filing Meeting Summary - Summary of the June 29, 2021
Filing Meeting. The BLA is fileable. ( NAIK, RAMACHANDRA )
29-JUN-2021 Y Telecon. Information Request - Clinical IR regarding Study C4591001. (
SMITH, MICHAEL )
01-JUL-2021 Y Memo. Filing Checklist/RPM - RPM Filing Checklist - the application is
fileable. ( GOTTSCHALK, LAURA )
02-JUL-2021 Y Memo. Committee Memo/APLB - PNR COMIRNATY: ACCEPTABLE (
ELEKWACHI, OLUCHI )
02-JUL-2021 Y Telecon. Advice - Advice: Pfizer¿s assumption as outlined in Elisa Harkins
June 29, 2021 e-mail RE the bnt162-01-interim3-report-body are correct. (
SMITH, MICHAEL )
02-JUL-2021 Y Telecon. Information Request - Comments regarding CMC information and
categorical exclusion for an environment analysis ( NAIK, RAMACHANDRA
)
06-JUL-2021 Y Telecon. PNR Acceptance / Advice - The Applicant was informed that their
proprietary name ""COMIRNATY"" is acceptable. ( SMITH, MICHAEL )
06-JUL-2021 Y Telecon. Information Request - Clinical IR RE the document titled
¿c4591001-interim-mth6-report-body.pdf."" ( SMITH, MICHAEL )
09-JUL-2021 Y Telecon. Information Request - IR RE the validation of the RNA Integrity by
capillary gel electrophoresis (CGE) method. ( SMITH, MICHAEL )
13-JUL-2021 Y Telecon. Information Request - OBE IR RE adding myocarditis and
pericarditis to the PVP. ( SMITH, MICHAEL )
13-JUL-2021 Y Telecon. Information Request - DVP IR regarding exception or alternative to
the requirement that products in multiple-dose vials include a preservative (
NAIK, RAMACHANDRA )
15-JUL-2021 Y Letter. Filing Notification Letter / No Deficiencies Identified - Filing
Notification
No Deficiencies Identified ( SMITH, MICHAEL )
15-JUL-2021 Y Telecon. Information Request - IR RE Study C4591007; please provide
updated goal dates for final protocol submission. ( SMITH, MICHAEL )
15-JUL-2021 Y Meeting Summary. Committee Meeting Summary - Summary of the July 15,
2021 Monthly Committee Meeting. ( GOTTSCHALK, LAURA )
15-JUL-2021 Y Telecon. Information Request - F/U IR RE updated PVP by 7/29/21. ( SMITH,
MICHAEL )
16-JUL-2021 Y Telecon. Information Request - DBSQC IR regarding lot release protocol
template and drug substance handling instructions. ( GOTTSCHALK, LAURA
)
December 20, 2021 8:32 AM License Action Recommendation Documents for Submissions and FDA Communication Page 2
***FOR OFFICIAL USE ONLY*** Exclude Inspection Related
Order: FDA/Appl, Then Date Ascending
***THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION***
STN: L 125742/0
Applicant: BioNTech Manufacturing GmbH #2229
Product: COVID-19 Vaccine, mRNA
Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.
Date Elec Post Description FDA Recd Date Login ID
16-JUL-2021 Y Telecon. Information Request - DBSQC IR regarding (b) (4) and
(b) (4) test methods ( GOTTSCHALK, LAURA )
19-JUL-2021 Y Telecon. Advice - US license number 2229 was provided to the applicant
prior to approval in response to the request included in the cover letter of the
first roll of their BLA on May 6, 2021. ( NAIK, RAMACHANDRA )
20-JUL-2021 Y Memo. Review - CDISC validation results and discussion ( BALDWIN,
BRENDA )
20-JUL-2021 Y Telecon. Information Request - Clinical IR for a revised pediatric plan to
include study C4591007 for subject 6 months to 11 years of age and proposal
of another study to enroll infants <6 months of age. ( NAIK,
RAMACHANDRA )
22-JUL-2021 Y Telecon. Information Request - Clinical and stats IR regarding shell tables to
include safety and efficacy data from study C4591001 and other clinical
comments ( GOTTSCHALK, LAURA )
26-JUL-2021 Y Telecon. Information Request - Clinical IR regarding the disposition of
participants in safety populations who experienced pregnancy. (
GOTTSCHALK, LAURA )
26-JUL-2021 Y Telecon. Information Request - DMPQ IR regarding manufacturing and
equipment ( GOTTSCHALK, LAURA )
27-JUL-2021 Y Telecon. Information Request - Clinical IR RE vaccine effectiveness (
SMITH, MICHAEL )
27-JUL-2021 Y Telecon. Information Request - Third clinical IR RE vaccine effectiveness. (
SMITH, MICHAEL )
28-JUL-2021 Y Telecon. Labeling Target Closure / Labeling via FAX/e-mail - First set of
labeling comments regarding the PI ( NAIK, RAMACHANDRA )
28-JUL-2021 Y Telecon. Information Request - OBE IR regarding postmarketing safety
study(ies) ( NAIK, RAMACHANDRA )
29-JUL-2021 Y Telecon. Information Request - Clinical IR regarding safety analysis for two
age groups ( GOTTSCHALK, LAURA )
02-AUG-2021 Y Telecon. Information Request - Questions regarding the Validation Report
VR-MVR-10077 ( SMITH, MICHAEL )
02-AUG-2021 Y Telecon. Information Request - Five questions regarding validation of assay
methods and lot release. ( SMITH, MICHAEL )
03-AUG-2021 Y Telecon. Information Request - Six CMC-related questions. ( SMITH,
MICHAEL )
03-AUG-2021 Y Telecon. Information Request - Two clinical/stats questions regarding July 26,
2021, submission and SAS programs. ( SMITH, MICHAEL )
04-AUG-2021 Y Telecon. Information Request - Two questions regarding the potency assay
for determination of (b) (4) by (b) (4) . ( SMITH,
MICHAEL )
04-AUG-2021 Y Telecon. Information Request - F/U IR RE the LRP that was submitted to
BLA 125742/0.14 on July 20, 2021. ( SMITH, MICHAEL )
04-AUG-2021 Y Telecon. Information Request - Secondary e-mail with attachment RE 8/4/21
F/U LRP comments. ( SMITH, MICHAEL )
05-AUG-2021 Y Telecon. Advice - Informed the applicant regarding the PROPER NAME for
their product in this BLA. ( GOTTSCHALK, LAURA )
05-AUG-2021 Y Telecon. Information Request - 11 facility questions. ( SMITH, MICHAEL )
05-AUG-2021 Y Telecon. Information Request - Four questions regarding the diluent. (
SMITH, MICHAEL )
05-AUG-2021 Y Telecon. Labeling via FAX/e-mail - 2nd round of PI labeling comments. (
SMITH, MICHAEL )
06-AUG-2021 Y Letter. UNII Code Notification - Unique Ingredient Identifier (UNII) Code
Assignment ( SMITH, MICHAEL )
06-AUG-2021 Y Memo. Committee Memo/APLB - APLB BLA LR ( ELEKWACHI,
OLUCHI )
December 20, 2021 8:32 AM License Action Recommendation Documents for Submissions and FDA Communication Page 3
***FOR OFFICIAL USE ONLY*** Exclude Inspection Related
Order: FDA/Appl, Then Date Ascending
***THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION***
STN: L 125742/0
Applicant: BioNTech Manufacturing GmbH #2229
Product: COVID-19 Vaccine, mRNA
Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.
Date Elec Post Description FDA Recd Date Login ID
06-AUG-2021 Y Y Memo. Review - OBE/DE Pharmacovigilance Review ( THOMPSON,
DEBORAH )
06-AUG-2021 Y Telecon. Information Request - IR RE two DP documents. ( SMITH,
MICHAEL )
06-AUG-2021 Y Telecon. Information Request - Three DBSQC questions RE measurement of
(b) (4) using the (b) (4) procedures. (
SMITH, MICHAEL )
09-AUG-2021 Y Telecon. Advice - Advice RE submitting samples, LRP and distribution of
EUA and BLA labeled product after COMIRNATY is licensed. ( SMITH,
MICHAEL )
09-AUG-2021 Y Telecon. Information Request - Clinical IR RE sequencing data. ( SMITH,
MICHAEL )
09-AUG-2021 Y Telecon. Labeling via FAX/e-mail - Comments on the Carton and Container
labels ( SMITH, MICHAEL )
10-AUG-2021 Y Telecon. Information Request - Second OBE IR regarding safety-related
postmarketing studies. ( NAIK, RAMACHANDRA )
10-AUG-2021 Y Telecon. Information Request - One testing related question from DBSQC. (
SMITH, MICHAEL )
11-AUG-2021 Y Telecon. Information Request - One question from DMPQ regarding the
diluent that is to be provided with the vaccine. ( SMITH, MICHAEL )
11-AUG-2021 Y Telecon. Other - This teleconference between CBER and Pfizer was to seek
clarity on availability of EUA and BLA products and plans for distribution after
licensure of COMIRNATY. ( SMITH, MICHAEL )
12-AUG-2021 Y Memo. Committee Memo/Require Pre-Approval Inspection ( CHEUNG,
ANISSA )
12-AUG-2021 Y Telecon. Other - Teleconference between CBER and Pfizer to receive
clarification on how EUA lots and BLA lots will be indentified. ( NAIK,
RAMACHANDRA )
13-AUG-2021 Y Y Memo. Committee Memo/BIMO - BIMO Discipline Review Memo ( CHUN,
HAECIN )
13-AUG-2021 Y Memo. Request For Compliance Check - Request for Compliance check. (
ZUBKOVA, IRYNA )
13-AUG-2021 Y Telecon. Information Request - Three clinical questions. ( SMITH,
MICHAEL )
13-AUG-2021 Y Telecon. Information Request - DBQSC IR LRP and testing. ( SMITH,
MICHAEL )
13-AUG-2021 Y Telecon. Information Request - 7 facility questions from the DMPQ team. (
SMITH, MICHAEL )
13-AUG-2021 Y Telecon. Information Request - A clinical IR was sent on 13AUG21 and
Pfizer had a clarification question. This IR t-con was in response to the F/U
clarification question. ( SMITH, MICHAEL )
13-AUG-2021 Y Telecon. Labeling via FAX/e-mail - 3rd set of PI labeling comments. (
SMITH, MICHAEL )
13-AUG-2021 Y Telecon. Information Request - One clinical question. ( SMITH, MICHAEL )
13-AUG-2021 Y Telecon. Information Request - IR RE PMR's and PMC's. ( SMITH,
MICHAEL )
16-AUG-2021 Y Telecon. Information Request - DMPQ IR RE (b) (4)
(b) (4) . ( SMITH,
MICHAEL )
16-AUG-2021 Y Telecon. Labeling via FAX/e-mail - Second set of comments and questions
on the carton and container labels. ( SMITH, MICHAEL )
16-AUG-2021 Y Telecon. Information Request - Teleconference regarding measurement of
(b) (4) .(cid:13)
Pfizer commits to implement (b) (4) testing method on
(b) (4) . ( SMITH, MICHAEL )
December 20, 2021 8:32 AM License Action Recommendation Documents for Submissions and FDA Communication Page 4
***FOR OFFICIAL USE ONLY*** Exclude Inspection Related
Order: FDA/Appl, Then Date Ascending
***THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION***
STN: L 125742/0
Applicant: BioNTech Manufacturing GmbH #2229
Product: COVID-19 Vaccine, mRNA
Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.
Date Elec Post Description FDA Recd Date Login ID
16-AUG-2021 Y Telecon. Information Request - Please submit this same CMC stability
information that was submitted to EUA 27034.260 to your BLA STN 125742
.0 so that we can consider a 9-month shelf-life for the licensed product. (
NAIK, RAMACHANDRA )
17-AUG-2021 Y Memo. Lot Release Clearance Memo / Lot Release Clearance Request - Lot
Release Clearance Request and Lot Release Clearance Memo. ( BESHIR,
LEYLA )
17-AUG-2021 Y Memo. Other; Non-proprietary name does not include a suffix - Justification
memo regarding approving non-proprietary name without a suffix ( GRUBER,
MARION )
17-AUG-2021 Y Telecon. Other - The purpose of the teleconference between DMPQ and
Pfizer was to discuss items 2b, 2c, 6 and 9c from the FDA form 483 for the
Andover site. ( SMITH, MICHAEL )
17-AUG-2021 Y Telecon. Information Request - Two questions from Xiao Wang regarding
drug substance. ( SMITH, MICHAEL )
17-AUG-2021 Y Telecon. Labeling via FAX/e-mail - 4th set of PI labeling comments. (
SMITH, MICHAEL )
17-AUG-2021 Y Telecon. Information Request - Follow up IR RE PMR & PMC's
commitments that were received in amendment 51 dated August 16, 2021. (
NAIK, RAMACHANDRA )
17-AUG-2021 Y Telecon. Information Request - DVP IR regarding two questions on shelf life
and date of manufacture. ( SMITH, MICHAEL )
18-AUG-2021 Y Memo. Committee Memo/Review - DBSQC LRP template review memo (
ANDERSON, MARIE )
18-AUG-2021 Y Y Memo. Committee Memo/Statistical Non-Clinical - Statistical review memo
for non-clinical data ( TANG, XINYU )
18-AUG-2021 Y Telecon. Advice - Pfizer e-mailed clarification questions on August 18, 2021,
to DVP's two DS questions dated August 17, 2021. This e-mail was guidance
in response to their clarification questions. ( SMITH, MICHAEL )
18-AUG-2021 Y Telecon. Information Request - Two DBSQC questions on amendments 54
and 50 RE (b) (4) testing and specific parameters/instructions for (b) (4)
(b) (4) test method. ( SMITH, MICHAEL )
18-AUG-2021 Y Telecon. Information Request - DVP follow-up response to Pfizer August 18,
2021, clarification questions regarding DVP's August 17, 2021, IR on shelf life
and date of manufacture. ( SMITH, MICHAEL )
18-AUG-2021 Y Telecon. Labeling via FAX/e-mail - 5th set of PI labeling comments. (
SMITH, MICHAEL )
18-AUG-2021 Y Telecon. Labeling via FAX/e-mail - 3rd set of comments on the carton and
container labels. ( GOTTSCHALK, LAURA )
18-AUG-2021 Y Telecon. Information Request - Identification of BLA-compliant lots and
Letter to HCP. ( NAIK, RAMACHANDRA )
19-AUG-2021 Y Y Memo. Committee Memo/Statistical Clinical - Statistical memo for clinical
efficacy data ( HUANG, LEI )
19-AUG-2021 Y Y Memo. Committee Memo/Statistical Clinical - Statistical review for safety
data. ( YANG, YE )
19-AUG-2021 Y Memo. Compliance Check Acceptable - Compliance check is acceptable. (
DECIERO, DANIEL )
19-AUG-2021 Y Telecon. Information Request - IR RE PMR's and PMC's that were listed in
amendment 51. ( SMITH, MICHAEL )
19-AUG-2021 Y Telecon. Labeling via FAX/e-mail - 6th set of PI labeling comments. (
GOTTSCHALK, LAURA )
19-AUG-2021 Y Telecon. Information Request - IR RE PMC Study Completion Date and
Final Report Submission date for PMC Study C4591014. ( SMITH, MICHAEL
)
20-AUG-2021 Y Memo. Committee Memo/Labeling - Review Memo: Containers, Cartons,
Sticker, Stamp ( STEWART, DAPHNE )
December 20, 2021 8:32 AM License Action Recommendation Documents for Submissions and FDA Communication Page 5
***FOR OFFICIAL USE ONLY*** Exclude Inspection Related
Order: FDA/Appl, Then Date Ascending
***THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION***
STN: L 125742/0
Applicant: BioNTech Manufacturing GmbH #2229
Product: COVID-19 Vaccine, mRNA
Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.
Date Elec Post Description FDA Recd Date Login ID
20-AUG-2021 Y Memo. Other - CONFIDENTIAL - DO NOT POST TO THE WEB CBER
Laboratory Quality Product Testing Plan ( ANDERSON, MARIE )
20-AUG-2021 Y Y Memo. Review - Pharmacovigilance Plan Review; Addendum Memorandum
( WELSH, KERRY )
20-AUG-2021 Y Memo. Test Results - In-support (b) (4) Test
Results ( KONG, HYESUK )
20-AUG-2021 Y Memo. Test Results - Test memo for(b) (4) (
WANG, HSIAOLING )
20-AUG-2021 Y Telecon. Labeling via FAX/e-mail - 7th set of PI comments and shell table. (
GOTTSCHALK, LAURA )
20-AUG-2021 Y Telecon. Information Request / Advice - Lot Numbers for the COVID Launch
Lots ( NAIK, RAMACHANDRA )
20-AUG-2021 Y Telecon. Information Request - CBER comments regarding label for
identification of BLA lots and(cid:13)
Dear HCP Letter(cid:13)
( NAIK, RAMACHANDRA )
20-AUG-2021 Y Telecon. Labeling via FAX/e-mail - Comment regarding vial label to include
the name of the diluent on vial labels. ( GOTTSCHALK, LAURA )
21-AUG-2021 Y Y Memo. Committee Memo/CMC - CMC Product Review Memo ( WANG,
XIAO )
21-AUG-2021 Y Y Memo. Committee Memo/CMC - DBSQC Analytical Review Memo (
YITBAREK, EMNET )
21-AUG-2021 Y Telecon. Information Request - IR RE request to resubmit all PMR's and
PMC's and a commitment to conduct them in the timeframe noted in an
amendment to the BLA. Also, revised study completion date for study
C4591007. ( SMITH, MICHAEL )
21-AUG-2021 Y Telecon. Labeling via FAX/e-mail - 8th set of PI labeling comments (
GOTTSCHALK, LAURA )
21-AUG-2021 Y Telecon. Labeling via FAX/e-mail - The Applicant was notified that the
Carton and Container labels submitted in Amendment 63 dated August 19,
2021, are considered the Final Draft Labels for approval. ( GOTTSCHALK,
LAURA )
21-AUG-2021 Y Telecon. Information Request - CBER comments regarding label for
identification of BLA lots and Dear HCP Letter. ( NAIK, RAMACHANDRA )
21-AUG-2021 Y Telecon. Advice - The Applicant was notified that there are no additional
comments on the Dear HCP letter submitted in Amendment 73 submitted
August 21, 2021. ( NAIK, RAMACHANDRA )
22-AUG-2021 Y Y Memo. Committee Memo/Postmarketing Safety Epidemiological - OBE Real
World Evidence Memo ( LU, YUN )
22-AUG-2021 Y Y Memo. Committee Memo/Review - DMPQ Review Memo - Recommend
approval ( JONES, KATHLEEN )
22-AUG-2021 Y Y Memo. Other - Employee/Officer List Memo ( GOTTSCHALK, LAURA )
22-AUG-2021 Y Telecon. Labeling via FAX/e-mail - The Applicant was notified that the
Package Insert submitted in Amendment 74 dated August 21, 2021, is
considered the Final Draft Label for approval ( GOTTSCHALK, LAURA )
23-AUG-2021 Y Y Letter. Approval - BLA Approval Letter ( SMITH, MICHAEL )
23-AUG-2021 Y Y Memo. Committee Memo/SBRA - SBRA - Summary Basis for Regulatory
Action ( NAIK, RAMACHANDRA )
23-AUG-2021 Y Y Memo. Committee Memo/Toxicology - Committee Memo/Toxicology ( AL-
HUMADI, NABIL )
23-AUG-2021 Y Memo. Other - OCOD Transmittal Memo for web posting ( SMITH,
MICHAEL )
23-AUG-2021 Y Y Memo. Review - OBE Sentinel Sufficiency Assessment ( OBIDI, JOYCE )
December 20, 2021 8:32 AM License Action Recommendation Documents for Submissions and FDA Communication Page 6
***FOR OFFICIAL USE ONLY*** Exclude Inspection Related
Order: FDA/Appl, Then Date Ascending
***THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION***
STN: L 125742/0
Applicant: BioNTech Manufacturing GmbH #2229
Product: COVID-19 Vaccine, mRNA
Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.
Date Elec Post Description FDA Recd Date Login ID
30-AUG-2021 Y Telecon. Other - Amendment 125742.0.41 was reviewed in the DBSQC
memo dated 08/20/2021. Pfizer's responses were acceptable. ( WANG,
HSIAOLING )
30-AUG-2021 Y Telecon. Other - Amendment 125742.0.60 was reviewed in the Andover 483
response memo. Pfizer's responses were acceptable. ( JONES, KATHLEEN )
01-SEP-2021 Y Memo. Committee Memo/Labeling - RPM Labeling Review Memo (
GOTTSCHALK, LAURA )
02-SEP-2021 Y Y Memo. Committee Memo/Clinical Review - Committee Memo/Clinical
Review. Ann Schwartz and Lucia Lee contributed to this review memo. (
WOLLERSHEIM, SUSAN )
13-SEP-2021 Y Y Memo. Committee Memo/Review / Benefit-Risk assessment - Benefit-Risk
assessment review memo; Patrick Funk, Ph.D., and Osman N. Yogurtcu, Ph.D.,
also contributed to the review memo. ( YANG, HONG )
13-SEP-2021 Y Memo. Committee Memo/Review - Documentation review memo. ( SMITH,
MICHAEL )
30-SEP-2021 Y Y Memo. Revised Post Lockdown / Committee Memo/Toxicology - Revised
Post Lockdown/ Committee Memo/Toxicology/23-Aug-2021 ( AL-HUMADI,
NABIL )
08-NOV-2021 Y Y Memo. Revised Post Lockdown / Committee Memo/SBRA - Table 2 header
and value for water in the table were changed. ( NAIK, RAMACHANDRA )
________________________________________________________________
06-MAY-2021 Y Original Application. For active immunization to prevent COVID-19 disease 06-MAY-2021 1067058
caused by SARS-CoV-2 in individuals 16 years of age and older.
18-MAY-2021 Y Amendment # 1. Second and final rolling piece to start the review clock. 18-MAY-2021 1086158
19-MAY-2021 Y Amendment # 2. Request for Proprietary Name Review 19-MAY-2021 1087747
19-MAY-2021 Y Amendment # 3. Response to May 18, 2021, clinical IR RE three dataset 19-MAY-2021 1088844
questions.
24-MAY-2021 Y Amendment # 4. Response to DMPQ¿s May 20, 2021, IR RE four facilities 24-MAY-2021 1094917
questions and a request for a t-con on 5/25/21 or 5/26/21 to discuss production
schedules and the shutdown activities planned for the Puurs, Belgium site.
07-JUN-2021 Y Amendment # 5. COVID-19 case strain sequencing data. 07-JUN-2021 1119355
16-JUN-2021 Y Amendment # 6. Response to June 8, 2021, clinical IR on three clinical 16-JUN-2021 1137474
questions regarding datasets and the PI.
17-JUN-2021 Y Amendment # 7. Response to June 9, 2021, clinical IR requesting dates for 17-JUN-2021 1139420
PREA deferred studies.
02-JUL-2021 Y Amendment # 8. Response to June 29, 2021, clinical IR RE latest date of 02-JUL-2021 1168170
randomization for participants included in the reactogenicity subset for Study
C4591001.
02-JUL-2021 Y Amendment # 9. Response to June 25, 2021, clinical IR regarding IR 02-JUL-2021 1168177
regarding the document titled ¿bnt162-01-interim3-report-body¿
09-JUL-2021 Y Amendment # 10. Response to DBSQC¿s June 25, 2021, IR regarding the lot 09-JUL-2021 1183932
release protocol (LRP) template and samples & reagents.
15-JUL-2021 Y Amendment # 11. Response to DVP¿s July 13, 2021, IR regarding exception 15-JUL-2021 1199647
or alternative to the requirement that products in multiple-dose vials include a
preservative.
16-JUL-2021 Y Amendment # 12. Response to July 6, 2021, clinical IR regarding IR 16-JUL-2021 1201833
regarding the document titled ¿c4591001-interim-mth6-report-body.pdf.¿
19-JUL-2021 Y Amendment # 13. The applicant waives their rights to the mid- and late-cycle 19-JUL-2021 1204967
review meetings for BLA 125742.
20-JUL-2021 Y Amendment # 14. 20-JUL-2021 1207929
December 20, 2021 8:32 AM License Action Recommendation Documents for Submissions and FDA Communication Page 7
***FOR OFFICIAL USE ONLY*** Exclude Inspection Related
Order: FDA/Appl, Then Date Ascending
***THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION***
STN: L 125742/0
Applicant: BioNTech Manufacturing GmbH #2229
Product: COVID-19 Vaccine, mRNA
Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.
Date Elec Post Description FDA Recd Date Login ID
23-JUL-2021 Y Amendment # 15. Response to July 15, 2021, Clinical IR RE study C4591007 23-JUL-2021 1217479
to provide updated goal dates for final protocol submission and July 20, 2021
follow-up Clinical IR for a revised pediatric plan to include study C4591007
for subject 6 months to 11 years of age and proposal of another study to enroll
infants <6 months of age.
23-JUL-2021 Y Amendment # 16. Response to July 9, 2021 IR RE the validation of the RNA 23-JUL-2021 1217492
Integrity by capillary gel electrophoresis method.
26-JUL-2021 Y Amendment # 17. Responses to questions 3-5 of July 22, 2021 clinical and 26-JUL-2021 1221258
stats IR regarding shell tables to include safety and efficacy data from study
C4591001 and other clinical comments.
28-JUL-2021 Y Amendment # 18. Responses to questions 1-2 of July 22, 2021 clinical and 28-JUL-2021 1227088
stats IR regarding shell tables to include safety and efficacy data from study
C4591001 and other clinical comments.
28-JUL-2021 Y Amendment # 19. Response to July 2, 2021 DVP IR regarding 18 question on 28-JUL-2021 1227383
product related issues and categorical exclusion for an environmental
assessment.
30-JUL-2021 Y Amendment # 22. Response to July 27, 2021 third Clinical IR RE vaccine 30-JUL-2021 1233501
effectiveness.
30-JUL-2021 Y Amendment # 24. Response to July 26, 2021 DMPQ IR regarding 30-JUL-2021 1236249
manufacturing and equipment.
02-AUG-2021 Y Amendment # 25. Response to the observations contained in the FDA form 02-AUG-2021 1236634
483 that was issued for the pre-approval inspection of the Pfizer Andover
facility.
02-AUG-2021 Y Amendment # 26. Response to July 29, 2021 clinical IR regarding safety 02-AUG-2021 1237210
analysis for two age groups.
02-AUG-2021 Y Amendment # 27. Response to 7/28/2021 first set of labeling comments02-AUG-2021 1237211
regarding the PI.
02-AUG-2021 Y Amendment # 28. Response to comment 5b of July 22, 2021 clinical- 02-AUG-2021 1237740
statistical IR.
03-AUG-2021 Y Amendment # 29. Follow-up response (remaining supporting documents to 03-AUG-2021 1241021
response 10) to July 26, 2021 DMPQ IR regarding manufacturing and
equipment.
03-AUG-2021 Y Amendment # 30. Response to OBE¿s July 28, 2021 comments regarding post 03-AUG-2021 1241533
marketing observational safety study(ies) to assess myocarditis/pericarditis
following administration of COMIRNATY as well as providing plans to
characterize subclinical cases of myocarditis.
05-AUG-2021 Y Amendment # 31. Response to DVP and OBE Questions regarding the 05-AUG-2021 1247205
Validation Report VR-MVR-10077.
05-AUG-2021 Y Amendment # 32. Response to clinical and stats IR¿s fromJuly 22nd and 05-AUG-2021 1247821
August 4th regarding shell tables and two additional clinical/stats questions
regarding July 26, 2021, submission and SAS program.
06-AUG-2021 Y Amendment # 33. Responses to DVP¿s six CMC-related questions from 06-AUG-2021 1249468
August 3, 2021.
06-AUG-2021 Y Amendment # 34. Responses to August 4, 2021, IR RE two questions 06-AUG-2021 1249503
regarding the potency assay for determination of (b) (4) by
(b) (4) .
09-AUG-2021 Y Amendment # 35. Response to DBSQC and Xiao Wang's August 2, 2021, 09-AUG-2021 1252956
questions regarding validation of assay methods and lot release.
09-AUG-2021 Y Amendment # 36. Response to four questions regarding the diluent dated 09-AUG-2021 1252957
August 5, 2021.
09-AUG-2021 Y Amendment # 37. Response to July 22nd Clinical and stats IR regarding shell 09-AUG-2021 1252966
tables to include safety and efficacy data from study C4591001.
09-AUG-2021 Y Amendment # 38. Revised PI labeling in response to August 5, 2021, second 09-AUG-2021 1253712
round of labeling comments.
10-AUG-2021 Y Amendment # 39. Response to Xiao Wang¿s August 6, 2021, questions 10-AUG-2021 1258976
regarding two drug product (DP) documents.
December 20, 2021 8:32 AM License Action Recommendation Documents for Submissions and FDA Communication Page 8
***FOR OFFICIAL USE ONLY*** Exclude Inspection Related
Order: FDA/Appl, Then Date Ascending
***THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION***
STN: L 125742/0
Applicant: BioNTech Manufacturing GmbH #2229
Product: COVID-19 Vaccine, mRNA
Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.
Date Elec Post Description FDA Recd Date Login ID
11-AUG-2021 Y Amendment # 40. Response to August 4, 2021, F/U IR RE the LRP that was 11-AUG-2021 1271302
submitted to BLA 125742/0.14 on July 20, 2021.
11-AUG-2021 Y Amendment # 41. Response to one testing related question from DBSQC on 11-AUG-2021 1271303
August 10, 2021.
11-AUG-2021 Y Amendment # 42. Response to August 10, 2021, second OBE IR regarding 11-AUG-2021 1271308
safety-related postmarketing studies.
11-AUG-2021 Y Amendment # 43. Responses to DMPQ¿s August 5, 2021 11 facilities 11-AUG-2021 1273180
questions.
11-AUG-2021 Y Amendment # 44. This amendment was skipped by the Applicant. 11-AUG-2021 1273179
12-AUG-2021 Y Amendment # 45. Response to August 9. 2021, clinical IR RE sequencing 12-AUG-2021 1278583
data.
13-AUG-2021 Y Amendment # 46. Response to August 9, 2021 IR RE Carton and Container 13-AUG-2021 1284081
labeling comments.
13-AUG-2021 Y Amendment # 47. Response to DMPQ¿s August 11, 2021, diluent IR and 13-AUG-2021 1284082
amended response to Theresa Finn¿s August 5, 2021, IR regarding diluent.
13-AUG-2021 Y Amendment # 48. Response to DBSQC¿s August 6, 2021, three questions RE 13-AUG-2021 1284088
measurement of (b) (4) using (b) (4)
(b) (4) procedures.
16-AUG-2021 Y Amendment # 49. Response to 3rd set of PI labeling comments that were sent 16-AUG-2021 1310580
on August 13, 2021.
16-AUG-2021 Y Amendment # 50. Response to DBSQC¿s August 13, 2021, IR RE LRP and 16-AUG-2021 1310586
testing.
16-AUG-2021 Y Amendment # 51. Response to August 13, 2021, IR RE Safety-related 16-AUG-2021 1310587
Postmarketing Requirement/Postmarketing Commitment studies.
16-AUG-2021 Y Amendment # 52. Response to three clinical questions dated August 13, 2021, 16-AUG-2021 1310589
plus an additional clinical question dated August 13, 2021 (four total clinical
questions dated August 13, 2021).
17-AUG-2021 Y Amendment # 53. Response to August 16, 2021 IR RE Carton and Container 17-AUG-2021 1318912
labeling comments.
17-AUG-2021 Y Amendment # 54. Response to follow-up to August 13, 2021, (b) (4) IR 17-AUG-2021 1320863
and August 16, 2021, teleconference on this subject containing a commitment
to implement (b) (4) method on(b) (4) .
17-AUG-2021 Y Amendment # 55. Response to Xiao Wang¿s August 16, 2021, IR to please 17-AUG-2021 1320989
submit the same CMC stability information that was submitted to EUA
27034.260 to your BLA STN 125742 .0.
17-AUG-2021 Y Amendment # 56. Response to DMPQ¿s August 16, 2021, IR to(b) (4) 17-AUG-2021 1321046
(b) (4) .
17-AUG-2021 Y Amendment # 57. Response to DMPQ¿s 7 facility questions dated August 13, 17-AUG-2021 1321051
2021.
18-AUG-2021 Y Amendment # 58. Response to August 17, 2021, 4th set of PI labeling 18-AUG-2021 1329921
comments.
18-AUG-2021 Y Amendment # 59. Response to August 17, 2021, follow up IR RE PMR & 18-AUG-2021 1329922
PMC's commitments that were received in amendment 51 dated August 16,
2021.
18-AUG-2021 Y Amendment # 60. Updated response to FDA form 483 for the Andover site 18-AUG-2021 1331100
based off of teleconference with CBER on August 17, 2021.
19-AUG-2021 Y Amendment # 61. Responses to DVP¿s August 17, 2021, two questions 19-AUG-2021 1337760
regarding shelf life and date of manufacture.
19-AUG-2021 Y Amendment # 62. Responses to DVP¿s August 17, 2021, two questions 19-AUG-2021 1337762
regarding the drug substance.
19-AUG-2021 Y Amendment # 63. Responses to the third set of comments and questions on 19-AUG-2021 1338337
the carton and container labels.
19-AUG-2021 Y Amendment # 64. Response to August 18, 2021, IR RE Identification of 19-AUG-2021 1338338
BLA-compliant lots and Letter to HCP.
19-AUG-2021 Y Amendment # 65. Responses to DBSQC¿s August 18, 2021, IR. 19-AUG-2021 1338341
December 20, 2021 8:32 AM License Action Recommendation Documents for Submissions and FDA Communication Page 9
***FOR OFFICIAL USE ONLY*** Exclude Inspection Related
Order: FDA/Appl, Then Date Ascending
***THIS REPORT MAY CONTAIN CONFIDENTIAL INFORMATION***
STN: L 125742/0
Applicant: BioNTech Manufacturing GmbH #2229
Product: COVID-19 Vaccine, mRNA
Short Summary: For active immunization to prevent COVID-19 disease caused by SARS-CoV-2 in individuals 16 years of age and older.
Date Elec Post Description FDA Recd Date Login ID
19-AUG-2021 Y Amendment # 66. Response to August 18, 2021, 5th set of PI labeling 19-AUG-2021 1338872
comments.(cid:13)
19-AUG-2021 Y Amendment # 67. Response August 19, 2021, IR RE PMR¿s and PMC¿s that 19-AUG-2021 1339769
were submitted in amendment 51.
20-AUG-2021 Y Amendment # 68. Response to August 19, 2021, 6th set of PI labeling 20-AUG-2021 1341754
comments.
20-AUG-2021 Y Amendment # 69. Additional Response to August 19, 2021, IR RE PMR¿s 20-AUG-2021 1341755
and PMC¿s that were submitted in amendment 51.
20-AUG-2021 Y Amendment # 70. Letter of authorization for a new U.S. agent. This 20-AUG-2021 1342120
amendment was not in response to an information request.
20-AUG-2021 Y Amendment # 71. Response to August 20, 2021, 7th set of PI comments and 20-AUG-2021 1344590
shell table.
20-AUG-2021 Y Amendment # 72. Response to August 20, 2021, clinical IR regarding the 20-AUG-2021 1344591
shell table.
20-AUG-2021 Y Amendment # 73. Response to August 20, 2021, CBER comments regarding 20-AUG-2021 1344771
label for identification of BLA lots and Dear HCP Letter
21-AUG-2021 Y Amendment # 74. Response to August 21, 2021, 8th set of comments on the 23-AUG-2021 1344786
PI.
21-AUG-2021 Y Amendment # 75. Response to August 21, 2021, IR RE PMR¿s and PMC¿s 23-AUG-2021 1344787
and final study protocol date for study C4591007
21-AUG-2021 Y Amendment # 76. Response to August 21, 2021, IR RE regarding 23-AUG-2021 1344788
identification of BLA lots/Dear HCP Letter.
23-AUG-2021 Y Amendment # 77. Final PI (when compared to the PI received in STN 23-AUG-2021 1346819
125.0.74 it was the same EXCEPT Pfizer¿s version number at the very end of
the PI was changed from LAB-1448-.9 to LAB-1448-1.0).
24-AUG-2021 Y Amendment # 78. Final PI which has been revised to include the license 24-AUG-2021 1350971
number
07-MAY-2023 Y Amendment # 20. Response to July 13, 2021 OBE IR to add myocarditis and 29-JUL-2021 1230081
pericarditis to the PVP.
07-JUN-2023 Y Amendment # 21. Response to July 16, 2021 DBSQC IR regarding (b) (4) 30-JUL-2021 1232318
(b) (4) test methods.
07-JUN-2023 Y Amendment # 23. Response to July 26, 2021 clinical IR regarding the 30-JUL-2021 1235714
disposition of participants in safety populations who experienced pregnancy.",,17
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_24032022/125742_S1_M1_priority-review-request.pdf,17.0,"BNT162b2
1.2 Requestfor Priority Review
REQUEST FOR PRIORITY REVIEW
COVID-19 Vaccine (BNT162, PF-07302048)
BLA 125742
MAY2021
CONFIDENTIAL
Page 1
FDA-CBER-2021-5683-0013748
BNT162b2
1.2 Requestfor Priority Review
TABLE OF CONTENTS
ABBREVIATIONS...................................................................................................................3
1. OVERVIEW..........................................................................................................................5
1.1. Rationale for Priority Review....................................................................................5
1.2. Serious and Life-threatening Disease........................................................................5
1.2.1. Background and Clinical Presentation of COVID-19..................................5
1.2.2. Incidence and Prevalence of COVID-19......................................................6
1.3. Unmet Medical Need................................................................................................6
1.4. Significant Improvement in Safety and Effectiveness through Prevention of
COVID-19 Disease......................................................................................................6
1.4.1. Overview of Nonclinical Data......................................................................6
1.4.2. Overview of Completed and Ongoing Clinical Trials..................................7
1.4.2.1. Safety...........................................................................................8
1.4.2.2. Efficacy.....................................................................................10
1.4.2.3. Immunogenicity........................................................................13
1.4.3. Vaccine Effectivness..................................................................................13
1.4.4. Overview of Post-authorization Safety Data..............................................14
1.5. Conclusions.............................................................................................................14
2. REFERENCES....................................................................................................................16
CONFIDENTIAL
Page 2
FDA-CBER-2021-5683-0013749
BNT162b2
1.2 Requestfor Priority Review
ABBREVIATIONS
Abbreviation Definition
ADR adverse drug reaction
AE adverse event
AESI adverse event of special interest
BLA Biologics License Application
CDC Centers for Disease Control and Prevention
CI confidence interval
COVID-19 Coronavirus Disease 2019
DART Developmental and Reproductive Toxicology
EUA Emergency Use Authorization
FDA (US) Food and Drug Administration
FIH first-in-human
GLP Good Laboratory Practice
GMC geometric mean concentration
GMT geometric mean titer
HCS human convalescent serum
HIV human immunodeficiency virus
IFN interferon-gamma
IgG immunoglobulin G
IL-2 interleukin-2
IM intramuscular(ly)
IND Investigational New Drug
LTCF long term care facility
NHP non-human primate
PDUFA Prescription Drug User Fee Act
RNA ribonucleic acid
SAE serious adverse event
SARS-CoV-2 severe acute respiratory syndromeCoronavirus-2; virus causing the disease COVID-19
SOC System Organ Class
US United States
Th1 helper T cell type 1
VAED vaccine-associated enhanced disease
CONFIDENTIAL
Page 3
FDA-CBER-2021-5683-0013750
BNT162b2
1.2 Requestfor Priority Review
Abbreviation Definition
VE vaccine efficacy
WHO World Health Organization
CONFIDENTIAL
Page 4
FDA-CBER-2021-5683-0013751
BNT162b2
1.2 Requestfor Priority Review
1. OVERVIEW
In accordance with theprovisions outlined in the Prescription Drug User Fee Act (PDUFA) and
the Food and Drug Administration (FDA) Guidancefor Industry Expedited Programs for Serious
Conditions –Drugs and Biologics (May2014)1, Pfizer and BioNTech are requesting Priority
Review Designation for BNT162b2. BNT162b2 is a prophylacticvaccine that targets severe
acute respiratory syndrome Coronavirus-2(SARS-CoV-2), which causes Coronavirus Disease
2019 (COVID-19). The proposed indication for the candidate vaccine is active immunization to
prevent COVID-19disease caused bySARS-CoV-2 in individuals ≥16 years of age.The
proposed dosage is30 µg via intramuscular (IM) injection following a dosing regimen of two
0.3-mL doses given 3 weeks apart. The Investigational New Drug Application (IND) for
BNT162b2 was effective on 29 April 2020.Fast Track Designation was granted on 07 July 2020
for individuals 18 years of age and older(a copy of the Fast Track Designation Grant Letter is
provided in Module 1.7.4). On 11 December 2020, Emergency Use Authorization (EUA 27034)
for active immunization to prevent COVID-19 in individuals 16 years of ageand older was
issued for this vaccine (EUA product identified as Pfizer-BioNTech COVID-19 Vaccine).
1.1. Rationale forPriority Review
Pfizer and BioNTech are seekingUS licensure of BNT162b2for use in individuals ≥16 years of
age. The Biologics License Application (BLA) for BNT162b2 meets the criteria for priority
review designation, as outlined in the 2014 Guidance for Industry: Expedited Programs for
Serious Conditions –Drugs and Biologics because BNT162b2 preventsaserious and life-
threatening condition (COVID-19)and, if approved, would provide a significant improvement in
safety and effectiveness because there are currently no vaccines licensedfor the prevention of
COVID-19in the US (Section 1.2and Section 1.4).1
1.2. Serious and Life-threatening Disease
1.2.1. Background and Clinical Presentation of COVID-19
COVID-19 is caused by SARS-CoV-2, a zoonotic virus that first emerged as a human pathogen
in China and has rapidly spread around the world by human to human transmission.SARS-CoV-
2 infections and the resulting disease COVID-19 have spread globally, and on 11March 2020
the World Health Organization (WHO)characterized the COVID-19 outbreak as a pandemic. At
the time of this submission, the ongoing pandemic remains a significant challenge to public
health and economic stability worldwide, for which for a licensed prophylactic vaccineis a
necessary and critical mitigation.
COVID-19 presentation is generally with cough and fever, with chest radiography showing
ground-glass opacities or patchy shadowing.2 However, many patients present without fever or
radiographic changes, and infections may be asymptomatic which is relevant to controlling
transmission. For symptomatic patients, disease progression may lead to acute respiratory
distress syndrome requiring ventilation, subsequent multi-organ failure, and death.2
Common symptoms in hospitalized patients (in order of highest to lowest frequency) include
fever, dry cough, shortness of breath, fatigue, myalgias, nausea/vomiting or diarrhea, headache,
weakness, and rhinorrhea.2 Anosmia (loss of smell) or ageusia (loss of taste) may be the sole
presenting symptom in approximately 3% of individuals who have COVID-19.2
CONFIDENTIAL
Page 5
FDA-CBER-2021-5683-0013752
BNT162b2
1.2 Requestfor Priority Review
1.2.2. Incidence and Prevalence of COVID-19
On 25April 2021, The Center for Systems Science and Engineering at Johns Hopkins University
reported more than 146.7 million cases globally, with over 3.1million deaths from 192
countries/regions. The US (United States)has reported 32million cases and over 572,000
deaths.3
1.3. Unmet Medical Need
There are no vaccines licensedin the US for the prevention of COVID-19 disease.4
The FDA issued an EUA for the Pfizer-BioNTech COVID-19 Vaccineand Moderna COVID-19
Vaccineon 11 and 18December 2020, respectively. An EUA was issued for the Janssen
COVID-19 Vaccine on 27February 2021. These vaccines havebeen, and continue to be,
rigorously tested in large safety and efficacy studies that meet regulatory requirements in the US;
however, the EUA places limitations on eligibility and access to the vaccines.
Mass immunization with a safe and effective vaccineagainst COVID-19 can dramaticallyalter
the trajectory ofthe pandemic. According to policy briefing by the Institute for Health Metrics
and Evaluationpublished on 31 March 2021, COVID-19 remains a leading cause of death in the
US with up to 100,000additional deaths projected in the US between March and July2021,
many of which can likely be prevented with COVID-19 vaccination.5,6 Vaccination against
COVID-19 began with EUA/conditional approvals in December 2020, in a phased rollout
defined by national/regional guidance. However, there continue to be concerning trends that may
counteract the impacts of this vaccination effort, including:
 limitations in access to obtaining a vaccine due to infrastructurechallenges (ie, clinic and
appointment capacity and systems)7
 increasing viral transmission fueled by relaxed compliance with mitigations as the pandemic
surpasses the 1-year mark (ie, masks, physical distancing, limiting travel)5,7
 increasing circulation of emerging variants of concern (which are currently driving continued
spread of viral infection in Europe despite extensive mitigation mandates).5,7
1.4. Significant Improvement in Safety and Effectivenessthrough Prevention of COVID-19
Disease
1.4.1. Overview of Nonclinical Data
Key nonclinical evaluations of BNT162b2 included pharmacology (mouse immunogenicity
studies, non-human primate [NHP] immunogenicity and challenge studies) and toxicity
(twoGood Laboratory Practice [GLP] rat repeat-dose toxicity studies)invitro and invivo.
Adevelopmental and reproductive toxicity (DART)study was completedin rats.
Nonclinical studies in mice and NHP demonstrate that BNT162b2 elicits a rapid antibody
response with measurable SARS-CoV-2 neutralizing titers after a single dose and substantial
increases in titers after a second dose that exceed titers in sera from SARS-CoV-2/ COVID-19-
recovered individuals. A Th1-dominant T cell response was evident in both mice and NHPs.
S-specific CD8+ T cell responses were also detectable in BNT162b2-immunized animals. The
CONFIDENTIAL
Page 6
FDA-CBER-2021-5683-0013753
BNT162b2
1.2 Requestfor Priority Review
strongly Th1-biased CD4+ T cell response and interferon-γ (IFNγ)+ CD8+ Tcell response after
immunization with BNT162b2 is a pattern favored for vaccine safety and efficacy and provided
added reassurance for clinical safety.8 In aSARS-CoV-2 rhesus challenge model, BNT162b2
provided complete protection from the presence of detectable viral RNA in the lungs compared
to the saline control withno clinical, radiological, or histopathological evidence of vaccine-
elicited disease enhancement.9
Administration of BNT162b2 by IM injection to male and female Wistar Han rats once every
week, for a total of 3weekly cycles of dosing, was tolerated without evidence of systemic
toxicityin GLP-compliant repeat-dose toxicity studies.
In a DART study, 0.06 mL of a vaccine formulation containing the same quantity of nucleoside-
modified mRNA (30 µg) and other ingredients included in a single human dose ofBNT162b2
was administered to female rats by the IM route on four occasions: 21 and 14 days prior to
mating, and on gestation days 9 and 20. No vaccine-related adverse effects on female fertility,
fetal development,or postnatal development were reported in the study.
In summary, the nonclinical package summarized above supports BNT162b2 administered twice
by IM injection at a dose of 30 µg RNA. Additional details of nonclinical studies are provided in
Module 2.4.
1.4.2. Overview of Completed and Ongoing Clinical Trials
The COVID-19 vaccine candidate is currently being studied in a global clinical trial
(StudyC4591001 and other clinical trialsunder BB-IND 19736,as well as a German clinical
trial (Study BNT162-01, not under the IND).
The German first-in-human (FIH)Phase 1/2 study (BNT162-01) was conducted to gather safety
and immunogenicity data on several BNT162 vaccine candidates to inform the overall clinical
development of a COVID-19 vaccine. Phase 1 of Study C4591001 evaluated 2 vaccine
candidates, and safety and immunogenicity results led to the selection ofa single candidate,
BNT162b2(30 µg). The first 360 Phase 2/3 subjects comprised the Phase 2 portion of the study;
these subjects contributedto efficacy, immunogenicity, and safety endpoints. Study C4591001 is
currently in Phase 3and available results as of the latest data cutoff dates are summarized in the
sections below.
Efficacy analyses are event-driven in pivotal Study C4591001 Phase2/3 participants ≥12 years of
age. Prespecified analyses were conducted on 94 confirmed COVID-19 cases (interim analysis data
cutoff date: 04November 2020)and 170confirmed cases (final analysis data cutoff date:
14November2020) reported in participants without prior evidence of SARS-CoV-2 infection
before or during the vaccine regimen. Updated analyses of 1165 confirmed cases in blinded
placebo-controlled follow-up from Dose 1 to a data cutoff date of 13March 2021 evaluated
duration of protection.
Immunogenicity analyses of adults (18 to 85 years of age) in Study C4591001 include data up to
1month after Dose 2 in Phase 2, and up to 6 months after Dose 2 in Phase 1.
CONFIDENTIAL
Page 7
FDA-CBER-2021-5683-0013754
BNT162b2
1.2 Requestfor Priority Review
Safety data are collected cumulatively in Study C4591001. Some participants ≥16 years of age
have been unblinded to treatment assignment; therefore,safety data are presented separately for
blinded placebo-controlled and open-label periods. Keysafety data in the BLA submission
include:
 Blinded placebo-controlled period: Dose 1 to 1 month after Dose 2 and to unblinding date:
 Phase 1 participants randomized to BNT162b230 µg (to ~6 months after Dose 2)
 Phase 2/3 participants ≥16 years of age including HIV+ subset (to ~5 months after Dose 2)
 Open-label observational period: from unblinding dateto data cutoff date:
 Phase 2/3 participants ≥16 years of age originally randomized to BNT162b2
 Phase 2/3 participants ≥16 years of age originally randomized to placebo who then
received BNT162b2 after being unblinded
 Cumulative follow-up from Dose 1 to 6 months after Dose 2: Phase 2/3 participants
originally randomized to BNT162b2 (inclusive of blinded data and open-label data), comprised
of at least 3000 in each adult age group (16 to 55 years of age, >55 years of age)
Supportive analyses from Study BNT162-01 are provided in this submission for immunogenicity
data including T cell responses, and safety data including reactogenicity and adverse events
(AEs), for adult participants in the Phase 1 portion of the study.
Further efficacy, immunogenicity, and safety details are summarized in the Clinical Overview in
Module 2.5.
1.4.2.1. Safety
1.4.2.1.1. Phase 1 Safety
Based on Phase 1 data from the FIH Study BNT162-01, BNT162b1 and BNT162b2 were safe
and well-tolerated in healthy adults 18 to 55 years of age, with no unanticipated safety findings.
Reactogenicity and AEs tended to increase in incidence and/or severity with increasing dose of
BNT162b2. Reactogenicity was mostly mild to moderate and short-lived after dosing (eg, arose
and resolved within the first 1 to 2 days after dosing), and the AE profile and clinical laboratory
results did not suggest any safety concerns.
Based on Phase 1 data from Study C4591001 and Study BNT162-01, BNT162b1 and BNT162b2
were safe and well-tolerated in younger healthy adults 18 to 85 years of age, with no
unanticipated safety findings. Reactogenicity and AEs were generally milder and less frequent in
participants in the older group compared with the younger group and overall tended to increase
with increasing BNT162b2 dose. Reactogenicity was mostly mild to moderate and short-lived
after dosing, and the AE profile did notsuggest any safety concerns, including up to
approximately 6 months after Dose 2 for BNT162b2 30 µg groups. Clinical laboratory
evaluations showed a transient decrease in lymphocytes that was observed in all age and dose
groups after Dose 1, which resolved within approximately 1week, were not associated with any
other clinical sequelae, and were not considered clinically relevant.
CONFIDENTIAL
Page 8
FDA-CBER-2021-5683-0013755
BNT162b2
1.2 Requestfor Priority Review
Ribonucleic acid (RNA) vaccines are known to induce type I interferon,10 and type I interferons
regulate lymphocyte recirculation and are associated with transient migration and/or
redistribution of lymphocytes.11 This rapid rebound of lymphocytes supports that the
lymphocytes are not depleted, but temporarily migrated out of the peripheral blood, and
subsequently re-entered the bloodstream by the time of the next assessment.
1.4.2.1.2. Phase 2/3 Safety
Based on Phase 2/3 data from approximately 44,000 participants ≥16 years of age with up to at
least 6months of follow-up after Dose 2 in Study C4591001, BNT162b2 at 30 µg was safe and
well-tolerated across age groups. Reactogenicity and AEs were generally milder and less
frequent in participants in the older group (>55 years of age) compared with the younger group
(≤55 years of age). Reactogenicity was mostly mild to moderate and short-lived after dosing for
both younger and older age groups (ie, median onset between 1 to 4days after dosing and
resolution within 1 to 2 days after onset), and the AE profile did not suggest any serious safety
concerns. The incidence of serious adverse events (SAEs)and deaths were low in the context of
the number of participants enrolled and comparable between BNT162b2 and placebo. The
incidence of discontinuations due to AEs was also generally low and similar between BNT162b2
and placebo groups.
Cumulative safety follow-up to at least 6 months after Dose 2 for approximately 12,000 Phase
2/3 participants originally randomized to BNT162b2, comprising the combined blinded and
open-label periods,showed no new safety signals or suggested anynew safety concerns arising
from longer-term follow-up.
Similarly, open-label follow-up of participants randomized to placebo from the time of
unblindingto receive BNT162b2 until the data cutoff date showed no new safety signals or
concerns.
Safety analysis results for subgroups based on demographics (age, race, ethnicity) and by
baseline SARS-CoV-2 positive versus negative status have not shown any clinically important
differences in the BNT162b2 safety profile. Analysis of the subset of individuals with stable
human immunodeficiency virus (HIV)did not suggest any safety concerns in this population.
Analysis of participants originally randomized to placebo who then received BNT162b2 (Dose
3) by demographic subgroups and based on prior evidence of SARS-CoV-2 infection orprior
COVID-19 did not suggest any safety concerns.
Phase 2/3 safety data were generally concordant with safety data in Phase 1 of the study, both
overall and with regard to younger and older participants.
CONFIDENTIAL
Page 9
FDA-CBER-2021-5683-0013756
BNT162b2
1.2 Requestfor Priority Review
1.4.2.2. Efficacy
1.4.2.2.1. Phase 2/3 Efficacy Final Analysis
Evaluable Efficacy Population
In the final efficacy analysis, among participants without evidence of SARS-CoV-2 infection
before and during vaccination regimen, vaccine efficacy (VE) against confirmed COVID-19
occurring at least 7days after Dose 2 was 95.0%, with 8 COVID-19 cases in the BNT162b2
group compared to 162 COVID-19 cases in the placebo group. The 95% credible interval for the
vaccine efficacy was 90.3% to 97.6%.
For the second primary endpoint, VE against confirmed COVID-19 occurring at least 7 days
after Dose 2 in participants with or without evidence of SARS-CoV-2 infection before and
during vaccination regimen was 94.6%, with 9 and 169cases in the BNT162b2 and placebo
groups respectively. The posterior probability of >99.99% for the true VE greater than 30% met
the prespecified success criterion of >98.6% for this endpoint. The 95% credible interval for the
vaccine efficacy was 89.9% to 97.3%.
Observed VE was very high for the first primary efficacy endpoint across subgroups of age, sex,
race, ethnicity, and country, as VE was >93% in all subgroups, with the exception of “all others”
race group (89.3% VE) and Brazil (87.7% VE).
For the secondary efficacy endpoint analyses, observed VE against confirmed COVID-19
occurring at least 14 days after Dose 2 in participants without evidence of SARS-CoV-2
infection before and during vaccination regimen, was 94.2%, with 8 and 139 cases in the
BNT162b2 and placebo groups respectively. The posterior probability of >99.99% for the true
VE >30% met the prespecified success criterion of >98.6% for this endpoint. The 95% credible
interval for the vaccine efficacy was 88.7% to 97.2%.
Similarly, among participants with or without evidence of SARS-CoV-2 infection before and
during vaccination regimen, VE against confirmed COVID-19 occurring at least 14 days after
Dose 2 was 94.4%, with 8 and 144 cases in the BNT162b2 and placebo groups respectively. The
posterior probability of >99.99% for the true VE >30% met the prespecified success criterion of
>98.6% for this endpoint. The 95% credible interval for the vaccine efficacy was 89.1% to
97.3%.
Amongparticipants without evidence of SARS-CoV-2 infection before and during vaccination
regimen, observed VE of 66.3% against severe COVID-19 occurring at least 7 days after Dose 2
did not meet the prespecified success criterion of the posterior probability >98.6%, due to the
small number of severe cases (1 in the BNT162b2 group, 3 in the placebo group)observed after
Dose 2 in the study.
The efficacy analyses using Centers for Disease Control and Prevention (CDC)defined
symptoms to identify a COVID-19 case gave similar efficacy results as the primary endpoints.
CONFIDENTIAL
Page 10
FDA-CBER-2021-5683-0013757
BNT162b2
1.2 Requestfor Priority Review
All-Available Efficacy Population
The early onset of protection is readily apparent from cumulative incidence curves, which show
that disease onset tracks conjointly for BNT162b2 and placebo until approximately 14 days after
Dose 1, at which point the curves diverge, with cases steadily accumulating in the placebo group,
while remaining virtually flat after BNT162b2.
Among all participants (regardless of evidence of infection before or during the vaccination
regimen) 50 cases of COVID-19 occurred after Dose 1 in the BNT162b2 group compared with
275 cases in the placebo group, indicating an estimated VE of 82% (2-sided 95% confidence
interval [CI]: 75.6%, 86.9%) against confirmed COVID-19 occurring after Dose 1, with VE of
52.4% (95% CI: 29.5%, 68.4%) between Dose 1 and Dose 2.
Among the total of 10 severe COVID-19 cases observed after Dose 1, only 1 severe case was
seen in BNT162b2 recipients compared to 9 severe COVID-19 cases in placebo recipients; these
results, as well as case splits between Dose 1 and Dose 2 and after Dose 2, were consistent with
overall efficacy seen against COVID-19. Similar results were observed when using the CDC
definition of severe disease.
Overall Conclusions
Final efficacy results show that BNT162b2 at 30 µg provided protection against COVID-19 in
participants with or without evidence of prior infection with SARS-CoV-2, including across
demographic subgroups, with severe cases observed predominantly in the placebo group.
1.4.2.2.2. Phase 2/3 Efficacy Updated Analysis
Updated Analysis –Efficacy Against Confirmed COVID-19
In the updated descriptiveefficacy analysis (data cutoff date: 13 March 2021), among
participants in the evaluable efficacy population without evidence of SARS-CoV-2 infection
before and duringthe vaccination regimen, the estimated VE against confirmed COVID-19
occurring at least 7days after Dose 2 was 91.3% (2-sided 95% CI: 89.0%, 93.2%), with 77cases
in the BNT162b2 group and 850 cases in the placebo group. Among participants with or without
evidence of SARS-CoV-2 infection before and during the vaccination regimen, the estimated VE
against confirmed COVID-19 occurring at least 7 days after Dose2 was 91.1% (2-sided 95% CI:
88.9%, 93.0%), with 81and 873cases in the BNT162b2 and placebo groups,respectively.
All cases of confirmed COVID-19 are accounted for in the analyses of VE in the Dose 1
all-available (modified intention-to-treat)population,regardless of evidence of infection before
or during the vaccination regimen. In this analysis, the estimated VE against all cases occurring
at any time after Dose 1 was 87.8% (2-sided 95% CI: 85.3%, 89.9%), with 131 cases in the
BNT162b2 group and 1034 cases in the placebo group.
In this same Dose 1 all-available (modified intention-to-treat) population, the estimated VE
against all cases occurring ≥7days after Dose 2 was 91.2%. The estimated VE was 91.7% from
≥11 days after Dose 1 to before Dose 2, 96.2% for cases occurring from ≥7days after Dose 2 to
CONFIDENTIAL
Page 11
FDA-CBER-2021-5683-0013758
BNT162b2
1.2 Requestfor Priority Review
<2 months after Dose 2, 90.1%for the period from ≥2months to <4 months after Dose 2, and
83.7% for the period ≥4months after Dose2.
Efficacy in Subgroups
Among participants without evidence of SARS-CoV-2 infection before and during the
vaccination regimen (efficacy evaluable population),VE against COVID-19 occurring at least
7days after Dose 2 was evaluated for demographic and risk subgroups, as follows:
 Estimated VE was ≥90% in most demographic subgroups, similar to 91.3% overall VE.
 High estimated VE was observed across age subgroups:
 100.0% in participants 12 to 15 years of age
 90.6% in participants 16 to 64 years of age
 94.5% in participants ≥65 years of age
 96.2% in participants ≥75 years of age.
 Estimated VE by country was 86.5% in Argentina; 86.2% in Brazil; 92.6% in the US; and
100.0% in South Africa, Germany, and Turkey.
The estimated VE was similar for participants at risk (91.6%) and thosenot at risk (91.0%). The
estimated VEfor participants ≥65 years of age who were at risk was 91.8%, as compared with
98.1% for those ≥65 years of age andnot at risk. The estimated VE was similar in obese (91.6%) and
non-obese (91.1%) participants. When evaluated by type of comorbidity,the estimatedVE was
>85% for participants with each comorbidity evaluated, including any malignancy, cardiovascular
disease, chronic pulmonary disease, diabetes, obesity, and hypertension.
Efficacy Against Severe Disease
Among participants without evidence of SARS-CoV-2 infection before and during the
vaccination regimen (evaluable efficacy population), the estimated VE against FDA-defined
severe COVID-19 (protocol definition) occurring at least 7 days after Dose 2 was 95.3% (2-sided
95% CI: 71.0%, 99.9%), with 1 and 21 cases in the BNT162b2 and placebo groups, respectively.
Similarly, the estimated VE was also 95.3% (2-sided 95%CI: 70.9%, 99.9%) among participants
with or without evidence of SARS-CoV-2 infection, also with 1 and 21cases in the BNT162b2
and placebo groups, respectively.
Among participants without evidence of SARS-CoV-2 infection before and during the
vaccination regimen (evaluable efficacy population), the estimated VEagainst CDC-defined
severe COVID-19 occurring at least 7 days after Dose 2 was 100.0%(2-sided 95% CI: 88.1%,
100.0%), with 0 and 32 cases in the BNT162b2 and placebo groups, respectively.Similarly, the
estimated VE was also 100.0% (2-sided 95%CI: 88.0%, 100.0%) among participants with or
without evidence of SARS-CoV-2 infection before and during the vaccination regimen, also with
0and 32cases in the BNT162b2 and placebo groups, respectively.
Among participants in the Dose 1all-available (modified intention-to-treat) population, regardless of
evidence of infection before or during the vaccination regimen, the estimated VE against
CONFIDENTIAL
Page 12
FDA-CBER-2021-5683-0013759
BNT162b2
1.2 Requestfor Priority Review
FDA-defined severe cases of COVID-19 occurring at any time after Dose 1 was 96.7% (2-sided 95%
CI: 80.3%, 99.9%), with 1 case of severe COVID-19 in the BNT162b2 group compared to 30 cases
in the placebo group.
1.4.2.3. Immunogenicity
1.4.2.3.1. Phase 1 Immunogenicity
Study BNT162-01 provides evidence for robust T cell-mediated immunity, with antigeninduced
interferon-gamma (IFN expression demonstrating a Th1 CD4+ and CD8+ phenotype following
the second dose of either BNT162b1 or BNT162b2. Immunogenicity data from Study
BNT162-01 were generally concordant with results in pivotal Study C4591001, showing robust
SARS CoV-2 neutralization following the second dose and complimentary T cell immune
response data for both younger and older adults.The durability of T cell responses to BNT162b2
vaccination was evident from maintenance of the Th1 phenotype and persistent IFN and IL-2
production by CD4+ and CD8+ T cells up to approximately 6 months.
In Study C4591001, both BNT162b1 and BNT162b2 elicited robust SARS-CoV-2 neutralizing
antibody response starting from 7 days after Dose 2 in younger and older adults. Responses were
generally stronger in younger adults than in older adults. Neutralizing antibody response was
maintained through Day 52 and was similar for the candidates within the corresponding age and
dose groups. Comparisons of SARS-CoV-2 neutralizingtiters for both vaccine candidates with a
panel of HCS support the benefit of a two-dose vaccine regimen with a dose response up to 30 µg.
For the groupsthat received BNT162b2 at 30 µg, persistence of the immune response was
observed through 6 months after Dose 2.SARS-CoV-2 serum neutralizing titers and serum
S1-binding IgG concentrations at 6 months after Dose 2had decreased relative tothose observed
at 1 month after Dose2 but remained abovepre-vaccination and placebo levels.
The Phase 1 immunogenicity data from both the pivotal and supportive study collectively
showed robust immunogenicity elicited by BNT162b2 in both younger and older adults at the
30µg dose level, which was ultimately selected to proceed to Phase 2/3 development.
1.4.2.3.2. Phase 2 Immunogenicity
Based on immunogenicity results from 360 participants in Phase 2 of Study C4591001,
BNT162b2 at 30 µg elicited robust SARS-CoV-2 neutralization and S1-binding IgG antibody
responses at 1 month after Dose 2 similar to those previously observed in Phase1 of the study.
Notably, SARS-CoV-2 neutralizing titers were higher in the younger adult compared to the older
adult cohort. Of note, geometric mean titers (GMTs)for younger and older participants at
1month after Dose 2 were comparable to the GMTs of a comparative panel of human
convalescent serum (HCS). S1-bindinggeometric mean concentrations (GMCs)were generally
higher in the younger age cohort compared to the older age cohort, again concordant with
observations in the Phase 1 portion of the study.
1.4.3. Vaccine Effectivness
Recent data have confirmed effectiveness of BNT162b2 in the real world: in a nationwide study
among individuals aged >16 years in Israel (population 9.1M) reported VE at >7 days after
CONFIDENTIAL
Page 13
FDA-CBER-2021-5683-0013760
BNT162b2
1.2 Requestfor Priority Review
second dose was 95.3% (95% CI 94.9-97.7%) and at >14 days after second dose was 96.5%
(95% CI 96.3-96.8%)12; in a prospective cohort of healthcare workers in the United Kingdom,
which reported VE at >7 days after second dose of 86% (95% CI 76-97%)13; in a retrospective
nationwide registry study of healthcare workers in Denmark, which reported VE at >7 days after
second dose of 90% (95% CI 82-95%)14; in a test-negative case control study of individuals aged
>80 years in England, which reported VE at >14 days after second dose of 89% (95% CI 85-
93%)15; in a retrospective cohort study of long term care facility (LTCF)-residents after an
COVID-19 outbreak in a LTCF in Kentucky caused by SARS-CoV-2 variant R.1 with the
E484K mutation, which reported VE at >7 days after second dose of 64.4% (95% CI 38.5-
79.5)16; in a retrospective registry study of individuals aged 18-64 years in Sweden, which
reported VE at >7 days after the second dose of 86% (95% CI 72-94%).17
1.4.4. Overview of Post-authorization Safety Data
Post-authorization safety data are continually monitored by Pfizer and BioNTech for
pharmacovigilance and risk management purposes. Pfizer’s safety database contains cases of
AEs reported spontaneously to Pfizer, cases reported by the health authorities, cases published in
the medical literature, cases from Pfizer-sponsored marketing programs, non-interventional
studies, and cases of serious AEs reported from clinical studies regardless of causality
assessment.Through 28 February 2021(data lock point aligned with Pharmacovigilance Plan),
there were a total of 42,086 case reports (25,379 medically confirmed and 16,707 non-medically
confirmed) containing 158,893 events.Cases were received from 63 countries.
Consistent with what was seen in Phase 2/3 of Study C4591001, most reported AEs were in
System Organ Classes (SOCs)with reactogenicity events: general disorders and administration
site conditions (51,335), nervous system disorders (25,957), musculoskeletal and connective
tissue disorders (17,283), andgastrointestinal disorders (14,096). Post-authorization data have
also informed the addition of adverse drug reactions (ADRs)related to the experience of
reactogenicity to the product labeling.
Aside from addition of anaphylaxis and hypersensitivity,the analyses of cumulative post-
authorization safety data, including a review of adverse events of special interest (AESIs), are
consistent with the analysis of this pivotal clinical trial. Review of post-authorization data has
not revealed anynovel safety concerns, except for anaphylaxis, and has confirmed the favorable
benefit-risk profile of the vaccine.
Further details regarding the cumulative analysis of post-authorization safety data are presented
in Module5.3.6.
1.5. Conclusions
The BLA for BNT162b2 fulfills the criteria for priority reviewdesignation. BNT162b2 prevents
aserious and life-threatening condition (COVID-19) and, if approved, would provide a
significant improvement in safety and effectiveness because there are currently no vaccines
licensedfor the prevention of COVID-19 in the US.
CONFIDENTIAL
Page 14
FDA-CBER-2021-5683-0013761
BNT162b2
1.2 Requestfor Priority Review
The available clinical evidence for BNT162b2(30 µg) effectiveness includes induction of strong
immune responses and overwhelmingly high vaccine efficacy, suggesting the vaccine confers
protection against COVID-19 in individuals ≥16years of age.
The potential risks are based on the observed safetyprofile to date, which shows mostly mild
reactogenicity, low incidence of severe or serious events, and no clinically concerning safety
observations or safety concerns. The vaccine appears to be safeand well-tolerated across the
safety population comprising approximately 44,000 study participants ≥16 years of age, among
whom approximately 12,000 have been followed for at least 6months after completing the two-
dose regimen. Safety analyses have also included demographic subgroups based on age, sex, race,
ethnicity, and baseline SARS-CoV-2 status and the subset with stable HIV. The confinement of
severe cases of COVID-19 predominantly to the placebo group versus the BNT162b2 group
suggests no evidence of vaccine-associated enhanced disease (VAED).Post-authorization safety
review reinforces that BNT162b2 is safe and tolerable.
Vaccine efficacy was remarkably high, ≥95% for participants without prior evidence of
SARS-CoV-2 infection and >94% for those with or without prior infection, in the prespecified
interim and/orfinal analyses. Updated analyses with all confirmed cases accrued up to
approximately 6 months after Dose 2 showed persistence of protection with estimated VE of
≥91.1%. Overall, observed VE was >90% across subgroups identified by age, sex, race, ethnicity,
country, and risk factors and remained high in the updated analysis. Severe cases have beenconfined
overwhelminglyto the placebo groupin all efficacy analyses. Efficacy data suggest highly effective
protection against COVID-19 in a broad population of individuals across demographic
characteristics, with durable immune responses and protection from COVID-19 disease observed up
to approximately 6months after completing the vaccination regimen.
Avaccine program must be implemented expedientlyand rapidly expandedto have a significant
impact on the pandemic course.6,18Licensure of BNT162b2 is likely to enhance vaccine uptake
by facilitating supply of vaccine from Pfizer/BioNTech directly to pharmacies and healthcare
providers/facilities. Thegreatest impact of BNT162b2 licensure may be direct supply to
healthcare providers who serve vulnerable populations such as elderly patients and those who
live in rural and underserved communities (ie, individuals who might be unable to navigate the
challenges of securing vaccine access using the systems in place for EUA). Expansion of vaccine
via licensurewould ultimately improve the prospect of achievingpopulation herd immunity to
bring the pandemic under control.19
CONFIDENTIAL
Page 15
FDA-CBER-2021-5683-0013762
BNT162b2
1.2 Requestfor Priority Review
2. REFERENCES
1 CBER. Guidance for Industry Expedited Programs for Serious Conditions – Drugs and
Biologics. Available: https://www.fda.gov/media/86377/download. Accessed: 30 January 2021.
2 Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and
treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA 2020;
324(8)(Jul):782-93. [ePub]doi:10.1001/jama.2020.12839 090177e194d1ded0
3 COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns
Hopkins University. Available:
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423
467b48e9ecf6. Accessed 25 April 2021.
4 US Food and Drug Administration. COVID-19 Vaccines. Available:
https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-
covid-19/covid-19-vaccines. Accessed: 28 April 2021.
5 Institute for Health Metrics and Evaluation. COVID-19 policy briefings: United States of
America COVID-19 results briefing. 31 March 2021. Available at:
http://www.healthdata.org/sites/default/files/files/Projects/COVID/2021/102_briefing_Unite
d_States_of_America_11.pdf. Accessed 07 April 2021.
6 Biggerstaff M. Oct 2020 ACIP meeting. Available:
https://www.cdc.gov/vaccines/acip/meetings/slides-2020-10.html. Accessed: 15 February 2021.
7 Coronavirus (COVID-19) Vaccinations –Statistics and Research – Our World in Data.
Available at: https://ourworldindata.org/covid-vaccinations#vaccination-policies. Accessed
07 April 2021.
8 Lambert, P-H, Ambrosino DM, Andersen SR, et al. Consensus summary report for
CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with
COVID-19 vaccines. Vaccine 2020; 38:4783-91; doi:10.1016/j.vaccine.2020.05.064.
9 Vogel AB, Kanevsky I, Che Y, et al. A prefusion SARS-CoV-2 spike RNA vaccine is
highly immunogenic and prevents lung infection in non-human primate. 2020.Available:
https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1. Accessed: 30 April 2021.
10 Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits
antiviral defence for cancer immunotherapy. Nature 2016;534, 396-401.
11 Kamphuis E, Junt T, Waibler Z, et al. Type I interferons directly regulate lymphocyte
recirculation and cause transient blood lymphopenia. Blood 2006;108(10):3253-61.
12 Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of Pfizer/BioNTech
mRNA COVID-19 BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19
CONFIDENTIAL
Page 16
FDA-CBER-2021-5683-0013763
BNT162b2
1.2 Requestfor Priority Review
cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel.
Accepted by The Lancet. Available Upon Request.
13 Hall V, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA vaccine against
infection and COVID-19 vaccine coverage in healthcare workers in England, multicentre
prospective cohort study (the SIREN study). SSRN preprint server. Available:
https://ssrn.com/abstract=3790399.Accessed April 8 22, 2021.
14 Moustsen-Helms IR, Emborg HD, Nielsen J, et al. Vaccine effectiveness after 1st and 2nd
dose of the BNT162b2mRNA Covid-19 Vaccine in long-term care facility residents and
healthcare workers –a Danish cohort study. MedRxiv preprint server. Available:
https://www.doi.org/10.1101/2021.03.08.21252200. Accessed April 8, 2021.
15 Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with
BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic
disease, hospitalisations and mortality in older adults in England. MedRix preprint server.
Available: https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1. Accessed:
30 April 2021.
16 Cavanaugh AM, Fortier S, Lewis P,et al. COVID-19 Outbreak Associated with a SARS-
CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program —
Kentucky, March 2021. Morbidity and Mortality Weekly Report. ePub: 21 April 2021.
Available: https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e2.htm. Accessed: 30 April
2021.
17 Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F.
Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age
population –first results from a cohort study in Southern Sweden. MedRix preprint server.
Available: https://www.doi.org/10.1101/2021.04.20.2125463.Accessed April 23, 2021.
18 Biggerstaff M, Reed C, Swerdlow D, et al. Estimating the potential effects of a vaccine
program against an emerging influenza pandemic—United States.Clinical Infectious
Diseases 2015;60(S1):S20-9.
19 Anderson R, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to
SARS-CoV-2 infection by mass vaccination. Lancet 2020;[ePub]:doi.org/10.1016/ S0140-
6736(20)32318-7.
CONFIDENTIAL
Page 17
FDA-CBER-2021-5683-0013764","[[['Abbreviation', 'Definition'], ['ADR', 'adverse drug reaction'], ['AE', 'adverse event'], ['AESI', 'adverse event of special interest'], ['BLA', 'Biologics License Application'], ['CDC', 'Centers for Disease Control and Prevention'], ['CI', 'confidence interval'], ['COVID-19', 'Coronavirus Disease 2019'], ['DART', 'Developmental and Reproductive Toxicology'], ['EUA', 'Emergency Use Authorization'], ['FDA', '(US) Food and Drug Administration'], ['FIH', 'first-in-human'], ['GLP', 'Good Laboratory Practice'], ['GMC', 'geometric mean concentration'], ['GMT', 'geometric mean titer'], ['HCS', 'human convalescent serum'], ['HIV', 'human immunodeficiency virus'], ['IFN\uf067', 'interferon-gamma'], ['IgG', 'immunoglobulin G'], ['IL-2', 'interleukin-2'], ['IM', 'intramuscular(ly)'], ['IND', 'Investigational New Drug'], ['LTCF', 'long term care facility'], ['NHP', 'non-human primate'], ['PDUFA', 'Prescription Drug User Fee Act'], ['RNA', 'ribonucleic acid'], ['SAE', 'serious adverse event'], ['SARS-CoV-2', 'severe acute respiratory syndromeCoronavirus-2; virus causing the disease COVID-19'], ['SOC', 'System Organ Class'], ['US', 'United States'], ['Th1', 'helper T cell type 1'], ['VAED', 'vaccine-associated enhanced disease']], [['Abbreviation', 'Definition'], ['VE', 'vaccine efficacy'], ['WHO', 'World Health Organization']]]",17
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_c4591001-interim-mth6-sponsor-signature.pdf,3.0,")TMG(
44:31
1202-rpA-92
:nO
devorppA\devorppA\651a9e691e771090 29.04.2021
FDA-CBER-2021-5683-0035550
Page 1
InterimClinical Study Report
Protocol C4591001
16.1.5.1SPONSOR AGENT
CLINICAL STUDY REPORT APPROVAL FORM
PROTOCOL NUMBER: C4591001
REPORT TITLE: Interim Report –6 Month Update: A Phase 1/2/3,
Placebo-Controlled, Randomized, Observer-Blind,
Dose-Finding Study to Evaluate the Safety, Tolerability,
Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine
Candidates Against COVID-19 in Healthy Individuals
AUTHOR: Dzung Nguyen
I have reviewedthis clinical study report, which is from its definitive source and final in
content. I confirm that it is a complete and accurate representation of the relevant data and
statistical analyses forthis report.
Known deviations in the study did not impact overall compliance withGood Clinical Practice
and local regulations.
STATISTICS LINE HEAD: Kenneth Koury, PhD
CLINICAL LEAD: John L. Perez, MD, MBA, MA
CONFIDENTIAL
Template date: 01-July-2020
Page 1
)TMG(
22:31
1202-rpA-92
:nO
devorppA\devorppA\fd859e691e771090
FDA-CBER-2021-5683-0035551
Page 2
Document Approval Record
DocumentName:
(cid:5)(cid:6)(cid:7)(cid:5)(cid:7)(cid:8)(cid:7)(cid:5)(cid:9)(cid:10)(cid:11)(cid:12)(cid:13)(cid:14)(cid:12)(cid:15)(cid:16)(cid:17)(cid:18)(cid:13)(cid:19)
DocumentTitle:
(cid:20)(cid:21)(cid:8)(cid:22)(cid:5)(cid:23)(cid:23)(cid:5)(cid:16)(cid:24)(cid:24)(cid:25)(cid:19)(cid:25)(cid:12)(cid:13)(cid:26)(cid:27)(cid:16)(cid:13)(cid:26)(cid:27)(cid:28)(cid:14)(cid:25)(cid:14)
SignedBy: Date(GMT) SigningCapacity
(cid:29)(cid:18)(cid:15)(cid:18)(cid:30)(cid:31)(cid:32)(cid:12)(cid:33)(cid:13) (cid:34)(cid:22)(cid:9)(cid:16)(cid:11)(cid:15)(cid:9)(cid:34)(cid:23)(cid:34)(cid:5)(cid:5)(cid:34)(cid:35)(cid:34)(cid:22)(cid:35)(cid:34)(cid:5) (cid:36)(cid:25)(cid:13)(cid:26)(cid:27)(cid:16)(cid:11)(cid:11)(cid:15)(cid:12)(cid:37)(cid:26)(cid:27)
(cid:38)(cid:12)(cid:39)(cid:15)(cid:28)(cid:31)(cid:38)(cid:18)(cid:13)(cid:13)(cid:18)(cid:19)(cid:33) (cid:34)(cid:22)(cid:9)(cid:16)(cid:11)(cid:15)(cid:9)(cid:34)(cid:23)(cid:34)(cid:5)(cid:5)(cid:40)(cid:35)(cid:34)(cid:34)(cid:35)(cid:40)(cid:41) (cid:36)(cid:25)(cid:13)(cid:26)(cid:27)(cid:16)(cid:11)(cid:11)(cid:15)(cid:12)(cid:37)(cid:26)(cid:27)
)TMG(
22:31
1202-rpA-92
:nO
devorppA\devorppA\fd859e691e771090
FDA-CBER-2021-5683-0035552
Page 3","[[['DocumentName:'], ['DocumentTitle:']]]",3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-invest-signature.pdf,1.0,")TMG(
33:60
1202-raM-32
:nO
devorppA\devorppA\8a5179691e771090
FDA-CBER-2021-5683-0049331",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-notes-for-reader.pdf,3.0,"BioNTech RNA Page 1 of 1
Interim Clinical Study Report
Pharmaceuticals GmbH Version: 2.0
BNT162-01
Confidential Date: 27 NOV 2020
Participant data listings - Notes for the reader
To harmonize data reporting across the different BNT162 clinical studies, the following
terminology was harmonized in this interim clinical study report (CSR). The protocol,
Statistical Analysis Plan (SAP), and the CSR Section 14 tables/figures, and the Section 16
listings use the original BioNTech terminology:
BioNTech terminology in the protocol, SAP Harmonized terminology used
and the CSR appendices in the interim CSR
Boost (dose) Dose 2
Cohort Dose group
Immunization Dosing
Immunized Dosed
Prime (dose) Dose 1
(Trial) Subject Participant
Trial Study
Vaccinated Dosed
Vaccination Dosing
Vaccine Investigational medicinal product
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\46573a591e771090
FDA-CBER-2021-5683-0049414
Page 1
BioNTech RNA Pharmaceuticals GmbH / Listings - 6. Snapshot All TLFs Final 1.0 BNT162b1
BNT162-01 Created on 20NOV2020
General considerations
General details:
The programming is based on SAP final version 4.0.
The last digit of the numbering of tables, figures and listings indicates the vaccine: 1 for BNT162b1, 2 for BNT162a1, 3 for BNT162b2, 4 for BNT162c2 (single dose) and 5 for
BNT162c2 (prime/boost).
Some tables presenting adverse events are presented twice: once using the safety set and once using the safety boost set.
The adverse events based on solicited reporting via subjects diaries are defined in the file BNT162-01_AEs_based_on_solicited_reporting_via_subjects_diaries_v2.0 MBx_SSt.
The SDTM data used was received on 03NOV2020 in the folder SDTM_Group_BC_cutoff_20201023.
The adverse events intensity was assessed on different scales:
- the 1 µg, 10 µg, 30 µg, 50 µg and 60 µg young cohorts was assessed on a 3-point scale (mild, moderate, severe)
- the 3 µg and 20 µg young cohorts as well as the older cohorts were assessed on a 4-point scale (mild, moderate, severe, potentially life-threatening).
Programming details:
If a table which presents categories has any all zero rows, these rows are suppressed.
Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.
)TMG(
83:30
0202-voN-72
:nO
devorppA\devorppA\f277f9591e771090
FDA-CBER-2021-5683-0049415
Page 2
BioNTech RNA Pharmaceuticals GmbH / Listings - 6. Snapshot All TLFs Final 1.0 BNT162b2
BNT162-01 Created on 20NOV2020
General considerations
General details:
The programming is based on SAP final version 4.0.
The last digit of the numbering of tables, figures and listings indicates the vaccine: 1 for BNT162b1, 2 for BNT162a1, 3 for BNT162b2, 4 for BNT162c2 (single dose) and 5 for
BNT162c2 (prime/boost).
Some tables presenting adverse events are presented twice: once using the safety set and once using the safety boost set.
The adverse events based on solicited reporting via subjects diaries are defined in the file BNT162-01_AEs_based_on_solicited_reporting_via_subjects_diaries_v2.0 MBx_SSt.
The SDTM data used was received on 03NOV2020 in the folder SDTM_Group_BC_cutoff_20201023.
The adverse events intensity was assessed on different scales:
- the 10 µg young cohort was assessed on a 3-point scale (mild, moderate, severe)
- the 1 µg, 3 µg, 20 µg and 30 µg young cohorts as well as the older cohorts were assessed on a 4-point scale (mild, moderate, severe, potentially life-threatening).
Programming details:
If a table which presents categories has any all zero rows, these rows are suppressed.
Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.
)TMG(
83:30
0202-voN-72
:nO
devorppA\devorppA\d577f9591e771090
FDA-CBER-2021-5683-0049416
Page 3","[[['BioNTech RNA Pharmaceuticals GmbH /', 'Listings - 6. Snapshot All TLFs Final 1.0', 'BNT162b1', None], ['BNT162-01', 'Created on 20NOV2020', '', '']], [[''], ['Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.']], [['BioNTech RNA Pharmaceuticals GmbH /', 'Listings - 6. Snapshot All TLFs Final 1.0', 'BNT162b2', None], ['BNT162-01', 'Created on 20NOV2020', '', '']], [[''], ['Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.']]]",3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-synopsis.pdf,20.0,"Page 1 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
2 SYNOPSIS
Title of study A multi-site, Phase I/II, 2-part, dose-escalation trial investigating the safety and
immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19
using different dosing regimens in healthy and immunocompromised adults
Study number BNT162-01
Protocol version Version 9.0 (dated 05 OCT 2020); the version valid at the 23 OCT 2020
reactogenicity, safety, disposition, and immunogenicity data cut-off
Type of report Interim report (the BNT162-01 study is clinically ongoing; see the below notes)
This clinical study is still clinically ongoing. This third interim clinical study report (CSR) summarizes reactogenicity and
safety data available for BNT162b1 and BNT162b2 collected up until Visit 8 (the first follow-up visit at ~63 d after the
second dose) for dose-escalation and dose-expansion cohorts (dose groups) in Part A of this study, therefore this CSR
only describes the study conduct relevant for these dose groups. This CSR differs from the second interim CSR in that
additional cell-mediated immunity (CMI) data were added for a small number of participants that received 10, 20, and
30 µg BNT162b2 using research samples collected at Visit 8 (63 d post-Dose 2) and Visit 9 (162 d post-Dose 2).
The respective data cut-off dates are: reactogenicity, safety, disposition, and immunogenicity data (23 OCT 2020); T-
cell response data (ELISpot data) data (02 MAR 2021); intracellular cytokine staining (ICS) data (17 NOV 2020 for
BNT162b1 and 02 MAR 2021 for BNT162b2).
The data reported here, together with data from other sources including the study BNT162-02/C4591001, were used to
select the BNT162 vaccine and dose level for further study in the Phase II/III evaluation of efficacy.
Data not included here will be provided in later interim reports and/or the final CSR, which will include data for the other
IMPs under investigation in this study (i.e., BNT162a1 and BNT162c2).
Regulatory EudraCT no.: 2020-001038-36; ClinicalTrials.gov: NCT04380701; WHO UTN:
identifiers U1111-1249-4220
IMPs BNT162: SARS-CoV-2 - RNA lipid nanoparticle (RNA-LNP) vaccines utilizing
different RNA formats, i.e., BNT162b1 and BNT162b2
Phase of I/II
development
Study sponsor BioNTech SE, 55131 Mainz, Germany
Coordinating Dr. Dr. med. Armin Schultz, CRS Clinical Research Services Mannheim GmbH,
investigator Germany
Study sites Sites in Berlin and Mannheim, Germany
Study period Study start / end date: 23 APR 2020 / Ongoing
Study design
This is a multi-site, Phase I/II, 2-part, dose-escalation and dose-expansion study.
The study includes the first in human dose and dose ranging groups in healthy younger
participants (aged 18 to 55 years [yrs]) and older participants (aged 56 to 85 yrs). For a summary
of this study as a flow diagram, see Figure 1.
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046669
Page 1
Page 2 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
Dose groups 1 to 7 with younger participants (aged 18 to 55 yrs)
Dose groups 8 to 10 with older participants (aged 56 to 85 yrs)
Figure 1: Dose group schema for BNT162b1 and BNT162b2 (Dose 1 and Dose 2, ~21 d apart) c
a) The data assessed by the SRC for progressing comprises 48 h data for six participants.
b) Subjects will be dosed using a sentinel dosing/subject (2-4-6) staggering process unless the planned dose is the same or lower than
previously found to show acceptable tolerability (in which case, all subjects may be dosed on one day).
c) For the dose regimens, see the synopsis section “Study treatments”.
d = day(s); FIH = first in humans; SRC = Safety Review Committee; subject = participant.
Note: This report only presents data and background nformation relevant for the reported Dose Groups 1 to 10.
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046670
Page 2
FDA-CBER-2021-5683-0046671
Page 4 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
Study treatments
Name: BNT162 vaccines - Antiviral RNA vaccines for active immunization against COVID-19.
IMP and dose Younger participants aged 18 to 55 yrs:
levels: BNT162b1: 1 µg, 3 µg, 10 µg, 20 µg, 30 µg, 50 µg, and 60 µg.
BNT162b2: 1 µg, 3 µg, 10 µg, 20 µg, 30 µg.
Older participants aged 56 to 85 yrs:
BNT162b1: 10 µg, 20 µg, and 30 µg.
BNT162b2: 10 µg, 20 µg, and 30 µg.
Dosing Two injections ~21 d apart. Injection volumes were up to 0.5 mL. Use of the same arm
regimen: for both doses was allowed. The non-dominant arm was preferred.
Dosing route: Intramuscular (IM); upper arm, musculus deltoideus.
Batch Nr. BNT162b1: E220195-0001L, E220195-0004L, E220195-0014L.
BNT162b2: E220195-0004L, E220195-0017L, E220195-0018L.
This was an open-label study. There was no randomization to treatment groups.
Study population
Healthy younger participants aged 18 to 55 yrs (Dose Groups 1 to 7) and healthy older participants
aged 56 to 85 yrs (Dose Groups 8 to 10). There were no protocol waivers or exemptions to the
defined inclusion/exclusion criteria.
Methodology
Study participants were selected based on their reported background and the outcomes of
assessments performed at up to 30 d before Day 1. Study participants meeting all
inclusion/exclusion criteria were allocated to study treatment and dosed with IMP at Visits 1 and 4,
i.e., with ~21 d between doses.
There are nine planned visits in this study, starting with Visit 1 (the day of administration of the first
IMP dose, Dose 1). Visit 7 on Day 50 (i.e., at Dose 2 + 28 d) was the end of treatment (EoT) visit.
Assessments for safety (physical examination, vital signs, blood/urine clinical laboratory
assessments) were performed at baseline (pre-dose on Day 1) and thereafter at predefined times
until Visit 7. Unsolicited TEAEs reported were recorded from after the first IMP dose until Visit 7.
Solicited local reactions/systemic reactions were recorded continuously using participant diaries
from after the first IMP until Visit 7. The primary reactogenicity endpoints focus on data recorded
up to 7±1 d (Day 8) after each IMP dosing. The primary safety endpoint focuses on unsolicited
TEAE occurring up to 21±2 d after Dose 1 (Day 22) and 28±4 d after Dose 2 (Day 50).
Assessments of binding antibodies, functional antibody titers (neutralizing antibodies), and cell-
mediated immunity (antigen-specific T cells) were performed at baseline (pre-dose on Day 1) and
thereafter at predefined times until Visit 8 (follow-up visit at 63 d after Dose 2).
Two follow-up visits are planned, one at 63 d after Dose 2 and one at 162 d after Dose 2.
Statistical methods
No formal sample size calculations were performed. The inclusion of 12 participants per dose
group was considered to be adequate for a safety assessment of each IMP per dose level. The
probability to observe a particular TEAE with incidence of 15% at least once in 12 participants per
dose group is 85.8%.
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046672
Page 4
Page 5 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
In Part A, no formal statistical hypothesis was tested.
In general, data were summarized by dose groups and groups were combined as appropriate.
Continuous variables were summarized by dose group using descriptive statistics. Categorical
variables were summarized by dose group presenting absolute and relative frequencies (n and %)
of participants in each category.
Baseline was defined as last available value prior to first dose of IMP.
In general, TEAEs were analyzed by dose group (i.e., by IMP and dose level), for each dose, and
each observation interval, e.g., Day 1 to 21 (pre-Dose 2). Additionally, TEAEs were summarized
for all dose levels combined for each type.
For each analysis, the number and percentage of participants reporting at least one adverse event
(AE) was summarized by preferred term (PT) nested within system organ class (SOC) for
predefined AE types: any AE, any AE excluding AEs based on solicited reporting via participant
diaries, any related AE, Grade ≥3 AEs, related Grade ≥3 AEs, treatment-emergent serious AEs
(TESAE), TEAEs of special interest (TEAE-SIs), and related TESAEs. Moreover, the number and
percentage of participants with any AE were summarized by worst grade by PT nested within SOC.
Local reactions and systemic reactions were graded using criteria based on the guidance given in
US FDA Guidance for Industry “Toxicity Grading Scale for Healthy Adult and Adolescent
Volunteers Enrolled in Preventive Vaccine Clinical Trials”.
For each dose, the number and percentage of participants reporting at least one local reaction or
systemic reaction (i.e., solicited data collected using participant diaries) were summarized for
predefined reaction types.
Study performance
This study is ongoing clinically. There were six protocol amendments implemented at the
reactogenicity, safety, disposition, and immunogenicity data cut-off for this CSR (23 OCT 2020).
There were no investigator-reported protocol deviations considered by the sponsor to have
impacted either GCP compliance, participant safety, or the statistical analyses.
Summary of results
Demographics
All participants met the inclusion criteria for age, weight, and body mass index (BMI).
In total 120 younger and older participants were treated with BNT162b1 and included in the Safety
Set. All participants met the inclusion criteria for age, weight, and BMI. Across the dose groups, the
mean (SD) age was 46.53 (15.94) yrs, the mean (SD) participant weight was 74.28 (12.57) kg, and
the mean (SD) participant BMI was 25.10 (2.70) kg/m2. Of these participants, 57 (48%) were male
and 63 (53%) were female, 117 (98%) participants were White (there were 2 Asian and 1 Black
participants), and 118 (98%) participants were not of Hispanic or Latino origin.
In total 96 younger and older participants were treated with BNT162b2 and included in the Safety
Set. All participants met the inclusion criteria for age, weight, and BMI. Across the dose groups, the
mean (SD) participant age was 49.56 (15.01) yrs, the mean (SD) weight was 76.77 (11.15) kg, and
the mean (SD) participant BMI was 25.40 (2.38) kg/m2. Of these participants, 44 (46%) were male
and 52 (54%) were female, 96 (100%) participants were White, and 96 (100%) participants were
not of Hispanic or Latino origin.
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046673
Page 5
Page 6 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
Participant disposition
Disposition of younger participants – BNT162b1
AE = adverse; EoT Visit (Visit 7) completed = end of treatment visit completed (as recorded in the database at the 23 OCT 2020 data
cut-off date); N = number of participants; SAF = safety set; SAFB = safety boost set; Dose 2 + 28 d assessed (CB28) = Dose 2 + 28 d
completer set.
Source: Based on data from Table 14.1-2-1, Table 14.1-3.1-1, and Listing 16.2.1-1-1.
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046674
Page 6
Page 7 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
Disposition of older participants – BNT162b1
AE = adverse; EoT Visit (Visit 7) completed = end of treatment visit completed (as recorded in the database at the 23 OCT 2020 data
cut-off date); N = number of participants; SAF = safety set; SAFB = safety boost set; Dose 2 + 28 d assessed (CB28) = Dose 2 + 28 d
completer set.
Source: Based on data from Table 14.1-2-1, Table 14.1-3.1-1, and Listing 16.2.3.1-1-1.
Disposition of younger participants – BNT162b2
AE = adverse; EoT Visit (Visit 7) completed = end of treatment visit completed (as recorded in the database at the 23 OCT 2020 data
cut-off date); N = number of participants; SAF = safety set; SAFB = safety boost set; Dose 2 + 28 d assessed (CB28) = Dose 2 + 28 d
completer set.
Source: Based on data from Table 14.1-2-3, Table 14.1-3.1-3, and Listing 16.2.1-1-3.
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046675
Page 7
Page 8 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
Disposition of older participants – BNT162b2
EoT Visit (Visit 7) completed = end of treatment visit completed (as recorded in the database at the 23 OCT 2020 data cut-off date); N =
number of participants; SAF = safety set; SAFB = safety boost set; Dose 2 + 28 d assessed (CB28) = Dose 2 + 28 d completer set.
Source: Based on data from Table 14.1-2-3, Table 14.1-3.1-3, and Listing 16.2.1-1-3.
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046676
Page 8
FDA-CBER-2021-5683-0046677
FDA-CBER-2021-5683-0046678
FDA-CBER-2021-5683-0046679
FDA-CBER-2021-5683-0046680
FDA-CBER-2021-5683-0046681
Page 14 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
 For nausea, headache, fatigue, myalgia, chills, arthralgia and malaise each symptom was
assessed as severe in <10% of participants.
 A possible dose dependency for both severe fatigue and arthralgia was seen with
0 participants at 10 µg vs. 2 participants at 30 µg, and 0 participants at 10 µg vs.
3 participants at 30 µg, respectively.
 Similarly, no clear pattern of dose dependency was seen across the symptom terms for mild
reactions or moderate reactions, with the exception of moderate intensity malaise which was
reported for 1 participant receiving 10 µg and 6 participants with 30 µg dose.
 For the 30 µg dose selected for further development, there were consistently slightly higher
rates of reporting systemic reactions than for the next lowest 20 µg level for every individual
symptom term except headache, diarrhoea, fatigue, and fever. The difference is pronounced
for malaise 33% (20 µg) vs. 58% (30 µg) and arthralgia 17% (20 µg) vs. 50% (30 µg).
 No major differences were noted between the pattern seen for the combined time intervals
and the individual reporting period.
Older participants and all (younger and older) participants
Overall, in the combined time interval after both doses, the majority of the older participants
experienced mild (n=25, 69%) followed by moderate (n=13, 36%) solicited systemic reactions. A
few participants experienced severe (n=4, 11%) solicited systemic reactions.
 Severe grade systemic reactions were reported in 30 µg (2 participants [17%]) and 10 µg
(2 participants [17%]) dose groups.
 The most frequently reported solicited systemic reactions of any severity were fatigue (n=20,
56%), followed by headache (n=17, 47%), malaise (n=12, 33%), and myalgia (n=12, 33%).
The remaining symptom terms were less frequent.
 Most symptom terms reported were predominantly at mild intensity with a ratio of mild to
moderate reports of between 3:1 and 2:1.
 Only mild reactions were reported for diarrhoea and fever.
 All symptoms were assessed as severe in <10% of participants.
 For the 30 µg dose selected for further development, there were consistently slightly higher
rates of reporting systemic reactions than for the next lowest 20 µg level for every individual
symptom term. The difference is pronounced for moderate malaise 8% (20 µg) vs. 50%
(30 µg).
 No major differences were noted between the pattern seen for the combined time intervals
and the individual reporting period.
Note: For BNT162b1, a summary of TEAEs without AEs based on solicited reporting via diaries is
given using Safety Dose 2 set (SAFB), because the decision was made not to give the second
60 µg dose (Dose 2).
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046682
Page 14
FDA-CBER-2021-5683-0046683
FDA-CBER-2021-5683-0046684
Page 17 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
the 60 µg dose group, which was only dosed once, neutralizing GMTs remained at a lower level,
indicating that a booster dose is necessary to increase functional antibody titers.
On Day 43 (21 d after Dose 2 BNT162b1), neutralizing GMTs decreased (with exception of the
1 µg dose level). Day 43 neutralizing GMTs were 0.7-fold (1 µg) to 3.6-fold (50 µg) those of a
COVID-19 human convalescent serum (HCS) panel.
Participants dosed with BNT162b2 showed a strong IMP-induced antibody response. Virus
neutralizing GMTs were detected after Dose 1 and showed a substantial booster response by 7 d
after Dose 2 (Day 29) for dose level groups ≥3 µg. Day 29 neutralizing GMTs were comparable
between the younger and older participants in the 20 µg dose groups.
On Day 43 (21 d after the second dose of BNT162b2), virus neutralizing GMTs in the younger
adult dose groups decreased for the 3, 20, and 30 µg dose levels. Thereafter, neutralizing GMTs
remained stable up to Day 85 (63 d after the boost) for younger participant dose groups 10, 20,
and 30 µg, and were 1.3-fold to 1.9-fold those of a COVID-19 HCS panel.
All participants dosed with Dose 1 at ≥30 µg BNT162b1 or BNT162b2 seroconverted either by 7 d
or 21 d after Dose 2 (Days 29 or 43). All participants immunized with 30 µg BNT162b2 remained
seropositive throughout the follow-up until Day 85.
Exploratory endpoints – Binding antibody concentrations
Binding antibody concentration data is available up until Day 43 for BNT162b1-dosed younger
participants aged 18 to 55 yrs dosed with 1, 10, 30, 50, and 60 µg on Day 1 (all dose levels) and
Day 22 (all dose levels except 60 µg) (n=12 per group).
For BNT162b2-dosed participants, data is available for younger participants aged 18 to 55 yrs
dosed with 1, 3, 10, 20, and 30 µg, and older adults aged 56 to 85 yrs dosed with 20 µg on Days 1
and 22 (n=12 per group). Binding antibody data for younger adult participants is available up until
Day 50 for the 1 µg and 3 µg dose groups, and up until Day 85 for the 10, 20, and 30 µg dose
groups. For the BNT162b2-dosed older participants, data is available up until Day 29.
Participants dosed with BNT162b1 showed a strong dose-dependent antibody response against
the SARS-CoV-2 spike (S) protein S1 subunit and receptor binding domain (RBD) at 21 d after
Dose 1 (Day 22). At 7 d after Dose 2 (Day 29), S1- and RBD-binding immunoglobulin (IgG) GMCs
showed a strong, dose-dependent booster response. In the 60 µg dose group, which was only
dosed once, S1- and RBD-binding IgG GMCs remained at a lower level, indicating that a booster
dose is necessary to increase antibody concentrations.
At 21 d after the second BNT162b1 dose (Day 43), S1- and RBD-binding IgG GMCs decreased
(with exception of the 1 µg dose group), but were clearly above those of a COVID-19 HCS panel
for all dose levels tested.
BNT162b2 dosed participants showed a strong BNT162b2-induced S1- and RBD-binding IgG
response at 21 d after Dose 1 (Day 22) with evidence of a dose-dependent response only between
the 1 µg and 10 µg dose levels. S1- and RBD-binding IgG GMCs showed a substantial booster
response by 7 d after Dose 2 (Day 29). Day 29 S1- and RBD-binding IgG GMCs were comparable
between the younger and older adult 20 µg dose groups. Across all dose groups, antibody levels
decreased over time, but with S1- and RBD-binding antibody GMCs well above that observed in a
COVID 19 HCS panel at Day 85 (63 d after Dose 2; 10 µg to 30 µg dose level).
Independent of age, all participants dosed with Dose 1 at ≥20 µg BNT162b1 and or BNT162b2
seroconverted either by 7 d or 21 d after Dose 2 (Day 29 or Day 43).
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046685
Page 17
Page 18 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
Exploratory endpoints – SARS-CoV-2-specific CD4+ and CD8+ T-cell responses
As of 02 MAR 2021, evaluable CD4+ and CD8+ T-cell response data were available from 97 study
participants that received BNT162b1, 70 younger participants at dose levels of 1, 3, 10, 20, 30, 50,
or 60 µg (note: Dose 2 was not given in the 60 µg dose group), and 27 older participants at dose
levels of 10, 20, or 30 µg, as well as 76 participants that received BNT162b2 at dose levels of 1, 3,
10, 20, or 30 µg (47 younger participants), or 10, 20, or 30 µg (29 older participants).
To assess the persistence of cell-mediated immune responses, as of 02 MAR 2021, evaluable
CD4+/CD8+ T-cell response data at Days 85 and 184 (i.e., 9 and 23 wks post-Dose 2, respectively)
are also available for 24 study participants that received BNT162b2 (20 younger participants at
dose levels of 10, 20, or 30 µg, and 4 older participants at dose levels of 10, 20, or 30 µg).
The following results are based on assessment of T cell data collected on Day 1 (before Dose 1),
Day 29, Day 85, and Day 184 (i.e., 1, 9, and 23 wks post-Dose 2, respectively).
In both younger and older participants, two doses of BNT162b1 and BNT162b2 induced strong
SARS-CoV-2 RBD-specific and S protein-specific T-cell responses. RBD- and S protein-specific
CD4+ T-cell responses were induced by BNT162b1 in 97.5% of participants and by BNT162b2 in
100% of participants. RBD- and S protein-specific CD8+ T-cell responses were induced by
BNT162b1 in 95.5% of participants and by BNT162b2 in 96.6% of participants.
The T-cell responses elicited by BNT162b2 were directed against additional epitopes of the
S antigen outside RBD, indicating the induction of multi-epitopic responses by BNT162b2 in both
age groups. The magnitude of the T-cell responses did not show clear dose dependency.
Dosing twice with BNT162b1 or BNT162b2 led to a substantial increase in incidence and
magnitude of T-cell responses in both age groups, and across all dose levels for BNT162b1. While
the magnitude of CD4+ T-cell responses induced by BNT162b2 was also similar across different
dose levels, the magnitude of CD8+ T-cell responses was highest at the 30 µg dose level. The
participants with the strongest CD4+ T-cell responses had more than 10-fold of the memory
responses observed in the same participants against immunodominant peptides from
cytomegalovirus, Epstein-Barr virus, influenza virus, and tetanus toxoid. The same participants
also had strong CD8+ T-cell responses that were comparable to memory responses against the
above mentioned viral antigens.
BNT162b2-induced CD4+ and CD8+ T-cell responses showed a decrease on Day 85, but remained
detectable on Day 184 in almost all participants vaccinated with >10 µg at levels higher than or in
range of recall antigen memory responses.
Exploratory endpoints – Functional and pro-inflammatory CD4+/CD8+ T-cell responses
As of 17 NOV 2020 (BNT162b1) and 02 MAR 2021 (BNT162b2), evaluable functional and pro-
inflammatory CD4+/CD8+ T-cell response data at baseline (before Dose 1) and at Day 29 (28 d
post-Dose 1) are available for 95 study participants that received BNT162b1 (68 younger
participants at dose levels of 1, 3, 10, 20, 30, 50, or 60 µg, and 27 older participants at dose levels
of 10, 20, or 30 µg), as well as for 79 study participants that received BNT162b2 (50 younger
participants at dose levels of 1, 3, 10, 20, or 30 µg, and 29 older participants at dose levels of 10,
20, or 30 µg).
To assess the persistence of cell-mediated immune responses, as of 02 MAR 2021, evaluable
functional and pro-inflammatory CD4+/CD8+ T-cell response data at Days 43, 85, and 184 (i.e., 3,
9, and 23 wks post-Dose 2, respectively) are also available for 41 study participants that received
BNT162b2 (23 younger participants at dose levels of 10, 20, or 30 µg, and 18 older participants at
dose levels of 10, 20, or 30 µg).
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046686
Page 18
Page 19 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
De novo induction of SARS-CoV-2 S protein or RBD protein directed T cells was confirmed using
ICS. IFN-producing CD4+ and CD8+ T cells against SARS-CoV-2 S protein or RBD were induced
robustly by both BNT162b1 and BNT162b2. No clear dose dependency was observed for both
IMPs. The cytokine responses elicited after dosing with either BNT162b1 or BNT162b2 in older
participants was mostly identical in response pattern and intensity with that in younger participants.
BNT162b1 and BNT162b2 induced poly-functional and pro-inflammatory CD4+/CD8+ T-cell
responses in almost all participants. The detection of interferon (IFN), interleukin (IL)-2 but not
IL-4 indicates a favorable Th1 profile and the absence of a potentially deleterious Th2 immune
response. No notable age-related differences were observed.
BNT162b2 induced poly-functional and pro-inflammatory CD4+/CD8+ T-cell responses in almost all
participants persisting in the majority of participants for up to 6 months after Dose 1. The Th1
polarization of the helper T-cell response was characterized by a robust IFN/IL-2 and only minor
IL-4 production upon antigen-specific (wild-type SARS-CoV-2 S protein peptide pools) re-
stimulation which was still observed, although with a reduced magnitude, at later time points.
Conclusions
 The majority of events reported were reactogenicity symptoms compared to TEAEs which
were anticipated for IM-administered vaccines. The observed reactogenicity was mild or
moderate in severity. The results of this study show that BNT162b1 and BNT162b2 are well
tolerated and have an acceptable safety profile in younger participants aged 18 to 55 yrs and
older participants aged 56 to 85 yrs.
 The frequency of local and systemic reactogenicity was generally lower for BNT162b2
compared to BNT162b1. BNT162b2 generally had a milder and therefore more favorable
reactogenicity profile than BNT162b1 across dose levels.
 Participants dosed with BNT162b1 (1 to 50 µg) showed a strong, IMP- and dose-dependent
antibody response in a SARS-CoV-2 neutralization assay by Day 22 (at 21 d after Dose 1).
This response increased further by Day 29 (at 7 d after Dose 2), and the second dose elicited
a booster effect. By Day 43 (21 d after Dose 2), the observed responses decreased for most
dose levels. For participants dosed at ≥10 µg BNT162b1, Day 43 neutralizing GMTs were
comparable or even superior to those of a COVID-19 HCS panel.
 Independent of age, participants dosed with BNT162b2 (1 to 30 µg) showed strong IMP-
induced antibody responses. Virus neutralizing GMTs were detected after Dose 1 and
showed a substantial booster response by 7 d after Dose 2 (Day 29) for dose level groups
≥3 µg. On Day 43, neutralizing GMTs in the younger participant dose groups decreased for
the 3, 20, and 30 µg dose levels. Thereafter, GMTs remained stable up to Day 85 (63 d after
Dose 2) for younger adult dose groups 10, 20, and 30 µg BNT162b2 and were comparable or
even superior to those of a COVID-19 HCS panel.
 After dosing with ≥30 µg BNT162b1 and BNT162b2, all participants showed GMC- and GMT-
based seroconversion by either 7 d or 21 d after Dose 2 (Day 29 or Day 43). All participants
dosed with 30 µg BNT162b2 remained seropositive throughout the follow-up until Day 85.
 The observed kinetics of the BNT162b1 and BNT162b2 induced neutralizing antibody
response is typical of antigen-activated B cells going through over proliferation, followed by
rebound contraction with a gradual decline in numbers before stabilization of the immune
response.
 In both younger and older participants, two doses of BNT162b1 and BNT162b2 induced
strong SARS-CoV-2 RBD-specific and S protein-specific T-cell responses. RBD- and
S protein-specific CD4+ T-cell responses were induced by BNT162b1 in 97.5% of participants
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046687
Page 19
Page 20 of 20
BioNTech SE Interim Clinical Study Report - BNT162-01
Version: 3.0
Confidential Synopsis
Date: 20 MAR 2021
and by BNT162b2 in 100% of participants. RBD- and S protein-specific CD8+ T-cell
responses were induced by BNT162b1 in 95.5% of participants and by BNT162b2 in 96.6%
of participants. The magnitude of the T-cell responses did not show clear dose dependency.
 BNT162b2-induced CD4+ and CD8+ T-cell responses showed a decrease on Day 85, but
remained detectable on Day 184 in almost all participants vaccinated with >10 µg at levels
higher than or in range of recall antigen memory responses.
 BNT162b1 and BNT162b2 induced poly-functional and pro-inflammatory CD4+/CD8+ T-cell
responses in almost all participants. The detection of IFN and IL-2, but no or only minor IL-4
production, indicates a favorable Th1 profile. No notable age-related differences were
observed.
 For the majority of participants, the strong S-specific IFN+ and IL-2+CD8+ and Th1 CD4+
T-cell responses contracted by Day 43 (21 d post-Dose 2) and plateaued at a lower level
towards Day 85 (63 d post-Dose 2). This observation held true for all dose groups analyzed
with varying response magnitudes between individuals. For the younger participants, the cell-
mediated immune responses remained detectable until Day 184 (162 d post-Dose 2).
 The favorable tolerability profile was the major driver for choosing BNT162b2 for further study
in the Phase II/III evaluation of efficacy.
)TMG(
23:60
1202-raM-32
:nO
devorppA\devorppA\b5c079691e771090
FDA-CBER-2021-5683-0046688
Page 20","[[['\uf0b7 For nausea, headache, fatigue, myalgia, chills, arthralgia and malaise each symptom was'], ['assessed as severe in <10% of participants.'], ['\uf0b7 A possible dose dependency for both severe fatigue and arthralgia was seen with'], ['0 participants at 10 µg vs. 2 participants at 30 µg, and 0 participants at 10 µg vs.'], ['3 participants at 30 µg, respectively.'], ['\uf0b7 Similarly, no clear pattern of dose dependency was seen across the symptom terms for mild'], ['reactions or moderate reactions, with the exception of moderate intensity malaise which was'], ['reported for 1 participant receiving 10 µg and 6 participants with 30 µg dose.'], ['\uf0b7 For the 30 µg dose selected for further development, there were consistently slightly higher'], ['rates of reporting systemic reactions than for the next lowest 20 µg level for every individual'], ['symptom term except headache, diarrhoea, fatigue, and fever. The difference is pronounced'], ['for malaise 33% (20 µg) vs. 58% (30 µg) and arthralgia 17% (20 µg) vs. 50% (30 µg).'], ['\uf0b7 No major differences were noted between the pattern seen for the combined time intervals'], ['and the individual reporting period.']], [['Overall, in the combined time interval after both doses, the majority of the older participants'], ['experienced mild (n=25, 69%) followed by moderate (n=13, 36%) solicited systemic reactions. A'], ['few participants experienced severe (n=4, 11%) solicited systemic reactions.']], [[None, '\uf0b7 Severe grade systemic reactions were reported in 30 µg (2 participants [17%]) and 10 µg'], [None, '(2 participants [17%]) dose groups.'], [None, '\uf0b7 The most frequently reported solicited systemic reactions of any severity were fatigue (n=20,'], [None, '56%), followed by headache (n=17, 47%), malaise (n=12, 33%), and myalgia (n=12, 33%).'], [None, 'The remaining symptom terms were less frequent.'], [None, '\uf0b7 Most symptom terms reported were predominantly at mild intensity with a ratio of mild to'], [None, 'moderate reports of between 3:1 and 2:1.'], [None, '\uf0b7 Only mild reactions were reported for diarrhoea and fever.'], [None, '\uf0b7 All symptoms were assessed as severe in <10% of participants.'], [None, '\uf0b7 For the 30 µg dose selected for further development, there were consistently slightly higher'], [None, 'rates of reporting systemic reactions than for the next lowest 20 µg level for every individual'], [None, 'symptom term. The difference is pronounced for moderate malaise 8% (20 µg) vs. 50%'], [None, '(30 µg).'], [None, '\uf0b7 No major differences were noted between the pattern seen for the combined time intervals'], [None, 'and the individual reporting period.'], [None, ''], ['Note: For BNT162b1, a summary of TEAEs without AEs based on solicited reporting via diaries is', None], ['given using Safety Dose 2 set (SAFB), because the decision was made not to give the second', None], ['60 µg dose (Dose 2).', None]], [['the 60 µg dose group, which was only dosed once, neutralizing GMTs remained at a lower level,'], ['indicating that a booster dose is necessary to increase functional antibody titers.'], ['On Day 43 (21 d after Dose 2 BNT162b1), neutralizing GMTs decreased (with exception of the'], ['1 µg dose level). Day 43 neutralizing GMTs were 0.7-fold (1 µg) to 3.6-fold (50 µg) those of a'], ['COVID-19 human convalescent serum (HCS) panel.'], ['Participants dosed with BNT162b2 showed a strong IMP-induced antibody response. Virus'], ['neutralizing GMTs were detected after Dose 1 and showed a substantial booster response by 7 d'], ['after Dose 2 (Day 29) for dose level groups ≥3 µg. Day 29 neutralizing GMTs were comparable'], ['between the younger and older participants in the 20 µg dose groups.'], ['On Day 43 (21 d after the second dose of BNT162b2), virus neutralizing GMTs in the younger'], ['adult dose groups decreased for the 3, 20, and 30 µg dose levels. Thereafter, neutralizing GMTs'], ['remained stable up to Day 85 (63 d after the boost) for younger participant dose groups 10, 20,'], ['and 30 µg, and were 1.3-fold to 1.9-fold those of a COVID-19 HCS panel.'], ['All participants dosed with Dose 1 at ≥30 µg BNT162b1 or BNT162b2 seroconverted either by 7 d'], ['or 21 d after Dose 2 (Days 29 or 43). All participants immunized with 30 µg BNT162b2 remained'], ['seropositive throughout the follow-up until Day 85.'], ['Exploratory endpoints – Binding antibody concentrations'], ['Binding antibody concentration data is available up until Day 43 for BNT162b1-dosed younger'], ['participants aged 18 to 55 yrs dosed with 1, 10, 30, 50, and 60 µg on Day 1 (all dose levels) and'], ['Day 22 (all dose levels except 60 µg) (n=12 per group).'], ['For BNT162b2-dosed participants, data is available for younger participants aged 18 to 55 yrs'], ['dosed with 1, 3, 10, 20, and 30 µg, and older adults aged 56 to 85 yrs dosed with 20 µg on Days 1'], ['and 22 (n=12 per group). Binding antibody data for younger adult participants is available up until'], ['Day 50 for the 1 µg and 3 µg dose groups, and up until Day 85 for the 10, 20, and 30 µg dose'], ['groups. For the BNT162b2-dosed older participants, data is available up until Day 29.'], ['Participants dosed with BNT162b1 showed a strong dose-dependent antibody response against'], ['the SARS-CoV-2 spike (S) protein S1 subunit and receptor binding domain (RBD) at 21 d after'], ['Dose 1 (Day 22). At 7 d after Dose 2 (Day 29), S1- and RBD-binding immunoglobulin (IgG) GMCs'], ['showed a strong, dose-dependent booster response. In the 60 µg dose group, which was only'], ['dosed once, S1- and RBD-binding IgG GMCs remained at a lower level, indicating that a booster'], ['dose is necessary to increase antibody concentrations.'], ['At 21 d after the second BNT162b1 dose (Day 43), S1- and RBD-binding IgG GMCs decreased'], ['(with exception of the 1 µg dose group), but were clearly above those of a COVID-19 HCS panel'], ['for all dose levels tested.'], ['BNT162b2 dosed participants showed a strong BNT162b2-induced S1- and RBD-binding IgG'], ['response at 21 d after Dose 1 (Day 22) with evidence of a dose-dependent response only between'], ['the 1 µg and 10 µg dose levels. S1- and RBD-binding IgG GMCs showed a substantial booster'], ['response by 7 d after Dose 2 (Day 29). Day 29 S1- and RBD-binding IgG GMCs were comparable'], ['between the younger and older adult 20 µg dose groups. Across all dose groups, antibody levels'], ['decreased over time, but with S1- and RBD-binding antibody GMCs well above that observed in a'], ['COVID 19 HCS panel at Day 85 (63 d after Dose 2; 10 µg to 30 µg dose level).'], ['Independent of age, all participants dosed with Dose 1 at ≥20 µg BNT162b1 and or BNT162b2'], ['seroconverted either by 7 d or 21 d after Dose 2 (Day 29 or Day 43).']], [['Exploratory endpoints – SARS-CoV-2-specific CD4+ and CD8+ T-cell responses'], ['As of 02 MAR 2021, evaluable CD4+ and CD8+ T-cell response data were available from 97 study'], ['participants that received BNT162b1, 70 younger participants at dose levels of 1, 3, 10, 20, 30, 50,'], ['or 60 µg (note: Dose 2 was not given in the 60 µg dose group), and 27 older participants at dose'], ['levels of 10, 20, or 30 µg, as well as 76 participants that received BNT162b2 at dose levels of 1, 3,'], ['10, 20, or 30 µg (47 younger participants), or 10, 20, or 30 µg (29 older participants).'], ['To assess the persistence of cell-mediated immune responses, as of 02 MAR 2021, evaluable'], ['CD4+/CD8+ T-cell response data at Days 85 and 184 (i.e., 9 and 23 wks post-Dose 2, respectively)'], ['are also available for 24 study participants that received BNT162b2 (20 younger participants at'], ['dose levels of 10, 20, or 30 µg, and 4 older participants at dose levels of 10, 20, or 30 µg).'], ['The following results are based on assessment of T cell data collected on Day 1 (before Dose 1),'], ['Day 29, Day 85, and Day 184 (i.e., 1, 9, and 23 wks post-Dose 2, respectively).'], ['In both younger and older participants, two doses of BNT162b1 and BNT162b2 induced strong'], ['SARS-CoV-2 RBD-specific and S protein-specific T-cell responses. RBD- and S protein-specific'], ['CD4+ T-cell responses were induced by BNT162b1 in 97.5% of participants and by BNT162b2 in'], ['100% of participants. RBD- and S protein-specific CD8+ T-cell responses were induced by'], ['BNT162b1 in 95.5% of participants and by BNT162b2 in 96.6% of participants.'], ['The T-cell responses elicited by BNT162b2 were directed against additional epitopes of the'], ['S antigen outside RBD, indicating the induction of multi-epitopic responses by BNT162b2 in both'], ['age groups. The magnitude of the T-cell responses did not show clear dose dependency.'], ['Dosing twice with BNT162b1 or BNT162b2 led to a substantial increase in incidence and'], ['magnitude of T-cell responses in both age groups, and across all dose levels for BNT162b1. While'], ['the magnitude of CD4+ T-cell responses induced by BNT162b2 was also similar across different'], ['dose levels, the magnitude of CD8+ T-cell responses was highest at the 30 µg dose level. The'], ['participants with the strongest CD4+ T-cell responses had more than 10-fold of the memory'], ['responses observed in the same participants against immunodominant peptides from'], ['cytomegalovirus, Epstein-Barr virus, influenza virus, and tetanus toxoid. The same participants'], ['also had strong CD8+ T-cell responses that were comparable to memory responses against the'], ['above mentioned viral antigens.'], ['BNT162b2-induced CD4+ and CD8+ T-cell responses showed a decrease on Day 85, but remained'], ['detectable on Day 184 in almost all participants vaccinated with >10 µg at levels higher than or in'], ['range of recall antigen memory responses.'], ['Exploratory endpoints – Functional and pro-inflammatory CD4+/CD8+ T-cell responses'], ['As of 17 NOV 2020 (BNT162b1) and 02 MAR 2021 (BNT162b2), evaluable functional and pro-'], ['inflammatory CD4+/CD8+ T-cell response data at baseline (before Dose 1) and at Day 29 (28 d'], ['post-Dose 1) are available for 95 study participants that received BNT162b1 (68 younger'], ['participants at dose levels of 1, 3, 10, 20, 30, 50, or 60 µg, and 27 older participants at dose levels'], ['of 10, 20, or 30 µg), as well as for 79 study participants that received BNT162b2 (50 younger'], ['participants at dose levels of 1, 3, 10, 20, or 30 µg, and 29 older participants at dose levels of 10,'], ['20, or 30 µg).'], ['To assess the persistence of cell-mediated immune responses, as of 02 MAR 2021, evaluable'], ['functional and pro-inflammatory CD4+/CD8+ T-cell response data at Days 43, 85, and 184 (i.e., 3,'], ['9, and 23 wks post-Dose 2, respectively) are also available for 41 study participants that received'], ['BNT162b2 (23 younger participants at dose levels of 10, 20, or 30 µg, and 18 older participants at'], ['dose levels of 10, 20, or 30 µg).']], [['De novo induction of SARS-CoV-2 S protein or RBD protein directed T cells was confirmed using'], ['ICS. IFN\uf067-producing CD4+ and CD8+ T cells against SARS-CoV-2 S protein or RBD were induced'], ['robustly by both BNT162b1 and BNT162b2. No clear dose dependency was observed for both'], ['IMPs. The cytokine responses elicited after dosing with either BNT162b1 or BNT162b2 in older'], ['participants was mostly identical in response pattern and intensity with that in younger participants.'], ['BNT162b1 and BNT162b2 induced poly-functional and pro-inflammatory CD4+/CD8+ T-cell'], ['responses in almost all participants. The detection of interferon (IFN)\uf067, interleukin (IL)-2 but not'], ['IL-4 indicates a favorable Th1 profile and the absence of a potentially deleterious Th2 immune'], ['response. No notable age-related differences were observed.'], ['BNT162b2 induced poly-functional and pro-inflammatory CD4+/CD8+ T-cell responses in almost all'], ['participants persisting in the majority of participants for up to 6 months after Dose 1. The Th1'], ['polarization of the helper T-cell response was characterized by a robust IFN\uf067/IL-2 and only minor'], ['IL-4 production upon antigen-specific (wild-type SARS-CoV-2 S protein peptide pools) re-'], ['stimulation which was still observed, although with a reduced magnitude, at later time points.'], ['Conclusions']], [['\uf0b7 The majority of events reported were reactogenicity symptoms compared to TEAEs which'], ['were anticipated for IM-administered vaccines. The observed reactogenicity was mild or'], ['moderate in severity. The results of this study show that BNT162b1 and BNT162b2 are well'], ['tolerated and have an acceptable safety profile in younger participants aged 18 to 55 yrs and'], ['older participants aged 56 to 85 yrs.'], ['\uf0b7 The frequency of local and systemic reactogenicity was generally lower for BNT162b2'], ['compared to BNT162b1. BNT162b2 generally had a milder and therefore more favorable'], ['reactogenicity profile than BNT162b1 across dose levels.'], ['\uf0b7 Participants dosed with BNT162b1 (1 to 50 µg) showed a strong, IMP- and dose-dependent'], ['antibody response in a SARS-CoV-2 neutralization assay by Day 22 (at 21 d after Dose 1).'], ['This response increased further by Day 29 (at 7 d after Dose 2), and the second dose elicited'], ['a booster effect. By Day 43 (21 d after Dose 2), the observed responses decreased for most'], ['dose levels. For participants dosed at ≥10 µg BNT162b1, Day 43 neutralizing GMTs were'], ['comparable or even superior to those of a COVID-19 HCS panel.'], ['\uf0b7 Independent of age, participants dosed with BNT162b2 (1 to 30 µg) showed strong IMP-'], ['induced antibody responses. Virus neutralizing GMTs were detected after Dose 1 and'], ['showed a substantial booster response by 7 d after Dose 2 (Day 29) for dose level groups'], ['≥3 µg. On Day 43, neutralizing GMTs in the younger participant dose groups decreased for'], ['the 3, 20, and 30 µg dose levels. Thereafter, GMTs remained stable up to Day 85 (63 d after'], ['Dose 2) for younger adult dose groups 10, 20, and 30 µg BNT162b2 and were comparable or'], ['even superior to those of a COVID-19 HCS panel.'], ['\uf0b7 After dosing with ≥30 µg BNT162b1 and BNT162b2, all participants showed GMC- and GMT-'], ['based seroconversion by either 7 d or 21 d after Dose 2 (Day 29 or Day 43). All participants'], ['dosed with 30 µg BNT162b2 remained seropositive throughout the follow-up until Day 85.'], ['\uf0b7 The observed kinetics of the BNT162b1 and BNT162b2 induced neutralizing antibody'], ['response is typical of antigen-activated B cells going through over proliferation, followed by'], ['rebound contraction with a gradual decline in numbers before stabilization of the immune'], ['response.'], ['\uf0b7 In both younger and older participants, two doses of BNT162b1 and BNT162b2 induced'], ['strong SARS-CoV-2 RBD-specific and S protein-specific T-cell responses. RBD- and'], ['S protein-specific CD4+ T-cell responses were induced by BNT162b1 in 97.5% of participants']], [['and by BNT162b2 in 100% of participants. RBD- and S protein-specific CD8+ T-cell'], ['responses were induced by BNT162b1 in 95.5% of participants and by BNT162b2 in 96.6%'], ['of participants. The magnitude of the T-cell responses did not show clear dose dependency.'], ['\uf0b7 BNT162b2-induced CD4+ and CD8+ T-cell responses showed a decrease on Day 85, but'], ['remained detectable on Day 184 in almost all participants vaccinated with >10 µg at levels'], ['higher than or in range of recall antigen memory responses.'], ['\uf0b7 BNT162b1 and BNT162b2 induced poly-functional and pro-inflammatory CD4+/CD8+ T-cell'], ['responses in almost all participants. The detection of IFN\uf067 and IL-2, but no or only minor IL-4'], ['production, indicates a favorable Th1 profile. No notable age-related differences were'], ['observed.'], ['\uf0b7 For the majority of participants, the strong S-specific IFN\uf067+ and IL-2+CD8+ and Th1 CD4+'], ['T-cell responses contracted by Day 43 (21 d post-Dose 2) and plateaued at a lower level'], ['towards Day 85 (63 d post-Dose 2). This observation held true for all dose groups analyzed'], ['with varying response magnitudes between individuals. For the younger participants, the cell-'], ['mediated immune responses remained detectable until Day 184 (162 d post-Dose 2).'], ['\uf0b7 The favorable tolerability profile was the major driver for choosing BNT162b2 for further study'], ['in the Phase II/III evaluation of efficacy.']]]",20
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-sponsor-personnel-list.pdf,1.0,"BioNTech RNA Page 1 of 1
Interim Clinical Study Report
Pharmaceuticals GmbH Version: 2.0
BNT162-01
Confidential Date: 26 Nov 2020
16.1.13 List of sponsor personnel who materially affected the trial conduct
The following table presents a list of sponsor personnel who materially affected the trial conduct. The full list of all involved sponsor
personnel is maintained in the trial master file (TMF).
Name Role
Özlem Türeci, MD Chief Medical Officer (Sponsor’s medically qualified person) b
Svetlana Shpyro, MD Medical Expert
Dr. Stefan Liebscher Biostatistician (External BioNTech Consultant)
Sean Murphy Biostatistician (External BioNTech Consultant)
Dr. Christopher Marshallsay Head Scientific-Medical Writing a
Dr. Frans van Huizen Senior Scientific / Medical Writer
Dr. David Langer Clinical Study Manager
Dr. Stefanie Bolte Clinical Study Manager
Martin Bexon, MD Medical Monitor (External BioNTech Consultant)
Amélie Caneparo Pharmacovigilance Manager
Claudia Müller Clinical Data Manager (External BioNTech Consultant)
Dr. Tania Palanche Senior Clinical Data Manager
a) Document owner fulfills the requirements of the author according to ICH E3.
b) Corresponds to the medical officer defined in ICH E3.
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\26573a591e771090
FDA-CBER-2021-5683-0049413
Page 1",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-investigators.pdf,13.0,"BioNTech RNA Page 1 of 1
Interim Clinical Study Report
Pharmaceuticals GmbH Version: NA
BNT162-01
Confidential Date: 02 Sep 2020
16.1.4.1 List of investigators
Site number Investigator Site type Site address Site status Deputy investigator(s) at the site
276-01 (Coordinating investigator & Clinical CRO CRS Clinical Research Services Open Dr. med. Friedeborg Seitz
Principal investigator site Mannheim GmbH
Mannheim) Grenadier Str. 1
Dr. Dr. med. Armin Schultz 68167 Mannheim
Germany
276-02 (Principal investigator Berlin) Clinical CRO CRS Clinical Research Services Open Dr. med. Matthias Berse,
Dr. med. Sybille Baumann site Berlin GmbH Manuela Casjens MD
Seller Str. 31
13353 Berlin
Germany
CRO = contract research organization.
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\2fb63f491e771090
FDA-CBER-2021-5683-0049318
Page 1
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\ceb63f491e771090
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049319
Page 2
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\ceb63f491e771090
FDA-CBER-2021-5683-0049320
Page 3
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\ceb63f491e771090
FDA-CBER-2021-5683-0049321
Page 4
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\deb63f491e771090
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049322
Page 5
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\deb63f491e771090
FDA-CBER-2021-5683-0049323
Page 6
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\eeb63f491e771090
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049324
Page 7
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\eeb63f491e771090
FDA-CBER-2021-5683-0049325
Page 8
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\feb63f491e771090
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049326
Page 9
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\feb63f491e771090
FDA-CBER-2021-5683-0049327
Page 10
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\0fb63f491e771090
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0049328
Page 11
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\0fb63f491e771090
FDA-CBER-2021-5683-0049329
Page 12
BioNTech RNA Page 1 of 1
Interim Clinical Study Report
Pharmaceuticals GmbH Version: 2.0
BNT162-01
Confidential Date: 26 Nov 2020
16.1.4.3 List of providers
Services provided Name and address (including country)
Bexon Cinical Consulting, LLC, P.O. Box 3143,
Medical monitoring
Memorial Station, Upper Montclair, NJ 07043, USA
CRS Clinical Research Services Andernach GmbH
Trial conduct
Rennweg 72, 56626 Andernach, Germany (no site, only main office)
Origio Clinical Monitoring GmbH
Clinical Monitoring
An den Deichwiesen 21a, Hannover, 30659 Germany
MLM Medical Labs GmbH
Central laboratory analyses
Dohrweg 63, D-41066 Moenchengladbach, Germany
Statistics Staburo GmbH, Aschauer Str. 26b, 81549 München, Germany
SCRATCH Pharmacovigilance GmbH & Co. KG
Pharmacovigilance consultancy activities
Schlossstrasse 25, D-35510 Butzbach, Germany
PHARMSOFT Dr. B. Rodust GmbH
PV consultant activities
Königswall 22, 44137 Dortmund, Germany
Precision for Medicine / Epiontis GmbH
Sample processing
Barbara-McClintock- Str. 6, 12489 Berlin, Germany
Specialty analysis VisMederi, Strada del Petriccio e Belriguardo, 35, 53100 Siena, Italy
Pfizer Vaccine Research & Development
Specialty analysis
401 North Middletown Road, Pearl River, NY 10965, USA
Regeneron Pharmaceuticals
Specialty analysis
777 Old Saw Mill River Rd, Tarrytown, NY 10591, USA
BioNTech RNA Pharmaceuticals GmbH,
Sample processing
An der Goldgrube 12, 55131 Mainz, Germany
BioNTech SE,
Specialty analysis
An der Goldgrube 12, 55131 Mainz, Germany
)TMG(
73:20
0202-voN-82
:nO
devorppA\devorppA\16573a591e771090
FDA-CBER-2021-5683-0049330
Page 13","[[['', 'Services provided', '', '', 'Name and address (including country)', '']]]",13
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-excluded-patients.pdf,4.0,"BioNTech RNA Pharmaceuticals GmbH / Listings - 6. Snapshot All TLFs Final 1.0 BNT162b1
BNT162-01 Created on 20NOV2020
Listing 16.2.1-4.2-1: Listing of subjects excluded from Safety boost set - BNT162b1
Safety set
Subject Date of first Date of
Dose group number Reason for exclusion informed consent screening
10 µg 10010 Subject did not receive two doses of IMP 22APR2020 22APR2020
Younger
20 µg 10182 Subject did not receive two doses of IMP 09JUL2020 09JUL2020
Younger
50 µg 10050 Subject did not receive two doses of IMP 05MAY2020 05MAY2020
Younger
60 µg 10066 Subject did not receive two doses of IMP 08MAY2020 08MAY2020
Younger
10075 Subject did not receive two doses of IMP 11MAY2020 11MAY2020
10076 Subject did not receive two doses of IMP 11MAY2020 11MAY2020
10078 Subject did not receive two doses of IMP 11MAY2020 11MAY2020
10083 Subject did not receive two doses of IMP 12MAY2020 12MAY2020
10084 Subject did not receive two doses of IMP 12MAY2020 12MAY2020
10085 Subject did not receive two doses of IMP 12MAY2020 12MAY2020
10089 Subject did not receive two doses of IMP 12MAY2020 12MAY2020
10093 Subject did not receive two doses of IMP 12MAY2020 12MAY2020
10096 Subject did not receive two doses of IMP 12MAY2020 12MAY2020
10103 Subject did not receive two doses of IMP 14MAY2020 14MAY2020
10104 Subject did not receive two doses of IMP 14MAY2020 14MAY2020
20 µg Older 20242 Subject did not receive two doses of IMP 28AUG2020 28AUG2020
IMP = investigational medicinal product.
Program: Lbase_Disp_4_2.sas (Page 1 of 1)
Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.
)TMG(
83:30
0202-voN-72
:nO
devorppA\devorppA\e577f9591e771090
FDA-CBER-2021-5683-0049449
Page 1
BioNTech RNA Pharmaceuticals GmbH / Listings - 6. Snapshot All TLFs Final 1.0 BNT162b1
BNT162-01 Created on 20NOV2020
Listing 16.2.1-4.3-1: Listing of subjects excluded from Immunogenicity set - BNT162b1
Safety set
Subject Date of first Date of
Dose group number Reason for exclusion informed consent screening
30 µg Older 10350 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10351 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10352 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10353 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10358 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10360 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10361 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10362 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10363 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10364 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10365 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
10366 Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment 14SEP2020 14SEP2020
IMP = investigational medicinal product.
Program: Lbase_Disp_4_2.sas (Page 1 of 1)
Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.
)TMG(
83:30
0202-voN-72
:nO
devorppA\devorppA\e577f9591e771090
FDA-CBER-2021-5683-0049450
Page 2
BioNTech RNA Pharmaceuticals GmbH / Listings - 6. Snapshot All TLFs Final 1.0 BNT162b2
BNT162-01 Created on 20NOV2020
Listing 16.2.1-4.2-3: Listing of subjects excluded from Safety boost set - BNT162b2
Safety set
Subject Date of first Date of
Dose group number Reason for exclusion informed consent screening
1 µg Younger 20160 Subject did not receive two doses of IMP 15JUN2020 15JUN2020
10 µg 20116 Subject did not receive two doses of IMP 20MAY2020 20MAY2020
Younger
IMP = investigational medicinal product.
Program: Lbase_Disp_4_2.sas (Page 1 of 1)
Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.
)TMG(
83:30
0202-voN-72
:nO
devorppA\devorppA\f577f9591e771090
FDA-CBER-2021-5683-0049451
Page 3
BioNTech RNA Pharmaceuticals GmbH / Listings - 6. Snapshot All TLFs Final 1.0 BNT162b2
BNT162-01 Created on 20NOV2020
Listing 16.2.1-4.3-3: Listing of subjects excluded from Immunogenicity set - BNT162b2
Safety set
No subjects were excluded from Immunogenicity set.
Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.
)TMG(
83:30
0202-voN-72
:nO
devorppA\devorppA\f577f9591e771090
FDA-CBER-2021-5683-0049452
Page 4","[[['BioNTech RNA Pharmaceuticals GmbH /', 'Listings - 6. Snapshot All TLFs Final 1.0', 'BNT162b1', None], ['BNT162-01', 'Created on 20NOV2020', '', '']], [['Dose group', 'Subject\nnumber', 'Reason for exclusion', 'Date of first\ninformed consent', 'Date of\nscreening'], ['10 µg\nYounger', '10010', 'Subject did not receive two doses of IMP', '22APR2020', '22APR2020'], ['20 µg\nYounger', '10182', 'Subject did not receive two doses of IMP', '09JUL2020', '09JUL2020'], ['50 µg\nYounger', '10050', 'Subject did not receive two doses of IMP', '05MAY2020', '05MAY2020'], ['60 µg\nYounger', '10066', 'Subject did not receive two doses of IMP', '08MAY2020', '08MAY2020'], [None, '10075', 'Subject did not receive two doses of IMP', '11MAY2020', '11MAY2020'], [None, '10076', 'Subject did not receive two doses of IMP', '11MAY2020', '11MAY2020'], [None, '10078', 'Subject did not receive two doses of IMP', '11MAY2020', '11MAY2020'], [None, '10083', 'Subject did not receive two doses of IMP', '12MAY2020', '12MAY2020'], [None, '10084', 'Subject did not receive two doses of IMP', '12MAY2020', '12MAY2020'], [None, '10085', 'Subject did not receive two doses of IMP', '12MAY2020', '12MAY2020'], [None, '10089', 'Subject did not receive two doses of IMP', '12MAY2020', '12MAY2020'], [None, '10093', 'Subject did not receive two doses of IMP', '12MAY2020', '12MAY2020'], [None, '10096', 'Subject did not receive two doses of IMP', '12MAY2020', '12MAY2020'], [None, '10103', 'Subject did not receive two doses of IMP', '14MAY2020', '14MAY2020'], [None, '10104', 'Subject did not receive two doses of IMP', '14MAY2020', '14MAY2020'], ['20 µg Older', '20242', 'Subject did not receive two doses of IMP', '28AUG2020', '28AUG2020'], ['IMP = investigational medicinal product.', None, None, None, None], ['', None, None, None, None], ['Program: Lbase_Disp_4_2.sas (Page 1 of 1)', None, None, None, None]], [[''], ['Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.']], [['BioNTech RNA Pharmaceuticals GmbH /', 'Listings - 6. Snapshot All TLFs Final 1.0', 'BNT162b1', None], ['BNT162-01', 'Created on 20NOV2020', '', '']], [['Dose group', 'Subject\nnumber', 'Reason for exclusion', 'Date of first\ninformed consent', 'Date of\nscreening'], ['30 µg Older', '10350', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10351', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10352', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10353', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10358', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10360', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10361', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10362', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10363', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10364', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10365', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], [None, '10366', 'Subject did not receive one dose of IMP or did not have one post-baseline immunogenicity assessment', '14SEP2020', '14SEP2020'], ['IMP = investigational medicinal product.', None, None, None, None], ['', None, None, None, None], ['Program: Lbase_Disp_4_2.sas (Page 1 of 1)', None, None, None, None]], [[''], ['Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.']], [['BioNTech RNA Pharmaceuticals GmbH /', 'Listings - 6. Snapshot All TLFs Final 1.0', 'BNT162b2', None], ['BNT162-01', 'Created on 20NOV2020', '', '']], [['Dose group', 'Subject\nnumber', 'Reason for exclusion', 'Date of first\ninformed consent', 'Date of\nscreening'], ['1 µg Younger', '20160', 'Subject did not receive two doses of IMP', '15JUN2020', '15JUN2020'], ['10 µg\nYounger', '20116', 'Subject did not receive two doses of IMP', '20MAY2020', '20MAY2020'], ['IMP = investigational medicinal product.', None, None, None, None], ['', None, None, None, None], ['Program: Lbase_Disp_4_2.sas (Page 1 of 1)', None, None, None, None]], [[''], ['Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.']], [['BioNTech RNA Pharmaceuticals GmbH /', 'Listings - 6. Snapshot All TLFs Final 1.0', 'BNT162b2', None], ['BNT162-01', 'Created on 20NOV2020', '', '']], [[''], ['Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.']]]",4
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-sponsor-signature.pdf,2.0,"FDA-CBER-2021-5683-0049332
FDA-CBER-2021-5683-0049333",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-discontinued-patients.pdf,2.0,"BioNTech RNA Pharmaceuticals GmbH / Listings - 6. Snapshot All TLFs Final 1.0 BNT162b1
BNT162-01 Created on 20NOV2020
Listing 16.2.1-3-1: Listing of subjects with premature discontinuation - BNT162b1
Safety set
Date of last Date of premature Epi/ Pandemic
Dose group Subject number visit/contact termination Main reason for premature termination related
10 µg Younger 10010 22MAY2020 19MAY2020 Adverse Event No
20 µg Younger 10178 09SEP2020 09SEP2020 Other (private reason) No
10182 06OCT2020 23JUL2020 Withdrawal By Subject No
50 µg Younger 10050 03JUN2020 03JUN2020 Other (due to private reason.) No
Program: Lbase_Disp_3.sas (Page 1 of 1)
Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.
)TMG(
83:30
0202-voN-72
:nO
devorppA\devorppA\d277f9591e771090
FDA-CBER-2021-5683-0049417
Page 1
BioNTech RNA Pharmaceuticals GmbH / Listings - 6. Snapshot All TLFs Final 1.0 BNT162b2
BNT162-01 Created on 20NOV2020
Listing 16.2.1-3-3: Listing of subjects with premature discontinuation - BNT162b2
Safety set
Date of last Date of premature Epi/ Pandemic
Dose group Subject number visit/contact termination Main reason for premature termination related
1 µg Younger 20160 31JUL2020 30JUL2020 Withdrawal By Subject No
10 µg Younger 20116 04AUG2020 16JUL2020 Adverse Event No
Program: Lbase_Disp_3.sas (Page 1 of 1)
Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.
)TMG(
83:30
0202-voN-72
:nO
devorppA\devorppA\e277f9591e771090
FDA-CBER-2021-5683-0049418
Page 2","[[['BioNTech RNA Pharmaceuticals GmbH /', 'Listings - 6. Snapshot All TLFs Final 1.0', 'BNT162b1', None], ['BNT162-01', 'Created on 20NOV2020', '', '']], [['Dose group', 'Subject number', 'Date of last\nvisit/contact', 'Date of premature\ntermination', 'Main reason for premature termination', 'Epi/ Pandemic'], [None, None, None, None, None, 'related'], ['10 µg Younger', '10010', '22MAY2020', '19MAY2020', 'Adverse Event', 'No'], ['20 µg Younger', '10178', '09SEP2020', '09SEP2020', 'Other (private reason)', 'No'], [None, '10182', '06OCT2020', '23JUL2020', 'Withdrawal By Subject', 'No'], ['50 µg Younger', '10050', '03JUN2020', '03JUN2020', 'Other (due to private reason.)', 'No'], ['', None, None, None, None, None], ['Program: Lbase_Disp_3.sas (Page 1 of 1)', None, None, None, None, None]], [[''], ['Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.']], [['BioNTech RNA Pharmaceuticals GmbH /', 'Listings - 6. Snapshot All TLFs Final 1.0', 'BNT162b2', None], ['BNT162-01', 'Created on 20NOV2020', '', '']], [['Dose group', 'Subject number', 'Date of last\nvisit/contact', 'Date of premature\ntermination', 'Main reason for premature termination', 'Epi/ Pandemic'], [None, None, None, None, None, 'related'], ['1 µg Younger', '20160', '31JUL2020', '30JUL2020', 'Withdrawal By Subject', 'No'], ['10 µg Younger', '20116', '04AUG2020', '16JUL2020', 'Adverse Event', 'No'], ['', None, None, None, None, None], ['Program: Lbase_Disp_3.sas (Page 1 of 1)', None, None, None, None, None]], [[''], ['Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.']]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-iec-irb.pdf,1.0,"BioNTech RNA Page 1 of 1
Interim Clinical Study Report
Pharmaceuticals GmbH Version: 1.0
BNT162-01
Confidential Date: 12 Sep 2020
16.1.3 List of independent ethics committees
Site number IEC including address and country, registration number, contact details Chairperson
276-01 Medical Board Baden-Württemberg, Prof. Dr. med. Gerlinde Egerer
Ethical Commission
Liebknechtstr. 33
70565 Stuttgart
Germany
Phone: ++49-711-76989-0
Fax: ++49-711-76989-856
Internet: www.aertzekammer@laek-bw-de/ethic
276-02 Landesamt für Gesundheit und Soziales Prof. Dr. med. Martin Hildebrandt
Geschäftsstelle der Ethikkommission des Landes Berlin
Turmstr. 21, Haus A
D-10559 Berlin
Germany
Phone: ++49-30-90229122-0
Fax: ++49-30-90283383
Internet: https://www.berlin.de/lageso/gesundheit/ethik-kommission/
IEC = Independent ethics committee.
)TMG(
71:70
0202-peS-81
:nO
devorppA\devorppA\1fb63f491e771090
FDA-CBER-2021-5683-0049317
Page 1",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-patient-batches.pdf,18.0,"BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page 1 of 9
Confidential Investigational Product Tracking Table for: BNT162b1 Date: 23 NOV 2020
RNA DS Batch DP Batch Packaging Trial site
RNA Medication Sequence
Variant No. No. Batch No. Expiry Date SO-No. Country No.
No. No.
(kit) Pharmacy
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10002 2 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10003 3 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10004 4 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10005 5 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10006 6 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10007 7 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10008 8 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10009 9 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10010 10 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10011 11 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10012 12 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10013 13 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10014 14 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10015 15 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10016 16 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10017 17 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10018 18 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10019 19 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10020 20 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10021 21 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10022 22 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10023 23 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10024 24 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10025 25 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10026 26 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10027 27 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10028 28 25. Sep 20 SO-20-0022 Germany #1/Mannheim
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\2bc73a591e771090
FDA-CBER-2021-5683-0049334
Page 1
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page 2 of 9
Confidential Investigational Product Tracking Table for: BNT162b1 Date: 23 NOV 2020
Date of Date of
Packaging
Medication Sequence Shipment Arrival at
Batch No. Subject No.
No. No. to study study
(kit)
site/pharmacy site/pharmacy
E220195-0001L 10002 2 19. Apr 20 21. Apr 20 276-01-0021, 276-01-0032, 276-01-0034
E220195-0001L 10003 3 19. Apr 20 21. Apr 20 276-01-0028, 276-01-0031, 276-01-0038
E220195-0001L 10004 4 19. Apr 20 21. Apr 20 276-01-0056
E220195-0001L 10005 5 19. Apr 20 21. Apr 20 276-01-0096
E220195-0001L 10006 6 19. Apr 20 21. Apr 20 276-01-0053
E220195-0001L 10007 7 19. Apr 20 21. Apr 20 276-01-0067
E220195-0001L 10008 8 19. Apr 20 21. Apr 20 276-01-0057
E220195-0001L 10009 9 19. Apr 20 21. Apr 20 276-01-0007
E220195-0001L 10010 10 19. Apr 20 21. Apr 20 276-01-0025, 276-01-0023, 276-01-0033, 276-01-0045
E220195-0001L 10011 11 19. Apr 20 21. Apr 20 276-01-0083
E220195-0001L 10012 12 19. Apr 20 21. Apr 20 276-01-0066
E220195-0001L 10013 13 19. Apr 20 21. Apr 20 276-01-0016, 276-01-0020
E220195-0001L 10014 14 19. Apr 20 21. Apr 20 276-01-0003, 276-01-0006, 276-01-0008, 276-01-0009, 276-01-0019, 276-01-0017
E220195-0001L 10015 15 19. Apr 20 21. Apr 20 276-01-0011, 276-01-0005, 276-01-0004, 276-01-0001
E220195-0001L 10016 16 19. Apr 20 21. Apr 20 276-01-0073
E220195-0001L 10017 17 19. Apr 20 21. Apr 20 276-01-0055
E220195-0001L 10018 18 19. Apr 20 21. Apr 20 276-01-0070
E220195-0001L 10019 19 19. Apr 20 21. Apr 20 276-01-0049
E220195-0001L 10020 20 19. Apr 20 21. Apr 20 276-01-0059
E220195-0001L 10021 21 19. Apr 20 21. Apr 20 276-01-0037
E220195-0001L 10022 22 19. Apr 20 21. Apr 20 276-01-0015, 276-01-0018
E220195-0001L 10023 23 19. Apr 20 21. Apr 20 276-01-0007
E220195-0001L 10024 24 19. Apr 20 21. Apr 20 276-01-0039, 276-01-0043, 276-01-0047
E220195-0001L 10025 25 19. Apr 20 21. Apr 20 276-01-0011, 276-01-0010, 276-01-0005, 276-01-0004, 276-01-0001
E220195-0001L 10026 26 19. Apr 20 21. Apr 20 276-01-0036, 276-01-0040, 276-01-0041, 276-01-0042, 276-01-0048, 276-01-0052
E220195-0001L 10027 27 19. Apr 20 21. Apr 20 276-01-0003, 276-01-0006, 276-01-0008, 276-01-0009, 276-01-0019, 276-01-0017
E220195-0001L 10028 28 19. Apr 20 21. Apr 20 276-01-0050
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\2bc73a591e771090
FDA-CBER-2021-5683-0049335
Page 2
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page 3 of 9
Confidential Investigational Product Tracking Table for: BNT162b1 Date: 23 NOV 2020
Deviation
Packaging
Medication Sequence Drug accountability Yes/No
Batch No. Date used comments
No. No. finally checked on if yes
(kit)
Deviation No.
E220195-0001L 10002 2 05. Mai 20 08. Mai 20 N
E220195-0001L 10003 3 07. Mai 20 08. Mai 20 N
E220195-0001L 10004 4 13. Mai 20 15. Mai 20 N
E220195-0001L 10005 5 19. Mai 20 20. Mai 20 N
E220195-0001L 10006 6 12. Mai 20 15. Mai 20 N
E220195-0001L 10007 7 15. Mai 20 15. Mai 20 N
E220195-0001L 10008 8 15. Mai 20 15. Mai 20 N
E220195-0001L 10009 9 14. Mai 20 15. Mai 20 N
E220195-0001L 10010 10 05. Mai 20 08. Mai 20 N
E220195-0001L 10011 11 20. Mai 20 20. Mai 20 N
E220195-0001L 10012 12 19. Mai 20 20. Mai 20 N
E220195-0001L 10013 13 29. Apr 20 30. Apr 20 N
E220195-0001L 10014 14 28. Apr 20 30. Apr 20 N
E220195-0001L 10015 15 15. Mai 20 15. Mai 20 N
E220195-0001L 10016 16 15. Mai 20 15. Mai 20 N
E220195-0001L 10017 17 13. Mai 20 15. Mai 20 N
E220195-0001L 10018 18 15. Mai 20 15. Mai 20 N
E220195-0001L 10019 19 12. Mai 20 15. Mai 20 N
E220195-0001L 10020 20 13. Mai 20 15. Mai 20 N
E220195-0001L 10021 21 05. Mai 20 08. Mai 20 N
E220195-0001L 10022 22 29. Apr 20 30. Apr 20 N
E220195-0001L 10023 23 23. Apr 20 30. Apr 20 N
E220195-0001L 10024 24 07. Mai 20 08. Mai 20 N
E220195-0001L 10025 25 24. Apr 20 30. Apr 20 N
E220195-0001L 10026 26 08. Mai 20 08. Mai 20 N
E220195-0001L 10027 27 19. Mai 20 20. Mai 20 N
E220195-0001L 10028 28 15. Mai 20 15. Mai 20 N
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\2bc73a591e771090
FDA-CBER-2021-5683-0049336
Page 3
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page 4 of 9
Confidential Investigational Product Tracking Table for: BNT162b1 Date: 23 NOV 2020
RNA DS Batch DP Batch Packaging Trial site
RNA Medication Sequence
Variant No. No. Batch No. Expiry Date SO-No. Country No.
No. No.
(kit) Pharmacy
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10029 29 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10030 30 25. Sep 20 SO-20-0022 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10031 31 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10032 32 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10033 33 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10034 34 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10035 35 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10036 36 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10037 37 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10038 38 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10039 39 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10040 40 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10041 41 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10042 42 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10043 43 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10044 44 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10045 45 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0001L 10046 46 25. Sep 20 SO-20-0033 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10047 47 25. Sep 20 SO-20-0038 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10048 48 25. Sep 20 SO-20-0038 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10049 49 25. Sep 20 SO-20-0038 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10050 50 25. Sep 20 SO-20-0038 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10051 51 25. Sep 20 SO-20-0038 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10052 52 25. Sep 20 SO-20-0038 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10053 53 25. Sep 20 SO-20-0038 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10054 54 25. Sep 20 SO-20-0038 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10055 55 25. Sep 20 SO-20-0038 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0004L 10056 56 25. Sep 20 SO-20-0038 Germany #1/Mannheim
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\2bc73a591e771090
FDA-CBER-2021-5683-0049337
Page 4
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page 5 of 9
Confidential Investigational Product Tracking Table for: BNT162b1 Date: 23 NOV 2020
Date of Date of
Packaging
Medication Sequence Shipment Arrival at
Batch No. Subject No.
No. No. to study study
(kit)
site/pharmacy site/pharmacy
E220195-0001L 10029 29 19. Apr 20 21. Apr 20 276-01-0060
E220195-0001L 10030 30 19. Apr 20 21. Apr 20 276-01-0068
E220195-0001L 10031 31 11. Mai 20 13. Mai 20 276-01-0025, 276-01-0023, 276-01-0033, 276-01-0045
E220195-0001L 10032 32 11. Mai 20 13. Mai 20 276-01-0084
E220195-0001L 10033 33 11. Mai 20 13. Mai 20 276-01-0028, 276-01-0031, 276-01-0038
E220195-0001L 10034 34 11. Mai 20 13. Mai 20 276-01-0021, 276-01-0032
E220195-0001L 10035 35 11. Mai 20 13. Mai 20 276-01-0089
E220195-0001L 10036 36 11. Mai 20 13. Mai 20 276-01-0075
E220195-0001L 10037 37 11. Mai 20 13. Mai 20 276-01-0103
E220195-0001L 10038 38 11. Mai 20 13. Mai 20 276-01-0104
E220195-0001L 10039 39 11. Mai 20 13. Mai 20 276-01-0093
E220195-0001L 10040 40 11. Mai 20 13. Mai 20 276-01-0078
E220195-0001L 10041 41 11. Mai 20 13. Mai 20 276-01-0034, 276-01-0037
E220195-0001L 10042 42 11. Mai 20 13. Mai 20 276-01-0015, 276-01-0018, 276-01-0015, 276-01-0018
E220195-0001L 10043 43 11. Mai 20 13. Mai 20 276-01-0016, 276-01-0020
E220195-0001L 10044 44 11. Mai 20 13. Mai 20 276-01-0085
E220195-0001L 10045 45 11. Mai 20 13. Mai 20 276-01-0076
E220195-0001L 10046 46 11. Mai 20 13. Mai 20 276-01-0039, 276-01-0043, 276-01-0047
E220195-0004L 10047 47 26. Mai 20 28. Mai 20 276-01-0049, 276-01-0053
E220195-0004L 10048 48 26. Mai 20 28. Mai 20 276-01-0178, 276-01-0179, 276-01-0181
E220195-0004L 10049 49 26. Mai 20 28. Mai 20 276-01-0060, 276-01-0059
E220195-0004L 10050 50 26. Mai 20 28. Mai 20 276-01-0171, 276-01-0172, 276-01-0173
E220195-0004L 10051 51 26. Mai 20 28. Mai 20 276-01-0067, 276-01-0057
E220195-0004L 10052 52 26. Mai 20 28. Mai 20 276-01-0036, 276-01-0052, 276-01-0048, 276-01-0042, 276-01-0041, 276-01-0040
E220195-0004L 10053 53 26. Mai 20 28. Mai 20 276-01-0056, 276-01-0055
E220195-0004L 10054 54 26. Mai 20 28. Mai 20 276-01-0070, 276-01-0068
E220195-0004L 10055 55 26. Mai 20 28. Mai 20 276-01-0151, 276-01-0175, 276-01-0176,
E220195-0004L 10056 56 26. Mai 20 28. Mai 20 276-01-0073
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\2bc73a591e771090
FDA-CBER-2021-5683-0049338
Page 5
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page 6 of 9
Confidential Investigational Product Tracking Table for: BNT162b1 Date: 23 NOV 2020
Deviation
Packaging
Medication Sequence Drug accountability Yes/No
Batch No. Date used comments
No. No. finally checked on if yes
(kit)
Deviation No.
E220195-0001L 10029 29 13. Mai 20 15. Mai 20 N
E220195-0001L 10030 30 15. Mai 20 15. Mai 20 N
E220195-0001L 10031 31 26. Mai 20 28. Mai 20 N
E220195-0001L 10032 32 22. Mai 20 28. Mai 20 N
E220195-0001L 10033 33 28. Mai 20 28. Mai 20 N
E220195-0001L 10034 34 26. Mai 20 28. Mai 20 N
E220195-0001L 10035 35 20. Mai 20 20. Mai 20 N
E220195-0001L 10036 36 22. Mai 20 28. Mai 20 N
E220195-0001L 10037 37 22. Mai 20 28. Mai 20 N
E220195-0001L 10038 38 20. Mai 20 20. Mai 20 N
E220195-0001L 10039 39 20. Mai 20 20. Mai 20 N
E220195-0001L 10040 40 22. Mai 20 28. Mai 20 N
E220195-0001L 10041 41 26. Mai 20 28. Mai 20 N
E220195-0001L 10042 42 20. Mai 20 20. Mai 20 N
E220195-0001L 10043 43 20. Mai 20 20. Mai 20 N
E220195-0001L 10044 44 22. Mai 20 28. Mai 20 N
E220195-0001L 10045 45 22. Mai 20 28. Mai 20 N
E220195-0001L 10046 46 28. Mai 20 28. Mai 20 N
E220195-0004L 10047 47 02. Jun 20 03. Jun 20 N
E220195-0004L 10048 48 16. Jun 20 17. Jun 20 N
E220195-0004L 10049 49 03. Jun 20 03. Jun 20 N
E220195-0004L 10050 50 16. Jun 20 17. Jun 20 N
E220195-0004L 10051 51 05. Jun 20 24. Jun 20 N
E220195-0004L 10052 52 29. Mai 20 03. Jun 20 N
E220195-0004L 10053 53 03. Jun 20 03. Jun 20 N
E220195-0004L 10054 54 05. Jun 20 24. Jun 20 N
E220195-0004L 10055 55 16. Jun 20 17. Jun 20 N
E220195-0004L 10056 56 05. Jun 20 24. Jun 20 N
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\2bc73a591e771090
FDA-CBER-2021-5683-0049339
Page 6
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page 7 of 9
Confidential Investigational Product Tracking Table for: BNT162b1 Date: 23 NOV 2020
RNA DS Batch DP Batch Packaging Trial site
RNA Medication Sequence
Variant No. No. Batch No. Expiry Date SO-No. Country No.
No. No.
(kit) Pharmacy
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10103 103 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10104 104 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10105 105 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10106 106 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10107 107 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10108 108 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10109 109 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10111 111 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10112 112 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10113 113 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10115 115 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10116 116 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10117 117 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10118 118 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10119 119 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10120 120 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10124 124 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10125 125 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10126 126 25. Sep 20 SO-20-0058 Germany #1/Mannheim
V5modRNA RBP020.3 R425-P020.3-DS BCV10320-A E220195-0014L 10130 130 25. Sep 20 SO-20-0058 Germany #1/Mannheim
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\2bc73a591e771090
FDA-CBER-2021-5683-0049340
Page 7
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page 8 of 9
Confidential Investigational Product Tracking Table for: BNT162b1 Date: 23 NOV 2020
Date of Date of
Packaging
Medication Sequence Shipment Arrival at
Batch No. Subject No.
No. No. to study study
(kit)
site/pharmacy site/pharmacy
E220195-0014L 10103 103 14.06.2020 16.06.2020 276-01-0351, 276-01-0363, 276-01-0364
E220195-0014L 10104 104 14.06.2020 16.06.2020 276-01-0366, 276-01-0365
E220195-0014L 10105 105 14.06.2020 16.06.2020 276-01-0282, 276-01-0289
E220195-0014L 10106 106 14.06.2020 16.06.2020 276-01-0181, 276-01-0179, 276-01-0178
E220195-0014L 10107 107 14.06.2020 16.06.2020 276-01-273, 276-01-0274, 276-01-0283, 276-01-0292, 276-01-0320, 276-01-298
E220195-0014L 10108 108 14.06.2020 16.06.2020 276-01-0194, 276-01-0200, 276-01-0204, 276-01-0198, 276-01-0209, 276-01-0212
E220195-0014L 10109 109 14.06.2020 16.06.2020 276-01-0287, 276-01-0286, 276-01-0291, 276-01-0288,
E220195-0014L 10111 111 14.06.2020 16.06.2020 276-01-0286, 276-01-0287, 276-01-0288, 276-01-0291
E220195-0014L 10112 112 14.06.2020 16.06.2020 276-01-0352
E220195-0014L 10113 113 14.06.2020 16.06.2020 276-01-0197, 276-01-0183,
E220195-0014L 10115 115 14.06.2020 16.06.2020 276-01-0360, 276-01-0358
E220195-0014L 10116 116 14.06.2020 16.06.2020 276-01-0182, 276-01-0183, 276-01-0187
E220195-0014L 10117 117 14.06.2020 16.06.2020 276-01-0320, 276-01-0273, 276-01-0283, 276-01-0292, 276-01-0298, 276-01-0274
E220195-0014L 10118 118 14.06.2020 16.06.2020 276-01-0361, 276-01-0350, 276-01-0362
E220195-0014L 10119 119 14.06.2020 16.06.2020 276-01-0171, 276-01-0151, 276-01-0172,
E220195-0014L 10120 120 14.06.2020 16.06.2020 276-01-0175, 276-01-0173, 276-01-0176,
E220195-0014L 10124 124 14.06.2020 16.06.2020 276-01-0227, 276-01-0221, 276-01-0226, 276-01-0225, 276-01-0224, 276-01-0170
E220195-0014L 10125 125 14.06.2020 16.06.2020 276-01-0282, 276-01-0289,
E220195-0014L 10126 126 14.06.2020 16.06.2020 276-01-0194, 276-01-0198, 276-01-0200, 276-01-0204, 276-01-0209, 276-01-0212
E220195-0014L 10130 130 14.06.2020 16.06.2020 276-01-0170, 276-01-0227, 276-01-0221, 276-01-0226, 276-01-0225, 276-01-0224,
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\2bc73a591e771090
FDA-CBER-2021-5683-0049341
Page 8
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page 9 of 9
Confidential Investigational Product Tracking Table for: BNT162b1 Date: 23 NOV 2020
Deviation
Packaging
Medication Sequence Drug accountability Yes/No
Batch No. Date used comments
No. No. finally checked on if yes
(kit)
Deviation No.
E220195-0014L 10103 103 25. Sep 20 01. Oct 20 N
E220195-0014L 10104 104 23. Sep 20 23. Sep 20 N
E220195-0014L 10105 105 20. Aug 20 02. Sep 20 N
E220195-0014L 10106 106 06. Aug 20 02. Sep 20 N
E220195-0014L 10107 107 17. Sep 20 23. Sep 20 N
E220195-0014L 10108 108 22. Jul 20 30. Jul 20 N
E220195-0014L 10109 109 25. Aug 20 02. Sep 20 N
E220195-0014L 10111 111 15. Sep 20 23. Sep 20 N
E220195-0014L 10112 112 22. Sep 20 23. Sep 20 N
E220195-0014L 10113 113 06. Aug 20 02. Sep 20 N
E220195-0014L 10115 115 23. Sep 20 23. Sep 20 N
E220195-0014L 10116 116 16. Jun 20 17. Jun 20 N
E220195-0014L 10117 117 27. Aug 20 02. Sep 20 N
E220195-0014L 10118 118 25.Sep.20 01.Oct 20 N
E220195-0014L 10119 119 06. Aug 20 02. Sep 20 N
E220195-0014L 10120 120 06. Aug 20 02. Sep 20 N
E220195-0014L 10124 124 31. Jul 20 02. Sep 20 N
E220195-0014L 10125 125 10. Sep 20 23. Sep 20 N
E220195-0014L 10126 126 12. Aug 20 02. Sep 20 N
E220195-0014L 10130 130 21. Aug 20 02. Sep 20 N
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\2bc73a591e771090
FDA-CBER-2021-5683-0049342
Page 9
FDA-CBER-2021-5683-0049343
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page: 2 of 9
Confidential Investigational Product Tracking Table for: BNT162b2 Date: 23 NOV 2020
Date of Date of
Packaging
Medication Sequence Shipment Arrival at
Batch No. Subject No.
No. No. to study study
(kit)
site/pharmacy site/pharmacy
E220195-0004L 20001 10001 05. Jun 20 07. Jun 20 276-02-0103
E220195-0004L 20003 10003 05. Jun 20 07. Jun 20 276-02-0110, 276-02-0105, 276-02-0104, 276-02-0101, 276-02-0102
E220195-0004L 20004 10004 05. Jun 20 07. Jun 20 276-02-0118, 276-02-0116, 276-02-0121, 276-02-0111,276-02-0117, 276-02-0114
E220195-0004L 20005 10005 05. Jun 20 07. Jun 20 276-02-0149, 276-02-0127
E220195-0004L 20006 10006 05. Jun 20 07. Jun 20 276-02-0155, 276-02-0150
E220195-0004L 20007 10007 05. Jun 20 07. Jun 20 276-02-0137, 276-02-0128
E220195-0004L 20008 10008 05. Jun 20 07. Jun 20 145, 276-02-0143, 276-02-0134
E220195-0004L 20009 10009 05. Jun 20 07. Jun 20 276-02-0138, 276-02-0144, 276-02-0142
E220195-0004L 20010 10010 05. Jun 20 07. Jun 20 276-02-0154, 276-02-0166, 276-02-0163, 276-02-0157, 276-02-0160, 276-02-0153
E220195-0004L 20011 10011 05. Jun 20 07. Jun 20 276-02-0137, 276-02-0128, 276-02-0155
E220195-0004L 20012 10012 05. Jun 20 07. Jun 20 276-02-0153, 276-02-0157, 276-02-0163, 276-02-0166, 276-02-0154
E220195-0004L 20013 10013 05. Jun 20 07. Jun 20 276-02-0134, 276-02-0143, 276-02-0145
E220195-0004L 20014 10014 05. Jun 20 07. Jun 20 276-02-0142, 276-02-0144, 276-02-0138
E220195-0004L 20016 10016 05. Jun 20 07. Jun 20 276-02-0111
E220195-0004L 20018 10018 05. Jun 20 07. Jun 20 276-02-0118, 276-02-0121, 276-02-0117, 276-02-0114
E220195-0004L 20019 10019 05. Jun 20 07. Jun 20 276-02-0164, 276-02-0171, 276-02-0158
E220195-0004L 20021 10021 05. Jun 20 07. Jun 20 276-02-0183, 276-02-0180
E220195-0004L 20022 10022 05. Jun 20 07. Jun 20 276-02-0150, 276-02-0149, 276-02-0127
E220195-0004L 20023 10023 05. Jun 20 07. Jun 20 276-02-0159, 276-02-0168
E220195-0004L 20024 10024 05. Jun 20 07. Jun 20 276-02-0173, 276-02-0156, 276-02-0172
E220195-0004L 20025 10025 05. Jun 20 07. Jun 20 276-02-0105, 276-02-0103
E220195-0004L 20027 10027 05. Jun 20 07. Jun 20 276-02-0181, 276-02-0179, 276-02-0175
E220195-0004L 20029 10029 05. Jun 20 07. Jun 20 276-02-0174, 276-02-0177, 276-02-0178
E220195-0004L 20030 10030 05. Jun 20 07. Jun 20 276-02-0110, 276-02-0104, 276-02-0101, 276-02-0102
E220195-0004L 20031 10031 14. Jul 20 16. Jul 20 276-02-0159, 276-02-0168
E220195-0004L 20032 10032 14. Jul 20 16. Jul 20 276-02-0172, 276-02-0156, 276-02-0173
E220195-0004L 20033 10033 14. Jul 20 16. Jul 20 276-02-0175, 276-02-0178, 276-02-0177
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\3bc73a591e771090
FDA-CBER-2021-5683-0049344
Page 11
FDA-CBER-2021-5683-0049345
FDA-CBER-2021-5683-0049346
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page: 5 of 9
Confidential Investigational Product Tracking Table for: BNT162b2 Date: 23 NOV 2020
Date of Date of
Packaging
Medication Sequence Shipment Arrival at
Batch No. Subject No.
No. No. to study study
(kit)
site/pharmacy site/pharmacy
E220195-0004L 20034 10034 14. Jul 20 16. Jul 20 276-02-0174
E220195-0004L 20035 10035 14. Jul 20 16. Jul 20 276-02-0188, 276-02-0189, 276-02-0181
E220195-0004L 20038 10038 14. Jul 20 16. Jul 20 276-02-0179
E220195-0004L 20039 10039 14. Jul 20 16. Jul 20 276-02-0185, 276-02-0193, 276-02-0176, 276-02-0194
E220195-0004L 20040 10040 14. Jul 20 16. Jul 20 276-02-0195, 276-02-0203, 276-02-0204
E220195-0004L 20042 10042 14. Jul 20 16. Jul 20 276-02-0158, 276-02-0171, 276-02-0164
E220195-0004L 20043 10043 14. Jul 20 16. Jul 20 276-02-0180, 276-02-0183
E220195-0004L 20044 10044 14. Jul 20 16. Jul 20 276-02-201, 276-02-191
E220195-0004L 20045 10045 14. Jul 20 16. Jul 20 276-02-0197, 276-02-0192
E220195-0004L 20046 10046 14. Jul 20 16. Jul 20 276-01-0201, 276-01-0191
E220195-0004L 20047 10047 14. Jul 20 16. Jul 20 276-01-0223
E220195-0004L 20048 10048 14. Jul 20 16. Jul 20 276-01-0203
E220195-0004L 20049 10049 14. Jul 20 16. Jul 20 276-01-0203 (not dosed), 276-01-0204, 276-01-0200, 276-01-0195
E220195-0004L 20050 10050 14. Jul 20 16. Jul 20 276-01-0192, 276-01-0197, 276-01-0194, 276-01-0176, 276-01-0193, 276-01-0185
E220195-0004L 20051 10051 14. Jul 20 16. Jul 20 276-02-0200
E220195-0004L 20053 10053 14. Jul 20 16. Jul 20 276-01-0225, 276-01-0222, 276-01-0214,
E220195-0004L 20054 10054 14. Jul 20 16. Jul 20 276-01-0229, 276-01-0215, 276-01-0224
E220195-0004L 20055 10055 14. Jul 20 16. Jul 20 276-01-0208, 276-01-0216
E220195-0004L 20056 10056 14. Jul 20 16. Jul 20 276-01-0181, 276-01-0189, 276-01-0188
E220195-0018L 20057 10057 05. Aug 20 07. Aug 20 276-01-0233, 276-01-0226, 276-01-0221
E220195-0018L 20062 10062 05. Aug 20 07. Aug 20 276-01-0306
E220195-0018L 20063 10063 05. Aug 20 07. Aug 20 276-01-0310, 276-01-0309,
E220195-0018L 20064 10064 05. Aug 20 07. Aug 20 276-01-0268, 276-01-0267, 276-01-0265, 276-01-0269
E220195-0018L 20065 10065 05. Aug 20 07. Aug 20 276-01-0261, 276-01-0263
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\3bc73a591e771090
FDA-CBER-2021-5683-0049347
Page 14
FDA-CBER-2021-5683-0049348
FDA-CBER-2021-5683-0049349
BioNTech RNA Pharmaceuticals GmbH Interim Clinical Study Report - BNT162-01 Page: 8 of 9
Confidential Investigational Product Tracking Table for: BNT162b2 Date: 23 NOV 2020
Date of Date of
Packaging
Medication Sequence Shipment Arrival at
Batch No. Subject No.
No. No. to study study
(kit)
site/pharmacy site/pharmacy
E220195-0018L 20066 10066 05. Aug 20 07. Aug 20 276-01-0261
E220195-0018L 20067 10067 05. Aug 20 07. Aug 20 276-01-0324, 276-01-0314
E220195-0018L 20068 10068 05. Aug 20 07. Aug 20 276-01-0300, 276-01-0299, 276-01-0279, 276-01-0277, 276-01-0276, 276-01-0275
E220195-0018L 20069 10069 05. Aug 20 07. Aug 20 276-01-0269, 276-01-0268, 276-01-0267, 276-01-0265
E220195-0018L 20070 10070 05. Aug 20 07. Aug 20 276-01-0261, 276-01-0263
E220195-0018L 20071 10071 05. Aug 20 07. Aug 20 276-01-0323, 276-01-0319, 276-01-0308
E220195-0018L 20072 10072 05. Aug 20 07. Aug 20 276-01-0316
E220195-0018L 20073 10073 05. Aug 20 07. Aug 20 276-01-0305, 276-01-0303, 276-01-0272
E220195-0018L 20074 10074 05. Aug 20 07. Aug 20 276-01-0319, 276-01-0308, 276-01-0323
E220195-0018L 20075 10075 05. Aug 20 07. Aug 20 276-01-0303, 276-01-0272
E220195-0018L 20076 10076 05. Aug 20 07. Aug 20 276-01-0300, 276-01-0299, 276-01-0279, 276-01-0275, 276-01-0277, 276-01-0276
E220195-0017L 20077 10077 21. Aug 20 24. Aug 20 276-01-0305
E220195-0017L 20083 10083 21. Aug 20 24. Aug 20 276-01-0324
E220195-0017L 20088 10088 21. Aug 20 24. Aug 20 276-01-0314, 276-01-0310, 276-01-0309
)TMG(
34:20
0202-voN-82
:nO
devorppA\devorppA\3bc73a591e771090
FDA-CBER-2021-5683-0049350
Page 17
FDA-CBER-2021-5683-0049351","[[['RNA\nVariant', 'RNA', 'DS Batch\nNo.', 'DP Batch\nNo.', 'Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Expiry Date', 'SO-No.', 'Country', 'Trial site\nNo.\nPharmacy'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10002', '2', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10003', '3', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10004', '4', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10005', '5', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10006', '6', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10007', '7', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10008', '8', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10009', '9', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10010', '10', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10011', '11', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10012', '12', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10013', '13', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10014', '14', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10015', '15', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10016', '16', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10017', '17', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10018', '18', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10019', '19', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10020', '20', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10021', '21', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10022', '22', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10023', '23', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10024', '24', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10025', '25', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10026', '26', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10027', '27', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10028', '28', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim']], [['Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Date of\nShipment\nto study\nsite/pharmacy', 'Date of\nArrival at\nstudy\nsite/pharmacy', 'Subject No.'], ['E220195-0001L', '10002', '2', '19. Apr 20', '21. Apr 20', '276-01-0021, 276-01-0032, 276-01-0034'], ['E220195-0001L', '10003', '3', '19. Apr 20', '21. Apr 20', '276-01-0028, 276-01-0031, 276-01-0038'], ['E220195-0001L', '10004', '4', '19. Apr 20', '21. Apr 20', '276-01-0056'], ['E220195-0001L', '10005', '5', '19. Apr 20', '21. Apr 20', '276-01-0096'], ['E220195-0001L', '10006', '6', '19. Apr 20', '21. Apr 20', '276-01-0053'], ['E220195-0001L', '10007', '7', '19. Apr 20', '21. Apr 20', '276-01-0067'], ['E220195-0001L', '10008', '8', '19. Apr 20', '21. Apr 20', '276-01-0057'], ['E220195-0001L', '10009', '9', '19. Apr 20', '21. Apr 20', '276-01-0007'], ['E220195-0001L', '10010', '10', '19. Apr 20', '21. Apr 20', '276-01-0025, 276-01-0023, 276-01-0033, 276-01-0045'], ['E220195-0001L', '10011', '11', '19. Apr 20', '21. Apr 20', '276-01-0083'], ['E220195-0001L', '10012', '12', '19. Apr 20', '21. Apr 20', '276-01-0066'], ['E220195-0001L', '10013', '13', '19. Apr 20', '21. Apr 20', '276-01-0016, 276-01-0020'], ['E220195-0001L', '10014', '14', '19. Apr 20', '21. Apr 20', '276-01-0003, 276-01-0006, 276-01-0008, 276-01-0009, 276-01-0019, 276-01-0017'], ['E220195-0001L', '10015', '15', '19. Apr 20', '21. Apr 20', '276-01-0011, 276-01-0005, 276-01-0004, 276-01-0001'], ['E220195-0001L', '10016', '16', '19. Apr 20', '21. Apr 20', '276-01-0073'], ['E220195-0001L', '10017', '17', '19. Apr 20', '21. Apr 20', '276-01-0055'], ['E220195-0001L', '10018', '18', '19. Apr 20', '21. Apr 20', '276-01-0070'], ['E220195-0001L', '10019', '19', '19. Apr 20', '21. Apr 20', '276-01-0049'], ['E220195-0001L', '10020', '20', '19. Apr 20', '21. Apr 20', '276-01-0059'], ['E220195-0001L', '10021', '21', '19. Apr 20', '21. Apr 20', '276-01-0037'], ['E220195-0001L', '10022', '22', '19. Apr 20', '21. Apr 20', '276-01-0015, 276-01-0018'], ['E220195-0001L', '10023', '23', '19. Apr 20', '21. Apr 20', '276-01-0007'], ['E220195-0001L', '10024', '24', '19. Apr 20', '21. Apr 20', '276-01-0039, 276-01-0043, 276-01-0047'], ['E220195-0001L', '10025', '25', '19. Apr 20', '21. Apr 20', '276-01-0011, 276-01-0010, 276-01-0005, 276-01-0004, 276-01-0001'], ['E220195-0001L', '10026', '26', '19. Apr 20', '21. Apr 20', '276-01-0036, 276-01-0040, 276-01-0041, 276-01-0042, 276-01-0048, 276-01-0052'], ['E220195-0001L', '10027', '27', '19. Apr 20', '21. Apr 20', '276-01-0003, 276-01-0006, 276-01-0008, 276-01-0009, 276-01-0019, 276-01-0017'], ['E220195-0001L', '10028', '28', '19. Apr 20', '21. Apr 20', '276-01-0050']], [['Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Date used', 'Drug accountability\nfinally checked on', 'Deviation\nYes/No\nif yes\nDeviation No.', 'comments'], ['E220195-0001L', '10002', '2', '05. Mai 20', '08. Mai 20', 'N', ''], ['E220195-0001L', '10003', '3', '07. Mai 20', '08. Mai 20', 'N', ''], ['E220195-0001L', '10004', '4', '13. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10005', '5', '19. Mai 20', '20. Mai 20', 'N', ''], ['E220195-0001L', '10006', '6', '12. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10007', '7', '15. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10008', '8', '15. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10009', '9', '14. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10010', '10', '05. Mai 20', '08. Mai 20', 'N', ''], ['E220195-0001L', '10011', '11', '20. Mai 20', '20. Mai 20', 'N', ''], ['E220195-0001L', '10012', '12', '19. Mai 20', '20. Mai 20', 'N', ''], ['E220195-0001L', '10013', '13', '29. Apr 20', '30. Apr 20', 'N', ''], ['E220195-0001L', '10014', '14', '28. Apr 20', '30. Apr 20', 'N', ''], ['E220195-0001L', '10015', '15', '15. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10016', '16', '15. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10017', '17', '13. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10018', '18', '15. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10019', '19', '12. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10020', '20', '13. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10021', '21', '05. Mai 20', '08. Mai 20', 'N', ''], ['E220195-0001L', '10022', '22', '29. Apr 20', '30. Apr 20', 'N', ''], ['E220195-0001L', '10023', '23', '23. Apr 20', '30. Apr 20', 'N', ''], ['E220195-0001L', '10024', '24', '07. Mai 20', '08. Mai 20', 'N', ''], ['E220195-0001L', '10025', '25', '24. Apr 20', '30. Apr 20', 'N', ''], ['E220195-0001L', '10026', '26', '08. Mai 20', '08. Mai 20', 'N', ''], ['E220195-0001L', '10027', '27', '19. Mai 20', '20. Mai 20', 'N', ''], ['E220195-0001L', '10028', '28', '15. Mai 20', '15. Mai 20', 'N', '']], [['RNA\nVariant', 'RNA', 'DS Batch\nNo.', 'DP Batch\nNo.', 'Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Expiry Date', 'SO-No.', 'Country', 'Trial site\nNo.\nPharmacy'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10029', '29', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10030', '30', '25. Sep 20', 'SO-20-0022', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10031', '31', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10032', '32', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10033', '33', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10034', '34', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10035', '35', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10036', '36', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10037', '37', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10038', '38', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10039', '39', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10040', '40', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10041', '41', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10042', '42', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10043', '43', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10044', '44', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10045', '45', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0001L', '10046', '46', '25. Sep 20', 'SO-20-0033', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10047', '47', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10048', '48', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10049', '49', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10050', '50', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10051', '51', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10052', '52', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10053', '53', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10054', '54', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10055', '55', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0004L', '10056', '56', '25. Sep 20', 'SO-20-0038', 'Germany', '#1/Mannheim']], [['Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Date of\nShipment\nto study\nsite/pharmacy', 'Date of\nArrival at\nstudy\nsite/pharmacy', 'Subject No.'], ['E220195-0001L', '10029', '29', '19. Apr 20', '21. Apr 20', '276-01-0060'], ['E220195-0001L', '10030', '30', '19. Apr 20', '21. Apr 20', '276-01-0068'], ['E220195-0001L', '10031', '31', '11. Mai 20', '13. Mai 20', '276-01-0025, 276-01-0023, 276-01-0033, 276-01-0045'], ['E220195-0001L', '10032', '32', '11. Mai 20', '13. Mai 20', '276-01-0084'], ['E220195-0001L', '10033', '33', '11. Mai 20', '13. Mai 20', '276-01-0028, 276-01-0031, 276-01-0038'], ['E220195-0001L', '10034', '34', '11. Mai 20', '13. Mai 20', '276-01-0021, 276-01-0032'], ['E220195-0001L', '10035', '35', '11. Mai 20', '13. Mai 20', '276-01-0089'], ['E220195-0001L', '10036', '36', '11. Mai 20', '13. Mai 20', '276-01-0075'], ['E220195-0001L', '10037', '37', '11. Mai 20', '13. Mai 20', '276-01-0103'], ['E220195-0001L', '10038', '38', '11. Mai 20', '13. Mai 20', '276-01-0104'], ['E220195-0001L', '10039', '39', '11. Mai 20', '13. Mai 20', '276-01-0093'], ['E220195-0001L', '10040', '40', '11. Mai 20', '13. Mai 20', '276-01-0078'], ['E220195-0001L', '10041', '41', '11. Mai 20', '13. Mai 20', '276-01-0034, 276-01-0037'], ['E220195-0001L', '10042', '42', '11. Mai 20', '13. Mai 20', '276-01-0015, 276-01-0018, 276-01-0015, 276-01-0018'], ['E220195-0001L', '10043', '43', '11. Mai 20', '13. Mai 20', '276-01-0016, 276-01-0020'], ['E220195-0001L', '10044', '44', '11. Mai 20', '13. Mai 20', '276-01-0085'], ['E220195-0001L', '10045', '45', '11. Mai 20', '13. Mai 20', '276-01-0076'], ['E220195-0001L', '10046', '46', '11. Mai 20', '13. Mai 20', '276-01-0039, 276-01-0043, 276-01-0047'], ['E220195-0004L', '10047', '47', '26. Mai 20', '28. Mai 20', '276-01-0049, 276-01-0053'], ['E220195-0004L', '10048', '48', '26. Mai 20', '28. Mai 20', '276-01-0178, 276-01-0179, 276-01-0181'], ['E220195-0004L', '10049', '49', '26. Mai 20', '28. Mai 20', '276-01-0060, 276-01-0059'], ['E220195-0004L', '10050', '50', '26. Mai 20', '28. Mai 20', '276-01-0171, 276-01-0172, 276-01-0173'], ['E220195-0004L', '10051', '51', '26. Mai 20', '28. Mai 20', '276-01-0067, 276-01-0057'], ['E220195-0004L', '10052', '52', '26. Mai 20', '28. Mai 20', '276-01-0036, 276-01-0052, 276-01-0048, 276-01-0042, 276-01-0041, 276-01-0040'], ['E220195-0004L', '10053', '53', '26. Mai 20', '28. Mai 20', '276-01-0056, 276-01-0055'], ['E220195-0004L', '10054', '54', '26. Mai 20', '28. Mai 20', '276-01-0070, 276-01-0068'], ['E220195-0004L', '10055', '55', '26. Mai 20', '28. Mai 20', '276-01-0151, 276-01-0175, 276-01-0176,'], ['E220195-0004L', '10056', '56', '26. Mai 20', '28. Mai 20', '276-01-0073']], [['Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Date used', 'Drug accountability\nfinally checked on', 'Deviation\nYes/No\nif yes\nDeviation No.', 'comments'], ['E220195-0001L', '10029', '29', '13. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10030', '30', '15. Mai 20', '15. Mai 20', 'N', ''], ['E220195-0001L', '10031', '31', '26. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10032', '32', '22. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10033', '33', '28. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10034', '34', '26. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10035', '35', '20. Mai 20', '20. Mai 20', 'N', ''], ['E220195-0001L', '10036', '36', '22. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10037', '37', '22. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10038', '38', '20. Mai 20', '20. Mai 20', 'N', ''], ['E220195-0001L', '10039', '39', '20. Mai 20', '20. Mai 20', 'N', ''], ['E220195-0001L', '10040', '40', '22. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10041', '41', '26. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10042', '42', '20. Mai 20', '20. Mai 20', 'N', ''], ['E220195-0001L', '10043', '43', '20. Mai 20', '20. Mai 20', 'N', ''], ['E220195-0001L', '10044', '44', '22. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10045', '45', '22. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0001L', '10046', '46', '28. Mai 20', '28. Mai 20', 'N', ''], ['E220195-0004L', '10047', '47', '02. Jun 20', '03. Jun 20', 'N', ''], ['E220195-0004L', '10048', '48', '16. Jun 20', '17. Jun 20', 'N', ''], ['E220195-0004L', '10049', '49', '03. Jun 20', '03. Jun 20', 'N', ''], ['E220195-0004L', '10050', '50', '16. Jun 20', '17. Jun 20', 'N', ''], ['E220195-0004L', '10051', '51', '05. Jun 20', '24. Jun 20', 'N', ''], ['E220195-0004L', '10052', '52', '29. Mai 20', '03. Jun 20', 'N', ''], ['E220195-0004L', '10053', '53', '03. Jun 20', '03. Jun 20', 'N', ''], ['E220195-0004L', '10054', '54', '05. Jun 20', '24. Jun 20', 'N', ''], ['E220195-0004L', '10055', '55', '16. Jun 20', '17. Jun 20', 'N', ''], ['E220195-0004L', '10056', '56', '05. Jun 20', '24. Jun 20', 'N', '']], [['RNA\nVariant', 'RNA', 'DS Batch\nNo.', 'DP Batch\nNo.', 'Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Expiry Date', 'SO-No.', 'Country', 'Trial site\nNo.\nPharmacy'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10103', '103', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10104', '104', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10105', '105', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10106', '106', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10107', '107', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10108', '108', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10109', '109', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10111', '111', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10112', '112', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10113', '113', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10115', '115', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10116', '116', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10117', '117', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10118', '118', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10119', '119', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10120', '120', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10124', '124', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10125', '125', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10126', '126', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim'], ['V5modRNA', 'RBP020.3', 'R425-P020.3-DS', 'BCV10320-A', 'E220195-0014L', '10130', '130', '25. Sep 20', 'SO-20-0058', 'Germany', '#1/Mannheim']], [['Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Date of\nShipment\nto study\nsite/pharmacy', 'Date of\nArrival at\nstudy\nsite/pharmacy', 'Subject No.'], ['E220195-0014L', '10103', '103', '14.06.2020', '16.06.2020', '276-01-0351, 276-01-0363, 276-01-0364'], ['E220195-0014L', '10104', '104', '14.06.2020', '16.06.2020', '276-01-0366, 276-01-0365'], ['E220195-0014L', '10105', '105', '14.06.2020', '16.06.2020', '276-01-0282, 276-01-0289'], ['E220195-0014L', '10106', '106', '14.06.2020', '16.06.2020', '276-01-0181, 276-01-0179, 276-01-0178'], ['E220195-0014L', '10107', '107', '14.06.2020', '16.06.2020', '276-01-273, 276-01-0274, 276-01-0283, 276-01-0292, 276-01-0320, 276-01-298'], ['E220195-0014L', '10108', '108', '14.06.2020', '16.06.2020', '276-01-0194, 276-01-0200, 276-01-0204, 276-01-0198, 276-01-0209, 276-01-0212'], ['E220195-0014L', '10109', '109', '14.06.2020', '16.06.2020', '276-01-0287, 276-01-0286, 276-01-0291, 276-01-0288,'], ['E220195-0014L', '10111', '111', '14.06.2020', '16.06.2020', '276-01-0286, 276-01-0287, 276-01-0288, 276-01-0291'], ['E220195-0014L', '10112', '112', '14.06.2020', '16.06.2020', '276-01-0352'], ['E220195-0014L', '10113', '113', '14.06.2020', '16.06.2020', '276-01-0197, 276-01-0183,'], ['E220195-0014L', '10115', '115', '14.06.2020', '16.06.2020', '276-01-0360, 276-01-0358'], ['E220195-0014L', '10116', '116', '14.06.2020', '16.06.2020', '276-01-0182, 276-01-0183, 276-01-0187'], ['E220195-0014L', '10117', '117', '14.06.2020', '16.06.2020', '276-01-0320, 276-01-0273, 276-01-0283, 276-01-0292, 276-01-0298, 276-01-0274'], ['E220195-0014L', '10118', '118', '14.06.2020', '16.06.2020', '276-01-0361, 276-01-0350, 276-01-0362'], ['E220195-0014L', '10119', '119', '14.06.2020', '16.06.2020', '276-01-0171, 276-01-0151, 276-01-0172,'], ['E220195-0014L', '10120', '120', '14.06.2020', '16.06.2020', '276-01-0175, 276-01-0173, 276-01-0176,'], ['E220195-0014L', '10124', '124', '14.06.2020', '16.06.2020', '276-01-0227, 276-01-0221, 276-01-0226, 276-01-0225, 276-01-0224, 276-01-0170'], ['E220195-0014L', '10125', '125', '14.06.2020', '16.06.2020', '276-01-0282, 276-01-0289,'], ['E220195-0014L', '10126', '126', '14.06.2020', '16.06.2020', '276-01-0194, 276-01-0198, 276-01-0200, 276-01-0204, 276-01-0209, 276-01-0212'], ['E220195-0014L', '10130', '130', '14.06.2020', '16.06.2020', '276-01-0170, 276-01-0227, 276-01-0221, 276-01-0226, 276-01-0225, 276-01-0224,']], [['Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Date used', 'Drug accountability\nfinally checked on', 'Deviation\nYes/No\nif yes\nDeviation No.', 'comments'], ['E220195-0014L', '10103', '103', '25. Sep 20', '01. Oct 20', 'N', ''], ['E220195-0014L', '10104', '104', '23. Sep 20', '23. Sep 20', 'N', ''], ['E220195-0014L', '10105', '105', '20. Aug 20', '02. Sep 20', 'N', ''], ['E220195-0014L', '10106', '106', '06. Aug 20', '02. Sep 20', 'N', ''], ['E220195-0014L', '10107', '107', '17. Sep 20', '23. Sep 20', 'N', ''], ['E220195-0014L', '10108', '108', '22. Jul 20', '30. Jul 20', 'N', ''], ['E220195-0014L', '10109', '109', '25. Aug 20', '02. Sep 20', 'N', ''], ['E220195-0014L', '10111', '111', '15. Sep 20', '23. Sep 20', 'N', ''], ['E220195-0014L', '10112', '112', '22. Sep 20', '23. Sep 20', 'N', ''], ['E220195-0014L', '10113', '113', '06. Aug 20', '02. Sep 20', 'N', ''], ['E220195-0014L', '10115', '115', '23. Sep 20', '23. Sep 20', 'N', ''], ['E220195-0014L', '10116', '116', '16. Jun 20', '17. Jun 20', 'N', ''], ['E220195-0014L', '10117', '117', '27. Aug 20', '02. Sep 20', 'N', ''], ['E220195-0014L', '10118', '118', '25.Sep.20', '01.Oct 20', 'N', ''], ['E220195-0014L', '10119', '119', '06. Aug 20', '02. Sep 20', 'N', ''], ['E220195-0014L', '10120', '120', '06. Aug 20', '02. Sep 20', 'N', ''], ['E220195-0014L', '10124', '124', '31. Jul 20', '02. Sep 20', 'N', ''], ['E220195-0014L', '10125', '125', '10. Sep 20', '23. Sep 20', 'N', ''], ['E220195-0014L', '10126', '126', '12. Aug 20', '02. Sep 20', 'N', ''], ['E220195-0014L', '10130', '130', '21. Aug 20', '02. Sep 20', 'N', '']], [['Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Date of\nShipment\nto study\nsite/pharmacy', 'Date of\nArrival at\nstudy\nsite/pharmacy', 'Subject No.'], ['E220195-0004L', '20001', '10001', '05. Jun 20', '07. Jun 20', '276-02-0103'], ['E220195-0004L', '20003', '10003', '05. Jun 20', '07. Jun 20', '276-02-0110, 276-02-0105, 276-02-0104, 276-02-0101, 276-02-0102'], ['E220195-0004L', '20004', '10004', '05. Jun 20', '07. Jun 20', '276-02-0118, 276-02-0116, 276-02-0121, 276-02-0111,276-02-0117, 276-02-0114'], ['E220195-0004L', '20005', '10005', '05. Jun 20', '07. Jun 20', '276-02-0149, 276-02-0127'], ['E220195-0004L', '20006', '10006', '05. Jun 20', '07. Jun 20', '276-02-0155, 276-02-0150'], ['E220195-0004L', '20007', '10007', '05. Jun 20', '07. Jun 20', '276-02-0137, 276-02-0128'], ['E220195-0004L', '20008', '10008', '05. Jun 20', '07. Jun 20', '145, 276-02-0143, 276-02-0134'], ['E220195-0004L', '20009', '10009', '05. Jun 20', '07. Jun 20', '276-02-0138, 276-02-0144, 276-02-0142'], ['E220195-0004L', '20010', '10010', '05. Jun 20', '07. Jun 20', '276-02-0154, 276-02-0166, 276-02-0163, 276-02-0157, 276-02-0160, 276-02-0153'], ['E220195-0004L', '20011', '10011', '05. Jun 20', '07. Jun 20', '276-02-0137, 276-02-0128, 276-02-0155'], ['E220195-0004L', '20012', '10012', '05. Jun 20', '07. Jun 20', '276-02-0153, 276-02-0157, 276-02-0163, 276-02-0166, 276-02-0154'], ['E220195-0004L', '20013', '10013', '05. Jun 20', '07. Jun 20', '276-02-0134, 276-02-0143, 276-02-0145'], ['E220195-0004L', '20014', '10014', '05. Jun 20', '07. Jun 20', '276-02-0142, 276-02-0144, 276-02-0138'], ['E220195-0004L', '20016', '10016', '05. Jun 20', '07. Jun 20', '276-02-0111'], ['E220195-0004L', '20018', '10018', '05. Jun 20', '07. Jun 20', '276-02-0118, 276-02-0121, 276-02-0117, 276-02-0114'], ['E220195-0004L', '20019', '10019', '05. Jun 20', '07. Jun 20', '276-02-0164, 276-02-0171, 276-02-0158'], ['E220195-0004L', '20021', '10021', '05. Jun 20', '07. Jun 20', '276-02-0183, 276-02-0180'], ['E220195-0004L', '20022', '10022', '05. Jun 20', '07. Jun 20', '276-02-0150, 276-02-0149, 276-02-0127'], ['E220195-0004L', '20023', '10023', '05. Jun 20', '07. Jun 20', '276-02-0159, 276-02-0168'], ['E220195-0004L', '20024', '10024', '05. Jun 20', '07. Jun 20', '276-02-0173, 276-02-0156, 276-02-0172'], ['E220195-0004L', '20025', '10025', '05. Jun 20', '07. Jun 20', '276-02-0105, 276-02-0103'], ['E220195-0004L', '20027', '10027', '05. Jun 20', '07. Jun 20', '276-02-0181, 276-02-0179, 276-02-0175'], ['E220195-0004L', '20029', '10029', '05. Jun 20', '07. Jun 20', '276-02-0174, 276-02-0177, 276-02-0178'], ['E220195-0004L', '20030', '10030', '05. Jun 20', '07. Jun 20', '276-02-0110, 276-02-0104, 276-02-0101, 276-02-0102'], ['E220195-0004L', '20031', '10031', '14. Jul 20', '16. Jul 20', '276-02-0159, 276-02-0168'], ['E220195-0004L', '20032', '10032', '14. Jul 20', '16. Jul 20', '276-02-0172, 276-02-0156, 276-02-0173'], ['E220195-0004L', '20033', '10033', '14. Jul 20', '16. Jul 20', '276-02-0175, 276-02-0178, 276-02-0177']], [['Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Date of\nShipment\nto study\nsite/pharmacy', 'Date of\nArrival at\nstudy\nsite/pharmacy', 'Subject No.'], ['E220195-0004L', '20034', '10034', '14. Jul 20', '16. Jul 20', '276-02-0174'], ['E220195-0004L', '20035', '10035', '14. Jul 20', '16. Jul 20', '276-02-0188, 276-02-0189, 276-02-0181'], ['E220195-0004L', '20038', '10038', '14. Jul 20', '16. Jul 20', '276-02-0179'], ['E220195-0004L', '20039', '10039', '14. Jul 20', '16. Jul 20', '276-02-0185, 276-02-0193, 276-02-0176, 276-02-0194'], ['E220195-0004L', '20040', '10040', '14. Jul 20', '16. Jul 20', '276-02-0195, 276-02-0203, 276-02-0204'], ['E220195-0004L', '20042', '10042', '14. Jul 20', '16. Jul 20', '276-02-0158, 276-02-0171, 276-02-0164'], ['E220195-0004L', '20043', '10043', '14. Jul 20', '16. Jul 20', '276-02-0180, 276-02-0183'], ['E220195-0004L', '20044', '10044', '14. Jul 20', '16. Jul 20', '276-02-201, 276-02-191'], ['E220195-0004L', '20045', '10045', '14. Jul 20', '16. Jul 20', '276-02-0197, 276-02-0192'], ['E220195-0004L', '20046', '10046', '14. Jul 20', '16. Jul 20', '276-01-0201, 276-01-0191'], ['E220195-0004L', '20047', '10047', '14. Jul 20', '16. Jul 20', '276-01-0223'], ['E220195-0004L', '20048', '10048', '14. Jul 20', '16. Jul 20', '276-01-0203'], ['E220195-0004L', '20049', '10049', '14. Jul 20', '16. Jul 20', '276-01-0203 (not dosed), 276-01-0204, 276-01-0200, 276-01-0195'], ['E220195-0004L', '20050', '10050', '14. Jul 20', '16. Jul 20', '276-01-0192, 276-01-0197, 276-01-0194, 276-01-0176, 276-01-0193, 276-01-0185'], ['E220195-0004L', '20051', '10051', '14. Jul 20', '16. Jul 20', '276-02-0200'], ['E220195-0004L', '20053', '10053', '14. Jul 20', '16. Jul 20', '276-01-0225, 276-01-0222, 276-01-0214,'], ['E220195-0004L', '20054', '10054', '14. Jul 20', '16. Jul 20', '276-01-0229, 276-01-0215, 276-01-0224'], ['E220195-0004L', '20055', '10055', '14. Jul 20', '16. Jul 20', '276-01-0208, 276-01-0216'], ['E220195-0004L', '20056', '10056', '14. Jul 20', '16. Jul 20', '276-01-0181, 276-01-0189, 276-01-0188'], ['E220195-0018L', '20057', '10057', '05. Aug 20', '07. Aug 20', '276-01-0233, 276-01-0226, 276-01-0221'], ['E220195-0018L', '20062', '10062', '05. Aug 20', '07. Aug 20', '276-01-0306'], ['E220195-0018L', '20063', '10063', '05. Aug 20', '07. Aug 20', '276-01-0310, 276-01-0309,'], ['E220195-0018L', '20064', '10064', '05. Aug 20', '07. Aug 20', '276-01-0268, 276-01-0267, 276-01-0265, 276-01-0269'], ['E220195-0018L', '20065', '10065', '05. Aug 20', '07. Aug 20', '276-01-0261, 276-01-0263']], [['Packaging\nBatch No.\n(kit)', 'Medication\nNo.', 'Sequence\nNo.', 'Date of\nShipment\nto study\nsite/pharmacy', 'Date of\nArrival at\nstudy\nsite/pharmacy', 'Subject No.'], ['', '', '', '05. Aug 20', '07. Aug 20', '276-01-0261'], ['E220195-0018L', '20066', '10066', None, None, None], ['E220195-0018L', '20067', '10067', '05. Aug 20', '07. Aug 20', '276-01-0324, 276-01-0314'], ['E220195-0018L', '20068', '10068', '05. Aug 20', '07. Aug 20', '276-01-0300, 276-01-0299, 276-01-0279, 276-01-0277, 276-01-0276, 276-01-0275'], ['E220195-0018L', '20069', '10069', '05. Aug 20', '07. Aug 20', '276-01-0269, 276-01-0268, 276-01-0267, 276-01-0265'], ['E220195-0018L', '20070', '10070', '05. Aug 20', '07. Aug 20', '276-01-0261, 276-01-0263'], ['E220195-0018L', '20071', '10071', '05. Aug 20', '07. Aug 20', '276-01-0323, 276-01-0319, 276-01-0308'], ['E220195-0018L', '20072', '10072', '05. Aug 20', '07. Aug 20', '276-01-0316'], ['E220195-0018L', '20073', '10073', '05. Aug 20', '07. Aug 20', '276-01-0305, 276-01-0303, 276-01-0272'], ['E220195-0018L', '20074', '10074', '05. Aug 20', '07. Aug 20', '276-01-0319, 276-01-0308, 276-01-0323'], ['E220195-0018L', '20075', '10075', '05. Aug 20', '07. Aug 20', '276-01-0303, 276-01-0272'], ['E220195-0018L', '20076', '10076', '05. Aug 20', '07. Aug 20', '276-01-0300, 276-01-0299, 276-01-0279, 276-01-0275, 276-01-0277, 276-01-0276'], ['E220195-0017L', '20077', '10077', '21. Aug 20', '24. Aug 20', '276-01-0305'], ['E220195-0017L', '20083', '10083', '21. Aug 20', '24. Aug 20', '276-01-0324'], ['E220195-0017L', '20088', '10088', '21. Aug 20', '24. Aug 20', '276-01-0314, 276-01-0310, 276-01-0309']]]",18
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_27_literature-references.pdf,2.0,"BNT162b2
2.7.5Literature References
2.7.5 LITERATURE REFERENCES
References are listed in the clinical summary documents as indicated below:
Module 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical
Methods -None
Module 2.7.2 Summary of Clinical Pharmacology Studies -Not Applicable
Module 2.7.3 Summary of Clinical Efficacy, References
Module 2.7.4 Summary of Clinical Safety, References
Copies of the literature references are provided in Module 5.4 Literature References.
CONFIDENTIAL
Page 1
)TMG(
85:32
0202-ceD-10
:nO
devorppA\devorppA\2569aa591e771090
FDA-CBER-2021-5683-0013921
Document Approval Record
DocumentName:
(cid:5)(cid:6)(cid:7)(cid:8)(cid:9)(cid:8)(cid:9)(cid:10)(cid:11)(cid:12)(cid:13)(cid:5)(cid:14)(cid:15)(cid:16)(cid:12)(cid:17)(cid:7)(cid:7)(cid:18)(cid:19)(cid:6)(cid:8)(cid:9)(cid:8)(cid:9)(cid:8)(cid:20)(cid:21)(cid:20)(cid:22)(cid:23)(cid:18)(cid:24)(cid:6)(cid:25)(cid:17)(cid:24)(cid:26)(cid:25)(cid:6)(cid:27)(cid:6)(cid:28)(cid:6)(cid:25)(cid:6)(cid:19)(cid:7)(cid:6)(cid:29)
DocumentTitle:
(cid:5)(cid:6)(cid:7)(cid:8)(cid:9)(cid:8)(cid:9)(cid:10)(cid:11)(cid:12)(cid:13)(cid:5)(cid:14)(cid:15)(cid:16)(cid:12)(cid:17)(cid:7)(cid:7)(cid:18)(cid:19)(cid:6)(cid:8)(cid:9)(cid:8)(cid:9)(cid:8)(cid:20)(cid:21)(cid:20)(cid:22)(cid:23)(cid:18)(cid:24)(cid:6)(cid:25)(cid:17)(cid:24)(cid:26)(cid:25)(cid:6)(cid:27)(cid:6)(cid:28)(cid:6)(cid:25)(cid:6)(cid:19)(cid:7)(cid:6)(cid:29)
SignedBy: Date(GMT) SigningCapacity
(cid:30)(cid:6)(cid:25)(cid:6)(cid:31)(cid:32)(cid:33)(cid:34)(cid:35)(cid:19) (cid:9)(cid:15)(cid:14)(cid:5)(cid:6)(cid:7)(cid:14)(cid:8)(cid:9)(cid:8)(cid:9)(cid:8)(cid:36)(cid:37)(cid:22)(cid:38)(cid:37)(cid:9)(cid:16) (cid:39)(cid:18)(cid:19)(cid:17)(cid:40)(cid:41)(cid:42)(cid:42)(cid:25)(cid:34)(cid:43)(cid:17)(cid:40)
)TMG(
85:32
0202-ceD-10
:nO
devorppA\devorppA\2569aa591e771090
FDA-CBER-2021-5683-0013922","[[['DocumentName:'], ['DocumentTitle:']]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-lymphoma.pdf,6.0,"CCI_Lymphoma
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Lymphoma
Code: 90002957
Extension: CCI
Report Date/Time: 27-Oct-2020:10:47:45 AM EDT
Term Code Level Category Weight Scope
Waldenstrom's macroglobulinaemia stage IV 10047809 PT
Waldenstrom's macroglobulinaemia stage III 10047808 PT
Waldenstrom's macroglobulinaemia stage II 10047807 PT
Waldenstrom's macroglobulinaemia stage I 10047806 PT
Waldenstrom's macroglobulinaemia refractory 10047805 PT
Waldenstrom's macroglobulinaemia recurrent 10047804 PT
Waldenstrom's macroglobulinaemia 10047801 PT
Thyroid B-cell lymphoma 10072613 PT
T-cell unclassifiable lymphoma low grade 10042990 PT
T-cell unclassifiable lymphoma high grade 10042989 PT
T-cell lymphoma stage IV 10042984 PT
T-cell lymphoma stage III 10042983 PT
T-cell lymphoma stage II 10042982 PT
T-cell lymphoma stage I 10042981 PT
T-cell lymphoma refractory 10042980 PT
T-cell lymphoma recurrent 10042979 PT
T-cell lymphoma 10042971 PT
Splenic marginal zone lymphoma stage IV 10041657 PT
Splenic marginal zone lymphoma stage III 10041656 PT
Splenic marginal zone lymphoma stage II 10041655 PT
Splenic marginal zone lymphoma stage I 10041654 PT
Splenic marginal zone lymphoma refractory 10041653 PT
Splenic marginal zone lymphoma recurrent 10041652 PT
Splenic marginal zone lymphoma 10062113 PT
Richter's syndrome 10058728 PT
Nodal marginal zone B-cell lymphoma recurrent 10029463 PT
Nodal marginal zone B-cell lymphoma 10029460 PT
Natural killer-cell lymphoblastic lymphoma 10058975 PT
Cutaneous T-cell lymphoma stage IV 10011683 PT
Primary mediastinal large B-cell lymphoma stage IV 10036718 PT
Primary mediastinal large B-cell lymphoma stage III 10036717 PT
Primary mediastinal large B-cell lymphoma stage II 10036716 PT
Primary mediastinal large B-cell lymphoma stage I 10036715 PT
Primary mediastinal large B-cell lymphoma refractory 10036714 PT
B-cell small lymphocytic lymphoma stage III 10003915 PT
B-cell small lymphocytic lymphoma stage II 10003914 PT
B-cell small lymphocytic lymphoma stage I 10003913 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c32dde691e771090
FDA-CBER-2021-5683-0023938
B-cell small lymphocytic lymphoma refractory 10003912 PT
B-cell small lymphocytic lymphoma recurrent 10003911 PT
B-cell small lymphocytic lymphoma 10003908 PT
B-cell prolymphocytic leukaemia 10073480 PT
B-cell lymphoma stage IV 10003907 PT
B-cell lymphoma stage III 10003906 PT
B-cell lymphoma stage II 10003905 PT
B-cell lymphoma stage I 10003904 PT
B-cell lymphoma refractory 10003903 PT
B-cell lymphoma recurrent 10003902 PT
B-cell lymphoma 10003899 PT
Angioimmunoblastic T-cell lymphoma stage IV 10002457 PT
Angioimmunoblastic T-cell lymphoma stage III 10002456 PT
Angioimmunoblastic T-cell lymphoma stage II 10002455 PT
Angioimmunoblastic T-cell lymphoma stage I 10002454 PT
Angioimmunoblastic T-cell lymphoma refractory 10002453 PT
Angioimmunoblastic T-cell lymphoma recurrent 10002452 PT
Angioimmunoblastic T-cell lymphoma 10002449 PT
Angiocentric lymphoma stage IV 10002419 PT
Angiocentric lymphoma stage III 10002418 PT
Angiocentric lymphoma stage II 10002417 PT
Primary mediastinal large B-cell lymphoma recurrent 10036713 PT
Primary mediastinal large B-cell lymphoma 10036710 PT
Primary effusion lymphoma 10065857 PT
Primary cardiac lymphoma 10075993 PT
Precursor T-lymphoblastic lymphoma/leukaemia stage IV 10036551 PT
Precursor T-lymphoblastic lymphoma/leukaemia stage III 10036550 PT
Precursor T-lymphoblastic lymphoma/leukaemia stage II 10036549 PT
Precursor T-lymphoblastic lymphoma/leukaemia stage I 10036548 PT
Precursor T-lymphoblastic lymphoma/leukaemia refractory 10036547 PT
Precursor T-lymphoblastic lymphoma/leukaemia recurrent 10036546 PT
Precursor T-lymphoblastic lymphoma/leukaemia 10036543 PT
Precursor B-lymphoblastic lymphoma stage IV 10036535 PT
Precursor B-lymphoblastic lymphoma stage III 10036534 PT
Precursor B-lymphoblastic lymphoma stage II 10036533 PT
Precursor B-lymphoblastic lymphoma stage I 10036532 PT
Precursor B-lymphoblastic lymphoma refractory 10060911 PT
Precursor B-lymphoblastic lymphoma recurrent 10060910 PT
Precursor B-lymphoblastic lymphoma 10036523 PT
Plasmablastic lymphoma 10065039 PT
Peripheral T-cell lymphoma unspecified stage IV 10034630 PT
Peripheral T-cell lymphoma unspecified stage III 10034629 PT
Peripheral T-cell lymphoma unspecified stage II 10034628 PT
Peripheral T-cell lymphoma unspecified stage I 10034627 PT
Peripheral T-cell lymphoma unspecified refractory 10034626 PT
Peripheral T-cell lymphoma unspecified recurrent 10034625 PT
Follicle centre lymphoma diffuse small cell lymphoma recurrent 10016897 PT
Follicle centre lymphoma diffuse small cell lymphoma 10061957 PT
Extranodal marginal zone B-cell lymphoma (MALT type) stage IV 10015828 PT
Extranodal marginal zone B-cell lymphoma (MALT type) stage III 10015827 PT
Extranodal marginal zone B-cell lymphoma (MALT type) stage II 10015826 PT
Extranodal marginal zone B-cell lymphoma (MALT type) stage I 10015825 PT
Non-Hodgkin's lymphoma unspecified histology indolent 10065856 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c32dde691e771090
FDA-CBER-2021-5683-0023939
Non-Hodgkin's lymphoma unspecified histology aggressive stage IV 10029614 PT
Non-Hodgkin's lymphoma unspecified histology aggressive stage III 10029613 PT
Non-Hodgkin's lymphoma unspecified histology aggressive stage II 10029612 PT
Non-Hodgkin's lymphoma unspecified histology aggressive stage I 10029611 PT
Non-Hodgkin's lymphoma unspecified histology aggressive refractory 10029610 PT
Non-Hodgkin's lymphoma unspecified histology aggressive recurrent 10029609 PT
Non-Hodgkin's lymphoma unspecified histology aggressive 10063908 PT
Non-Hodgkin's lymphoma transformed recurrent 10061871 PT
Non-Hodgkin's lymphoma stage IV 10029605 PT
Non-Hodgkin's lymphoma stage III 10029604 PT
Non-Hodgkin's lymphoma stage II 10029603 PT
Non-Hodgkin's lymphoma stage I 10029602 PT
Non-Hodgkin's lymphoma refractory 10029601 PT
Non-Hodgkin's lymphoma recurrent 10029600 PT
Non-Hodgkin's lymphoma 10029547 PT
Nodal marginal zone B-cell lymphoma stage IV 10029468 PT
Nodal marginal zone B-cell lymphoma stage III 10029467 PT
Nodal marginal zone B-cell lymphoma stage II 10029466 PT
Nodal marginal zone B-cell lymphoma stage I 10029465 PT
Nodal marginal zone B-cell lymphoma refractory 10029464 PT
Hodgkin's disease mixed cellularity stage IV 10020241 PT
Hodgkin's disease mixed cellularity stage III 10020240 PT
Hodgkin's disease mixed cellularity stage II supradiaphragmatic 10020239 PT
Cutaneous T-cell lymphoma stage III 10011682 PT
Cutaneous T-cell lymphoma stage II 10011681 PT
Cutaneous T-cell lymphoma stage I 10011680 PT
Cutaneous T-cell lymphoma refractory 10011679 PT
Cutaneous T-cell lymphoma recurrent 10011678 PT
Cutaneous T-cell lymphoma 10011677 PT
Marginal zone lymphoma stage IV 10077532 PT
Marginal zone lymphoma stage III 10077531 PT
Marginal zone lymphoma stage II 10077530 PT
Marginal zone lymphoma stage I 10077529 PT
Marginal zone lymphoma refractory 10077534 PT
Marginal zone lymphoma recurrent 10077533 PT
Marginal zone lymphoma 10076596 PT
Mantle cell lymphoma stage IV 10026805 PT
Mantle cell lymphoma stage III 10026804 PT
Mantle cell lymphoma stage II 10026803 PT
Mantle cell lymphoma stage I 10026802 PT
Mantle cell lymphoma refractory 10026801 PT
Mantle cell lymphoma recurrent 10026800 PT
Mantle cell lymphoma 10061275 PT
Malignant lymphoma unclassifiable low grade 10025636 PT
Malignant lymphoma unclassifiable high grade 10025635 PT
Malignant lymphoid neoplasm 10061240 PT
Lymphoproliferative disorder in remission 10061233 PT
Lymphoproliferative disorder 10061232 PT
Lymphoplasmacytoid lymphoma/immunocytoma stage IV 10025350 PT
Lymphoplasmacytoid lymphoma/immunocytoma stage III 10025349 PT
Lymphoplasmacytoid lymphoma/immunocytoma stage II 10025348 PT
Lymphoplasmacytoid lymphoma/immunocytoma stage I 10025347 PT
Lymphoplasmacytoid lymphoma/immunocytoma refractory 10025346 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c32dde691e771090
FDA-CBER-2021-5683-0023940
Lymphoplasmacytoid lymphoma/immunocytoma recurrent 10025345 PT
Lymphoplasmacytoid lymphoma/immunocytoma 10025342 PT
Lymphoma transformation 10064344 PT
Cutaneous lymphoma 10079945 PT
Lymphoma 10025310 PT
Lymphocytic lymphoma 10052178 PT
Leukaemic lymphoma 10024325 PT
Intestinal T-cell lymphoma stage IV 10022711 PT
Intestinal T-cell lymphoma stage III 10022710 PT
Intestinal T-cell lymphoma stage II 10022709 PT
Intestinal T-cell lymphoma stage I 10022708 PT
Intestinal T-cell lymphoma refractory 10022707 PT
Extranodal marginal zone B-cell lymphoma (MALT type) refractory 10015824 PT
Extranodal marginal zone B-cell lymphoma (MALT type) recurrent 10015823 PT
Extranodal marginal zone B-cell lymphoma (MALT type) 10061850 PT
Epstein-Barr virus associated lymphoma 10071441 PT
Enteropathy-associated T-cell lymphoma 10073481 PT
Disseminated large cell lymphoma 10054951 PT
Diffuse large B-cell lymphoma stage IV 10012826 PT
Diffuse large B-cell lymphoma stage III 10012825 PT
Diffuse large B-cell lymphoma stage II 10012824 PT
Diffuse large B-cell lymphoma stage I 10012823 PT
Diffuse large B-cell lymphoma refractory 10012822 PT
Diffuse large B-cell lymphoma recurrent 10012821 PT
Diffuse large B-cell lymphoma 10012818 PT
Composite lymphoma 10073957 PT
Central nervous system lymphoma 10007953 PT
Burkitt's lymphoma stage IV 10006603 PT
Burkitt's lymphoma stage III 10006602 PT
Burkitt's lymphoma stage II 10006601 PT
Burkitt's lymphoma stage I 10006600 PT
Burkitt's lymphoma refractory 10006599 PT
Burkitt's lymphoma recurrent 10006598 PT
Burkitt's lymphoma 10006595 PT
Blastic plasmacytoid dendritic cell neoplasia 10075460 PT
B-cell unclassifiable lymphoma low grade 10003923 PT
B-cell unclassifiable lymphoma high grade 10003922 PT
B-cell small lymphocytic lymphoma stage IV 10003916 PT
Peripheral T-cell lymphoma unspecified 10034623 PT
Ocular lymphoma 10075324 PT
Non-Hodgkin's lymphoma unspecified histology indolent stage IV 10029625 PT
Non-Hodgkin's lymphoma unspecified histology indolent stage III 10029624 PT
Non-Hodgkin's lymphoma unspecified histology indolent stage II 10029623 PT
Non-Hodgkin's lymphoma unspecified histology indolent stage I 10029622 PT
Intestinal T-cell lymphoma recurrent 10022706 PT
Immunoblastic lymphoma 10053574 PT
Hodgkin's disease unclassifiable 10020271 PT
Hodgkin's disease stage IV 10061597 PT
Hodgkin's disease stage III 10020270 PT
Hodgkin's disease stage II 10020269 PT
Hodgkin's disease stage I 10020268 PT
Hodgkin's disease refractory 10020267 PT
Hodgkin's disease recurrent 10020266 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c32dde691e771090
FDA-CBER-2021-5683-0023941
Hodgkin's disease nodular sclerosis stage IV 10020253 PT
Hodgkin's disease nodular sclerosis stage III 10020252 PT
Hodgkin's disease nodular sclerosis stage II 10073534 PT
Hodgkin's disease nodular sclerosis stage I 10073535 PT
Hodgkin's disease nodular sclerosis refractory 10020246 PT
Hodgkin's disease nodular sclerosis recurrent 10020245 PT
Hodgkin's disease nodular sclerosis 10020244 PT
Hodgkin's disease mixed cellularity stage unspecified 10020242 PT
Hodgkin's disease mixed cellularity stage II subdiaphragmatic 10020238 PT
Hodgkin's disease mixed cellularity stage I supradiaphragmatic 10020237 PT
Hodgkin's disease mixed cellularity stage I subdiaphragmatic 10020236 PT
Hodgkin's disease mixed cellularity stage I site unspecified 10020235 PT
Hodgkin's disease mixed cellularity refractory 10020234 PT
Hodgkin's disease mixed cellularity recurrent 10020233 PT
Hodgkin's disease lymphocyte predominance type stage unspecified 10020231 PT
Hodgkin's disease lymphocyte predominance type stage IV 10020230 PT
Hodgkin's disease lymphocyte predominance type stage III 10020229 PT
Hodgkin's disease lymphocyte predominance type refractory 10020228 PT
Hodgkin's disease lymphocyte predominance type recurrent 10020227 PT
Hodgkin's disease lymphocyte predominance stage II supradiaphragm 10020225 PT
Hodgkin's disease lymphocyte predominance stage II subdiaphragm 10020224 PT
Hodgkin's disease lymphocyte predominance stage II site unspec 10020223 PT
Hodgkin's disease lymphocyte predominance stage I supradiaphragm 10020222 PT
Hodgkin's disease lymphocyte predominance stage I subdiaphragm 10020221 PT
Hodgkin's disease lymphocyte predominance stage I site unspec 10020220 PT
Hodgkin's disease lymphocyte depletion type stage unspecified 10020219 PT
Hodgkin's disease lymphocyte depletion type stage IV 10020218 PT
Hodgkin's disease lymphocyte depletion type stage III 10020217 PT
Hodgkin's disease lymphocyte depletion type refractory 10020216 PT
Hodgkin's disease lymphocyte depletion type recurrent 10020215 PT
Hodgkin's disease lymphocyte depletion stage II supradiaphragm 10020213 PT
Hodgkin's disease lymphocyte depletion stage II subdiaphragm 10020212 PT
Hodgkin's disease lymphocyte depletion stage II site unspecified 10020211 PT
Hodgkin's disease lymphocyte depletion stage I supradiaphragm 10020210 PT
Hodgkin's disease lymphocyte depletion stage I subdiaphragm 10020209 PT
Hodgkin's disease lymphocyte depletion stage I site unspecified 10020208 PT
Hodgkin's disease 10020206 PT
High grade B-cell lymphoma Burkitt-like lymphoma stage IV 10020075 PT
High grade B-cell lymphoma Burkitt-like lymphoma stage III 10020074 PT
High grade B-cell lymphoma Burkitt-like lymphoma stage II 10020073 PT
High grade B-cell lymphoma Burkitt-like lymphoma stage I 10020072 PT
High grade B-cell lymphoma Burkitt-like lymphoma refractory 10020071 PT
High grade B-cell lymphoma Burkitt-like lymphoma recurrent 10020070 PT
Angiocentric lymphoma stage I 10002416 PT
Angiocentric lymphoma refractory 10002415 PT
Angiocentric lymphoma recurrent 10002414 PT
Angiocentric lymphoma 10002411 PT
Anaplastic large-cell lymphoma 10073478 PT
Anaplastic large cell lymphoma T- and null-cell types stage IV 10002234 PT
Anaplastic large cell lymphoma T- and null-cell types stage III 10002233 PT
Anaplastic large cell lymphoma T- and null-cell types stage II 10002232 PT
Anaplastic large cell lymphoma T- and null-cell types stage I 10002231 PT
Anaplastic large cell lymphoma T- and null-cell types refractory 10002230 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c32dde691e771090
FDA-CBER-2021-5683-0023942
Anaplastic large cell lymphoma T- and null-cell types recurrent 10002229 PT
Anaplastic large cell lymphoma T- and null-cell types 10002227 PT
Adult T-cell lymphoma/leukaemia stage IV 10001421 PT
Adult T-cell lymphoma/leukaemia stage III 10001420 PT
Adult T-cell lymphoma/leukaemia stage II 10001419 PT
Adult T-cell lymphoma/leukaemia stage I 10001418 PT
Adult T-cell lymphoma/leukaemia refractory 10001417 PT
Adult T-cell lymphoma/leukaemia recurrent 10001416 PT
Adult T-cell lymphoma/leukaemia 10001413 PT
High grade B-cell lymphoma Burkitt-like lymphoma 10020067 PT
Hepatosplenic T-cell lymphoma 10066957 PT
Follicle centre lymphoma, follicular grade I, II, III stage IV 10016910 PT
Follicle centre lymphoma, follicular grade I, II, III stage III 10016909 PT
Follicle centre lymphoma, follicular grade I, II, III stage II 10016908 PT
Follicle centre lymphoma, follicular grade I, II, III stage I 10016907 PT
Follicle centre lymphoma, follicular grade I, II, III refractory 10016906 PT
Follicle centre lymphoma, follicular grade I, II, III recurrent 10016905 PT
Follicle centre lymphoma, follicular grade I, II, III 10061170 PT
Follicle centre lymphoma diffuse small cell lymphoma stage IV 10016902 PT
Follicle centre lymphoma diffuse small cell lymphoma stage III 10016901 PT
Follicle centre lymphoma diffuse small cell lymphoma stage II 10016900 PT
Follicle centre lymphoma diffuse small cell lymphoma stage I 10016899 PT
Follicle centre lymphoma diffuse small cell lymphoma refractory 10016898 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c32dde691e771090
FDA-CBER-2021-5683-0023943",,6
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdf,1.0,"CCI_Diabetes with comp
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Diabetes with comp
Code: 90002931
Extension: CCI
Report Date/Time: 27-Oct-2020:10:45:08 AM EDT
Term Code Level Category Weight Scope
Diabetic vascular disorder 10061815 PT
Diabetic ulcer 10056340 PT
Diabetic retinopathy 10012689 PT
Diabetic neuropathy 10012680 PT
Diabetic nephropathy 10061835 PT
Diabetic mononeuropathy 10012676 PT
Diabetic microangiopathy 10054044 PT
Diabetic macroangiopathy 10063547 PT
Diabetic gangrene 10012665 PT
Diabetic eye disease 10012661 PT
Diabetic endorgan damage 10071091 PT
Diabetic end stage renal disease 10012660 PT
Diabetic complication 10061104 PT
Diabetic autonomic neuropathy 10012645 PT
Diabetic amyotrophy 10012643 PT
Cataract diabetic 10007749 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\a83dde691e771090
FDA-CBER-2021-5683-0023927",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_financial-cert-bias.pdf,3.0,"BNT162b2 1.3.4 Financial Certification and Disclosure
1.3.4 FINANCIAL CERTIFICATION AND DISCLOSURE – BIAS STATEMENT
Protocol Number: C4591001
Study Title: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-
Finding Study To Evaluate The Safety, Tolerability, Immunogenicity, And Efficacy Of
SARS-COV-2 RNA Vaccine Candidates Against COVID-19 In Healthy Individuals
STEPS TAKEN TO MINIMIZE THE POTENTIAL FOR BIAS
The above-referenced trial was conducted according to ICH Good Clinical Practices. The
study was conducted according to Pfizer SOPs.
Other processes used to minimize potential bias are as follows:
• The facilities performing the safety and efficacy evaluations were determined to be
acceptable based on appropriate certification or historical performance and/or
qualifications and credentials.
• Electronic diaries were used to collect patient reported outcomes, to ensure real time
completion of outcomes questionnaires.
• Subjects were allocated randomly to vaccine group through use of an Interactive
Response System.
• An independent external data monitoring committee (DMC), operating under a
written charter, reviewed unblinded safety data on a weekly basis during Phase 2/3
and was responsible for the review of the efficacy interim analysis.
• Ongoing accrual of protocol-defined cases was monitored in a blinded manner and,
when sufficient cases were available, the unblinded analysis was performed by a
limited number of individuals who are not involved in ongoing conduct of the study
(statistical team supporting the DMC).
• Microbiological confirmation of cases by Polymerase Chain Reaction (PCR) was
performed by individuals blinded to treatment allocation in a central laboratory.
• An independent unblinded submissions team separate from the study team, operating
under a written charter, analyzed defined endpoints for regulatory submissions (EUA,
MAA). Analyses were stored on restricted sites. Access to the restricted sites was
governed by charter and tracked.
• Investigator trial sites were monitored frequently.
PFIZER CONFIDENTIAL
Page 1
)TMG(
80:91
1202-rpA-92
:nO
laniF\laniF\cf4d4e691e771090
FDA-CBER-2021-5683-0013768
BNT162b2 1.3.4 Financial Certification and Disclosure
• The validity of the data collected during the study was confirmed by standard
monitoring procedures.
• During the course of processing, analyzing and reporting data from clinical trials,
Pfizer applied procedures (e.g., querying data through electronic edit checks and
clinical reviews) designed to ensure that errors were eliminated.
• Appropriate statistical methods were employed by use of an approved statistical
analysis plan.
• The study report was reviewed by the Sponsor’s Quality Control Group.
PFIZER CONFIDENTIAL
Page 2
)TMG(
80:91
1202-rpA-92
:nO
laniF\laniF\cf4d4e691e771090
FDA-CBER-2021-5683-0013769
BNT162b2 1.3.4 Financial Certification and Disclosure
1.3.4 FINANCIAL CERTIFICATION AND DISCLOSURE – BIAS STATEMENT
Protocol number: BNT162-01
Study title: A multi-site, Phase I/II, 2-part, dose-escalation trial investigating the safety
and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-
19 using different dosing regimens in healthy and immunocompromised adults
STEPS TAKEN TO MINIMIZE THE POTENTIAL FOR BIAS
The clinical study BNT162-01 is being conducted according to ICH Good Clinical
Practices, relevant regulatory guidance, and BioNTech SOPs. The study is still ongoing
clinically.
The study has an open-label exploratory design and does not include testing of a formal
statistical hypothesis.
Other processes used to minimize potential bias are as follows:
• The contract research organization (CRO) conducting the study was qualified
according to the sponsor’s standard operating procedures (SOPs) in cooperation with
the sponsor’s quality assurance department.
• Study sites were monitored frequently and the validity of the data collected during the
study was confirmed according to BioNTech SOPs.
• Data verification was performed on the data in the database using computerized
checks looking for missing data, inconsistencies, and incorrect values. A manual
review of the data was also performed. If necessary, data clarification forms were
generated and transmitted to the site. The investigator was requested to confirm or
make corrections or enter additional or missing data as required. Further data quality
control measures were defined in the data validation plan. In addition, a reconciliation
of reportable adverse events between the global drug safety and clinical databases as
well as a reconciliation of other non-CRF data were performed.
• Appropriate statistical methods were employed by use of an approved statistical
analysis plan according to BioNTech SOPs.
• The study report was reviewed and subjected to quality control checks according to
BioNTech SOPs.
CONFIDENTIAL
Page 3
)TMG(
80:91
1202-rpA-92
:nO
laniF\laniF\cf4d4e691e771090
FDA-CBER-2021-5683-0013770",,3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_cover.pdf,6.0,"Pfizer Global Regulatory Affairs
Pfizer Inc.
400 Arcola Road Collegeville, PA 19426
Global Product Development
06May2021 THIS DOCUMENT CONTAINS CONFIDENTIAL
AND/OR TRADE SECRET INFORMATION
THAT IS DISCLOSED ONLY IN CONNECTION
Marion Gruber, Ph.D. WITH THE LICENSING AND/OR
Director REGISTRATION OF PRODUCTS FOR PFIZER
INCOR ITS AFFILIATED COMPANIES. THIS
Office of Vaccines Research and Review
DOCUMENT SHOULD NOT BE DISCLOSED OR
Food and Drug Administration USED, IN WHOLE OR IN PART, FOR ANY
Center for Biologics Evaluation and Research OTHER PURPOSE WITHOUT THE PRIOR
WRITTEN CONSENT OF PFIZER INC.
Document Control Center
10903 New Hampshire Avenue
WO71, G112
Silver Spring, MD 20993-0002
Re: BLA 125742
COVID-19 mRNA Vaccine (BNT162/PF-07302048)
Part 1 of the Original Submission –Rolling Biologics License Application (BLA)
Request for Priority Review Designation
Dear Dr. Gruber,
Please find enclosed Part 1 of the Original Submission of the rolling Biologics License
Application (BLA) for the BNT162b2 vaccine candidate developed by BioNTech and Pfizer
under BB-IND 19736 for the prevention of COVID-19caused by SARS-CoV-2in
individuals ≥16 years of age. This vaccinewas granted Fast Track Designationfor
individuals >18 years of age on 07July2020.The Grant Fast Track Designation Letteris
providedin Module 1.7.4. Submission of this BLA as a rolling application was agreed during
the teleconference of 16 April 2021.
BioNTechand Pfizer are requesting Priority Review Designationfor this BLA. It meets the
criteria for Priority Review Designation, as outlined in the 2014 Guidance for Industry:
Expedited Programs for Serious Conditions –Drugs and Biologics because BNT162b2
prevents aserious and life-threatening condition (COVID-19) and, if approved, would
provide a significant improvement in safety andeffectivenessbecause there are currently no
vaccines licensedfor the prevention of COVID-19 in the US. The PriorityReview
Designation Request is providedin Module1.2.
Awire transfer for $2,875,842.00 was made to the U.S. Department of Treasury (TREAS
FDA-CBER-2021-5683-0013742
Marion Gruber, Ph.D., Director Page 2of 6
BLA125742 06May2021
NYC 33 Liberty Street, New York, NY 10045) on 05May2021 (User Fee ID#
PD3017966) for the user fee for this application. A copy of the user fee cover sheet (Form
3397) is providedin Module 1.1.
The purposeof this submission is to provide the complete non-clinical and clinical contents
of theapplication. This submission is provided in electronic Common Technical Document
(eCTD) format. The Table of Contents is attached. Part 2 of the Original Submission of the
BLA containing the rest of the BLA contents will be submitted on 21May2021.
Additionally, as agreed during the teleconference of 16 April 2016, sequencing data
requested by the Agency on 09 March 2021 will be provided by 07June 2021.
Any reference not included with this submission is available upon request.
In addition, via email on 10August 2020,it was agreed that BioNTech could be provided
their US License Number upon submission of the BLA (as opposed to at approval). We
kindly request the US License Number for BioNTech at this time with agreement that they
will not use it until after the BLA is approved.
Should you have any questions regarding this submission, or require additional information,
pleasecontact me viaphone at 215-280-5503; via facsimile at 845-474-3500; or via e-mail at
elisa.harkinstull@pfizer.com.
Sincerely,
Elisa Harkins
Global Regulatory Lead
Global Regulatory Affairs –Vaccines
CC: Ramachandra S. Naik, Ph.D.
Pfizer Confidential
Page 2
FDA-CBER-2021-5683-0013743
Marion Gruber, Ph.D., Director Page 3of 6
BLA125742 06May2021
BLA 125742 Part 1 Table of Contents
MODULE 1
1 Administrative Information and Prescribing Information
1.1 Forms
FDA 356h Form: Application Form
FDA 3397 Form: User Fee Cover Sheet
FDA 3674 Form: Certification of Compliance with ClinicalTrials.gov
1.2 Cover Letters
CoverLetter
Priority Review Designation Request
1.3 Administrative Information
1.3.1 Contact/Sponsor/Applicant Information
1.3.1.4 Transfer of Obligation
Transfer of Obligation
1.3.3 Debarment Certification
Debarment Certification
1.3.4 FinancialCertification and Disclosure
Financial Certification and Disclosure -Summary Note
Financial Certification and Disclosure -Bias Statement
Financial Certification and Disclosure -Form FDA 3454
Financial Certification and Disclosure -Form FDA3455
1.3.5 Patent and Exclusivity
1.3.5.3 Exclusivity Claim
Notice of Claimed Exclusivity
1.4 References
1.4.3 List of authorized persons to incorporate by reference
Letter of Authorization to Appoint US Agent
1.6 Meetings
1.6.3 Correspondence Regarding Meetings
Correspondence RegardingMeetings
1.7 Fast Track
1.7.4 Correspondence regarding fast track/rolling review
Grant Fast Track Designation Letter
1.9 Pediatric Administrative Information
1.9.2 Request for Deferral of Pediatric Studies
Request for Deferral of Pediatric Studies
1.9.4 Proposed Pediatric Study Request and Amendments
Agreed initial Pediatric Study Plan
1.9.6 Other Correspondence Regarding Pediatric Exclusivity/Study Plans
Letter of FDA Agreement with initial Pediatric Study Plan
1.12 Other Correspondence
1.12.5 Request for Waiver
Pfizer Confidential
Page 3
FDA-CBER-2021-5683-0013744
Marion Gruber, Ph.D., Director Page 4of 6
BLA125742 06May2021
Waiver Request for FDA-Designated Suffix for Biologics
MODULE 2
2 CTD SUMMARIES
2.2 Introduction to Summary
2.4 Nonclinical Overview
2.5 Clinical Overview
2.6 Nonclinical Written and Tabulated Summaries
2.6.1 Introduction
2.6.2 Pharmacology Written Summary
2.6.3 Pharmacology Tabulated Summary
2.6.4 Pharmacokinetics Written Summary
2.6.5 Pharmacokinetics Tabulated Summary
2.6.6 Toxicology Written Summary
2.6.7 Toxicology Tabulated Summary
2.7 Clinical Summary
2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
2.7.3 Summary of Clinical Efficacy
2.7.4 Summary of Clinical Safety
2.7.5 References
2.7.6 Synopses of Individual Studies
MODULE 4
4 NON-CLINICAL STUDY REPORTS
4.2 Study Reports
4.2.1 Pharmacology
4.2.1.1 Primary Pharmacodynamics
R-20-0085-COVID-19:Immunogenicity Study of the LNP-Formulated Modrna Encoding the
Viral S Protein-V9
R-20-0112-Characterizing the Immunophenotype in Spleen and Lymph Node of Mice Treated
with SARS-COV-2 Vaccine Candidates
R-20-0211-In vitro Expression of BNT162b2 Drug Substance and Drug Product
VR-VTR-10671-BNT162b2 (V9) Immunogenicity and Evaluation of Protection against SARS-
CoV-2 Challenge in Rhesus Macaques
VR-VTR-10741-Structural and Biophysical Characterization of SARS-CoV-2 Spike Glycoprotein
(P2 S) as a Vaccine Antigen
4.2.2 Pharmacokinetics
4.2.2.2 Absorption
PF-07302048_06Jul20_072424-A Single Dose Rat Pharmacokinetic Study of ALC-0315 and
ALC-0159 Following Intravenous Bolus Injection of PF-07302048 Nanoparticle Formulation in
Wistar Han Rats
4.2.2.3 Distribution
R-20-0072 -Expression of Luciferase-Encoding ModRNA After I.M. Application of GMP-Ready
Acuitas LNP Formulation
185350-A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle-mRNA Formulation
Containing ALC-0315 and ALC-0159 Following Intramuscular Administration in Wistar Han Rats
4.2.2.4 Metabolism
Pfizer Confidential
Page 4
FDA-CBER-2021-5683-0013745
Marion Gruber, Ph.D., Director Page 5of 6
BLA125742 06May2021
01049-20008 -In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley
Rat, Wistar Han Rat, Cynomolgus Monkey, and Human Liver Microsomes
01049-20009 -In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley
Rat, Cynomolgus Monkey, and Human LiverS9 Fractions
01049-20010 -In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley
Rat, Wistar Han Rat, Cynomolgus Monkey, and Human Hepatocytes
01049-20020 -In Vitro Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley
Rat, Wistar Han Rat, Cynomolgus Monkey, andHuman Liver Microsomes
01049-20021 -In Vitro Metabolic Stability of ALC-0159 in CD-1/ICRMouse, Sprague Dawley
Rat, Cynomolgus Monkey, and Human Liver S9 Fractions
01049-20022 -In Vitro Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley
Rat, Wistar Han Rat, Cynomolgus Monkey, and Human Hepatocytes
PF-07302048_05Aug20_043725 -Investigation of the Biotransformation of ALC-0159 and ALC-
0315 In Vitro and In Vivo in Rats
4.2.3 Toxicology
4.2.3.2 Repeat-Dose Toxicity
38166-Repeat-Dose Toxicity Study of Three LNP-Formulated RNA Platforms Encoding for Viral
Proteins by Repeated Intramuscular Administration to Wistar Han Rats
38166 -SEND Datasets
20GR142 -17-Day IntramuscularToxicity Study of BNT162b2 (V9) and BNT162b3c in Wistar
Han Rats with a 3-Week Recovery
20GR142 -SEND Datasets
4.2.3.5 Reproductive and Developmental Toxicity
4.2.3.5.1 Fertility and Early Embryonic Development
20256434 -(RN9391R58) -Combined Fertility and Developmental Study (Including
Teratogenicity and Postnatal Investigations) of BNT162b1, BNT162b2 and BNT162b3 by the
Intramuscular Route in the Wistar Rat
4.3 Literature References
MODULE 5
5 CLINICAL STUDY REPORTS
5.2 Tabular Listingof All Clinical Studies
Tabular Listing
Listing of Clinical Sites and CVs
5.3 Clinical Study Reports
5.3.1 Reports ofBiopharmaceutic Studies
5.3.1.4 Reports of Bioanalytical and Analytical Methodsfor Human Studies
VR-MVR-10080 -Report on Method Validation of a Cepheid Xpert Express PCR Assay to Detect
SARS-CoV-2
VR-MVR-10081 -Method Validation Report for the Elecsys Anti-SARS-CoV-2 Assay
VR-MVR-10083-Validation Report for the SARS-CoV-2 mNeonGreen Virus Microneutralization
Assay
VR-MQR-10211 -Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for
Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Sera
VR-MQR-10212 -Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for
Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Sera
VR-MQR-10214 -Qualification of the SARS-CoV-2 mNeonGreen Virus Microneutralization
Assay
VR-TM-10293 -Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-
2S1 Protein in Human Serum
Pfizer Confidential
Page 5
FDA-CBER-2021-5683-0013746
Marion Gruber, Ph.D., Director Page 6of 6
BLA125742 06May2021
VR-TM-10294 -Single-plex Luminex Assay forQuantitation of IgG Antibodies to SARS-CoV-2
RBD Protein in Human Serum
VR-TM-10298 -Manual 96-well Neutralization Assay for the Detection of Functional Antibodies
to SARS-CoV-2 in Test Serum
VR-TM-10304 -Test Method for the SARS CoV-2 Nucleocapsid (N) Antigen Detection Assay
VR-SOP-LC-11120 -Data Review Procedures for Direct Luminex Immunoassays in LIMS v6
SHI-SOP-10011 -Manual 96-well Neutralization Assay for the Detection ofFunctional Antibodies
to SARS-CoV-2 in Test Serum using Cytation 7 Image Reader
5.3.5 Reports of Efficacy and Safety Studies
5.3.5.1 Reports of Controlled Clinical Studies Pertinent to the Claimed Indication
C4591001 -A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study
to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-CoV-2 RNA Vaccine
Candidates Against COVID-19 in Healthy Individuals
C4591001 -Final Analysis Interim CSR
C4591001 -6-Month Update Interim CSR
C4591001 -Case ReportForms
C4591001 -ADaM and SDTMDatasets
C4591001 -ADaM and SDTMSupplementalDatasets
BNT162-01 -AMulti-Site, Phase I/II,2-Part, Dose-Escalation Trial Investigating the Safety and
Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using
Different Dosing Regimens in Healthy Adults
BNT162-01 -Interim CSR v3.0
BNT162-01 -Case Report Forms
BNT 162-01 -ADaMand SDTMDatasets
5.3.6 Postmarketing Experience
Cumulative Analysis of Post-Authorization Adverse Event Reports of
PF-07302048 (BNT162b2) Received Cumulatively through 28-Feb-2021
5.4 Literature References
Pfizer Confidential
Page 6
FDA-CBER-2021-5683-0013747","[[['', 'MODULE 1'], ['1', 'Administrative Information and Prescribing Information'], ['1.1', 'Forms'], ['', 'FDA 356h Form: Application Form'], ['', 'FDA 3397 Form: User Fee Cover Sheet'], ['', 'FDA 3674 Form: Certification of Compliance with ClinicalTrials.gov'], ['1.2', 'Cover Letters'], ['', 'CoverLetter'], ['', 'Priority Review Designation Request'], ['1.3', 'Administrative Information'], ['1.3.1', 'Contact/Sponsor/Applicant Information'], ['1.3.1.4', 'Transfer of Obligation'], ['', 'Transfer of Obligation'], ['1.3.3', 'Debarment Certification'], ['', 'Debarment Certification'], ['1.3.4', 'FinancialCertification and Disclosure'], ['', 'Financial Certification and Disclosure -Summary Note'], ['', 'Financial Certification and Disclosure -Bias Statement'], ['', 'Financial Certification and Disclosure -Form FDA 3454'], ['', 'Financial Certification and Disclosure -Form FDA3455'], ['1.3.5', 'Patent and Exclusivity'], ['1.3.5.3', 'Exclusivity Claim'], ['', 'Notice of Claimed Exclusivity'], ['1.4', 'References'], ['1.4.3', 'List of authorized persons to incorporate by reference'], ['', 'Letter of Authorization to Appoint US Agent'], ['1.6', 'Meetings'], ['1.6.3', 'Correspondence Regarding Meetings'], ['', 'Correspondence RegardingMeetings'], ['1.7', 'Fast Track'], ['1.7.4', 'Correspondence regarding fast track/rolling review'], ['', 'Grant Fast Track Designation Letter'], ['1.9', 'Pediatric Administrative Information'], ['1.9.2', 'Request for Deferral of Pediatric Studies'], ['', 'Request for Deferral of Pediatric Studies'], ['1.9.4', 'Proposed Pediatric Study Request and Amendments'], ['', 'Agreed initial Pediatric Study Plan'], ['1.9.6', 'Other Correspondence Regarding Pediatric Exclusivity/Study Plans'], ['', 'Letter of FDA Agreement with initial Pediatric Study Plan'], ['1.12', 'Other Correspondence'], ['1.12.5', 'Request for Waiver']], [['', 'Waiver Request for FDA-Designated Suffix for Biologics'], ['', 'MODULE 2'], ['2', 'CTD SUMMARIES'], ['2.2', 'Introduction to Summary'], ['2.4', 'Nonclinical Overview'], ['2.5', 'Clinical Overview'], ['2.6', 'Nonclinical Written and Tabulated Summaries'], ['2.6.1', 'Introduction'], ['2.6.2', 'Pharmacology Written Summary'], ['2.6.3', 'Pharmacology Tabulated Summary'], ['2.6.4', 'Pharmacokinetics Written Summary'], ['2.6.5', 'Pharmacokinetics Tabulated Summary'], ['2.6.6', 'Toxicology Written Summary'], ['2.6.7', 'Toxicology Tabulated Summary'], ['2.7', 'Clinical Summary'], ['2.7.1', 'Summary of Biopharmaceutic Studies and Associated Analytical Methods'], ['2.7.3', 'Summary of Clinical Efficacy'], ['2.7.4', 'Summary of Clinical Safety'], ['2.7.5', 'References'], ['2.7.6', 'Synopses of Individual Studies'], ['', 'MODULE 4'], ['4', 'NON-CLINICAL STUDY REPORTS'], ['4.2', 'Study Reports'], ['4.2.1', 'Pharmacology'], ['4.2.1.1', 'Primary Pharmacodynamics'], ['', 'R-20-0085-COVID-19:Immunogenicity Study of the LNP-Formulated Modrna Encoding the\nViral S Protein-V9'], ['', 'R-20-0112-Characterizing the Immunophenotype in Spleen and Lymph Node of Mice Treated\nwith SARS-COV-2 Vaccine Candidates'], ['', 'R-20-0211-In vitro Expression of BNT162b2 Drug Substance and Drug Product'], ['', 'VR-VTR-10671-BNT162b2 (V9) Immunogenicity and Evaluation of Protection against SARS-\nCoV-2 Challenge in Rhesus Macaques'], ['', 'VR-VTR-10741-Structural and Biophysical Characterization of SARS-CoV-2 Spike Glycoprotein\n(P2 S) as a Vaccine Antigen'], ['4.2.2', 'Pharmacokinetics'], ['4.2.2.2', 'Absorption'], ['', 'PF-07302048_06Jul20_072424-A Single Dose Rat Pharmacokinetic Study of ALC-0315 and\nALC-0159 Following Intravenous Bolus Injection of PF-07302048 Nanoparticle Formulation in\nWistar Han Rats'], ['4.2.2.3', 'Distribution'], ['', 'R-20-0072 -Expression of Luciferase-Encoding ModRNA After I.M. Application of GMP-Ready\nAcuitas LNP Formulation'], ['', '185350-A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle-mRNA Formulation\nContaining ALC-0315 and ALC-0159 Following Intramuscular Administration in Wistar Han Rats'], ['4.2.2.4', 'Metabolism']], [['', '01049-20008 -In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley\nRat, Wistar Han Rat, Cynomolgus Monkey, and Human Liver Microsomes'], ['', '01049-20009 -In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley\nRat, Cynomolgus Monkey, and Human LiverS9 Fractions'], ['', '01049-20010 -In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley\nRat, Wistar Han Rat, Cynomolgus Monkey, and Human Hepatocytes'], ['', '01049-20020 -In Vitro Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley\nRat, Wistar Han Rat, Cynomolgus Monkey, andHuman Liver Microsomes'], ['', '01049-20021 -In Vitro Metabolic Stability of ALC-0159 in CD-1/ICRMouse, Sprague Dawley\nRat, Cynomolgus Monkey, and Human Liver S9 Fractions'], ['', '01049-20022 -In Vitro Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley\nRat, Wistar Han Rat, Cynomolgus Monkey, and Human Hepatocytes'], ['', 'PF-07302048_05Aug20_043725 -Investigation of the Biotransformation of ALC-0159 and ALC-\n0315 In Vitro and In Vivo in Rats'], ['4.2.3', 'Toxicology'], ['4.2.3.2', 'Repeat-Dose Toxicity'], ['', '38166-Repeat-Dose Toxicity Study of Three LNP-Formulated RNA Platforms Encoding for Viral\nProteins by Repeated Intramuscular Administration to Wistar Han Rats'], ['', '38166 -SEND Datasets'], ['', '20GR142 -17-Day IntramuscularToxicity Study of BNT162b2 (V9) and BNT162b3c in Wistar\nHan Rats with a 3-Week Recovery'], ['', '20GR142 -SEND Datasets'], ['4.2.3.5', 'Reproductive and Developmental Toxicity'], ['4.2.3.5.1', 'Fertility and Early Embryonic Development'], ['', '20256434 -(RN9391R58) -Combined Fertility and Developmental Study (Including\nTeratogenicity and Postnatal Investigations) of BNT162b1, BNT162b2 and BNT162b3 by the\nIntramuscular Route in the Wistar Rat'], ['4.3', 'Literature References'], ['', 'MODULE 5'], ['5', 'CLINICAL STUDY REPORTS'], ['5.2', 'Tabular Listingof All Clinical Studies'], ['', 'Tabular Listing'], ['', 'Listing of Clinical Sites and CVs'], ['5.3', 'Clinical Study Reports'], ['5.3.1', 'Reports ofBiopharmaceutic Studies'], ['5.3.1.4', 'Reports of Bioanalytical and Analytical Methodsfor Human Studies'], ['', 'VR-MVR-10080 -Report on Method Validation of a Cepheid Xpert Express PCR Assay to Detect\nSARS-CoV-2'], ['', 'VR-MVR-10081 -Method Validation Report for the Elecsys Anti-SARS-CoV-2 Assay'], ['', 'VR-MVR-10083-Validation Report for the SARS-CoV-2 mNeonGreen Virus Microneutralization\nAssay'], ['', 'VR-MQR-10211 -Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for\nQuantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Sera'], ['', 'VR-MQR-10212 -Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for\nQuantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Sera'], ['', 'VR-MQR-10214 -Qualification of the SARS-CoV-2 mNeonGreen Virus Microneutralization\nAssay'], ['', 'VR-TM-10293 -Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-\n2S1 Protein in Human Serum']], [['', 'VR-TM-10294 -Single-plex Luminex Assay forQuantitation of IgG Antibodies to SARS-CoV-2\nRBD Protein in Human Serum'], ['', 'VR-TM-10298 -Manual 96-well Neutralization Assay for the Detection of Functional Antibodies\nto SARS-CoV-2 in Test Serum'], ['', 'VR-TM-10304 -Test Method for the SARS CoV-2 Nucleocapsid (N) Antigen Detection Assay'], ['', 'VR-SOP-LC-11120 -Data Review Procedures for Direct Luminex Immunoassays in LIMS v6'], ['', 'SHI-SOP-10011 -Manual 96-well Neutralization Assay for the Detection ofFunctional Antibodies\nto SARS-CoV-2 in Test Serum using Cytation 7 Image Reader'], ['5.3.5', 'Reports of Efficacy and Safety Studies'], ['5.3.5.1', 'Reports of Controlled Clinical Studies Pertinent to the Claimed Indication'], ['', 'C4591001 -A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study\nto Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-CoV-2 RNA Vaccine\nCandidates Against COVID-19 in Healthy Individuals'], ['', 'C4591001 -Final Analysis Interim CSR'], ['', 'C4591001 -6-Month Update Interim CSR'], ['', 'C4591001 -Case ReportForms'], ['', 'C4591001 -ADaM and SDTMDatasets'], ['', 'C4591001 -ADaM and SDTMSupplementalDatasets'], ['', 'BNT162-01 -AMulti-Site, Phase I/II,2-Part, Dose-Escalation Trial Investigating the Safety and\nImmunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using\nDifferent Dosing Regimens in Healthy Adults'], ['', 'BNT162-01 -Interim CSR v3.0'], ['', 'BNT162-01 -Case Report Forms'], ['', 'BNT 162-01 -ADaMand SDTMDatasets'], ['5.3.6', 'Postmarketing Experience'], ['', 'Cumulative Analysis of Post-Authorization Adverse Event Reports of\nPF-07302048 (BNT162b2) Received Cumulatively through 28-Feb-2021'], ['5.4', 'Literature References']]]",6
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-rheumatic.pdf,2.0,"CCI_Rheumatic
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Rheumatic
Code: 90002944
Extension: CCI
Report Date/Time: 27-Oct-2020:10:55:35 AM EDT
Term Code Level Category Weight Scope
Scleroderma-like reaction 10039714 PT
Scleroderma renal crisis 10062553 PT
Scleroderma 10039710 PT
Rheumatoid vasculitis 10048628 PT
Rheumatoid scleritis 10067427 PT
Rheumatoid nodule removal 10053291 PT
Rheumatoid nodule 10048694 PT
Rheumatoid neutrophilic dermatosis 10072362 PT
Rheumatoid lung 10039081 PT
Rheumatoid factor quantitative increased 10060234 PT
Rheumatoid factor positive 10039080 PT
Rheumatoid factor increased 10057962 PT
Rheumatoid arthritis 10039073 PT
Reynold's syndrome 10070953 PT
Psoriatic arthropathy 10037162 PT
Pseudoxanthoma elasticum-like syndrome 10076864 PT
Polymyositis 10036102 PT
Polymyalgia rheumatica 10036099 PT
Peritonitis lupus 10062898 PT
Pericarditis lupus 10058149 PT
Paraneoplastic dermatomyositis 10066267 PT
Paraneoplastic arthritis 10077507 PT
Palindromic rheumatism 10033534 PT
Overlap syndrome 10068786 PT
Neuropsychiatric lupus 10063663 PT
Mixed connective tissue disease 10027754 PT
Lupus-like syndrome 10050551 PT
Lupus vulgaris 10025143 PT
Lupus vasculitis 10058143 PT
Lupus pneumonitis 10057481 PT
Lupus pleurisy 10073694 PT
Lupus pancreatitis 10067750 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\a32dde691e771090
FDA-CBER-2021-5683-0023981
Lupus nephritis 10025140 PT
Lupus myocarditis 10066391 PT
Lupus miliaris disseminatus faciei 10056301 PT
Lupus hepatitis 10067737 PT
Lupus enteritis 10067738 PT
Lupus endocarditis 10058225 PT
Lupus encephalitis 10025130 PT
Lupus cystitis 10074714 PT
Laryngeal rheumatoid arthritis 10059669 PT
Juvenile psoriatic arthritis 10076674 PT
Juvenile idiopathic arthritis 10059176 PT
Immunoglobulin G4 related disease 10077271 PT
Felty's syndrome 10016386 PT
Dermatomyositis 10012503 PT
Cutaneous lupus erythematosus 10056509 PT
CREST syndrome 10011380 PT
Connective tissue disorder 10061087 PT
Collagen disorder 10009903 PT
Chronic cutaneous lupus erythematosus 10057929 PT
Central nervous system lupus 10076328 PT
Carcinomatous polyarthritis 10069494 PT
Caplan's syndrome 10065917 PT
Autoimmune arthritis 10071155 PT
Arthritis enteropathic 10003253 PT
Antithyroid arthritis syndrome 10073029 PT
Amyloid arthropathy 10064554 PT
Acute cutaneous lupus erythematosus 10057928 PT
Undifferentiated connective tissue disease 10071575 PT
Giant cell arteritis 10018250 PT
Systemic sclerosis pulmonary 10042954 PT
Systemic scleroderma 10078638 PT
Systemic lupus erythematosus rash 10042946 PT
Systemic lupus erythematosus disease activity index increased 10067657 PT
Systemic lupus erythematosus disease activity index decreased 10067658 PT
Systemic lupus erythematosus disease activity index abnormal 10067659 PT
Systemic lupus erythematosus 10042945 PT
Subacute cutaneous lupus erythematosus 10057903 PT
Still's disease 10042061 PT
SLE arthritis 10040968 PT
Sjogren's syndrome 10040767 PT
Seronegative arthritis 10062164 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\a32dde691e771090
FDA-CBER-2021-5683-0023982",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_userfee.pdf,2.0,"Form Approved: OMB No. 0910 - 0297 Expiration Date: March 31, 2022. See instructions
for OMB Statement, below.
DEPARTMENT OF HEALTH AND
PRESCRIPTION DRUG USER FEE
HUMAN SERVICES
COVERSHEET FY 2021
FOOD AND DRUG ADMINISTRATION
A completed form must be signed and accompany each new drug or biologic product
application. If payment is sent by U.S. mail or courier, please include a copy of this
completed form with payment. Payment instructions and fee rates can be found on FDA's
website:
http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm119184.htm
1. APPLICANT'S NAME AND ADDRESS 4. BLA SUBMISSION TRACKING NUMBER
(STN) / NDA NUMBER
(cid:37)(cid:76)(cid:82)(cid:49)(cid:55)(cid:72)(cid:70)(cid:75)
(cid:48)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74) (cid:42)(cid:80)(cid:69)(cid:43) 125742
(cid:36)(cid:81) (cid:71)(cid:72)(cid:85) (cid:42)(cid:82)(cid:79)(cid:71)(cid:74)(cid:85)(cid:88)(cid:69)(cid:72) (cid:20)(cid:21)
(cid:24)(cid:24)(cid:20)(cid:22)(cid:20) (cid:48)(cid:68)(cid:76)(cid:81)(cid:93)
(cid:42)(cid:72)(cid:85)(cid:80)(cid:68)(cid:81)(cid:92)
5. DOES THIS APPLICATION REQUIRE
2. NAME AND TELEPHONE NUMBER OF
CLINICAL DATA FOR APPROVAL?
REPRESENTATIVE
[X] YES [ ] NO
(cid:49)(cid:72)(cid:71)(cid:68) (cid:36)(cid:74)(cid:75)(cid:68)(cid:77)(cid:68)(cid:81)(cid:76) (cid:48)(cid:72)(cid:80)(cid:68)(cid:85) IF YOUR RESPONSE IS ""NO"", STOP HERE
(cid:21)(cid:20)(cid:21)(cid:16)(cid:26)(cid:22)(cid:22)(cid:16)(cid:21)(cid:25)(cid:20)(cid:22) AND SIGN THIS FORM.
IF RESPONSE IS ""YES"", CHECK THE
APPROPRIATE RESPONSE BELOW:
[X] THE REQUIRED CLINICAL DATA ARE
CONTAINED IN THE APPLICATION
[ ] THE REQUIRED CLINICAL DATA ARE
SUBMITTED BY REFERENCE TO:
3. PRODUCT NAME
6. USER FEE I.D. NUMBER
COMIRNATY ( COVID-19 mRNA Vaccine
PD3017966
(nucleoside modified) )
7. ARE YOU REDEEMING A PRIORITY REVIEW VOUCHER FOR THE TREATMENT OF
TROPICAL DISEASES? [ ] YES [X] NO
PRIORITY REVIEW VOUCHER NUMBER:
8. ARE YOU REDEEMING A PRIORITY REVIEW VOUCHER FOR MEDICAL COUNTER
MEASURES? [ ] YES [X] NO
PRIORITY REVIEW VOUCHER NUMBER:
9. IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USER FEE EXCEPTIONS?
IF SO, CHECK THE APPLICABLE EXCEPTION.
[ ] THE APPLICATION QUALIFIES FOR THE ORPHAN EXCEPTION UNDER SECTION 736(a)
(1)(F) of the Federal Food,Drug, and Cosmetic Act
FDA-CBER-2021-5683-0013734
[ ] THE APPLICATION IS SUBMITTED BY A STATE OR FEDERAL GOVERNMENT ENTITY
FOR A DRUG THAT IS NOT DISTRIBUTED COMMERCIALLY
10. HAS A WAIVER OF AN APPLICATION FEE BEEN GRANTED FOR THIS APPLICATION?
[ ] YES [X] NO
If a waiver has been granted, include a copy of the official FDA notification with your
submission.
Privacy Act Notice:
This notice is provided pursuant to the Privacy Act of 1974, 5 U.S.C. 552a. The collection
of this information is authorized by 21 U.S.C. 371, 379, 379e, 379h, 379h-1, 379j, 379j-
12, 379j-21, 387s, and 393(d)(2); 42 U.S.C. 263b(r)(1); 5 U.S.C. 301 and 552; and 42
U.S.C. 3101. FDA will use the information to assess, collect and process user fee
payments, and, facilitate debt collection under the Debt Collection Improvement Act. FDA
may disclose information to courts and the Department of Justice in the context of
litigation and requests for legal advice; to other Federal agencies in response to
subpoenas issued by such agencies; to HHS and FDA employees and contractors to
perform user fee services; to the National Archives and Records Administration and
General Services Administration for records management inspections; to the Department
of Homeland Security and other Federal agencies and contractors in order to respond to
system breaches; to banks in order to process payment made by credit card; to Dun and
Bradstreet to validate submitter contact information, and to other entities as permitted
under the Debt Collection Improvement Act. Furnishing the requested information is
mandatory. Failure to supply the information could prevent FDA from processing user fee
payments. Additional detail regarding FDA's use of information is available online:
http://www.fda.gov/RegulatoryInformation/FOI/PrivacyAct/default.htm.
OMB Statement:
Public reporting burden for this collection of information is estimated to average
30 minutes per response, including the time for reviewing instructions, searching existing
data sources, gathering and maintaining the data needed, and completing and reviewing
the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden to:
Department of Health and Human An agency may not conduct or sponsor, and a
Services person is not required to respond to, a
Food and Drug Administration collection of information unless it displays a
Office of Chief Information Officer currently valid OMB control number.
Paper Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
PRINTED NAME AND SIGNATURE OF TITLE DATE
AUTHORIZED REPRESENTATIVE
Digitally signed by Neda Aghajani Memar Director,
Neda Aghajani MemarDN: cn=Neda Aghajani Memar, o, ou, 4/20/2021
email=nedaaghajanimemar@pfizercom, c=US
R De aa teso : 2n 0: 2I a 1t .0te 4s .2t 0to 0 t 9h :4e 0 a :3cc 3u -r 0a 4c 'y 0 0a 'nd integrity of this document GlobalRegulatoryAffairs
11. USER FEE PAYMENT AMOUNT FOR THIS APPLICATION
$2,875,842.00
Form FDA 3397 (04/19)
FDA-CBER-2021-5683-0013735","[[['Form Approved: OMB No. 0910 - 0297 Expiration Date: March 31, 2022. See instructions\nfor OMB Statement, below.\nDEPARTMENT OF HEALTH AND\nPRESCRIPTION DRUG USER FEE\nHUMAN SERVICES\nCOVERSHEET FY 2021\nFOOD AND DRUG ADMINISTRATION\nA completed form must be signed and accompany each new drug or biologic product\napplication. If payment is sent by U.S. mail or courier, please include a copy of this\ncompleted form with payment. Payment instructions and fee rates can be found on FDA\'s\nwebsite:\nhttp://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm119184.htm\n1. APPLICANT\'S NAME AND ADDRESS 4. BLA SUBMISSION TRACKING NUMBER\n(STN) / NDA NUMBER\n(cid:37)(cid:76)(cid:82)(cid:49)(cid:55)(cid:72)(cid:70)(cid:75)\n(cid:48)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74) (cid:42)(cid:80)(cid:69)(cid:43) 125742\n(cid:36)(cid:81) (cid:71)(cid:72)(cid:85) (cid:42)(cid:82)(cid:79)(cid:71)(cid:74)(cid:85)(cid:88)(cid:69)(cid:72) (cid:20)(cid:21)\n(cid:24)(cid:24)(cid:20)(cid:22)(cid:20) (cid:48)(cid:68)(cid:76)(cid:81)(cid:93)\n(cid:42)(cid:72)(cid:85)(cid:80)(cid:68)(cid:81)(cid:92)\n5. DOES THIS APPLICATION REQUIRE\n2. NAME AND TELEPHONE NUMBER OF\nCLINICAL DATA FOR APPROVAL?\nREPRESENTATIVE\n[X] YES [ ] NO\n(cid:49)(cid:72)(cid:71)(cid:68) (cid:36)(cid:74)(cid:75)(cid:68)(cid:77)(cid:68)(cid:81)(cid:76) (cid:48)(cid:72)(cid:80)(cid:68)(cid:85) IF YOUR RESPONSE IS ""NO"", STOP HERE\n(cid:21)(cid:20)(cid:21)(cid:16)(cid:26)(cid:22)(cid:22)(cid:16)(cid:21)(cid:25)(cid:20)(cid:22) AND SIGN THIS FORM.\nIF RESPONSE IS ""YES"", CHECK THE\nAPPROPRIATE RESPONSE BELOW:\n[X] THE REQUIRED CLINICAL DATA ARE\nCONTAINED IN THE APPLICATION\n[ ] THE REQUIRED CLINICAL DATA ARE\nSUBMITTED BY REFERENCE TO:\n3. PRODUCT NAME\n6. USER FEE I.D. NUMBER\nCOMIRNATY ( COVID-19 mRNA Vaccine\nPD3017966\n(nucleoside modified) )\n7. ARE YOU REDEEMING A PRIORITY REVIEW VOUCHER FOR THE TREATMENT OF\nTROPICAL DISEASES? [ ] YES [X] NO\nPRIORITY REVIEW VOUCHER NUMBER:\n8. ARE YOU REDEEMING A PRIORITY REVIEW VOUCHER FOR MEDICAL COUNTER\nMEASURES? [ ] YES [X] NO\nPRIORITY REVIEW VOUCHER NUMBER:\n9. IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USER FEE EXCEPTIONS?\nIF SO, CHECK THE APPLICABLE EXCEPTION.\n[ ] THE APPLICATION QUALIFIES FOR THE ORPHAN EXCEPTION UNDER SECTION 736(a)\n(1)(F) of the Federal Food,Drug, and Cosmetic Act\nFDA-CBER-2021-5683-0013734', None, None], ['Form Approved: OMB No. 0910 - 0297 Expiration Date: March 31, 2022. See instructions\nfor OMB Statement, below.', None, None], ['DEPARTMENT OF HEALTH AND\nHUMAN SERVICES\nFOOD AND DRUG ADMINISTRATION', 'PRESCRIPTION DRUG USER FEE\nCOVERSHEET FY 2021', None], [""A completed form must be signed and accompany each new drug or biologic product\napplication. If payment is sent by U.S. mail or courier, please include a copy of this\ncompleted form with payment. Payment instructions and fee rates can be found on FDA's\nwebsite:\nhttp://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm119184.htm"", None, None], [""1. APPLICANT'S NAME AND ADDRESS\n(cid:37)(cid:76)(cid:82)(cid:49)(cid:55)(cid:72)(cid:70)(cid:75)\n(cid:48)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74) (cid:42)(cid:80)(cid:69)(cid:43)\n(cid:36)(cid:81) (cid:71)(cid:72)(cid:85) (cid:42)(cid:82)(cid:79)(cid:71)(cid:74)(cid:85)(cid:88)(cid:69)(cid:72) (cid:20)(cid:21)\n(cid:24)(cid:24)(cid:20)(cid:22)(cid:20) (cid:48)(cid:68)(cid:76)(cid:81)(cid:93)\n(cid:42)(cid:72)(cid:85)(cid:80)(cid:68)(cid:81)(cid:92)"", None, '4. BLA SUBMISSION TRACKING NUMBER\n(STN) / NDA NUMBER\n125742'], ['2. NAME AND TELEPHONE NUMBER OF\nREPRESENTATIVE\n(cid:49)(cid:72)(cid:71)(cid:68) (cid:36)(cid:74)(cid:75)(cid:68)(cid:77)(cid:68)(cid:81)(cid:76) (cid:48)(cid:72)(cid:80)(cid:68)(cid:85)\n(cid:21)(cid:20)(cid:21)(cid:16)(cid:26)(cid:22)(cid:22)(cid:16)(cid:21)(cid:25)(cid:20)(cid:22)', None, '5. DOES THIS APPLICATION REQUIRE\nCLINICAL DATA FOR APPROVAL?\n[X] YES [ ] NO\nIF YOUR RESPONSE IS ""NO"", STOP HERE\nAND SIGN THIS FORM.\nIF RESPONSE IS ""YES"", CHECK THE\nAPPROPRIATE RESPONSE BELOW:\n[X] THE REQUIRED CLINICAL DATA ARE\nCONTAINED IN THE APPLICATION\n[ ] THE REQUIRED CLINICAL DATA ARE\nSUBMITTED BY REFERENCE TO:'], ['3. PRODUCT NAME\n6. USER FEE I.D. NUMBER\nCOMIRNATY ( COVID-19 mRNA Vaccine\nPD3017966\n(nucleoside modified) )', None, None], ['7. ARE YOU REDEEMING A PRIORITY REVIEW VOUCHER FOR THE TREATMENT OF\nTROPICAL DISEASES? [ ] YES [X] NO\nPRIORITY REVIEW VOUCHER NUMBER:', None, None], ['8. ARE YOU REDEEMING A PRIORITY REVIEW VOUCHER FOR MEDICAL COUNTER\nMEASURES? [ ] YES [X] NO\nPRIORITY REVIEW VOUCHER NUMBER:', None, None], ['9. IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USER FEE EXCEPTIONS?\nIF SO, CHECK THE APPLICABLE EXCEPTION.\n[ ] THE APPLICATION QUALIFIES FOR THE ORPHAN EXCEPTION UNDER SECTION 736(a)\n(1)(F) of the Federal Food,Drug, and Cosmetic Act\nFDA-CBER-2021-5683-0', None, None], ['', None, None]], [['10. HAS A WAIVER OF AN APPLICATION FEE BEEN GRANTED FOR THIS APPLICATION?\n[ ] YES [X] NO\nIf a waiver has been granted, include a copy of the official FDA notification with your\nsubmission.', None, None], [""Privacy Act Notice:\nThis notice is provided pursuant to the Privacy Act of 1974, 5 U.S.C. 552a. The collection\nof this information is authorized by 21 U.S.C. 371, 379, 379e, 379h, 379h-1, 379j, 379j-\n12, 379j-21, 387s, and 393(d)(2); 42 U.S.C. 263b(r)(1); 5 U.S.C. 301 and 552; and 42\nU.S.C. 3101. FDA will use the information to assess, collect and process user fee\npayments, and, facilitate debt collection under the Debt Collection Improvement Act. FDA\nmay disclose information to courts and the Department of Justice in the context of\nlitigation and requests for legal advice; to other Federal agencies in response to\nsubpoenas issued by such agencies; to HHS and FDA employees and contractors to\nperform user fee services; to the National Archives and Records Administration and\nGeneral Services Administration for records management inspections; to the Department\nof Homeland Security and other Federal agencies and contractors in order to respond to\nsystem breaches; to banks in order to process payment made by credit card; to Dun and\nBradstreet to validate submitter contact information, and to other entities as permitted\nunder the Debt Collection Improvement Act. Furnishing the requested information is\nmandatory. Failure to supply the information could prevent FDA from processing user fee\npayments. Additional detail regarding FDA's use of information is available online:\nhttp://www.fda.gov/RegulatoryInformation/FOI/PrivacyAct/default.htm.\nOMB Statement:\nPublic reporting burden for this collection of information is estimated to average\n30 minutes per response, including the time for reviewing instructions, searching existing\ndata sources, gathering and maintaining the data needed, and completing and reviewing\nthe collection of information. Send comments regarding this burden estimate or any other\naspect of this collection of information, including suggestions for reducing this burden to:\nDepartment of Health and Human An agency may not conduct or sponsor, and a\nServices person is not required to respond to, a\nFood and Drug Administration collection of information unless it displays a\nOffice of Chief Information Officer currently valid OMB control number.\nPaper Reduction Act (PRA) Staff\nPRAStaff@fda.hhs.gov"", None, None], [""PRINTED NAME AND SIGNATURE OF\nAUTHORIZED REPRESENTATIVE\nDigitally signed by Neda Aghajani Memar\nNeda Aghajani MemarDN: cn=Neda Aghajani Memar, o, ou,\nemail=nedaaghajanimemar@pfizercom, c=US\nReason: I attest to the accuracy and integrity of this document\nDate: 2021.04.20 09:40:33 -04'00'"", 'TITLE\nDirector,\nGlobalRegulatoryAffairs', 'DATE\n4/20/2021'], ['11. USER FEE PAYMENT AMOUNT FOR THIS APPLICATION\n$2,875,842.00', None, None], ['Form FDA 3397 (04/19)', None, None]]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_26_pharmkin-written-summary.pdf,10.0,"BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
MODULE 2.6.4. PHARMACOKINETICS WRITTEN SUMMARY
This document contains confidential information belonging to BioNTech/Pfizer. Except as may be
otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such
information in confidence and not to disclose it to others (except where required by applicable
law), nor to use it for unauthorized purposes. In the event of actual or suspected breach of this
obligation, BioNTech/Pfizershould be promptly notified.
CONFIDENTIAL
Page 1
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013897
BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
TABLE OF CONTENTS
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS..............................................3
2.6.4. PHARMACOKINETICS WRITTEN SUMMARY........................................................4
2.6.4.1. Brief Summary....................................................................................................4
2.6.4.2. Methods of Analysis............................................................................................4
2.6.4.3. Absorption...........................................................................................................4
2.6.4.4. Distribution..........................................................................................................5
2.6.4.5. Metabolism..........................................................................................................7
2.6.4.6. Excretion.............................................................................................................9
2.6.4.7. Pharmacokinetic Drug Interactions.....................................................................9
2.6.4.8. Discussion and Conclusions................................................................................9
2.6.4.9. References.........................................................................................................10
CONFIDENTIAL
Page 2
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013898
BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
ADME Absorption, distribution, metabolism, excretion
ALC-0159 Proprietary PEG-lipid included as an excipient in the LNP formulation
used in BNT162b2
ALC-0315 Proprietary amino-lipid included as an excipient in the LNP formulation
used in BNT162b2
[3H]-CHE Radiolabeled [Cholesteryl-1,2-3H(N)]-Cholesteryl Hexadecyl Ether
DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine
GLP Good Laboratory Practice
H Human (in metabolite scheme)
IM Intramuscular(ly)
IV Intravenous(ly)
LNP Lipid-nanoparticle
Luc Luciferase (from firefly Pyractomena lucifera)
Mk Monkey (in metabolite scheme)
Mo Mouse (in metabolite scheme)
modRNA Nucleoside-modified mRNA
mRNA Messenger RNA
PEG Polyethylene glycol
PK Pharmacokinetics
R Rat (in metabolite scheme)
RNA Ribonucleic acid
S9 Supernatant fraction obtained from liver homogenate by centrifuging at
9000 g
WHO World Health Organization
CONFIDENTIAL
Page 3
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013899
BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
2.6.4. PHARMACOKINETICS WRITTEN SUMMARY
2.6.4.1. Brief Summary
TheADME profile of BNT162b2(BioNTech code number BNT162, Pfizer code number
PF-07302048) included evaluation ofthe PK and metabolism of two novel lipid excipients
(ALC-0315 and ALC-0159) in the LNP and potential biodistribution using luciferase
expression as a surrogate reporteror a radiolabeled lipid marker.The PK study showed the
LNP distributes from the blood to the liver, ~1% of ALC-0315 and ~50% of ALC-0159 were
excreted unchanged in feces, and there was no detectable excretion of unchanged ALC-0315
and ALC-0159 in the urine.
In a mousebiodistribution study, protein expression was demonstrated at the site of injection
and to a lesser extent in the liver after BALB/c mice received an IM injection of modRNA
encoding luciferase in an LNP formulation,with the identical lipid compositionas
BNT162b2. Luciferase expression was identified at the injection site at 6hours after injection
and was not detectedafter9days. Liver expression was also present at 6hours after injection
and was no longer detectedby 48hours after injection. A quantitativebiodistribution study
was also carried out in Wistar Han rats using a radiolabeled lipid markerand a luciferase
modRNA in the same LNP formulation as BNT162b2.Following IM administration, the
greatest mean concentration remained at the injection site, while up to 18% of the
administered dose was found in the liver.
The metabolism of ALC-0315 (aminolipid) and ALC-0159(PEG-lipid)was evaluated in
vitro using blood, liver microsomes, S9 fractions,and hepatocytes from mice, rats, monkeys,
and humans.The in vivo metabolism was examined in rat plasma, urine, feces, and liver
samples collected during thePK study. In vitro and in vivo studies indicated ALC-0315 and
ALC-0159 are metabolizedslowly by hydrolytic metabolism of the ester and amide
functionalities, respectively, across the species evaluated.
2.6.4.2. Methods of Analysis
No methods of analysis have been validated to support GLP TK studies of components of
BNT162b2; however, a qualified LC/MS method was developed to support quantitation of
the two novel LNP excipients for the non-GLP IV PK study in
rats (PF-07302048_06Jul20_072424). Methods for immunogenicity and efficacy studies are
described in Section 2.6.2.12.
2.6.4.3. Absorption
An intravenous rat PK study was performed using LNPs containing surrogate luciferase
RNA, with the identical lipid composition as BNT162b2, to explore the disposition of
ALC-0159 and ALC-0315 (Table2.6.4-1, StudyPF-07302048_06Jul20_072424; Tabulated
Summary 2.6.5.3). The distribution of the LNP from the blood to the liver was rapid and
essentially complete by 24h, with <1% of the maximum observed plasma concentrations
remaining (Figure 2.6.4-1).The liver appears to be the major site of drug uptake from the
blood.
CONFIDENTIAL
Page 4
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013900
BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
Table2.6.4-1. PKof ALC-0315 and ALC-0159 in Wistar Han Rats After IV
Administration of LNPs Containing Surrogate Luciferase RNA at 1 mg/kg
Analyte Dose Gender /N t½ AUCinf AUClast Estimated fraction
of Analyte (mg/kg) (h) (µg•h/mL) (µg•h/mL) of dose distributed
to liver (%)a
ALC-0315 15.3 Male/3b 139 1030 1020 60
ALC-0159 1.96 Male/3b 72.7 99.2 98.6 20
a.Calculated as highest mean amount in the liver (µg)/total mean dose (µg) of ALC-0315 or ALC-0159.
b. 3 animals per timepoint; non-serial sampling.
Figure 2.6.4-1. Plasma and Liver Concentrations of ALC-0315 and ALC-0159 in Wistar
Han Rats After IV Administration of LNPs Containing Surrogate
Luciferase RNAat 1 mg/kg
No absorption studies were conducted for BNT162b2, as the administration route is IM.
Pharmacokinetic studies have not been conducted with BNT162b2 and are generally not
considered necessary to support the development and licensure of vaccine products for
infectious diseases (WHO, 2005; WHO, 2014).
2.6.4.4. Distribution
In an in vivo study in BALB/c mice (StudyR-20-0072; Tabulated Summary 2.6.5.5A), the
biodistribution of BNT162b2 was assessed using luciferase as a surrogate marker protein.
RNA encoding luciferase was formulated like BNT162b2, with the identical lipid
composition, and mice received IM injections of 1 µg each in the right and left hind leg (for a
total of 2 µg) of LNP-formulated modRNA encoding luciferase. Luciferase protein
expression was detected at different timepoints, by measuring the in vivo bioluminescence
(Figure 2.6.4-2) after injection of luciferin substrate, at the site of injection and to a lesser
extent in the liver.Distribution to the liver is likely mediated by LNPs entering the blood
stream. The repeat-dose toxicity studies in rats showed no evidence of liver injury (Section
2.6.6.3). The luciferase expression at the injection site, the tissue with the highest
CONFIDENTIAL
Page 5
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013901
BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
bioluminescence, dropped to background levels after 9 days. As detailed in Section 2.6.4.3,
following systemic (IV) administration the liver appears to be the major organ into which the
LNPs distribute, this is consistent with the observations made following IM administration.
Figure 2.6.4-2.Bioluminescence Emission in BALB/c Mice after IM Injection of an LNP
Formulation of modRNA Encoding Luciferase
These qualitative data are supported by a biodistribution study (Study 185350; Tabulated
Summary 2.6.5.5B) carried out with LNPs with a comparablelipid composition as
BNT162b2 but with a luciferase mRNA and a [3H]-CHE lipid radiolabel. Following IM
administration to male and female Wistar Han rats at a dose of 50 µg (1.29 mg total lipid),
the greatest mean concentration was found remaining in the injection siteat each time point
in both sexes. Outside the injection site, thehighest levels of radioactivity were observed in
plasma at 1-4 hours post-dose. Over 48 hours, the radiolabel distributed mainly to the liver,
adrenal glands, spleen and ovaries, with maximum concentrationsobserved at 8-48 hours
post-dose. Total recovery of radioactivity (% of injected dose) outside the injection site was
greatest in the liver (up to 18%) and was much less in the spleen(≤1.0%), adrenal glands
(≤0.11%) and ovaries (≤0.095%). The mean concentrations and tissuedistribution pattern
were broadly similar between sexes.
The biodistribution of theexpression of theantigen encoded by the RNA component of
BNT162b2is expected to be dependent on the LNP distribution. Therefore, results of these
biodistribution studies should be representative for BNT162b2, as the LNP-formulated
luciferase-encoding modRNA had the same lipid composition.
CONFIDENTIAL
Page 6
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013902
BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
2.6.4.5. Metabolism
Metabolism studies were conducted to evaluate ALC-0315 (aminolipid) and ALC-0159
(PEG-lipid). These novel lipids were evaluated for in vitro metabolic stability in CD-1/ICR
mouse, Wistar Han and/or Sprague Dawley rat, cynomolgus monkey, and human liver
microsomes, S9 fractions, and hepatocytes. ALC-0315 and ALC-0159 were stable (>82%
remaining) over 120 min in liver microsomes and S9 fractions and over 240 min in
hepatocytes in all species and test systems (Studies 01049-20008, 01049-20009,
01049-20010, 01049-20020, 01049-20021, and 01049-20022; Tabulated Summaries
2.6.5.10A and 2.6.5.10B).
The metabolism of ALC-0315 and ALC-0159 was further evaluated (Study
PF-07302048_05Aug20_043725; Tabulated Summaries 2.6.5.9, 2.6.5.10C, and 2.6.5.10D)
in vitro using blood, liver S9 fractions, and hepatocytes from CD-1 mice, Wistar Han rats,
cynomolgus monkeys, and humans and in vivo using the rat plasma, urine, feces, and liver
from the PK study (Section 2.6.4.3). This study determined ALC-0315 and ALC-0159 are
metabolized slowly and undergo hydrolytic metabolism of the ester and amide
functionalities, respectively. This hydrolytic metabolism was observed across the species
evaluated, as shown in Figure 2.6.4-3 and Figure 2.6.4-4.
CONFIDENTIAL
Page 7
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013903
BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
Figure 2.6.4-3. Proposed Biotransformation Pathway of ALC-0315 in Various Species
Metabolism of ALC-0315 occurs via two sequential ester hydrolysis reactions, first yielding
the monoester metabolite (m/z 528) followed by the doubly deesterified metabolite (m/z 290).
Subsequent metabolism of the doubly deesterified metabolite resulted in a glucuronide
metabolite (m/z 466),which was only observed in urine from the rat PK study. The acid
product of both hydrolysis reactions of ALC-0315, 6-hexyldecanoic acid (m/z 255), was also
identified.
CONFIDENTIAL
Page 8
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013904
BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
Figure 2.6.4-4. Proposed Biotransformation Pathway of ALC-0159 in Various Species
The primary route of metabolism identified for ALC-0159 involves amide bond hydrolysis
yielding N,N-ditetradecylamine (m/z 410). This metabolite was identified in mouse and rat
blood, as well as hepatocytes and liver S9 from mouse, rat, monkey,and human. No
metabolites of ALC-0159 were identified from in vivo samples.
The other two lipids in the LNP are naturally occurring (cholesterol and DSPC) and willbe
metabolized and excreted like other endogenous lipids.As the protein encoded by the mRNA
in BNT162b2is expected to be proteolytically degraded and RNA is degraded by cellular
RNases and subjected to nucleic acid metabolism, no RNA or protein metabolism or
excretion studies will be conducted.
2.6.4.6. Excretion
In the rat PK study(Section 2.6.4.3), there was no detectable excretion ALC-0315 and
ALC-0159 in urine after IV administration of LNPs containing surrogate luciferase RNA at 1
mg/kg.The percent excreted unchanged in feces was ~1% for ALC-0315 and ~50% for
ALC-0159. Metabolites of ALC-0315 were detected in the urine of rats(Figure 2.6.4-3). No
excretionstudieshave been conductedwith BNT162b2for the reasons described in Section
2.6.4.5.
2.6.4.7. Pharmacokinetic Drug Interactions
No PK drug interaction studies have been conductedwith BNT162b2.
2.6.4.8. Discussion and Conclusions
In the rat PK study, concentrations of ALC-0159 dropped approximately 8000-and
>250-fold in plasma and liver, respectively, during this 2-week study. For ALC-0315, the
elimination of the molecule from plasma and liver was slower, but concentrations fell
approximately 7000-and 4-fold in two weeks for plasma and liver, respectively. Overall, the
apparent terminal t in plasma and liver were similar in both tissues and were 2-3 and 6-8
½
days for ALC-0159 and ALC-0315, respectively. The apparent terminal t in plasma likely
½
represents the re-distribution of the respective lipids from the tissues into which they have
distributed as the LNP back to plasma where they are eliminated.
Overall, it appears that 50%of ALC-0159 was eliminated unchanged in feces. Metabolism
playeda role in the elimination of ALC-0315,as little to no unchanged material was detected
in either urine or feces. Investigations of urine, feces and plasma from the rat PK study
CONFIDENTIAL
Page 9
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013905
BNT162b2
Module 2.6.4. Pharmacokinetics Written Summary
identified a series of ester cleavage products of ALC-0315; this likely represents the primary
clearance mechanism acting on this molecule, although no quantitative data is available to
confirm this hypothesis. In vitro, ALC-0159 was metabolized slowly by hydrolytic
metabolism of the amide functionality.
The potential biodistribution of BNT162b2was assessed using luciferase expression as a
surrogate reporter.Protein expression was demonstrated at the site of injection and to a lesser
extent, and more transiently,in the liver after BALB/c mice received an IM injection of RNA
encoding luciferase in an LNP formulation like BNT162b2. Luciferase expression was
identified at the injection site at 6hours after injection and was not detected by 9days.
Expression in the liver was also present at 6hours after injection and was not detected by
48hours after injection.These findings are supported by a quantitativebiodistribution study
in Wistar Han rats. After IM administration of a radiolabeledlipid marker and a luciferase
modRNAin the same LNP formulation as BNT162b2to rats, the percent of administered
dose was greatest at the injection site. Outside of the injection site, total recovery of
radioactivity was highest in the liver and much lower in the spleen, with very little recovery
in the adrenal glands and ovaries.
2.6.4.9. References
1. World Health Organization. Annex 1. Guidelines on the nonclinical evaluation of
vaccines. In: WHO Technical Report Series No. 927, Geneva, Switzerland. World
Health Organization; 2005:31-63.
2. World Health Organization. Annex 2. Guidelines on the nonclinical evaluation of
vaccine adjuvants and adjuvanted vaccines. In: WHO Technical Report Series No. 987,
Geneva, Switzerland. World Health Organization 2014:59-100.
CONFIDENTIAL
Page 10
)TMG(
94:71
1202-beF-80
:nO
devorppA\devorppA\38c1d1691e771090
FDA-CBER-2021-5683-0013906","[[['ADME', 'Absorption, distribution, metabolism, excretion'], ['ALC-0159', 'Proprietary PEG-lipid included as an excipient in the LNP formulation\nused in BNT162b2'], ['ALC-0315', 'Proprietary amino-lipid included as an excipient in the LNP formulation\nused in BNT162b2'], ['[3H]-CHE', 'Radiolabeled [Cholesteryl-1,2-3H(N)]-Cholesteryl Hexadecyl Ether'], ['DSPC', '1,2-distearoyl-sn-glycero-3-phosphocholine'], ['GLP', 'Good Laboratory Practice'], ['H', 'Human (in metabolite scheme)'], ['IM', 'Intramuscular(ly)'], ['IV', 'Intravenous(ly)'], ['LNP', 'Lipid-nanoparticle'], ['Luc', 'Luciferase (from firefly Pyractomena lucifera)'], ['Mk', 'Monkey (in metabolite scheme)'], ['Mo', 'Mouse (in metabolite scheme)'], ['modRNA', 'Nucleoside-modified mRNA'], ['mRNA', 'Messenger RNA'], ['PEG', 'Polyethylene glycol'], ['PK', 'Pharmacokinetics'], ['R', 'Rat (in metabolite scheme)'], ['RNA', 'Ribonucleic acid'], ['S9', 'Supernatant fraction obtained from liver homogenate by centrifuging at\n9000 g'], ['WHO', 'World Health Organization']], [['the two novel LNP excipients for the non-GLP IV PK study in'], ['rats (']]]",10
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-T-S-suppl-arg.pdf,3.0,"Supplemental Analysis
Reviewer Guide
BLA Analysis for Participants ≥16 Years of Age
BioNTech SE and PFIZER INC.
Study C4591001
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\80a91f691e771090
FDA-CBER-2021-5683-0023988
Study C4591001
Table of Contents
Contents
1. Introduction ................................................................................................................................. 3
2
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\80a91f691e771090
FDA-CBER-2021-5683-0023989
Study C4591001
1. Introduction
This document provides details on the supplemental analysis package created as a supplement
to the BLA esub package to revise the reactogenicity SDTM and ADaM data to address the
agreements made with CBER during the teleconference of 08 April 2021.
SDTM includes DM, EX and updated domains (AE, CE, FACE, VS, SUPPAE, SUPPCE,
SUPPFACE, SUPPVS, RELREC), define and aCRF. ADaM includes ADSL and updated
datasets (ADAE, ADCEVD, ADFACEVD) and define in Module 5.3.5.1. The following are
provided in Module 5.3.5.1 as well:
• A roadmap describing the SDTM dataset updates
• Table summary of changes (CSR vs Update)
• Updated reactogenicity TLFs
• Final reactogenicity tables with track changes
3
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\80a91f691e771090
FDA-CBER-2021-5683-0023990",,3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdf,14.0,"Local Reactions, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) – Phase 2/3 Subjects ≥16 Years of Age – Safety
Population ...................................................................................................................................................................................................................................... 2
Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) – Phase 2/3 Subjects ≥16 Years of Age – Safety
Population ...................................................................................................................................................................................................................................... 5
Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, by Requested Subgroup – Subjects With or Without Evidence of Infection Prior
to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population ............................................................................................................................................. 13
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014040
Local Reactions, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Local Reaction Na nb (%) (95% CIc) Na nb (%) (95% CIc)
1 Rednessd
Any 4907 262 (5.3) (4.7, 6.0) 4897 48 (1.0) (0.7, 1.3)
Mild 4907 184 (3.7) (3.2, 4.3) 4897 32 (0.7) (0.4, 0.9)
Moderate 4907 66 (1.3) (1.0, 1.7) 4897 11 (0.2) (0.1, 0.4)
Severe 4907 12 (0.2) (0.1, 0.4) 4897 5 (0.1) (0.0, 0.2)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
Swellingd
Any 4907 325 (6.6) (5.9, 7.4) 4897 39 (0.8) (0.6, 1.1)
Mild 4907 211 (4.3) (3.7, 4.9) 4897 17 (0.3) (0.2, 0.6)
Moderate 4907 106 (2.2) (1.8, 2.6) 4897 20 (0.4) (0.2, 0.6)
Severe 4907 8 (0.2) (0.1, 0.3) 4897 2 (0.0) (0.0, 0.1)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
Pain at the injection sitee
Any 4907 3834 (78.1) (77.0, 79.3) 4897 599 (12.2) (11.3, 13.2)
Mild 4907 2572 (52.4) (51.0, 53.8) 4897 568 (11.6) (10.7, 12.5)
Moderate 4907 1219 (24.8) (23.6, 26.1) 4897 28 (0.6) (0.4, 0.8)
Severe 4907 43 (0.9) (0.6, 1.2) 4897 3 (0.1) (0.0, 0.2)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
Any local reactionf 4907 3877 (79.0) (77.8, 80.1) 4897 639 (13.0) (12.1, 14.0)
2 Rednessd
Any 4542 284 (6.3) (5.6, 7.0) 4517 32 (0.7) (0.5, 1.0)
Mild 4542 155 (3.4) (2.9, 4.0) 4517 22 (0.5) (0.3, 0.7)
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014041
Local Reactions, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Local Reaction Na nb (%) (95% CIc) Na nb (%) (95% CIc)
Moderate 4542 108 (2.4) (2.0, 2.9) 4517 9 (0.2) (0.1, 0.4)
Severe 4542 21 (0.5) (0.3, 0.7) 4517 1 (0.0) (0.0, 0.1)
Grade 4 4542 0 (0.0, 0.1) 4517 0 (0.0, 0.1)
Swellingd
Any 4542 328 (7.2) (6.5, 8.0) 4517 18 (0.4) (0.2, 0.6)
Mild 4542 190 (4.2) (3.6, 4.8) 4517 8 (0.2) (0.1, 0.3)
Moderate 4542 127 (2.8) (2.3, 3.3) 4517 9 (0.2) (0.1, 0.4)
Severe 4542 11 (0.2) (0.1, 0.4) 4517 1 (0.0) (0.0, 0.1)
Grade 4 4542 0 (0.0, 0.1) 4517 0 (0.0, 0.1)
Pain at the injection sitee
Any 4542 3331 (73.3) (72.0, 74.6) 4517 455 (10.1) (9.2, 11.0)
Mild 4542 2147 (47.3) (45.8, 48.7) 4517 422 (9.3) (8.5, 10.2)
Moderate 4542 1135 (25.0) (23.7, 26.3) 4517 33 (0.7) (0.5, 1.0)
Severe 4542 49 (1.1) (0.8, 1.4) 4517 0 (0.0, 0.1)
Grade 4 4542 0 (0.0, 0.1) 4517 0 (0.0, 0.1)
Any local reactionf 4542 3351 (73.8) (72.5, 75.1) 4517 483 (10.7) (9.8, 11.6)
Any dose Rednessd
Any 4924 486 (9.9) (9.1, 10.7) 4915 72 (1.5) (1.1, 1.8)
Mild 4924 300 (6.1) (5.4, 6.8) 4915 47 (1.0) (0.7, 1.3)
Moderate 4924 153 (3.1) (2.6, 3.6) 4915 20 (0.4) (0.2, 0.6)
Severe 4924 33 (0.7) (0.5, 0.9) 4915 5 (0.1) (0.0, 0.2)
Grade 4 4924 0 (0.0, 0.1) 4915 0 (0.0, 0.1)
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014042
Local Reactions, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Local Reaction Na nb (%) (95% CIc) Na nb (%) (95% CIc)
Swellingd
Any 4924 546 (11.1) (10.2, 12.0) 4915 51 (1.0) (0.8, 1.4)
Mild 4924 329 (6.7) (6.0, 7.4) 4915 21 (0.4) (0.3, 0.7)
Moderate 4924 198 (4.0) (3.5, 4.6) 4915 27 (0.5) (0.4, 0.8)
Severe 4924 19 (0.4) (0.2, 0.6) 4915 3 (0.1) (0.0, 0.2)
Grade 4 4924 0 (0.0, 0.1) 4915 0 (0.0, 0.1)
Pain at the injection sitee
Any 4924 4153 (84.3) (83.3, 85.3) 4915 849 (17.3) (16.2, 18.4)
Mild 4924 2356 (47.8) (46.4, 49.3) 4915 789 (16.1) (15.0, 17.1)
Moderate 4924 1709 (34.7) (33.4, 36.1) 4915 57 (1.2) (0.9, 1.5)
Severe 4924 88 (1.8) (1.4, 2.2) 4915 3 (0.1) (0.0, 0.2)
Grade 4 4924 0 (0.0, 0.1) 4915 0 (0.0, 0.1)
Any local reactionf 4924 4187 (85.0) (84.0, 86.0) 4915 903 (18.4) (17.3, 19.5)
Note: Reactions were collected in the electronic diary (e-diary) from Day 1 through Day 7 after each dose.
Note: Grade 4 reactions were classified by the investigator or medically qualified person.
a. N = number of subjects reporting at least 1 yes or no response for the specified reaction after the specified dose.
b. n = Number of subjects with the specified characteristic.
c. Exact 2-sided CI based on the Clopper and Pearson method.
d. Mild: >2.0 to 5.0 cm; moderate: >5.0 to 10.0 cm; severe: >10.0 cm; Grade 4: necrosis (redness and swelling categories) or exfoliative dermatitis
(redness category only).
e. Mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity; Grade 4: emergency room visit or
hospitalization for severe pain at the injection site.
f. Any local reaction: any redness >2.0 cm, any swelling >2.0 cm, or any pain at the injection site.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 07APR2021 (17:02)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA1/adce_s010_lr_16_p3_saf
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014043
Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Systemic Event Na nb (%) (95% CIc) Na nb (%) (95% CIc)
1 Fever
≥38.0°C 4907 145 (3.0) (2.5, 3.5) 4897 33 (0.7) (0.5, 0.9)
≥38.0°C to 38.4°C 4907 109 (2.2) (1.8, 2.7) 4897 19 (0.4) (0.2, 0.6)
>38.4°C to 38.9°C 4907 27 (0.6) (0.4, 0.8) 4897 8 (0.2) (0.1, 0.3)
>38.9°C to 40.0°C 4907 9 (0.2) (0.1, 0.3) 4897 6 (0.1) (0.0, 0.3)
>40.0°C 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
Fatigued
Any 4907 2108 (43.0) (41.6, 44.4) 4897 1407 (28.7) (27.5, 30.0)
Mild 4907 1175 (23.9) (22.8, 25.2) 4897 851 (17.4) (16.3, 18.5)
Moderate 4907 889 (18.1) (17.0, 19.2) 4897 535 (10.9) (10.1, 11.8)
Severe 4907 44 (0.9) (0.7, 1.2) 4897 21 (0.4) (0.3, 0.7)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
Headached
Any 4907 1765 (36.0) (34.6, 37.3) 4897 1338 (27.3) (26.1, 28.6)
Mild 4907 1166 (23.8) (22.6, 25.0) 4897 900 (18.4) (17.3, 19.5)
Moderate 4907 564 (11.5) (10.6, 12.4) 4897 411 (8.4) (7.6, 9.2)
Severe 4907 35 (0.7) (0.5, 1.0) 4897 27 (0.6) (0.4, 0.8)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
Chillsd
Any 4907 609 (12.4) (11.5, 13.4) 4897 268 (5.5) (4.9, 6.1)
Mild 4907 440 (9.0) (8.2, 9.8) 4897 197 (4.0) (3.5, 4.6)
Moderate 4907 154 (3.1) (2.7, 3.7) 4897 68 (1.4) (1.1, 1.8)
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014044
Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Systemic Event Na nb (%) (95% CIc) Na nb (%) (95% CIc)
Severe 4907 15 (0.3) (0.2, 0.5) 4897 3 (0.1) (0.0, 0.2)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
Vomitinge
Any 4907 44 (0.9) (0.7, 1.2) 4897 45 (0.9) (0.7, 1.2)
Mild 4907 38 (0.8) (0.5, 1.1) 4897 39 (0.8) (0.6, 1.1)
Moderate 4907 6 (0.1) (0.0, 0.3) 4897 5 (0.1) (0.0, 0.2)
Severe 4907 0 (0.0, 0.1) 4897 1 (0.0) (0.0, 0.1)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
Diarrheaf
Any 4907 477 (9.7) (8.9, 10.6) 4897 453 (9.3) (8.5, 10.1)
Mild 4907 388 (7.9) (7.2, 8.7) 4897 373 (7.6) (6.9, 8.4)
Moderate 4907 82 (1.7) (1.3, 2.1) 4897 78 (1.6) (1.3, 2.0)
Severe 4907 7 (0.1) (0.1, 0.3) 4897 2 (0.0) (0.0, 0.1)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
New or worsened muscle paind
Any 4907 938 (19.1) (18.0, 20.2) 4897 494 (10.1) (9.3, 11.0)
Mild 4907 536 (10.9) (10.1, 11.8) 4897 342 (7.0) (6.3, 7.7)
Moderate 4907 386 (7.9) (7.1, 8.7) 4897 147 (3.0) (2.5, 3.5)
Severe 4907 16 (0.3) (0.2, 0.5) 4897 5 (0.1) (0.0, 0.2)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
New or worsened joint paind
Any 4907 517 (10.5) (9.7, 11.4) 4897 292 (6.0) (5.3, 6.7)
Mild 4907 319 (6.5) (5.8, 7.2) 4897 190 (3.9) (3.4, 4.5)
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014045
Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Systemic Event Na nb (%) (95% CIc) Na nb (%) (95% CIc)
Moderate 4907 190 (3.9) (3.3, 4.5) 4897 100 (2.0) (1.7, 2.5)
Severe 4907 8 (0.2) (0.1, 0.3) 4897 2 (0.0) (0.0, 0.1)
Grade 4 4907 0 (0.0, 0.1) 4897 0 (0.0, 0.1)
Any systemic eventg 4907 2963 (60.4) (59.0, 61.8) 4897 2308 (47.1) (45.7, 48.5)
Use of antipyretic or pain medicationh 4907 1187 (24.2) (23.0, 25.4) 4897 622 (12.7) (11.8, 13.7)
2 Fever
≥38.0°C 4542 659 (14.5) (13.5, 15.6) 4517 15 (0.3) (0.2, 0.5)
≥38.0°C to 38.4°C 4542 412 (9.1) (8.3, 9.9) 4517 7 (0.2) (0.1, 0.3)
>38.4°C to 38.9°C 4542 200 (4.4) (3.8, 5.0) 4517 5 (0.1) (0.0, 0.3)
>38.9°C to 40.0°C 4542 46 (1.0) (0.7, 1.3) 4517 3 (0.1) (0.0, 0.2)
>40.0°C 4542 1 (0.0) (0.0, 0.1) 4517 0 (0.0, 0.1)
Fatigued
Any 4542 2598 (57.2) (55.7, 58.6) 4517 920 (20.4) (19.2, 21.6)
Mild 4542 949 (20.9) (19.7, 22.1) 4517 500 (11.1) (10.2, 12.0)
Moderate 4542 1446 (31.8) (30.5, 33.2) 4517 404 (8.9) (8.1, 9.8)
Severe 4542 202 (4.4) (3.9, 5.1) 4517 16 (0.4) (0.2, 0.6)
Grade 4 4542 1 (0.0) (0.0, 0.1) 4517 0 (0.0, 0.1)
Headached
Any 4542 2181 (48.0) (46.6, 49.5) 4517 911 (20.2) (19.0, 21.4)
Mild 4542 1163 (25.6) (24.3, 26.9) 4517 593 (13.1) (12.2, 14.1)
Moderate 4542 914 (20.1) (19.0, 21.3) 4517 295 (6.5) (5.8, 7.3)
Severe 4542 104 (2.3) (1.9, 2.8) 4517 23 (0.5) (0.3, 0.8)
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014046
Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Systemic Event Na nb (%) (95% CIc) Na nb (%) (95% CIc)
Grade 4 4542 0 (0.0, 0.1) 4517 0 (0.0, 0.1)
Chillsd
Any 4542 1450 (31.9) (30.6, 33.3) 4517 171 (3.8) (3.2, 4.4)
Mild 4542 706 (15.5) (14.5, 16.6) 4517 134 (3.0) (2.5, 3.5)
Moderate 4542 654 (14.4) (13.4, 15.5) 4517 35 (0.8) (0.5, 1.1)
Severe 4542 90 (2.0) (1.6, 2.4) 4517 2 (0.0) (0.0, 0.2)
Grade 4 4542 0 (0.0, 0.1) 4517 0 (0.0, 0.1)
Vomitinge
Any 4542 71 (1.6) (1.2, 2.0) 4517 35 (0.8) (0.5, 1.1)
Mild 4542 52 (1.1) (0.9, 1.5) 4517 25 (0.6) (0.4, 0.8)
Moderate 4542 13 (0.3) (0.2, 0.5) 4517 10 (0.2) (0.1, 0.4)
Severe 4542 6 (0.1) (0.0, 0.3) 4517 0 (0.0, 0.1)
Grade 4 4542 0 (0.0, 0.1) 4517 0 (0.0, 0.1)
Diarrheaf
Any 4542 421 (9.3) (8.4, 10.1) 4517 307 (6.8) (6.1, 7.6)
Mild 4542 344 (7.6) (6.8, 8.4) 4517 245 (5.4) (4.8, 6.1)
Moderate 4542 69 (1.5) (1.2, 1.9) 4517 57 (1.3) (1.0, 1.6)
Severe 4542 8 (0.2) (0.1, 0.3) 4517 5 (0.1) (0.0, 0.3)
Grade 4 4542 0 (0.0, 0.1) 4517 0 (0.0, 0.1)
New or worsened muscle paind
Any 4542 1592 (35.1) (33.7, 36.5) 4517 336 (7.4) (6.7, 8.2)
Mild 4542 670 (14.8) (13.7, 15.8) 4517 215 (4.8) (4.2, 5.4)
Moderate 4542 840 (18.5) (17.4, 19.7) 4517 117 (2.6) (2.1, 3.1)
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014047
Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Systemic Event Na nb (%) (95% CIc) Na nb (%) (95% CIc)
Severe 4542 82 (1.8) (1.4, 2.2) 4517 4 (0.1) (0.0, 0.2)
Grade 4 4542 0 (0.0, 0.1) 4517 0 (0.0, 0.1)
New or worsened joint paind
Any 4542 991 (21.8) (20.6, 23.0) 4517 219 (4.8) (4.2, 5.5)
Mild 4542 474 (10.4) (9.6, 11.4) 4517 126 (2.8) (2.3, 3.3)
Moderate 4542 481 (10.6) (9.7, 11.5) 4517 88 (1.9) (1.6, 2.4)
Severe 4542 36 (0.8) (0.6, 1.1) 4517 5 (0.1) (0.0, 0.3)
Grade 4 4542 0 (0.0, 0.1) 4517 0 (0.0, 0.1)
Any systemic eventg 4542 3237 (71.3) (69.9, 72.6) 4517 1542 (34.1) (32.8, 35.5)
Use of antipyretic or pain medicationh 4542 1901 (41.9) (40.4, 43.3) 4517 490 (10.8) (10.0, 11.8)
Any dose Fever
≥38.0°C 4924 749 (15.2) (14.2, 16.2) 4915 45 (0.9) (0.7, 1.2)
≥38.0°C to 38.4°C 4924 478 (9.7) (8.9, 10.6) 4915 25 (0.5) (0.3, 0.7)
>38.4°C to 38.9°C 4924 219 (4.4) (3.9, 5.1) 4915 12 (0.2) (0.1, 0.4)
>38.9°C to 40.0°C 4924 51 (1.0) (0.8, 1.4) 4915 8 (0.2) (0.1, 0.3)
>40.0°C 4924 1 (0.0) (0.0, 0.1) 4915 0 (0.0, 0.1)
Fatigued
Any 4924 3185 (64.7) (63.3, 66.0) 4915 1758 (35.8) (34.4, 37.1)
Mild 4924 1157 (23.5) (22.3, 24.7) 4915 956 (19.5) (18.4, 20.6)
Moderate 4924 1789 (36.3) (35.0, 37.7) 4915 769 (15.6) (14.6, 16.7)
Severe 4924 238 (4.8) (4.3, 5.5) 4915 33 (0.7) (0.5, 0.9)
Grade 4 4924 1 (0.0) (0.0, 0.1) 4915 0 (0.0, 0.1)
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014048
Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Systemic Event Na nb (%) (95% CIc) Na nb (%) (95% CIc)
Headached
Any 4924 2814 (57.1) (55.8, 58.5) 4915 1717 (34.9) (33.6, 36.3)
Mild 4924 1458 (29.6) (28.3, 30.9) 4915 1075 (21.9) (20.7, 23.1)
Moderate 4924 1223 (24.8) (23.6, 26.1) 4915 593 (12.1) (11.2, 13.0)
Severe 4924 133 (2.7) (2.3, 3.2) 4915 49 (1.0) (0.7, 1.3)
Grade 4 4924 0 (0.0, 0.1) 4915 0 (0.0, 0.1)
Chillsd
Any 4924 1707 (34.7) (33.3, 36.0) 4915 380 (7.7) (7.0, 8.5)
Mild 4924 870 (17.7) (16.6, 18.8) 4915 285 (5.8) (5.2, 6.5)
Moderate 4924 734 (14.9) (13.9, 15.9) 4915 90 (1.8) (1.5, 2.2)
Severe 4924 103 (2.1) (1.7, 2.5) 4915 5 (0.1) (0.0, 0.2)
Grade 4 4924 0 (0.0, 0.1) 4915 0 (0.0, 0.1)
Vomitinge
Any 4924 110 (2.2) (1.8, 2.7) 4915 74 (1.5) (1.2, 1.9)
Mild 4924 86 (1.7) (1.4, 2.2) 4915 58 (1.2) (0.9, 1.5)
Moderate 4924 18 (0.4) (0.2, 0.6) 4915 15 (0.3) (0.2, 0.5)
Severe 4924 6 (0.1) (0.0, 0.3) 4915 1 (0.0) (0.0, 0.1)
Grade 4 4924 0 (0.0, 0.1) 4915 0 (0.0, 0.1)
Diarrheaf
Any 4924 758 (15.4) (14.4, 16.4) 4915 659 (13.4) (12.5, 14.4)
Mild 4924 603 (12.2) (11.3, 13.2) 4915 524 (10.7) (9.8, 11.6)
Moderate 4924 140 (2.8) (2.4, 3.3) 4915 128 (2.6) (2.2, 3.1)
Severe 4924 15 (0.3) (0.2, 0.5) 4915 7 (0.1) (0.1, 0.3)
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014049
Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Systemic Event Na nb (%) (95% CIc) Na nb (%) (95% CIc)
Grade 4 4924 0 (0.0, 0.1) 4915 0 (0.0, 0.1)
New or worsened muscle paind
Any 4924 1980 (40.2) (38.8, 41.6) 4915 692 (14.1) (13.1, 15.1)
Mild 4924 826 (16.8) (15.7, 17.8) 4915 442 (9.0) (8.2, 9.8)
Moderate 4924 1059 (21.5) (20.4, 22.7) 4915 241 (4.9) (4.3, 5.5)
Severe 4924 95 (1.9) (1.6, 2.4) 4915 9 (0.2) (0.1, 0.3)
Grade 4 4924 0 (0.0, 0.1) 4915 0 (0.0, 0.1)
New or worsened joint paind
Any 4924 1232 (25.0) (23.8, 26.3) 4915 442 (9.0) (8.2, 9.8)
Mild 4924 586 (11.9) (11.0, 12.8) 4915 259 (5.3) (4.7, 5.9)
Moderate 4924 602 (12.2) (11.3, 13.2) 4915 176 (3.6) (3.1, 4.1)
Severe 4924 44 (0.9) (0.7, 1.2) 4915 7 (0.1) (0.1, 0.3)
Grade 4 4924 0 (0.0, 0.1) 4915 0 (0.0, 0.1)
Any systemic eventg 4924 3878 (78.8) (77.6, 79.9) 4915 2716 (55.3) (53.9, 56.7)
Use of antipyretic or pain medicationh 4924 2301 (46.7) (45.3, 48.1) 4915 924 (18.8) (17.7, 19.9)
Note: Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 through Day 7 after each dose. Grade 4
events were classified by the investigator or medically qualified person.
a. N = number of subjects reporting at least 1 yes or no response for the specified event after the specified dose.
b. n = Number of subjects with the specified characteristic.
c. Exact 2-sided CI based on the Clopper and Pearson method.
d. Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity; Grade 4: emergency room visit or
hospitalization for severe fatigue, severe headache, severe chills, severe muscle pain, or severe joint pain.
e. Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration; Grade 4: emergency room visit or
hospitalization for severe vomiting.
f. Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours; Grade 4: emergency room
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014050
Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –
Phase 2/3 Subjects ≥16 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Dose Systemic Event Na nb (%) (95% CIc) Na nb (%) (95% CIc)
visit or hospitalization for severe diarrhea.
g. Any systemic event: any fever ≥38.0°C, any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any
new or worsened joint pain.
h. Severity was not collected for use of antipyretic or pain medication.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 07APR2021 (17:15)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA1/adce s020 se 16 p3 saf
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014051
Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, by Requested Subgroup – Subjects With or
Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population
Vaccine Group (as Randomized)
BNT162b2 (30 μg) Placebo
(Na=19965) (Na=20172)
Efficacy Endpoint Surveillance Surveillance
Subgroup n1b Timec (n2d) n1b Timec (n2d) VE (%) (95% CIe)
First COVID-19 occurrence from 7 days after Dose 2
Overall 9 2.332 (18559) 169 2.345 (18708) 94.6 (89.6, 97.6)
Age group (years)
12 to 15 0 0.000 (14) 0 0.000 (14) NE (NE, NE)
16 to 17 0 0.003 (58) 1 0.003 (61) 100.0 (-3969.9, 100.0)
18 to 64 8 1.799 (14443) 149 1.811 (14566) 94.6 (89.1, 97.7)
65 to 74 1 0.424 (3239) 14 0.423 (3255) 92.9 (53.2, 99.8)
≥75 0 0.106 (805) 5 0.109 (812) 100.0 (-12.1, 100.0)
Race
White 7 1.975 (15294) 153 1.990 (15473) 95.4 (90.3, 98.2)
Black or African American 0 0.187 (1758) 7 0.188 (1758) 100.0 (30.4, 100.0)
American Indian or Alaska native 0 0.011 (104) 1 0.010 (104) 100.0 (-3511.0, 100.0)
Asian 1 0.095 (796) 4 0.097 (808) 74.4 (-158.7, 99.5)
Native Hawaiian or other Pacific Islander 0 0.006 (50) 1 0.003 (29) 100.0 (-2112.1, 100.0)
Multiracial 1 0.047 (467) 1 0.042 (424) 10.4 (-6934.9, 98.9)
Not reported 0 0.010 (90) 2 0.013 (112) 100.0 (-581.6, 100.0)
Baseline SARS-CoV-2 status
Positivef 1 0.056 (526) 1 0.060 (567) -7.1 (-8309.9, 98.6)
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014052
Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, by Requested Subgroup – Subjects With or
Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population
Vaccine Group (as Randomized)
BNT162b2 (30 μg) Placebo
(Na=19965) (Na=20172)
Efficacy Endpoint Surveillance Surveillance
Subgroup n1b Timec (n2d) n1b Timec (n2d) VE (%) (95% CIe)
Negativeg 8 2.237 (17637) 164 2.242 (17720) 95.1 (90.1, 97.9)
Unknown 0 0.039 (396) 4 0.043 (421) 100.0 (-68.9, 100.0)
Abbreviations: N-binding = SARS-CoV-2 nucleoprotein–binding; NAAT = nucleic acid amplification test; SARS-CoV-2 = severe acute respiratory
syndrome coronavirus 2; VE = vaccine efficacy.
a. N = number of subjects in the specified group.
b. n1 = Number of subjects meeting the endpoint definition.
c. Total surveillance time in 1000 person-years for the given endpoint across all subjects within each group at risk for the endpoint. Time period for
COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.
d. n2 = Number of subjects at risk for the endpoint.
e. Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time.
f. Positive N-binding antibody result at Visit 1, positive NAAT result at Visit 1, or medical history of COVID-19.
g. Negative N-binding antibody result at Visit 1, negative NAAT result at Visit 1, and no medical history of COVID-19.
PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (09:54) Source Data: adc19ef Table Generation: 23NOV2020 (16:39)
(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_EUA_FAEF_RR/adc19ef_ve_cov_7pd2_req_sg_eval
)TMG(
30:51
1202-yaM-50
:nO
laniF\laniF\4c045f691e771090
FDA-CBER-2021-5683-0014053","[[['', None, None, None, None, None, None, None, None, None], ['', 'Local Reactions, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose Local Reaction Na nb (%) (95% CIc) Na nb (%) (95% CIc)', None, None, None, None, None, None, None, None, None], ['1 Rednessd', None, None, None, None, None, None, None, None, None], ['', '', 'Any', '4907', '262 (5.3)', '(4.7, 6.0)', '4897', '48 (1.0)', '(0.7, 1.3)', ''], ['', '', 'Mild', '4907', '184 (3.7)', '(3.2, 4.3)', '4897', '32 (0.7)', '(0.4, 0.9)', ''], ['', '', 'Moderate', '4907', '66 (1.3)', '(1.0, 1.7)', '4897', '11 (0.2)', '(0.1, 0.4)', ''], ['', '', 'Severe', '4907', '12 (0.2)', '(0.1, 0.4)', '4897', '5 (0.1)', '(0.0, 0.2)', ''], ['', None, 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', None], ['', '', 'Swellingd', '', '', '', '', '', '', ''], ['', '', 'Any', '4907', '325 (6.6)', '(5.9, 7.4)', '4897', '39 (0.8)', '(0.6, 1.1)', ''], ['', '', 'Mild', '4907', '211 (4.3)', '(3.7, 4.9)', '4897', '17 (0.3)', '(0.2, 0.6)', ''], ['', '', 'Moderate', '4907', '106 (2.2)', '(1.8, 2.6)', '4897', '20 (0.4)', '(0.2, 0.6)', ''], ['', '', 'Severe', '4907', '8 (0.2)', '(0.1, 0.3)', '4897', '2 (0.0)', '(0.0, 0.1)', ''], ['', '', 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', ''], ['', None, 'Pain at the injection sitee', '', '', '', '', '', '', None], ['', '', 'Any', '4907', '3834 (78.1)', '(77.0, 79.3)', '4897', '599 (12.2)', '(11.3, 13.2)', ''], ['', '', 'Mild', '4907', '2572 (52.4)', '(51.0, 53.8)', '4897', '568 (11.6)', '(10.7, 12.5)', ''], ['', '', 'Moderate', '4907', '1219 (24.8)', '(23.6, 26.1)', '4897', '28 (0.6)', '(0.4, 0.8)', ''], ['', '', 'Severe', '4907', '43 (0.9)', '(0.6, 1.2)', '4897', '3 (0.1)', '(0.0, 0.2)', ''], ['', None, 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', None], ['', '', 'Any local reactionf', '4907', '3877 (79.0)', '(77.8, 80.1)', '4897', '639 (13.0)', '(12.1, 14.0)', ''], ['2', None, 'Rednessd', '', '', '', '', '', '', None], ['', '', 'Any', '4542', '284 (6.3)', '(5.6, 7.0)', '4517', '32 (0.7)', '(0.5, 1.0)', ''], ['', '', 'Mild', '4542', '155 (3.4)', '(2.9, 4.0)', '4517', '22 (0.5)', '(0.3, 0.7)', '']], [['', None, None, None, None, None, None, None, None, None], ['', 'Local Reactions, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose', None, 'Local Reaction', 'Na', 'nb (%)', '(95% CIc)', 'Na', 'nb (%)', '(95% CIc)', None], ['', '', 'Moderate', '4542', '108 (2.4)', '(2.0, 2.9)', '4517', '9 (0.2)', '(0.1, 0.4)', ''], ['', '', 'Severe', '4542', '21 (0.5)', '(0.3, 0.7)', '4517', '1 (0.0)', '(0.0, 0.1)', ''], ['', None, 'Grade 4', '4542', '0', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', None], ['', '', 'Swellingd', '', '', '', '', '', '', ''], ['', '', 'Any', '4542', '328 (7.2)', '(6.5, 8.0)', '4517', '18 (0.4)', '(0.2, 0.6)', ''], ['', '', 'Mild', '4542', '190 (4.2)', '(3.6, 4.8)', '4517', '8 (0.2)', '(0.1, 0.3)', ''], ['', '', 'Moderate', '4542', '127 (2.8)', '(2.3, 3.3)', '4517', '9 (0.2)', '(0.1, 0.4)', ''], ['', '', 'Severe', '4542', '11 (0.2)', '(0.1, 0.4)', '4517', '1 (0.0)', '(0.0, 0.1)', ''], ['', '', 'Grade 4', '4542', '0', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', ''], ['', None, 'Pain at the injection sitee', '', '', '', '', '', '', None], ['', '', 'Any', '4542', '3331 (73.3)', '(72.0, 74.6)', '4517', '455 (10.1)', '(9.2, 11.0)', ''], ['', '', 'Mild', '4542', '2147 (47.3)', '(45.8, 48.7)', '4517', '422 (9.3)', '(8.5, 10.2)', ''], ['', '', 'Moderate', '4542', '1135 (25.0)', '(23.7, 26.3)', '4517', '33 (0.7)', '(0.5, 1.0)', ''], ['', '', 'Severe', '4542', '49 (1.1)', '(0.8, 1.4)', '4517', '0', '(0.0, 0.1)', ''], ['', None, 'Grade 4', '4542', '0', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', None], ['', '', 'Any local reactionf', '4542', '3351 (73.8)', '(72.5, 75.1)', '4517', '483 (10.7)', '(9.8, 11.6)', ''], ['Any dose', None, 'Rednessd', '', '', '', '', '', '', None], ['', '', 'Any', '4924', '486 (9.9)', '(9.1, 10.7)', '4915', '72 (1.5)', '(1.1, 1.8)', ''], ['', '', 'Mild', '4924', '300 (6.1)', '(5.4, 6.8)', '4915', '47 (1.0)', '(0.7, 1.3)', ''], ['', '', 'Moderate', '4924', '153 (3.1)', '(2.6, 3.6)', '4915', '20 (0.4)', '(0.2, 0.6)', ''], ['', '', 'Severe', '4924', '33 (0.7)', '(0.5, 0.9)', '4915', '5 (0.1)', '(0.0, 0.2)', ''], ['', '', 'Grade 4', '4924', '0', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', '']], [['', None, None, None, None, None, None, None, None, None], ['', 'Local Reactions, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose', None, 'Local Reaction', 'Na', 'nb (%)', '(95% CIc)', 'Na', 'nb (%)', '(95% CIc)', None], ['', '', 'Swellingd', '', '', '', '', '', '', ''], ['', '', 'Any', '4924', '546 (11.1)', '(10.2, 12.0)', '4915', '51 (1.0)', '(0.8, 1.4)', ''], ['', '', 'Mild', '4924', '329 (6.7)', '(6.0, 7.4)', '4915', '21 (0.4)', '(0.3, 0.7)', ''], ['', '', 'Moderate', '4924', '198 (4.0)', '(3.5, 4.6)', '4915', '27 (0.5)', '(0.4, 0.8)', ''], ['', '', 'Severe', '4924', '19 (0.4)', '(0.2, 0.6)', '4915', '3 (0.1)', '(0.0, 0.2)', ''], ['', '', 'Grade 4', '4924', '0', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', ''], ['', None, 'Pain at the injection sitee', '', '', '', '', '', '', None], ['', '', 'Any', '4924', '4153 (84.3)', '(83.3, 85.3)', '4915', '849 (17.3)', '(16.2, 18.4)', ''], ['', '', 'Mild', '4924', '2356 (47.8)', '(46.4, 49.3)', '4915', '789 (16.1)', '(15.0, 17.1)', ''], ['', '', 'Moderate', '4924', '1709 (34.7)', '(33.4, 36.1)', '4915', '57 (1.2)', '(0.9, 1.5)', ''], ['', '', 'Severe', '4924', '88 (1.8)', '(1.4, 2.2)', '4915', '3 (0.1)', '(0.0, 0.2)', ''], ['', None, 'Grade 4', '4924', '0', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', None], ['', '', 'Any local reactionf', '4924', '4187 (85.0)', '(84.0, 86.0)', '4915', '903 (18.4)', '(17.3, 19.5)', ''], ['Note: Reactions were collected in the electronic diary (e-diary) from Day 1 through Day 7 after each dose.\nNote: Grade 4 reactions were classified by the investigator or medically qualified person.\na. N = number of subjects reporting at least 1 yes or no response for the specified reaction after the specified dose.\nb. n = Number of subjects with the specified characteristic.\nc. Exact 2-sided CI based on the Clopper and Pearson method.\nd. Mild: >2.0 to 5.0 cm; moderate: >5.0 to 10.0 cm; severe: >10.0 cm; Grade 4: necrosis (redness and swelling categories) or exfoliative dermatitis\n(redness category only).\ne. Mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity; Grade 4: emergency room visit or\nhospitalization for severe pain at the injection site.\nf. Any local reaction: any redness >2.0 cm, any swelling >2.0 cm, or any pain at the injection site.\nPFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 07APR2021 (17:02)\n(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA1/adce_s010_lr_16_p3_saf', None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None]], [['Note: Grade 4 reactions were classified by the investigator or medically qualified person.'], ['a. N = number of subjects reporting at least 1 yes or no response for the specified reaction after the specified dose.'], ['b. n = Number of subjects with the specified characteristic.'], ['c. Exact 2-sided CI based on the Clopper and Pearson method.'], ['d. Mild: >2.0 to 5.0 cm; moderate: >5.0 to 10.0 cm; severe: >10.0 cm; Grade 4: necrosis (redness and swelling categories) or exfoliative dermatitis'], ['(redness category only).'], ['e. Mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity; Grade 4: emergency room visit or'], ['hospitalization for severe pain at the injection site.'], ['f. Any local reaction: any redness >2.0 cm, any swelling >2.0 cm, or any pain at the injection site.'], ['PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 07APR2021 (17:02)'], ['(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA1/adce_s010_lr_16_p3_saf']], [['', None, None, None, None, None, None, None, None, None], ['', 'Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose Systemic Event Na nb (%) (95% CIc) Na nb (%) (95% CIc)', None, None, None, None, None, None, None, None, None], ['1 Fever', None, None, None, None, None, None, None, None, None], ['', '', '≥38.0°C', '4907', '145 (3.0)', '(2.5, 3.5)', '4897', '33 (0.7)', '(0.5, 0.9)', ''], ['', '', '≥38.0°C to 38.4°C', '4907', '109 (2.2)', '(1.8, 2.7)', '4897', '19 (0.4)', '(0.2, 0.6)', ''], ['', '', '>38.4°C to 38.9°C', '4907', '27 (0.6)', '(0.4, 0.8)', '4897', '8 (0.2)', '(0.1, 0.3)', ''], ['', '', '>38.9°C to 40.0°C', '4907', '9 (0.2)', '(0.1, 0.3)', '4897', '6 (0.1)', '(0.0, 0.3)', ''], ['', None, '>40.0°C', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', None], ['', '', 'Fatigued', '', '', '', '', '', '', ''], ['', '', 'Any', '4907', '2108 (43.0)', '(41.6, 44.4)', '4897', '1407 (28.7)', '(27.5, 30.0)', ''], ['', '', 'Mild', '4907', '1175 (23.9)', '(22.8, 25.2)', '4897', '851 (17.4)', '(16.3, 18.5)', ''], ['', '', 'Moderate', '4907', '889 (18.1)', '(17.0, 19.2)', '4897', '535 (10.9)', '(10.1, 11.8)', ''], ['', '', 'Severe', '4907', '44 (0.9)', '(0.7, 1.2)', '4897', '21 (0.4)', '(0.3, 0.7)', ''], ['', '', 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', ''], ['', None, 'Headached', '', '', '', '', '', '', None], ['', '', 'Any', '4907', '1765 (36.0)', '(34.6, 37.3)', '4897', '1338 (27.3)', '(26.1, 28.6)', ''], ['', '', 'Mild', '4907', '1166 (23.8)', '(22.6, 25.0)', '4897', '900 (18.4)', '(17.3, 19.5)', ''], ['', '', 'Moderate', '4907', '564 (11.5)', '(10.6, 12.4)', '4897', '411 (8.4)', '(7.6, 9.2)', ''], ['', '', 'Severe', '4907', '35 (0.7)', '(0.5, 1.0)', '4897', '27 (0.6)', '(0.4, 0.8)', ''], ['', None, 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', None], ['', '', 'Chillsd', '', '', '', '', '', '', ''], ['', '', 'Any', '4907', '609 (12.4)', '(11.5, 13.4)', '4897', '268 (5.5)', '(4.9, 6.1)', ''], ['', '', 'Mild', '4907', '440 (9.0)', '(8.2, 9.8)', '4897', '197 (4.0)', '(3.5, 4.6)', ''], ['', '', 'Moderate', '4907', '154 (3.1)', '(2.7, 3.7)', '4897', '68 (1.4)', '(1.1, 1.8)', '']], [['', None, None, None, None, None, None, None, None, None], ['', 'Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose', None, 'Systemic Event', 'Na', 'nb (%)', '(95% CIc)', 'Na', 'nb (%)', '(95% CIc)', None], ['', '', 'Severe', '4907', '15 (0.3)', '(0.2, 0.5)', '4897', '3 (0.1)', '(0.0, 0.2)', ''], ['', None, 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', None], ['', '', 'Vomitinge', '', '', '', '', '', '', ''], ['', '', 'Any', '4907', '44 (0.9)', '(0.7, 1.2)', '4897', '45 (0.9)', '(0.7, 1.2)', ''], ['', '', 'Mild', '4907', '38 (0.8)', '(0.5, 1.1)', '4897', '39 (0.8)', '(0.6, 1.1)', ''], ['', '', 'Moderate', '4907', '6 (0.1)', '(0.0, 0.3)', '4897', '5 (0.1)', '(0.0, 0.2)', ''], ['', '', 'Severe', '4907', '0', '(0.0, 0.1)', '4897', '1 (0.0)', '(0.0, 0.1)', ''], ['', '', 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', ''], ['', None, 'Diarrheaf', '', '', '', '', '', '', None], ['', '', 'Any', '4907', '477 (9.7)', '(8.9, 10.6)', '4897', '453 (9.3)', '(8.5, 10.1)', ''], ['', '', 'Mild', '4907', '388 (7.9)', '(7.2, 8.7)', '4897', '373 (7.6)', '(6.9, 8.4)', ''], ['', '', 'Moderate', '4907', '82 (1.7)', '(1.3, 2.1)', '4897', '78 (1.6)', '(1.3, 2.0)', ''], ['', '', 'Severe', '4907', '7 (0.1)', '(0.1, 0.3)', '4897', '2 (0.0)', '(0.0, 0.1)', ''], ['', '', 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', ''], ['', None, 'New or worsened muscle paind', '', '', '', '', '', '', None], ['', '', 'Any', '4907', '938 (19.1)', '(18.0, 20.2)', '4897', '494 (10.1)', '(9.3, 11.0)', ''], ['', '', 'Mild', '4907', '536 (10.9)', '(10.1, 11.8)', '4897', '342 (7.0)', '(6.3, 7.7)', ''], ['', '', 'Moderate', '4907', '386 (7.9)', '(7.1, 8.7)', '4897', '147 (3.0)', '(2.5, 3.5)', ''], ['', '', 'Severe', '4907', '16 (0.3)', '(0.2, 0.5)', '4897', '5 (0.1)', '(0.0, 0.2)', ''], ['', None, 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', None], ['', '', 'New or worsened joint paind', '', '', '', '', '', '', ''], ['', '', 'Any', '4907', '517 (10.5)', '(9.7, 11.4)', '4897', '292 (6.0)', '(5.3, 6.7)', ''], ['', '', 'Mild', '4907', '319 (6.5)', '(5.8, 7.2)', '4897', '190 (3.9)', '(3.4, 4.5)', '']], [['', None, None, None, None, None, None, None, None, None], ['', 'Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose', None, 'Systemic Event', 'Na', 'nb (%)', '(95% CIc)', 'Na', 'nb (%)', '(95% CIc)', None], ['', '', 'Moderate', '4907', '190 (3.9)', '(3.3, 4.5)', '4897', '100 (2.0)', '(1.7, 2.5)', ''], ['', '', 'Severe', '4907', '8 (0.2)', '(0.1, 0.3)', '4897', '2 (0.0)', '(0.0, 0.1)', ''], ['', None, 'Grade 4', '4907', '0', '(0.0, 0.1)', '4897', '0', '(0.0, 0.1)', None], ['', '', 'Any systemic eventg', '4907', '2963 (60.4)', '(59.0, 61.8)', '4897', '2308 (47.1)', '(45.7, 48.5)', ''], ['', None, 'Use of antipyretic or pain medicationh', '4907', '1187 (24.2)', '(23.0, 25.4)', '4897', '622 (12.7)', '(11.8, 13.7)', None], ['', '2', 'Fever', '', '', '', '', '', '', ''], ['', '', '≥38.0°C', '4542', '659 (14.5)', '(13.5, 15.6)', '4517', '15 (0.3)', '(0.2, 0.5)', ''], ['', '', '≥38.0°C to 38.4°C', '4542', '412 (9.1)', '(8.3, 9.9)', '4517', '7 (0.2)', '(0.1, 0.3)', ''], ['', '', '>38.4°C to 38.9°C', '4542', '200 (4.4)', '(3.8, 5.0)', '4517', '5 (0.1)', '(0.0, 0.3)', ''], ['', '', '>38.9°C to 40.0°C', '4542', '46 (1.0)', '(0.7, 1.3)', '4517', '3 (0.1)', '(0.0, 0.2)', ''], ['', '', '>40.0°C', '4542', '1 (0.0)', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', ''], ['', None, 'Fatigued', '', '', '', '', '', '', None], ['', '', 'Any', '4542', '2598 (57.2)', '(55.7, 58.6)', '4517', '920 (20.4)', '(19.2, 21.6)', ''], ['', '', 'Mild', '4542', '949 (20.9)', '(19.7, 22.1)', '4517', '500 (11.1)', '(10.2, 12.0)', ''], ['', '', 'Moderate', '4542', '1446 (31.8)', '(30.5, 33.2)', '4517', '404 (8.9)', '(8.1, 9.8)', ''], ['', '', 'Severe', '4542', '202 (4.4)', '(3.9, 5.1)', '4517', '16 (0.4)', '(0.2, 0.6)', ''], ['', None, 'Grade 4', '4542', '1 (0.0)', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', None], ['', '', 'Headached', '', '', '', '', '', '', ''], ['', '', 'Any', '4542', '2181 (48.0)', '(46.6, 49.5)', '4517', '911 (20.2)', '(19.0, 21.4)', ''], ['', '', 'Mild', '4542', '1163 (25.6)', '(24.3, 26.9)', '4517', '593 (13.1)', '(12.2, 14.1)', ''], ['', '', 'Moderate', '4542', '914 (20.1)', '(19.0, 21.3)', '4517', '295 (6.5)', '(5.8, 7.3)', ''], ['', '', 'Severe', '4542', '104 (2.3)', '(1.9, 2.8)', '4517', '23 (0.5)', '(0.3, 0.8)', '']], [['', None, None, None, None, None, None, None, None, None], ['', 'Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose', None, 'Systemic Event', 'Na', 'nb (%)', '(95% CIc)', 'Na', 'nb (%)', '(95% CIc)', None], ['', '', 'Grade 4', '4542', '0', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', ''], ['', None, 'Chillsd', '', '', '', '', '', '', None], ['', '', 'Any', '4542', '1450 (31.9)', '(30.6, 33.3)', '4517', '171 (3.8)', '(3.2, 4.4)', ''], ['', '', 'Mild', '4542', '706 (15.5)', '(14.5, 16.6)', '4517', '134 (3.0)', '(2.5, 3.5)', ''], ['', '', 'Moderate', '4542', '654 (14.4)', '(13.4, 15.5)', '4517', '35 (0.8)', '(0.5, 1.1)', ''], ['', '', 'Severe', '4542', '90 (2.0)', '(1.6, 2.4)', '4517', '2 (0.0)', '(0.0, 0.2)', ''], ['', None, 'Grade 4', '4542', '0', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', None], ['', '', 'Vomitinge', '', '', '', '', '', '', ''], ['', '', 'Any', '4542', '71 (1.6)', '(1.2, 2.0)', '4517', '35 (0.8)', '(0.5, 1.1)', ''], ['', '', 'Mild', '4542', '52 (1.1)', '(0.9, 1.5)', '4517', '25 (0.6)', '(0.4, 0.8)', ''], ['', '', 'Moderate', '4542', '13 (0.3)', '(0.2, 0.5)', '4517', '10 (0.2)', '(0.1, 0.4)', ''], ['', '', 'Severe', '4542', '6 (0.1)', '(0.0, 0.3)', '4517', '0', '(0.0, 0.1)', ''], ['', '', 'Grade 4', '4542', '0', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', ''], ['', None, 'Diarrheaf', '', '', '', '', '', '', None], ['', '', 'Any', '4542', '421 (9.3)', '(8.4, 10.1)', '4517', '307 (6.8)', '(6.1, 7.6)', ''], ['', '', 'Mild', '4542', '344 (7.6)', '(6.8, 8.4)', '4517', '245 (5.4)', '(4.8, 6.1)', ''], ['', '', 'Moderate', '4542', '69 (1.5)', '(1.2, 1.9)', '4517', '57 (1.3)', '(1.0, 1.6)', ''], ['', '', 'Severe', '4542', '8 (0.2)', '(0.1, 0.3)', '4517', '5 (0.1)', '(0.0, 0.3)', ''], ['', None, 'Grade 4', '4542', '0', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', None], ['', '', 'New or worsened muscle paind', '', '', '', '', '', '', ''], ['', '', 'Any', '4542', '1592 (35.1)', '(33.7, 36.5)', '4517', '336 (7.4)', '(6.7, 8.2)', ''], ['', '', 'Mild', '4542', '670 (14.8)', '(13.7, 15.8)', '4517', '215 (4.8)', '(4.2, 5.4)', ''], ['', '', 'Moderate', '4542', '840 (18.5)', '(17.4, 19.7)', '4517', '117 (2.6)', '(2.1, 3.1)', '']], [['', None, None, None, None, None, None, None, None, None], ['', 'Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose', None, 'Systemic Event', 'Na', 'nb (%)', '(95% CIc)', 'Na', 'nb (%)', '(95% CIc)', None], ['', '', 'Severe', '4542', '82 (1.8)', '(1.4, 2.2)', '4517', '4 (0.1)', '(0.0, 0.2)', ''], ['', None, 'Grade 4', '4542', '0', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', None], ['', '', 'New or worsened joint paind', '', '', '', '', '', '', ''], ['', '', 'Any', '4542', '991 (21.8)', '(20.6, 23.0)', '4517', '219 (4.8)', '(4.2, 5.5)', ''], ['', '', 'Mild', '4542', '474 (10.4)', '(9.6, 11.4)', '4517', '126 (2.8)', '(2.3, 3.3)', ''], ['', '', 'Moderate', '4542', '481 (10.6)', '(9.7, 11.5)', '4517', '88 (1.9)', '(1.6, 2.4)', ''], ['', '', 'Severe', '4542', '36 (0.8)', '(0.6, 1.1)', '4517', '5 (0.1)', '(0.0, 0.3)', ''], ['', '', 'Grade 4', '4542', '0', '(0.0, 0.1)', '4517', '0', '(0.0, 0.1)', ''], ['', None, 'Any systemic eventg', '4542', '3237 (71.3)', '(69.9, 72.6)', '4517', '1542 (34.1)', '(32.8, 35.5)', None], ['', None, 'Use of antipyretic or pain medicationh', '4542', '1901 (41.9)', '(40.4, 43.3)', '4517', '490 (10.8)', '(10.0, 11.8)', None], ['', 'Any dose', 'Fever', '', '', '', '', '', '', ''], ['', '', '≥38.0°C', '4924', '749 (15.2)', '(14.2, 16.2)', '4915', '45 (0.9)', '(0.7, 1.2)', ''], ['', '', '≥38.0°C to 38.4°C', '4924', '478 (9.7)', '(8.9, 10.6)', '4915', '25 (0.5)', '(0.3, 0.7)', ''], ['', '', '>38.4°C to 38.9°C', '4924', '219 (4.4)', '(3.9, 5.1)', '4915', '12 (0.2)', '(0.1, 0.4)', ''], ['', '', '>38.9°C to 40.0°C', '4924', '51 (1.0)', '(0.8, 1.4)', '4915', '8 (0.2)', '(0.1, 0.3)', ''], ['', '', '>40.0°C', '4924', '1 (0.0)', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', ''], ['', None, 'Fatigued', '', '', '', '', '', '', None], ['', '', 'Any', '4924', '3185 (64.7)', '(63.3, 66.0)', '4915', '1758 (35.8)', '(34.4, 37.1)', ''], ['', '', 'Mild', '4924', '1157 (23.5)', '(22.3, 24.7)', '4915', '956 (19.5)', '(18.4, 20.6)', ''], ['', '', 'Moderate', '4924', '1789 (36.3)', '(35.0, 37.7)', '4915', '769 (15.6)', '(14.6, 16.7)', ''], ['', '', 'Severe', '4924', '238 (4.8)', '(4.3, 5.5)', '4915', '33 (0.7)', '(0.5, 0.9)', ''], ['', '', 'Grade 4', '4924', '1 (0.0)', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', '']], [['', None, None, None, None, None, None, None, None, None], ['', 'Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose', None, 'Systemic Event', 'Na', 'nb (%)', '(95% CIc)', 'Na', 'nb (%)', '(95% CIc)', None], ['', '', 'Headached', '', '', '', '', '', '', ''], ['', '', 'Any', '4924', '2814 (57.1)', '(55.8, 58.5)', '4915', '1717 (34.9)', '(33.6, 36.3)', ''], ['', '', 'Mild', '4924', '1458 (29.6)', '(28.3, 30.9)', '4915', '1075 (21.9)', '(20.7, 23.1)', ''], ['', '', 'Moderate', '4924', '1223 (24.8)', '(23.6, 26.1)', '4915', '593 (12.1)', '(11.2, 13.0)', ''], ['', '', 'Severe', '4924', '133 (2.7)', '(2.3, 3.2)', '4915', '49 (1.0)', '(0.7, 1.3)', ''], ['', '', 'Grade 4', '4924', '0', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', ''], ['', None, 'Chillsd', '', '', '', '', '', '', None], ['', '', 'Any', '4924', '1707 (34.7)', '(33.3, 36.0)', '4915', '380 (7.7)', '(7.0, 8.5)', ''], ['', '', 'Mild', '4924', '870 (17.7)', '(16.6, 18.8)', '4915', '285 (5.8)', '(5.2, 6.5)', ''], ['', '', 'Moderate', '4924', '734 (14.9)', '(13.9, 15.9)', '4915', '90 (1.8)', '(1.5, 2.2)', ''], ['', '', 'Severe', '4924', '103 (2.1)', '(1.7, 2.5)', '4915', '5 (0.1)', '(0.0, 0.2)', ''], ['', None, 'Grade 4', '4924', '0', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', None], ['', '', 'Vomitinge', '', '', '', '', '', '', ''], ['', '', 'Any', '4924', '110 (2.2)', '(1.8, 2.7)', '4915', '74 (1.5)', '(1.2, 1.9)', ''], ['', '', 'Mild', '4924', '86 (1.7)', '(1.4, 2.2)', '4915', '58 (1.2)', '(0.9, 1.5)', ''], ['', '', 'Moderate', '4924', '18 (0.4)', '(0.2, 0.6)', '4915', '15 (0.3)', '(0.2, 0.5)', ''], ['', '', 'Severe', '4924', '6 (0.1)', '(0.0, 0.3)', '4915', '1 (0.0)', '(0.0, 0.1)', ''], ['', '', 'Grade 4', '4924', '0', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', ''], ['', None, 'Diarrheaf', '', '', '', '', '', '', None], ['', '', 'Any', '4924', '758 (15.4)', '(14.4, 16.4)', '4915', '659 (13.4)', '(12.5, 14.4)', ''], ['', '', 'Mild', '4924', '603 (12.2)', '(11.3, 13.2)', '4915', '524 (10.7)', '(9.8, 11.6)', ''], ['', '', 'Moderate', '4924', '140 (2.8)', '(2.4, 3.3)', '4915', '128 (2.6)', '(2.2, 3.1)', ''], ['', '', 'Severe', '4924', '15 (0.3)', '(0.2, 0.5)', '4915', '7 (0.1)', '(0.1, 0.3)', '']], [['', None, None, None, None, None, None, None, None, None], ['', 'Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['Dose', None, 'Systemic Event', 'Na', 'nb (%)', '(95% CIc)', 'Na', 'nb (%)', '(95% CIc)', None], ['', '', 'Grade 4', '4924', '0', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', ''], ['', None, 'New or worsened muscle paind', '', '', '', '', '', '', None], ['', '', 'Any', '4924', '1980 (40.2)', '(38.8, 41.6)', '4915', '692 (14.1)', '(13.1, 15.1)', ''], ['', '', 'Mild', '4924', '826 (16.8)', '(15.7, 17.8)', '4915', '442 (9.0)', '(8.2, 9.8)', ''], ['', '', 'Moderate', '4924', '1059 (21.5)', '(20.4, 22.7)', '4915', '241 (4.9)', '(4.3, 5.5)', ''], ['', '', 'Severe', '4924', '95 (1.9)', '(1.6, 2.4)', '4915', '9 (0.2)', '(0.1, 0.3)', ''], ['', None, 'Grade 4', '4924', '0', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', None], ['', '', 'New or worsened joint paind', '', '', '', '', '', '', ''], ['', '', 'Any', '4924', '1232 (25.0)', '(23.8, 26.3)', '4915', '442 (9.0)', '(8.2, 9.8)', ''], ['', '', 'Mild', '4924', '586 (11.9)', '(11.0, 12.8)', '4915', '259 (5.3)', '(4.7, 5.9)', ''], ['', '', 'Moderate', '4924', '602 (12.2)', '(11.3, 13.2)', '4915', '176 (3.6)', '(3.1, 4.1)', ''], ['', '', 'Severe', '4924', '44 (0.9)', '(0.7, 1.2)', '4915', '7 (0.1)', '(0.1, 0.3)', ''], ['', '', 'Grade 4', '4924', '0', '(0.0, 0.1)', '4915', '0', '(0.0, 0.1)', ''], ['', None, 'Any systemic eventg', '4924', '3878 (78.8)', '(77.6, 79.9)', '4915', '2716 (55.3)', '(53.9, 56.7)', None], ['', None, 'Use of antipyretic or pain medicationh', '4924', '2301 (46.7)', '(45.3, 48.1)', '4915', '924 (18.8)', '(17.7, 19.9)', None], ['Note: Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 through Day 7 after each dose. Grade 4\nevents were classified by the investigator or medically qualified person.\na. N = number of subjects reporting at least 1 yes or no response for the specified event after the specified dose.\nb. n = Number of subjects with the specified characteristic.\nc. Exact 2-sided CI based on the Clopper and Pearson method.\nd. Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity; Grade 4: emergency room visit or\nhospitalization for severe fatigue, severe headache, severe chills, severe muscle pain, or severe joint pain.\ne. Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration; Grade 4: emergency room visit or\nhospitalization for severe vomiting.\nf. Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours; Grade 4: emergency room', None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None]], [['events were classified by the investigator or medically qualified person.'], ['a. N = number of subjects reporting at least 1 yes or no response for the specified event after the specified dose.'], ['b. n = Number of subjects with the specified characteristic.'], ['c. Exact 2-sided CI based on the Clopper and Pearson method.'], ['d. Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity; Grade 4: emergency room visit or'], ['hospitalization for severe fatigue, severe headache, severe chills, severe muscle pain, or severe joint pain.'], ['e. Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration; Grade 4: emergency room visit or'], ['hospitalization for severe vomiting.'], ['f. Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours; Grade 4: emergency room']], [['', None, None, None, None, None, None, None, None, None], ['', 'Systemic Events, by Maximum Severity, Within 7 Days After Each Dose (Reactogenicity Subset) –', None, None, None, None, None, None, None, ''], [None, 'Phase 2/3 Subjects ≥16 Years of Age – Safety Population', None, None, None, None, None, None, None, None], ['', '', None, 'Vaccine Group (as Administered)', None, None, None, None, None, ''], [None, '', None, '', None, None, None, None, None, None], [None, None, None, '', None, None, None, None, None, None], ['', '', None, 'BNT162b2 (30 μg)', None, None, 'Placebo', None, None, ''], ['', 'Dose', 'Systemic Event', 'Na', 'nb (%)', '(95% CIc)', 'Na', 'nb (%)', '(95% CIc)', ''], ['visit or hospitalization for severe diarrhea.\ng. Any systemic event: any fever ≥38.0°C, any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any\nnew or worsened joint pain.\nh. Severity was not collected for use of antipyretic or pain medication.\nPFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 07APR2021 (17:15)\n(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA1/adce s020 se 16 p3 saf', None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None]], [['g. Any systemic event: any fever ≥38.0°C, any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any'], ['new or worsened joint pain.'], ['h. Severity was not collected for use of antipyretic or pain medication.'], ['PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 07APR2021 (17:15)'], ['(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA1/adce s020 se 16 p3 saf']], [['', None, None, None, None, None, None, None, None], ['', 'Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, by Requested Subgroup – Subjects With or', None, None, None, None, None, None, ''], [None, 'Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population', None, None, None, None, None, None, None], ['', '', 'Vaccine Group (as Randomized)', None, None, None, '', None, ''], [None, '', '', None, None, None, '', None, None], [None, None, '', None, None, None, None, None, None], ['', '', 'BNT162b2 (30 μg)', None, 'Placebo', None, '', None, ''], [None, None, '(Na=19965)', None, '(Na=20172)', None, None, None, None], [None, '', '', None, '', None, '', None, None], [None, None, '', None, '', None, None, None, None], ['Efficacy Endpoint\nSubgroup', 'Efficacy Endpoint', '', 'Surveillance', '', 'Surveillance', '', '', None], [None, None, 'n1b', 'Timec (n2d)', 'n1b', 'Timec (n2d)', 'VE (%)', None, None], ['', 'First COVID-19 occurrence from 7 days after Dose 2', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', ''], ['Overall', None, '9', '2.332 (18559)', '169', '2.345 (18708)', '94.6', '(89.6, 97.6)', None], ['', 'Age group (years)', '', '', '', '', '', '', ''], ['', '12 to 15', '0', '0.000 (14)', '0', '0.000 (14)', 'NE', '(NE, NE)', ''], ['', '16 to 17', '0', '0.003 (58)', '1', '0.003 (61)', '100.0', '(-3969.9, 100.0)', ''], ['', '18 to 64', '8', '1.799 (14443)', '149', '1.811 (14566)', '94.6', '(89.1, 97.7)', ''], ['', '65 to 74', '1', '0.424 (3239)', '14', '0.423 (3255)', '92.9', '(53.2, 99.8)', ''], ['', '≥75', '0', '0.106 (805)', '5', '0.109 (812)', '100.0', '(-12.1, 100.0)', ''], ['Race', None, '', '', '', '', '', '', None], ['', 'White', '7', '1.975 (15294)', '153', '1.990 (15473)', '95.4', '(90.3, 98.2)', ''], ['', 'Black or African American', '0', '0.187 (1758)', '7', '0.188 (1758)', '100.0', '(30.4, 100.0)', ''], ['', 'American Indian or Alaska native', '0', '0.011 (104)', '1', '0.010 (104)', '100.0', '(-3511.0, 100.0)', ''], ['', 'Asian', '1', '0.095 (796)', '4', '0.097 (808)', '74.4', '(-158.7, 99.5)', ''], ['', 'Native Hawaiian or other Pacific Islander', '0', '0.006 (50)', '1', '0.003 (29)', '100.0', '(-2112.1, 100.0)', ''], ['', 'Multiracial', '1', '0.047 (467)', '1', '0.042 (424)', '10.4', '(-6934.9, 98.9)', ''], ['', 'Not reported', '0', '0.010 (90)', '2', '0.013 (112)', '100.0', '(-581.6, 100.0)', ''], ['Baseline SARS-CoV-2 status', None, '', '', '', '', '', '', None], ['', 'Positivef', '1', '0.056 (526)', '1', '0.060 (567)', '-7.1', '(-8309.9, 98.6)', '']], [['', None, None, None, None, None, None, None, None], ['', 'Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, by Requested Subgroup – Subjects With or', None, None, None, None, None, None, ''], [None, 'Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population', None, None, None, None, None, None, None], ['', '', 'Vaccine Group (as Randomized)', None, None, None, '', None, ''], [None, '', '', None, None, None, '', None, None], [None, None, '', None, None, None, None, None, None], ['', '', 'BNT162b2 (30 μg)', None, 'Placebo', None, '', None, ''], [None, None, '(Na=19965)', None, '(Na=20172)', None, None, None, None], [None, '', '', None, '', None, '', None, None], [None, None, '', None, '', None, None, None, None], ['Efficacy Endpoint\nSubgroup', 'Efficacy Endpoint', '', 'Surveillance', '', 'Surveillance', '', '', None], [None, None, 'n1b', 'Timec (n2d)', 'n1b', 'Timec (n2d)', 'VE (%)', None, None], ['', 'Negativeg', '8', '2.237 (17637)', '164', '2.242 (17720)', '95.1', '(90.1, 97.9)', ''], ['', 'Unknown', '0', '0.039 (396)', '4', '0.043 (421)', '100.0', '(-68.9, 100.0)', ''], ['Abbreviations: N-binding = SARS-CoV-2 nucleoprotein–binding; NAAT = nucleic acid amplification test; SARS-CoV-2 = severe acute respiratory\nsyndrome coronavirus 2; VE = vaccine efficacy.\na. N = number of subjects in the specified group.\nb. n1 = Number of subjects meeting the endpoint definition.\nc. Total surveillance time in 1000 person-years for the given endpoint across all subjects within each group at risk for the endpoint. Time period for\nCOVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.\nd. n2 = Number of subjects at risk for the endpoint.\ne. Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time.\nf. Positive N-binding antibody result at Visit 1, positive NAAT result at Visit 1, or medical history of COVID-19.\ng. Negative N-binding antibody result at Visit 1, negative NAAT result at Visit 1, and no medical history of COVID-19.\nPFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (09:54) Source Data: adc19ef Table Generation: 23NOV2020 (16:39)\n(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_EUA_FAEF_RR/adc19ef_ve_cov_7pd2_req_sg_eval', None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None]], [['syndrome coronavirus 2; VE = vaccine efficacy.'], ['a. N = number of subjects in the specified group.'], ['b. n1 = Number of subjects meeting the endpoint definition.'], ['c. Total surveillance time in 1000 person-years for the given endpoint across all subjects within each group at risk for the endpoint. Time period for'], ['COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.'], ['d. n2 = Number of subjects at risk for the endpoint.'], ['e. Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time.'], ['f. Positive N-binding antibody result at Visit 1, positive NAAT result at Visit 1, or medical history of COVID-19.'], ['g. Negative N-binding antibody result at Visit 1, negative NAAT result at Visit 1, and no medical history of COVID-19.'], ['PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (09:54) Source Data: adc19ef Table Generation: 23NOV2020 (16:39)'], ['(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_EUA_FAEF_RR/adc19ef_ve_cov_7pd2_req_sg_eval']]]",14
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_ipsp-agreed-letter.pdf,2.0,"Our Reference: IND 19736 AGREED INITIAL
PEDIATRIC STUDY PLAN-AGREEMENT
April 23, 2021
BioNTech SE/Pfizer, Inc.
Attention: Neda Aghajani Memar
235 East 42nd Street, 219/9/69
New York, NY 10017
Dear Ms. Aghajani Memar:
Please refer to your Investigational New Drug Application (IND) submitted under section
505(i) of the Federal Food, Drug, and Cosmetic Act for “Human Coronavirus mRNA
Vaccines (SARS-CoV-2 Spike Protein; BNT162a1 (uRNA; variant RBL063.3);
BNT162b1 (modRNA; variant RBP020.3); BNT162b2 (modRNA; variant RBP020.2);
BNT162c2 (saRNA; variant RBS004.2)) in Lipid Nanoparticles (ALC-0315, ALC-0159,
DSPC and Cholesterol).”
We also refer to your amendment submitted and received on April 2, 2021, containing
your final Agreed Initial Pediatric Study Plan (iPSP) as requested in the March 24, 2021
correspondence from the Agency.
We have completed our review of your Agreed iPSP and agree with your planned
pediatric study and your plan to request a deferral of the pediatric assessment for the
pediatric population 0 to (cid:1938)16 years of age.
This agreement does not necessarily imply agreement with other contents of the
document in its entirety.
Please be advised that this agreement with your Agreed iPSP, and acknowledgment of
your intention to request a deferral as stated above, does not constitute the “granting” of
such a deferral. This can only occur at such time if/when this investigational product is
licensed. A copy of your Agreed iPSP must be included in Module 1 of your Biologics
License Application.
In the event that it becomes necessary to make any changes to this “Agreed iPSP”
before submission of your Biologics License Application, please contact the Regulatory
Project Manager to discuss the appropriate mechanisms for submitting this to FDA and
for instructions on identifying your submission in order to ensure timely review. FDA
must agree to any amendments to an Agreed iPSP.
U.S. Food &DrugAdministration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
)TMG(
64:31
1202-rpA-32
:nO
laniF\laniF\108dcd691e771090
FDA-CBER-2021-5683-0013857
Page 2 – IND 19736 – Ms. Neda Aghajani Memar
If you have any questions, please contact the Regulatory Project Manager,
Ramachandra Naik, Ph.D., by email at ramachandra.naik@fda.hhs.gov.
Sincerely,
Doran Fink -SD Di Ng :i t ca =ll Uy S s ,i g on =e Ud .S b . y G oD vo er ra nn m F ein nk t ,- oS u=HHS, ou=FDA,
ou=People, cn=Doran Fink -S,
0.9.2342.19200300.100.1.1=0013724088
Date: 2021.04.23 07:58:47 -04'00'
Doran L. Fink, M.D., Ph.D.
Deputy Director – Clinical
Division of Vaccines and Related Products Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
)TMG(
64:31
1202-rpA-32
:nO
laniF\laniF\108dcd691e771090
FDA-CBER-2021-5683-0013858",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_356h.pdf,6.0,"(cid:49)(cid:72)(cid:91)(cid:87)(cid:51)(cid:68)(cid:74)(cid:72) (cid:40)(cid:91)(cid:83)(cid:82)(cid:85)(cid:87)(cid:39)(cid:68)(cid:87)(cid:68) (cid:44)(cid:80)(cid:83)(cid:82)(cid:85)(cid:87)(cid:39)(cid:68)(cid:87)(cid:68) (cid:53)(cid:72)(cid:86)(cid:72)(cid:87)(cid:41)(cid:82)(cid:85)(cid:80)
(cid:39)(cid:40)(cid:51)(cid:36)(cid:53)(cid:55)(cid:48)(cid:40)(cid:49)(cid:55)(cid:50)(cid:41)(cid:43)(cid:40)(cid:36)(cid:47)(cid:55)(cid:43)(cid:36)(cid:49)(cid:39)(cid:43)(cid:56)(cid:48)(cid:36)(cid:49)(cid:54)(cid:40)(cid:53)(cid:57)(cid:44)(cid:38)(cid:40)(cid:54) Form Approved: OMB No. 0910-0338
Food and Drug Administration Expiration Date: March 31, 2020
(cid:36)(cid:51)(cid:51)(cid:47)(cid:44)(cid:38)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49) (cid:55)(cid:50) (cid:48)(cid:36)(cid:53)(cid:46)(cid:40)(cid:55)(cid:36)(cid:49)(cid:40)(cid:58) (cid:50)(cid:53)(cid:36)(cid:37)(cid:37)(cid:53)(cid:40)(cid:57)(cid:44)(cid:36)(cid:55)(cid:40)(cid:39) (cid:49)(cid:40)(cid:58) See PRA Statement on page 3.
(cid:39)(cid:53)(cid:56)(cid:42) (cid:50)(cid:53) (cid:37)(cid:44)(cid:50)(cid:47)(cid:50)(cid:42)(cid:44)(cid:38) (cid:41)(cid:50)(cid:53) (cid:43)(cid:56)(cid:48)(cid:36)(cid:49) (cid:56)(cid:54)(cid:40) 1. Date of Submission (mm/dd/yyyy)
(Title 21, Code of Federal Regulations, Parts 314 & 601) 05/06/2021
(cid:36)(cid:51)(cid:51)(cid:47)(cid:44)(cid:38)(cid:36)(cid:49)(cid:55)(cid:44)(cid:49)(cid:41)(cid:50)(cid:53)(cid:48)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49) 2. Name of Applicant
BioNTech Manufacturing GmbH
3. Telephone Number (Include country code if applicable and area code) 4. Facsimile (FAX) Number (Include country
+49 (0) 6131 9084-7593 code if applicable and area code) +49 (0) 6131 9084-390
5. Applicant Address
Address 1 (Street address, P.O. box, company name c/o) Email Address
An der Goldgrube 12
Ruben.Rizzi@biontech.de
Address 2 (Apartment, suite, unit, building, floor, etc.)
Applicant DUNS
City State/Province/Region 117645848
Mainz N/A
U.S. License Number if previously issued
Country ZIP or Postal Code
Germany 55131
6. Authorized U.S. Agent (Required for non-U.S. applicants)
Authorized U.S. Agent Name Telephone Number (Include area code)
Elisa Harkins, Global Regulatory Lead, Pfizer Global Regulatory Affairs - Vaccines
215-280-5503
Address 1 (Street address, P.O. box, company name c/o)
FAX Number (Include area code)
500 Arcola Road
Address 2 (Apartment, suite, unit, building, floor, etc.) 845-474-3500
Email Address
City State
Elisa.HarkinsTull@pfizer.com
Collegeville PA
U.S. Agent DUNS
ZIP Code
19426
(cid:51)(cid:53)(cid:50)(cid:39)(cid:56)(cid:38)(cid:55)(cid:39)(cid:40)(cid:54)(cid:38)(cid:53)(cid:44)(cid:51)(cid:55)(cid:44)(cid:50)(cid:49) 7. NDA, ANDA, or BLA Application Number 8. Supplement Number (If applicable)
125742
9. Established Name (e.g., proper name, USP/USAN name)
[COVID-19 mRNA Vaccine (nucleoside modified)]
10. Proprietary Name (Trade Name) (If any)
COMIRNATY
11. Chemical/Biochemical/Blood Product Name (If any)
COVID-19 Vaccine (BNT162, PF-07302048)
12. Dosage Form 13. Strengths 14. Route of Administration
Liquid 30 mcg Intramuscular
15A. Proposed Indication for Use Is this indication for a rare disease (prevalence <200,000 in U.S.)? Yes ✔ No
Active immunization to prevent COVID-19 caused by
SARS-CoV-2 in individuals (cid:149)16 years of age Does this product have an FDA If yes, provide the Orphan
Orphan Designation for this Designation number for this
(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
indication? indication: (cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:20)(cid:24)
Yes ✔ No
15B. SNOMED CT Indication Disease Term (Use continuation page for each additional indication and respective coded disease term)
COVID-19; SARS-CoV-2; Disease caused by severe acute respiratory syndrome coronavirus 2; SARS-CoV-2 vaccination; COVID-19 vaccination
(cid:36)(cid:51)(cid:51)(cid:47)(cid:44)(cid:38)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)(cid:44)(cid:49)(cid:41)(cid:50)(cid:53)(cid:48)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49) 16. Application Type New Drug Application (NDA) ✔ Biologics License Application (BLA)
(Select one)
Abbreviated New Drug Application (ANDA)
17. If an NDA, identify the type 505(b)(1) 505(b)(2) 18. If a BLA, identify the type ✔ 351(a) 351(k)
19. If a 351(k), identify the biological reference product that is the basis for the submission.
Name of Biologic: Holder of Licensed Application:
20. If an ANDA, or 505(b)(2), identify the listed drug product that is/are the basis for the submission.
Name of Drug: Application Number of Relied Upon Product:
Indicate Patent Certification: P1 P2 P3 P4 Section viii - MOU Statement of no relevant patents
(cid:41)(cid:50)(cid:53)(cid:48)(cid:41)(cid:39)(cid:36)(cid:22)(cid:24)(cid:25)(cid:75)(cid:11)(cid:19)(cid:27)(cid:18)(cid:20)(cid:27)(cid:16)(cid:51)(cid:53)(cid:40)(cid:57)(cid:44)(cid:50)(cid:56)(cid:54)(cid:40)(cid:39)(cid:44)(cid:55)(cid:44)(cid:50)(cid:49)(cid:54)(cid:50)(cid:37)(cid:54)(cid:50)(cid:47)(cid:40)(cid:55)(cid:40)(cid:12) (cid:51)(cid:68)(cid:74)(cid:72)(cid:20)(cid:82)(cid:73)6 FDA-CBER-2021P-S5C 6Pu8bl3is-h0ing0 S1er3vi7ce2s (8301) 443-6740 EF
(cid:51)(cid:85)(cid:72)(cid:89)(cid:76)(cid:82)(cid:88)(cid:86)(cid:51)(cid:68)(cid:74)(cid:72) (cid:49)(cid:72)(cid:91)(cid:87)(cid:51)(cid:68)(cid:74)(cid:72)
21. Submission (See ✔ Original Labeling Supplement CMC Supplement Efficacy Supplement Annual Report
instructions)
Product Correspondence REMS Supplement Postmarketing Requirements or Commitments Periodic Safety Report
Request for Proprietary Name Review Other (Specify):
22. Submission 23. If a supplement, identify
✔ Presubmission Amendment CBE Prior Approval (PA)
Sub-Type the appropriate category.
Initial Submission Resubmission CBE-30
24. For Originals and all Supplements, is the product a Combination Product Request for Designation
combination product (21 CFR 3.2(e))? Yes ✔ No Type (See instructions) (RFD) Number
25. Does the submission contain: Human factors information? 26. Proposed Marketing Status (Select one)
Only Pediatric data? Yes ✔ No Yes ✔ No ✔ Prescription Product (Rx) Over-The-Counter Product (OTC)
27. Reasons for Submission
Rolling Submission 0001 for STN/BL 125742
28. Establishment Information (Full establishment information should be provided in the body of the application.)
Establishment Name
Pharmacia and Upjohn Company LLC (Pfizer)
Address 1 (Street address, P.O. box, company name c/o) Registration (FEI) Number
7000 Portage Road
1810189
Address 2 (Apartment, suite, unit, building, floor, etc.)
MF Number
City State/Province/Region
Kalamazoo MI
Establishment DUNS Number
Country ZIP or Postal Code
618054084
USA 49001
Is the establishment new to the application? What is the status of the establishment?
✔ Yes No ✔ Pending Active Inactive Withdrawn
Establishment Contact Information at the site/facility
Name of Contact for the Establishment Telephone Number (Include area code)
Christopher S. Nagra
Address 1 (Street address, P.O. box, company name c/o) 269-720-1003
7000 Portage Road
FAX Number (Include area code)
Address 2 (Apartment, suite, unit, building, floor, etc.)
269-833-8707
City State/Province/Region
Email Address
Kalamazoo MI
Country ZIP or Postal Code
christopher.s.nagra@pfizer.com
USA 49001
Manufacturing Steps and/or Type of Testing Is the site ready ✔ Yes No N/A
LNP production and bulk drug product formulation, Fill and finish, Primary packaging, Secondary packaging, for inspection?
Drug product testing If No, when will site be
ready? (mm/dd/yyyy)
(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:21)(cid:27)
29. Cross References (List related BLAs, INDs, NDAs, PMAs, 510(k)s, IDEs, BMFs, MAFs, and DMFs referenced in the current application.)
IND 19736, DMF 012683, DMF 9543, DMF 15209, DMF 011793, DMF 011820, DMF 011321, DMF 10953,
(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:17)
(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)
(cid:6)(cid:21)(cid:28)
30. This application contains the following items (Select all that apply)
✔ 1. Index 2. Labeling (Select one): Draft Labeling Final Printed Labeling ✔ 3. Summary (21 CFR 314.50 (c))
4. Chemistry Section A. Chemistry, manufacturing, and controls information (e.g., 21 CFR 314.50(d)(1); 21 CFR 601.2)
B. Samples (21 CFR 314.50 (e)(1); 21 CFR 601.2 (a)) (Submit only upon FDA’s request)
C. Methods validation package (e.g., 21 CFR 314.50(e)(2)(i); 21 CFR 601.2)
✔ 5. Nonclinical pharmacology and toxicology section 6. Human pharmacokinetics and bioavailability section
(e.g., 21 CFR 314.50(d)(2); 21 CFR 601.2) (e.g., 21 CFR 314.50(d)(3); 21 CFR 601.2)
7. Clinical microbiology section (e.g., 21 CFR 314.50(d)(4)) ✔ 8. Clinical data section (e.g., 21 CFR 314.50(d)(5); 21 CFR 601.2)
Item 30 continued on page 3
(cid:41)(cid:50)(cid:53)(cid:48)(cid:41)(cid:39)(cid:36)(cid:22)(cid:24)(cid:25)(cid:75)(cid:11)(cid:19)(cid:27)(cid:18)(cid:20)(cid:27)(cid:16)(cid:51)(cid:53)(cid:40)(cid:57)(cid:44)(cid:50)(cid:56)(cid:54)(cid:40)(cid:39)(cid:44)(cid:55)(cid:44)(cid:50)(cid:49)(cid:54)(cid:50)(cid:37)(cid:54)(cid:50)(cid:47)(cid:40)(cid:55)(cid:40)(cid:12) (cid:51)(cid:68)(cid:74)(cid:72)(cid:21)(cid:82)(cid:73)6 FDA-CBER-2021-5683-0013729
(cid:51)(cid:85)(cid:72)(cid:89)(cid:76)(cid:82)(cid:88)(cid:86)(cid:51)(cid:68)(cid:74)(cid:72) (cid:49)(cid:72)(cid:91)(cid:87)(cid:51)(cid:68)(cid:74)(cid:72)
30. This application contains the following items (Continued; select all that apply)
✔ 9. Safety update report (e.g., 21 CFR 314.50(d)(5)(vi)(b); ✔ 10. Statistical section (e.g., 21 CFR 314.50(d)(6); 21 CFR 601.2)
21 CFR 601.2)
✔ 11. Case report tabulations (e.g., 21 CFR 314.50(f)(1); ✔ 12. Case report forms (e.g., 21 CFR 314.50 (f)(2); 21 CFR 601.2)
21 CFR 601.2)
13. Patent information on any patent that claims the drug/ 14. A patent certification with respect to any patent that claims the
biologic (21 U.S.C. 355(b) or (c)) drug/biologic (21 U.S.C. 355 (b)(2) or (j)(2)(A))
15. Establishment description (21 CFR Part 600, if applicable) ✔ 16. Debarment certification (FD&C Act 306 (k)(1))
17. Field copy certification (21 CFR 314.50 (l)(3)) ✔ 18. User Fee Cover Sheet (PDUFA Form FDA 3397, GDUFA Form
FDA 3794, BsUFA Form FDA 3792, or MDUFA Form FDA 3601)
✔ 19. Financial Disclosure Information (21 CFR Part 54)
20. Other (Specify):
(cid:38)(cid:40)(cid:53)(cid:55)(cid:44)(cid:41)(cid:44)(cid:38)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)
I agree to update this application with new safety information about the product that may reasonably affect the statement of contraindications,
warnings, precautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as
requested by FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications,
including, but not limited to, the following:
1. Good manufacturing practice regulations in 21 CFR Parts 210, 211 or applicable regulations, Parts 606, and/or 820.
2. Biological establishment standards in 21 CFR Part 600.
3. Labeling regulations in 21 CFR Parts 201, 606, 610, 660, and/or 809.
4. In the case of a prescription drug or biological product, prescription drug advertising regulations in 21 CFR Part 202.
5. Regulations on making changes in application in FD&C Act section 506A, 21 CFR 314.71, 314.72, 314.97, 314.99, and 601.12.
6. Regulations on Reports in 21 CFR 314.80, 314.81, 600.80, and 600.81.
7. Local, state, and Federal environmental impact laws.
If this application applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act, I agree not to market
the product until the Drug Enforcement Administration makes a final scheduling decision.
The data and information in this submission have been reviewed and, to the best of my knowledge, are certified to be true and accurate.
(cid:58)(cid:68)(cid:85)(cid:81)(cid:76)(cid:81)(cid:74)(cid:29) A willfully false statement is a criminal offense, U.S. Code, title 18, section 1001.
31. Typed Name and Title of Applicant’s Responsible Official 32. Date (mm/dd/yyyy)
Elisa Harkins, Global Regulatory Lead, Global Regulatory Affairs - Vaccines, Pfizer Inc. 05/05/2021
33. Telephone Number (Include country 34. FAX Number (Include country code if 35. Email Address
code if applicable and area code) applicable and area code)
215-280-5503 845-474-3500 Elisa.HarkinsTull@pfizer.com
36. Address of Applicant’s Responsible Official
Address 1 (Street address, P.O. box, company name c/o)
500 Arcola Road
Address 2 (Apartment, suite, unit, building, floor, etc.)
City State/Province/Region
Collegeville PA
Country ZIP or Postal Code
United States of America 19426
37. Signature of Applicant’s Responsible Official or 38. Countersignature of Authorized U.S. Agent
(cid:54)(cid:76)(cid:74)(cid:81) (cid:54)(cid:76)(cid:74)(cid:81)
Other Authorized Official
Elisa Harkins Digitally signed by Elisa Harkins Tull
DN: o=Pfizer Inc, cn=Elisa Harkins Tull
Reason: I attest to the accuracy and
Tull integrity of this document
Date: 20210505 18:43:29 -04'00'
(cid:55)(cid:75)(cid:72)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:69)(cid:72)(cid:79)(cid:82)(cid:90)(cid:68)(cid:83)(cid:83)(cid:79)(cid:76)(cid:72)(cid:86)(cid:82)(cid:81)(cid:79)(cid:92)(cid:87)(cid:82)(cid:85)(cid:72)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:82)(cid:73)(cid:87)(cid:75)(cid:72)(cid:51)(cid:68)(cid:83)(cid:72)(cid:85)(cid:90)(cid:82)(cid:85)(cid:78)(cid:53)(cid:72)(cid:71)(cid:88)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:36)(cid:70)(cid:87)(cid:82)(cid:73)(cid:20)(cid:28)(cid:28)(cid:24)(cid:17)
The burden time for this collection of information is estimated to average 24 hours per response, Department of Health and Human Services
including the time to review instructions, search existing data sources, gather and maintain the Food and Drug Administration
data needed and complete and review the collection of information. Send comments regarding Office of Operations
this burden estimate or any other aspect of this information collection, including suggestions Paperwork Reduction Act (PRA) Staff
for reducing this burden to the address to the right: PRAStaff@fda.hhs.gov
“An agency may not conduct or sponsor, and a person is not required to respond to, a (cid:39)(cid:50)(cid:49)(cid:50)(cid:55)(cid:54)(cid:40)(cid:49)(cid:39)(cid:60)(cid:50)(cid:56)(cid:53)(cid:38)(cid:50)(cid:48)(cid:51)(cid:47)(cid:40)(cid:55)(cid:40)(cid:39)(cid:41)(cid:50)(cid:53)(cid:48)
collection of information unless it displays a currently valid OMB number.” (cid:55)(cid:50)(cid:55)(cid:43)(cid:44)(cid:54)(cid:51)(cid:53)(cid:36)(cid:54)(cid:55)(cid:36)(cid:41)(cid:41)(cid:40)(cid:48)(cid:36)(cid:44)(cid:47)(cid:36)(cid:39)(cid:39)(cid:53)(cid:40)(cid:54)(cid:54)(cid:17)
(cid:41)(cid:50)(cid:53)(cid:48)(cid:41)(cid:39)(cid:36)(cid:22)(cid:24)(cid:25)(cid:75)(cid:11)(cid:19)(cid:27)(cid:18)(cid:20)(cid:27)(cid:16)(cid:51)(cid:53)(cid:40)(cid:57)(cid:44)(cid:50)(cid:56)(cid:54)(cid:40)(cid:39)(cid:44)(cid:55)(cid:44)(cid:50)(cid:49)(cid:54)(cid:50)(cid:37)(cid:54)(cid:50)(cid:47)(cid:40)(cid:55)(cid:40)(cid:12) (cid:51)(cid:68)(cid:74)(cid:72)(cid:22)(cid:82)(cid:73)6 FDA-CBER-2021-5683-0013730
(cid:53)(cid:72)(cid:80)(cid:82)(cid:89)(cid:72)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72) (cid:53)(cid:72)(cid:87)(cid:88)(cid:85)(cid:81)(cid:87)(cid:82)(cid:41)(cid:82)(cid:85)(cid:80)
Provide information for additional
(cid:41)(cid:44)(cid:53)(cid:54)(cid:55)(cid:38)(cid:50)(cid:49)(cid:55)(cid:44)(cid:49)(cid:56)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)(cid:51)(cid:36)(cid:42)(cid:40)(cid:41)(cid:50)(cid:53)(cid:44)(cid:55)(cid:40)(cid:48)(cid:21)(cid:27)(cid:177)(cid:40)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:80)(cid:72)(cid:81)(cid:87)(cid:44)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
establishments below, as needed.
Establishment Name
Pfizer Manufacturing Belgium NV
Address 1 (Street address, P.O. box, company name c/o) Registration (FEI) Number
Rijksweg 12
1000654629
Address 2 (Apartment, suite, unit, building, floor, etc.)
MF Number
City State/Province/Region
Puurs N/A
Establishment DUNS Number
Country ZIP or Postal Code
370156507
Belgium 2870
Is the establishment new to the application? What is the status of the establishment?
✔ Yes No ✔ Pending Active Inactive Withdrawn
Establishment Contact Information at the site/facility
Name of Contact for the Establishment Telephone Number (Include area code)
Sofie Depuydt
Address 1 (Street address, P.O. box, company name c/o) + 32 (0)4 778 098 00
Rijksweg 12
FAX Number (Include area code)
Address 2 (Apartment, suite, unit, building, floor, etc.)
+ 32(0)3 889 65 32
City State/Province/Region
Email Address
Puurs N/A
Country ZIP or Postal Code
sofie.depuydt@pfizer.com
Belgium 2870
Manufacturing Steps and/or Type of Testing Is the site ready
✔ Yes No N/A
LNP production and bulk drug product formulation, Fill and finish, Primary packaging, Secondary for inspection?
packaging, Drug product testing If No, when will site be
ready? (mm/dd/yyyy)
Establishment Name
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
Address 1 (Street address, P.O. box, company name c/o) Registration (FEI) Number
1 Burtt Road
1222181
Address 2 (Apartment, suite, unit, building, floor, etc.)
MF Number
City State/Province/Region
Andover MA
Establishment DUNS Number
Country ZIP or Postal Code
174350868
United States 01810
Is the establishment new to the application? What is the status of the establishment?
✔ Yes No ✔ Pending Active Inactive Withdrawn
Establishment Contact Information at the site/facility
Name of Contact for the Establishment Telephone Number (Include area code)
Nicole Barrera
Address 1 (Street address, P.O. box, company name c/o) (978) 247-3717
1 Burtt Road
FAX Number (Include area code)
Address 2 (Apartment, suite, unit, building, floor, etc.)
(212) 338-1872
City State/Province/Region
Email Address
Andover MA
Country ZIP or Postal Code
nicole.barrera@pfizer.com
United States 01810
Manufacturing Steps and/or Type of Testing Is the site ready
✔ Yes No N/A
for inspection?
Manufacture of drug substance, Drug substance testing, Drug product testing
If No, when will site be
ready? (mm/dd/yyyy)
(cid:36)(cid:71)(cid:71)(cid:54)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:21)(cid:27)
(cid:41)(cid:50)(cid:53)(cid:48)(cid:41)(cid:39)(cid:36)(cid:22)(cid:24)(cid:25)(cid:75)(cid:11)(cid:19)(cid:27)(cid:18)(cid:20)(cid:27)(cid:16)(cid:51)(cid:53)(cid:40)(cid:57)(cid:44)(cid:50)(cid:56)(cid:54)(cid:40)(cid:39)(cid:44)(cid:55)(cid:44)(cid:50)(cid:49)(cid:54)(cid:50)(cid:37)(cid:54)(cid:50)(cid:47)(cid:40)(cid:55)(cid:40)(cid:12) (cid:51)(cid:68)(cid:74)(cid:72)4 (cid:82)(cid:73)6 FDA-CBER-2021-5683-0013731
(cid:53)(cid:72)(cid:80)(cid:82)(cid:89)(cid:72)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72) (cid:53)(cid:72)(cid:87)(cid:88)(cid:85)(cid:81)(cid:87)(cid:82)(cid:41)(cid:82)(cid:85)(cid:80)
(cid:53)(cid:72)(cid:80)(cid:82)(cid:89)(cid:72)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72) (cid:53)(cid:72)(cid:87)(cid:88)(cid:85)(cid:81)(cid:87)(cid:82)(cid:41)(cid:82)(cid:85)(cid:80)
Provide information for additional
(cid:54)(cid:40)(cid:38)(cid:50)(cid:49)(cid:39)(cid:38)(cid:50)(cid:49)(cid:55)(cid:44)(cid:49)(cid:56)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)(cid:51)(cid:36)(cid:42)(cid:40)(cid:41)(cid:50)(cid:53)(cid:44)(cid:55)(cid:40)(cid:48)(cid:21)(cid:27)(cid:177)(cid:40)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:80)(cid:72)(cid:81)(cid:87)(cid:44)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
establishments below, as needed.
Establishment Name
Pfizer Inc
Address 1 (Street address, P.O. box, company name c/o) Registration (FEI) Number
875 Chesterfield Parkway West
1940118
Address 2 (Apartment, suite, unit, building, floor, etc.)
MF Number
City State/Province/Region
Chesterfield MO
Establishment DUNS Number
Country ZIP or Postal Code
004954111
United States 63017
Is the establishment new to the application? What is the status of the establishment?
✔ Yes No ✔ Pending Active Inactive Withdrawn
Establishment Contact Information at the site/facility
Name of Contact for the Establishment Telephone Number (Include area code)
Edward Bourneuf
Address 1 (Street address, P.O. box, company name c/o) (636) 247-8253
875 Chesterfield Parkway West
FAX Number (Include area code)
Address 2 (Apartment, suite, unit, building, floor, etc.)
(845) 474-4618
City State/Province/Region
Email Address
Chesterfield MO
Country ZIP or Postal Code
ed.v.bourneuf@pfizer.com
United States 63017
Manufacturing Steps and/or Type of Testing Is the site ready ✔ Yes No N/A
for inspection?
Drug substance testing, Drug product testing
If No, when will site be
ready? (mm/dd/yyyy)
Establishment Name
Pfizer Ireland Pharmaceuticals
Address 1 (Street address, P.O. box, company name c/o) Registration (FEI) Number
Grange Castle Business Park Clondalkin
3004145594
Address 2 (Apartment, suite, unit, building, floor, etc.)
MF Number
City State/Province/Region
Dublin 22 N/A
Establishment DUNS Number
Country ZIP or Postal Code
985586408
Ireland N/A
Is the establishment new to the application? What is the status of the establishment?
✔ Yes No ✔ Pending Active Inactive Withdrawn
Establishment Contact Information at the site/facility
Name of Contact for the Establishment Telephone Number (Include area code)
Ciaran Tobin
Address 1 (Street address, P.O. box, company name c/o) +353 876380768
Grange Castle Business Park Clondalkin
FAX Number (Include area code)
Address 2 (Apartment, suite, unit, building, floor, etc.)
+353 (0) 1469 4001
City State/Province/Region
Email Address
Dublin 22 N/A
Country ZIP or Postal Code
ciaran.tobin@pfizer.com
Ireland N/A
Manufacturing Steps and/or Type of Testing Is the site ready
✔ Yes No N/A
for inspection?
Drug product testing
If No, when will site be
ready? (mm/dd/yyyy)
(cid:36)(cid:71)(cid:71)(cid:55)(cid:75)(cid:76)(cid:85)(cid:71)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:21)(cid:27)
(cid:41)(cid:50)(cid:53)(cid:48)(cid:41)(cid:39)(cid:36)(cid:22)(cid:24)(cid:25)(cid:75)(cid:11)(cid:19)(cid:27)(cid:18)(cid:20)(cid:27)(cid:16)(cid:51)(cid:53)(cid:40)(cid:57)(cid:44)(cid:50)(cid:56)(cid:54)(cid:40)(cid:39)(cid:44)(cid:55)(cid:44)(cid:50)(cid:49)(cid:54)(cid:50)(cid:37)(cid:54)(cid:50)(cid:47)(cid:40)(cid:55)(cid:40)(cid:12) (cid:51)(cid:68)(cid:74)(cid:72)5 (cid:82)(cid:73)6 FDA-CBER-2021-5683-0013732
(cid:53)(cid:72)(cid:80)(cid:82)(cid:89)(cid:72)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72) (cid:53)(cid:72)(cid:87)(cid:88)(cid:85)(cid:81)(cid:87)(cid:82)(cid:41)(cid:82)(cid:85)(cid:80)
(cid:53)(cid:72)(cid:80)(cid:82)(cid:89)(cid:72)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72) (cid:53)(cid:72)(cid:87)(cid:88)(cid:85)(cid:81)(cid:87)(cid:82)(cid:41)(cid:82)(cid:85)(cid:80)
Provide information for additional
(cid:55)(cid:43)(cid:44)(cid:53)(cid:39)(cid:38)(cid:50)(cid:49)(cid:55)(cid:44)(cid:49)(cid:56)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)(cid:51)(cid:36)(cid:42)(cid:40)(cid:41)(cid:50)(cid:53)(cid:44)(cid:55)(cid:40)(cid:48)(cid:21)(cid:27)(cid:177)(cid:40)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:80)(cid:72)(cid:81)(cid:87)(cid:44)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
establishments below, as needed.
Establishment Name
Hospira Zagrab Ltd.
Address 1 (Street address, P.O. box, company name c/o) Registration (FEI) Number
Prudnicka cesta 60
3010630287
Address 2 (Apartment, suite, unit, building, floor, etc.)
MF Number
City State/Province/Region
Prigorje Brdovecko
Establishment DUNS Number
Country ZIP or Postal Code
500625201
Croatia 10291
Is the establishment new to the application? What is the status of the establishment?
✔ Yes No ✔ Pending Active Inactive Withdrawn
Establishment Contact Information at the site/facility
Name of Contact for the Establishment Telephone Number (Include area code)
Marko Vuleticm
Address 1 (Street address, P.O. box, company name c/o) +385 164122202
Prudnicka cesta 60
FAX Number (Include area code)
Address 2 (Apartment, suite, unit, building, floor, etc.)
+385 1 641 2299
City State/Province/Region
Email Address
Prigorje Brdovecko
Country ZIP or Postal Code
Marko.Vuletic@pfizer.com
Croatia 10291
Manufacturing Steps and/or Type of Testing Is the site ready
✔ Yes No N/A
for inspection?
Drug Product Release Testing (Sterility)
If No, when will site be
ready? (mm/dd/yyyy)
Establishment Name
SGS Lab Simon SA
Address 1 (Street address, P.O. box, company name c/o) Registration (FEI) Number
Vieux Chemin du Poete 10
3004186644
Address 2 (Apartment, suite, unit, building, floor, etc.)
MF Number
City State/Province/Region
Wavre N/A
Establishment DUNS Number
Country ZIP or Postal Code
283063907
Belgium 1301
Is the establishment new to the application? What is the status of the establishment?
✔ Yes No ✔ Pending Active Inactive Withdrawn
Establishment Contact Information at the site/facility
Name of Contact for the Establishment Telephone Number (Include area code)
Stani Litwinski
Address 1 (Street address, P.O. box, company name c/o) +32 10 42 11 13
Vieux Chemin du Poete 10
FAX Number (Include area code)
Address 2 (Apartment, suite, unit, building, floor, etc.)
+32 10 42 11 00
City State/Province/Region
Email Address
Wavre N/A
Country ZIP or Postal Code
stani.litwinski@sgs.com
Belgium 1301
Manufacturing Steps and/or Type of Testing Is the site ready ✔ Yes No N/A
for inspection?
Drug Product Release Testing (Sterility)
If No, when will site be
ready? (mm/dd/yyyy)
(cid:36)(cid:71)(cid:71)(cid:41)(cid:82)(cid:88)(cid:85)(cid:87)(cid:75)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:21)(cid:27)
(cid:41)(cid:50)(cid:53)(cid:48)(cid:41)(cid:39)(cid:36)(cid:22)(cid:24)(cid:25)(cid:75)(cid:11)(cid:19)(cid:27)(cid:18)(cid:20)(cid:27)(cid:16)(cid:51)(cid:53)(cid:40)(cid:57)(cid:44)(cid:50)(cid:56)(cid:54)(cid:40)(cid:39)(cid:44)(cid:55)(cid:44)(cid:50)(cid:49)(cid:54)(cid:50)(cid:37)(cid:54)(cid:50)(cid:47)(cid:40)(cid:55)(cid:40)(cid:12) (cid:51)(cid:68)(cid:74)(cid:72)6 (cid:82)(cid:73) 6 FDA-CBER-2021-5683-0013733
(cid:53)(cid:72)(cid:80)(cid:82)(cid:89)(cid:72)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72) (cid:53)(cid:72)(cid:87)(cid:88)(cid:85)(cid:81)(cid:87)(cid:82)(cid:41)(cid:82)(cid:85)(cid:80)","[[['(cid:39)(cid:40)(cid:51)(cid:36)(cid:53)(cid:55)(cid:48)(cid:40)(cid:49)(cid:55)(cid:50)(cid:41)(cid:43)(cid:40)(cid:36)(cid:47)(cid:55)(cid:43)(cid:36)(cid:49)(cid:39)(cid:43)(cid:56)(cid:48)(cid:36)(cid:49)(cid:54)(cid:40)(cid:53)(cid:57)(cid:44)(cid:38)(cid:40)(cid:54)\nFood and Drug Administration\n(cid:36)(cid:51)(cid:51)(cid:47)(cid:44)(cid:38)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49) (cid:55)(cid:50) (cid:48)(cid:36)(cid:53)(cid:46)(cid:40)(cid:55)(cid:36)(cid:49)(cid:40)(cid:58) (cid:50)(cid:53)(cid:36)(cid:37)(cid:37)(cid:53)(cid:40)(cid:57)(cid:44)(cid:36)(cid:55)(cid:40)(cid:39) (cid:49)(cid:40)(cid:58)\n(cid:39)(cid:53)(cid:56)(cid:42) (cid:50)(cid:53) (cid:37)(cid:44)(cid:50)(cid:47)(cid:50)(cid:42)(cid:44)(cid:38) (cid:41)(cid:50)(cid:53) (cid:43)(cid:56)(cid:48)(cid:36)(cid:49) (cid:56)(cid:54)(cid:40)\n(Title 21, Code of Federal Regulations, Parts 314 & 601)', None, None, None, None, None, None, None, None, None, None, 'Form Approved: OMB No. 0910-0338\nExpiration Date: March 31, 2020\nSee PRA Statement on page 3.', None], [None, None, None, None, None, None, None, None, None, None, None, '1. Date of Submission (mm/dd/yyyy)\n05/06/2021', None], ['(cid:36)(cid:51)(cid:51)(cid:47)(cid:44)(cid:38)(cid:36)(cid:49)(cid:55)(cid:44)(cid:49)(cid:41)(cid:50)(cid:53)(cid:48)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)', None, '2. Name of Applicant\nBioNTech Manufacturing GmbH', None, None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None, None, None, None], ['3. Telephone Number (Include country code if applicable and area code)\n+49 (0) 6131 9084-7593', None, None, None, None, None, None, '4. Facsimile (FAX) Number (Include country\ncode if applicable and area code) +49 (0) 6131 9084-390', None, None, None, None, None], ['5. Applicant Address', None, None, None, None, None, None, None, None, None, None, None, None], ['', 'Address 1 (Street address, P.O. box, company name c/o)\nAn der Goldgrube 12', None, None, None, None, None, None, None, '', 'Email Address\nRuben.Rizzi@biontech.de', None, None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None, None, None, None, None, None, None], [None, None, None, None, None, None, None, None, None, None, 'Applicant DUNS\n117645848', None, None], [None, 'City\nMainz', None, None, 'State/Province/Region\nN/A', None, None, None, None, None, None, None, None], [None, None, None, None, None, None, None, None, None, None, 'U.S. License Number if previously issued', None, None], [None, 'Country\nGermany', None, None, None, None, 'ZIP or Postal Code\n55131', None, None, None, None, None, None], ['6. Authorized U.S. Agent (Required for non-U.S. applicants)', None, None, None, None, None, None, None, None, None, None, None, None], ['', 'Authorized U.S. Agent Name\nElisa Harkins, Global Regulatory Lead, Pfizer Global Regulatory Affairs - Vaccines', None, None, None, None, None, None, None, '', 'Telephone Number (Include area code)\n215-280-5503', None, None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\n500 Arcola Road', None, None, None, None, None, None, None, None, None, None, None], [None, None, None, None, None, None, None, None, None, None, 'FAX Number (Include area code)\n845-474-3500', None, None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None, None, None, None, None, None, None], [None, None, None, None, None, None, None, None, None, None, 'Email Address\nElisa.HarkinsTull@pfizer.com', None, None], [None, 'City\nCollegeville', None, None, 'State\nPA', None, None, None, None, None, None, None, None], [None, None, None, None, None, None, None, None, None, None, 'U.S. Agent DUNS', None, None], [None, 'ZIP Code\n19426', None, None, None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None, None, None, None], ['(cid:51)(cid:53)(cid:50)(cid:39)(cid:56)(cid:38)(cid:55)(cid:39)(cid:40)(cid:54)(cid:38)(cid:53)(cid:44)(cid:51)(cid:55)(cid:44)(cid:50)(cid:49)', None, '7. NDA, ANDA, or BLA Application Number\n125742', None, None, None, None, None, '8. Supplement Number (If applicable)', None, None, None, None], ['', None, None, None, None, None, None, None, None, None, None, None, None], ['9. Established Name (e.g., proper name, USP/USAN name)\n[COVID-19 mRNA Vaccine (nucleoside modified)]', None, None, None, None, None, None, None, None, None, None, None, None], ['10. Proprietary Name (Trade Name) (If any)\nCOMIRNATY', None, None, None, None, None, None, None, None, None, None, None, None], ['11. Chemical/Biochemical/Blood Product Name (If any)\nCOVID-19 Vaccine (BNT162, PF-07302048)', None, None, None, None, None, None, None, None, None, None, None, None], ['12. Dosage Form\nLiquid', None, None, '13. Strengths\n30 mcg', None, None, None, None, None, '14. Route of Administration\nIntramuscular', None, None, None], ['15A. Proposed Indication for Use\nActive immunization to prevent COVID-19 caused by\nSARS-CoV-2 in individuals (cid:149)16 years of age', None, None, None, None, 'Is this indication for a rare disease (prevalence <200,000 in U.S.)? Yes ✔ No', None, None, None, None, None, None, None], [None, None, None, None, None, 'Does this product have an FDA If yes, provide the Orphan\nOrphan Designation for this Designation number for this\nindication? indication:\nYes ✔ No', None, None, None, None, None, None, '(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)\n(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:20)(cid:24)'], ['15B. SNOMED CT Indication Disease Term (Use continuation page for each additional indication and respective coded disease term)\nCOVID-19; SARS-CoV-2; Disease caused by severe acute respiratory syndrome coronavirus 2; SARS-CoV-2 vaccination; COVID-19 vaccination', None, None, None, None, None, None, None, None, None, None, None, None], ['(cid:36)(cid:51)(cid:51)(cid:47)(cid:44)(cid:38)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)(cid:44)(cid:49)(cid:41)(cid:50)(cid:53)(cid:48)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)', None, '16. Application Type New Drug Application (NDA) ✔ Biologics License Application (BLA)\n(Select one)\nAbbreviated New Drug Application (ANDA)', None, None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None, None, None, None], ['17. If an NDA, identify the type\n505(b)(1) 505(b)(2)', None, None, None, None, None, None, '18. If a BLA, identify the type ✔ 351(a) 351(k)', None, None, None, None, None], ['19. If a 351(k), identify the biological reference product that is the basis for the submission.\nName of Biologic: Holder of Licensed Application:', None, None, None, None, None, None, None, None, None, None, None, None], ['20. If an ANDA, or 505(b)(2), identify the listed drug product that is/are the basis for the submission.\nName of Drug: Application Number of Relied Upon Product:\nIndicate Patent Certification: P1 P2 P3 P4 Section viii - MOU Statement of no relevant patents', None, None, None, None, None, None, None, None, None, None, None, None]], [[''], ['']], [['21. Submission (See ✔ Original Labeling Supplement CMC Supplement Efficacy Supplement Annual Report\ninstructions)\nProduct Correspondence REMS Supplement Postmarketing Requirements or Commitments Periodic Safety Report\nRequest for Proprietary Name Review Other (Specify):', None, None, None, None, None, None, None], ['22. Submission 23\n✔ Presubmission Amendment\nSub-Type\nInitial Submission Resubmission', None, None, None, None, '. If a supplement, identify\nCBE Prior Approval (PA)\nthe appropriate category.\nCBE-30', None, None], ['24. For Originals and all Supplements, is the product a\ncombination product (21 CFR 3.2(e))? Yes ✔ No', None, None, None, 'Combination Product\nType (See instructions)', None, 'Request for Designation\n(RFD) Number', None], ['25. Does the submission contain:\nOnly Pediatric data? Yes ✔ No', None, None, 'Human factors information? 2\nYes ✔ No', None, '6. Proposed Marketing Status (Select one)\n✔ Prescription Product (Rx) Over-The-Counter Product (OTC)', None, None], ['27. Reasons for Submission\nRolling Submission 0001 for STN/BL 125742', None, None, None, None, None, None, None], ['28. Establishment Information (Full establishment information should be provided in the body of the application.)', None, None, None, None, None, None, None], ['', 'Establishment Name\nPharmacia and Upjohn Company LLC (Pfizer)', None, None, None, None, None, None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\n7000 Portage Road\nAddress 2 (Apartment, suite, unit, building, floor, etc.)\nCity State/Province/Region\nKalamazoo MI\nCountry ZIP or Postal Code\nUSA 49001', None, None, None, None, 'Registration (FEI) Number\n1810189', None], [None, None, None, None, None, None, 'MF Number', None], [None, 'City\nKalamazoo', None, None, None, None, None, None], [None, None, None, None, None, None, 'Establishment DUNS Number\n618054084', None], [None, 'Country\nUSA', None, None, None, None, None, None], [None, 'Is the establishment new to the application? W\n✔ Yes No', None, None, None, 'hat is the status of the establishment?\n✔ Pending Active Inactive Withdrawn', None, None], [None, '', None, None, None, None, None, None], [None, 'Establishment Contact Information at the site/facility', None, None, None, None, None, None], [None, 'Name of Contact for the Establishment\nChristopher S. Nagra\nAddress 1 (Street address, P.O. box, company name c/o)\n7000 Portage Road\nAddress 2 (Apartment, suite, unit, building, floor, etc.)\nCity State/Province/Region\nKalamazoo MI\nCountry ZIP or Postal Code\nUSA 49001', None, None, None, None, 'Telephone Number (Include area code)\n269-720-1003', None], [None, None, None, None, None, None, 'FAX Number (Include area code)\n269-833-8707', None], [None, 'City\nKalamazoo', None, None, None, None, None, None], [None, None, None, None, None, None, 'Email Address\nchristopher.s.nagra@pfizer.com', None], [None, 'Country\nUSA', None, None, None, None, None, None], [None, '', None, None, None, None, None, None], [None, 'Manufacturing Steps and/or Type of Testing\nLNP production and bulk drug product formulation, Fill and finish, Primary packaging, Secondary packaging,\nDrug product testing', None, None, None, None, 'Is the site ready ✔ Yes No N/A\nfor inspection?\nIf No, when will site be\nready? (mm/dd/yyyy)\n(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:21)(cid:27)', None], ['29. Cross References (List related BLAs, INDs, NDAs, PMAs, 510(k)s, IDEs, BMFs, MAFs, and DMFs referenced in the current application.)\nIND 19736, DMF 012683, DMF 9543, DMF 15209, DMF 011793, DMF 011820, DMF 011321, DMF 10953,\n(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:17)\n(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)\n(cid:6)(cid:21)(cid:28)', None, None, None, None, None, None, None], ['30. This application contains the following items (Select all that apply)', None, None, None, None, None, None, None], ['', '✔ 1. Index', '2. Labeling (Select one): Draft Labeling Final Printed Labeling', None, None, None, None, '✔ 3. Summary (21 CFR 314.50 (c))'], [None, '4. Chemistry Section A. Chemistry, manufacturing, and controls information (e.g., 21 CFR 314.50(d)(1); 21 CFR 601.2)\nB. Samples (21 CFR 314.50 (e)(1); 21 CFR 601.2 (a)) (Submit only upon FDA’s request)\nC. Methods validation package (e.g., 21 CFR 314.50(e)(2)(i); 21 CFR 601.2)', None, None, None, None, None, None], [None, '✔ 5. Nonclinical pharmacology and toxicology section\n(e.g., 21 CFR 314.50(d)(2); 21 CFR 601.2)', None, None, None, '6. Human pharmacokinetics and bioavailability section\n(e.g., 21 CFR 314.50(d)(3); 21 CFR 601.2)', None, None], [None, '7. Clinical microbiology section (e.g., 21 CFR 314.50(d)(4))', None, None, None, '✔ 8. Clinical data section (e.g., 21 CFR 314.50(d)(5); 21 CFR 601.2)', None, None], ['Item 30 continued on page 3', None, None, None, None, None, None, None]], [[''], ['']], [['30. This application contains the following items (Continued; select all that apply)', None, None, None, None, None, None, None, None], ['', '✔ 9. Safety update report (e.g., 21 CFR 314.50(d)(5)(vi)(b);\n21 CFR 601.2)', None, None, None, '✔ 10. Statistical section (e.g., 21 CFR 314.50(d)(6); 21 CFR 601.2)', None, None, None], [None, '✔ 11. Case report tabulations (e.g., 21 CFR 314.50(f)(1);\n21 CFR 601.2)', None, None, None, '✔ 12. Case report forms (e.g., 21 CFR 314.50 (f)(2); 21 CFR 601.2)', None, None, None], [None, '13. Patent information on any patent that claims the drug/\nbiologic (21 U.S.C. 355(b) or (c))', None, None, None, '14. A patent certification with respect to any patent that claims the\ndrug/biologic (21 U.S.C. 355 (b)(2) or (j)(2)(A))', None, None, None], [None, '15. Establishment description (21 CFR Part 600, if applicable)', None, None, None, '✔ 16. Debarment certification (FD&C Act 306 (k)(1))', None, None, None], [None, '17. Field copy certification (21 CFR 314.50 (l)(3))', None, None, None, '✔ 18. User Fee Cover Sheet (PDUFA Form FDA 3397, GDUFA Form\nFDA 3794, BsUFA Form FDA 3792, or MDUFA Form FDA 3601)', None, None, None], [None, '✔ 19. Financial Disclosure Information (21 CFR Part 54)', None, None, None, None, None, None, None], [None, '20. Other (Specify):', None, None, None, None, None, None, None], ['(cid:38)(cid:40)(cid:53)(cid:55)(cid:44)(cid:41)(cid:44)(cid:38)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)\nI agree to update this application with new safety information about the product that may reasonably affect the statement of contraindications,\nwarnings, precautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as\nrequested by FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications,\nincluding, but not limited to, the following:\n1. Good manufacturing practice regulations in 21 CFR Parts 210, 211 or applicable regulations, Parts 606, and/or 820.\n2. Biological establishment standards in 21 CFR Part 600.\n3. Labeling regulations in 21 CFR Parts 201, 606, 610, 660, and/or 809.\n4. In the case of a prescription drug or biological product, prescription drug advertising regulations in 21 CFR Part 202.\n5. Regulations on making changes in application in FD&C Act section 506A, 21 CFR 314.71, 314.72, 314.97, 314.99, and 601.12.\n6. Regulations on Reports in 21 CFR 314.80, 314.81, 600.80, and 600.81.\n7. Local, state, and Federal environmental impact laws.\nIf this application applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act, I agree not to market\nthe product until the Drug Enforcement Administration makes a final scheduling decision.\nThe data and information in this submission have been reviewed and, to the best of my knowledge, are certified to be true and accurate.\n(cid:58)(cid:68)(cid:85)(cid:81)(cid:76)(cid:81)(cid:74)(cid:29) A willfully false statement is a criminal offense, U.S. Code, title 18, section 1001.', None, None, None, None, None, None, None, None], ['31. Typed Name and Title of Applicant’s Responsible Official\nElisa Harkins, Global Regulatory Lead, Global Regulatory Affairs - Vaccines, Pfizer Inc.', None, None, None, None, None, None, None, '32. Date (mm/dd/yyyy)\n05/05/2021'], ['33. Telephone Number (Include country\ncode if applicable and area code)\n215-280-5503', None, '34. FAX Number (Include country code if\napplicable and area code)\n845-474-3500', None, None, None, '35. Email Address\nElisa.HarkinsTull@pfizer.com', None, None], ['36. Address of Applicant’s Responsible Official', None, None, None, None, None, None, '', None], ['', 'Address 1 (Street address, P.O. box, company name c/o)\n500 Arcola Road', None, None, None, None, None, None, None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None, None, None], [None, 'City\nCollegeville', None, 'State/Province/Region\nPA', None, None, None, None, None], [None, 'Country\nUnited States of America', None, None, 'ZIP or Postal Code\n19426', None, None, None, None], [""37. Signature of Applicant’s Responsible Official or\n(cid:54)(cid:76)(cid:74)(cid:81)\nOther Authorized Official\nElisa Harkins Digitally signed by Elisa Harkins Tull\nDN: o=Pfizer Inc, cn=Elisa Harkins Tull\nReason: I attest to the accuracy and\nTull integrity of this document\nDate: 20210505 18:43:29 -04'00'"", None, None, None, None, '38. Countersignature of Authorized U.S. Agent\n(cid:54)(cid:76)(cid:74)(cid:81)', None, None, None], ['(cid:55)(cid:75)(cid:72)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:69)(cid:72)(cid:79)(cid:82)(cid:90)(cid:68)(cid:83)(cid:83)(cid:79)(cid:76)(cid:72)(cid:86)(cid:82)(cid:81)(cid:79)(cid:92)(cid:87)(cid:82)(cid:85)(cid:72)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:82)(cid:73)(cid:87)(cid:75)(cid:72)(cid:51)(cid:68)(cid:83)(cid:72)(cid:85)(cid:90)(cid:82)(cid:85)(cid:78)(cid:53)(cid:72)(cid:71)(cid:88)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:36)(cid:70)(cid:87)(cid:82)(cid:73)(cid:20)(cid:28)(cid:28)(cid:24)(cid:17)\nThe burden time for this collection of information is estimated to average 24 hours per response, Department of Health and Human Services\nincluding the time to review instructions, search existing data sources, gather and maintain the Food and Drug Administration\ndata needed and complete and review the collection of information. Send comments regarding Office of Operations\nthis burden estimate or any other aspect of this information collection, including suggestions Paperwork Reduction Act (PRA) Staff\nfor reducing this burden to the address to the right: PRAStaff@fda.hhs.gov\n“An agency may not conduct or sponsor, and a person is not required to respond to, a (cid:39)(cid:50)(cid:49)(cid:50)(cid:55)(cid:54)(cid:40)(cid:49)(cid:39)(cid:60)(cid:50)(cid:56)(cid:53)(cid:38)(cid:50)(cid:48)(cid:51)(cid:47)(cid:40)(cid:55)(cid:40)(cid:39)(cid:41)(cid:50)(cid:53)(cid:48)\ncollection of information unless it displays a currently valid OMB number.” (cid:55)(cid:50)(cid:55)(cid:43)(cid:44)(cid:54)(cid:51)(cid:53)(cid:36)(cid:54)(cid:55)(cid:36)(cid:41)(cid:41)(cid:40)(cid:48)(cid:36)(cid:44)(cid:47)(cid:36)(cid:39)(cid:39)(cid:53)(cid:40)(cid:54)(cid:54)(cid:17)', None, None, None, None, None, None, None, None]], [['(cid:41)(cid:44)(cid:53)(cid:54)(cid:55)(cid:38)(cid:50)(cid:49)(cid:55)(cid:44)(cid:49)(cid:56)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)(cid:51)(cid:36)(cid:42)(cid:40)(cid:41)(cid:50)(cid:53)(cid:44)(cid:55)(cid:40)(cid:48)(cid:21)(cid:27)(cid:177)(cid:40)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:80)(cid:72)(cid:81)(cid:87)(cid:44)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)', None, None, None, None, 'Provide information for additional\nestablishments below, as needed.', None], ['', 'Establishment Name\nPfizer Manufacturing Belgium NV', None, None, None, None, None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\nRijksweg 12', None, None, None, 'Registration (FEI) Number\n1000654629', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, None, None, None, None, 'MF Number', None], [None, 'City\nPuurs', 'State/Province/Region\nN/A', None, None, None, None], [None, None, None, None, None, 'Establishment DUNS Number\n370156507', None], [None, 'Country\nBelgium', None, 'ZIP or Postal Code\n2870', None, None, None], [None, 'Is the establishment new to the application?\n✔ Yes No', None, None, 'What is the status of the establishment?\n✔ Pending Active Inactive Withdrawn', None, None], [None, '', None, None, None, None, None], [None, 'Establishment Contact Information at the site/facility', None, None, None, None, None], [None, 'Name of Contact for the Establishment\nSofie Depuydt', None, None, None, 'Telephone Number (Include area code)\n+ 32 (0)4 778 098 00', None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\nRijksweg 12', None, None, None, None, None], [None, None, None, None, None, 'FAX Number (Include area code)\n+ 32(0)3 889 65 32', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, 'City\nPuurs', 'State/Province/Region\nN/A', None, None, None, None], [None, None, None, None, None, 'Email Address\nsofie.depuydt@pfizer.com', None], [None, 'Country\nBelgium', None, 'ZIP or Postal Code\n2870', None, None, None], [None, '', None, None, None, None, None], [None, 'Manufacturing Steps and/or Type of Testing\nLNP production and bulk drug product formulation, Fill and finish, Primary packaging, Secondary\npackaging, Drug product testing', None, None, None, None, 'Is the site ready\n✔ Yes No N/A\nfor inspection?\nIf No, when will site be\nready? (mm/dd/yyyy)'], [None, None, None, None, None, None, ''], ['', 'Establishment Name\nWyeth BioPharma Division of Wyeth Pharmaceuticals LLC', None, None, None, None, None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\n1 Burtt Road', None, None, None, 'Registration (FEI) Number\n1222181', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, None, None, None, None, 'MF Number', None], [None, 'City\nAndover', 'State/Province/Region\nMA', None, None, None, None], [None, None, None, None, None, 'Establishment DUNS Number\n174350868', None], [None, 'Country\nUnited States', None, 'ZIP or Postal Code\n01810', None, None, None], [None, 'Is the establishment new to the application?\n✔ Yes No', None, None, 'What is the status of the establishment?\n✔ Pending Active Inactive Withdrawn', None, None], [None, '', None, None, None, None, None], [None, 'Establishment Contact Information at the site/facility', None, None, None, None, None], [None, 'Name of Contact for the Establishment\nNicole Barrera', None, None, None, 'Telephone Number (Include area code)\n(978) 247-3717', None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\n1 Burtt Road', None, None, None, None, None], [None, None, None, None, None, 'FAX Number (Include area code)\n(212) 338-1872', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, 'City\nAndover', 'State/Province/Region\nMA', None, None, None, None], [None, None, None, None, None, 'Email Address\nnicole.barrera@pfizer.com', None], [None, 'Country\nUnited States', None, 'ZIP or Postal Code\n01810', None, None, None], [None, '', None, None, None, None, None], [None, 'Manufacturing Steps and/or Type of Testing\nManufacture of drug substance, Drug substance testing, Drug product testing', None, None, None, None, 'Is the site ready\n✔ Yes No N/A\nfor inspection?\nIf No, when will site be\nready? (mm/dd/yyyy)'], [None, None, None, None, None, None, '(cid:36)(cid:71)(cid:71)(cid:54)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:21)(cid:27)']], [['(cid:54)(cid:40)(cid:38)(cid:50)(cid:49)(cid:39)(cid:38)(cid:50)(cid:49)(cid:55)(cid:44)(cid:49)(cid:56)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)(cid:51)(cid:36)(cid:42)(cid:40)(cid:41)(cid:50)(cid:53)(cid:44)(cid:55)(cid:40)(cid:48)(cid:21)(cid:27)(cid:177)(cid:40)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:80)(cid:72)(cid:81)(cid:87)(cid:44)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)', None, None, None, None, 'Provide information for additional\nestablishments below, as needed.', None], ['', 'Establishment Name\nPfizer Inc', None, None, None, None, None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\n875 Chesterfield Parkway West', None, None, None, 'Registration (FEI) Number\n1940118', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, None, None, None, None, 'MF Number', None], [None, 'City\nChesterfield', 'State/Province/Region\nMO', None, None, None, None], [None, None, None, None, None, 'Establishment DUNS Number\n004954111', None], [None, 'Country\nUnited States', None, 'ZIP or Postal Code\n63017', None, None, None], [None, 'Is the establishment new to the application?\n✔ Yes No', None, None, 'What is the status of the establishment?\n✔ Pending Active Inactive Withdrawn', None, None], [None, '', None, None, None, None, None], [None, 'Establishment Contact Information at the site/facility', None, None, None, None, None], [None, 'Name of Contact for the Establishment\nEdward Bourneuf', None, None, None, 'Telephone Number (Include area code)\n(636) 247-8253', None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\n875 Chesterfield Parkway West', None, None, None, None, None], [None, None, None, None, None, 'FAX Number (Include area code)\n(845) 474-4618', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, 'City\nChesterfield', 'State/Province/Region\nMO', None, None, None, None], [None, None, None, None, None, 'Email Address\ned.v.bourneuf@pfizer.com', None], [None, 'Country\nUnited States', None, 'ZIP or Postal Code\n63017', None, None, None], [None, '', None, None, None, None, None], [None, 'Manufacturing Steps and/or Type of Testing\nDrug substance testing, Drug product testing', None, None, None, None, 'Is the site ready ✔ Yes No N/A\nfor inspection?\nIf No, when will site be\nready? (mm/dd/yyyy)'], [None, None, None, None, None, None, ''], ['', 'Establishment Name\nPfizer Ireland Pharmaceuticals', None, None, None, None, None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\nGrange Castle Business Park Clondalkin', None, None, None, 'Registration (FEI) Number\n3004145594', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, None, None, None, None, 'MF Number', None], [None, 'City\nDublin 22', 'State/Province/Region\nN/A', None, None, None, None], [None, None, None, None, None, 'Establishment DUNS Number\n985586408', None], [None, 'Country\nIreland', None, 'ZIP or Postal Code\nN/A', None, None, None], [None, 'Is the establishment new to the application?\n✔ Yes No', None, None, 'What is the status of the establishment?\n✔ Pending Active Inactive Withdrawn', None, None], [None, '', None, None, None, None, None], [None, 'Establishment Contact Information at the site/facility', None, None, None, None, None], [None, 'Name of Contact for the Establishment\nCiaran Tobin', None, None, None, 'Telephone Number (Include area code)\n+353 876380768', None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\nGrange Castle Business Park Clondalkin', None, None, None, None, None], [None, None, None, None, None, 'FAX Number (Include area code)\n+353 (0) 1469 4001', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, 'City\nDublin 22', 'State/Province/Region\nN/A', None, None, None, None], [None, None, None, None, None, 'Email Address\nciaran.tobin@pfizer.com', None], [None, 'Country\nIreland', None, 'ZIP or Postal Code\nN/A', None, None, None], [None, '', None, None, None, None, None], [None, 'Manufacturing Steps and/or Type of Testing\nDrug product testing', None, None, None, None, 'Is the site ready\n✔ Yes No N/A\nfor inspection?\nIf No, when will site be\nready? (mm/dd/yyyy)'], [None, None, None, None, None, None, '(cid:36)(cid:71)(cid:71)(cid:55)(cid:75)(cid:76)(cid:85)(cid:71)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:21)(cid:27)']], [['(cid:55)(cid:43)(cid:44)(cid:53)(cid:39)(cid:38)(cid:50)(cid:49)(cid:55)(cid:44)(cid:49)(cid:56)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)(cid:51)(cid:36)(cid:42)(cid:40)(cid:41)(cid:50)(cid:53)(cid:44)(cid:55)(cid:40)(cid:48)(cid:21)(cid:27)(cid:177)(cid:40)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:80)(cid:72)(cid:81)(cid:87)(cid:44)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)', None, None, None, None, 'Provide information for additional\nestablishments below, as needed.', None], ['', 'Establishment Name\nHospira Zagrab Ltd.', None, None, None, None, None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\nPrudnicka cesta 60', None, None, None, 'Registration (FEI) Number\n3010630287', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, None, None, None, None, 'MF Number', None], [None, 'City\nPrigorje', 'State/Province/Region\nBrdovecko', None, None, None, None], [None, None, None, None, None, 'Establishment DUNS Number\n500625201', None], [None, 'Country\nCroatia', None, 'ZIP or Postal Code\n10291', None, None, None], [None, 'Is the establishment new to the application?\n✔ Yes No', None, None, 'What is the status of the establishment?\n✔ Pending Active Inactive Withdrawn', None, None], [None, '', None, None, None, None, None], [None, 'Establishment Contact Information at the site/facility', None, None, None, None, None], [None, 'Name of Contact for the Establishment\nMarko Vuleticm', None, None, None, 'Telephone Number (Include area code)\n+385 164122202', None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\nPrudnicka cesta 60', None, None, None, None, None], [None, None, None, None, None, 'FAX Number (Include area code)\n+385 1 641 2299', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, 'City\nPrigorje', 'State/Province/Region\nBrdovecko', None, None, None, None], [None, None, None, None, None, 'Email Address\nMarko.Vuletic@pfizer.com', None], [None, 'Country\nCroatia', None, 'ZIP or Postal Code\n10291', None, None, None], [None, '', None, None, None, None, None], [None, 'Manufacturing Steps and/or Type of Testing\nDrug Product Release Testing (Sterility)', None, None, None, None, 'Is the site ready\n✔ Yes No N/A\nfor inspection?\nIf No, when will site be\nready? (mm/dd/yyyy)'], [None, None, None, None, None, None, ''], ['', 'Establishment Name\nSGS Lab Simon SA', None, None, None, None, None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\nVieux Chemin du Poete 10', None, None, None, 'Registration (FEI) Number\n3004186644', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, None, None, None, None, 'MF Number', None], [None, 'City\nWavre', 'State/Province/Region\nN/A', None, None, None, None], [None, None, None, None, None, 'Establishment DUNS Number\n283063907', None], [None, 'Country\nBelgium', None, 'ZIP or Postal Code\n1301', None, None, None], [None, 'Is the establishment new to the application?\n✔ Yes No', None, None, 'What is the status of the establishment?\n✔ Pending Active Inactive Withdrawn', None, None], [None, '', None, None, None, None, None], [None, 'Establishment Contact Information at the site/facility', None, None, None, None, None], [None, 'Name of Contact for the Establishment\nStani Litwinski', None, None, None, 'Telephone Number (Include area code)\n+32 10 42 11 13', None], [None, 'Address 1 (Street address, P.O. box, company name c/o)\nVieux Chemin du Poete 10', None, None, None, None, None], [None, None, None, None, None, 'FAX Number (Include area code)\n+32 10 42 11 00', None], [None, 'Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None, None, None, None], [None, 'City\nWavre', 'State/Province/Region\nN/A', None, None, None, None], [None, None, None, None, None, 'Email Address\nstani.litwinski@sgs.com', None], [None, 'Country\nBelgium', None, 'ZIP or Postal Code\n1301', None, None, None], [None, '', None, None, None, None, None], [None, 'Manufacturing Steps and/or Type of Testing\nDrug Product Release Testing (Sterility)', None, None, None, None, 'Is the site ready ✔ Yes No N/A\nfor inspection?\nIf No, when will site be\nready? (mm/dd/yyyy)'], [None, None, None, None, None, None, '(cid:36)(cid:71)(cid:71)(cid:41)(cid:82)(cid:88)(cid:85)(cid:87)(cid:75)(cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:51)(cid:68)(cid:74)(cid:72)(cid:73)(cid:82)(cid:85)(cid:6)(cid:21)(cid:27)']]]",6
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdf,2.0,"Level Term Code SOC
PT Acute HIV infection 10000807 INFECTIONS AND INFESTATIONS
PT Asymptomatic HIV infection 10003581 INFECTIONS AND INFESTATIONS
PT Blood HIV RNA 10049826 INVESTIGATIONS
PT Blood HIV RNA below assay limit 10049829 INVESTIGATIONS
PT Blood HIV RNA decreased 10049828 INVESTIGATIONS
PT Blood HIV RNA fluctuation 10076287 INVESTIGATIONS
PT Blood HIV RNA increased 10049827 INVESTIGATIONS
PT Congenital HIV infection 10010504 CONGENITAL, FAMILIAL AND GENETIC DISORDERS
PT CSF HIV escape syndrome 10081027 INFECTIONS AND INFESTATIONS
PT CSF HIV virus identified 10081028 INVESTIGATIONS
PT HIV antibody 10058761 INVESTIGATIONS
PT HIV antibody positive 10058736 INVESTIGATIONS
PT HIV antigen 10058763 INVESTIGATIONS
PT HIV antigen positive 10058737 INVESTIGATIONS
PT HIV associated nephropathy 10070737 INFECTIONS AND INFESTATIONS
PT HIV cardiomyopathy 10069658 INFECTIONS AND INFESTATIONS
PT HIV carrier 10020159 INFECTIONS AND INFESTATIONS
PT HIV enteropathy 10069691 INFECTIONS AND INFESTATIONS
PT HIV infection 10020161 INFECTIONS AND INFESTATIONS
PT HIV infection CDC category A 10075708 INFECTIONS AND INFESTATIONS
PT HIV infection CDC category B 10075709 INFECTIONS AND INFESTATIONS
PT HIV infection CDC category C 10075710 INFECTIONS AND INFESTATIONS
PT HIV infection CDC Group I 10020162 INFECTIONS AND INFESTATIONS
PT HIV infection CDC Group II 10020163 INFECTIONS AND INFESTATIONS
PT HIV infection CDC Group III 10020164 INFECTIONS AND INFESTATIONS
PT HIV infection CDC group IV 10061519 INFECTIONS AND INFESTATIONS
PT HIV infection CDC Group IV subgroup A 10020166 INFECTIONS AND INFESTATIONS
PT HIV infection CDC Group IV subgroup B 10020167 INFECTIONS AND INFESTATIONS
PT HIV infection CDC Group IV subgroup C1 10020168 INFECTIONS AND INFESTATIONS
PT HIV infection CDC Group IV subgroup C2 10020169 INFECTIONS AND INFESTATIONS
PT HIV infection CDC Group IV subgroup D 10020170 INFECTIONS AND INFESTATIONS
PT HIV infection CDC Group IV subgroup E 10020171 INFECTIONS AND INFESTATIONS
PT HIV infection WHO clinical stage I 10064446 INFECTIONS AND INFESTATIONS
PT HIV infection WHO clinical stage II 10064447 INFECTIONS AND INFESTATIONS
PT HIV infection WHO clinical stage III 10064448 INFECTIONS AND INFESTATIONS
PT HIV infection WHO clinical stage IV 10064456 INFECTIONS AND INFESTATIONS
PT HIV lipodystrophy 10078720 INFECTIONS AND INFESTATIONS
PT HIV meningoencephalitis 10083411 INFECTIONS AND INFESTATIONS
PT HIV peripheral neuropathy 10065681 INFECTIONS AND INFESTATIONS
PT HIV test positive 10020188 INVESTIGATIONS
PT HIV tropism identified 10080517 INVESTIGATIONS
PT HIV tropism test 10067158 INVESTIGATIONS
PT HIV viraemia 10077716 INFECTIONS AND INFESTATIONS
PT HIV wasting syndrome 10050309 INFECTIONS AND INFESTATIONS
PT HIV-2 infection 10020194 INFECTIONS AND INFESTATIONS
PT HIV-associated neurocognitive disorder 10078164 INFECTIONS AND INFESTATIONS
PT Papular pruritic eruption of HIV 10082425 INFECTIONS AND INFESTATIONS
)TMG(
01:00
1202-yaM-10
:nO
laniF\laniF\532dde691e771090
FDA-CBER-2021-5683-0023985
PT Perinatal HIV infection 10071049 INFECTIONS AND INFESTATIONS
)TMG(
01:00
1202-yaM-10
:nO
laniF\laniF\532dde691e771090
FDA-CBER-2021-5683-0023986",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdf,8.0,"SUBJECTN Informed
UMBERST consent
R date Cohort selection
10071038 6/10/2020 STAGE 1 SENTINEL COHORTS
10021069 6/10/2020 STAGE 1 SENTINEL COHORTS
10031054 6/10/2020 STAGE 1 SENTINEL COHORTS
10071052 6/11/2020 STAGE 1 SENTINEL COHORTS
10031038 6/5/2020 STAGE 1 SENTINEL COHORTS
10071049 6/11/2020 STAGE 1 SENTINEL COHORTS
10011064 6/16/2020 STAGE 1 SENTINEL COHORTS
10011063 6/16/2020 STAGE 1 SENTINEL COHORTS
10031069 6/15/2020 STAGE 1 SENTINEL COHORTS
10071051 6/11/2020 STAGE 1 SENTINEL COHORTS
10071057 6/15/2020 STAGE 1 SENTINEL COHORTS
10011058 6/15/2020 STAGE 1 SENTINEL COHORTS
10011061 6/15/2020 STAGE 1 SENTINEL COHORTS
10071056 6/15/2020 STAGE 1 SENTINEL COHORTS
10011055 6/12/2020 STAGE 1 SENTINEL COHORTS
10021074 6/12/2020 STAGE 1 SENTINEL COHORTS
10021073 6/12/2020 STAGE 1 SENTINEL COHORTS
10031067 6/15/2020 STAGE 1 SENTINEL COHORTS
10021077 6/12/2020 STAGE 1 SENTINEL COHORTS
10021075 6/12/2020 STAGE 1 SENTINEL COHORTS
10011059 6/15/2020 STAGE 1 SENTINEL COHORTS
10011057 6/12/2020 STAGE 1 SENTINEL COHORTS
10071073 6/22/2020 STAGE 1 SENTINEL COHORTS
10071075 6/22/2020 STAGE 1 SENTINEL COHORTS
10031079 6/24/2020 STAGE 1 SENTINEL COHORTS
10071074 6/22/2020 STAGE 1 SENTINEL COHORTS
10071071 6/22/2020 STAGE 1 SENTINEL COHORTS
10071077 6/24/2020 STAGE 1 SENTINEL COHORTS
10031078 6/24/2020 STAGE 1 SENTINEL COHORTS
10031083 6/25/2020 STAGE 1 SENTINEL COHORTS
10031076 6/23/2020 STAGE 1 SENTINEL COHORTS
10031077 6/23/2020 STAGE 1 SENTINEL COHORTS
10071053 6/11/2020 STAGE 1 SENTINEL COHORTS
10011053 6/11/2020 STAGE 1 SENTINEL COHORTS
10021049 6/1/2020 STAGE 1 SENTINEL COHORTS
10071023 6/3/2020 STAGE 1 SENTINEL COHORTS
10021052 6/3/2020 STAGE 1 SENTINEL COHORTS
10071017 6/2/2020 STAGE 1 SENTINEL COHORTS
10021047 6/1/2020 STAGE 1 SENTINEL COHORTS
10071025 6/3/2020 STAGE 1 SENTINEL COHORTS
10021050 6/3/2020 STAGE 1 SENTINEL COHORTS
10021045 5/29/2020 STAGE 1 SENTINEL COHORTS
10071040 6/10/2020 STAGE 1 SENTINEL COHORTS
10031063 6/12/2020 STAGE 1 SENTINEL COHORTS
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\022dde691e771090
FDA-CBER-2021-5683-0023492
10071032 6/8/2020 STAGE 1 SENTINEL COHORTS
10031055 6/10/2020 STAGE 1 SENTINEL COHORTS
10031058 6/10/2020 STAGE 1 SENTINEL COHORTS
10071034 6/8/2020 STAGE 1 SENTINEL COHORTS
10031056 6/10/2020 STAGE 1 SENTINEL COHORTS
10021043 5/29/2020 STAGE 1 SENTINEL COHORTS
10011050 6/10/2020 STAGE 1 SENTINEL COHORTS
10071042 6/11/2020 STAGE 1 SENTINEL COHORTS
10021067 6/10/2020 STAGE 1 SENTINEL COHORTS
10071039 6/10/2020 STAGE 1 SENTINEL COHORTS
10031043 6/5/2020 STAGE 1 SENTINEL COHORTS
10021071 6/11/2020 STAGE 1 SENTINEL COHORTS
10011044 6/4/2020 STAGE 1 SENTINEL COHORTS
10011048 6/8/2020 STAGE 1 SENTINEL COHORTS
10021044 5/29/2020 STAGE 1 SENTINEL COHORTS
10011052 6/10/2020 STAGE 1 SENTINEL COHORTS
10021068 6/10/2020 STAGE 1 SENTINEL COHORTS
10021042 5/29/2020 STAGE 1 SENTINEL COHORTS
10021062 6/5/2020 STAGE 1 SENTINEL COHORTS
10011042 6/4/2020 STAGE 1 SENTINEL COHORTS
10071026 6/3/2020 STAGE 1 SENTINEL COHORTS
10011040 6/4/2020 STAGE 1 SENTINEL COHORTS
10071027 6/3/2020 STAGE 1 SENTINEL COHORTS
10071044 6/11/2020 STAGE 1 SENTINEL COHORTS
10011043 6/4/2020 STAGE 1 SENTINEL COHORTS
10011045 6/5/2020 STAGE 1 SENTINEL COHORTS
10011049 6/8/2020 STAGE 1 SENTINEL COHORTS
10071043 6/11/2020 STAGE 1 SENTINEL COHORTS
10071035 6/8/2020 STAGE 1 SENTINEL COHORTS
10021072 6/11/2020 STAGE 1 SENTINEL COHORTS
10011041 6/4/2020 STAGE 1 SENTINEL COHORTS
10071045 6/11/2020 STAGE 1 SENTINEL COHORTS
10021054 6/3/2020 STAGE 1 SENTINEL COHORTS
10011046 6/5/2020 STAGE 1 SENTINEL COHORTS
10031053 6/9/2020 STAGE 1 SENTINEL COHORTS
10071029 6/3/2020 STAGE 1 SENTINEL COHORTS
10071031 6/8/2020 STAGE 1 SENTINEL COHORTS
10031051 6/8/2020 STAGE 1 SENTINEL COHORTS
10031027 6/4/2020 STAGE 1 SENTINEL COHORTS
10031087 6/25/2020 STAGE 1 SENTINEL COHORTS
10031026 6/4/2020 STAGE 1 SENTINEL COHORTS
10021053 6/3/2020 STAGE 1 SENTINEL COHORTS
10071037 6/8/2020 STAGE 1 SENTINEL COHORTS
10021060 6/4/2020 STAGE 1 SENTINEL COHORTS
10031028 6/4/2020 STAGE 1 SENTINEL COHORTS
10021059 6/4/2020 STAGE 1 SENTINEL COHORTS
10031080 6/25/2020 STAGE 1 SENTINEL COHORTS
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\022dde691e771090
FDA-CBER-2021-5683-0023493
10031047 6/8/2020 STAGE 1 SENTINEL COHORTS
10031037 6/5/2020 STAGE 1 SENTINEL COHORTS
10031046 6/5/2020 STAGE 1 SENTINEL COHORTS
10021064 6/5/2020 STAGE 1 SENTINEL COHORTS
10021063 6/5/2020 STAGE 1 SENTINEL COHORTS
10031036 6/5/2020 STAGE 1 SENTINEL COHORTS
10011039 6/3/2020 STAGE 1 SENTINEL COHORTS
10011037 6/1/2020 STAGE 1 SENTINEL COHORTS
10031035 6/5/2020 STAGE 1 SENTINEL COHORTS
10031031 6/5/2020 STAGE 1 SENTINEL COHORTS
10071019 6/3/2020 STAGE 1 SENTINEL COHORTS
10031050 6/8/2020 STAGE 1 SENTINEL COHORTS
10031030 6/5/2020 STAGE 1 SENTINEL COHORTS
10031018 6/1/2020 STAGE 1 SENTINEL COHORTS
10031032 6/5/2020 STAGE 1 SENTINEL COHORTS
10031034 6/5/2020 STAGE 1 SENTINEL COHORTS
10031029 6/4/2020 STAGE 1 SENTINEL COHORTS
10021081 6/22/2020 STAGE 1 SENTINEL COHORTS
10011068 6/23/2020 STAGE 1 SENTINEL COHORTS
10011070 6/23/2020 STAGE 1 SENTINEL COHORTS
10031072 6/19/2020 STAGE 1 SENTINEL COHORTS
10021080 6/22/2020 STAGE 1 SENTINEL COHORTS
10021079 6/22/2020 STAGE 1 SENTINEL COHORTS
10011071 6/24/2020 STAGE 1 SENTINEL COHORTS
10011069 6/23/2020 STAGE 1 SENTINEL COHORTS
10011067 6/23/2020 STAGE 1 SENTINEL COHORTS
10071064 6/15/2020 STAGE 1 SENTINEL COHORTS
10071066 6/17/2020 STAGE 1 SENTINEL COHORTS
10071050 6/11/2020 STAGE 1 SENTINEL COHORTS
10071063 6/15/2020 STAGE 1 SENTINEL COHORTS
10071015 6/2/2020 STAGE 1 SENTINEL COHORTS
10021082 6/22/2020 STAGE 1 SENTINEL COHORTS
10021087 6/25/2020 STAGE 1 SENTINEL COHORTS
10021084 6/23/2020 STAGE 1 SENTINEL COHORTS
10021085 6/23/2020 STAGE 1 SENTINEL COHORTS
10021083 6/22/2020 STAGE 1 SENTINEL COHORTS
10031059 6/10/2020 STAGE 1 SENTINEL COHORTS
10071046 6/11/2020 STAGE 1 SENTINEL COHORTS
10031066 6/12/2020 STAGE 1 SENTINEL COHORTS
10031057 6/10/2020 STAGE 1 SENTINEL COHORTS
10031065 6/12/2020 STAGE 1 SENTINEL COHORTS
10011076 6/25/2020 STAGE 1 SENTINEL COHORTS
10031061 6/12/2020 STAGE 1 SENTINEL COHORTS
10011066 6/22/2020 STAGE 1 SENTINEL COHORTS
10071058 6/15/2020 STAGE 1 SENTINEL COHORTS
10071065 6/15/2020 STAGE 1 SENTINEL COHORTS
10031070 6/18/2020 STAGE 1 SENTINEL COHORTS
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\022dde691e771090
FDA-CBER-2021-5683-0023494
10021009 4/30/2020 STAGE 1 SENTINEL COHORTS
10011004 5/1/2020 STAGE 1 SENTINEL COHORTS
10021006 4/30/2020 STAGE 1 SENTINEL COHORTS
10021007 4/30/2020 STAGE 1 SENTINEL COHORTS
10021018 5/1/2020 STAGE 1 SENTINEL COHORTS
10021008 4/30/2020 STAGE 1 SENTINEL COHORTS
10021003 4/29/2020 STAGE 1 SENTINEL COHORTS
10011020 5/7/2020 STAGE 1 SENTINEL COHORTS
10021017 5/1/2020 STAGE 1 SENTINEL COHORTS
10021005 4/29/2020 STAGE 1 SENTINEL COHORTS
10021015 5/1/2020 STAGE 1 SENTINEL COHORTS
10011009 5/4/2020 STAGE 1 SENTINEL COHORTS
10011011 5/5/2020 STAGE 1 SENTINEL COHORTS
10021011 4/30/2020 STAGE 1 SENTINEL COHORTS
10021022 5/4/2020 STAGE 1 SENTINEL COHORTS
10011005 5/4/2020 STAGE 1 SENTINEL COHORTS
10011012 5/5/2020 STAGE 1 SENTINEL COHORTS
10011017 5/7/2020 STAGE 1 SENTINEL COHORTS
10021013 5/1/2020 STAGE 1 SENTINEL COHORTS
10011008 5/4/2020 STAGE 1 SENTINEL COHORTS
10021020 5/1/2020 STAGE 1 SENTINEL COHORTS
10011019 5/7/2020 STAGE 1 SENTINEL COHORTS
10021014 5/1/2020 STAGE 1 SENTINEL COHORTS
10021021 5/4/2020 STAGE 1 SENTINEL COHORTS
10021004 4/29/2020 STAGE 1 SENTINEL COHORTS
10031019 6/1/2020 STAGE 1 SENTINEL COHORTS
10031017 6/1/2020 STAGE 1 SENTINEL COHORTS
10031016 6/1/2020 STAGE 1 SENTINEL COHORTS
10071014 6/2/2020 STAGE 1 SENTINEL COHORTS
10011015 5/6/2020 STAGE 1 SENTINEL COHORTS
10011024 5/11/2020 STAGE 1 SENTINEL COHORTS
10011006 5/4/2020 STAGE 1 SENTINEL COHORTS
10011007 5/4/2020 STAGE 1 SENTINEL COHORTS
10071020 6/3/2020 STAGE 1 SENTINEL COHORTS
10071021 6/3/2020 STAGE 1 SENTINEL COHORTS
10031021 6/2/2020 STAGE 1 SENTINEL COHORTS
10071016 6/2/2020 STAGE 1 SENTINEL COHORTS
10031022 6/3/2020 STAGE 1 SENTINEL COHORTS
10021012 4/30/2020 STAGE 1 SENTINEL COHORTS
10071022 6/3/2020 STAGE 1 SENTINEL COHORTS
10031020 6/1/2020 STAGE 1 SENTINEL COHORTS
10031024 6/3/2020 STAGE 1 SENTINEL COHORTS
10021010 4/30/2020 STAGE 1 SENTINEL COHORTS
10031012 5/6/2020 STAGE 1 SENTINEL COHORTS
10021028 5/5/2020 STAGE 1 SENTINEL COHORTS
10011003 5/1/2020 STAGE 1 SENTINEL COHORTS
10011001 4/30/2020 STAGE 1 SENTINEL COHORTS
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\022dde691e771090
FDA-CBER-2021-5683-0023495
10021026 5/5/2020 STAGE 1 SENTINEL COHORTS
10011002 4/30/2020 STAGE 1 SENTINEL COHORTS
10021033 5/6/2020 STAGE 1 SENTINEL COHORTS
10031014 5/6/2020 STAGE 1 SENTINEL COHORTS
10071005 5/4/2020 STAGE 1 SENTINEL COHORTS
10021001 4/29/2020 STAGE 1 SENTINEL COHORTS
10021016 5/1/2020 STAGE 1 SENTINEL COHORTS
10021002 4/29/2020 STAGE 1 SENTINEL COHORTS
10021019 5/1/2020 STAGE 1 SENTINEL COHORTS
10071004 5/4/2020 STAGE 1 SENTINEL COHORTS
10011016 5/6/2020 STAGE 1 SENTINEL COHORTS
10031013 5/6/2020 STAGE 1 SENTINEL COHORTS
10071007 5/4/2020 STAGE 1 SENTINEL COHORTS
10031001 5/4/2020 STAGE 1 SENTINEL COHORTS
10071006 5/4/2020 STAGE 1 SENTINEL COHORTS
10021032 5/6/2020 STAGE 1 SENTINEL COHORTS
10071003 5/4/2020 STAGE 1 SENTINEL COHORTS
10071009 5/4/2020 STAGE 1 SENTINEL COHORTS
10031015 5/6/2020 STAGE 1 SENTINEL COHORTS
10071008 5/4/2020 STAGE 1 SENTINEL COHORTS
10071002 5/4/2020 STAGE 1 SENTINEL COHORTS
10011018 5/7/2020 STAGE 1 SENTINEL COHORTS
10011014 5/5/2020 STAGE 1 SENTINEL COHORTS
10031011 5/6/2020 STAGE 1 SENTINEL COHORTS
10011023 5/11/2020 STAGE 1 SENTINEL COHORTS
10031007 5/4/2020 STAGE 1 SENTINEL COHORTS
10021030 5/6/2020 STAGE 1 SENTINEL COHORTS
10071012 5/6/2020 STAGE 1 SENTINEL COHORTS
10021029 5/6/2020 STAGE 1 SENTINEL COHORTS
10021037 5/7/2020 STAGE 1 SENTINEL COHORTS
10031008 5/5/2020 STAGE 1 SENTINEL COHORTS
10071010 5/6/2020 STAGE 1 SENTINEL COHORTS
10071011 5/6/2020 STAGE 1 SENTINEL COHORTS
10031004 5/4/2020 STAGE 1 SENTINEL COHORTS
10011010 5/5/2020 STAGE 1 SENTINEL COHORTS
10031003 5/4/2020 STAGE 1 SENTINEL COHORTS
10031002 5/4/2020 STAGE 1 SENTINEL COHORTS
10031010 5/6/2020 STAGE 1 SENTINEL COHORTS
10021039 5/7/2020 STAGE 1 SENTINEL COHORTS
10021031 5/6/2020 STAGE 1 SENTINEL COHORTS
10021040 5/7/2020 STAGE 1 SENTINEL COHORTS
10031005 5/4/2020 STAGE 1 SENTINEL COHORTS
10031009 5/5/2020 STAGE 1 SENTINEL COHORTS
10031006 5/4/2020 STAGE 1 SENTINEL COHORTS
10021025 5/5/2020 STAGE 1 SENTINEL COHORTS
10071001 5/4/2020 STAGE 1 SENTINEL COHORTS
10021046 5/29/2020 STAGE 1 SENTINEL COHORTS
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\022dde691e771090
FDA-CBER-2021-5683-0023496
10071013 6/2/2020 STAGE 1 SENTINEL COHORTS
10021048 6/1/2020 STAGE 1 SENTINEL COHORTS
10031023 6/3/2020 STAGE 1 SENTINEL COHORTS
10021051 6/3/2020 STAGE 1 SENTINEL COHORTS
10011036 6/1/2020 STAGE 1 SENTINEL COHORTS
10011038 6/1/2020 STAGE 1 SENTINEL COHORTS
10031025 6/3/2020 STAGE 1 SENTINEL COHORTS
10071024 6/3/2020 STAGE 1 SENTINEL COHORTS
10011029 5/14/2020 STAGE 1 SENTINEL COHORTS
10071018 6/2/2020 STAGE 1 SENTINEL COHORTS
10011033 5/15/2020 STAGE 1 SENTINEL COHORTS
10011022 5/8/2020 STAGE 1 SENTINEL COHORTS
10011035 5/15/2020 STAGE 1 SENTINEL COHORTS
10011025 5/12/2020 STAGE 1 SENTINEL COHORTS
10011031 5/15/2020 STAGE 1 SENTINEL COHORTS
10021061 6/5/2020 STAGE 1 SENTINEL COHORTS
10021070 6/10/2020 STAGE 1 SENTINEL COHORTS
10011027 5/12/2020 STAGE 1 SENTINEL COHORTS
10031045 6/5/2020 STAGE 1 SENTINEL COHORTS
10071041 6/10/2020 STAGE 1 SENTINEL COHORTS
10011051 6/10/2020 STAGE 1 SENTINEL COHORTS
10031048 6/8/2020 STAGE 1 SENTINEL COHORTS
10071036 6/8/2020 STAGE 1 SENTINEL COHORTS
10011047 6/5/2020 STAGE 1 SENTINEL COHORTS
10071033 6/8/2020 STAGE 1 SENTINEL COHORTS
10031052 6/8/2020 STAGE 1 SENTINEL COHORTS
10071030 6/8/2020 STAGE 1 SENTINEL COHORTS
10071028 6/3/2020 STAGE 1 SENTINEL COHORTS
10021065 6/9/2020 STAGE 1 SENTINEL COHORTS
10021058 6/4/2020 STAGE 1 SENTINEL COHORTS
10031033 6/5/2020 STAGE 1 SENTINEL COHORTS
10021056 6/3/2020 STAGE 1 SENTINEL COHORTS
10031044 6/5/2020 STAGE 1 SENTINEL COHORTS
10021055 6/3/2020 STAGE 1 SENTINEL COHORTS
10031041 6/5/2020 STAGE 1 SENTINEL COHORTS
10031039 6/5/2020 STAGE 1 SENTINEL COHORTS
10031042 6/5/2020 STAGE 1 SENTINEL COHORTS
10031040 6/5/2020 STAGE 1 SENTINEL COHORTS
10021066 6/9/2020 STAGE 1 SENTINEL COHORTS
10021057 6/4/2020 STAGE 1 SENTINEL COHORTS
10031049 6/8/2020 STAGE 1 SENTINEL COHORTS
10071060 6/15/2020 STAGE 1 SENTINEL COHORTS
10011054 6/12/2020 STAGE 1 SENTINEL COHORTS
10031062 6/12/2020 STAGE 1 SENTINEL COHORTS
10071054 6/15/2020 STAGE 1 SENTINEL COHORTS
10011056 6/12/2020 STAGE 1 SENTINEL COHORTS
10021078 6/15/2020 STAGE 1 SENTINEL COHORTS
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\022dde691e771090
FDA-CBER-2021-5683-0023497
10021076 6/12/2020 STAGE 1 SENTINEL COHORTS
10011065 6/16/2020 STAGE 1 SENTINEL COHORTS
10071047 6/11/2020 STAGE 1 SENTINEL COHORTS
10071055 6/15/2020 STAGE 1 SENTINEL COHORTS
10071061 6/15/2020 STAGE 1 SENTINEL COHORTS
10071048 6/11/2020 STAGE 1 SENTINEL COHORTS
10071059 6/15/2020 STAGE 1 SENTINEL COHORTS
10031064 6/12/2020 STAGE 1 SENTINEL COHORTS
10031060 6/12/2020 STAGE 1 SENTINEL COHORTS
10031085 6/25/2020 STAGE 1 SENTINEL COHORTS
10031071 6/18/2020 STAGE 1 SENTINEL COHORTS
10071070 6/18/2020 STAGE 1 SENTINEL COHORTS
10071068 6/18/2020 STAGE 1 SENTINEL COHORTS
10071062 6/15/2020 STAGE 1 SENTINEL COHORTS
10071067 6/18/2020 STAGE 1 SENTINEL COHORTS
10031081 6/25/2020 STAGE 1 SENTINEL COHORTS
10031074 6/22/2020 STAGE 1 SENTINEL COHORTS
10071072 6/22/2020 STAGE 1 SENTINEL COHORTS
10031082 6/25/2020 STAGE 1 SENTINEL COHORTS
10011062 6/15/2020 STAGE 1 SENTINEL COHORTS
10011077 6/25/2020 STAGE 1 SENTINEL COHORTS
10071069 6/18/2020 STAGE 1 SENTINEL COHORTS
10011060 6/15/2020 STAGE 1 SENTINEL COHORTS
10031068 6/15/2020 STAGE 1 SENTINEL COHORTS
10011072 6/24/2020 STAGE 1 SENTINEL COHORTS
10031073 6/19/2020 STAGE 1 SENTINEL COHORTS
10011074 6/24/2020 STAGE 1 SENTINEL COHORTS
10031075 6/22/2020 STAGE 1 SENTINEL COHORTS
10021086 6/23/2020 STAGE 1 SENTINEL COHORTS
10011073 6/24/2020 STAGE 1 SENTINEL COHORTS
10011075 6/24/2020 STAGE 1 SENTINEL COHORTS
10071078 6/24/2020 STAGE 1 SENTINEL COHORTS
10071076 6/22/2020 STAGE 1 SENTINEL COHORTS
10031084 6/25/2020 STAGE 1 SENTINEL COHORTS
10031086 6/25/2020 STAGE 1 SENTINEL COHORTS
10011080 6/29/2020 STAGE 1 SENTINEL COHORTS
10011078 6/29/2020 STAGE 1 SENTINEL COHORTS
10011079 6/29/2020 STAGE 1 SENTINEL COHORTS
10021027 5/5/2020 STAGE 1 SENTINEL COHORTS
10011028 5/12/2020 STAGE 1 SENTINEL COHORTS
10021023 5/5/2020 STAGE 1 SENTINEL COHORTS
10011021 5/7/2020 STAGE 1 SENTINEL COHORTS
10011013 5/5/2020 STAGE 1 SENTINEL COHORTS
10011030 5/14/2020 STAGE 1 SENTINEL COHORTS
10021038 5/7/2020 STAGE 1 SENTINEL COHORTS
10021024 5/5/2020 STAGE 1 SENTINEL COHORTS
10021034 5/7/2020 STAGE 1 SENTINEL COHORTS
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\022dde691e771090
FDA-CBER-2021-5683-0023498
10021036 5/7/2020 STAGE 1 SENTINEL COHORTS
10021035 5/7/2020 STAGE 1 SENTINEL COHORTS
10021041 5/18/2020 STAGE 1 SENTINEL COHORTS
10011026 5/12/2020 STAGE 1 SENTINEL COHORTS
10011032 5/15/2020 STAGE 1 SENTINEL COHORTS
10011034 5/15/2020 STAGE 1 SENTINEL COHORTS
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\022dde691e771090
FDA-CBER-2021-5683-0023499",,8
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-bmi-12-15-scale.pdf,3.0,"Age (in 95th Percentile BMI
Gender months) Value
Male 143.5 24.1475
Male 144.5 24.22985
Male 145.5 24.31172
Male 146.5 24.3931
Male 147.5 24.47397
Male 148.5 24.55434
Male 149.5 24.6342
Male 150.5 24.71352
Male 151.5 24.79232
Male 152.5 24.87058
Male 153.5 24.94829
Male 154.5 25.02545
Male 155.5 25.10206
Male 156.5 25.17811
Male 157.5 25.2536
Male 158.5 25.32853
Male 159.5 25.40289
Male 160.5 25.47668
Male 161.5 25.5499
Male 162.5 25.62256
Male 163.5 25.69464
Male 164.5 25.76616
Male 165.5 25.83712
Male 166.5 25.90751
Male 167.5 25.97734
Male 168.5 26.04662
Male 169.5 26.11535
Male 170.5 26.18353
Male 171.5 26.25117
Male 172.5 26.31828
Male 173.5 26.38485
Male 174.5 26.45091
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\d47cde691e771090
FDA-CBER-2021-5683-0023487
Male 175.5 26.51646
Male 176.5 26.58151
Male 177.5 26.64606
Male 178.5 26.71014
Male 179.5 26.77374
Male 180.5 26.83688
Male 181.5 26.89958
Male 182.5 26.96184
Male 183.5 27.02368
Male 184.5 27.08511
Male 185.5 27.14616
Male 186.5 27.20683
Male 187.5 27.26714
Male 188.5 27.3271
Male 189.5 27.38675
Male 190.5 27.44609
Male 191.5 27.50514
Male 192.5 27.56393
Female 143.5 25.16522
Female 144.5 25.25564
Female 145.5 25.34557
Female 146.5 25.43498
Female 147.5 25.52387
Female 148.5 25.61223
Female 149.5 25.70005
Female 150.5 25.78731
Female 151.5 25.87401
Female 152.5 25.96013
Female 153.5 26.04568
Female 154.5 26.13065
Female 155.5 26.21502
Female 156.5 26.2988
Female 157.5 26.38197
Female 158.5 26.46453
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\d47cde691e771090
FDA-CBER-2021-5683-0023488
Female 159.5 26.54648
Female 160.5 26.62782
Female 161.5 26.70853
Female 162.5 26.78862
Female 163.5 26.86808
Female 164.5 26.94692
Female 165.5 27.02513
Female 166.5 27.1027
Female 167.5 27.17965
Female 168.5 27.25597
Female 169.5 27.33167
Female 170.5 27.40673
Female 171.5 27.48118
Female 172.5 27.555
Female 173.5 27.6282
Female 174.5 27.70079
Female 175.5 27.77277
Female 176.5 27.84414
Female 177.5 27.91491
Female 178.5 27.98509
Female 179.5 28.05468
Female 180.5 28.12369
Female 181.5 28.19213
Female 182.5 28.26
Female 183.5 28.32732
Female 184.5 28.39408
Female 185.5 28.46031
Female 186.5 28.52602
Female 187.5 28.5912
Female 188.5 28.65588
Female 189.5 28.72007
Female 190.5 28.78378
Female 191.5 28.84702
Female 192.5 28.90981
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\d47cde691e771090
FDA-CBER-2021-5683-0023489","[[['Age (in\nmonths)', '95th Percentile BMI\nValue'], ['143.5', '24.1475'], ['144.5', '24.22985'], ['145.5', '24.31172'], ['146.5', '24.3931'], ['147.5', '24.47397'], ['148.5', '24.55434'], ['149.5', '24.6342'], ['150.5', '24.71352'], ['151.5', '24.79232'], ['152.5', '24.87058'], ['153.5', '24.94829'], ['154.5', '25.02545'], ['155.5', '25.10206'], ['156.5', '25.17811'], ['157.5', '25.2536'], ['158.5', '25.32853'], ['159.5', '25.40289'], ['160.5', '25.47668'], ['161.5', '25.5499'], ['162.5', '25.62256'], ['163.5', '25.69464'], ['164.5', '25.76616'], ['165.5', '25.83712'], ['166.5', '25.90751'], ['167.5', '25.97734'], ['168.5', '26.04662'], ['169.5', '26.11535'], ['170.5', '26.18353'], ['171.5', '26.25117'], ['172.5', '26.31828'], ['173.5', '26.38485'], ['174.5', '26.45091']], [['175.5', '26.51646'], ['176.5', '26.58151'], ['177.5', '26.64606'], ['178.5', '26.71014'], ['179.5', '26.77374'], ['180.5', '26.83688'], ['181.5', '26.89958'], ['182.5', '26.96184'], ['183.5', '27.02368'], ['184.5', '27.08511'], ['185.5', '27.14616'], ['186.5', '27.20683'], ['187.5', '27.26714'], ['188.5', '27.3271'], ['189.5', '27.38675'], ['190.5', '27.44609'], ['191.5', '27.50514'], ['192.5', '27.56393'], ['143.5', '25.16522'], ['144.5', '25.25564'], ['145.5', '25.34557'], ['146.5', '25.43498'], ['147.5', '25.52387'], ['148.5', '25.61223'], ['149.5', '25.70005'], ['150.5', '25.78731'], ['151.5', '25.87401'], ['152.5', '25.96013'], ['153.5', '26.04568'], ['154.5', '26.13065'], ['155.5', '26.21502'], ['156.5', '26.2988'], ['157.5', '26.38197'], ['158.5', '26.46453']], [['159.5', '26.54648'], ['160.5', '26.62782'], ['161.5', '26.70853'], ['162.5', '26.78862'], ['163.5', '26.86808'], ['164.5', '26.94692'], ['165.5', '27.02513'], ['166.5', '27.1027'], ['167.5', '27.17965'], ['168.5', '27.25597'], ['169.5', '27.33167'], ['170.5', '27.40673'], ['171.5', '27.48118'], ['172.5', '27.555'], ['173.5', '27.6282'], ['174.5', '27.70079'], ['175.5', '27.77277'], ['176.5', '27.84414'], ['177.5', '27.91491'], ['178.5', '27.98509'], ['179.5', '28.05468'], ['180.5', '28.12369'], ['181.5', '28.19213'], ['182.5', '28.26'], ['183.5', '28.32732'], ['184.5', '28.39408'], ['185.5', '28.46031'], ['186.5', '28.52602'], ['187.5', '28.5912'], ['188.5', '28.65588'], ['189.5', '28.72007'], ['190.5', '28.78378'], ['191.5', '28.84702'], ['192.5', '28.90981']]]",3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_us-agent-authorization.pdf,2.0,")TMG(
40:51
1202-raM-52
:nO
laniF\laniF\c541f9691e771090
FDA-CBER-2021-5683-0013853
)TMG(
40:51
1202-raM-52
:nO
laniF\laniF\c541f9691e771090
FDA-CBER-2021-5683-0013854",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-T-S-roadmap.pdf,4.0,"C4591001: Roadmap for Event Selection and SDTM Dataset Updates for Reactogenicity
Background: As discussed with the Agency on 08 April 2021, any events reported in the general
adverse event data (AE domain) which meet criteria for reactogenicity have been added to the FACE
and VS domains and used to update the summary records in the CE domain, as described below.
Start
Add a flag in SUPPDM: QNAM=REACTOFL, QLABEL=Reactogenicity Population Flag
For vaccinated subjects (DM.RFXSTDTC non-missing):
a. Assign QVAL as “N” if “NO - REACTOGENICITY E-DIARY NOT COLLECTED FOR THIS SUBJECT” was
selected in REACTOGENICITY DIARY CRF
b. Otherwise assigned as “Y”
Select from AE data: If AECAT = “ADVERSE EVENT” and AEREL =
Select subjects from SUPPDM
‘RELATED’ and AEDECOD in (preferred term list corresponding to
with QVAL = “Y” where
pre-defined reactogenicity symptoms – see Table 1 below) and
QNAM = REACTOFL
occurs within 7 days of Vax 1 or Vax 2).
Y
Table 1
Reactogenicity Symptom PT (AEDECOD)
(CETERM)
PAIN AT INJECTION SITE Injection site pain
Vaccination site pain
REDNESS Injection site erythema
Vaccination site erythema
SWELLING Injection site swelling
Vaccination site swelling
FEVER Pyrexia
Body temperature increased
VOMITING Vomiting
DIARRHEA Diarrhoea
HEADACHE Headache
FATIGUE Fatigue
CHILLS Chills
NEW OR WORSENED Myalgia
MUSCLE PAIN
NEW OR WORSENED JOINT Arthralgia
PAIN
If meet both criteria, then add flag in SUPPAE to identify that these
meet reactogenicity criteria (QVAL = “Y” where QNAM = “REACCRIT”)
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\29091f691e771090
FDA-CBER-2021-5683-0023991
For general AE records identified
as meeting reactogenicity criteria
(SUPPAE.QNAM.REACCRIT = “Y”):
N Y
Fever?
Add records to FACE for investigator’s assessment from Add records to VS for investigator’s assessment from
AE form: AE form:
a. For each day AE overlaps with diary period, a. For each day AE overlaps with diary period,
insert a pair of records for FATESTCD = insert a record for VSTESTCD = ‘TEMP’:
‘OCCUR’ (set to ‘Y’) and FATESTCD = ‘SEV’ VSORRES is null, VSSTRESC = “FEVER” for that
(from AETOXGR, converted to severity date (VSDTC).
according to Table 2 below) for that date b. VSDRVDL is set to “Y”.
(FADTC). c. VSCAT = “REACTOGENICITY – ADVERSE
b. Assign FAOBJ based on the symptom EVENT”.
corresponding to AEDECOD (CETERM from d. VSSCAT = “SYSTEMIC”.
Table 1). e. VSSPID is assigned the value of AESPID from
c. FACAT = “REACTOGENICITY – ADVERSE source AE record.
EVENT”. f. VSEVAL = ‘INVESTIGATOR’.
d. FASCAT (“SYSTEMIC” or “ADMINISTRATION
SITE”) assigned based on FAOBJ.
e. FASPID is assigned the value of AESPID from
source AE record.
f. FAEVAL = ‘INVESTIGATOR’.
Table 2
AETOXGR Severity
1 MI LD
2 MODERATE
3 SEVERE
4 POTENTIALLY LIFE THREATENING
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\29091f691e771090
FDA-CBER-2021-5683-0023992
When general AE data affects the
corresponding summary event
record in CE  CE/SUPPCE updates
a. Flag in SUPPCE that event was modified based on AE data (QNAM =
‘AE_MOD’)
b. Create record in SUPPCE with QNAM = ‘CEDIFFRS’/QLABEL = ‘Reason
Investigator Changed Assessment’.
c. Assign SUPPCE.CEEVAL = “INVESTIGATOR”.
Originally CEOCCUR was “Y” Originally CEOCCUR was not “Y”
a. Re-derive CESTDTC by taking the earliest of a. Assign CEOCCUR= “Y” and set
AESTDTC and original CESTDTC. CESTAT/CEREASND/CEDRVFL to null.
b. Re-derive CEENDTC by taking the latest of b. Populate CESTDTC/CEENDTC with
AEENDTC and original CEENDTC. AESTDTC/AEENDTC.
c. For any date changes, write original date to c. Derive CESTDY/CEENDY and CEDUR.
SUPPCE.CESTDTC1 and/or CEENDTC1. d. Set CESEV based on AETOXGR, mapped to
d. CESTDY/CEENDY/CEDUR are updated based on severity values in Table 2.
any changes to CESTDTC/CEENDTC. e. If stop date is after diary period, then
e. Re-derive CESEV by taking the maximum severity assign CEENRTPT = “ONGOING” and
from AETOXGR (mapped to severity according to CEENTPT = “DAY 7”.
Table 2) or original CESEV. If AE severity is worse
than original CESEV, then write out original value
to SUPPCE where QNAM = CESEV1. Note:
Severity is not assigned for Fever events.
f. If stop date is after diary period, then assign
CEENRTPT = “ONGOING” and CEENTPT = “DAY 7”.
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\29091f691e771090
FDA-CBER-2021-5683-0023993
Identify events from updated CE
which went past the diary period
(CEENRTPT = “ONGOING”)
Add or update records to AE dataset where AECAT =
‘REACTOGENICITY’.
a. Calculate AEDUR based on time occurring after diary
period using updated CEENDTC.
b. Derive AEELTM.
c. AESEV can be populated using AETOXGR, mapped to
severity from Table 2.
Update RELREC to link any newly added records.
Link source general AE records to updated CE records.
End
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\29091f691e771090
FDA-CBER-2021-5683-0023994","[[[None, 'Table 1', None], ['Reactogenicity Symptom\n(CETERM)', None, 'PT (AEDECOD)'], ['PAIN AT INJECTION SITE', None, 'Injection site pain\nVaccination site pain'], ['REDNESS', None, 'Injection site erythema\nVaccination site erythema'], ['SWELLING', None, 'Injection site swelling\nVaccination site swelling'], ['FEVER', None, 'Pyrexia\nBody temperature increased'], ['VOMITING', None, 'Vomiting'], ['DIARRHEA', None, 'Diarrhoea'], ['HEADACHE', None, 'Headache'], ['FATIGUE', None, 'Fatigue'], ['CHILLS', None, 'Chills'], ['NEW OR WORSENED\nMUSCLE PAIN', None, 'Myalgia'], ['NEW OR WORSENED JOINT\nPAIN', None, 'Arthralgia']], [['Table 2', None], ['AETOXGR', 'Severity'], ['1', 'MI LD'], ['2', 'MODERATE'], ['3', 'SEVERE'], ['4', 'POTENTIALLY LIFE THREATENING']]]",4
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdf,2.0,"CCI_AIDS HIV
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_AIDS HIV
Code: 90002940
Extension: CCI
Report Date/Time: 27-Oct-2020:10:39:40 AM EDT
Term Code Level Category Weight Scope
Blood HIV RNA increased 10049827 PT
Blood HIV RNA fluctuation 10076287 PT
Asymptomatic HIV infection 10003581 PT
AIDS retinopathy 10053227 PT
AIDS related complex 10001513 PT
AIDS cholangiopathy 10067092 PT
Acute HIV infection 10000807 PT
Acquired immunodeficiency syndrome 10000565 PT
Perinatal HIV infection 10071049 PT
Lymphoma AIDS related 10025312 PT
Kaposi's sarcoma AIDS related 10023286 PT
Human immunodeficiency virus transmission 10053500 PT
HIV-associated neurocognitive disorder 10078164 PT
HIV wasting syndrome 10050309 PT
HIV viraemia 10077716 PT
HIV tropism test 10067158 PT
HIV test positive 10020188 PT
HIV peripheral neuropathy 10065681 PT
HIV lipodystrophy 10078720 PT
HIV infection WHO clinical stage IV 10064456 PT
HIV infection WHO clinical stage III 10064448 PT
HIV infection WHO clinical stage II 10064447 PT
HIV infection WHO clinical stage I 10064446 PT
HIV infection CDC Group IV subgroup E 10020171 PT
HIV infection CDC Group IV subgroup D 10020170 PT
HIV infection CDC Group IV subgroup C2 10020169 PT
HIV infection CDC Group IV subgroup C1 10020168 PT
HIV infection CDC Group IV subgroup B 10020167 PT
HIV infection CDC Group IV subgroup A 10020166 PT
HIV infection CDC group IV 10061519 PT
HIV infection CDC Group III 10020164 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\a73dde691e771090
FDA-CBER-2021-5683-0023876
HIV infection CDC Group II 10020163 PT
HIV infection CDC Group I 10020162 PT
HIV infection CDC category C 10075710 PT
HIV infection CDC category B 10075709 PT
HIV infection CDC category A 10075708 PT
HIV infection 10020161 PT
HIV enteropathy 10069691 PT
HIV carrier 10020159 PT
HIV cardiomyopathy 10069658 PT
HIV associated nephropathy 10070737 PT
HIV antigen positive 10058737 PT
HIV antibody positive 10058736 PT
Enterocolitis AIDS 10014894 PT
End stage AIDS 10049076 PT
Congenital HIV infection 10010504 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\a73dde691e771090
FDA-CBER-2021-5683-0023877",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-dementia.pdf,1.0,"CCI_Dementia
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Dementia
Code: 90002953
Extension: CCI
Report Date/Time: 27-Oct-2020:10:44:39 AM EDT
Term Code Level Category Weight Scope
Vascular dementia 10057678 PT
Senile psychosis 10039987 PT
Senile dementia 10039966 PT
Progressive supranuclear palsy 10036813 PT
Prodromal Alzheimer's disease 10074616 PT
Presenile dementia 10036631 PT
Posterior cortical atrophy 10078207 PT
Neurodegenerative disorder 10053643 PT
Mixed dementia 10075174 PT
HIV-associated neurocognitive disorder 10078164 PT
Frontotemporal dementia 10068968 PT
Dementia with Lewy bodies 10067889 PT
Dementia of the Alzheimer's type, with depressed mood 10012296 PT
Dementia of the Alzheimer's type, with delusions 10012295 PT
Dementia of the Alzheimer's type, with delirium 10012294 PT
Dementia of the Alzheimer's type, uncomplicated 10012293 PT
Dementia Alzheimer's type 10012271 PT
Dementia 10012267 PT
Corticobasal degeneration 10078208 PT
Alcohol induced persisting dementia 10001596 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\183dde691e771090
FDA-CBER-2021-5683-0023925",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-renal.pdf,2.0,"CCI_Renal
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Renal
Code: 90002943
Extension: CCI
Report Date/Time: 27-Oct-2020:10:54:51 AM EDT
Term Code Level Category Weight Scope
Renal cortical necrosis 10038422 PT
Renal cell dysplasia 10078656 PT
Renal atrophy 10038381 PT
Renal artery thrombosis 10038380 PT
Renal artery stenosis 10038378 PT
Renal artery perforation 10075737 PT
Renal artery occlusion 10048988 PT
Renal artery hyperplasia 10038377 PT
Renal artery fibromuscular dysplasia 10049739 PT
Renal arteritis 10038373 PT
Renal arteriosclerosis 10038372 PT
Renal aneurysm 10038366 PT
Peritoneal equilibration test 10064772 PT
Peritoneal dialysis 10034660 PT
Pericarditis uraemic 10034498 PT
Page kidney 10076704 PT
Nephropathy 10029151 PT
Nephrogenic diabetes insipidus 10029147 PT
Nephroangiosclerosis 10052242 PT
Nephritis haemorrhagic 10029132 PT
Nephritis 10029117 PT
Nephritic syndrome 10065673 PT
Mesangioproliferative glomerulonephritis 10066453 PT
Malnutrition-inflammation-atherosclerosis syndrome 10071138 PT
Malignant renal hypertension 10026674 PT
Ischaemic nephropathy 10069384 PT
Hypertensive nephropathy 10055171 PT
Hyperparathyroidism secondary 10020708 PT
Haemodialysis 10018875 PT
Glomerulonephritis rapidly progressive 10018378 PT
Glomerulonephritis proliferative 10018376 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\0e0cce691e771090
FDA-CBER-2021-5683-0023977
Glomerulonephritis membranous 10018372 PT
Glomerulonephritis membranoproliferative 10018370 PT
Glomerulonephritis chronic 10018367 PT
Glomerulonephritis 10018364 PT
Glomerular vascular disorder 10018362 PT
Focal segmental glomerulosclerosis 10067757 PT
End stage renal disease 10077512 PT
Dialysis efficacy test 10070418 PT
Dialysis device insertion 10059015 PT
Dialysis 10061105 PT
Diabetic end stage renal disease 10012660 PT
Chronic kidney disease-mineral and bone disorder 10078095 PT
Chronic kidney disease 10064848 PT
Chronic autoimmune glomerulonephritis 10073016 PT
Azotaemia 10003885 PT
Arteriovenous fistula operation 10003190 PT
Uraemic neuropathy 10046328 PT
Tubulointerstitial nephritis 10048302 PT
Scleroderma renal crisis 10062553 PT
Renal vessel disorder 10038553 PT
Renal vein varices 10077278 PT
Renal vein thrombosis 10038548 PT
Renal vein occlusion 10056293 PT
Renal vein embolism 10038547 PT
Renal vein compression 10074386 PT
Renal vasculitis 10038546 PT
Renal vascular thrombosis 10072226 PT
Renal tubular necrosis 10038540 PT
Renal tubular acidosis 10038535 PT
Renal transplant 10038533 PT
Renal rickets 10038519 PT
Renal papillary necrosis 10038491 PT
Renal necrosis 10038481 PT
Renal ischaemia 10063897 PT
Renal infarct 10038470 PT
Renal impairment 10062237 PT
Renal hypertension 10038464 PT
Renal failure 10038435 PT
Renal embolism 10063544 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\0e0cce691e771090
FDA-CBER-2021-5683-0023978",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-comorbidity-categories.pdf,1.0,"Category Sheet
AIDS/HIV Report_CCI_AIDS HIV
Any Malignancy Report_CCI_Any malignancy
Cerebrovascular Disease Report_CCI_Cerebrovascular
Chronic Pulmonary Disease Report_CCI_Pulmonary
Congestive Heart Failure Report_CCI_CHF
Dementia Report_CCI_Dementia
Diabetes With Chronic Complication Report_CCI_Diabetes with comp
Diabetes Without Chronic Complication Report_CCI_Diabetes without comp
Hemiplegia or Paraplegia Report_CCI_Hemiplegia
Leukemia Report_CCI_Leukemia
Lymphoma Report_CCI_Lymphoma
Metastatic Solid Tumor Report_CCI_Metastatic tumour
Mild Liver Disease Report_CCI_Mild liver
Moderate or Severe Liver Disease Report_CCI_Mod sev liver
Myocardial Infarction Report_CCI_MI
Peptic Ulcer Disease Report_CCI_Peptic ulcer
Peripheral Vascular Disease Report_CCI_Periph vasc
Renal Disease Report_CCI_Renal
Rheumatic Disease Report_CCI_Rheumatic
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\6e2dde691e771090
FDA-CBER-2021-5683-0023539",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdf,15.0,"USUBJID SUBJID
C4591001 1005 10051328 10051328
C4591001 1005 10051400 10051400
C4591001 1005 10051412 10051412
C4591001 1005 10051416 10051416
C4591001 1005 10051419 10051419
C4591001 1006 10061136 10061136
C4591001 1006 10061137 10061137
C4591001 1006 10061159 10061159
C4591001 1006 10061162 10061162
C4591001 1006 10061170 10061170
C4591001 1006 10061184 10061184
C4591001 1006 10061192 10061192
C4591001 1006 10061194 10061194
C4591001 1006 10061202 10061202
C4591001 1006 10061209 10061209
C4591001 1006 10061212 10061212
C4591001 1006 10061220 10061220
C4591001 1006 10061225 10061225
C4591001 1006 10061227 10061227
C4591001 1006 10061230 10061230
C4591001 1006 10061231 10061231
C4591001 1006 10061234 10061234
C4591001 1006 10061248 10061248
C4591001 1006 10061249 10061249
C4591001 1006 10061256 10061256
C4591001 1006 10061261 10061261
C4591001 1006 10061263 10061263
C4591001 1006 10061265 10061265
C4591001 1006 10061274 10061274
C4591001 1006 10061280 10061280
C4591001 1006 10061282 10061282
C4591001 1007 10071289 10071289
C4591001 1007 10071385 10071385
C4591001 1007 10071417 10071417
C4591001 1007 10071434 10071434
C4591001 1007 10071439 10071439
C4591001 1007 10071447 10071447
C4591001 1007 10071454 10071454
C4591001 1007 10071467 10071467
C4591001 1007 10071469 10071469
C4591001 1007 10071471 10071471
C4591001 1007 10071473 10071473
C4591001 1007 10071481 10071481
C4591001 1007 10071488 10071488
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023508
C4591001 1007 10071494 10071494
C4591001 1007 10071504 10071504
C4591001 1007 10071506 10071506
C4591001 1007 10071512 10071512
C4591001 1007 10071517 10071517
C4591001 1007 10071521 10071521
C4591001 1007 10071523 10071523
C4591001 1007 10071525 10071525
C4591001 1007 10071526 10071526
C4591001 1007 10071529 10071529
C4591001 1007 10071536 10071536
C4591001 1007 10071537 10071537
C4591001 1007 10071541 10071541
C4591001 1007 10071546 10071546
C4591001 1007 10071550 10071550
C4591001 1007 10071555 10071555
C4591001 1007 10071558 10071558
C4591001 1007 10071560 10071560
C4591001 1007 10071561 10071561
C4591001 1007 10071562 10071562
C4591001 1007 10071564 10071564
C4591001 1007 10071567 10071567
C4591001 1007 10071574 10071574
C4591001 1007 10071575 10071575
C4591001 1007 10071579 10071579
C4591001 1007 10071580 10071580
C4591001 1007 10071587 10071587
C4591001 1008 10081558 10081558
C4591001 1008 10081743 10081743
C4591001 1008 10081747 10081747
C4591001 1008 10081754 10081754
C4591001 1008 10081760 10081760
C4591001 1008 10081764 10081764
C4591001 1008 10081770 10081770
C4591001 1008 10081792 10081792
C4591001 1008 10081795 10081795
C4591001 1008 10081797 10081797
C4591001 1008 10081800 10081800
C4591001 1008 10081802 10081802
C4591001 1008 10081805 10081805
C4591001 1008 10081808 10081808
C4591001 1008 10081810 10081810
C4591001 1008 10081813 10081813
C4591001 1008 10081814 10081814
C4591001 1008 10081818 10081818
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023509
C4591001 1009 10091028 10091028
C4591001 1009 10091070 10091070
C4591001 1009 10091205 10091205
C4591001 1009 10091210 10091210
C4591001 1009 10091217 10091217
C4591001 1009 10091221 10091221
C4591001 1009 10091233 10091233
C4591001 1009 10091234 10091234
C4591001 1009 10091235 10091235
C4591001 1009 10091250 10091250
C4591001 1009 10091256 10091256
C4591001 1009 10091265 10091265
C4591001 1009 10091270 10091270
C4591001 1009 10091272 10091272
C4591001 1009 10091273 10091273
C4591001 1009 10091280 10091280
C4591001 1009 10091281 10091281
C4591001 1009 10091284 10091284
C4591001 1009 10091288 10091288
C4591001 1009 10091298 10091298
C4591001 1009 10091310 10091310
C4591001 1009 10091313 10091313
C4591001 1009 10091314 10091314
C4591001 1009 10091315 10091315
C4591001 1009 10091317 10091317
C4591001 1009 10091318 10091318
C4591001 1009 10091319 10091319
C4591001 1009 10091321 10091321
C4591001 1009 10091322 10091322
C4591001 1009 10091331 10091331
C4591001 1009 10091332 10091332
C4591001 1009 10091335 10091335
C4591001 1009 10091341 10091341
C4591001 1009 10091342 10091342
C4591001 1009 10091348 10091348
C4591001 1009 10091351 10091351
C4591001 1009 10091354 10091354
C4591001 1009 10091355 10091355
C4591001 1009 10091358 10091358
C4591001 1009 10091360 10091360
C4591001 1009 10091362 10091362
C4591001 1009 10091364 10091364
C4591001 1011 10111213 10111213
C4591001 1011 10111215 10111215
C4591001 1013 10131059 10131059
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023510
C4591001 1013 10131060 10131060
C4591001 1013 10131171 10131171
C4591001 1013 10131276 10131276
C4591001 1013 10131653 10131653
C4591001 1013 10131763 10131763
C4591001 1013 10131817 10131817
C4591001 1013 10131822 10131822
C4591001 1013 10131828 10131828
C4591001 1013 10131829 10131829
C4591001 1013 10131834 10131834
C4591001 1013 10131836 10131836
C4591001 1013 10131841 10131841
C4591001 1013 10131843 10131843
C4591001 1013 10131845 10131845
C4591001 1013 10131848 10131848
C4591001 1013 10131850 10131850
C4591001 1013 10131855 10131855
C4591001 1013 10131867 10131867
C4591001 1015 10151081 10151081
C4591001 1015 10151150 10151150
C4591001 1016 10161028 10161028
C4591001 1016 10161284 10161284
C4591001 1016 10161288 10161288
C4591001 1016 10161289 10161289
C4591001 1016 10161293 10161293
C4591001 1016 10161295 10161295
C4591001 1016 10161299 10161299
C4591001 1016 10161324 10161324
C4591001 1016 10161325 10161325
C4591001 1016 10161332 10161332
C4591001 1016 10161334 10161334
C4591001 1016 10161338 10161338
C4591001 1016 10161339 10161339
C4591001 1016 10161340 10161340
C4591001 1016 10161350 10161350
C4591001 1016 10161356 10161356
C4591001 1016 10161361 10161361
C4591001 1016 10161362 10161362
C4591001 1016 10161363 10161363
C4591001 1016 10161364 10161364
C4591001 1018 10181032 10181032
C4591001 1018 10181194 10181194
C4591001 1022 10221112 10221112
C4591001 1028 10281029 10281029
C4591001 1028 10281053 10281053
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023511
C4591001 1028 10281094 10281094
C4591001 1028 10281184 10281184
C4591001 1028 10281211 10281211
C4591001 1028 10281248 10281248
C4591001 1030 10301072 10301072
C4591001 1038 10381006 10381006
C4591001 1039 10391247 10391247
C4591001 1039 10391255 10391255
C4591001 1039 10391256 10391256
C4591001 1039 10391269 10391269
C4591001 1039 10391272 10391272
C4591001 1039 10391276 10391276
C4591001 1039 10391281 10391281
C4591001 1039 10391282 10391282
C4591001 1039 10391284 10391284
C4591001 1039 10391286 10391286
C4591001 1042 10421111 10421111
C4591001 1042 10421112 10421112
C4591001 1042 10421114 10421114
C4591001 1044 10441193 10441193
C4591001 1044 10441235 10441235
C4591001 1044 10441241 10441241
C4591001 1044 10441255 10441255
C4591001 1044 10441260 10441260
C4591001 1044 10441263 10441263
C4591001 1044 10441268 10441268
C4591001 1044 10441272 10441272
C4591001 1044 10441276 10441276
C4591001 1044 10441278 10441278
C4591001 1044 10441285 10441285
C4591001 1044 10441291 10441291
C4591001 1044 10441295 10441295
C4591001 1046 10461125 10461125
C4591001 1046 10461171 10461171
C4591001 1046 10461319 10461319
C4591001 1046 10461338 10461338
C4591001 1046 10461346 10461346
C4591001 1047 10471275 10471275
C4591001 1047 10471306 10471306
C4591001 1054 10541007 10541007
C4591001 1054 10541090 10541090
C4591001 1055 10551021 10551021
C4591001 1056 10561171 10561171
C4591001 1056 10561392 10561392
C4591001 1057 10571044 10571044
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023512
C4591001 1057 10571217 10571217
C4591001 1057 10571234 10571234
C4591001 1057 10571366 10571366
C4591001 1057 10571368 10571368
C4591001 1057 10571378 10571378
C4591001 1057 10571395 10571395
C4591001 1057 10571396 10571396
C4591001 1057 10571399 10571399
C4591001 1057 10571400 10571400
C4591001 1057 10571403 10571403
C4591001 1057 10571409 10571409
C4591001 1057 10571412 10571412
C4591001 1066 10661166 10661166
C4591001 1066 10661290 10661290
C4591001 1066 10661394 10661394
C4591001 1066 10661395 10661395
C4591001 1066 10661402 10661402
C4591001 1066 10661405 10661405
C4591001 1066 10661408 10661408
C4591001 1066 10661409 10661409
C4591001 1066 10661417 10661417
C4591001 1066 10661420 10661420
C4591001 1068 10681098 10681098
C4591001 1068 10681119 10681119
C4591001 1071 10711233 10711233
C4591001 1077 10771262 10771262
C4591001 1077 10771273 10771273
C4591001 1077 10771274 10771274
C4591001 1077 10771279 10771279
C4591001 1077 10771284 10771284
C4591001 1077 10771288 10771288
C4591001 1077 10771292 10771292
C4591001 1079 10791162 10791162
C4591001 1079 10791288 10791288
C4591001 1080 10801055 10801055
C4591001 1080 10801179 10801179
C4591001 1082 10821014 10821014
C4591001 1082 10821036 10821036
C4591001 1082 10821196 10821196
C4591001 1082 10821201 10821201
C4591001 1084 10841423 10841423
C4591001 1084 10841546 10841546
C4591001 1085 10851050 10851050
C4591001 1085 10851373 10851373
C4591001 1087 10871061 10871061
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023513
C4591001 1087 10871214 10871214
C4591001 1087 10871267 10871267
C4591001 1087 10871529 10871529
C4591001 1087 10871565 10871565
C4591001 1088 10881200 10881200
C4591001 1089 10891273 10891273
C4591001 1089 10891306 10891306
C4591001 1090 10901031 10901031
C4591001 1090 10901043 10901043
C4591001 1090 10901157 10901157
C4591001 1090 10901328 10901328
C4591001 1090 10901443 10901443
C4591001 1090 10901517 10901517
C4591001 1090 10901559 10901559
C4591001 1091 10911382 10911382
C4591001 1091 10911389 10911389
C4591001 1091 10911391 10911391
C4591001 1091 10911394 10911394
C4591001 1091 10911395 10911395
C4591001 1091 10911399 10911399
C4591001 1091 10911400 10911400
C4591001 1091 10911401 10911401
C4591001 1091 10911407 10911407
C4591001 1091 10911413 10911413
C4591001 1091 10911416 10911416
C4591001 1091 10911420 10911420
C4591001 1091 10911424 10911424
C4591001 1091 10911435 10911435
C4591001 1091 10911436 10911436
C4591001 1091 10911440 10911440
C4591001 1092 10921083 10921083
C4591001 1092 10921146 10921146
C4591001 1093 10931088 10931088
C4591001 1093 10931174 10931174
C4591001 1093 10931203 10931203
C4591001 1094 10941069 10941069
C4591001 1094 10941076 10941076
C4591001 1095 10951106 10951106
C4591001 1095 10951170 10951170
C4591001 1095 10951271 10951271
C4591001 1095 10951310 10951310
C4591001 1095 10951312 10951312
C4591001 1095 10951315 10951315
C4591001 1096 10961010 10961010
C4591001 1096 10961032 10961032
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023514
C4591001 1096 10961168 10961168
C4591001 1096 10961196 10961196
C4591001 1096 10961219 10961219
C4591001 1096 10961319 10961319
C4591001 1096 10961392 10961392
C4591001 1098 10981177 10981177
C4591001 1101 11011033 11011033
C4591001 1101 11011062 11011062
C4591001 1101 11011079 11011079
C4591001 1101 11011088 11011088
C4591001 1109 11091309 11091309
C4591001 1109 11091370 11091370
C4591001 1109 11091391 11091391
C4591001 1109 11091532 11091532
C4591001 1111 11111183 11111183
C4591001 1112 11121019 11121019
C4591001 1112 11121125 11121125
C4591001 1112 11121217 11121217
C4591001 1112 11121260 11121260
C4591001 1112 11121297 11121297
C4591001 1114 11141021 11141021
C4591001 1116 11161256 11161256
C4591001 1116 11161320 11161320
C4591001 1116 11161322 11161322
C4591001 1117 11171113 11171113
C4591001 1118 11181017 11181017
C4591001 1118 11181059 11181059
C4591001 1118 11181101 11181101
C4591001 1120 11201337 11201337
C4591001 1123 11231116 11231116
C4591001 1123 11231381 11231381
C4591001 1123 11231383 11231383
C4591001 1123 11231413 11231413
C4591001 1123 11231416 11231416
C4591001 1123 11231417 11231417
C4591001 1123 11231423 11231423
C4591001 1123 11231429 11231429
C4591001 1123 11231430 11231430
C4591001 1123 11231431 11231431
C4591001 1123 11231432 11231432
C4591001 1123 11231438 11231438
C4591001 1123 11231439 11231439
C4591001 1123 11231440 11231440
C4591001 1123 11231441 11231441
C4591001 1123 11231446 11231446
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023515
C4591001 1123 11231447 11231447
C4591001 1123 11231448 11231448
C4591001 1123 11231455 11231455
C4591001 1123 11231458 11231458
C4591001 1123 11231459 11231459
C4591001 1124 11241071 11241071
C4591001 1124 11241238 11241238
C4591001 1124 11241239 11241239
C4591001 1124 11241243 11241243
C4591001 1124 11241248 11241248
C4591001 1124 11241249 11241249
C4591001 1124 11241251 11241251
C4591001 1124 11241254 11241254
C4591001 1125 11251144 11251144
C4591001 1125 11251240 11251240
C4591001 1126 11261211 11261211
C4591001 1126 11261216 11261216
C4591001 1126 11261229 11261229
C4591001 1126 11261231 11261231
C4591001 1126 11261234 11261234
C4591001 1126 11261241 11261241
C4591001 1126 11261242 11261242
C4591001 1126 11261243 11261243
C4591001 1126 11261246 11261246
C4591001 1126 11261255 11261255
C4591001 1126 11261267 11261267
C4591001 1126 11261269 11261269
C4591001 1126 11261273 11261273
C4591001 1126 11261277 11261277
C4591001 1126 11261278 11261278
C4591001 1126 11261281 11261281
C4591001 1126 11261285 11261285
C4591001 1126 11261291 11261291
C4591001 1126 11261293 11261293
C4591001 1127 11271021 11271021
C4591001 1127 11271033 11271033
C4591001 1129 11291262 11291262
C4591001 1129 11291265 11291265
C4591001 1130 11301089 11301089
C4591001 1131 11311064 11311064
C4591001 1131 11311266 11311266
C4591001 1131 11311268 11311268
C4591001 1131 11311275 11311275
C4591001 1131 11311278 11311278
C4591001 1133 11331485 11331485
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023516
C4591001 1133 11331602 11331602
C4591001 1133 11331609 11331609
C4591001 1134 11341327 11341327
C4591001 1135 11351088 11351088
C4591001 1135 11351113 11351113
C4591001 1135 11351216 11351216
C4591001 1135 11351239 11351239
C4591001 1135 11351323 11351323
C4591001 1135 11351355 11351355
C4591001 1135 11351410 11351410
C4591001 1135 11351461 11351461
C4591001 1135 11351492 11351492
C4591001 1135 11351497 11351497
C4591001 1135 11351556 11351556
C4591001 1136 11361007 11361007
C4591001 1139 11391132 11391132
C4591001 1139 11391141 11391141
C4591001 1139 11391144 11391144
C4591001 1139 11391145 11391145
C4591001 1139 11391151 11391151
C4591001 1139 11391155 11391155
C4591001 1139 11391156 11391156
C4591001 1139 11391161 11391161
C4591001 1139 11391162 11391162
C4591001 1139 11391165 11391165
C4591001 1139 11391167 11391167
C4591001 1139 11391170 11391170
C4591001 1139 11391178 11391178
C4591001 1139 11391179 11391179
C4591001 1140 11401316 11401316
C4591001 1140 11401327 11401327
C4591001 1140 11401328 11401328
C4591001 1140 11401332 11401332
C4591001 1140 11401335 11401335
C4591001 1140 11401336 11401336
C4591001 1140 11401337 11401337
C4591001 1141 11411006 11411006
C4591001 1141 11411072 11411072
C4591001 1141 11411081 11411081
C4591001 1141 11411141 11411141
C4591001 1141 11411187 11411187
C4591001 1141 11411226 11411226
C4591001 1141 11411227 11411227
C4591001 1141 11411236 11411236
C4591001 1141 11411263 11411263
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023517
C4591001 1141 11411269 11411269
C4591001 1142 11421037 11421037
C4591001 1142 11421100 11421100
C4591001 1142 11421274 11421274
C4591001 1142 11421319 11421319
C4591001 1142 11421330 11421330
C4591001 1142 11421335 11421335
C4591001 1142 11421338 11421338
C4591001 1142 11421343 11421343
C4591001 1142 11421346 11421346
C4591001 1142 11421350 11421350
C4591001 1142 11421353 11421353
C4591001 1142 11421360 11421360
C4591001 1142 11421362 11421362
C4591001 1146 11461292 11461292
C4591001 1146 11461316 11461316
C4591001 1146 11461342 11461342
C4591001 1146 11461378 11461378
C4591001 1147 11471255 11471255
C4591001 1147 11471260 11471260
C4591001 1147 11471262 11471262
C4591001 1147 11471268 11471268
C4591001 1147 11471274 11471274
C4591001 1147 11471277 11471277
C4591001 1147 11471279 11471279
C4591001 1147 11471282 11471282
C4591001 1149 11491050 11491050
C4591001 1149 11491079 11491079
C4591001 1149 11491218 11491218
C4591001 1149 11491255 11491255
C4591001 1149 11491302 11491302
C4591001 1150 11501016 11501016
C4591001 1150 11501118 11501118
C4591001 1150 11501119 11501119
C4591001 1150 11501127 11501127
C4591001 1150 11501129 11501129
C4591001 1150 11501130 11501130
C4591001 1150 11501132 11501132
C4591001 1150 11501133 11501133
C4591001 1150 11501179 11501179
C4591001 1150 11501180 11501180
C4591001 1150 11501181 11501181
C4591001 1150 11501186 11501186
C4591001 1150 11501187 11501187
C4591001 1150 11501188 11501188
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023518
C4591001 1150 11501191 11501191
C4591001 1150 11501194 11501194
C4591001 1150 11501197 11501197
C4591001 1150 11501208 11501208
C4591001 1150 11501210 11501210
C4591001 1150 11501211 11501211
C4591001 1150 11501216 11501216
C4591001 1150 11501217 11501217
C4591001 1150 11501221 11501221
C4591001 1150 11501226 11501226
C4591001 1150 11501227 11501227
C4591001 1152 11521009 11521009
C4591001 1152 11521011 11521011
C4591001 1152 11521019 11521019
C4591001 1152 11521114 11521114
C4591001 1152 11521115 11521115
C4591001 1152 11521149 11521149
C4591001 1152 11521164 11521164
C4591001 1152 11521222 11521222
C4591001 1152 11521357 11521357
C4591001 1152 11521451 11521451
C4591001 1152 11521464 11521464
C4591001 1152 11521505 11521505
C4591001 1152 11521534 11521534
C4591001 1152 11521587 11521587
C4591001 1152 11521588 11521588
C4591001 1152 11521589 11521589
C4591001 1152 11521600 11521600
C4591001 1152 11521601 11521601
C4591001 1152 11521605 11521605
C4591001 1152 11521614 11521614
C4591001 1152 11521619 11521619
C4591001 1152 11521625 11521625
C4591001 1152 11521632 11521632
C4591001 1152 11521634 11521634
C4591001 1152 11521635 11521635
C4591001 1152 11521636 11521636
C4591001 1152 11521637 11521637
C4591001 1152 11521640 11521640
C4591001 1152 11521641 11521641
C4591001 1152 11521645 11521645
C4591001 1152 11521648 11521648
C4591001 1152 11521650 11521650
C4591001 1152 11521655 11521655
C4591001 1152 11521656 11521656
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023519
C4591001 1152 11521657 11521657
C4591001 1152 11521661 11521661
C4591001 1152 11521667 11521667
C4591001 1152 11521671 11521671
C4591001 1152 11521674 11521674
C4591001 1152 11521677 11521677
C4591001 1152 11521679 11521679
C4591001 1152 11521683 11521683
C4591001 1152 11521684 11521684
C4591001 1152 11521686 11521686
C4591001 1152 11521689 11521689
C4591001 1152 11521692 11521692
C4591001 1152 11521694 11521694
C4591001 1152 11521697 11521697
C4591001 1152 11521699 11521699
C4591001 1152 11521701 11521701
C4591001 1156 11561155 11561155
C4591001 1156 11561203 11561203
C4591001 1156 11561229 11561229
C4591001 1156 11561243 11561243
C4591001 1156 11561245 11561245
C4591001 1156 11561246 11561246
C4591001 1156 11561249 11561249
C4591001 1156 11561250 11561250
C4591001 1156 11561257 11561257
C4591001 1156 11561258 11561258
C4591001 1156 11561259 11561259
C4591001 1156 11561264 11561264
C4591001 1156 11561288 11561288
C4591001 1156 11561291 11561291
C4591001 1156 11561304 11561304
C4591001 1156 11561310 11561310
C4591001 1156 11561311 11561311
C4591001 1156 11561313 11561313
C4591001 1156 11561314 11561314
C4591001 1156 11561317 11561317
C4591001 1156 11561321 11561321
C4591001 1156 11561324 11561324
C4591001 1156 11561329 11561329
C4591001 1162 11621051 11621051
C4591001 1162 11621110 11621110
C4591001 1162 11621418 11621418
C4591001 1162 11621479 11621479
C4591001 1163 11631048 11631048
C4591001 1163 11631106 11631106
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023520
C4591001 1166 11661008 11661008
C4591001 1166 11661048 11661048
C4591001 1167 11671142 11671142
C4591001 1167 11671224 11671224
C4591001 1168 11681035 11681035
C4591001 1168 11681069 11681069
C4591001 1168 11681088 11681088
C4591001 1168 11681090 11681090
C4591001 1168 11681098 11681098
C4591001 1168 11681135 11681135
C4591001 1168 11681219 11681219
C4591001 1168 11681224 11681224
C4591001 1170 11701089 11701089
C4591001 1170 11701392 11701392
C4591001 1170 11701419 11701419
C4591001 1171 11711027 11711027
C4591001 1171 11711152 11711152
C4591001 1171 11711211 11711211
C4591001 1171 11711221 11711221
C4591001 1171 11711240 11711240
C4591001 1177 11771393 11771393
C4591001 1177 11771428 11771428
C4591001 1177 11771540 11771540
C4591001 1177 11771550 11771550
C4591001 1178 11781098 11781098
C4591001 1178 11781156 11781156
C4591001 1178 11781161 11781161
C4591001 1178 11781187 11781187
C4591001 1178 11781301 11781301
C4591001 1204 12041061 12041061
C4591001 1204 12041088 12041088
C4591001 1204 12041144 12041144
C4591001 1204 12041275 12041275
C4591001 1218 12181047 12181047
C4591001 1220 12201015 12201015
C4591001 1221 12211006 12211006
C4591001 1221 12211036 12211036
C4591001 1223 12231113 12231113
C4591001 1223 12231117 12231117
C4591001 1224 12241136 12241136
C4591001 1224 12241183 12241183
C4591001 1224 12241187 12241187
C4591001 1232 12321028 12321028
C4591001 1232 12321302 12321302
C4591001 1235 12351003 12351003
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023521
C4591001 1235 12351014 12351014
C4591001 1235 12351053 12351053
C4591001 1235 12351230 12351230
C4591001 1235 12351233 12351233
C4591001 1235 12351242 12351242
C4591001 1235 12351245 12351245
C4591001 1235 12351246 12351246
C4591001 1235 12351250 12351250
C4591001 1248 12481033 12481033
C4591001 1248 12481038 12481038
C4591001 1254 12541121 12541121
C4591001 1254 12541178 12541178
C4591001 1254 12541193 12541193
C4591001 1258 12581023 12581023
C4591001 1258 12581065 12581065
C4591001 1258 12581069 12581069
C4591001 1264 12641095 12641095
C4591001 1270 12701153 12701153
C4591001 1270 12701156 12701156
C4591001 1270 12701169 12701169
C4591001 1270 12701173 12701173
C4591001 1270 12701174 12701174
C4591001 1270 12701177 12701177
C4591001 1270 12701184 12701184
C4591001 1270 12701187 12701187
C4591001 1270 12701195 12701195
C4591001 1270 12701200 12701200
C4591001 1270 12701210 12701210
C4591001 1270 12701214 12701214
C4591001 1270 12701218 12701218
C4591001 1270 12701220 12701220
)TMG(
11:00
1202-yaM-10
:nO
laniF\laniF\c47cde691e771090
FDA-CBER-2021-5683-0023522",,15
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-mi.pdf,1.0,"CCI_MI
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_MI
Code: 90002929
Extension: CCI
Report Date/Time: 27-Oct-2020:10:48:20 AM EDT
Term Code Level Category Weight Scope
Silent myocardial infarction 10049768 PT
Postinfarction angina 10058144 PT
Papillary muscle infarction 10033697 PT
Myocardial infarction 10028596 PT
ECG signs of myocardial infarction 10075299 PT
Coronary artery occlusion 10011086 PT
Acute myocardial infarction 10000891 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\832dde691e771090
FDA-CBER-2021-5683-0023959",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-leukemia.pdf,3.0,"CCI_Leukemia
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Leukemia
Code: 90002928
Extension: CCI
Report Date/Time: 27-Oct-2020:10:46:53 AM EDT
Term Code Level Category Weight Scope
Leukaemic infiltration ovary 10075853 PT
Leukaemic infiltration hepatic 10058671 PT
Leukaemic infiltration gingiva 10067431 PT
Leukaemic infiltration extramedullary 10067117 PT
Leukaemic infiltration 10069360 PT
Leukaemic cardiac infiltration 10077563 PT
Leukaemia recurrent 10062489 PT
Leukaemia monocytic 10024305 PT
Leukaemia in remission 10061220 PT
Leukaemia granulocytic 10024299 PT
Leukaemia cutis 10053180 PT
Leukaemia basophilic 10024293 PT
Leukaemia 10024288 PT
Large granular lymphocytosis 10023791 PT
Juvenile chronic myelomonocytic leukaemia 10023249 PT
Hairy cell leukaemia recurrent 10077403 PT
Hairy cell leukaemia 10019053 PT
Acute erythroid leukaemia 10000739 PT
Erythraemic myelosis (in remission) 10015246 PT
Eosinophilic leukaemia 10014958 PT
Chronic myelomonocytic leukaemia (in remission) 10009019 PT
Chronic myelomonocytic leukaemia 10009018 PT
Chronic myeloid leukaemia transformation 10068232 PT
Chronic myeloid leukaemia recurrent 10075081 PT
Chronic myeloid leukaemia (in remission) 10009014 PT
Chronic myeloid leukaemia 10009013 PT
Chronic lymphocytic leukaemia transformation 10058717 PT
Chronic lymphocytic leukaemia stage 4 10008967 PT
Chronic lymphocytic leukaemia stage 3 10008966 PT
Chronic lymphocytic leukaemia stage 2 10008965 PT
Chronic lymphocytic leukaemia stage 1 10008964 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c83dde691e771090
FDA-CBER-2021-5683-0023933
Chronic lymphocytic leukaemia stage 0 10008963 PT
Chronic lymphocytic leukaemia refractory 10008962 PT
Chronic lymphocytic leukaemia recurrent 10008961 PT
Chronic lymphocytic leukaemia (in remission) 10008959 PT
Chronic lymphocytic leukaemia 10008958 PT
T-cell type acute leukaemia 10042987 PT
T-cell prolymphocytic leukaemia 10042985 PT
T-cell chronic lymphocytic leukaemia 10042970 PT
Refractory cytopenia with unilineage dysplasia 10072684 PT
Refractory cytopenia with multilineage dysplasia 10067959 PT
Refractory anaemia with ringed sideroblasts 10038272 PT
Refractory anaemia with an excess of blasts 10038270 PT
Prolymphocytic leukaemia 10036888 PT
Plasma cell leukaemia in remission 10060406 PT
Plasma cell leukaemia 10035222 PT
Natural killer-cell leukaemia 10028811 PT
Myeloid leukaemia in remission 10061301 PT
Myeloid leukaemia 10028549 PT
Myelodysplastic syndrome unclassifiable 10028535 PT
Myelodysplastic syndrome transformation 10067387 PT
Myelodysplastic syndrome 10028533 PT
Monocytic leukaemia in remission 10061295 PT
Mature B-cell type acute leukaemia 10026945 PT
Mastocytic leukaemia 10056450 PT
Lymphoid leukaemia (in remission) 10025300 PT
Lymphocytic leukaemia 10025270 PT
Leukoerythroblastosis 10024383 PT
Leukaemic retinopathy 10059239 PT
Leukaemic infiltration renal 10069359 PT
Leukaemic infiltration pulmonary 10052368 PT
Acute myeloid leukaemia (in remission) 10000881 PT
Acute myeloid leukaemia 10000880 PT
Acute monocytic leukaemia (in remission) 10000872 PT
Acute monocytic leukaemia 10000871 PT
Acute megakaryocytic leukaemia (in remission) 10057194 PT
Acute megakaryocytic leukaemia 10000860 PT
Acute lymphocytic leukaemia refractory 10076866 PT
Acute lymphocytic leukaemia recurrent 10063620 PT
Acute lymphocytic leukaemia (in remission) 10000847 PT
Acute lymphocytic leukaemia 10000846 PT
Acute leukaemia in remission 10060930 PT
Acute leukaemia 10000830 PT
Acute biphenotypic leukaemia 10067399 PT
5q minus syndrome 10068532 PT
Chronic leukaemia in remission 10061042 PT
Chronic leukaemia 10008943 PT
Chronic eosinophilic leukaemia 10065854 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c83dde691e771090
FDA-CBER-2021-5683-0023934
Chloroma (in remission) 10008584 PT
Chloroma 10008583 PT
Central nervous system leukaemia 10066231 PT
Burkitt's leukaemia 10067184 PT
Bone marrow leukaemic cell infiltration 10049557 PT
Blast crisis in myelogenous leukaemia 10050282 PT
Blast cell crisis 10053747 PT
B-cell type acute leukaemia 10003917 PT
B precursor type acute leukaemia 10003890 PT
Aleukaemic leukaemia 10001660 PT
Acute undifferentiated leukaemia 10073479 PT
Acute promyelocytic leukaemia 10001019 PT
Acute myelomonocytic leukaemia 10000890 PT
Acute myeloid leukaemia recurrent 10059034 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c83dde691e771090
FDA-CBER-2021-5683-0023935",,3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdf,16.0,"CCI_Any malignancy
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Any malignancy
Code: 90002950
Extension: CCI
Report Date/Time: 27-Oct-2020:10:42:05 AM EDT
Term Code Level Category Weight Scope
Ovarian germ cell embryonal carcinoma stage I 10033196 PT
Ovarian germ cell choriocarcinoma stage IV 10033195 PT
Ovarian germ cell choriocarcinoma stage III 10033191 PT
Ovarian germ cell choriocarcinoma stage II 10033187 PT
Ovarian germ cell choriocarcinoma stage I 10033183 PT
Ovarian germ cell choriocarcinoma 10073262 PT
Ovarian germ cell cancer stage IV 10061897 PT
Ovarian germ cell cancer stage III 10061896 PT
Ovarian germ cell cancer stage II 10061895 PT
Ovarian germ cell cancer stage I 10061894 PT
Lip and/or oral cavity cancer 10061523 PT
Linitis plastica 10024520 PT
Light chain disease 10024459 PT
Leptomeningeal myelomatosis 10078282 PT
Leiomyosarcoma recurrent 10024194 PT
Leiomyosarcoma 10024189 PT
Laryngeal squamous cell carcinoma 10023856 PT
Laryngeal cancer stage IV 10023833 PT
Laryngeal cancer stage III 10023832 PT
Laryngeal cancer stage II 10023831 PT
Laryngeal cancer stage I 10023830 PT
Laryngeal cancer stage 0 10023829 PT
Laryngeal cancer recurrent 10023828 PT
Laryngeal cancer 10023825 PT
Large cell lung cancer stage IV 10023780 PT
Large cell lung cancer stage III 10023779 PT
Large cell lung cancer stage II 10023778 PT
Large cell lung cancer stage I 10023777 PT
Large cell lung cancer stage 0 10023776 PT
Large cell lung cancer recurrent 10023775 PT
Large cell lung cancer 10023774 PT
Langerhans' cell histiocytosis 10069698 PT
Keratinising squamous cell carcinoma of nasopharynx 10073324 PT
Kaposi's sarcoma classical type 10023288 PT
Kaposi's sarcoma 10023284 PT
Adenosquamous cell lung cancer stage 0 10001248 PT
Adenosquamous cell lung cancer recurrent 10001247 PT
Adenosquamous cell lung cancer 10001245 PT
Adenosquamous cell carcinoma 10068873 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023879
Adenosquamous carcinoma of vagina 10073978 PT
Adenosquamous carcinoma of the cervix 10001244 PT
Adenoid cystic carcinoma of salivary gland 10073370 PT
External ear neoplasm malignant 10082277 PT
Adenoid cystic carcinoma 10053231 PT
Adenocarcinoma pancreas 10052747 PT
Adenocarcinoma of the cervix 10001197 PT
Adenocarcinoma of salivary gland 10068068 PT
Adenocarcinoma of colon 10001167 PT
Adenocarcinoma of appendix 10073359 PT
Adenocarcinoma gastric 10001150 PT
Adenocarcinoma 10001141 PT
Acinic cell carcinoma of salivary gland 10073369 PT
Acinar cell carcinoma of pancreas 10073363 PT
Abdominal wall neoplasm malignant 10071023 PT
Yolk sac tumour site unspecified 10048251 PT
Vulvar adenocarcinoma 10063536 PT
Vulval cancer stage IV 10047749 PT
Vulval cancer stage III 10047748 PT
Vulval cancer stage II 10047747 PT
Vulval cancer stage I 10047746 PT
Vulval cancer stage 0 10047745 PT
Vulval cancer recurrent 10047744 PT
Vulval cancer 10047741 PT
Vaginal cancer stage IVB 10046895 PT
Vaginal cancer stage IVA 10046894 PT
Vaginal cancer stage III 10046893 PT
Vaginal cancer stage II 10046892 PT
Vaginal cancer stage I 10046891 PT
Vaginal cancer stage 0 10046890 PT
Vaginal cancer recurrent 10046889 PT
Vaginal cancer 10046885 PT
Vaginal adenocarcinoma 10065349 PT
Uterine carcinoma in situ 10046770 PT
Uterine cancer 10046766 PT
Urinary tract carcinoma in situ 10061396 PT
Urinary bladder sarcoma 10051690 PT
Urethral cancer recurrent 10046435 PT
Urethral cancer 10046431 PT
Ureteric cancer regional 10046397 PT
Ureteric cancer recurrent 10046396 PT
Ureteric cancer local 10046393 PT
Ureteric cancer 10046392 PT
Undifferentiated sarcoma 10045515 PT
Undifferentiated nasopharyngeal carcinoma 10073328 PT
Undifferentiated carcinoma of colon 10073362 PT
Tumour of ampulla of Vater 10073851 PT
Tumour invasion 10064390 PT
Tumour budding 10076969 PT
Tubular breast carcinoma 10073104 PT
Triple negative breast cancer 10075566 PT
Transitional cell carcinoma urethra 10044426 PT
Transitional cell carcinoma recurrent 10077051 PT
Ovarian germ cell cancer 10061893 PT
Ovarian epithelial cancer stage IV 10033164 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023880
Ovarian epithelial cancer stage III 10033163 PT
Ovarian epithelial cancer stage II 10033162 PT
Ovarian epithelial cancer stage I 10033161 PT
Ovarian epithelial cancer recurrent 10033160 PT
Ovarian epithelial cancer 10061328 PT
Ovarian endometrioid carcinoma 10073269 PT
Ovarian embryonal carcinoma 10056266 PT
Ovarian dysgerminoma stage unspecified 10052759 PT
Ovarian dysgerminoma stage IV 10033156 PT
Ovarian dysgerminoma stage III 10033152 PT
Ovarian dysgerminoma stage II 10033148 PT
Ovarian dysgerminoma stage I 10033144 PT
Ovarian clear cell carcinoma 10073268 PT
Ovarian cancer stage IV 10070908 PT
Ovarian cancer stage III 10070907 PT
Ovarian cancer stage II 10070906 PT
Ovarian cancer stage I 10070905 PT
Ovarian cancer recurrent 10066697 PT
Ovarian cancer 10033128 PT
Osteosarcoma recurrent 10031296 PT
Osteosarcoma 10031291 PT
Oropharyngeal squamous cell carcinoma 10031112 PT
Oropharyngeal lymphoepithelioma 10031104 PT
Oropharyngeal cancer stage IV 10064099 PT
Oropharyngeal cancer stage III 10031102 PT
Oropharyngeal cancer stage II 10031101 PT
Oropharyngeal cancer stage I 10031100 PT
Oropharyngeal cancer stage 0 10031099 PT
Oropharyngeal cancer recurrent 10031098 PT
Oropharyngeal cancer 10031096 PT
Optic glioma 10073338 PT
Oligodendroglioma 10030286 PT
Oligoastrocytoma 10073131 PT
Hormone receptor positive breast cancer 10083234 PT
Oesophageal squamous cell carcinoma stage IV 10030192 PT
Oesophageal squamous cell carcinoma stage III 10030191 PT
Oesophageal squamous cell carcinoma stage II 10030190 PT
Oesophageal squamous cell carcinoma stage I 10030189 PT
Oesophageal squamous cell carcinoma stage 0 10030188 PT
Oesophageal squamous cell carcinoma recurrent 10030187 PT
Oesophageal squamous cell carcinoma 10061534 PT
Oesophageal carcinoma stage 0 10030162 PT
Oesophageal carcinoma recurrent 10030159 PT
Oesophageal carcinoma 10030155 PT
Oesophageal adenocarcinoma stage IV 10030145 PT
Oesophageal adenocarcinoma stage III 10030144 PT
Oesophageal adenocarcinoma stage II 10030143 PT
Oesophageal adenocarcinoma stage I 10030142 PT
Oesophageal adenocarcinoma stage 0 10030141 PT
Oesophageal adenocarcinoma recurrent 10030140 PT
Oesophageal adenocarcinoma 10030137 PT
Ocular haemangiopericytoma 10057416 PT
NUT midline carcinoma 10078295 PT
Non-small cell lung cancer stage IV 10029522 PT
Non-small cell lung cancer stage IIIB 10029521 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023881
Non-small cell lung cancer stage IIIA 10029520 PT
Non-small cell lung cancer stage III 10029519 PT
Non-small cell lung cancer stage II 10029518 PT
Non-small cell lung cancer stage I 10029517 PT
Non-small cell lung cancer stage 0 10029516 PT
Non-small cell lung cancer recurrent 10029515 PT
Non-small cell lung cancer 10061873 PT
Non-secretory adenoma of pituitary 10029556 PT
Non-renal cell carcinoma of kidney 10061872 PT
Nonkeratinising carcinoma of nasopharynx 10073325 PT
Nongerminomatous germ cell tumour of the CNS 10065871 PT
Neurofibrosarcoma recurrent 10029277 PT
Inflammatory carcinoma of breast recurrent 10021977 PT
Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma 10072796 PT
Hypopharyngeal cancer stage IV 10021049 PT
Hypopharyngeal cancer stage III 10021048 PT
Hypopharyngeal cancer stage II 10021047 PT
Hypopharyngeal cancer stage I 10021046 PT
Hypopharyngeal cancer stage 0 10021045 PT
Hypopharyngeal cancer recurrent 10021044 PT
Hypopharyngeal cancer 10021042 PT
Huerthle cell carcinoma 10066136 PT
Hormone-refractory prostate cancer 10062904 PT
Hormone-dependent prostate cancer 10071119 PT
Hormone refractory breast cancer 10076935 PT
Histiocytic sarcoma 10076876 PT
Histiocytic medullary reticulosis 10068785 PT
HER2 positive gastric cancer 10066896 PT
HER2 positive breast cancer 10065430 PT
Hepatocellular carcinoma 10073071 PT
Hepatoblastoma recurrent 10019823 PT
Hepatoblastoma 10062001 PT
Hepatobiliary cancer in situ 10073074 PT
Hepatobiliary cancer 10073073 PT
Hepatic cancer stage IV 10059325 PT
Hepatic cancer stage III 10059324 PT
Hepatic cancer stage II 10059319 PT
Hepatic cancer stage I 10059318 PT
Hepatic cancer recurrent 10073070 PT
Hepatic cancer 10073069 PT
Hepatic angiosarcoma 10067388 PT
Heavy chain disease 10019350 PT
Head and neck cancer stage IV 10071536 PT
Head and neck cancer stage III 10071537 PT
Head and neck cancer stage II 10071538 PT
Head and neck cancer stage I 10071539 PT
Head and neck cancer 10067821 PT
Haematological malignancy 10066476 PT
Haemangiopericytoma of meninges 10018826 PT
Haemangiopericytoma 10018825 PT
Glottis carcinoma 10018395 PT
Gliosarcoma 10018340 PT
Gliomatosis cerebri 10066254 PT
Glioma 10018338 PT
Glioblastoma multiforme 10018337 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023882
Transitional cell carcinoma 10044412 PT
Transitional cell cancer of the renal pelvis and ureter regional 10044411 PT
Transitional cell cancer of the renal pelvis and ureter recurrent 10044410 PT
Transitional cell cancer of the renal pelvis and ureter localised 10044408 PT
Transitional cell cancer of the renal pelvis and ureter 10044407 PT
Tracheal cancer 10044285 PT
Tonsil cancer 10044002 PT
Tongue neoplasm malignant stage unspecified 10043966 PT
Tongue carcinoma stage IV 10058433 PT
Tongue carcinoma stage III 10058432 PT
Tongue carcinoma stage II 10058431 PT
Tongue carcinoma stage I 10058430 PT
Tongue carcinoma stage 0 10058429 PT
Tongue cancer recurrent 10071251 PT
Thyroid cancer stage IV 10071030 PT
Thyroid cancer stage III 10071029 PT
Thyroid cancer stage II 10071028 PT
Thyroid cancer stage I 10071027 PT
Thyroid cancer stage 0 10070567 PT
Thyroid cancer recurrent 10072162 PT
Thyroid cancer 10066474 PT
Thymoma malignant recurrent 10043674 PT
Thymoma malignant 10061031 PT
Throat cancer 10043515 PT
Testis cancer recurrent 10069813 PT
Testis cancer 10057644 PT
Testicular yolk sac tumour stage III 10043359 PT
Testicular yolk sac tumour stage II 10043358 PT
Glioblastoma 10018336 PT
Gingival cancer 10067807 PT
Germ cell cancer 10061184 PT
Genitourinary melanoma 10077166 PT
Genital neoplasm malignant female 10018160 PT
Genital cancer male in situ 10073124 PT
Genital cancer male 10073116 PT
Gastrooesophageal cancer 10062878 PT
Gastrointestinal stromal tumour 10051066 PT
Gastrointestinal melanoma 10077167 PT
Gastrointestinal carcinoma in situ 10061168 PT
Gastrointestinal carcinoma 10017940 PT
Gastrinoma malignant 10051709 PT
Gastric sarcoma 10055008 PT
Colon cancer stage 0 10063523 PT
Colon cancer recurrent 10009952 PT
Colon cancer 10009944 PT
CNS germinoma 10065852 PT
Clear cell sarcoma of the kidney 10009253 PT
Clear cell sarcoma of soft tissue 10073140 PT
Clear cell renal cell carcinoma 10073251 PT
Clear cell endometrial carcinoma 10009252 PT
Testicular yolk sac tumour stage I 10043357 PT
Testicular yolk sac tumour 10073121 PT
Testicular seminoma (pure) stage III 10043352 PT
Testicular seminoma (pure) stage II 10043351 PT
Testicular seminoma (pure) stage I 10043350 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023883
Testicular seminoma (pure) 10062124 PT
Testicular malignant teratoma stage III 10043341 PT
Testicular malignant teratoma stage II 10043340 PT
Testicular malignant teratoma stage I 10043339 PT
Testicular malignant teratoma 10073120 PT
Extragonadal primary seminoma (pure) stage I 10015811 PT
Extragonadal primary seminoma (pure) 10073057 PT
Extragonadal primary non-seminoma stage IV 10015810 PT
Extragonadal primary non-seminoma stage III 10015809 PT
Extragonadal primary non-seminoma stage II 10015806 PT
Extragonadal primary non-seminoma stage I 10015805 PT
Extragonadal primary non-seminoma 10061849 PT
Testicular leiomyosarcoma 10057340 PT
Testicular germ cell tumour mixed stage III 10043333 PT
Testicular germ cell tumour mixed stage II 10043332 PT
Testicular germ cell tumour mixed stage I 10043331 PT
Testicular germ cell tumour mixed 10073119 PT
Testicular germ cell cancer 10061378 PT
Testicular embryonal carcinoma stage III 10043311 PT
Testicular embryonal carcinoma stage II 10043310 PT
Testicular embryonal carcinoma stage I 10043309 PT
Testicular embryonal carcinoma 10062123 PT
Testicular choriocarcinoma stage III 10043305 PT
Testicular choriocarcinoma stage II 10043304 PT
Testicular choriocarcinoma stage I 10043303 PT
Testicular choriocarcinoma recurrent 10069812 PT
Testicular choriocarcinoma 10062122 PT
Synovial sarcoma recurrent 10042867 PT
Synovial sarcoma 10042863 PT
Stewart-Treves syndrome 10059498 PT
Squamous endometrial carcinoma 10041883 PT
Squamous cell carcinoma of the vulva 10041875 PT
Squamous cell carcinoma of the vagina 10041866 PT
Squamous cell carcinoma of the tongue 10041865 PT
Squamous cell carcinoma of the oral cavity 10041857 PT
Squamous cell carcinoma of the hypopharynx 10041849 PT
Squamous cell carcinoma of the cervix 10041848 PT
Squamous cell carcinoma of pharynx 10066471 PT
Squamous cell carcinoma of lung 10041826 PT
Squamous cell carcinoma of head and neck 10060121 PT
Spindle cell sarcoma 10049067 PT
Spinal meningioma malignant 10041580 PT
Spermatocytic seminoma 10073118 PT
Somatostatinoma 10041329 PT
Solid pseudopapillary tumour of the pancreas 10069345 PT
Soft tissue sarcoma 10075333 PT
Small intestine leiomyosarcoma 10041127 PT
Small intestine carcinoma stage IV 10059372 PT
Small intestine carcinoma stage III 10059371 PT
Small intestine carcinoma stage II 10059370 PT
Small intestine carcinoma stage I 10059369 PT
Small intestine carcinoma stage 0 10059368 PT
Small intestine carcinoma recurrent 10041124 PT
Small intestine carcinoma 10054184 PT
Small intestine adenocarcinoma 10073373 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023884
Small cell lung cancer recurrent 10041070 PT
Small cell lung cancer limited stage 10041069 PT
Small cell lung cancer extensive stage 10041068 PT
Small cell lung cancer 10041067 PT
Small cell carcinoma of the cervix 10041057 PT
Small cell carcinoma 10041056 PT
Signet-ring cell carcinoma 10057266 PT
Serous cystadenocarcinoma ovary 10054913 PT
Cystadenocarcinoma pancreas 10065908 PT
Seminoma 10039956 PT
Secretory adenoma of pituitary 10039893 PT
Second primary malignancy 10039801 PT
Scrotal cancer 10039744 PT
Sarcomatosis 10039500 PT
Clear cell carcinoma of cervix 10074909 PT
Choroid plexus carcinoma 10067478 PT
Choroid melanoma 10008773 PT
Choriocarcinoma 10008757 PT
Chordoma 10008747 PT
Chondrosarcoma recurrent 10008738 PT
Chondrosarcoma 10008734 PT
Cholangiosarcoma 10077861 PT
Cholangiocarcinoma 10008593 PT
Cervix carcinoma stage IV 10008348 PT
Cervix carcinoma stage III 10008347 PT
Cervix carcinoma stage II 10008346 PT
Cervix carcinoma stage I 10008345 PT
Cervix carcinoma stage 0 10061809 PT
Cervix carcinoma recurrent 10008344 PT
Cervix carcinoma 10008342 PT
Central nervous system neuroblastoma 10073130 PT
Central nervous system melanoma 10077160 PT
Cardiac teratoma 10057456 PT
Cardiac neoplasm malignant 10061025 PT
Carcinoma in situ of trachea 10007401 PT
Carcinoma in situ of penis 10007384 PT
Carcinoma in situ of eye 10007368 PT
Carcinoma in situ 10061450 PT
Carcinoma ex-pleomorphic adenoma 10077435 PT
Cancer in remission 10065305 PT
Bronchioloalveolar carcinoma 10058354 PT
Bronchial carcinoma 10006417 PT
Breast sarcoma recurrent 10068584 PT
Breast sarcoma 10068582 PT
Renal cancer recurrent 10038390 PT
Renal cancer 10038389 PT
Refractory cancer 10070308 PT
Recurrent cancer 10038111 PT
Rectosigmoid cancer stage IV 10038099 PT
Rectosigmoid cancer stage III 10038098 PT
Rectosigmoid cancer stage II 10038097 PT
Rectosigmoid cancer stage I 10038096 PT
Neuroendocrine carcinoma of the bladder 10078341 PT
Neuroendocrine carcinoma 10057270 PT
Neuroblastoma recurrent 10066595 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023885
Neuroblastoma 10029260 PT
Nephroblastoma 10029145 PT
Neoplasm malignant 10028997 PT
Nasopharyngeal cancer stage IV 10028792 PT
Nasopharyngeal cancer stage III 10028791 PT
Nasopharyngeal cancer stage II 10028790 PT
Nasopharyngeal cancer stage I 10028789 PT
Nasopharyngeal cancer stage 0 10028788 PT
Nasopharyngeal cancer recurrent 10028787 PT
Nasopharyngeal cancer 10061306 PT
Nasal sinus cancer 10028767 PT
Nasal cavity cancer 10028729 PT
Myxoid liposarcoma 10073137 PT
Myxofibrosarcoma 10066948 PT
Myelofibrosis 10028537 PT
Myeloblastoma 10051141 PT
Musculoskeletal cancer 10077675 PT
Multiple endocrine neoplasia Type 2 10073149 PT
Mueller's mixed tumour 10066057 PT
Mucoepidermoid carcinoma of salivary gland 10073371 PT
Mucoepidermoid carcinoma 10057269 PT
Mucinous endometrial carcinoma 10028076 PT
Malignant respiratory tract neoplasm 10061270 PT
Malignant polyp 10078695 PT
Malignant pituitary tumour 10026672 PT
Malignant peritoneal neoplasm 10061269 PT
Malignant pericardial neoplasm 10054946 PT
Malignant palate neoplasm 10026663 PT
Malignant ovarian cyst 10026662 PT
Malignant oligodendroglioma 10026659 PT
Malignant nipple neoplasm male 10053128 PT
Malignant nipple neoplasm female 10053129 PT
Malignant nipple neoplasm 10062051 PT
Malignant nervous system neoplasm 10061268 PT
Malignant neoplasm progression 10051398 PT
Malignant neoplasm papilla of Vater 10077303 PT
Malignant neoplasm of uterine adnexa 10026616 PT
Malignant neoplasm of unknown primary site 10073059 PT
Malignant neoplasm of thymus 10026533 PT
Malignant neoplasm of thorax 10026532 PT
Malignant neoplasm of spinal cord 10026472 PT
Malignant neoplasm of spermatic cord 10026470 PT
Malignant neoplasm of seminal vesicle 10068124 PT
Malignant neoplasm of retina 10026432 PT
Malignant neoplasm of renal pelvis 10026426 PT
Malignant neoplasm of pleura 10026351 PT
Malignant neoplasm of placenta 10026350 PT
Malignant neoplasm of paraurethral glands 10026326 PT
Malignant neoplasm of orbit 10026183 PT
Malignant neoplasm of lacrimal gland 10026031 PT
Malignant neoplasm of lacrimal duct 10026030 PT
Malignant neoplasm of islets of Langerhans 10025997 PT
Malignant neoplasm of eyelid 10063693 PT
Malignant neoplasm of eye 10025910 PT
Malignant neoplasm of cornea 10025871 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023886
Malignant neoplasm of conjunctiva 10025861 PT
Malignant neoplasm of choroid 10025839 PT
Malignant neoplasm of ampulla of Vater 10025697 PT
Malignant muscle neoplasm 10062050 PT
Malignant middle ear neoplasm 10061267 PT
Malignant mesenteric neoplasm 10067369 PT
Malignant mesenchymoma recurrent 10025677 PT
Malignant mesenchymoma 10061526 PT
Malignant melanoma of sites other than skin 10025654 PT
Malignant melanoma of eyelid 10063706 PT
Malignant melanoma 10025650 PT
Malignant mediastinal neoplasm 10061241 PT
Malignant mast cell neoplasm 10025638 PT
Malignant joint neoplasm 10078145 PT
Malignant hydatidiform mole 10025598 PT
Malignant histiocytosis 10025581 PT
Malignant haemangiopericytoma recurrent 10025570 PT
Malignant haemangiopericytoma 10025566 PT
Malignant glioma 10065443 PT
Malignant giant cell fibrous histiocytoma 10073141 PT
Malignant genitourinary tract neoplasm 10074419 PT
Malignant fibrous histiocytoma recurrent 10025561 PT
Malignant fibrous histiocytoma of bone 10025557 PT
Malignant fibrous histiocytoma 10025552 PT
Malignant cranial nerve neoplasm 10061238 PT
Malignant connective tissue neoplasm 10074340 PT
Malignant anorectal neoplasm 10061237 PT
Lymphangiosarcoma 10025223 PT
Lung squamous cell carcinoma stage IV 10025125 PT
Lung squamous cell carcinoma stage III 10025124 PT
Lung squamous cell carcinoma stage II 10025123 PT
Lung squamous cell carcinoma stage I 10025122 PT
Lung squamous cell carcinoma stage 0 10025121 PT
Lung squamous cell carcinoma recurrent 10025120 PT
Lung neoplasm malignant 10058467 PT
Lung infiltration malignant 10062041 PT
Lung carcinoma cell type unspecified stage IV 10025070 PT
Lung carcinoma cell type unspecified stage III 10025069 PT
Lung carcinoma cell type unspecified stage II 10025068 PT
Lung carcinoma cell type unspecified stage I 10025067 PT
Lung carcinoma cell type unspecified stage 0 10025066 PT
Lung carcinoma cell type unspecified recurrent 10025065 PT
Lung adenocarcinoma stage IV 10025038 PT
Lung adenocarcinoma stage III 10025037 PT
Lung adenocarcinoma stage II 10025036 PT
Lung adenocarcinoma stage I 10025035 PT
Lung adenocarcinoma stage 0 10025034 PT
Lung adenocarcinoma recurrent 10025033 PT
Lung adenocarcinoma 10025031 PT
Lobular breast carcinoma in situ 10073099 PT
Liver carcinoma ruptured 10050842 PT
Liposarcoma recurrent 10024632 PT
Liposarcoma 10024627 PT
Lip squamous cell carcinoma 10064055 PT
Mucinous cystadenocarcinoma ovary 10054914 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023887
Mucinous breast carcinoma 10073101 PT
Mucinous adenocarcinoma of appendix 10073361 PT
Mixed-type liposarcoma 10073136 PT
Mixed hepatocellular cholangiocarcinoma 10027761 PT
Mixed adenoneuroendocrine carcinoma 10076748 PT
Metaplastic breast carcinoma 10073100 PT
Extragonadal primary malignant teratoma 10061848 PT
Extragonadal primary embryonal carcinoma 10015789 PT
Ewing's sarcoma recurrent 10015564 PT
Ewing's sarcoma 10015560 PT
Erythroplasia of vulva 10052825 PT
Lip neoplasm malignant stage unspecified 10024557 PT
Lip and/or oral cavity cancer stage IV 10024540 PT
Lip and/or oral cavity cancer stage III 10024539 PT
Lip and/or oral cavity cancer stage II 10024538 PT
Lip and/or oral cavity cancer stage I 10024537 PT
Lip and/or oral cavity cancer stage 0 10024536 PT
Lip and/or oral cavity cancer recurrent 10024535 PT
Gastric cancer stage IV 10061967 PT
Gastric cancer stage III 10017765 PT
Gastric cancer stage II 10017764 PT
Gastric cancer stage I 10017763 PT
Gastric cancer stage 0 10017762 PT
Gastric cancer recurrent 10017761 PT
Gastric cancer 10017758 PT
Ganglioneuroblastoma 10017708 PT
Ganglioglioma 10017701 PT
Gallbladder squamous cell carcinoma 10073068 PT
Gallbladder cancer stage IV 10058283 PT
Gallbladder cancer stage III 10058282 PT
Gallbladder cancer stage II 10058281 PT
Gallbladder cancer stage I 10059317 PT
Gallbladder cancer stage 0 10059316 PT
Gallbladder cancer recurrent 10017619 PT
Gallbladder cancer 10017614 PT
Gallbladder adenosquamous carcinoma 10073067 PT
Gallbladder adenocarcinoma 10058286 PT
Follicular thyroid cancer 10016935 PT
Follicular dendritic cell sarcoma 10075332 PT
Fibrosarcoma 10016632 PT
Female reproductive tract carcinoma in situ 10061154 PT
Fallopian tube cancer stage IV 10016187 PT
Fallopian tube cancer stage III 10016186 PT
Fallopian tube cancer stage II 10016185 PT
Fallopian tube cancer stage I 10016184 PT
Fallopian tube cancer 10016180 PT
Extraskeletal osteosarcoma recurrent 10015852 PT
Extraskeletal osteosarcoma 10015847 PT
Extraskeletal myxoid chondrosarcoma 10073134 PT
Extraskeletal chondrosarcoma recurrent 10015843 PT
Extra-osseous Ewing's sarcoma recurrent 10015764 PT
Extra-osseous Ewing's sarcoma 10015759 PT
Extraocular retinoblastoma 10015831 PT
Extragonadal primary seminoma (pure) stage IV 10015816 PT
Extragonadal primary seminoma (pure) stage III 10015815 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023888
Extragonadal primary seminoma (pure) stage II 10015812 PT
Erythroplasia of lip 10052826 PT
Erythroblastosis 10049466 PT
Epithelioid sarcoma recurrent 10015104 PT
Epithelioid sarcoma 10015099 PT
Epithelioid mesothelioma 10073064 PT
Epiglottic cancer 10084056 PT
Epididymal cancer 10073115 PT
Ependymoma malignant 10014968 PT
Ependymoma 10014967 PT
Endotheliomatosis 10076868 PT
Endometrial stromal sarcoma 10048397 PT
Endometrial sarcoma recurrent 10067064 PT
Endometrial sarcoma 10057649 PT
Endometrial cancer stage IV 10014741 PT
Endometrial cancer stage III 10014740 PT
Endometrial cancer stage II 10014739 PT
Endometrial cancer stage I 10014738 PT
Endometrial cancer stage 0 10014737 PT
Endometrial cancer recurrent 10014736 PT
Endometrial cancer 10014733 PT
Endometrial adenocarcinoma 10014720 PT
Endocrine neoplasm malignant 10061122 PT
Embryonal rhabdomyosarcoma 10065868 PT
Ear neoplasm malignant 10055017 PT
Ductal adenocarcinoma of pancreas 10073364 PT
Desmoplastic small round cell tumour 10064581 PT
Desmoplastic mesothelioma 10073063 PT
Dermatofibrosarcoma protuberans 10057070 PT
Dedifferentiated liposarcoma 10073135 PT
Cystadenocarcinoma ovary 10054912 PT
Craniopharyngioma 10011318 PT
Conjunctival primary acquired melanosis 10066925 PT
Conjunctival melanoma 10066384 PT
Colorectal carcinoma stage 0 10010038 PT
Colorectal cancer stage IV 10010035 PT
Colorectal cancer stage III 10010034 PT
Colorectal cancer stage II 10010033 PT
Colorectal cancer stage I 10010032 PT
Colorectal cancer recurrent 10010030 PT
Colorectal cancer 10061451 PT
Colorectal adenocarcinoma 10052360 PT
Colon cancer stage IV 10009956 PT
Colon cancer stage III 10009955 PT
Colon cancer stage II 10009954 PT
Colon cancer stage I 10009953 PT
Mesothelioma malignant recurrent 10027411 PT
Mesothelioma malignant 10027407 PT
Meningioma malignant 10027193 PT
Medulloblastoma recurrent 10066594 PT
Medulloblastoma 10027107 PT
Medullary thyroid cancer 10027105 PT
Medullary carcinoma of breast 10027095 PT
Malignant urinary tract neoplasm 10061272 PT
Malignant transformation 10064912 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023889
Malignant splenic neoplasm 10026702 PT
Iris melanoma 10073086 PT
Invasive papillary breast carcinoma 10073098 PT
Invasive lobular breast carcinoma 10073096 PT
Invasive ductal breast carcinoma 10073095 PT
Invasive breast carcinoma 10075713 PT
Intraosseous angioma 10048846 PT
Intraocular melanoma 10061252 PT
Intraductal proliferative breast lesion 10073094 PT
Intraductal papillary-mucinous carcinoma of pancreas 10073365 PT
Intracranial meningioma malignant 10022770 PT
Intracranial germ cell tumour 10073751 PT
Intestinal adenocarcinoma 10051925 PT
Inflammatory malignant fibrous histiocytoma 10073142 PT
Breast cancer stage IV 10006202 PT
Breast cancer stage III 10006201 PT
Breast cancer stage II 10006200 PT
Breast cancer stage I 10006199 PT
Breast cancer recurrent 10006198 PT
Breast cancer male 10061020 PT
Breast cancer in situ 10006189 PT
Sarcomatoid mesothelioma 10073065 PT
Sarcoma uterus 10039497 PT
Sarcoma of skin 10039495 PT
Sarcoma 10039491 PT
Salivary gland cancer stage IV 10039403 PT
Salivary gland cancer stage III 10039402 PT
Salivary gland cancer stage II 10039401 PT
Salivary gland cancer stage I 10039400 PT
Salivary gland cancer stage 0 10039399 PT
Salivary gland cancer recurrent 10039398 PT
Salivary gland cancer 10061934 PT
Round cell liposarcoma 10073139 PT
Rhabdomyosarcoma recurrent 10039027 PT
Rhabdomyosarcoma 10039022 PT
Rhabdoid tumour of the kidney 10039019 PT
Rhabdoid tumour 10073334 PT
Retroperitoneal cancer 10038977 PT
Retinoblastoma 10038916 PT
Retinal melanoma 10038878 PT
Respiratory tract carcinoma in situ 10038724 PT
Renal cell carcinoma stage IV 10038414 PT
Renal cell carcinoma stage III 10038413 PT
Renal cell carcinoma stage II 10038412 PT
Renal cell carcinoma stage I 10038411 PT
Renal cell carcinoma recurrent 10038410 PT
Renal cell carcinoma 10067946 PT
Renal cancer stage IV 10038394 PT
Renal cancer stage III 10038393 PT
Renal cancer stage II 10038392 PT
Renal cancer stage I 10038391 PT
Inflammatory carcinoma of the breast 10021980 PT
Inflammatory carcinoma of breast stage IV 10021979 PT
Inflammatory carcinoma of breast stage III 10021978 PT
Rectosigmoid cancer stage 0 10038095 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023890
Rectosigmoid cancer recurrent 10038094 PT
Rectosigmoid cancer 10038086 PT
Rectal cancer stage IV 10038051 PT
Rectal cancer stage III 10038050 PT
Rectal cancer stage II 10038049 PT
Rectal cancer stage I 10038048 PT
Rectal cancer stage 0 10038047 PT
Rectal cancer recurrent 10038046 PT
Rectal cancer 10038038 PT
Rectal adenocarcinoma 10038019 PT
Prostate cancer stage IV 10036920 PT
Prostate cancer stage III 10036919 PT
Prostate cancer stage II 10036918 PT
Prostate cancer stage I 10036917 PT
Prostate cancer stage 0 10036912 PT
Prostate cancer recurrent 10036911 PT
Prostate cancer 10060862 PT
Primitive neuroectodermal tumour 10057846 PT
Penis carcinoma stage I 10034332 PT
Penis carcinoma recurrent 10034331 PT
Penile squamous cell carcinoma 10059631 PT
Penile cancer 10034299 PT
Parathyroid tumour malignant 10033965 PT
Paranasal sinus and nasal cavity malignant neoplasm stage IV 10033860 PT
Paranasal sinus and nasal cavity malignant neoplasm stage III 10033859 PT
Paranasal sinus and nasal cavity malignant neoplasm stage II 10033858 PT
Paranasal sinus and nasal cavity malignant neoplasm stage I 10033857 PT
Paranasal sinus and nasal cavity malignant neoplasm stage 0 10033856 PT
Paranasal sinus and nasal cavity malignant neoplasm recurrent 10033855 PT
Paranasal sinus and nasal cavity malignant neoplasm 10061909 PT
Paraganglion neoplasm malignant 10033791 PT
Papillary thyroid cancer 10033701 PT
Papillary serous endometrial carcinoma 10033700 PT
Papillary renal cell carcinoma 10078493 PT
Pancreatoblastoma 10073367 PT
Pancreatic sarcoma 10055006 PT
Pancreatic carcinoma stage IV 10059326 PT
Pancreatic carcinoma stage III 10059323 PT
Pancreatic carcinoma stage II 10059322 PT
Pancreatic carcinoma stage I 10059321 PT
Pancreatic carcinoma stage 0 10059320 PT
Pancreatic carcinoma recurrent 10033613 PT
Pancreatic carcinoma 10033609 PT
Pancoast's tumour 10033572 PT
Paget's disease of the vulva 10033369 PT
Paget's disease of penis 10033365 PT
Paget's disease of nipple 10033364 PT
Ovarian stromal cancer 10065858 PT
Ovarian low malignant potential tumour 10033268 PT
Ovarian germ cell tumour mixed 10073259 PT
Ovarian germ cell teratoma stage IV 10033249 PT
Ovarian germ cell teratoma stage III 10033245 PT
Ovarian germ cell teratoma stage II 10033241 PT
Ovarian germ cell teratoma stage I 10033237 PT
Ovarian germ cell teratoma 10073265 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023891
Ovarian germ cell polyembryoma stage IV 10033235 PT
Ovarian germ cell polyembryoma stage III 10033231 PT
Ovarian germ cell polyembryoma stage II 10033227 PT
Ovarian germ cell polyembryoma stage I 10033223 PT
Ovarian germ cell polyembryoma 10073264 PT
Ovarian germ cell endodermal sinus tumour stage IV 10033221 PT
Ovarian germ cell endodermal sinus tumour stage III 10033220 PT
Ovarian germ cell endodermal sinus tumour stage II 10033219 PT
Ovarian germ cell endodermal sinus tumour stage I 10033218 PT
Ovarian germ cell endodermal sinus tumour 10073263 PT
Ovarian germ cell embryonal carcinoma stage IV 10033208 PT
Ovarian germ cell embryonal carcinoma stage III 10033204 PT
Ovarian germ cell embryonal carcinoma stage II 10033200 PT
Breast cancer female 10057654 PT
Breast cancer 10006187 PT
Breast angiosarcoma 10072813 PT
Brain teratoma 10068394 PT
Brain stem glioma 10006143 PT
Brain sarcoma 10073857 PT
Brain neoplasm malignant 10006131 PT
Borderline serous tumour of ovary 10073267 PT
Borderline ovarian tumour 10006032 PT
Borderline mucinous tumour of ovary 10073266 PT
Bone sarcoma 10006007 PT
Bone marrow tumour cell infiltration 10049556 PT
Bone giant cell tumour malignant 10073106 PT
Bone cancer 10005949 PT
Bladder transitional cell carcinoma stage IV 10066752 PT
Bladder transitional cell carcinoma stage III 10066754 PT
Bladder transitional cell carcinoma stage II 10066753 PT
Bladder transitional cell carcinoma stage I 10066751 PT
Bladder transitional cell carcinoma stage 0 10066749 PT
Bladder transitional cell carcinoma recurrent 10066750 PT
Bladder transitional cell carcinoma 10005084 PT
Bladder squamous cell carcinoma stage unspecified 10005081 PT
Bladder squamous cell carcinoma stage IV 10005080 PT
Bladder squamous cell carcinoma stage III 10005079 PT
Bladder squamous cell carcinoma stage II 10005078 PT
Bladder squamous cell carcinoma stage I 10005077 PT
Bladder squamous cell carcinoma stage 0 10005076 PT
Bladder squamous cell carcinoma recurrent 10005075 PT
Bladder cancer stage IV 10005012 PT
Bladder cancer stage III 10005011 PT
Bladder cancer stage II 10005010 PT
Bladder cancer stage I, without cancer in situ 10005009 PT
Bladder cancer stage I, with cancer in situ 10005008 PT
Bladder cancer stage 0, without cancer in situ 10005007 PT
Bladder cancer stage 0, with cancer in situ 10005006 PT
Bladder cancer recurrent 10005005 PT
Bladder cancer 10005003 PT
Bladder adenocarcinoma stage unspecified 10004992 PT
Bladder adenocarcinoma stage IV 10004991 PT
Bladder adenocarcinoma stage III 10004990 PT
Bladder adenocarcinoma stage II 10004989 PT
Bladder adenocarcinoma stage I 10004988 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023892
Bladder adenocarcinoma stage 0 10004987 PT
Bladder adenocarcinoma recurrent 10004986 PT
Biphasic mesothelioma 10073062 PT
Bile duct squamous cell carcinoma 10004633 PT
Bile duct cancer stage IV 10059376 PT
Bile duct cancer stage III 10059375 PT
Bile duct cancer stage II 10059374 PT
Bile duct cancer stage I 10059373 PT
Postcricoid cancer 10036334 PT
Poorly differentiated thyroid carcinoma 10076603 PT
Polycythaemia vera 10036057 PT
Pleural sarcoma 10051950 PT
Pleural mesothelioma malignant recurrent 10035607 PT
Pleural mesothelioma malignant 10059518 PT
Pleural mesothelioma 10035603 PT
Pleomorphic malignant fibrous histiocytoma 10073143 PT
Pleomorphic liposarcoma 10073138 PT
Plasmacytoma 10035484 PT
Plasma cell myeloma recurrent 10073133 PT
Plasma cell myeloma in remission 10073132 PT
Plasma cell myeloma 10035226 PT
Pituitary neoplasm malignant recurrent 10057838 PT
Pinealoblastoma 10050487 PT
Pineal parenchymal neoplasm malignant 10061537 PT
Pineal germinoma 10035052 PT
Pharyngeal cancer stage IV 10034818 PT
Pharyngeal cancer stage III 10034817 PT
Pharyngeal cancer stage II 10034816 PT
Pharyngeal cancer stage I 10034815 PT
Pharyngeal cancer stage 0 10034814 PT
Pharyngeal cancer recurrent 10034813 PT
Pharyngeal cancer 10034811 PT
Phaeochromocytoma malignant 10051710 PT
Phaeochromocytoma crisis 10068778 PT
Phaeochromocytoma 10034800 PT
Peritoneal sarcoma 10051949 PT
Peritoneal mesothelioma malignant recurrent 10034671 PT
Peritoneal mesothelioma malignant 10056558 PT
Peritoneal gliomatosis 10070561 PT
Peripheral primitive neuroectodermal tumour of soft tissue 10073144 PT
Peripheral primitive neuroectodermal bone tumour 10073107 PT
Peripheral neuroepithelioma of soft tissue 10057646 PT
Peripheral neuroepithelioma of bone recurrent 10034605 PT
Peripheral neuroepithelioma of bone 10061342 PT
Neurofibrosarcoma 10061527 PT
Pericardial mesothelioma malignant recurrent 10034480 PT
Pericardial mesothelioma malignant 10073066 PT
Penis carcinoma stage IV 10034335 PT
Penis carcinoma stage III 10034334 PT
Penis carcinoma stage II 10034333 PT
Bile duct cancer stage 0 10059384 PT
Bile duct cancer recurrent 10004596 PT
Bile duct cancer 10004593 PT
Bile duct adenosquamous carcinoma 10004589 PT
Bile duct adenocarcinoma 10004585 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023893
Basosquamous carcinoma 10004178 PT
Atypical teratoid/rhabdoid tumour of CNS 10065907 PT
Astrocytoma malignant 10060971 PT
Astrocytoma 10003571 PT
APUDoma 10003069 PT
Appendix cancer 10073360 PT
Apocrine breast carcinoma 10066206 PT
Angiosarcoma recurrent 10002480 PT
Angiosarcoma non-metastatic 10057700 PT
Angiosarcoma 10002476 PT
Angiocentric glioma 10073129 PT
Anaplastic thyroid cancer 10002240 PT
Anaplastic oligodendroglioma 10073128 PT
Anaplastic meningioma 10073127 PT
Anaplastic astrocytoma 10002224 PT
Anal squamous cell carcinoma 10073358 PT
Anal cancer stage IV 10002138 PT
Anal cancer stage III 10002137 PT
Anal cancer stage II 10002136 PT
Anal cancer stage I 10002135 PT
Anal cancer stage 0 10002134 PT
Anal cancer recurrent 10002133 PT
Anal cancer 10061424 PT
Alveolar soft part sarcoma recurrent 10001887 PT
Alveolar soft part sarcoma 10001882 PT
Alveolar rhabdomyosarcoma 10065867 PT
Aesthesioneuroblastoma 10001433 PT
Adrenocortical carcinoma 10001388 PT
Adrenal gland cancer 10073152 PT
Adenosquamous cell lung cancer stage IV 10001254 PT
Adenosquamous cell lung cancer stage III 10001251 PT
Adenosquamous cell lung cancer stage II 10001250 PT
Adenosquamous cell lung cancer stage I 10001249 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\d12dde691e771090
FDA-CBER-2021-5683-0023894",,16
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdf,13.0,"16.2.3.1.1 Listing of Subjects Excluded From All-Available and Evaluable Immunogenicity Populations –
Phase 1, 2 Doses, 21 Days Apart
Vaccine Age Group Vaccine Group
Candidate (Years) (as Randomized) Subject Population Reason for Exclusion
BNT162b1 65-85 10 μg C4591001 1002 10021053 Dose 1 evaluable Had major protocol deviation(s) as determined by the clinician.
Dose 2 evaluable Had major protocol deviation(s) as determined by the clinician.
BNT162b2 18-55 10 μg C4591001 1003 10031021 Dose 1 evaluable Had major protocol deviation(s) as determined by the clinician.
Dose 2 evaluable Had major protocol deviation(s) as determined by the clinician.
30 μg C4591001 1007 10071050 Dose 2 evaluable Did not have blood collection within 6-8 days after Dose 2.
Placebo 18-55 Placebo C4591001 1003 10031017 Dose 1 evaluable Had major protocol deviation(s) as determined by the clinician.
Dose 2 evaluable Had major protocol deviation(s) as determined by the clinician.
C4591001 1003 10031070 Dose 1 evaluable Had major protocol deviation(s) as determined by the clinician.
Dose 2 evaluable Had major protocol deviation(s) as determined by the clinician.
BNT162b2 65-85 20 μg C4591001 1003 10031055 Dose 2 evaluable Did not have blood collection within 6-8 days after Dose 2.
30 μg C4591001 1003 10031047 Dose 1 evaluable Had major protocol deviation(s) as determined by the clinician.
Dose 2 evaluable Had major protocol deviation(s) as determined by the clinician.
PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 17SEP2020 (23:36)
(Cutoff Date: 24AUG2020, Snapshot Date: 17SEP2020) Output File: ./nda3/C4591001 IA P1 Serology/adsl l001 excl eval p1
)TMG(
35:10
0202-peS-91
:nO
laniF\laniF\54606f491e771090
FDA-CBER-2021-5683-0019382
Page 1
16.2.3.1.1.1 Listing of Subjects Excluded From All-Available and Evaluable Immunogenicity Populations – Phase 1 –
BNT162b1 (100 μg)
Vaccine Age Group Vaccine Group
Candidate (Years) (as Randomized) Subject Population Reason for Exclusion
No subject meets the reporting criteria.
PFIZER CONFIDENTIAL SDTM Creation: 17SEP2020 (22:01) Source Data: adsl Table Generation: 22SEP2020 (00:02)
(Cutoff Date: 24AUG2020, Snapshot Date: 17SEP2020) Output File: ./nda3/C4591001_IA_P1_100/adsl_l001_excl_eval_100_p1
)TMG(
04:10
0202-peS-42
:nO
laniF\laniF\8a5cff491e771090
FDA-CBER-2021-5683-0019383
Page 2
16.2.3.1.2 Listing of Subjects Excluded From All-Available and Evaluable Immunogenicity Populations – Phase 2
Age
Group
(Years) Subject Population Reason for Exclusion
18-55 C4591001 1003 10031101 Dose 2 Evaluable Had important protocol deviation(s) as determined by the clinician.
C4591001 1003 10031104 Dose 2 All-available Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
Dose 2 Evaluable Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
C4591001 1007 10071095 Dose 2 Evaluable Did not receive Dose 2 within 19-42 days after Dose 1.
C4591001 1013 10131019 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
C4591001 1013 10131025 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
C4591001 1079 10791004 Dose 2 All-available Did not receive Dose 2.
Dose 2 Evaluable Did not receive 2 doses of the vaccine to which they are randomly assigned.
C4591001 1082 10821004 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
C4591001 1085 10851003 Dose 2 All-available Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
Dose 2 Evaluable Did not have at least 1 valid and determinate immunogenicity result after
Dose 2; did not have blood collection within 28-42 days after Dose 2.
C4591001 1109 11091006 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
C4591001 1109 11091018 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
C4591001 1109 11091024 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
C4591001 1109 11091030 Dose 2 All-available Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
Dose 2 Evaluable Did not have at least 1 valid and determinate immunogenicity result after
Dose 2; did not have blood collection within 28-42 days after Dose 2.
C4591001 1120 11201001 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
C4591001 1129 11291005 Dose 2 All-available Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
Dose 2 Evaluable Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
)TMG(
04:50
0202-voN-71
:nO
laniF\laniF\72c0a8591e771090
FDA-CBER-2021-5683-0019384
Page 3
16.2.3.1.2 Listing of Subjects Excluded From All-Available and Evaluable Immunogenicity Populations – Phase 2
Age
Group
(Years) Subject Population Reason for Exclusion
C4591001 1129 11291014 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
56-85 C4591001 1001 10011096 Dose 2 All-available Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
Dose 2 Evaluable Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
C4591001 1082 10821001 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
C4591001 1084 10841006 Dose 2 Evaluable Did not receive Dose 2 within 19-42 days after Dose 1.
C4591001 1089 10891004 Dose 2 Evaluable Did not receive Dose 2 within 19-42 days after Dose 1.
C4591001 1109 11091032 Dose 2 Evaluable Did not have blood collection within 28-42 days after Dose 2.
C4591001 1127 11271002 Dose 2 Evaluable Did not receive Dose 2 within 19-42 days after Dose 1.
C4591001 1127 11271003 Dose 2 Evaluable Did not receive Dose 2 within 19-42 days after Dose 1.
C4591001 1140 11401002 Dose 2 All-available Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
Dose 2 Evaluable Did not have at least 1 valid and determinate immunogenicity result after
Dose 2; did not have blood collection within 28-42 days after Dose 2.
C4591001 1140 11401003 Dose 2 All-available Did not have at least 1 valid and determinate immunogenicity result after
Dose 2.
Dose 2 Evaluable Did not have at least 1 valid and determinate immunogenicity result after
Dose 2; did not have blood collection within 28-42 days after Dose 2.
PFIZER CONFIDENTIAL SDTM Creation: 02NOV2020 (19:23) Source Data: adsl Table Generation: 12NOV2020 (02:22)
(Cutoff Date: 12OCT2020, Snapshot Date: 02NOV2020) Output File: ./nda2_unblinded/C4591001_IA_P2_Serology/adsl_l001_excl_p2_eval
)TMG(
04:50
0202-voN-71
:nO
laniF\laniF\72c0a8591e771090
FDA-CBER-2021-5683-0019385
Page 4
16.2.3.2.1 Listing of Subjects Excluded From Safety Population – Phase 1, 2 Doses, 21 Days Apart
Vaccine Age Group Vaccine Group
Candidate (Years) (as Randomized) Subject Reason for Exclusion
No subject meets the reporting criteria.
PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 31AUG2020 (10:58)
(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: (CDISC)/C4591001 IA P1/adsl l001 excl saf p1
)TMG(
25:30
0202-peS-70
:nO
laniF\laniF\05587d491e771090
FDA-CBER-2021-5683-0019386
Page 5
16.2.3.2.1.1 Listing of Subjects Excluded From Safety Population – Phase 1 – BNT162b1 (100 μg)
Vaccine Age Group Vaccine Group
Candidate (Years) (as Randomized) Subject Reason for Exclusion
No subject meets the reporting criteria.
PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 18SEP2020 (13:43)
(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: ./nda3/C4591001 IA P1 100/adsl l001 excl saf 100 p1
)TMG(
42:41
0202-peS-22
:nO
laniF\laniF\605cbf491e771090
FDA-CBER-2021-5683-0019387
Page 6
16.2.3.2.2 Listing of Subjects Excluded From Safety Population – Phase 2
Age Group
(Years) Subject Reason for Exclusion
No subject meets the reporting criteria.
PFIZER CONFIDENTIAL SDTM Creation: 05SEP2020 (14:18) Source Data: adsl Table Generation: 09SEP2020 (23:18)
(Cutoff Date: 02SEP2020, Snapshot Date: 04SEP2020) Output File: ./nda2_unblinded/C4591001_IA_P2/adsl_l001_excl_p2_saf )TMG(
54:10
0202-peS-41
:nO
laniF\laniF\ba3a7e491e771090
FDA-CBER-2021-5683-0019388
Page 7
16.2.3.2.4 Listing of Subjects Excluded From Safety Population – All Subjects
Age Group
(Years) Subject Reason for Exclusion
16-55 C4591001 1003 10031140 Subject did not receive study vaccine.
C4591001 1003 10031143 Subject did not receive study vaccine.
C4591001 1005 10051381 Subject did not receive study vaccine.
C4591001 1013 10131017 Subject did not receive study vaccine.
C4591001 1013 10131740 Subject did not receive study vaccine.
C4591001 1036 10361050 Subject did not receive study vaccine.
C4591001 1057 10571031 Subject did not receive study vaccine.
C4591001 1057 10571211 Subject did not receive study vaccine.
C4591001 1057 10571212 Subject did not receive study vaccine.
C4591001 1057 10571215 Subject did not receive study vaccine.
C4591001 1057 10571268 Subject did not receive study vaccine.
C4591001 1066 10661335 Subject did not receive study vaccine.
C4591001 1071 10711162 Subject did not receive study vaccine.
C4591001 1081 10811105 Subject did not receive study vaccine.
C4591001 1082 10821013 Subject did not receive study vaccine.
C4591001 1089 10891346 Subject did not receive study vaccine.
C4591001 1089 10891351 Subject did not receive study vaccine.
C4591001 1092 10921128 Subject did not receive study vaccine.
C4591001 1093 10931055 Subject did not receive study vaccine.
C4591001 1109 11091349 Subject did not receive study vaccine.
C4591001 1112 11121229 Subject did not receive study vaccine.
C4591001 1116 11161015 Subject did not receive study vaccine.
C4591001 1120 11201038 Subject did not receive study vaccine.
C4591001 1120 11201252 Subject did not receive study vaccine.
C4591001 1120 11201299 Did not provide informed consent.
C4591001 1122 11221006 Subject did not receive study vaccine.
)TMG(
84:31
0202-voN-42
:nO
laniF\laniF\8512b9591e771090
FDA-CBER-2021-5683-0019389
Page 8
16.2.3.2.4 Listing of Subjects Excluded From Safety Population – All Subjects
Age Group
(Years) Subject Reason for Exclusion
C4591001 1122 11221026 Subject did not receive study vaccine.
C4591001 1123 11231027 Subject did not receive study vaccine.
C4591001 1123 11231301 Subject did not receive study vaccine.
C4591001 1126 11261074 Subject did not receive study vaccine.
C4591001 1129 11291048 Subject did not receive study vaccine.
C4591001 1133 11331162 Subject did not receive study vaccine.
C4591001 1135 11351389 Subject did not receive study vaccine.
C4591001 1162 11621024 Subject did not receive study vaccine.
C4591001 1162 11621477 Subject did not receive study vaccine.
C4591001 1167 11671003 Subject did not receive study vaccine.
C4591001 1168 11681030 Subject did not receive study vaccine.
C4591001 1205 12051028 Subject did not receive study vaccine.
C4591001 1212 12121023 Subject did not receive study vaccine.
C4591001 1223 12231200 Subject did not receive study vaccine.
C4591001 1223 12231234 Subject did not receive study vaccine.
C4591001 1231 12311409 Subject did not receive study vaccine.
C4591001 1231 12311516 Subject did not receive study vaccine.
C4591001 1231 12311926 Subject did not receive study vaccine.
C4591001 1231 12312176 Subject did not receive study vaccine.
C4591001 1231 12312483 Subject did not receive study vaccine.
C4591001 1231 12313443 Subject did not receive study vaccine.
C4591001 1231 12313527 Subject did not receive study vaccine.
C4591001 1231 12313869 Subject did not receive study vaccine.
C4591001 1231 12314738 Subject did not receive study vaccine.
C4591001 1231 12315308 Subject did not receive study vaccine.
C4591001 1232 12321037 Subject did not receive study vaccine.
)TMG(
84:31
0202-voN-42
:nO
laniF\laniF\8512b9591e771090
FDA-CBER-2021-5683-0019390
Page 9
16.2.3.2.4 Listing of Subjects Excluded From Safety Population – All Subjects
Age Group
(Years) Subject Reason for Exclusion
C4591001 1235 12351167 Subject did not receive study vaccine.
C4591001 1248 12481018 Subject did not receive study vaccine.
C4591001 1248 12481025 Subject did not receive study vaccine.
C4591001 1248 12481060 Subject did not receive study vaccine.
C4591001 1248 12481218 Subject did not receive study vaccine.
C4591001 1260 12601049 Subject did not receive study vaccine.
C4591001 1260 12601070 Subject did not receive study vaccine.
C4591001 1264 12641018 Subject did not receive study vaccine.
C4591001 4444 44441135 Subject did not receive study vaccine.
>55 C4591001 1013 10131097 Subject did not receive study vaccine.
C4591001 1019 10191033 Subject did not receive study vaccine.
C4591001 1019 10191300 Subject did not receive study vaccine.
C4591001 1022 10221015 Subject did not receive study vaccine.
C4591001 1022 10221057 Subject did not receive study vaccine.
C4591001 1022 10221150 Subject did not receive study vaccine.
C4591001 1037 10371057 Subject did not receive study vaccine.
C4591001 1037 10371117 Subject did not receive study vaccine.
C4591001 1044 10441113 Subject did not receive study vaccine.
C4591001 1054 10541071 Subject did not receive study vaccine.
C4591001 1054 10541175 Subject did not receive study vaccine.
C4591001 1056 10561078 Subject did not receive study vaccine.
C4591001 1082 10821062 Subject did not receive study vaccine.
C4591001 1084 10841366 Subject did not receive study vaccine.
C4591001 1084 10841446 Subject did not receive study vaccine.
C4591001 1087 10871434 Subject did not receive study vaccine.
C4591001 1087 10871512 Subject did not receive study vaccine.
)TMG(
84:31
0202-voN-42
:nO
laniF\laniF\8512b9591e771090
FDA-CBER-2021-5683-0019391
Page 10
16.2.3.2.4 Listing of Subjects Excluded From Safety Population – All Subjects
Age Group
(Years) Subject Reason for Exclusion
C4591001 1091 10911092 Subject did not receive study vaccine.
C4591001 1097 10971003 Subject did not receive study vaccine.
C4591001 1098 10981092 Subject did not receive study vaccine.
C4591001 1098 10981109 Subject did not receive study vaccine.
C4591001 1109 11091259 Subject did not receive study vaccine.
C4591001 1116 11161117 Subject did not receive study vaccine.
C4591001 1116 11161118 Subject did not receive study vaccine.
C4591001 1128 11281023 Subject did not receive study vaccine.
C4591001 1128 11281109 Subject did not receive study vaccine.
C4591001 1129 11291082 Subject did not receive study vaccine.
C4591001 1129 11291117 Subject did not receive study vaccine.
C4591001 1133 11331197 Subject did not receive study vaccine.
C4591001 1134 11341130 Subject did not receive study vaccine.
C4591001 1157 11571028 Subject did not receive study vaccine.
C4591001 1178 11781056 Subject did not receive study vaccine.
C4591001 1185 11851006 Subject did not receive study vaccine.
C4591001 1223 12231215 Subject did not receive study vaccine.
C4591001 1223 12231250 Subject did not receive study vaccine.
C4591001 1224 12241157 Subject did not receive study vaccine.
C4591001 1231 12312222 Subject did not receive study vaccine.
C4591001 1232 12321432 Subject did not receive study vaccine.
C4591001 1248 12481182 Subject did not receive study vaccine.
Note: Data for subjects randomized on or after 10OCT2020 are included to comprehensively show all data reported but are subject to change with
additional follow-up.
PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 17NOV2020 (21:33)
(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_IA_P3_2MPD2/adsl_l001_excl_p3_saf_all
)TMG(
84:31
0202-voN-42
:nO
laniF\laniF\8512b9591e771090
FDA-CBER-2021-5683-0019392
Page 11
16.2.3.2.5 Listing of Subjects with Unknown Actual Dosing – ~38000 Subjects for Phase 2/3 Analysis
Age Group
(Years) Subject Comments
16-55 C4591001 1163 11631006 Vaccinated per CRF but actual treatment not confirmed in IRT.
>55 C4591001 1163 11631005 Vaccinated per CRF but actual treatment not confirmed in IRT.
C4591001 1163 11631008 Vaccinated per CRF but actual treatment not confirmed in IRT.
PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 17NOV2020 (16:52)
(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_IA_P3_2MPD2/sl_l001_spc_p3_saf
)TMG(
31:20
0202-voN-52
:nO
laniF\laniF\476dc9591e771090
FDA-CBER-2021-5683-0019393
Page 12
16.2.3.2.6 Listing of Subjects with Unknown Actual Dosing – All Subjects
Age Group
(Years) Subject Comments
16-55 C4591001 1163 11631006 Vaccinated per CRF but actual treatment not confirmed in IRT.
>55 C4591001 1163 11631005 Vaccinated per CRF but actual treatment not confirmed in IRT.
C4591001 1163 11631008 Vaccinated per CRF but actual treatment not confirmed in IRT.
PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 17NOV2020 (16:52)
(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_IA_P3_2MPD2/sl_l001_spc_p3_saf_all
)TMG(
31:20
0202-voN-52
:nO
laniF\laniF\576dc9591e771090
FDA-CBER-2021-5683-0019394
Page 13","[[['', None, None, None, None, None], ['16.2.3.1.1 Listing of Subjects Excluded From All-Available and Evaluable Immunogenicity Populations –', None, None, None, None, None], ['Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None], ['Vaccine', 'Age Group', 'Vaccine Group', '', '', ''], ['Candidate', '(Years)', '(as Randomized)', 'Subject', 'Population', 'Reason for Exclusion'], ['BNT162b1', '65-85', '10 μg', 'C4591001 1002 10021053', 'Dose 1 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['', '', '', '', 'Dose 2 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['BNT162b2', '18-55', '10 μg', 'C4591001 1003 10031021', 'Dose 1 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['', '', '', '', 'Dose 2 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['', '', '30 μg', 'C4591001 1007 10071050', 'Dose 2 evaluable', 'Did not have blood collection within 6-8 days after Dose 2.'], ['Placebo', '18-55', 'Placebo', 'C4591001 1003 10031017', 'Dose 1 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['', '', '', '', 'Dose 2 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['', '', '', 'C4591001 1003 10031070', 'Dose 1 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['', '', '', '', 'Dose 2 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['BNT162b2', '65-85', '20 μg', 'C4591001 1003 10031055', 'Dose 2 evaluable', 'Did not have blood collection within 6-8 days after Dose 2.'], ['', '', '30 μg', 'C4591001 1003 10031047', 'Dose 1 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['', '', '', '', 'Dose 2 evaluable', 'Had major protocol deviation(s) as determined by the clinician.'], ['', '', '', '', '', ''], ['PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 17SEP2020 (23:36)', None, None, None, None, None], ['(Cutoff Date: 24AUG2020, Snapshot Date: 17SEP2020) Output File: ./nda3/C4591001 IA P1 Serology/adsl l001 excl eval p1', None, None, None, None, None], ['', None, None, None, None, None]], [['', None, None, None, None, None, None], ['16.2.3.1.1.1 Listing of Subjects Excluded From All-Available and Evaluable Immunogenicity Populations – Phase 1 –\nBNT162b1 (100 μg)', None, None, None, None, None, None], ['Vaccine\nCandidate', 'Vaccine', 'Age Group', 'Vaccine Group', '', '', ''], [None, None, '(Years)', '(as Randomized)', 'Subject', 'Population', None], ['No subject meets the reporting criteria.', None, '', '', '', '', ''], [None, '', '', '', '', '', ''], ['PFIZER CONFIDENTIAL SDTM Creation: 17SEP2020 (22:01) Source Data: adsl Table Generation: 22SEP2020 (00:02)\n(Cutoff Date: 24AUG2020, Snapshot Date: 17SEP2020) Output File: ./nda3/C4591001_IA_P1_100/adsl_l001_excl_eval_100_p1', None, None, None, None, None, None], ['', None, None, None, None, None, None]], [['', None, None, None, None, None], ['16.2.3.1.2 Listing of Subjects Excluded From All-Available and Evaluable Immunogenicity Populations – Phase 2', None, None, None, None, None], ['Age\nGroup\n(Years)', 'Age', '', '', '', None], [None, 'Group', None, None, None, None], [None, None, 'Subject', 'Population', None, None], ['18-55', None, 'C4591001 1003 10031101', 'Dose 2 Evaluable', 'Had important protocol deviation(s) as determined by the clinician.', None], ['', '', 'C4591001 1003 10031104', 'Dose 2 All-available', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None], ['', '', '', 'Dose 2 Evaluable', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None], ['', '', 'C4591001 1007 10071095', 'Dose 2 Evaluable', 'Did not receive Dose 2 within 19-42 days after Dose 1.', ''], ['', '', 'C4591001 1013 10131019', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', ''], ['', '', 'C4591001 1013 10131025', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', ''], ['', '', 'C4591001 1079 10791004', 'Dose 2 All-available', 'Did not receive Dose 2.', ''], ['', '', '', 'Dose 2 Evaluable', 'Did not receive 2 doses of the vaccine to which they are randomly assigned.', ''], ['', '', 'C4591001 1082 10821004', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', ''], ['', '', 'C4591001 1085 10851003', 'Dose 2 All-available', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None], ['', '', '', 'Dose 2 Evaluable', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2; did not have blood collection within 28-42 days after Dose 2.', None], ['', '', 'C4591001 1109 11091006', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', ''], ['', '', 'C4591001 1109 11091018', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', ''], ['', '', 'C4591001 1109 11091024', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', ''], ['', '', 'C4591001 1109 11091030', 'Dose 2 All-available', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None], ['', '', '', 'Dose 2 Evaluable', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2; did not have blood collection within 28-42 days after Dose 2.', None], ['', '', 'C4591001 1120 11201001', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', ''], ['', '', 'C4591001 1129 11291005', 'Dose 2 All-available', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None], ['', '', '', 'Dose 2 Evaluable', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None]], [['', None, None, None, None, None], ['16.2.3.1.2 Listing of Subjects Excluded From All-Available and Evaluable Immunogenicity Populations – Phase 2', None, None, None, None, None], ['Age\nGroup\n(Years)', 'Age', '', '', '', None], [None, 'Group', None, None, None, None], [None, None, 'Subject', 'Population', None, None], ['', None, 'C4591001 1129 11291014', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', None], ['', '56-85', 'C4591001 1001 10011096', 'Dose 2 All-available', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None], ['', '', '', 'Dose 2 Evaluable', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None], ['', '', 'C4591001 1082 10821001', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', ''], ['', '', 'C4591001 1084 10841006', 'Dose 2 Evaluable', 'Did not receive Dose 2 within 19-42 days after Dose 1.', ''], ['', '', 'C4591001 1089 10891004', 'Dose 2 Evaluable', 'Did not receive Dose 2 within 19-42 days after Dose 1.', ''], ['', '', 'C4591001 1109 11091032', 'Dose 2 Evaluable', 'Did not have blood collection within 28-42 days after Dose 2.', ''], ['', '', 'C4591001 1127 11271002', 'Dose 2 Evaluable', 'Did not receive Dose 2 within 19-42 days after Dose 1.', ''], ['', '', 'C4591001 1127 11271003', 'Dose 2 Evaluable', 'Did not receive Dose 2 within 19-42 days after Dose 1.', ''], ['', '', 'C4591001 1140 11401002', 'Dose 2 All-available', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None], ['', '', '', 'Dose 2 Evaluable', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2; did not have blood collection within 28-42 days after Dose 2.', None], ['', '', 'C4591001 1140 11401003', 'Dose 2 All-available', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2.', None], ['', '', '', 'Dose 2 Evaluable', 'Did not have at least 1 valid and determinate immunogenicity result after', ''], [None, '', '', '', 'Dose 2; did not have blood collection within 28-42 days after Dose 2.', None], [None, None, None, None, '', None], ['PFIZER CONFIDENTIAL SDTM Creation: 02NOV2020 (19:23) Source Data: adsl Table Generation: 12NOV2020 (02:22)\n(Cutoff Date: 12OCT2020, Snapshot Date: 02NOV2020) Output File: ./nda2_unblinded/C4591001_IA_P2_Serology/adsl_l001_excl_p2_eval', None, None, None, None, None], ['', None, None, None, None, None]], [['', None, None, None, None], ['16.2.3.2.1 Listing of Subjects Excluded From Safety Population – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None], ['Vaccine', 'Age Group', 'Vaccine Group', '', ''], ['Candidate', '(Years)', '(as Randomized)', 'Subject', 'Reason for Exclusion'], ['No subject meets the reporting criteria.', '', '', '', ''], ['', '', '', '', ''], ['PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 31AUG2020 (10:58)', None, None, None, None], ['(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: (CDISC)/C4591001 IA P1/adsl l001 excl saf p1', None, None, None, None], ['', None, None, None, None]], [['', None, None, None, None], ['16.2.3.2.1.1 Listing of Subjects Excluded From Safety Population – Phase 1 – BNT162b1 (100 μg)', None, None, None, None], ['Vaccine', 'Age Group', 'Vaccine Group', '', ''], ['Candidate', '(Years)', '(as Randomized)', 'Subject', 'Reason for Exclusion'], ['No subject meets the reporting criteria.', '', '', '', ''], ['', '', '', '', ''], ['PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 18SEP2020 (13:43)', None, None, None, None], ['(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: ./nda3/C4591001 IA P1 100/adsl l001 excl saf 100 p1', None, None, None, None], ['', None, None, None, None]], [['', None, None, None, None], ['', '16.2.3.2.2 Listing of Subjects Excluded From Safety Population – Phase 2', None, None, ''], ['Age Group\n(Years)', 'Age Group', '', '', None], [None, None, 'Subject', None, None], ['No subject meets the reporting criteria.', None, '', '', None], [None, '', '', '', None], ['', 'PFIZER CONFIDENTIAL SDTM Creation: 05SEP2020 (14:18) Source Data: adsl Table Generation: 09SEP2020 (23:18)', None, None, ''], [None, '(Cutoff Date: 02SEP2020, Snapshot Date: 04SEP2020) Output File: ./nda2_unblinded/C4591001_IA_P2/adsl_l001_excl_p2_saf', None, None, None], ['', None, None, None, None]], [['', None, None, None, None], ['', '16.2.3.2.4 Listing of Subjects Excluded From Safety Population – All Subjects', None, None, ''], ['Age Group\n(Years)', 'Age Group', '', '', None], [None, None, 'Subject', None, None], ['16-55', None, 'C4591001 1003 10031140', 'Subject did not receive study vaccine.', None], ['', '', 'C4591001 1003 10031143', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1005 10051381', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1013 10131017', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1013 10131740', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1036 10361050', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571031', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571211', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571212', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571215', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571268', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1066 10661335', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1071 10711162', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1081 10811105', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1082 10821013', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1089 10891346', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1089 10891351', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1092 10921128', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1093 10931055', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1109 11091349', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1112 11121229', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1116 11161015', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1120 11201038', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1120 11201252', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1120 11201299', 'Did not provide informed consent.', ''], ['', '', 'C4591001 1122 11221006', 'Subject did not receive study vaccine.', '']], [['', None, None, None, None], ['', '16.2.3.2.4 Listing of Subjects Excluded From Safety Population – All Subjects', None, None, ''], ['Age Group\n(Years)', 'Age Group', '', '', None], [None, None, 'Subject', None, None], ['', None, 'C4591001 1122 11221026', 'Subject did not receive study vaccine.', None], ['', '', 'C4591001 1123 11231027', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1123 11231301', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1126 11261074', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1129 11291048', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1133 11331162', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1135 11351389', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1162 11621024', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1162 11621477', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1167 11671003', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1168 11681030', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1205 12051028', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1212 12121023', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1223 12231200', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1223 12231234', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12311409', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12311516', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12311926', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12312176', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12312483', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12313443', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12313527', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12313869', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12314738', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12315308', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1232 12321037', 'Subject did not receive study vaccine.', '']], [['', None, None, None, None], ['', '16.2.3.2.4 Listing of Subjects Excluded From Safety Population – All Subjects', None, None, ''], ['Age Group\n(Years)', 'Age Group', '', '', None], [None, None, 'Subject', None, None], ['', None, 'C4591001 1235 12351167', 'Subject did not receive study vaccine.', None], ['', '', 'C4591001 1248 12481018', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1248 12481025', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1248 12481060', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1248 12481218', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1260 12601049', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1260 12601070', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1264 12641018', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 4444 44441135', 'Subject did not receive study vaccine.', ''], ['', '>55', 'C4591001 1013 10131097', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1019 10191033', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1019 10191300', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1022 10221015', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1022 10221057', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1022 10221150', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1037 10371057', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1037 10371117', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1044 10441113', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1054 10541071', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1054 10541175', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1056 10561078', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1082 10821062', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1084 10841366', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1084 10841446', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1087 10871434', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1087 10871512', 'Subject did not receive study vaccine.', '']], [['', None, None, None, None], ['', '16.2.3.2.4 Listing of Subjects Excluded From Safety Population – All Subjects', None, None, ''], ['Age Group\n(Years)', 'Age Group', '', '', None], [None, None, 'Subject', None, None], ['', None, 'C4591001 1091 10911092', 'Subject did not receive study vaccine.', None], ['', '', 'C4591001 1097 10971003', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1098 10981092', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1098 10981109', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1109 11091259', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1116 11161117', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1116 11161118', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1128 11281023', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1128 11281109', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1129 11291082', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1129 11291117', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1133 11331197', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1134 11341130', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1157 11571028', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1178 11781056', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1185 11851006', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1223 12231215', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1223 12231250', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1224 12241157', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12312222', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1232 12321432', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1248 12481182', 'Subject did not receive study vaccine.', ''], [None, '', '', '', None], ['', 'Note: Data for subjects randomized on or after 10OCT2020 are included to comprehensively show all data reported but are subject to change with', None, None, ''], [None, 'additional follow-up.', None, None, None], [None, 'PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 17NOV2020 (21:33)', None, None, None], [None, '(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_IA_P3_2MPD2/adsl_l001_excl_p3_saf_all', None, None, None], ['', None, None, None, None]], [['', None, None, None, None], ['', '16.2.3.2.5 Listing of Subjects with Unknown Actual Dosing – ~38000 Subjects for Phase 2/3 Analysis', None, None, ''], ['Age Group\n(Years)', 'Age Group', '', '', None], [None, None, 'Subject', None, None], ['16-55', None, 'C4591001 1163 11631006', 'Vaccinated per CRF but actual treatment not confirmed in IRT.', None], ['', '>55', 'C4591001 1163 11631005', 'Vaccinated per CRF but actual treatment not confirmed in IRT.', ''], ['', '', 'C4591001 1163 11631008', 'Vaccinated per CRF but actual treatment not confirmed in IRT.', ''], [None, '', '', '', None], ['', 'PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 17NOV2020 (16:52)', None, None, ''], [None, '(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_IA_P3_2MPD2/sl_l001_spc_p3_saf', None, None, None], ['', None, None, None, None]], [['', None, None, None, None], ['', '16.2.3.2.6 Listing of Subjects with Unknown Actual Dosing – All Subjects', None, None, ''], ['Age Group\n(Years)', 'Age Group', '', '', None], [None, None, 'Subject', None, None], ['16-55', None, 'C4591001 1163 11631006', 'Vaccinated per CRF but actual treatment not confirmed in IRT.', None], ['', '>55', 'C4591001 1163 11631005', 'Vaccinated per CRF but actual treatment not confirmed in IRT.', ''], ['', '', 'C4591001 1163 11631008', 'Vaccinated per CRF but actual treatment not confirmed in IRT.', ''], [None, '', '', '', None], ['', 'PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 17NOV2020 (16:52)', None, None, ''], [None, '(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2_unblinded/C4591001_IA_P3_2MPD2/sl_l001_spc_p3_saf_all', None, None, None], ['', None, None, None, None]]]",13
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdf,3.0,"CCI_Periph vasc
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Periph vasc
Code: 90002930
Extension: CCI
Report Date/Time: 27-Oct-2020:10:52:56 AM EDT
Term Code Level Category Weight Scope
Superior mesenteric artery syndrome 10054156 PT
Subclavian artery stenosis 10050180 PT
Subclavian artery occlusion 10069695 PT
Subclavian artery aneurysm 10042331 PT
Steal syndrome 10063900 PT
Spontaneous amputation 10076246 PT
Splenorenal shunt procedure 10077281 PT
Renal artery stent removal 10069948 PT
Renal artery stent placement 10064727 PT
Renal artery dissection 10049942 PT
Renal artery arteriosclerosis 10065561 PT
Renal artery angioplasty 10057493 PT
Pulmonary endarterectomy 10072893 PT
Popliteal artery entrapment syndrome 10071642 PT
Peripheral vascular disorder 10034636 PT
Peripheral revascularisation 10053351 PT
Peripheral ischaemia 10034576 PT
Peripheral endarterectomy 10072560 PT
Peripheral artery stent insertion 10072562 PT
Peripheral artery stenosis 10072563 PT
Peripheral artery occlusion 10057525 PT
Peripheral artery dissection 10057520 PT
Peripheral artery bypass 10072561 PT
Peripheral artery angioplasty 10057518 PT
Peripheral artery aneurysm 10057521 PT
Peripheral arterial occlusive disease 10062585 PT
Penetrating atherosclerotic ulcer 10074396 PT
Penetrating aortic ulcer 10077118 PT
Ocular vascular disorder 10052896 PT
Mesenteric vascular insufficiency 10027401 PT
Mesenteric artery stent insertion 10071261 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\ed0cce691e771090
FDA-CBER-2021-5683-0023968
Mesenteric arteriosclerosis 10065560 PT
Macroangiopathy 10054805 PT
Leriche syndrome 10024242 PT
Ischaemic limb pain 10062610 PT
Ischaemic enteritis 10074063 PT
Intra-thoracic aortic aneurysm repair 10022743 PT
Intestinal ischaemia 10022680 PT
Intermittent claudication 10022562 PT
Iliac artery rupture 10072789 PT
Iliac artery occlusion 10064601 PT
Iliac artery disease 10077115 PT
Gangrene 10017711 PT
Femoral artery dissection 10052326 PT
Femoral artery aneurysm 10016427 PT
False lumen dilatation of aortic dissection 10072788 PT
Extremity necrosis 10059385 PT
Erythromelalgia 10015284 PT
Erythrocyanosis 10048995 PT
Endarterectomy of aorta 10014649 PT
Dry gangrene 10049927 PT
Diabetic vascular disorder 10061815 PT
Diabetic macroangiopathy 10063547 PT
Colitis ischaemic 10009895 PT
Coeliac artery occlusion 10069696 PT
Claudication of jaw muscles 10009243 PT
Brachiocephalic artery stenosis 10075450 PT
Brachiocephalic artery occlusion 10069694 PT
Brachiocephalic arteriosclerosis 10075449 PT
Brachial artery entrapment syndrome 10078046 PT
Arteriosclerotic gangrene 10003222 PT
Arteriosclerosis Moenckeberg-type 10003212 PT
Arterioenteric fistula 10070296 PT
Arterial stenosis 10060965 PT
Aortoenteric fistula 10081100 PT
Thromboangiitis obliterans 10043540 PT
Aortitis syphilitic 10002923 PT
Aortic wall hypertrophy 10066243 PT
Aortic surgery 10061651 PT
Aortic stent insertion 10071256 PT
Aortic stenosis 10002906 PT
Aortic rupture 10060874 PT
Aortic occlusion 10058178 PT
Aortic necrosis 10002900 PT
Aortic intramural haematoma 10067975 PT
Aortic elongation 10065510 PT
Aortic dissection rupture 10068119 PT
Aortic dissection 10002895 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\ed0cce691e771090
FDA-CBER-2021-5683-0023969
Aortic disorder 10058648 PT
Aortic dilatation 10057453 PT
Aortic arteriosclerosis 10065558 PT
Aortic bypass 10057617 PT
Aortic aneurysm syphilitic 10002887 PT
Aortic aneurysm rupture 10002886 PT
Aortic aneurysm repair 10002885 PT
Aortic aneurysm 10002882 PT
Aortic anastomosis 10068859 PT
Aorta coarctation repair 10002879 PT
Adventitial cystic disease 10077466 PT
Acute aortic syndrome 10074337 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\ed0cce691e771090
FDA-CBER-2021-5683-0023970",,3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdf,3.0,"Table 1: Summary of Differences Between CSR Reactogenicity Data and Updated Reactogenicity Data for Study C4591001 –
Phase 2/3 Subjects 16-55 Years of Age – Safety Population ................................................................................................................. 2
Table 2: Summary of Differences Between CSR Reactogenicity Data and Updated Reactogenicity Data for Study C4591001 –
Phase 2/3 Subjects >55 Years of Age – Safety Population .................................................................................................................... 3
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\a0a91f691e771090
FDA-CBER-2021-5683-0023995
Summary of Differences Between CSR Reactogenicity Data and Updated Reactogenicity Data for Study C4591001 – Phase 2/3
Subjects 16-55 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Number of total reactogenicity records 447303 447749
Number (%) records affecteda 536 (0.12) 140 (0.03)
Number of subjects 2923 2941
Number (%) subjects with any records affected 109 (3.73) 48 (1.63)
Maximum difference (updated data-CSR data) across any local reaction term of the percentage 0.1 0.2
of subjects with a local reaction within 7 days of first vaccinationb
Maximum difference (updated data-CSR data) across any local reaction term of the percentage 0.1 0.1
of subjects with a local reaction within 7 days of second vaccinationb
Maximum difference (updated data-CSR data) across any systemic event term of the 0.1 0.0
percentage of subjects with a systemic event within 7 days of first vaccinationb
Maximum difference (updated data-CSR data) across any systemic event term of the 0.3 0.2
percentage of subjects with a systemic event within 7 days of second vaccinationb
Maximum difference (updated data-CSR data) across any local reaction term of the duration in 0.01 0.0
mean days following first vaccinationb
Maximum difference (updated data-CSR data) across any local reaction term of the duration in 0.0 0.0
mean days following second vaccinationb
Maximum difference (updated data-CSR data) across any systemic event term of the duration 0.01 0.0
in mean days following first vaccinationb
Maximum difference (updated data-CSR data) across any systemic event term of the duration 0.02 0.01
in mean days following second vaccinationb
Difference (updated data-CSR data) of number of subjects with a duration of any local reaction 1 0
>7 days following either vaccination
Difference (updated data-CSR data) of number of subjects with a duration of any systemic 5 3
event >7 days following either vaccination
Abbreviations: CRF = case report form; CSR = clinical study report
Note: CSR data is data reported in the CSR that was entered into the electronic diary by the subject and symptom resolved page by the investigator. Updated data
is the CSR data and the reactogenicity data entered in the AE log CRF page by the investigator.
a. An affected record is any record that changed during the reactogenicity update.
b. Maximum difference is displayed as a percentage and is for reactogenicity data.
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\a0a91f691e771090
FDA-CBER-2021-5683-0023996
Summary of Differences Between CSR Reactogenicity Data and Updated Reactogenicity Data for Study C4591001 – Phase 2/3
Subjects >55 Years of Age – Safety Population
Vaccine Group (as Administered)
BNT162b2 (30 μg) Placebo
Number of total reactogenicity records 311695 307249
Number (%) records affecteda 207 (0.07) 79 (0.03)
Number of subjects 2025 2007
Number (%) subjects with any records affected 49 (2.42) 22 (1.10)
Maximum difference (updated data-CSR data) across any local reaction term of the percentage 0.1 0.2
of subjects with a local reaction within 7 days of first vaccinationb
Maximum difference (updated data-CSR data) across any local reaction term of the percentage 0.2 0.2
of subjects with a local reaction within 7 days of second vaccinationb
Maximum difference (updated data-CSR data) across any systemic event term of the 0.1 0.0
percentage of subjects with a systemic event within 7 days of first vaccinationb
Maximum difference (updated data-CSR data) across any systemic event term of the 0.3 0.0
percentage of subjects with a systemic event within 7 days of second vaccinationb
Maximum difference (updated data-CSR data) across any local reaction term of the duration in 0.01 0.03
mean days following first vaccinationb
Maximum difference (updated data-CSR data) across any local reaction term of the duration in 0.0 0.17
mean days following second vaccinationb
Maximum difference (updated data-CSR data) across any systemic event term of the duration 0.01 0.01
in mean days following first vaccinationb
Maximum difference (updated data-CSR data) across any systemic event term of the duration 0.02 0.02
in mean days following second vaccinationb
Difference (updated data-CSR data) of number of subjects with a duration of any local reaction 1 1
>7 days following either vaccination
Difference (updated data-CSR data) of number of subjects with a duration of any systemic 2 1
event >7 days following either vaccination
Abbreviations: CRF = case report form; CSR = clinical study report
Note: CSR data is data reported in the CSR that was entered into the electronic diary by the subject and symptom resolved page by the investigator. Updated data
is the CSR data and the reactogenicity data entered in the AE log CRF page by the investigator.
a. An affected record is any record that changed during the reactogenicity update.
b. Maximum difference is displayed as a percentage and is for reactogenicity data.
)TMG(
14:60
1202-yaM-40
:nO
laniF\laniF\a0a91f691e771090
FDA-CBER-2021-5683-0023997",,3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-chf.pdf,2.0,"CCI_CHF
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_CHF
Code: 90002959
Extension: CCI
Report Date/Time: 27-Oct-2020:10:43:25 AM EDT
Term Code Level Category Weight Scope
Cardiac failure acute 10007556 PT
Cardiac failure 10007554 PT
Cardiac asthma 10007522 PT
Cardiac amyloidosis 10007509 PT
Acute right ventricular failure 10063082 PT
Acute pulmonary oedema 10001029 PT
Acute left ventricular failure 10063081 PT
Viral cardiomyopathy 10068767 PT
Ventricular failure 10060953 PT
Thyrotoxic cardiomyopathy 10075043 PT
Tachycardia induced cardiomyopathy 10074269 PT
Stress cardiomyopathy 10066286 PT
Non-compaction cardiomyopathy 10079253 PT
Shoshin beriberi 10049633 PT
Right ventricular failure 10039163 PT
Rheumatic heart disease 10062110 PT
Restrictive cardiomyopathy 10038748 PT
Peripartum cardiomyopathy 10049430 PT
Non-obstructive cardiomyopathy 10049813 PT
Metabolic cardiomyopathy 10070909 PT
Low cardiac output syndrome 10024899 PT
Left ventricular failure 10024119 PT
Kyphoscoliotic heart disease 10023508 PT
Ischaemic cardiomyopathy 10048858 PT
Hypertrophic cardiomyopathy 10020871 PT
Hypertensive cardiomyopathy 10058222 PT
HIV cardiomyopathy 10069658 PT
Hepatojugular reflux 10051448 PT
Diabetic cardiomyopathy 10012647 PT
Toxic cardiomyopathy 10083657 PT
Cor pulmonale acute 10010969 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\f73dde691e771090
FDA-CBER-2021-5683-0023922
Cor pulmonale 10010968 PT
Congestive cardiomyopathy 10056370 PT
Chronic right ventricular failure 10063084 PT
Chronic left ventricular failure 10063083 PT
Cardio-respiratory distress 10049874 PT
Cardiorenal syndrome 10068230 PT
Cardiopulmonary failure 10051093 PT
Cardiomyopathy alcoholic 10007637 PT
Cardiomyopathy acute 10048377 PT
Cardiomyopathy 10007636 PT
Cardiogenic shock 10007625 PT
Cardiac steatosis 10077905 PT
Cardiac iron overload 10080569 PT
Cardiac failure high output 10007560 PT
Cardiac failure congestive 10007559 PT
Cardiac failure chronic 10007558 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\f73dde691e771090
FDA-CBER-2021-5683-0023923",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdf,1.0,"CCI_Mod sev liver
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Mod sev liver
Code: 90002937
Extension: CCI
Report Date/Time: 27-Oct-2020:10:51:50 AM EDT
Term Code Level Category Weight Scope
Varices oesophageal 10056091 PT
Subacute hepatic failure 10056956 PT
Portal hypertension 10036200 PT
Oesophageal varices haemorrhage 10030210 PT
Hepatorenal syndrome 10019846 PT
Hepatorenal failure 10019845 PT
Hepatic vein occlusion 10058991 PT
Hepatic necrosis 10019692 PT
Hepatic failure 10019663 PT
Hepatic encephalopathy 10019660 PT
Gastric varices 10051012 PT
Coma hepatic 10010075 PT
Chronic hepatic failure 10057573 PT
Acute on chronic liver failure 10077305 PT
Acute hepatic failure 10000804 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\873dde691e771090
FDA-CBER-2021-5683-0023964",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_3674.pdf,2.0,"Form Approved: OMB No. 0910-0616. Expiration Date: 3/31/2021. See PRA Statement below.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Certification of Compliance
Under 42 U.S.C. § 282(j)(5)(B), with Requirements of ClinicalTrials.gov Data Bank
(For submission with an application/submission, including amendments, supplements, and resubmissions, under §§ 505, 515,
520(m), or 510(k) of the Federal Food, Drug, and Cosmetic Act or § 351 of the Public Health Service Act.)
SPONSOR / APPLICANT / SUBMITTER INFORMATION
1. Name of Sponsor/Applicant/Submitter 2. Date of the Application/Submission
BioNTech Manufacturing GmbH 05/06/2021
3. Address 4. Telephone and Fax Numbers
(Include country code if applicable and
Address 1 (Street address, P.O. box, company name c/o)
An der Goldgrube 12 area code)
Address 2 (Apartment, suite, unit, building, floor, etc.) (Tel):+49 (0) 6131 9084-7593
City State/Province/Region (Fax):+49 (0) 6131 9084-390
Mainz N/A
Country ZIP or Postal Code
Germany 55131
PRODUCT INFORMATION
5. For Drugs/Biologics: Include Any/All Available Established, Proprietary and/or Chemical/Biochemical/Blood/Cellular/Gene Therapy Product
Name(s).
For Devices: Include Any/All Common or Usual Name(s), Classification, Trade or Proprietary or Model Name(s) and/or Model Number(s)
COVID-19 Vaccine (BNT162, PF-07302048), [COVID-19 mRNA Vaccine (nucleoside modified)], COMIRNATY
Continuation Page for #5
APPLICATION / SUBMISSION INFORMATION
6. Type of Application/Submission Which This Certification Accompanies
IND NDA ANDA BLA PMA HDE 510(k) PDP Other
7. Include IND/NDA/ANDA/BLA/PMA/HDE/510(k)/PDP/ Other Number If BLA was selected in item 6, provide Supplement Number
(If number previously assigned)
125742
8. Serial Number Assigned to Application/Submission Which This Certification Accompanies
00001
CERTIFICATION STATEMENT / INFORMATION
9. Check only one of the following boxes (See instructions for additional information and explanation)
A. I certify that the requirements of 42 U.S.C. § 282(j), Section 402(j) of the Public Health Service Act, including 42 CFR part 11, do not
apply because the application/submission which this certification accompanies does not reference any clinical trial.
B. I certify that the requirements of 42 U.S.C. § 282(j), Section 402(j) of the Public Health Service Act, including 42 CFR part 11, do not
apply to any clinical trial referenced in the application/submission which this certification accompanies.
C. I certify that the requirements of 42 U.S.C. § 282(j), section 402(j) of the Public Health Service Act, apply to one or more of the clinical
trials referenced in the application/submission which this certification accompanies and that the requirements of 42 U.S.C. 282(j),
including any applicable provisions of 42 CFR part 11, have been met.
Certification Statement / Information section continued on page 2
FORM FDA 3674 (4/18) Page 1 of 2 FDA-CBER-2021 P- S5 C 6 Pu8 bl3 is- h0 ing0 S1 er3 vi7 ce3 s (6 301) 443-6740 EF
CERTIFICATION STATEMENT / INFORMATION (Continued)
10. If you checked box C, in number 9, provide the National Clinical Trial (NCT) Number(s) for any “applicable clinical trial(s),” for which you (the
sponsor/applicant/submitter) are the “responsble party” under 42 U.S.C. § 282(j)(1)(a)(i), section 402(j)(1)(a)(i) of the Public Health Service
Act referenced in the application/ submission which this Certification accompanies. (Add continuation page as necessary.)
NCT Number(s): NCT04368728 NCT04380701
Continuation Page for #10
The undersigned declares, to the best of her/his knowledge, that this is an accurate, true, and complete submission of information.
I understand that the failure to submit the certification required by 42 U.S.C. § 282(j)(5)(B), section 402(j)(5)(B) of the Public Health
Service Act, and the knowing submission of a false certification under such section are prohibited acts under 21 U.S.C. § 331, section
301 of the Federal Food, Drug, and Cosmetic Act.
Warning: A willfully and knowingly false statement is a criminal offense, U.S. Code, title 18, section 1001.
11. Name and Title of the Person who Signs Number 15
Name Title
Elisa Harkins Global Regulatory Lead, Global Regulatory Affairs - Vaccines, Pfizer Inc.
12. Address 13. Telephone and Fax Numbers
(Include country code if applicable and
Address 1 (Street address, P.O. box, company name c/o)
area code)
500 Arcola Road
Address 2 (Apartment, suite, unit, building, floor, etc.) (Tel):215-280-5503
City State/Province/Region (Fax):845-474-3500
Collegeville PA
Country ZIP or Postal Code
United States 19426
14. Date of Certification 15. Signature of Sponsor/Applicant/Submitter or an Authorized
Representative (Sign)
05/06/2021 Sign
Digitally signed by Elisa Harkins Tull
Elisa Harkins TullDN: o=Pfizer Inc, cn=Elisa Harkins Tull
Reason: I attest to the accuracy and integrity of
this document
Date: 2021.05.05 18:44:42 -04'00'
This section applies only to requirements of the Paperwork Reduction Act of 1995.
***DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.***
The burden time for this collection of information is estimated to average 15 minutes and 45 minutes (depending on the type of application/
submission) per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and
complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection,
including suggestions for reducing this burden to:
Department of Health and Human Services “An agency may not conduct or sponsor, and a person is not
Food and Drug Administration required to respond to, a collection of information unless it
Office of Chief Information Officer displays a currently valid OMB number.”
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
FORM FDA 3674 (4/18) Page 2 of 2 FDA-CBER-2021-5683-0013737","[[['Address 1 (Street address, P.O. box, company name c/o)\nAn der Goldgrube 12', None, None], ['Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None], ['City\nMainz', 'State/Province/Region\nN/A', None], ['Country\nGermany', None, 'ZIP or Postal Code\n55131']], [['Address 1 (Street address, P.O. box, company name c/o)\n500 Arcola Road', None, None], ['Address 2 (Apartment, suite, unit, building, floor, etc.)', None, None], ['City\nCollegeville', 'State/Province/Region\nPA', None], ['Country\nUnited States', None, 'ZIP or Postal Code\n19426']]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_22_introduction.pdf,2.0,"BNT162b2
2.2 Introduction
2.2 INTRODUCTION
1. Drug Name
Company code: BNT162b2
Dosage form: BNT162b2 is formulated as concentrate for dispersion for injection. Each vial
contains 6doses of 30 micrograms of COVID-19 mRNA Vaccine, embedded in lipid
nanoparticles (total volume: 0.45 mL).
2. Pharmacological Class
BNT162b2is ahighly purified single-stranded, 5’-capped messenger RNA produced using a
cell-free in vitro transcription from the corresponding DNA templates, encoding the viral
spike (S) protein of SARS-CoV-2.
3. Mode of Action
Upon intramuscular administration, the RNA is translated to the S protein, which in turn
induces a protective immune response in the vaccinated organism.
4. Proposed Clinical Use
The proposed indication is active immunization to prevent coronavirus disease 2019
(COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
individuals 16 years of age and older.
BNT162b2is administered intramuscularly after dilution as a course of 2 doses (0.3 mL
each). It is recommended to administer the second dose 3 weeks after the first dose.
CONFIDENTIAL
Page 1
)TMG(
13:71
1202-yaM-10
:nO
devorppA\devorppA\3ae1ee691e771090
FDA-CBER-2021-5683-0013859
Document Approval Record
DocumentName:
(cid:5)(cid:6)(cid:7)(cid:8)(cid:9)(cid:10)(cid:11)(cid:12)(cid:7)(cid:13)(cid:14)(cid:14)(cid:15)(cid:16)(cid:17)(cid:18)(cid:19)(cid:18)(cid:8)(cid:16)(cid:20)(cid:21)(cid:22)(cid:23)(cid:24)(cid:14)(cid:20)(cid:15)(cid:22)(cid:16)(cid:25)(cid:22)(cid:21)(cid:26)(cid:27)(cid:28)(cid:29)(cid:30)(cid:13)(cid:31)(cid:18)(cid:32)(cid:18)(cid:11)(cid:33)
DocumentTitle:
(cid:5)(cid:6)(cid:7)(cid:8)(cid:9)(cid:10)(cid:11)(cid:12)(cid:7)(cid:13)(cid:14)(cid:14)(cid:15)(cid:16)(cid:17)(cid:18)(cid:19)(cid:18)(cid:8)(cid:16)(cid:20)(cid:21)(cid:22)(cid:23)(cid:24)(cid:14)(cid:20)(cid:15)(cid:22)(cid:16)(cid:25)(cid:22)(cid:21)(cid:26)(cid:27)(cid:28)(cid:29)(cid:30)(cid:13)(cid:31)(cid:18)(cid:32)(cid:18)(cid:11)(cid:33)
SignedBy: Date(GMT) SigningCapacity
(cid:34)(cid:13)(cid:21)(cid:35)(cid:15)(cid:16)(cid:36)(cid:37)(cid:24)(cid:38)(cid:38)(cid:39)(cid:40)(cid:38)(cid:15)(cid:36)(cid:13) (cid:32)(cid:11)(cid:10)(cid:30)(cid:13)(cid:31)(cid:10)(cid:18)(cid:32)(cid:18)(cid:11)(cid:11)(cid:41)(cid:42)(cid:43)(cid:11)(cid:42)(cid:32)(cid:18) (cid:44)(cid:17)(cid:45)(cid:24)(cid:38)(cid:13)(cid:20)(cid:22)(cid:21)(cid:31)(cid:28)(cid:25)(cid:25)(cid:13)(cid:15)(cid:21)(cid:36)(cid:28)(cid:46)(cid:46)(cid:21)(cid:22)(cid:47)(cid:13)(cid:38)
)TMG(
13:71
1202-yaM-10
:nO
devorppA\devorppA\3ae1ee691e771090
FDA-CBER-2021-5683-0013860","[[['DocumentName:'], ['DocumentTitle:']]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_27_synopses-indiv-studies.pdf,2.0,"BNT162b2
2.7.6 Synopses of Individual Studies
2.7.6 SYNOPSES OF INDIVIDUAL STUDIES
The table entitled Tabular Listing of All Clinical Studies is located in Module 5.2. The left
hand column of this table contains a hypertext link tothe location of each Clinical Study
Report Body. The right hand column contains a hypertext link to the location of each Study
Synopsis.
CONFIDENTIAL
Page 1
)TMG(
85:32
0202-ceD-10
:nO
devorppA\devorppA\2769aa591e771090
FDA-CBER-2021-5683-0013923
Document Approval Record
DocumentName:
(cid:5)(cid:6)(cid:7)(cid:8)(cid:9)(cid:8)(cid:9)(cid:10)(cid:11)(cid:12)(cid:13)(cid:5)(cid:14)(cid:15)(cid:16)(cid:12)(cid:17)(cid:7)(cid:7)(cid:18)(cid:19)(cid:6)(cid:20)(cid:21)(cid:21)(cid:8)(cid:22)(cid:23)(cid:22)(cid:24)(cid:25)(cid:26)(cid:19)(cid:27)(cid:28)(cid:29)(cid:6)(cid:29)(cid:27)(cid:30)(cid:13)(cid:19)(cid:31)(cid:18)(cid:32)(cid:18)(cid:31)(cid:33)(cid:17)(cid:34)(cid:25)(cid:35)(cid:33)(cid:31)(cid:18)
(cid:6)(cid:29)
DocumentTitle:
(cid:5)(cid:6)(cid:7)(cid:8)(cid:9)(cid:8)(cid:9)(cid:10)(cid:11)(cid:12)(cid:13)(cid:5)(cid:14)(cid:15)(cid:16)(cid:12)(cid:17)(cid:7)(cid:7)(cid:18)(cid:19)(cid:6)(cid:20)(cid:21)(cid:21)(cid:8)(cid:22)(cid:23)(cid:22)(cid:24)(cid:25)(cid:26)(cid:19)(cid:27)(cid:28)(cid:29)(cid:6)(cid:29)(cid:27)(cid:30)(cid:13)(cid:19)(cid:31)(cid:18)(cid:32)(cid:18)(cid:31)(cid:33)(cid:17)(cid:34)(cid:25)(cid:35)(cid:33)(cid:31)(cid:18)
(cid:6)(cid:29)
SignedBy: Date(GMT) SigningCapacity
(cid:36)(cid:6)(cid:37)(cid:6)(cid:38)(cid:39)(cid:40)(cid:27)(cid:41)(cid:19) (cid:9)(cid:15)(cid:14)(cid:5)(cid:6)(cid:7)(cid:14)(cid:8)(cid:9)(cid:8)(cid:9)(cid:8)(cid:42)(cid:43)(cid:44)(cid:45)(cid:43)(cid:44)(cid:16) (cid:46)(cid:18)(cid:19)(cid:17)(cid:34)(cid:21)(cid:28)(cid:28)(cid:37)(cid:27)(cid:32)(cid:17)(cid:34)
)TMG(
85:32
0202-ceD-10
:nO
devorppA\devorppA\2769aa591e771090
FDA-CBER-2021-5683-0013924","[[['DocumentName:'], ['DocumentTitle:']]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdf,3.0,"CCI_Cerebrovascular
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Cerebrovascular
Code: 90002958
Extension: CCI
Report Date/Time: 27-Oct-2020:10:44:05 AM EDT
Term Code Level Category Weight Scope
Vertebrobasilar insufficiency 10047334 PT
Vertebral artery thrombosis 10057777 PT
Vertebral artery stenosis 10047330 PT
Vertebral artery perforation 10075735 PT
Vertebral artery occlusion 10048965 PT
Vertebral artery dissection 10071716 PT
Vascular encephalopathy 10063661 PT
Transient ischaemic attack 10044390 PT
Transient global amnesia 10044380 PT
Thrombotic stroke 10043647 PT
Thrombotic cerebral infarction 10067347 PT
Thalamus haemorrhage 10058939 PT
Thalamic infarction 10064961 PT
Subdural haemorrhage 10042364 PT
Subclavian steal syndrome 10042335 PT
Subarachnoid haemorrhage 10042316 PT
Subarachnoid haematoma 10076701 PT
Stroke in evolution 10059613 PT
Ruptured cerebral aneurysm 10039330 PT
Retinal artery occlusion 10038827 PT
Putamen haemorrhage 10058940 PT
Pseudostroke 10078090 PT
Precerebral artery thrombosis 10074717 PT
Precerebral artery occlusion 10036511 PT
Perinatal stroke 10073945 PT
Moyamoya disease 10028047 PT
Millard-Gubler syndrome 10067462 PT
Migrainous infarction 10056237 PT
Meningorrhagia 10052593 PT
Leukoencephalopathy 10024382 PT
Lateral medullary syndrome 10024033 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\dd0cce691e771090
FDA-CBER-2021-5683-0023916
Lacunar stroke 10076994 PT
Lacunar infarction 10051078 PT
Ischaemic stroke 10061256 PT
Ischaemic cerebral infarction 10060840 PT
Intraventricular haemorrhage 10022840 PT
Cerebral venous sinus thrombosis 10083037 PT
Intracranial haematoma 10059491 PT
Intracranial artery dissection 10073565 PT
Intracranial aneurysm 10022758 PT
Intra-cerebral aneurysm operation 10022736 PT
Hypertensive encephalopathy 10020803 PT
Haemorrhagic transformation stroke 10055677 PT
Haemorrhagic stroke 10019016 PT
Haemorrhagic cerebral infarction 10019005 PT
Haemorrhage intracranial 10018985 PT
Epidural haemorrhage 10073681 PT
Embolic stroke 10014498 PT
Embolic cerebral infarction 10060839 PT
Cerebrovascular stenosis 10061751 PT
Cerebrovascular insufficiency 10058842 PT
Cerebrovascular accident 10008190 PT
Cerebral venous thrombosis 10008138 PT
Cerebral vasoconstriction 10059109 PT
Cerebral vascular occlusion 10076895 PT
Cerebral thrombosis 10008132 PT
Cerebral revascularisation 10071508 PT
Cerebral microembolism 10078311 PT
Cerebral ischaemia 10008120 PT
Cerebral infarction foetal 10008119 PT
Cerebral infarction 10008118 PT
Cerebral haemorrhage foetal 10050157 PT
Cerebral haemorrhage 10008111 PT
Cerebral haematoma 10053942 PT
Cerebral gas embolism 10070813 PT
Cerebral endovascular aneurysm repair 10077079 PT
Cerebral artery thrombosis 10008092 PT
Cerebral artery stenosis 10063648 PT
Cerebral artery perforation 10075734 PT
Cerebral artery occlusion 10008089 PT
Cerebral artery embolism 10008088 PT
Cerebral arteritis 10008087 PT
Cerebral arteriovenous malformation haemorrhagic 10008086 PT
Cerebral arteriosclerosis 10065559 PT
Cerebral aneurysm perforation 10075394 PT
Cerebral amyloid angiopathy 10068044 PT
Cerebellar ischaemia 10068621 PT
Cerebellar infarction 10008034 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\dd0cce691e771090
FDA-CBER-2021-5683-0023917
Cerebellar haemorrhage 10008030 PT
Cerebellar haematoma 10061038 PT
Cerebellar embolism 10067167 PT
Cerebellar artery thrombosis 10008023 PT
Cerebellar artery occlusion 10053633 PT
Central nervous system haemorrhage 10072043 PT
Carotid revascularisation 10072559 PT
Carotid endarterectomy 10007692 PT
Carotid artery thrombosis 10007688 PT
Carotid artery stent removal 10069952 PT
Carotid artery stent insertion 10066102 PT
Carotid artery stenosis 10007687 PT
Carotid artery perforation 10075728 PT
Carotid artery occlusion 10048964 PT
Carotid artery dissection 10050403 PT
Carotid artery bypass 10053003 PT
Carotid artery aneurysm 10007686 PT
Carotid arterial embolus 10007684 PT
Carotid angioplasty 10071260 PT
Carotid aneurysm rupture 10051328 PT
Brain stem thrombosis 10062573 PT
Brain stem stroke 10068644 PT
Brain stem ischaemia 10006148 PT
Brain stem infarction 10006147 PT
Brain stem haemorrhage 10006145 PT
Brain stem haematoma 10073230 PT
Brain stem embolism 10074422 PT
Basilar artery thrombosis 10063093 PT
Basilar artery stenosis 10004163 PT
Basilar artery perforation 10075736 PT
Basilar artery occlusion 10048963 PT
Basal ganglia stroke 10071043 PT
Basal ganglia infarction 10069020 PT
Basal ganglia haemorrhage 10067057 PT
Basal ganglia haematoma 10077031 PT
Amaurosis fugax 10001903 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\dd0cce691e771090
FDA-CBER-2021-5683-0023918",,3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_fast-track-designation.pdf,2.0,"Our Reference: IND 19736 GRANT FAST TRACK DESIGNATION
July 7, 2020
BioNTech RNA Pharmaceuticals GmbH
Attention: Ms. Elisa Harkins
Pfizer, Inc.
500 Arcola Road
Collegeville, PA 19426
Dear Ms. Harkins:
Please refer to your Investigational New Drug Application (IND) submitted under section
505(i) of the Federal Food, Drug, and Cosmetic Act (FDCA) for “Human Coronavirus
mRNA Vaccines (SARS-CoV-2 Spike Protein; BNT162a1 (uRNA; variant RBL063.3);
BNT162b1 (modRNA; variant RBP020.3); BNT162b2 (modRNA; variant RBP020.2);
and BNT162c2 (saRNA; variant RBS004.2)) in Lipid Nanoparticles (ALC-0315, ALC-
0159, DSPC and Cholesterol).”
We also refer to your request for fast track designation submitted and received on
May 15, 2020, and amendment 18, submitted and received on June 18, 2020, under
section 506(b) of the FDCA. We have reviewed your request and have determined that
Human Coronavirus mRNA Vaccines [SARS-CoV-2 Spike Protein; BNT162b1
(modRNA; variant RBP020.3) and BNT162b2 (modRNA; variant RBP020.2)] in Lipid
Nanoparticles (ALC-0315, ALC-0159, DSPC and Cholesterol) for active immunization to
prevent COVID-19 disease caused by SARS-CoV-2 in adults 18 years of age and older
meet the criteria for fast track designation. Therefore, we are granting your request for
fast track designation. Please note that if the drug development program does not
continue to meet the criteria for fast track designation, we may rescind the designation.
For further information regarding fast track drug development programs, please refer to
the guidance for industry Expedited Programs for Serious Conditions – Drugs and
Biologics at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/UCM358301.pdf.
We remind you that under section 561A(f)(2) of the FDCA, you are required to make
your expanded access policy for Human Coronavirus mRNA Vaccines [SARS-CoV-2
Spike Protein; BNT162b1 (modRNA; variant RBP020.3) and BNT162b2 (modRNA;
variant RBP020.2)] in Lipid Nanoparticles (ALC-0315, ALC-0159, DSPC and
Cholesterol) publicly available within 15 days of the signature date of this letter. For
further information regarding how to make your expanded access policy publicly
available, you may visit our expanded access webpage on FDA.gov at
https://www.fda.gov/NewsEvents/PublicHealthFocus/Expanded
AccessCompassionateUse/ucm429687.htm.
U.S.Food&DrugAdministration
10903 NewHampshireAvenue
SilverSpring,MD 20993
www.fda.gov
FDA-CBER-2021-5683-0013855
Page 2 – IND 19736 – Ms. Elisa Harkins
If you have any questions, please contact the Regulatory Project Manager,
Ramachandra Naik, PhD, at Ramachandra.Naik@fda.hhs.gov or 301-796-2640.
Sincerely,
Doran Fink -SD Di Ng :i t ca =ll Uy S s ,i g on =e Ud .S b . y G oD vo er ra nn m F ein nk t ,- oS u=HHS, ou=FDA,
ou=People, cn=Doran Fink -S,
0.9.2342.19200300.100.1.1=0013724088
Date: 2020.07.07 08:23:22 -04'00'
Doran L. Fink, MD, PhD
Deputy Director - Clinical
Division of Vaccines and Related Products Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
FDA-CBER-2021-5683-0013856",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdf,3.0,"16.2.5.1.2 Listing of Subjects Who Received Vaccine Not as Randomized – Phase 2
Vaccine Group Age Group Randomization Vaccination Dose
(as Randomized) (Years) Subject Date Date No. Vaccine Received
No subject meets the reporting criteria.
PFIZER CONFIDENTIAL SDTM Creation: 05SEP2020 (14:18) Source Data: adsl Table Generation: 10SEP2020 (21:41)
(Cutoff Date: 02SEP2020, Snapshot Date: 04SEP2020) Output File: ./nda2_unblinded/C4591001_IA_P2/adsl_l001_p2_rand_notvax )TMG(
54:10
0202-peS-41
:nO
laniF\laniF\f54a7e491e771090
FDA-CBER-2021-5683-0019395
Page 1
16.2.5.1.4 Listing of Subjects Who Received Vaccine Not as Randomized – All Subjects
Vaccine Group Age Group Randomization Vaccination Dose
(as Randomized) (Years) Subject Date Date No. Vaccine Received
BNT162b1 (100 μg) 18-55 C4591001 1001 10011026 18MAY2020 13AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1001 10011028 20MAY2020 17AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1001 10011030 20MAY2020 17AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1001 10011032 20MAY2020 13AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1001 10011034 20MAY2020 17AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1002 10021023 18MAY2020 17AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1002 10021024 18MAY2020 31AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1002 10021027 18MAY2020 17AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1002 10021034 21MAY2020 17AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1002 10021035 21MAY2020 18AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1002 10021036 21MAY2020 18AUG2020 2 BNT162b1 (10 μg)
18-55 C4591001 1002 10021038 21MAY2020 17AUG2020 2 BNT162b1 (10 μg)
BNT162b2 (30 μg) 16-55 C4591001 1012 10121103 01SEP2020 22SEP2020 2 Placebo
16-55 C4591001 1088 10881077 21AUG2020 11SEP2020 2 Placebo
16-55 C4591001 1116 11161226 11SEP2020 11SEP2020 1 Placebo
16-55 C4591001 1116 11161226 11SEP2020 02OCT2020 2 Placebo
16-55 C4591001 1135 11351480 22OCT2020 22OCT2020 1
16-55 C4591001 1163 11631006 31JUL2020 31JUL2020 1
16-55 C4591001 1204 12041111 16SEP2020 16SEP2020 1
16-55 C4591001 1208 12081004 23OCT2020 13NOV2020 2
>55 C4591001 1081 10811053 17AUG2020 09SEP2020 2 Placebo
>55 C4591001 1121 11211071 22SEP2020 03SEP2020 1 Placebo
>55 C4591001 1121 11211071 22SEP2020 22SEP2020 2 Placebo
>55 C4591001 1163 11631005 31JUL2020 31JUL2020 1
>55 C4591001 1170 11701160 01SEP2020 22SEP2020 2
Placebo 16-55 C4591001 1042 10421266 20OCT2020 11NOV2020 2
)TMG(
84:31
0202-voN-42
:nO
laniF\laniF\5690b9591e771090
FDA-CBER-2021-5683-0019396
Page 2
16.2.5.1.4 Listing of Subjects Who Received Vaccine Not as Randomized – All Subjects
Vaccine Group Age Group Randomization Vaccination Dose
(as Randomized) (Years) Subject Date Date No. Vaccine Received
16-55 C4591001 1090 10901334 03SEP2020 03SEP2020 1 BNT162b2 (30 μg)
16-55 C4591001 1090 10901334 03SEP2020 24SEP2020 2 BNT162b2 (30 μg)
16-55 C4591001 1146 11461328 23OCT2020 13NOV2020 2
>55 C4591001 1054 10541024 21AUG2020 10OCT2020 2 BNT162b2 (30 μg)
>55 C4591001 1163 11631008 31JUL2020 31JUL2020 1
>55 C4591001 1177 11771089 19AUG2020 09SEP2020 2 BNT162b2 (30 μg)
>55 C4591001 1231 12311057 11AUG2020 11AUG2020 1 BNT162b2 (30 μg)
>55 C4591001 1265 12651026 31AUG2020 31AUG2020 1 BNT162b2 (30 μg)
>55 C4591001 1265 12651026 31AUG2020 21SEP2020 2 BNT162b2 (30 μg)
Note: Data for subjects randomized on or after 10OCT2020 are included to comprehensively show all data reported but are subject to change with
additional follow-up.
PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 17NOV2020 (22:37)
(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2 unblinded/C4591001 IA P3 2MPD2/adsl l001 p3 rand notvax
)TMG(
84:31
0202-voN-42
:nO
laniF\laniF\5690b9591e771090
FDA-CBER-2021-5683-0019397
Page 3","[[['', None, None, None, None, None, None, None], ['16.2.5.1.2 Listing of Subjects Who Received Vaccine Not as Randomized – Phase 2', None, None, None, None, None, None, None], ['Vaccine Group\n(as Randomized)', 'Vaccine Group', 'Age Group', '', 'Randomization', 'Vaccination', 'Dose', ''], [None, None, '(Years)', 'Subject', 'Date', 'Date', 'No.', None], ['No subject meets the reporting criteria.', None, '', '', '', '', '', ''], [None, '', '', '', '', '', '', ''], ['PFIZER CONFIDENTIAL SDTM Creation: 05SEP2020 (14:18) Source Data: adsl Table Generation: 10SEP2020 (21:41)\n(Cutoff Date: 02SEP2020, Snapshot Date: 04SEP2020) Output File: ./nda2_unblinded/C4591001_IA_P2/adsl_l001_p2_rand_notvax', None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None]], [['', None, None, None, None, None, None, None, None], ['16.2.5.1.4 Listing of Subjects Who Received Vaccine Not as Randomized – All Subjects', None, None, None, None, None, None, None, None], ['Vaccine Group\n(as Randomized)', 'Vaccine Group', 'Age Group', '', 'Randomization', 'Vaccination', 'Dose', '', None], [None, None, '(Years)', 'Subject', 'Date', 'Date', 'No.', None, None], ['BNT162b1 (100 μg)', None, '18-55', 'C4591001 1001 10011026', '18MAY2020', '13AUG2020', '2', 'BNT162b1 (10 μg)', None], ['', '', '18-55', 'C4591001 1001 10011028', '20MAY2020', '17AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1001 10011030', '20MAY2020', '17AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1001 10011032', '20MAY2020', '13AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1001 10011034', '20MAY2020', '17AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1002 10021023', '18MAY2020', '17AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1002 10021024', '18MAY2020', '31AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1002 10021027', '18MAY2020', '17AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1002 10021034', '21MAY2020', '17AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1002 10021035', '21MAY2020', '18AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1002 10021036', '21MAY2020', '18AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', '', '18-55', 'C4591001 1002 10021038', '21MAY2020', '17AUG2020', '2', 'BNT162b1 (10 μg)', ''], ['', 'BNT162b2 (30 μg)', '16-55', 'C4591001 1012 10121103', '01SEP2020', '22SEP2020', '2', 'Placebo', ''], ['', '', '16-55', 'C4591001 1088 10881077', '21AUG2020', '11SEP2020', '2', 'Placebo', ''], ['', '', '16-55', 'C4591001 1116 11161226', '11SEP2020', '11SEP2020', '1', 'Placebo', ''], ['', '', '16-55', 'C4591001 1116 11161226', '11SEP2020', '02OCT2020', '2', 'Placebo', ''], ['', '', '16-55', 'C4591001 1135 11351480', '22OCT2020', '22OCT2020', '1', '', ''], ['', '', '16-55', 'C4591001 1163 11631006', '31JUL2020', '31JUL2020', '1', '', ''], ['', '', '16-55', 'C4591001 1204 12041111', '16SEP2020', '16SEP2020', '1', '', ''], ['', '', '16-55', 'C4591001 1208 12081004', '23OCT2020', '13NOV2020', '2', '', ''], ['', '', '>55', 'C4591001 1081 10811053', '17AUG2020', '09SEP2020', '2', 'Placebo', ''], ['', '', '>55', 'C4591001 1121 11211071', '22SEP2020', '03SEP2020', '1', 'Placebo', ''], ['', '', '>55', 'C4591001 1121 11211071', '22SEP2020', '22SEP2020', '2', 'Placebo', ''], ['', '', '>55', 'C4591001 1163 11631005', '31JUL2020', '31JUL2020', '1', '', ''], ['', '', '>55', 'C4591001 1170 11701160', '01SEP2020', '22SEP2020', '2', '', ''], ['', 'Placebo', '16-55', 'C4591001 1042 10421266', '20OCT2020', '11NOV2020', '2', '', '']], [['', None, None, None, None, None, None, None, None], ['16.2.5.1.4 Listing of Subjects Who Received Vaccine Not as Randomized – All Subjects', None, None, None, None, None, None, None, None], ['Vaccine Group\n(as Randomized)', 'Vaccine Group', 'Age Group', '', 'Randomization', 'Vaccination', 'Dose', '', None], [None, None, '(Years)', 'Subject', 'Date', 'Date', 'No.', None, None], ['', None, '16-55', 'C4591001 1090 10901334', '03SEP2020', '03SEP2020', '1', 'BNT162b2 (30 μg)', None], ['', '', '16-55', 'C4591001 1090 10901334', '03SEP2020', '24SEP2020', '2', 'BNT162b2 (30 μg)', ''], ['', '', '16-55', 'C4591001 1146 11461328', '23OCT2020', '13NOV2020', '2', '', ''], ['', '', '>55', 'C4591001 1054 10541024', '21AUG2020', '10OCT2020', '2', 'BNT162b2 (30 μg)', ''], ['', '', '>55', 'C4591001 1163 11631008', '31JUL2020', '31JUL2020', '1', '', ''], ['', '', '>55', 'C4591001 1177 11771089', '19AUG2020', '09SEP2020', '2', 'BNT162b2 (30 μg)', ''], ['', '', '>55', 'C4591001 1231 12311057', '11AUG2020', '11AUG2020', '1', 'BNT162b2 (30 μg)', ''], ['', '', '>55', 'C4591001 1265 12651026', '31AUG2020', '31AUG2020', '1', 'BNT162b2 (30 μg)', ''], ['', '', '>55', 'C4591001 1265 12651026', '31AUG2020', '21SEP2020', '2', 'BNT162b2 (30 μg)', ''], [None, '', '', '', '', '', '', '', None], ['Note: Data for subjects randomized on or after 10OCT2020 are included to comprehensively show all data reported but are subject to change with\nadditional follow-up.\nPFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 17NOV2020 (22:37)\n(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2 unblinded/C4591001 IA P3 2MPD2/adsl l001 p3 rand notvax', None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None]], [['additional follow-up.'], ['PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 17NOV2020 (22:37)'], ['(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: ./nda2 unblinded/C4591001 IA P3 2MPD2/adsl l001 p3 rand notvax']]]",3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdf,4.0,"CCI_Metastatic tumour
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Metastatic tumour
Code: 90002954
Extension: CCI
Report Date/Time: 27-Oct-2020:10:48:51 AM EDT
Term Code Level Category Weight Scope
Metastatic neoplasm 10061289 PT
Metastatic malignant melanoma 10027480 PT
Metastatic lymphoma 10071541 PT
Metastatic glucagonoma 10075245 PT
Metastatic glioma 10063157 PT
Metastatic gastric cancer 10063916 PT
Metastatic choriocarcinoma 10071532 PT
Metastatic carcinoma of the bladder 10057352 PT
Metastatic carcinoid tumour 10068115 PT
Metastatic bronchial carcinoma 10058306 PT
Metastasis 10062194 PT
Metastases to vagina 10075555 PT
Metastases to uterus 10049726 PT
Metastases to urinary tract 10056251 PT
Metastases to trachea 10051685 PT
Metastases to tonsils 10077476 PT
Metastases to thyroid 10049723 PT
Metastases to thorax 10051684 PT
Metastases to the respiratory system 10061600 PT
Metastases to the mediastinum 10027469 PT
Metastases to testicle 10051683 PT
Metastases to stomach 10049718 PT
Metastases to spleen 10051682 PT
Metastases to spine 10027468 PT
Metastases to spinal cord 10078267 PT
Metastases to soft tissue 10062197 PT
Metastases to skin 10027465 PT
Metastases to salivary gland 10051681 PT
Metastases to retroperitoneum 10051680 PT
Metastases to reproductive organ 10061288 PT
Metastases to rectum 10051679 PT
Metastases to prostate 10051678 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\a47cde691e771090
FDA-CBER-2021-5683-0023951
Metastases to pleura 10027463 PT
Metastases to placenta 10049725 PT
Metastases to pituitary gland 10049728 PT
Metastases to pharynx 10051677 PT
Metastases to peritoneum 10051676 PT
Metastases to peripheral vascular system 10058307 PT
Metastases to peripheral nervous system 10051674 PT
Metastases to perineum 10051673 PT
Metastases to penis 10051672 PT
Metastases to pelvis 10070913 PT
Metastases to pancreas 10049721 PT
Metastases to ovary 10027462 PT
Metastases to oesophagus 10051671 PT
Metastases to nervous system 10061287 PT
Metastases to neck 10027460 PT
Metastases to nasal sinuses 10051670 PT
Metastases to muscle 10049730 PT
Metastases to mouth 10051669 PT
Metastases to meninges 10051696 PT
Metastases to lymph nodes 10027459 PT
Metastases to lung 10027458 PT
Metastases to liver 10027457 PT
Metastases to larynx 10051668 PT
Intestinal metastasis 10080311 PT
Metastases to kidney 10027455 PT
Metastases to heart 10049717 PT
Metastases to gastrointestinal tract 10062196 PT
Metastases to gallbladder 10051667 PT
Metastases to fallopian tube 10049727 PT
Metastases to eye 10049724 PT
Metastases to Eustachian tube 10051666 PT
Metastases to diaphragm 10051665 PT
Metastases to chest wall 10051663 PT
Metastases to central nervous system 10059282 PT
Metastases to breast 10027454 PT
Metastases to bone marrow 10051662 PT
Metastases to bone 10027452 PT
Metastases to bladder 10049722 PT
Metastases to biliary tract 10062195 PT
Metastases to adrenals 10027451 PT
Metastases to abdominal wall 10051664 PT
Metastases to abdominal cavity 10027450 PT
Malignant neoplasm of pleura metastatic 10072432 PT
Malignant mesenchymoma metastatic 10025674 PT
Malignant meningioma metastatic 10077758 PT
Malignant haemangiopericytoma metastatic 10025567 PT
Malignant fibrous histiocytoma metastatic 10025554 PT
Malignant ascites 10025538 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\a47cde691e771090
FDA-CBER-2021-5683-0023952
Lymphangiosis carcinomatosa 10053132 PT
Lung squamous cell carcinoma metastatic 10071533 PT
Lung cancer metastatic 10050017 PT
Liposarcoma metastatic 10024629 PT
Leiomyosarcoma metastatic 10024191 PT
Laryngeal cancer metastatic 10070902 PT
Large cell lung cancer metastatic 10069730 PT
Hepatic cancer metastatic 10055110 PT
Head and neck cancer metastatic 10071540 PT
Germ cell cancer metastatic 10068971 PT
Gastrointestinal cancer metastatic 10053548 PT
Gallbladder cancer metastatic 10066879 PT
Fibrosarcoma metastatic 10016635 PT
Fallopian tube cancer metastatic 10016182 PT
Extraskeletal osteosarcoma metastatic 10015849 PT
Extraskeletal chondrosarcoma metastatic 10015840 PT
Extra-osseous Ewing's sarcoma metastatic 10015761 PT
Ewing's sarcoma metastatic 10015562 PT
Epithelioid sarcoma metastatic 10015101 PT
Endometrial sarcoma metastatic 10067065 PT
Endometrial cancer metastatic 10014734 PT
Dermatofibrosarcoma protuberans metastatic 10073574 PT
Colorectal cancer metastatic 10052358 PT
Colon cancer metastatic 10055114 PT
Chondrosarcoma metastatic 10008736 PT
Cervix cancer metastatic 10055094 PT
Breast sarcoma metastatic 10068583 PT
Breast cancer metastatic 10055113 PT
Breast angiosarcoma metastatic 10072814 PT
Brain cancer metastatic 10055093 PT
Bone cancer metastatic 10055101 PT
Bladder transitional cell carcinoma metastatic 10071664 PT
Biliary cancer metastatic 10055111 PT
Angiosarcoma non-metastatic 10057700 PT
Angiosarcoma metastatic 10002477 PT
Anal cancer metastatic 10055096 PT
Alveolar soft part sarcoma metastatic 10001884 PT
Adrenal gland cancer metastatic 10055095 PT
Vulval cancer metastatic 10047742 PT
Vaginal cancer metastatic 10046887 PT
Urethral melanoma metastatic 10072793 PT
Urethral cancer metastatic 10046433 PT
Ureteric cancer metastatic 10046394 PT
Transitional cell carcinoma metastatic 10071080 PT
Transitional cell cancer of renal pelvis and ureter metastatic 10044406 PT
Tonsil cancer metastatic 10072792 PT
Tongue cancer metastatic 10055109 PT
Thyroid cancer metastatic 10055107 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\a47cde691e771090
FDA-CBER-2021-5683-0023953
Thymic cancer metastatic 10055108 PT
Testicular germ cell cancer metastatic 10068694 PT
Testicular cancer metastatic 10055103 PT
Synovial sarcoma metastatic 10042864 PT
Small intestine carcinoma metastatic 10041121 PT
Small cell lung cancer metastatic 10059514 PT
Skin squamous cell carcinoma metastatic 10077314 PT
Skin cancer metastatic 10055115 PT
Sinus cancer metastatic 10055105 PT
Sarcoma metastatic 10068595 PT
Retroperitoneal neoplasm metastatic 10062485 PT
Renal cancer metastatic 10050018 PT
Rectosigmoid cancer metastatic 10069728 PT
Rectal cancer metastatic 10055097 PT
Prostate cancer metastatic 10036909 PT
Primitive neuroectodermal tumour metastatic 10068910 PT
Pituitary cancer metastatic 10055106 PT
Pharyngeal cancer metastatic 10055104 PT
Peritoneal carcinoma metastatic 10068974 PT
Peripheral neuroepithelioma of bone metastatic 10034603 PT
Penis carcinoma metastatic 10034329 PT
Pancreatic neuroendocrine tumour metastatic 10068909 PT
Pancreatic carcinoma metastatic 10033610 PT
Ovarian epithelial cancer metastatic 10033158 PT
Ovarian cancer metastatic 10057529 PT
Otic cancer metastatic 10055100 PT
Osteosarcoma metastatic 10031294 PT
Oral cavity cancer metastatic 10055098 PT
Oesophageal squamous cell carcinoma metastatic 10058527 PT
Oesophageal cancer metastatic 10055102 PT
Ocular cancer metastatic 10055099 PT
Non-small cell lung cancer metastatic 10059515 PT
Non-Hodgkin's lymphoma metastatic 10071535 PT
Neurofibrosarcoma metastatic 10029274 PT
Neuroendocrine tumour of the lung metastatic 10078175 PT
Neuroendocrine carcinoma metastatic 10071542 PT
Metastatic uterine cancer 10068116 PT
Metastatic squamous cell carcinoma 10063569 PT
Metastatic salivary gland cancer 10066882 PT
Metastatic renal cell carcinoma 10050513 PT
Metastatic pulmonary embolism 10069909 PT
Metastatic ocular melanoma 10068117 PT
Metastatic nervous system neoplasm 10077703 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\a47cde691e771090
FDA-CBER-2021-5683-0023954",,4
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdf,1.0,"CCI_Diabetes without comp
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Diabetes without comp
Code: 90002932
Extension: CCI
Report Date/Time: 27-Oct-2020:10:45:46 AM EDT
Term Code Level Category Weight Scope
Type 3 diabetes mellitus 10072659 PT
Type 2 diabetes mellitus 10067585 PT
Type 1 diabetes mellitus 10067584 PT
Somogyi phenomenon 10052093 PT
Shock hypoglycaemic 10040576 PT
Pancreatogenous diabetes 10033660 PT
Monogenic diabetes 10075980 PT
Mauriac syndrome 10060761 PT
Latent autoimmune diabetes in adults 10066389 PT
Insulin-requiring type 2 diabetes mellitus 10053247 PT
Insulin resistant diabetes 10022491 PT
Increased insulin requirement 10021664 PT
Hypoglycaemic coma 10021000 PT
Hyperglycaemic hyperosmolar nonketotic syndrome 10063554 PT
Hyperinsulinaemic hypoglycaemia 10077216 PT
Fulminant type 1 diabetes mellitus 10072628 PT
Diabetic metabolic decompensation 10074309 PT
Diabetic ketoacidosis 10012671 PT
Diabetic hyperosmolar coma 10012669 PT
Diabetic hyperglycaemic coma 10012668 PT
Diabetic hepatopathy 10071265 PT
Diabetic dyslipidaemia 10070901 PT
Diabetic coma 10012650 PT
Diabetic cardiomyopathy 10012647 PT
Diabetes with hyperosmolarity 10012631 PT
Diabetes mellitus malnutrition-related 10050197 PT
Diabetes mellitus inadequate control 10012607 PT
Diabetes mellitus 10012601 PT
Decreased insulin requirement 10052340 PT
Acquired lipoatrophic diabetes 10073667 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\083dde691e771090
FDA-CBER-2021-5683-0023929",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-errata.pdf,1.0,"C4591001
ERRATA
Not applicable. There are no errata to report.
PFIZER CONFIDENTIAL
)TMG(
25:20
0202-ceD-30
:nO
devorppA\devorppA\40c038591e771090
FDA-CBER-2021-5683-0014039
Page 1",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_waiver-req-designated-suffix.pdf,4.0,"BNT162b2
Module 1.12.5 WaiverRequestfor FDA Designated Suffix for Biologics
BLA 125742
COVID-19 mRNA Vaccine (nucleoside modified)
WAIVER REQUEST FOR FDA-DESIGNATED SUFFIX FOR BIOLOGICS
MARCH 2020
PFIZER CONFIDENTIAL
Page 1
)TMG(
61:00
1202-raM-72
:nO
laniF\laniF\ad733a691e771090
FDA-CBER-2021-5683-0013738
BNT162b2
Module 1.12.5 WaiverRequestfor FDA Designated Suffix for Biologics
TABLE OF CONTENTS
1. INTRODUCTION.................................................................................................................3
2. EXISTING METHODS TO ENSURE SAFE DISPENSING AND OPTIMAL
PHARMACOVIGILANCE OFVACCINES.......................................................................3
2.1. VACCINATION RECORD KEEPING METHODS...............................................3
2.2. VACCINE SAFETY MONITORING SYSTEMS...................................................4
3. CONCLUSION......................................................................................................................4
PFIZER CONFIDENTIAL
Page 2
)TMG(
61:00
1202-raM-72
:nO
laniF\laniF\ad733a691e771090
FDA-CBER-2021-5683-0013739
BNT162b2
Module 1.12.5 WaiverRequestfor FDA Designated Suffix for Biologics
1. INTRODUCTION
Reference is made to BLA 125742for BNT162b2 [Proposed Proprietary Name
“COMIRNATY”; Proposed Nonproprietary Name “COVID-19 mRNA Vaccine (nucleoside
modified)”]. BNT162b2 is a prophylactic vaccine developed by BioNTech and Pfizer to
prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2 infection. The
proposed indicationthat is the subject of this initial BLA applicationis active immunization
to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)in individuals 16 years of age and older.
Further reference is made to the draft Guidance for Industry “Nonproprietary Naming of
Biological Products: Update (March 2019)”. As outlined in this guidance, the purpose of the
suffix is to ensure safe dispensing and optimal pharmacovigilance of biologic products
approved under section 351 of the Public Health Service Act (PHS) that do not contain an
FDA designated suffix. Further to this the guidance also states that “Vaccines are currently
within the scope of the naming convention described in the Naming Guidance. However,
“FDA is reconsidering that approach and is evaluating whether the currently available
identification systems associated with the administration of vaccines are sufficiently robust to
ensure safe dispensing practices and optimal pharmacovigilance without requiring
distinguishable proper names”. Pfizer believes that an additional suffix forCOVID-19
mRNA Vaccine (nucleoside modified)would be burdensome and redundant as the US
Department of Health and Human Services (HHS) has existing methods to ensure safe
dispensing and optimal pharmacovigilance of vaccines. These methods include existing
vaccination record keeping practices and vaccine safety and monitoring systems. Further to
this, the addition of a suffix may be redundant and lead to confusion in dispensing and
administrationof the vaccine.
2. EXISTING METHODS TO ENSURE SAFE DISPENSING AND OPTIMAL
PHARMACOVIGILANCE OFVACCINES
As noted above there are several methodologies currently used to ensure the safe use of
vaccines. These methods ensure robust adverse event reporting,monitoring and tracking of
vaccine administration. These methods combined are robust and support the fact that the
addition of a suffix would not be necessaryfor vaccines.
2.1. VACCINATION RECORD KEEPING METHODS
Existing vaccination record keeping methods include;
o The National Childhood Vaccine Injury Act which requires Health Care
Professionals to provide a vaccine information statement (VIS) to
patients/guardians prior to administration as well as to report adverse events to
the Vaccine Adverse Event Reporting System (VAERS)
o Immunization Information Systems consolidate vaccination histories to help
assure timely vaccination scheduling and provides aggregate vaccination data
for use in surveillance systems as well as to inform on public health decisions
and goals related to vaccines.
PFIZER CONFIDENTIAL
Page 3
)TMG(
61:00
1202-raM-72
:nO
laniF\laniF\ad733a691e771090
FDA-CBER-2021-5683-0013740
BNT162b2
Module 1.12.5 WaiverRequestfor FDA Designated Suffix for Biologics
2.2. VACCINE SAFETY MONITORING SYSTEMS
Vaccine safety monitoring systems include;
o Vaccine Adverse Event Reporting System (VAERS) is designed to detect
safety concerns with vaccines. HCPs and manufactures are required to report
adverse events to VAERS. Consumers can also report to this system and
further reporting may be burdensome and discouraging.
o Vaccine Safety Datalink (VSD) which utilizes data from doctors’ offices,
urgent care visits, emergency department visits, and hospital stays to monitors
vaccine safety and conduct studies on rare and serious side effects of vaccines.
These studies also include concerns raised in literature. The VSD also submits
their reports to VAERS.
o The Post-Licensure Rapid Immunization Monitoring System (PRISM) is yet
another means by which vaccine safety is evaluated.As part of the Agency’s
Sentinel system, PRISM is linked to statewide registries and is being used to
develop signal detection tools for evaluation of adverse events.
3. CONCLUSION
As outlined above, there are adequatepolicies and systems in place to ensure the safe
dispensing and optimal pharmacovigilance of vaccineswhich COVID-19 will be subject to.
Additional requirements such as a designated suffix may be redundant and burdensome.
Toward that end, werespectfully request a waiver from the requirement for anFDA
designated suffix for COVID-19mRNA Vaccine (nucleoside modified), the subject of this
BLA application.
PFIZER CONFIDENTIAL
Page 4
)TMG(
61:00
1202-raM-72
:nO
laniF\laniF\ad733a691e771090
FDA-CBER-2021-5683-0013741",,4
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdf,1.0,"CCI_Peptic ulcer
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Peptic ulcer
Code: 90002938
Extension: CCI
Report Date/Time: 27-Oct-2020:10:52:28 AM EDT
Term Code Level Category Weight Scope
Peptic ulcer 10034341 PT
Gastric ulcer, obstructive 10017840 PT
Gastric ulcer perforation, obstructive 10017836 PT
Gastric ulcer perforation 10017835 PT
Gastric ulcer haemorrhage, obstructive 10017829 PT
Gastric ulcer haemorrhage 10017826 PT
Gastric ulcer 10017822 PT
Duodenal ulcer, obstructive 10013855 PT
Duodenal ulcer perforation, obstructive 10013850 PT
Duodenal ulcer perforation 10013849 PT
Duodenal ulcer haemorrhage 10013839 PT
Duodenal ulcer 10013836 PT
Peptic ulcer, obstructive 10034365 PT
Peptic ulcer perforation, obstructive 10034358 PT
Peptic ulcer perforation 10034354 PT
Peptic ulcer haemorrhage 10034344 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\e47cde691e771090
FDA-CBER-2021-5683-0023966",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_debarment.pdf,1.0,"(cid:37)(cid:49)(cid:55)(cid:20)(cid:25)(cid:21)(cid:69)(cid:21)
(cid:20)(cid:17)(cid:22)(cid:17)(cid:22)(cid:39)(cid:72)(cid:69)(cid:68)(cid:85)(cid:80)(cid:72)(cid:81)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
(cid:37)(cid:47)(cid:36)(cid:20)(cid:21)(cid:24)(cid:26)(cid:23)(cid:21)
(cid:38)(cid:50)(cid:57)(cid:44)(cid:39)(cid:16)(cid:20)(cid:28)(cid:57)(cid:36)(cid:38)(cid:38)(cid:44)(cid:49)(cid:40)
(cid:39)(cid:40)(cid:37)(cid:36)(cid:53)(cid:48)(cid:40)(cid:49)(cid:55)(cid:38)(cid:40)(cid:53)(cid:55)(cid:44)(cid:41)(cid:44)(cid:38)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)
(cid:62)(cid:41)(cid:39)(cid:9)(cid:38)(cid:36)(cid:70)(cid:87)(cid:22)(cid:19)(cid:25)(cid:11)(cid:78)(cid:12)(cid:11)(cid:20)(cid:12)(cid:64)
(cid:37)(cid:76)(cid:82)(cid:49)(cid:55)(cid:72)(cid:70)(cid:75)(cid:48)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:42)(cid:80)(cid:69)(cid:43)(cid:75)(cid:72)(cid:85)(cid:72)(cid:69)(cid:92)(cid:70)(cid:72)(cid:85)(cid:87)(cid:76)(cid:73)(cid:76)(cid:72)(cid:86)(cid:87)(cid:75)(cid:68)(cid:87)(cid:76)(cid:87)(cid:71)(cid:76)(cid:71)(cid:81)(cid:82)(cid:87)(cid:68)(cid:81)(cid:71)(cid:90)(cid:76)(cid:79)(cid:79)(cid:81)(cid:82)(cid:87)(cid:88)(cid:86)(cid:72) (cid:76)(cid:81)(cid:68)(cid:81)(cid:92)(cid:70)(cid:68)(cid:83)(cid:68)(cid:70)(cid:76)(cid:87)(cid:92)
(cid:87)(cid:75)(cid:72) (cid:86)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86) (cid:82)(cid:73) (cid:68)(cid:81)(cid:92) (cid:83)(cid:72)(cid:85)(cid:86)(cid:82)(cid:81) (cid:71)(cid:72)(cid:69)(cid:68)(cid:85)(cid:85)(cid:72)(cid:71) (cid:88)(cid:81)(cid:71)(cid:72)(cid:85) (cid:54)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81) (cid:22)(cid:19)(cid:25) (cid:82)(cid:73) (cid:87)(cid:75)(cid:72) (cid:41)(cid:72)(cid:71)(cid:72)(cid:85)(cid:68)(cid:79) (cid:41)(cid:82)(cid:82)(cid:71) (cid:39)(cid:85)(cid:88)(cid:74) (cid:68)(cid:81)(cid:71) (cid:38)(cid:82)(cid:86)(cid:80)(cid:72)(cid:87)(cid:76)(cid:70)
(cid:36)(cid:70)(cid:87) (cid:76)(cid:81) (cid:70)(cid:82)(cid:81)(cid:81)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81) (cid:90)(cid:76)(cid:87)(cid:75) (cid:87)(cid:75)(cid:76)(cid:86) (cid:68)(cid:83)(cid:83)(cid:79)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:17)
Digitally signed by Ruben Rizzi
Ruben Rizzi
Date: 2021.03.30 08:33:08
+02'00'
(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
(cid:54)(cid:76)(cid:74)(cid:81)(cid:68)(cid:87)(cid:88)(cid:85)(cid:72) (cid:82)(cid:73)(cid:36)(cid:83)(cid:83)(cid:79)(cid:76)(cid:70)(cid:68)(cid:81)(cid:87) (cid:39)(cid:68)(cid:87)(cid:72)
(cid:53)(cid:88)(cid:69)(cid:72)(cid:81)(cid:53)(cid:76)(cid:93)(cid:93)(cid:76)
(cid:37)(cid:76)(cid:82)(cid:49)(cid:55)(cid:72)(cid:70)(cid:75)(cid:48)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:42)(cid:80)(cid:69)(cid:43)
Neda Aghajani Digitally signed by Neda Aghajani Memar
DN: cn=Neda Aghajani Memar, o, ou,
email=neda.aghajanimemar@pfizer.com, c=US
Memar Reason: I attest to the accuracy and integrity of this
document
(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)Da(cid:66)te:(cid:66) 20(cid:66)21.(cid:66)03.(cid:66)29 (cid:66)15:(cid:66)07(cid:66):36(cid:66) -04(cid:66)'00(cid:66)' (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66) (cid:66)(cid:66)2(cid:66)9(cid:66)M(cid:66)(cid:66)a(cid:66)rc(cid:66)h(cid:66)2(cid:66)0(cid:66)2(cid:66)1(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
(cid:54)(cid:76)(cid:74)(cid:81)(cid:68)(cid:87)(cid:88)(cid:85)(cid:72) (cid:82)(cid:73) (cid:36)(cid:88)(cid:87)(cid:75)(cid:82)(cid:85)(cid:76)(cid:93)(cid:72)(cid:71) (cid:56)(cid:54) (cid:36)(cid:74)(cid:72)(cid:81)(cid:87) (cid:39)(cid:68)(cid:87)(cid:72)
(cid:49)(cid:72)(cid:71)(cid:68) (cid:36)(cid:74)(cid:75)(cid:68)(cid:77)(cid:68)(cid:81)(cid:76) (cid:48)(cid:72)(cid:80)(cid:68)(cid:85)
(cid:51)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:44)(cid:81)(cid:70)(cid:17)
(cid:38)(cid:50)(cid:49)(cid:41)(cid:44)(cid:39)(cid:40)(cid:49)(cid:55)(cid:44)(cid:36)(cid:47)
(cid:51)(cid:68)(cid:74)(cid:72)(cid:20)
FDA-CBER-2021-5683-0013767",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdf,1.0,"CCI_Hemiplegia
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Hemiplegia
Code: 90002927
Extension: CCI
Report Date/Time: 27-Oct-2020:10:46:23 AM EDT
Term Code Level Category Weight Scope
Tropical spastic paresis 10044696 PT
Tick paralysis 10077336 PT
Thoracic spinal cord paralysis 10057277 PT
Supranuclear palsy 10048327 PT
Spinal cord paralysis 10057268 PT
Quadriplegia 10037714 PT
Quadriparesis 10049680 PT
Pseudobulbar palsy 10037114 PT
Peripheral paralysis 10054808 PT
Paresis 10033985 PT
Paraplegia 10033892 PT
Paraparesis 10033885 PT
Paralysis 10033799 PT
Monoplegia 10027926 PT
Monoparesis 10027925 PT
Man-in-the-barrel syndrome 10049642 PT
Lumbar spinal cord paralysis 10057278 PT
Locked-in syndrome 10024792 PT
Hereditary spastic paraplegia 10019903 PT
Hemiplegia 10019468 PT
Hemiparesis 10019465 PT
Gait spastic 10017585 PT
Diplegia 10013033 PT
Cervical spinal cord paralysis 10057276 PT
Cerebral palsy 10008129 PT
Cauda equina syndrome 10007821 PT
Acute post asthmatic amyotrophy 10066224 PT
)TMG(
21:00
1202-yaM-10
:nO
laniF\laniF\c73dde691e771090
FDA-CBER-2021-5683-0023931",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-pulmonary.pdf,2.0,"CCI_Pulmonary
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Pulmonary
Code: 90002942
Extension: CCI
Report Date/Time: 27-Oct-2020:10:53:42 AM EDT
Term Code Level Category Weight Scope
Pulmonary pneumatocele 10063749 PT
Pulmonary ossification 10070310 PT
Pulmonary necrosis 10058824 PT
Pulmonary interstitial emphysema syndrome 10037415 PT
Pulmonary hypertensive crisis 10068726 PT
Pulmonary hypertension 10037400 PT
Pulmonary fibrosis 10037383 PT
Pulmonary eosinophilia 10037382 PT
Pulmonary cavitation 10051738 PT
Pulmonary calcification 10051200 PT
Pulmonary artery wall hypertrophy 10063561 PT
Pulmonary arterial hypertension 10064911 PT
Pulmonary amyloidosis 10063945 PT
Pulmonary alveolar microlithiasis 10037315 PT
Progressive massive fibrosis 10036805 PT
Portopulmonary hypertension 10067281 PT
Pneumonitis 10035742 PT
Pneumoconiosis 10035653 PT
Organic dust toxic syndrome 10075078 PT
Occupational asthma 10070836 PT
Obstructive airways disorder 10061877 PT
Obliterative bronchiolitis 10029888 PT
Noninfective bronchitis 10062644 PT
Middle lobe syndrome 10056652 PT
MacLeod's syndrome 10025375 PT
Loeffler's syndrome 10024794 PT
Interstitial lung disease 10022611 PT
Infective exacerbation of chronic obstructive airways disease 10056971 PT
Infective exacerbation of bronchiectasis 10070295 PT
Childhood asthma 10081274 PT
Idiopathic pulmonary fibrosis 10021240 PT
Idiopathic pneumonia syndrome 10063725 PT
Idiopathic interstitial pneumonia 10078268 PT
Granulomatous pneumonitis 10069152 PT
Fibrinous bronchitis 10051011 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\812dde691e771090
FDA-CBER-2021-5683-0023973
Eosinophilic bronchitis 10065563 PT
Emphysema 10014561 PT
Dust inhalation pneumopathy 10061112 PT
Diffuse panbronchiolitis 10062952 PT
Diffuse alveolar damage 10060902 PT
Cor pulmonale chronic 10010970 PT
Cor pulmonale 10010968 PT
Combined pulmonary fibrosis and emphysema 10076515 PT
Chronic respiratory failure 10009126 PT
Chronic respiratory disease 10061768 PT
Chronic obstructive pulmonary disease 10009033 PT
Byssinosis 10006822 PT
Cystic lung disease 10078811 PT
Bronchostenosis 10006487 PT
Bronchospasm paradoxical 10006486 PT
Bronchospasm 10006482 PT
Bronchopulmonary disease 10053420 PT
Bronchopulmonary aspergillosis 10006473 PT
Bronchitis chronic 10006458 PT
Bronchiectasis 10006445 PT
Bronchial obstruction 10006440 PT
Berylliosis 10004485 PT
Atelectasis 10003598 PT
Asthmatic crisis 10064823 PT
Asthma-chronic obstructive pulmonary disease overlap syndrome 10077005 PT
Asthma late onset 10003559 PT
Asthma exercise induced 10003557 PT
Asthma 10003553 PT
Aspirin-exacerbated respiratory disease 10075084 PT
Asbestosis 10003441 PT
Alveolitis necrotising 10050343 PT
Hypersensitivity pneumonitis 10081988 PT
Alveolitis 10001889 PT
Alveolar proteinosis 10001881 PT
Alveolar lung disease 10073344 PT
Allergic bronchitis 10052613 PT
Airway remodelling 10075289 PT
Acute interstitial pneumonitis 10066728 PT
Systemic sclerosis pulmonary 10042954 PT
Status asthmaticus 10041961 PT
Silicosis 10040678 PT
Reversible airways obstruction 10062109 PT
Restrictive pulmonary disease 10048667 PT
Respiratory fume inhalation disorder 10061485 PT
Reactive airways dysfunction syndrome 10070832 PT
Radiation fibrosis - lung 10037758 PT
Pulmonary sarcoidosis 10037430 PT
Pulmonary radiation injury 10061473 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\812dde691e771090
FDA-CBER-2021-5683-0023974",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_trans-of-oblig.pdf,2.0,"BNT162b2
Module 1.3.1.4 Transfer of Obligations
TRANSFER OF OBLIGATIONS
In compliance with 21 CFR 312.52, Table 1 below lists the Sponsor responsibilities* that were
transferred from BioNTech SE to Pfizer Inc. in the conduct of the C4591001 clinical study, with
the specific obligations that were transferred. Any obligation not provided in the written
description below shall be deemed not to have been transferred.
Table 1. Sponsor Obligations Transferred to Pfizer Related to the Conduct of Study
C4591001
STUDY(S) OBLIGATIONS ASSUMED /
NAME AND
CONTRACTED TRANSFERRED
ADDRESS
Pfizer Inc.
C4591001 21 CFR 312.50 Ensuring that the investigation is
445 Eastern Point Road,
conducted in accordance with the approved investigational
Groton, CT 06340
plan, the approved protocol and Good Clinical Practice
United States
(GCP)
21 CFR 312.53(a) Selecting investigators with qualified
training and Experience
21 CFR 312.53(c) Obtaining information from
investigators, including a signed investigator statement
(Form FDA 1572); curriculum vitae; financial disclosure
information required under 21 CFR 54
21 CFR 312.53(d) Selecting monitors qualified by training
and experience
21 CFR 312.55(a) Providing investigators with the
information they need to conduct the investigation
properly
21 CFR 312.55(b) Informing investigators of new
observations with respect to adverse events and safe use
21 CFR 312.56(a) Ensuring proper monitoring of the
clinical trial
21 CFR 312.56(b) Secure compliance or discontinue
shipments from investigators found not to comply with
signed agreement (FDA 1572), the general investigational
plan, or other requirements under 21 CFR 312
21 CFR 312.56(c) Review and evaluate evidence of safety
and effectiveness of drug
Pfizer Confidential
1
FDA-CBER-2021-5683-0013765
BNT162b2
Module 1.3.1.4 Transfer of Obligations
Table 1. Sponsor Obligations Transferred to Pfizer Related to the Conduct of Study
C4591001
STUDY(S) OBLIGATIONS ASSUMED /
NAME AND
CONTRACTED TRANSFERRED
ADDRESS
21 CFR 312.56(d) Ensure discontinuation of the study if
the drug presents an unreasonable and significant risk to
study subjects; notification to FDA and IRB of
discontinuation
21 CFR 312.57 Maintenance of records and reports
21 CFR 312.59 Drug accountability (e.g. record of
shipment, receipt, method of disposal); ensuring all
unused drug is returned or properly disposed of
Responsible for maintaining an effective IND and
ensuring that FDA is promptly informed of: 1) reportable
adverse effects or risks with respect to the drug; 2)
significant changes to the protocol; 3) addition(s) of new
investigators; 4) annual reviews
*Where applicable, contractors who performed clinical supplies manufacturing, packaging, labeling and/or testing
are noted in Module 3 Section P.3.1 of the IND and are, therefore, not included in Table 1.
Pfizer Confidential
2 FDA-CBER-2021-5683-0013766","[[['', '', '', 'STUDY(S)\nCONTRACTED', 'OBLIGATIONS ASSUMED /\nTRANSFERRED'], [None, 'NAME AND', None, None, None], [None, 'ADDRESS', None, None, None], ['Pfizer Inc.\n445 Eastern Point Road,\nGroton, CT 06340\nUnited States', None, None, 'C4591001', '21 CFR 312.50 Ensuring that the investigation is\nconducted in accordance with the approved investigational\nplan, the approved protocol and Good Clinical Practice\n(GCP)\n21 CFR 312.53(a) Selecting investigators with qualified\ntraining and Experience\n21 CFR 312.53(c) Obtaining information from\ninvestigators, including a signed investigator statement\n(Form FDA 1572); curriculum vitae; financial disclosure\ninformation required under 21 CFR 54\n21 CFR 312.53(d) Selecting monitors qualified by training\nand experience\n21 CFR 312.55(a) Providing investigators with the\ninformation they need to conduct the investigation\nproperly\n21 CFR 312.55(b) Informing investigators of new\nobservations with respect to adverse events and safe use\n21 CFR 312.56(a) Ensuring proper monitoring of the\nclinical trial\n21 CFR 312.56(b) Secure compliance or discontinue\nshipments from investigators found not to comply with\nsigned agreement (FDA 1572), the general investigational\nplan, or other requirements under 21 CFR 312\n21 CFR 312.56(c) Review and evaluate evidence of safety\nand effectiveness of drug']], [['STUDY(S)'], ['CONTRACTED']], [['OBLIGATIONS ASSUMED /'], ['TRANSFERRED']], [['', '', '', 'STUDY(S)\nCONTRACTED', 'OBLIGATIONS ASSUMED /\nTRANSFERRED'], [None, 'NAME AND', None, None, None], [None, 'ADDRESS', None, None, None], ['', None, None, '', '21 CFR 312.56(d) Ensure discontinuation of the study if\nthe drug presents an unreasonable and significant risk to\nstudy subjects; notification to FDA and IRB of\ndiscontinuation\n21 CFR 312.57 Maintenance of records and reports\n21 CFR 312.59 Drug accountability (e.g. record of\nshipment, receipt, method of disposal); ensuring all\nunused drug is returned or properly disposed of\nResponsible for maintaining an effective IND and\nensuring that FDA is promptly informed of: 1) reportable\nadverse effects or risks with respect to the drug; 2)\nsignificant changes to the protocol; 3) addition(s) of new\ninvestigators; 4) annual reviews']], [['STUDY(S)'], ['CONTRACTED']], [['OBLIGATIONS ASSUMED /'], ['TRANSFERRED']]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_26_pharmkin-tabulated-summary.pdf,14.0,"BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
MODULE 2.6.5. PHARMACOKINETICS TABULATEDSUMMARY
This document contains confidential information belonging to BioNTech/Pfizer. Except as may be
otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such
information in confidence and not to disclose it to others (except where required by applicable
law), nor to use it for unauthorized purposes. In the event of actual or suspected breach of this
obligation, BioNTech/Pfizershould be promptly notified.
CONFIDENTIAL
Page 1
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013907
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.1. PHARMACOKINETICS OVERVIEW Test Article: BNT162b2
Type of Study Test System Test item Method of Testing Facility Report Number
Administration
Single Dose Pharmacokinetics
Single Dose Rat (Wistar Han) modRNA encoding IV bolus Pfizer Inca PF-07302048_06Jul20_072424
Pharmacokinetics and luciferase
Excretion in Urine and Feces formulated in LNP
of ALC-0159 and ALC-0315 comparable to
BNT162b2
Distribution
In Vivo Distribution Mice (BALB/c) modRNA encoding IM Injection BioNTechb R-20-0072
luciferase
formulated in LNP
comparable to
BNT162b2
In Vivo Distribution Rat (Wistar Han) modRNA encoding IM Injection 185350
luciferase
formulated in LNP
comparable to
BNT162b2 with
trace amounts of
[3H]-CHE as
non-diffusible label
Metabolism
In Vitro and In Vivo Metabolism
In Vitro Metabolic Stability Mouse (CD-1/ICR), rat ALC-0315 In vitro 01049-20008
of ALC-0315in Liver (Sprague Dawleyand
Microsomes Wistar Han), monkey
(Cynomolgus), and
human liver microsomes
In Vitro Metabolic Stability Mouse (CD-1/ICR), rat ALC-0315 In vitro 01049-20009
of ALC-0315in Liver S9 (Sprague Dawley),
monkey (Cynomolgus),
and human S9 liver
fractions
CONFIDENTIAL
Page 2
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-0013908
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.1. PHARMACOKINETICS OVERVIEW Test Article: BNT162b2
Type of Study Test System Test item Method of Testing Facility Report Number
Administration
In Vitro Metabolic Stability Mouse (CD-1/ICR), rat ALC-0315 In vitro 01049-20010
of ALC-0315in Hepatocytes (Sprague Dawley and
Wistar Han), monkey
(Cynomolgus), and
human hepatocytes
In Vitro Metabolic Stability Mouse (CD-1/ICR), rat ALC-0159 In vitro 01049-20020
of ALC-0159 in Liver (Sprague Dawley and
Microsomes Wistar Han), monkey
(Cynomolgus), and
human liver microsomes
In Vitro Metabolic Stability Mouse (CD-1/ICR), rat ALC-0159 In vitro 01049-20021
of ALC-0159 in Liver S9 (Sprague Dawley),
monkey (Cynomolgus),
and human S9 fractions
In Vitro Metabolic Stability Mouse (CD-1/ICR), rat ALC-0159 In vitro 01049-20022
of ALC-0159 in Hepatocytes (Sprague Dawley and
Wistar Han), monkey
(Cynomolgus), and
human hepatocytes
Biotransformation of In vitro: ALC-0315 and In vitro or Pfizer Ince PF-07302048_05Aug20_043725
ALC-0159 and ALC-0315 In CD-1mouse,Wistar ALC-0159 IV (in vivo in
Vitro and In Vivo in Rats Hanrat,cynomolgus rats)
monkey, and human
blood, liver S9fractions
and hepatocytes
In vivo: male Wistar Han
rats
CONFIDENTIAL
Page 3
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-0013909
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.1. PHARMACOKINETICS OVERVIEW Test Article: BNT162b2
Type of Study Test System Test item Method of Testing Facility Report Number
Administration
ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide), a proprietary polyethylene glycol-lipidincluded as an excipient in the LNP formulation
used in BNT162b2; ALC-0315 = (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), a proprietary aminolipid included as an excipient in the
LNP formulation used in BNT162b2;[3H]-CHE= radiolabeled [cholesteryl-1,2-3H(N)]-cholesteryl hexadecyl ether;IM = Intramuscular; IV = Intravenous; LNP
= lipid nanoparticles; S9 = Supernatant fraction obtained from liver homogenate by centrifuging at 9000 g.
a. La Jolla, California.
b. Mainz, Germany.
e. Groton, Connecticut.
CONFIDENTIAL
Page 4
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
(b) (4)
FDA-CBER-2021-5683-0013910
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.3. PHARMACOKINETICS: Test Article: modRNA encoding luciferasein LNP
PHARMACOKINETICS AFTER A SINGLE DOSE Report Number: PF-07302048_06Jul20_072424
Species (Strain) Rat (WistarHan)
Sex/Number of Animals Male/ 3 animals per timepointa
Feeding Condition Fasted
Method of Administration IV
Dose modRNA (mg/kg) 1
Dose ALC-0159 (mg/kg) 1.96
Dose ALC-0315 (mg/kg) 15.3
Sample Matrix Plasma, liver, urine and feces
Sampling Time Points (h post dose): Predose, 0.1, 0.25, 0.5, 1, 3, 6, 24, 48, 96, 192, 336
Analyte ALC-0315 ALC-0159
PK Parameters: Meanb Meanb
AUC (µg•h/mL)c 1030 99.2
inf
AUC (µg•h/mL) 1020 98.6
last
Initial t (h)d 1.62 1.74
½
Terminal elimination t (h)e 139 72.7
½
Estimated fraction of dose distributed to liver (%)f 59.5 20.3
Dose in Urine (%) NCg NCg
Dose in Feces (%)h 1.05 47.2
ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide), a proprietary polyethylene glycol-lipid included as an excipient in the LNP formulation
used in BNT162b2; ALC-0315 = (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), a proprietary aminolipid included as an excipient in the
LNP formulation used in BNT162b2; AUC = Area under the plasma drug concentration-time curve from 0 to infinite time; AUC = Area under the plasma
inf last
drug concentration-time curve from 0 to the last quantifiable time point; BLQ = Below the limit of quantitation; LNP = Lipid nanoparticle;
modRNA=Nucleoside modified messenger RNA; PK = Pharmacokinetics; t = Half-life.
½
a. Non-serial sampling, 36 animals total.
b. Only mean PK parameters are reported due to non-serial sampling.
c. Calculated using the terminallog-linear phase(determined using 48, 96, 192, and 336 h for regression calculation).
d. ln(2)/initial elimination rate constant (determined using 1,3, and 6 h for regression calculation).
e. ln(2)/terminal elimination rate constant (determined using 48, 96, 192, and 336 hfor regression calculation).
f. Calculated as follows: highest mean amount in the liver (µg)/total mean dose (µg) of ALC-0315 or ALC-0159.
g. Not calculated due to BLQ data.
h. Fecal excretion, calculated as: (mean µg of analytein feces/ mean µg of analyte administered) × 100
CONFIDENTIAL
Page 5
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013911
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.5A. PHARMACOKINETICS:ORGAN Test Article: modRNA encoding luciferasein LNP
DISTRIBUTION Report Number: R-20-0072
Species (Strain): Mice (BALB/c)
Sex/Number of Animals: Female/3 per group
Feeding Condition: Fed ad libitum
Vehicle/Formulation: Phosphate-buffered saline
Method of Administration: Intramuscular injection
Dose (mg/kg): 1 µg/hind leg in gastrocnemius muscle (2 µg total)
Number of Doses: 1
Detection: Bioluminescence measurement
Sampling Time(hour): 6, 24, 48, 72hours; 6 and 9 days post-injection
Time point Total Mean Bioluminescencesignal (photons/second) Mean Bioluminescence signal in
the liver (photons/second)
Buffer control modRNALuciferase in LNP modRNALuciferase in LNP
6 hours 1.28×105 1.26×109 4.94×107
24 hours 2.28×105 7.31×108 2.4×106
48 hours 1.40×105 2.10×108 Below detectiona
72 hours 1.33×105 7.87×107 Below detectiona
6 days 1.62×105 2.92×106 Below detectiona
9 days 7.66×104 5.09×105 Below detectiona
LNP = Lipid nanoparticle; modRNA=Nucleoside modified messenger RNA.
a. At or below the background level of the buffer control.
CONFIDENTIAL
Page 6
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013912
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.5B. PHARMACOKINETICS: ORGAN Test Article: [3H]-Labelled LNP-mRNAformulation containing
DISTRIBUTION CONTINUED ALC-0315 and ALC-0159
Report Number: 185350
Species (Strain): Rat (Wistar Han)
Sex/Number of Animals: Male and female/3animals/sex/timepoint (21 animals/sex totalfor the 50 µg dose)
Feeding Condition: Fed ad libitum
Method of Administration: Intramuscular injection
Dose: 50µg[3H]-08-A01-C0(lot # NC-0552-1)
Number of Doses: 1
Detection: Radioactivity quantitation using liquid scintillation counting
Sampling Time(hour): 0.25, 1, 2, 4, 8, 24, and 48hourspost-injection
Sample Mean total lipid concentration (µg lipid equivalent/g (or mL) % of administered dose (males and females combined)
(males and females combined)
0.25 min 1 h 2 h 4 h 8 h 24 h 48 h 0.25 min 1 h 2 h 4 h 8 h 24 h 48 h
Adiposetissue 0.057 0.100 0.126 0.128 0.093 0.084 0.181 -- -- -- -- -- -- --
Adrenalglands 0.271 1.48 2.72 2.89 6.80 13.8 18.2 0.001 0.007 0.010 0.015 0.035 0.066 0.106
Bladder 0.041 0.130 0.146 0.167 0.148 0.247 0.365 0.000 0.001 0.001 0.001 0.001 0.002 0.002
Bone (femur) 0.091 0.195 0.266 0.276 0.340 0.342 0.687 -- -- -- -- -- -- --
Bone marrow 0.479 0.960 1.24 1.24 1.84 2.49 3.77 -- -- -- -- -- -- --
(femur)
Brain 0.045 0.100 0.138 0.115 0.073 0.069 0.068 0.007 0.013 0.020 0.016 0.011 0.010 0.009
Eyes 0.010 0.035 0.052 0.067 0.059 0.091 0.112 0.000 0.001 0.001 0.002 0.002 0.002 0.003
Heart 0.282 1.03 1.40 0.987 0.790 0.451 0.546 0.018 0.056 0.084 0.060 0.042 0.027 0.030
Injection site 128 394 311 338 213 195 165 19.9 52.6 31.6 28.4 21.9 29.1 24.6
Kidneys 0.391 1.16 2.05 0.924 0.590 0.426 0.425 0.050 0.124 0.211 0.109 0.075 0.054 0.057
Large intestine 0.013 0.048 0.093 0.287 0.649 1.10 1.34 0.008 0.025 0.065 0.192 0.405 0.692 0.762
Liver 0.737 4.63 11.0 16.5 26.5 19.2 24.3 0.602 2.87 7.33 11.9 18.1 15.4 16.2
Lung 0.492 1.21 1.83 1.50 1.15 1.04 1.09 0.052 0.101 0.178 0.169 0.122 0.101 0.101
CONFIDENTIAL
Page 7
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013913
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.5B. PHARMACOKINETICS: ORGAN Test Article: [3H]-Labelled LNP-mRNAformulation containing
DISTRIBUTION CONTINUED ALC-0315 and ALC-0159
Report Number: 185350
Sample Total Lipid concentration (µg lipid equivalent/g [or mL]) % of Administered Dose (males and females combined)
(males and females combined)
0.25 min 1 h 2 h 4 h 8 h 24 h 48 h 0.25 min 1 h 2 h 4 h 8 h 24 h 48 h
Lymph node 0.064 0.189 0.290 0.408 0.534 0.554 0.727 -- -- -- -- -- -- --
(mandibular)
Lymph node 0.050 0.146 0.530 0.489 0.689 0.985 1.37 -- -- -- -- -- -- --
(mesenteric)
Muscle 0.021 0.061 0.084 0.103 0.096 0.095 0.192 -- -- -- -- -- -- --
Ovaries 0.104 1.34 1.64 2.34 3.09 5.24 12.3 0.001 0.009 0.008 0.016 0.025 0.037 0.095
(females)
Pancreas 0.081 0.207 0.414 0.380 0.294 0.358 0.599 0.003 0.007 0.014 0.015 0.015 0.011 0.019
Pituitary gland 0.339 0.645 0.868 0.854 0.405 0.478 0.694 0.000 0.001 0.001 0.001 0.000 0.000 0.001
Prostate 0.061 0.091 0.128 0.157 0.150 0.183 0.170 0.001 0.001 0.002 0.003 0.003 0.004 0.003
(males)
Salivary 0.084 0.193 0.255 0.220 0.135 0.170 0.264 0.003 0.007 0.008 0.008 0.005 0.006 0.009
glands
Skin 0.013 0.208 0.159 0.145 0.119 0.157 0.253 -- -- -- -- -- -- --
Small intestine 0.030 0.221 0.476 0.879 1.28 1.30 1.47 0.024 0.130 0.319 0.543 0.776 0.906 0.835
Spinal cord 0.043 0.097 0.169 0.250 0.106 0.085 0.112 0.001 0.002 0.002 0.003 0.001 0.001 0.001
Spleen 0.334 2.47 7.73 10.3 22.1 20.1 23.4 0.013 0.093 0.325 0.385 0.982 0.821 1.03
Stomach 0.017 0.065 0.115 0.144 0.268 0.152 0.215 0.006 0.019 0.034 0.030 0.040 0.037 0.039
Testes (males) 0.031 0.042 0.079 0.129 0.146 0.304 0.320 0.007 0.010 0.017 0.030 0.034 0.074 0.074
Thymus 0.088 0.243 0.340 0.335 0.196 0.207 0.331 0.004 0.007 0.010 0.012 0.008 0.007 0.008
Thyroid 0.155 0.536 0.842 0.851 0.544 0.578 1.00 0.000 0.001 0.001 0.001 0.001 0.001 0.001
Uterus 0.043 0.203 0.305 0.140 0.287 0.289 0.456 0.002 0.011 0.015 0.008 0.016 0.018 0.022
(females)
Whole blood 1.97 4.37 5.40 3.05 1.31 0.909 0.420 -- -- -- -- -- -- --
Plasma 3.97 8.13 8.90 6.50 2.36 1.78 0.805 -- -- -- -- -- -- --
Blood:Plasma 0.815 0.515 0.550 0.510 0.555 0.530 0.540 -- -- -- -- -- -- --
ratioa
CONFIDENTIAL
Page 8
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013914
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.5B. PHARMACOKINETICS: ORGAN Test Article: [3H]-Labelled LNP-mRNAformulation containing
DISTRIBUTION CONTINUED ALC-0315 and ALC-0159
Report Number: 185350
--= Not applicable, partial tissue taken; [3H]-08-A01-C0 = An aqueous dispersion of LNPs, including ALC-0315, ALC-0159,distearoylphosphatidylcholine,
cholesterol, mRNAencoding luciferaseandtrace amountsof radiolabeled [Cholesteryl-1,2-3H(N)]-Cholesteryl Hexadecyl Ether, a nonexchangeable,non-
metabolizable lipid marker used to monitor the disposition of the LNPs; ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N--ditetradecylacetamide), a proprietary
polyethylene glycol-lipid included as an excipient in the LNP formulation used in BNT162b2; ALC-0315=(4--hydroxybutyl)azanediyl)bis(hexane-6,1-
diyl)bis(2-hexyldecanoate), a proprietary aminolipid included as an excipient in the LNP formulation used in BNT162b2; LNP = Lipid nanoparticle;
mRNA=messenger RNA.
a. The mean male and female blood:plasma valueswere first calculated separately and this value represents the mean of the two values.
CONFIDENTIAL
Page 9
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013915
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.9. PHARMACOKINETICS: METABOLISM IN VIVO, Test Article: modRNA encoding luciferase in LNP
RAT Report Number: PF-07302048_05Aug20_043725
Species (Strain): Rat (Wistar Han)
Sex/ Number of animals Male/ 36 animals total for plasma and liver, 3 animals for urine and feces
Method of Administration: Intravenous
Dose (mg/kg): 1
Test System: Plasma, Urine, Feces, Liver
Analysis Method: Ultrahigh performance liquid chromatography/mass spectrometry
Biotransformation m/z Metabolites of ALC-0315 Detected
Plasma Urine Feces Liver
N-dealkylation,oxidation 102.0561a ND ND ND ND
N-Dealkylation, oxidation 104.0706b ND ND ND ND
N-dealkylation, oxidation 130.0874a ND ND ND ND
N-Dealkylation, oxidation 132.1019b ND ND ND ND
N-dealkylation, hydrolysis, oxidation 145.0506a ND ND ND ND
Hydrolysis (acid) 255.2330a + ND ND ND
Hydrolysis, hydroxylation 271.2279a ND ND ND ND
Bis-hydrolysis (amine) 290.2690b + + + +
Hydrolysis, glucuronidation 431.2650a ND ND ND ND
Bis-hydrolysis (amine), glucuronidation 464.2865a ND ND ND ND
Bis-hydrolysis (amine), glucuronidation 466.3011b ND + ND ND
Hydrolysis (amine) 528.4986b + ND ND +
Hydrolysis (amine), Glucuronidation 704.5307b ND ND ND ND
Oxidation to acid 778.6930a ND ND ND ND
Oxidation to acid 780.7076b ND ND ND ND
Hydroxylation 782.7232b ND ND ND ND
Sulfation 844.6706a ND ND ND ND
Sulfation 846.6851b ND ND ND ND
Glucuronidation 940.7458a ND ND ND ND
Glucuronidation 942.7604b ND ND ND ND
Note: Both theoretical and observed metabolites are included.
m/z = mass to charge ratio; ND = Not detected; + = minor metabolite as assessed by ultraviolet detection.
a. Negative ion mode.
b. Positive ion mode.
CONFIDENTIAL
Page 10
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013916
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
Test Article: ALC-0315
2.6.5.10A. PHARMACOKINETICS: METABOLISM IN VITRO
Report Numbers: 01049-20008
01049-20009
01049-20010
Type of Study: Stability of ALC-0315 InVitro
Study System: Liver Microsomes+ NADPH S9 Fraction+ NADPH, UDPGA, and Hepatocytes
alamethicin
ALC-0315 1µM 1µM 1µM
Concentration:
Duration of 120 min 120 min 240 min
Incubation (min):
Analysis Method: Ultra-high performance liquid chromatography-tandem mass spectrometry
Incubation time Percent ALC-0315 remaining
(min) Liver Microsomes Liver S9 Fraction Hepatocytes
Mouse Rat Rat Monkey Human Mouse Rat Monkey Human Mouse Rat Rat Monkey Human
(CD-1/ICR) (SD) (WH) (Cyno) (CD-1/ICR) (SD) (Cyno) (CD-1/ICR) (SD) (WH) (Cyno)
0 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
15 98.77 94.39 96.34 97.96 100.24 97.69 98.85 99.57 95.99 -- -- -- -- --
30 97.78 96.26 97.32 96.18 99.76 97.22 99.62 96.96 97.32 101.15 97.75 102.70 96.36 100.72
60 100.49 99.73 98.54 100.00 101.45 98.61 99.62 99.13 94.98 100.77 98.50 102.32 97.82 101.44
90 97.78 98.66 94.15 97.96 100.48 98.15 98.85 98.70 98.33 101.92 99.25 103.09 100.0 100.36
120 96.54 95.99 93.66 97.71 98.31 96.76 98.46 99.57 99.33 98.85 97.38 99.61 96.36 100.72
180 -- -- -- -- -- -- -- -- -- 101.15 98.88 103.47 95.64 98.92
240 -- -- -- -- -- -- -- -- -- 99.62 101.12 100.00 93.82 99.64
t½ (min) >120 >120 >120 >120 >120 >120 >120 >120 >120 >240 >240 >240 >240 >240
--= Data not available;ALC-0315 = (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), a proprietary aminolipid included as an excipient in the lipid
nanoparticle formulation used in BNT162b2;Cyno=Cynomolgus; NADPH=Reduced form of nicotinamide adenine dinucleotide phosphate; NC=not calculated; SD = Sprague
Dawley; t½ = half-life; WH = Wistar-Han; UDPGA= uridine-diphosphate-glucuronic acid trisodium salt.
CONFIDENTIAL
Page 11
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013917
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
Test Article: ALC-0159
2.6.5.10B. PHARMACOKINETICS: METABOLISM IN VITRO CONTINUED
Report Numbers: 01049-20020
01049-20021
01049-20022
Type of Study: Stability of ALC-0159InVitro
Study System: Liver Microsomes+ NADPH S9 Fraction+ NADPH, UDPGA, and Hepatocytes
alamethicin
ALC-0159 1µM 1µM 1µM
Concentration:
Duration of 120 min 120 min 240 min
Incubation (min):
Analysis Method: Ultra-high performance liquid chromatography-tandem mass spectrometry
Incubation time Percent ALC-0159remaining
(min) Liver Microsomes Liver S9Fraction Hepatocytes
Mouse Rat Rat Monkey Human Mouse Rat Monkey Human Mouse Rat Rat Monkey Human
(CD-1/ICR) (SD) (WH) (Cyno) (CD-1/ICR) (SD) (Cyno) (CD-1/ICR) (SD) (WH) (Cyno)
0 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
15 82.27 101.24 112.11 100.83 99.59 98.93 84.38 91.30 106.73 -- -- -- -- --
30 86.40 93.78 102.69 85.12 92.28 91.10 90.87 97.96 107.60 100.85 93.37 113.04 90.23 106.34
60 85.54 98.34 105.38 86.36 95.53 102.85 97.97 105.56 104.97 94.92 91.81 105.07 92.93 101.58
90 85.41 95.44 100.90 94.63 97.97 90.75 93.51 108.33 109.36 94.28 90.25 112.80 94.59 92.67
120 95.87 97.10 108.97 93.39 93.09 106.76 92.70 105.74 119.59 87.08 89.47 104.11 97.51 96.04
180 -- -- -- -- -- -- -- -- -- 94.92 93.96 102.90 89.81 93.66
240 -- -- -- -- -- -- -- -- -- 102.75 94.93 98.79 92.93 102.57
t½ (min) >120 >120 >120 >120 >120 >120 >120 >120 >120 >240 >240 >240 >240 >240
--= Data not available;ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide), a proprietary polyethylene glycol-lipid included as an excipient in the lipid
nanoparticle formulation used in BNT162b2; Cyno=Cynomolgus; NADPH=Reduced form of nicotinamide adenine dinucleotide phosphate; NC=not calculated; SD = Sprague
Dawley; WH = Wistar-Han; UDPGA= uridine-diphosphate-glucuronic acid trisodium salt.
CONFIDENTIAL
Page 12
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013918
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.10C. PHARMACOKINETICS: METABOLISM Test Article: ALC-0315
IN VITRO CONTINUED Report Number: PF-07302048_05Aug20_043725
Type of study Metabolism of ALC-0315 InVitro
Study system Blood Hepatocytes Liver S9 Fraction
ALC-0315 concentration 10 µM 10 µM 10 µM
Duration of incubation 24 h 4h 24 h
Analysis Method: Ultrahigh performance liquid chromatography/ mass spectrometry
Biotransformation m/z Blood Hepatocytes Liver S9 Fraction
Mouse Rat Monkey Human Mouse Rat Monkey Human Mouse Rat Monkey Human
N-dealkylation, oxidation 102.0561a ND ND ND ND ND ND ND ND ND ND ND ND
N-Dealkylation, oxidation 104.0706b ND ND ND ND ND ND ND ND ND ND ND ND
N-dealkylation, oxidation 130.0874a ND ND ND ND ND ND ND ND ND ND ND ND
N-Dealkylation, oxidation 132.1019b ND ND ND ND ND ND ND ND ND ND ND ND
N-dealkylation, hydrolysis, oxidation 145.0506a ND ND ND ND ND ND ND ND ND ND ND ND
Hydrolysis (acid) 255.2330a + + ND ND + + + + + + ND +
Hydrolysis, hydroxylation 271.2279a ND ND ND ND ND ND ND ND ND ND ND ND
Bis-hydrolysis (amine) 290.2690b + + ND ND ND ND ND ND ND ND + ND
Hydrolysis, glucuronidation 431.2650a ND ND ND ND ND ND ND ND ND ND ND ND
Bis-hydrolysis (amine), glucuronidation 464.2865a ND ND ND ND ND ND ND ND ND ND ND ND
Bis-hydrolysis (amine), glucuronidation 466.3011b ND ND ND ND ND ND ND ND ND ND ND ND
Hydrolysis (amine) 528.4986b ND + ND ND ND ND ND ND ND ND + ND
Hydrolysis (amine), glucuronidation 704.5307b ND ND ND ND ND ND ND ND ND ND ND ND
Oxidation to acid 778.6930a ND ND ND ND ND ND ND ND ND ND ND ND
Oxidation to acid 780.7076b ND ND ND ND ND ND ND ND ND ND ND ND
Hydroxylation 782.7232b ND ND ND ND ND ND ND ND ND ND ND ND
Sulfation 844.6706a ND ND ND ND ND ND ND ND ND ND ND ND
Sulfation 846.6851b ND ND ND ND ND ND ND ND ND ND ND ND
Glucuronidation 940.7458a ND ND ND ND ND ND ND ND ND ND ND ND
Glucuronidation 942.7604b ND ND ND ND ND ND ND ND ND ND ND ND
Note: Both theoretical and observed metabolites are included.
m/z = mass to charge ratio; ND = Not detected; + = metabolite present.
a. Negative ion mode.
b. Positive ion mode.
CONFIDENTIAL
Page 13
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013919
BNT162b2
2.6.5 Pharmacokinetics Tabulated Summary
2.6.5.10D. PHARMACOKINETICS: METABOLISM Test Article: ALC-0159
IN VITRO CONTINUED Report Number: PF-07302048_05Aug20_043725
Type of study Metabolism of ALC-0159InVitro
Study system Blood Hepatocytes Liver S9 Fraction
ALC-0159concentration 10 µM 10 µM 10 µM
Duration of incubation 24 h 4h 24 h
Analysis Method: Ultrahigh performance liquid chromatography/ mass spectrometry
Biotransformation m/z Blood Hepatocytes Liver S9 Fraction
Mouse Rat Monkey Human Mouse Rat Monkey Human Mouse Rat Monkey Human
O-Demethylation,O-dealkylation 107.0703b ND ND ND ND ND ND ND ND ND ND ND ND
O-Demethylation,O-dealkylation 151.0965b ND ND ND ND ND ND ND ND ND ND ND ND
O-Demethylation,O-dealkylation 195.1227b ND ND ND ND ND ND ND ND ND ND ND ND
Hydrolysis,N-Dealkylation 214.2529b ND ND ND ND ND ND ND ND ND ND ND ND
N-Dealkylation, oxidation 227.2017a ND ND ND ND ND ND ND ND ND ND ND ND
Hydrolysis (amine) 410.4720b + + ND ND + + + + + + + +
N,N-Didealkylation 531.5849b ND ND ND ND ND ND ND ND ND ND ND ND
N-Dealkylation 580.6396b ND ND ND ND ND ND ND ND ND ND ND ND
O-Demethylation, oxidation 629.6853b ND ND ND ND ND ND ND ND ND ND ND ND
Hydroxylation 633.6931b ND ND ND ND ND ND ND ND ND ND ND ND
ω-Hydroxylation, Oxidation 637.1880b ND ND ND ND ND ND ND ND ND ND ND ND
Hydrolysis (acid) 708.7721b ND ND ND ND ND ND ND ND ND ND ND ND
Note: Both theoretical and observed metabolites are included.
m/z = mass to charge ratio; ND = Not detected; + = metabolite present.
a. Negative ion mode.
b. Positive ion mode.
CONFIDENTIAL
Page 14
)TMG(
22:32
1202-naJ-12
:nO
devorppA\devorppA\960731691e771090
FDA-CBER-2021-5683-0013920","[[['CD-1mouse,Wistar'], ['Hanrat,cynomolgus'], ['monkey, and human']], [['Liver Microsomes', 'Liver S9 Fraction'], ['Mouse Rat Rat Monkey Human\n(CD-1/ICR) (SD) (WH) (Cyno)', 'Mouse Rat Monkey Human\n(CD-1/ICR) (SD) (Cyno)'], ['100.00 100.00 100.00 100.00 100.00\n98.77 94.39 96.34 97.96 100.24\n97.78 96.26 97.32 96.18 99.76\n100.49 99.73 98.54 100.00 101.45\n97.78 98.66 94.15 97.96 100.48\n96.54 95.99 93.66 97.71 98.31\n-- -- -- -- --\n-- -- -- -- --', '100.00 100.00 100.00 100.00\n97.69 98.85 99.57 95.99\n97.22 99.62 96.96 97.32\n98.61 99.62 99.13 94.98\n98.15 98.85 98.70 98.33\n96.76 98.46 99.57 99.33\n-- -- -- --\n-- -- -- --'], ['>120 >120 >120 >120 >120', '>120 >120 >120 >120']], [['Liver Microsomes', 'Liver S9Fraction'], ['Mouse Rat Rat Monkey Human\n(CD-1/ICR) (SD) (WH) (Cyno)', 'Mouse Rat Monkey Human\n(CD-1/ICR) (SD) (Cyno)'], ['100.00 100.00 100.00 100.00 100.00\n82.27 101.24 112.11 100.83 99.59\n86.40 93.78 102.69 85.12 92.28\n85.54 98.34 105.38 86.36 95.53\n85.41 95.44 100.90 94.63 97.97\n95.87 97.10 108.97 93.39 93.09\n-- -- -- -- --\n-- -- -- -- --', '100.00 100.00 100.00 100.00\n98.93 84.38 91.30 106.73\n91.10 90.87 97.96 107.60\n102.85 97.97 105.56 104.97\n90.75 93.51 108.33 109.36\n106.76 92.70 105.74 119.59\n-- -- -- --\n-- -- -- --'], ['>120 >120 >120 >120 >120', '>120 >120 >120 >120']], [['m/z', 'Blood', 'Hepatocytes'], [None, 'Mouse Rat Monkey Human', 'Mouse Rat Monkey Human'], [None, 'ND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\n+ + ND ND\nND ND ND ND\n+ + ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND + ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND', 'ND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\n+ + + +\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND']], [['m/z', 'Blood', 'Hepatocytes'], [None, 'Mouse Rat Monkey Human', 'Mouse Rat Monkey Human'], [None, 'ND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\n+ + ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND', 'ND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\n+ + + +\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND\nND ND ND ND']]]",14
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_exclusivity-claim.pdf,1.0,"COVID-19 Vaccine (BNT162; PF-07302048)
Module 1.3.5.3 Exclusivity Claim
NOTICE OF CLAIMED EXCLUSIVITY
A. BioNTech Manufacturing GmbHhereby requests a determination that the licensure of Pfizer-
BioNTech-COVID-19constitutes the “first licensure” of Pfizer-BioNTech-COVID-19 and
that BioNTech Manufacturing GmbHis entitled to exclusivity from the date of licensure
pursuant to section 351(k)(7) of the Public Health Service Act.
B. There are no licensed biological products that are structurally related to Pfizer-BioNTech-
COVID-19for which BioNTech Manufacturing GmbHor one of its affiliates, licensors,
predecessors in interest, or related entities are the current or previous license holders.
C. Accordingly, consistent with Section 351(k)(7)(C) of the Public Health Service Act, FDA’s
licensure of Pfizer-BioNTech-COVID-19under 351(a) will constitute the “first licensure” of
Pfizer-BioNTech-COVID-19.
1. Pursuant to Section 351(k)(7)(A), no approval of an application submitted under
Section 351(k) for which Pfizer-BioNTech-COVID-19is the reference product can
be made effective until 12 years after the date of licensure of Pfizer-BioNTech-
COVID-19.
2. Pursuant to Section 351(k)(7)(B), no application under Section 351(k) for which
Pfizer-BioNTech-COVID-19is the reference product can be submitted until 4 years
after the date of licensure of Pfizer-BioNTech-COVID-19.
PFIZER CONFIDENTIAL
Page 1
)TMG(
40:81
0202-peS-42
:nO
laniF\laniF\9e0b10591e771090
FDA-CBER-2021-5683-0013852","[[['2. Pursuant to Section 351(k)(7)(B), no application under Section 351(k) for which'], ['Pfizer-BioNTech-COVID-19is the reference product can be submitted until 4 years'], ['after the date of licensure of Pfizer-BioNTech-COVID-19.']]]",1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdf,9.0,"Site Subject ID
1001 10011081
1001 10011084
1001 10011085
1001 10011086
1001 10011087
1001 10011088
1001 10011089
1001 10011090
1001 10011091
1001 10011092
1001 10011093
1001 10011094
1001 10011095
1001 10011096
1001 10011097
1001 10011098
1001 10011099
1001 10011100
1001 10011101
1001 10011102
1001 10011103
1001 10011104
1003 10031088
1003 10031089
1003 10031090
1003 10031091
1003 10031092
1003 10031093
1003 10031094
1003 10031095
1003 10031096
1003 10031097
1003 10031098
1003 10031099
1003 10031100
1003 10031101
1003 10031102
1003 10031103
1003 10031104
1003 10031105
1003 10031106
1003 10031107
1003 10031108
1003 10031109
)TMG(
30:02
1202-yaM-40
:nO
laniF\laniF\b7683f691e771090
FDA-CBER-2021-5683-0023541
1003 10031110
1003 10031111
1003 10031112
1003 10031113
1003 10031114
1003 10031115
1003 10031117
1007 10071079
1007 10071080
1007 10071081
1007 10071082
1007 10071083
1007 10071084
1007 10071085
1007 10071086
1007 10071087
1007 10071088
1007 10071089
1007 10071090
1007 10071091
1007 10071092
1007 10071093
1007 10071094
1007 10071095
1007 10071096
1007 10071097
1007 10071098
1007 10071099
1007 10071100
1007 10071101
1007 10071102
1013 10131001
1013 10131002
1013 10131003
1013 10131004
1013 10131005
1013 10131006
1013 10131007
1013 10131008
1013 10131009
1013 10131010
1013 10131011
1013 10131012
1013 10131013
1013 10131014
)TMG(
30:02
1202-yaM-40
:nO
laniF\laniF\b7683f691e771090
FDA-CBER-2021-5683-0023542
1013 10131015
1013 10131016
1013 10131018
1013 10131019
1013 10131020
1013 10131021
1013 10131022
1013 10131023
1013 10131024
1013 10131025
1013 10131026
1013 10131028
1013 10131029
1013 10131030
1013 10131031
1013 10131032
1016 10161001
1016 10161002
1016 10161003
1016 10161004
1016 10161005
1016 10161006
1016 10161007
1016 10161009
1016 10161010
1016 10161011
1016 10161012
1016 10161013
1016 10161014
1016 10161015
1016 10161016
1018 10181001
1018 10181002
1018 10181003
1018 10181004
1018 10181005
1018 10181006
1018 10181007
1042 10421001
1042 10421002
1042 10421003
1042 10421004
1042 10421008
1042 10421009
1073 10731001
)TMG(
30:02
1202-yaM-40
:nO
laniF\laniF\b7683f691e771090
FDA-CBER-2021-5683-0023543
1073 10731002
1073 10731003
1073 10731004
1073 10731005
1073 10731006
1073 10731007
1073 10731008
1073 10731009
1073 10731010
1073 10731011
1073 10731012
1073 10731013
1073 10731014
1079 10791001
1079 10791002
1079 10791003
1079 10791004
1079 10791005
1079 10791006
1079 10791007
1079 10791008
1079 10791009
1079 10791010
1079 10791011
1079 10791013
1079 10791014
1082 10821001
1082 10821002
1082 10821003
1082 10821004
1083 10831001
1083 10831002
1083 10831003
1083 10831004
1083 10831005
1083 10831006
1084 10841001
1084 10841002
1084 10841003
1084 10841006
1085 10851001
1085 10851002
1085 10851003
1085 10851004
1085 10851005
)TMG(
30:02
1202-yaM-40
:nO
laniF\laniF\b7683f691e771090
FDA-CBER-2021-5683-0023544
1085 10851006
1085 10851007
1085 10851008
1089 10891001
1089 10891002
1089 10891003
1089 10891004
1089 10891005
1089 10891006
1089 10891007
1089 10891008
1089 10891009
1089 10891011
1089 10891012
1089 10891013
1089 10891014
1089 10891015
1089 10891016
1095 10951001
1095 10951002
1095 10951003
1095 10951004
1095 10951005
1095 10951006
1095 10951007
1107 11071001
1107 11071003
1107 11071004
1107 11071005
1107 11071006
1107 11071007
1107 11071008
1107 11071009
1107 11071010
1109 11091001
1109 11091002
1109 11091003
1109 11091004
1109 11091005
1109 11091006
1109 11091007
1109 11091008
1109 11091009
1109 11091010
1109 11091011
)TMG(
30:02
1202-yaM-40
:nO
laniF\laniF\b7683f691e771090
FDA-CBER-2021-5683-0023545
1109 11091012
1109 11091013
1109 11091014
1109 11091015
1109 11091016
1109 11091017
1109 11091018
1109 11091019
1109 11091020
1109 11091021
1109 11091022
1109 11091023
1109 11091024
1109 11091025
1109 11091026
1109 11091027
1109 11091028
1109 11091029
1109 11091030
1109 11091031
1109 11091032
1109 11091033
1111 11111001
1111 11111002
1111 11111003
1111 11111004
1111 11111005
1112 11121001
1112 11121002
1112 11121003
1112 11121004
1112 11121005
1112 11121006
1112 11121007
1112 11121008
1112 11121009
1112 11121010
1112 11121011
1112 11121012
1112 11121013
1112 11121015
1112 11121016
1120 11201001
1120 11201002
1120 11201003
)TMG(
30:02
1202-yaM-40
:nO
laniF\laniF\b7683f691e771090
FDA-CBER-2021-5683-0023546
1120 11201006
1120 11201007
1123 11231001
1123 11231002
1123 11231003
1127 11271001
1127 11271002
1127 11271003
1127 11271004
1127 11271005
1127 11271006
1127 11271007
1127 11271008
1127 11271009
1127 11271010
1127 11271011
1127 11271012
1127 11271014
1127 11271015
1127 11271016
1127 11271017
1129 11291001
1129 11291002
1129 11291003
1129 11291004
1129 11291005
1129 11291006
1129 11291007
1129 11291008
1129 11291009
1129 11291010
1129 11291011
1129 11291012
1129 11291013
1129 11291014
1129 11291015
1129 11291016
1133 11331001
1133 11331002
1133 11331003
1133 11331004
1133 11331005
1133 11331007
1133 11331008
1133 11331009
)TMG(
30:02
1202-yaM-40
:nO
laniF\laniF\b7683f691e771090
FDA-CBER-2021-5683-0023547
1133 11331010
1133 11331011
1133 11331012
1133 11331013
1133 11331014
1133 11331016
1139 11391001
1139 11391002
1139 11391003
1139 11391004
1139 11391005
1139 11391006
1139 11391007
1139 11391008
1139 11391009
1139 11391010
1139 11391011
1139 11391012
1139 11391013
1139 11391014
1139 11391015
1140 11401001
1140 11401002
1140 11401003
1140 11401004
1140 11401005
1140 11401006
1140 11401007
1140 11401008
1141 11411001
1142 11421001
1142 11421002
1142 11421003
1142 11421004
1142 11421005
1142 11421006
1142 11421007
1142 11421008
1142 11421010
1142 11421011
1142 11421012
1142 11421013
1142 11421014
1142 11421015
1142 11421016
)TMG(
30:02
1202-yaM-40
:nO
laniF\laniF\b7683f691e771090
FDA-CBER-2021-5683-0023548
1147 11471001
)TMG(
30:02
1202-yaM-40
:nO
laniF\laniF\b7683f691e771090
FDA-CBER-2021-5683-0023549",,9
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-mild-liver.pdf,2.0,"CCI_Mild liver
MedDRA Dictionary Version: 230
Status: ACTIVE
Term Name: CCI_Mild liver
Code: 90002941
Extension: CCI
Report Date/Time: 27-Oct-2020:10:50:21 AM EDT
Term Code Level Category Weight Scope
Venoocclusive liver disease 10047216 PT
Steatohepatitis 10076331 PT
Radiation hepatitis 10051015 PT
Portal fibrosis 10074726 PT
Peliosis hepatis 10034229 PT
Non-cirrhotic portal hypertension 10077259 PT
Non-alcoholic steatohepatitis 10053219 PT
Nonalcoholic fatty liver disease 10082249 PT
Lupus hepatitis 10067737 PT
Lupoid hepatic cirrhosis 10025129 PT
Liver transplant 10024714 PT
Liver sarcoidosis 10068664 PT
Liver disorder 10024670 PT
Ischaemic hepatitis 10023025 PT
Hepatitis toxic 10019795 PT
Hepatitis fulminant 10019772 PT
Hepatitis D 10019762 PT
Hepatitis chronic persistent 10019759 PT
Hepatitis chronic active 10019755 PT
Hepatitis B 10019731 PT
Hepatitis alcoholic 10019728 PT
Hepatitis acute 10019727 PT
Hepatic steatosis 10019708 PT
Hepatic steato-fibrosis 10077215 PT
Hepatic necrosis 10019692 PT
Hepatic infarction 10019680 PT
Hepatic fibrosis 10019668 PT
Hepatic displacement 10051565 PT
Congestive hepatopathy 10084058 PT
Hepatic cirrhosis 10019641 PT
Hepatic atrophy 10019637 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\783dde691e771090
FDA-CBER-2021-5683-0023961
Hepatic amyloidosis 10075251 PT
Granulomatous liver disease 10018704 PT
Fatty liver alcoholic 10016262 PT
Diabetic hepatopathy 10071265 PT
Cryptogenic cirrhosis 10063075 PT
Coma hepatic 10010075 PT
Cirrhosis alcoholic 10009208 PT
Chronic hepatitis C 10008912 PT
Chronic hepatitis B 10008910 PT
Chronic hepatitis 10008909 PT
Cholestasis 10008635 PT
Cholangitis sclerosing 10008609 PT
Cardiac cirrhosis 10054936 PT
Primary biliary cholangitis 10080429 PT
Biliary cirrhosis 10004659 PT
Autoimmune hepatitis 10003827 PT
Allergic hepatitis 10071198 PT
Alcoholic liver disease 10001627 PT
Acute yellow liver atrophy 10070815 PT
)TMG(
31:00
1202-yaM-10
:nO
laniF\laniF\783dde691e771090
FDA-CBER-2021-5683-0023962",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/056-ORDER-GRANTING-IN-PART-THE-MOTION-TO-MODIFY-THE-PRODUCTION-SCHEDULE-AND-ADDOPTS-THE-JOINT-STATUS-REPORT-MODIFIED-AGREED-PRODUCTION-SCHEDULE.pdf,2.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 5566 FFiilleedd 0022//0022//2222 PPaaggee 11 ooff 22 PPaaggeeIIDD 22114499
UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF TEXAS
FORT WORTH DIVISION
PUBLIC HEALTH AND MEDICAL
PROFESSIONALS FOR TRANSPARENCY,
Plaintiff,
v. No. 4:21-cv-1058-P
FOOD AND DRUG ADMINISTRATION,
Defendant.
ORDER
Before the Court is Defendant Food and Drug Administration’s
Motion to Partially Modify Scheduling Order (“Motion”). ECF No. 36.
Also before the Court is a Joint Status Report that articulates the
Parties’ agreed production schedule. ECF No. 55. Having considered the
Joint Status Report, the Court will adopt the Parties’ agreed-upon
terms; the Motion is therefore GRANTED in part.
In accordance with the Parties’ agreed production schedule detailed
in the Joint Status Report, the Court ORDERS that:
1. The Food and Drug Administration’s (“FDA”) rolling productions
will each be due on the first business day of each month, instead
of once every thirty days.
2. The FDA will produce 10,000 pages for the first two productions,
which will be due on or before March 1 and April 1, 2022.
3. The FDA will produce 80,000 pages on or before May 2, June 1,
and July 1, 2022; 70,000 pages on or before August 1, 2022; and
then 55,000 pages on or before the first business day of each
month thereafter.
4. The FDA can “bank” any processed pages in excess of its monthly
quota, such that, for example, if the FDA produces 90,000 pages
in May 2022 (or 65,000 pages in September 2022), it would bank
10,000 pages. Then, in a subsequent month, if the FDA is unable
to produce the full amount of pages required, it can apply the
banked pages toward its quota for that month.
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 5566 FFiilleedd 0022//0022//2222 PPaaggee 22 ooff 22 PPaaggeeIIDD 22115500
5. For the SAS files that duplicate the data in CRF files, the FDA
will count every 40 rows as one page instead of every 20 rows as
one page.
SO ORDERED on this 2nd day of February, 2022.
Mark T. Pittman
UNITED STATES DISTRICT JUDGE
2","[[['PUBLIC HEALTH AND MEDICAL'], ['PROFESSIONALS FOR TRANSPARENCY,']]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/037-Brief-Memorandum-in-Support-filed-by-FDA-re-36-MOTION-To-Partially-Modify-Scheduling-Order-1.pdf,12.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 11 ooff 1122 PPaaggeeIIDD 11772233
IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF TEXAS
____________________________________
)
PUBLIC HEALTH AND MEDICAL )
PROFESSIONALS FOR )
TRANSPARENCY, )
)
Plaintiff, )
)
v. ) Civil Action No. 4:21-cv-01058-P
)
UNITED STATES FOOD AND DRUG )
ADMINISTRATION, )
)
Defendant. )
___________________________________ )
MEMORANDUM IN SUPPORT OF DEFENDANT’S MOTION TO PARTIALLY
MODIFY SCHEDULING ORDER
INTRODUCTION
Defendant U.S. Food and Drug Administration (“FDA”) respectfully moves the Court to
partially modify its January 6, 2022 Scheduling Order (“January 6 Order” or “Order”), Dkt. No.
35. As the Court itself has acknowledged, the processing rate of 55,000 pages every 30 days1
established by the Order is “unprecedented,” id. at 3—and FDA is, in turn, undertaking
extraordinary and unprecedented steps to marshal every possible resource available to it, in its
best efforts to comply, while also meeting production schedules in other FOIA litigation and
continuing to process the thousands of other FOIA requests currently pending with FDA.
However, as explained in detail below, and in the attached supporting declarations, the most
1 For ease of reference, FDA will occasionally refer herein to this as the “monthly rate”
established by the January 6 Order.
1
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 22 ooff 1122 PPaaggeeIIDD 11772244
impactful of FDA’s interventions—including, inter alia, the agency’s plan to hire contractors,
advertise agency-wide for voluntary detail assignments, and work with Pfizer-BioNTech, as
appropriate, to speed the agency’s review will, of necessity, require some amount of lead time to
operationalize. Accordingly, FDA respectfully requests that the January 6 Order be modified to
provide that—for only the first two 30-day periods following FDA’s scheduled January 31, 2022
production—FDA’s monthly quota be adjusted to 10,000 pages per month. FDA would use this
period to “stand up” the extraordinary resources that will be required to bring full compliance
with the Order within the realm of possibility—while still processing records at a rate on par
with the most extreme processing rates that Plaintiff cited in its briefing. See Dkt. No. 26 p. 23
(Plaintiff’s second brief in advance of the scheduling conference, listing outlier cases—the
fastest of which is less than half the rate set by the January 6 Order). Under FDA’s proposed
modification, at the conclusion of this interim “stand up” period, i.e., beginning with the FDA’s
production due on May 2, 2022,2 the full 55,000-pages-per-month processing rate ordered by the
Court would then apply, until production is complete.
As the below-described agency actions make clear, FDA is doing everything within its
ability to attempt to comply with the January 6 Order. However, the unavoidable reality for FDA
is that, until additional resources are in place, full compliance with the January 6 Order is not
feasible. Even with the additional and unprecedented resources that FDA is actively marshalling,
compliance with the Court’s order will present extraordinary challenges. Accordingly, FDA
respectfully submits that the relatively modest modification it requests is both necessary, and in
2 Thirty days from March 31, 2022 is April 30, 2022—which, this year, falls on a Saturday.
Pursuant to Fed. R. Civ. P. 6(a)(1)(C), this production will thus be due on Monday, May 2, 2022.
2
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 33 ooff 1122 PPaaggeeIIDD 11772255
the public interest, in that it will afford FDA an adequate opportunity to gather, and
operationalize, resources necessary to achieve compliance with the Court’s Order.
ARGUMENT
I. Modification of the January 6 Order Is Necessary to Afford FDA a Period in
which to “Stand Up” Unprecedented and Extraordinary Operations
A. FDA’s Efforts to Channel Every Possible, Available Resource
As previewed above, FDA is not requesting additional time in order to spin its wheels, or
to merely assess its options to attempt to achieve compliance with the unprecedented processing
rate ordered by the Court. To the contrary, and as set forth in the Second Declaration of Suzann
Burk (“Second Burk Declaration”), although FDA received the Court’s January 6 Order only
seven business days prior to the filing of the instant motion, the agency is already making its best
efforts to comply, and is acting with maximal urgency to assemble every possible resource
available to it, as well as those not yet available to it. Specifically, FDA is actively taking the
following—and wholly unprecedented—steps:
• Hiring Contractors. FDA has initiated—at the anticipated cost of some $3
million dollars—the process of putting in place the contract and hiring a minimum of 15 full-
time contractors to assist with processing responsive records. 2d Burk Decl. ¶¶ 6, 22 (APPX004,
009). FDA anticipates that, of this total, 11 contractors will assist with processing those records
that do not require review for trade secret or confidential commercial information, and the
remaining four contractors will have additional experience that will allow them to assist with
processing more complex records. In addition to reviewing and redacting responsive records, the
contractors will assist with certain administrative, but often time-consuming, steps required for
final production, such as, inter alia, finalizing redactions and applying Bates numbers. Id. ¶ 6
(APPX004). FDA expects that, once these contract staff have been hired and trained, they will
3
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 44 ooff 1122 PPaaggeeIIDD 11772266
significantly expand FDA’s capacity to process the records at issue in this case. Id. ¶ 7
(APPX004).
• Although FDA is prepared to undertake the significant cost of these contractor
positions—and is moving forward as expeditiously as it can to finalize and implement the
relevant contract(s)—the unavoidable reality is that this process cannot occur overnight. Before
the contractors can begin their work, and thus contribute to FDA’s efforts to comply with the
January 6 Order, FDA must first advertise for these positions, select appropriate contract staff
members, and train selected workers so that they can meaningfully contribute to the review and
production process. Id. ¶ 7 (APPX004); see also Declaration of Sarah B. Kotler (“Kotler Decl.”),
Dkt. No. No. 30, ¶ 22.
• Details for FDA Staff. Separately, FDA’s Center for Biologics Evaluation and
Research (“CBER”)3 is preparing to publish an agency-wide advertisement for eight temporary
“detail” positions dedicated to processing the records at issue in this suit. 2d Burk Decl. ¶ 8
(APPX005). These details will reallocate resources currently devoted to other, important FDA
work to the agency’s efforts to comply with the January 6 Order. As with the contract staff
described above, however, there will—of necessity—be some lag time before the detailees are
able to begin contributing to this project. CBER is working to obtain the requisite approvals to
publish the advertisements, and anticipates that they will post by approximately February 1,
2022. As with the contractors (and, indeed, any similar hiring or recruitment process in any
workplace), CBER will need to allow time for applicants to respond to the posting, and will then
need to both select detailees from the applicant pool, and provide the selected detailees with the
3 As explained in prior filings, CBER is the FDA division that maintains the records at issue in
this suit.
4
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 55 ooff 1122 PPaaggeeIIDD 11772277
requisite training. CBER does not expect that agency staff selected for these details will have the
requisite experience and training to immediately begin working at full capacity. Id. ¶ 9
(APPX005); see also Kotler Decl. ¶ 22.
• Reassignment of Staff within CBER’s OCOD. Third—and in recognition that
the above-described efforts will take some time to ramp up—CBER has already reallocated
CBER resources and staff in order to prioritize FDA’s efforts to comply with the January 6
Order. First, within CBER’s Access Litigation and Freedom of Information Branch (“ALFOI”),
approximately five and a half of CBER’s ten “full-time equivalents” are, as of the date of this
filing, dedicated to the review and redaction of records related to this litigation. 2d Burk Decl. ¶
10 (APPX005).
Second, the Division of Disclosure and Oversight Management (“DDOM”) has also
already obtained the temporary reassignment of five additional staff members from other
divisions of CBER’s Office of Communication Outreach and Development (“OCOD”)—the
CBER office within which DDOM is situated—to assist ALFOI with processing Plaintiff’s
request, in the interim in which the above-described efforts are being ramped up. However, as
with other additional personnel described above, these reassigned staff members will require
training before they can work at full capacity on this project. Id. ¶ 11 (APPX006).
• Assistance with Other Litigation Deadlines. As discussed in prior filings, FDA
has disclosure obligations in several other FOIA suits implicating CBER. In at least one case,
where CBER had agreed to contribute 450 pages per month toward FDA’s overall (and court-
ordered) production quota, CBER has asked other agency components to take on extra work to
allow CBER to devote more resources to this matter. Under such an arrangement, CBER would
temporarily reduce its production obligation to zero in that case, so as to allow CBER ALFOI
5
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 66 ooff 1122 PPaaggeeIIDD 11772288
staff that would otherwise have been working on that production to devote more time to this
production. Id. ¶ 12 (APPX006).
• Working with Vaccine Sponsors to Identify Records that Do Not Contain
Exemption 4 Material. FDA has also reached out to Comirnaty4 sponsors Pfizer-BioNTech to
seek its assistance, initially, in identifying sections of the biologics license application (“BLA”)
that do not contain any trade secret or confidential commercial information subject to FOIA
Exemption 4. Once Pfizer-BioNTech has identified those sections (which FDA has requested that
it do by February 1, 2022), FDA will be able to streamline its disclosure review with respect to
this subset of records. Specifically, although FDA will still need to review the identified records
for other types of information protected by the FOIA Exemptions (most notably, Exemption 6,
which protects the privacy interests of clinical trial participants), it will not need to review this
particular subset of records for the presence of trade secret or confidential commercial
information. Id. ¶¶ 13-14 (APPX006-007).
As discussed in the earlier-filed Kotler Declaration, reviewing BLA files for trade secret
and confidential commercial information requires specialized training and experience. See Kotler
Decl. ¶ 24. Thus, by eliminating the need to review what FDA anticipates will be a large subset
of the BLA for information protected under Exemption 4, FDA will be able to assign less
experienced staff to work on this subset of records—thus freeing up more experienced staff to
focus on the more complex portions of the records at issue. Id. ¶ 14 (APPX007).
In addition, FDA is actively assessing other potential ways in which it can request that
the sponsors assist with streamlining the processing of the records at issue in this suit. Id. ¶ 15
(APPX007).
4 Comirnaty is the product name for what is colloquially referred to as the “Pfizer vaccine.”
6
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 77 ooff 1122 PPaaggeeIIDD 11772299
B. FDA’s Unprecedented Measures Will Take Time to Operationalize, Come at
Considerable Cost to Other Critical Agency Missions, and Represent the
Agency’s Maximal Possible Efforts
As described above and in the Second Burk Declaration, FDA is actively and
expeditiously responding to the unprecedented processing rate established by the January 6
Order by undertaking unprecedented measures, in a good faith effort to achieve full compliance.
Initially, FDA is taking immediate, temporary measures to increase its processing capabilities to
the maximal extent possible, in the short term. Specifically, between devoting approximately five
and a half out of the ten employees currently employed by AFLOI solely to the processing of the
relevant records, and temporarily re-assigning five other agency employees to assist with these
efforts until additional staff can be brought on, FDA has immediately allocated the equivalent of
nearly 11 full-time staff to this project. This re-allocation of resources is itself unprecedented
within the agency, and will allow FDA to meet its proposed production quota of 10,000 pages
per month for each of the first two months following the agency’s scheduled January 31, 2022
production—a rate that is on par with the most extreme processing cited in Plaintiff’s briefing.
See First Declaration of Suzann Burk, Dkt. No. 23, ¶ 31 (estimating that if each of ALFOI’s 10
staff members devoted all of their working hours solely to this production, they would be
expected to produce 25,410 pages in 11 weeks, which translates to approximately 10,000 pages
per month); Dkt. No. 26 p. 23 (Plaintiff’s second brief in advance of the scheduling conference,
collecting outlier cases).
However, in order to make compliance with the unprecedented processing rate entered by
the Court even possible, FDA recognizes that it must muster additional—and extraordinary—
resources. As described in detail above, FDA is moving swiftly to do so, most notably by
preparing to onboard a total of 23 additional contractor and agency staff to this project, and by
7
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 88 ooff 1122 PPaaggeeIIDD 11773300
requesting that Pfizer-BioNTech assist FDA by, initially, identifying those portions of the BLA
that do not need to be reviewed for trade secret or confidential commercial information. See 2d
Burk Decl. ¶¶ 6-9, 13-15 (APPX004-007). But notwithstanding that FDA is pressing forward
with these efforts with maximal speed, the unavoidable reality is that some minimal threshold
period of time is necessary for these endeavors to be fully operationalized, and to bear fruit. With
respect to the additional staffing, FDA must advertise the positions, select qualified candidates,
bring the selected candidates on board, and train them so that they can contribute to CBER’s
production efforts. Id. ¶¶ 7, 9 (APPX004-005). As a result, very few, if any, of the additional
individuals needed for the FDA to achieve full compliance will be in place before the extant
March 1, 2022 deadline to make a first initial production of 55,000 pages. Id. ¶ 19 (APPX008).
Similarly, FDA expects that, once the sponsors have identified to the agency those portions of
the BLA that do not need to be reviewed for Exemption 4 material, the agency will be able to
streamline its review of that subset of the records. Id. ¶ 14 (APPX007). Further, FDA is actively
assessing additional potential ways in which the agency may properly enlist and work with
Pfizer-BioNTech to speed up the ultimate resolution of this matter. Id. ¶ 15 (APPX007). Again,
however, while these efforts are actively underway, they will, unavoidably, take some time to
bear tangible results.
It also bears emphasizing that, while FDA is making every possible effort to comply with
the terms of the January 6 Order, the above-described measures far exceed what the agency
considers tenable for the processing a single FOIA request, and, in fact, represent the absolute
maximum efforts FDA can apply to this matter. Id. ¶ 21 (APPX009). Initially, while precise
numbers are not yet available, CBER estimates that its plan to hire at least 15 contract staff will
cost at least 3 million dollars—and, factoring in CBER’s other above-described efforts, CBER
8
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 99 ooff 1122 PPaaggeeIIDD 11773311
presently estimates that the total cost of its efforts to comply with the order will come to a
cumulative total of $4 to $5 million dollars. Id. ¶¶ 4, 22 ((APPX003, 009) These expenditures
must, necessarily, come at the expense of other crucial public health operations, such as, inter
alia, assessing new medical products and treatments, inspecting FDA-regulated establishments,
and purchasing laboratory equipment to run analytical testing. Id. ¶ 22 (APPX009). Further, the
Court’s direction for CBER to prioritize this FOIA case above all others will—again, of
necessity—require FDA to allocate resources away from the processing of the hundreds of other
FOIA requests that are currently pending before CBER, many of which also seek information
related to COVID-19. Id. ¶ 23 (APPX009). While these FOIA requesters are not before this
Court, the reallocation of resources away from processing their requests will be a direct
consequence of the Court’s Order.
Similarly, the reallocation of resources from other FDA components will also come with
tradeoffs for the agency overall. As explained above, CBER has obtained the temporary
reassignment of five OCOD employees, and it may in the future seek additional similar
reassignments from other FDA disclosure offices in order to meet the exigencies created by the
Court’s Order. These diversions of resources will, necessarily, detract from the output of these
other disclosure offices, as will the reallocation of eight agency employees through the detail
assignments described above. For these reasons—which is to say, because the FDA has a broad
public health mandate, but limited resources with which to accomplish its many crucial
missions—FDA emphasizes that the extraordinary measures it is undertaking in response to the
January 6 Order cannot be replicated in other FOIA cases, either presently or in the future. See
id. ¶ 25 (APPX010).
9
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 1100 ooff 1122 PPaaggeeIIDD 11773322
Finally, while the agency recognizes the public interest in the public disclosure of the
records here at issue, FDA must also ensure that the personal information of clinical trial
participants, as well any trade secret or commercially confidential information contained within
the records, is protected from disclosure. See Food Mktg. Inst. v. Argus Leader Media, 139 S. Ct.
2356, 2366 (2019) (“FOIA expressly recognizes that ‘important interests [are] served by [its]
exemptions,’ and ‘[t]hose exemptions are as much a part of [FOIA’s] purpose[s and policies] as
the [statute’s disclosure] requirement.’” (brackets in original) (quoting FBI v. Abramson, 456
U.S. 615, 630–631 (1982); Encino Motorcars, LLC v. Navarro, 138 S. Ct. 1134, 1142 (2018))).
While FDA is putting every available resource at its disposal into its efforts to achieve
compliance with the Court’s Order, it cannot achieve speed at the expense of its competing
obligation to protect the categories of information that FOIA exempts from disclosure. Ensuring
that such information is fully and properly redacted will, unavoidably, limit the speed with which
FDA can act. See generally the attached Declaration of Douglas Weinfield (explaining why
FDA’s FOIA reviews are often more time-intensive document reviews than those in garden-
variety private commercial litigation) (APPX015-019); id. at ¶ 13 (APPX018-109) (noting, in
particular, that “[i]dentification of commercially sensitive information in a biologics license
application” … “requires … specialized expertise” not typically implicated in a private
commercial dispute).
In sum, FDA is actively taking extraordinary measures to marshal every possible
resource, and to make every possible effort to comply with the Court’s Order. But because
operationalizing these resources will require an upfront investment of time, FDA respectfully
requests that the Court modify its Order, in part, so as to afford the agency a reasonable—and
limited—interim period of two months to put the above-described operations in place, while still
10
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 1111 ooff 1122 PPaaggeeIIDD 11773333
meeting monthly production quotas of 10,000 pages. For all of the reasons set forth above, FDA
respectfully submits that this modification is both necessary to afford the agency a practical
opportunity to achieve compliance with the Court’s Order, while simultaneously fulfilling its
statutory duty to protect the sensitive personal and commercial information contained within the
records here at issue.
CONCLUSION
For the foregoing reasons, FDA respectfully requests that the Court modify its January 6
Order so as to provide that, for the first two 30-day periods following FDA’s scheduled January
31, 2022 production, FDA’s monthly quota be adjusted to 10,000 pages per month. Following
this initial two-month “stand up” period, FDA would then be required to process 55,000 pages
per month, beginning with its May 2, 2022, production until such time as production is complete.
Dated: January 18, 2022 Respectfully submitted,
BRIAN M. BOYNTON
Acting Assistant Attorney General
Civil Division
ELIZABETH J. SHAPIRO
Deputy Director
Federal Programs Branch
/s/ Antonia Konkoly
ANTONIA KONKOLY
Trial Attorney
United States Department of Justice
Civil Division, Federal Programs Branch
1100 L Street, N.W.
Room 11110
Washington, D.C. 20005
Tel: (202) 514-2395
Email: antonia.konkoly@usdoj.gov
Counsel for Defendant
11
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3377 FFiilleedd 0011//1188//2222 PPaaggee 1122 ooff 1122 PPaaggeeIIDD 11773344
CERTIFICATE OF SERVICE
I hereby certify that on January 18, 2022, I electronically transmitted the foregoing to the
parties and the clerk of court for the United States District Court for the Northern District of
Texas using the CM/ECF filing system.
/s/ Antonia Konkoly
ANTONIA KONKOLY
Trial Attorney
United States Department of Justice
Civil Division, Federal Programs Branch
1100 L Street, N.W.
Room 11110
Washington, D.C. 20005
Tel: (202) 514-2395
Email: antonia.konkoly@usdoj.gov
12",,12
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/041-Memorandum-in-Support-filed-by-Pfizer-Inc.-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf,16.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 11 ooff 1166 PPaaggeeIIDD 11776655
UNITED STATES DISTRICT COURT FOR THE
NORTHERN DISTRICT OF TEXAS
FORT WORTH DIVISION
PUBLIC HEALTH AND MEDICAL §
PROFESSIONALS FOR §
TRANSPARENCY §
§
Plaintiff, § CASE NO. 4:21-CV-01058-P
§
v. §
§
FOOD AND DRUG §
ADMINISTRATION §
§
Defendant. §
§
§
§
§
§
§
MEMORANDUM OF POINTS AND AUTHORITIES
IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE
FOR A LIMITED PURPOSE
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 22 ooff 1166 PPaaggeeIIDD 11776666
TABLE OF CONTENTS
Page
PRELIMINARY STATEMENT .....................................................................................................1
FACTUAL BACKGROUND ..........................................................................................................3
ARGUMENT ...................................................................................................................................5
I. Pfizer Is Entitled To Intervene As A Matter Of Right Under Rule 24(a) ...................5
A. Pfizer’s Motion to Intervene is Timely ...........................................................6
B. Pfizer Has a Direct Interest Relating to the Action.........................................7
C. Disposition of this Action May Impair Pfizer’s Ability to Protect Its
Interests ...........................................................................................................7
D. Pfizer’s Interests Are Not Adequately Represented by Existing
Parties ..............................................................................................................8
E. Pfizer Has Standing in This Action. ...............................................................9
II. In The Alternative, This Court Should Permit Pfizer To Intervene Under
Rule 24(b) .................................................................................................................10
CONCLUSION ..............................................................................................................................11
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE i
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 33 ooff 1166 PPaaggeeIIDD 11776677
TABLE OF AUTHORITIES
Page(s)
Cases
Adam Joseph Res. v. CNA Metals Ltd.,
919 F.3d 856 (5th Cir. 2019) .....................................................................................................5
Appleton v. FDA,
310 F. Supp. 2d 194 (D.D.C. 2004) ...........................................................................................7
DeOtte v. Azar,
332 F.R.D. 173 (N.D. Tex. 2019) ..............................................................................................9
Entergy Gulf States Louisiana, L.L.C. v. U.S. EPA,
817 F.3d 198 (5th Cir. 2016) ................................................................................................ 5, 8
Franciscan All., Inc. v. Azar,
414 F. Supp. 3d 928 (N.D. Tex. 2019) ......................................................................................9
John Doe No. 1 v. Glickman,
256 F.3d 371 (5th Cir. 2001) .................................................................................................6, 8
In re Lease Oil Antitrust Litig.,
570 F.3d 244 (5th Cir. 2009) .....................................................................................................5
Pub. Citizen Health Rsch. Grp. v. FDA,
185 F.3d 898 (D.C. Cir. 1999) ...................................................................................................7
Sierra Club v. Espy,
18 F.3d 1202 (5th Cir. 1994) .....................................................................................................6
Texas v. United States,
805 F.3d 653 (5th Cir. 2015) .....................................................................................................7
Trbovich v. United Mine Workers,
404 U.S. 528 (1972) ...................................................................................................................8
United States v. Colvin,
203 B.R. 930 (N.D. Tex. 1996)................................................................................................10
Wal–Mart Stores, Inc. v. Texas Alcoholic Beverage Comm’n,
834 F.3d 562 (5th Cir. 2016) .....................................................................................................6
Statutes
Freedom of Information Act, 5 U.S.C. § 552 ........................................................................ passim
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE ii
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 44 ooff 1166 PPaaggeeIIDD 11776688
Regulations
21 C.F.R. § 601.51(e).......................................................................................................................3
Federal Rules
Fed. R. Civ. P. 24(a) .............................................................................................................. passim
Fed. R. Civ. P. 24(b) ..................................................................................................................1, 10
Other Authorities
Liu et al., Letter to the Editor: Neutralizing Activity of BNT162b2-Elicited
Serum, NEW ENG. J. MED. 384, 1466–68 (2021)..............................................................................3
Liu et al., BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2
variants, NATURE 596, 273–75 (2021) .............................................................................................3
Mulligan et al., Phase 1/2 Study to Describe the Safety and Immunogenicity of a
COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of
Age: Interim Report, medRxiv 2020.06.30.20142570 (June 30, 2020) ..........................................2
Muik et al., Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by
BNT162b2 vaccine-elicited human sera, bioRxiv 2021.01.18.426984 (Jan. 18,
2021) ................................................................................................................................................2
Muik et al., Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by
BNT162b2 vaccine–elicited human sera, SCIENCE 371, 1152–53 (2021). ......................................3
News Release, U.S. Food & Drug Admin., FDA Approves First COVID-19
Vaccine (Aug. 23, 2021) ..................................................................................................................1
Polack et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,
NEW ENG. J. MED. 383, 2603–15 (2020) .........................................................................................3
Presentation, BNT162b2 Vaccine Candidate Against COVID-19 (Dec. 10, 2020) ........................2
Presentation, BNT162b2 [COMIRNATY® (COVID-19 Vaccine, mRNA)]
Booster (Third) Dose (Sept. 17, 2021).............................................................................................2
Presentation, BNT162b2 (COVID-19 Vaccine, mRNA) Vaccine – Request for
Emergency Use Authorization in Individuals 5 to <12 Years of Age (Oct. 26,
2021) ................................................................................................................................................2
Protocol C4591001, A Phase 1/2/3 Study to Evaluate the Safety, Tolerability,
Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in
Healthy Individuals (Nov. 2020) .....................................................................................................2
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE iii
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 55 ooff 1166 PPaaggeeIIDD 11776699
Sahin et al., Concurrent human antibody and TH1 type T-cell responses elicited
by a COVID-19 RNA vaccine, medRxiv 2020.07.17.20140533 (July 17, 2020) ...........................2
Sahin et al., BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells
in humans, medRxiv 2020.12.09.20245175 (Dec. 9, 2020) ............................................................2
Thomas et al., Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-
19 Vaccine, medRxiv 2021.07.28.21261159 (July 28, 2021) .........................................................2
Thomas et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
through 6 Months, NEW ENG. J. MED. 385, 1761–73 (2021) ...........................................................3
VRBPAC Briefing Document, Pfizer-BioNTech COVID-19 Vaccine (BNT162,
PF-07302048) (Dec. 10, 2020) ........................................................................................................2
VRBPAC Briefing Document, BNT162b2 [COMIRNATY (COVID-19 Vaccine,
mRNA)] Evaluation of a Booster Dose (Third Dose) (Sept. 17, 2021) ...........................................2
VRBPAC Briefing Document, BNT162b2 [COMIRNATY (COVID-19 Vaccine,
mRNA)] (Oct. 26, 2021) ..................................................................................................................2
Walsh et al., RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal
Efficacy Study, medRxiv 2020.08.17.20176651 (Aug. 17, 2020) ..................................................2
Walsh et al., Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine
Candidates, NEW ENG. J. MED. 383, 2439–50 (2020) ......................................................................3
Walter et al., Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11
Years of Age, NEW ENG. J. MED. 386, 35–46 (2022) ......................................................................3
Xie et al., Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-
elicited sera, bioRxiv 2021.01.07.425740 (Jan. 7, 2021) ................................................................2
Xie et al., Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and
N501Y variants by BNT162b2 vaccine-elicited sera, bioRxiv 2021.01.27.427998
(Jan. 27, 2021)..................................................................................................................................2
Xie et al., Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and
N501Y variants by BNT162b2 vaccine-elicited sera, NATURE MED. 27, 620–21
(2021) ...............................................................................................................................................3
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE iv
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 66 ooff 1166 PPaaggeeIIDD 11777700
Pfizer Inc. (“Pfizer”), by and through undersigned counsel, hereby submits this
Memorandum of Points and Authorities in Support of Pfizer’s Motion for Leave to Intervene for
a Limited Purpose, pursuant to Rules 24(a) and 24(b) of the Federal Rules of Civil Procedure.
Pfizer seeks to intervene in this action brought by Public Health and Medical Professionals for
Transparency (“Plaintiff” or “PHMPT”) under the Freedom of Information Act, 5 U.S.C. § 552,
as amended (“FOIA”) for the limited purpose of protecting statutorily-protected confidential
information relating to its COVID-19 vaccine.
PRELIMINARY STATEMENT
In this action, Plaintiff seeks to compel the Food and Drug Administration (“FDA” or
“Agency”) to respond to its FOIA request on an expedited basis and to produce a significant
volume of data and information submitted by Pfizer to FDA as part of its application for regulatory
approval of the Pfizer-BioNTech COVID-19 vaccine (“the vaccine” or “Comirnaty”). The vaccine
received FDA approval, through a BLA, for use in individuals 16 years and older on August 23,
2021. See News Release, U.S. Food & Drug Admin., FDA Approves First COVID-19 Vaccine
(Aug. 23, 2021), https://www.fda.gov/news-events/press-announcements/fda-approves-first-
covid-19-vaccine.
Pfizer supports the public disclosure of the vast majority of this information to promote
transparency and the public’s confidence in the vaccine, and Pfizer seeks to intervene for the
limited purpose of ensuring that information that is exempt from disclosure under FOIA is not
disclosed inappropriately. Indeed Pfizer, FDA, the Centers for Disease Control and Prevention
(“CDC”), and other government agencies already have made public extensive data about the
vaccine. By way of example, Pfizer has shared the following information over the course of
developing the vaccine:
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 1
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 77 ooff 1166 PPaaggeeIIDD 11777711
 U.S. Food & Drug Admin. Vaccines and Related Biological Products Advisory
Committee Briefing Documents and Presentations, see, e.g., BNT162b2
[COMIRNATY (COVID-19 Vaccine, mRNA)] VRBPAC Briefing Document (Oct. 26,
2021), https://www.fda.gov/media/153409/download; Presentation, BNT162b2 (COVID-
19 Vaccine, mRNA) Vaccine – Request for Emergency Use Authorization in Individuals
5 to <12 Years of Age (Oct. 26, 2021), https://www.fda.gov/media/153513/download;
BNT162b2 [COMIRNATY (COVID-19 Vaccine, mRNA)] Evaluation of a Booster Dose
(Third Dose) VRBPAC Briefing Document (Sept. 17, 2021),
https://www.fda.gov/media/152161/download; Presentation, BNT162b2
[COMIRNATY® (COVID-19 Vaccine, mRNA)] Booster (Third) Dose (Sept. 17, 2021),
https://www.fda.gov/media/152240/download; Pfizer-BioNTech COVID-19 Vaccine
(BNT162, PF-07302048) VRBPAC Briefing Document (Dec. 10, 2020),
https://www.fda.gov/media/144246/download; Presentation, BNT162b2 Vaccine
Candidate Against COVID-19 (Dec. 10, 2020),
https://www.fda.gov/media/144325/download;
 Pfizer, PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001,
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy
of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (Nov. 2020),
https://cdn.pfizer.com/pfizercom/2020-11/C4591001_Clinical_Protocol_Nov2020.pdf;
 Preprints of safety and efficacy data as they became available, see, e.g., Stephen
Thomas et al., Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19
Vaccine, medRxiv 2021.07.28.21261159 (July 28, 2021),
https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full.pdf; Xuping Xie
et al., Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants
by BNT162b2 vaccine-elicited sera, bioRxiv 2021.01.27.427998 (Jan. 27, 2021),
https://www.biorxiv.org/content/10.1101/2021.01.27.427998v1.full.pdf; Alexander Muik
et al., Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2
vaccine-elicited human sera, bioRxiv 2021.01.18.426984 (Jan. 18, 2021),
https://www.biorxiv.org/content/10.1101/2021.01.18.426984v1.full.pdf; Xuping Xie et
al., Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera,
bioRxiv 2021.01.07.425740 (Jan. 7, 2021),
https://www.biorxiv.org/content/10.1101/2021.01.07.425740v1.full.pdf; Ugur Sahin et
al., BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans,
medRxiv 2020.12.09.20245175 (Dec. 9, 2020),
https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1.full.pdf; Edward
Walsh et al., RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy
Study, medRxiv 2020.08.17.20176651 (Aug. 17, 2020),
https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1.full.pdf; Ugur Sahin
et al., Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-
19 RNA vaccine, medRxiv 2020.07.17.20140533 (July 17, 2020),
https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1.full.pdf; Mark
Mulligan et al., Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-
19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim
Report, medRxiv 2020.06.30.20142570 (June 30, 2020),
https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1.full.pdf; and
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 2
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 88 ooff 1166 PPaaggeeIIDD 11777722
 Publications presenting safety and efficacy data, see, e.g., Emmanuel Walter et al.,
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age, NEW
ENG. J. MED. 386, 35–46 (2022),
https://www.nejm.org/doi/full/10.1056/NEJMoa2116298; Yang Liu et al., Letter to the
Editor: Neutralizing Activity of BNT162b2-Elicited Serum, NEW ENG. J. MED. 384,
1466–68 (2021), https://www.nejm.org/doi/full/10.1056/NEJMc2102017; Jianying Liu et
al., BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants,
NATURE 596, 273–75 (2021), https://www.nature.com/articles/s41586-021-03693-y;
Xuping Xie et al., Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and
N501Y variants by BNT162b2 vaccine-elicited sera, NATURE MED. 27, 620–21 (2021),
https://www.nature.com/articles/s41591-021-01270-4; Alexander Muik et al.,
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–
elicited human sera, SCIENCE 371, 1152–53 (2021),
https://www.science.org/doi/10.1126/science.abg6105; Stephen Thomas et al., Safety and
Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months, NEW ENG. J.
MED. 385, 1761–73 (2021), https://www.nejm.org/doi/full/10.1056/NEJMoa2110345;
Fernando Polack et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,
NEW ENG. J. MED. 383, 2603–15 (2020),
https://www.nejm.org/doi/full/10.1056/NEJMoa2034577; Edward Walsh et al., Safety
and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, NEW ENG. J.
MED. 383, 2439–50 (2020), https://www.nejm.org/doi/full/10.1056/NEJMoa2027906.
FACTUAL BACKGROUND
Plaintiff submitted its FOIA request for this information to FDA on August 27, 2021.
Compl., Ex. A.1, ECF No. 1-1 (the “FOIA Request”). In the FOIA request, Plaintiff seeks,
pursuant to 21 C.F.R. § 601.51(e), data and information contained in the biologics license
application (“BLA”) for the vaccine, including inter alia, test protocols, safety and effectiveness
data, correspondence and written summaries of discussions relating to the biological product file,
adverse event reports, lot testing records, and other data, “with the exception of publicly available
reports on the Vaccine Adverse Events Reporting System.” See FOIA Request 2. While Pfizer
supports the public review of much of this information which will help build trust and confidence
in the vaccine, the records Plaintiff has requested also contain information exempt from production
under FOIA, including the personal privacy information of individuals who participated in clinical
trials and confidential business and trade secret information of Pfizer, such as its proprietary
manufacturing processes. See 5 U.S.C. § 552(b)(4), (b)(6).
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 3
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 99 ooff 1166 PPaaggeeIIDD 11777733
After FDA denied Plaintiff’s request for expedited processing of the FOIA request,
Plaintiff commenced this action on September 16, 2021. See Compl. ¶¶ 41–53.
This Court held a Scheduling Conference in this matter on December 14, 2021. In briefing
submitted to this Court in advance of that Conference, counsel for FDA emphasized that the
Agency supports Plaintiff’s general right to the information sought in its FOIA request, subject to
standard exemptions under FOIA for sensitive business and confidential personal information.
See, e.g., First Joint Report 6 (Nov. 5, 2021), ECF No. 18 (“FDA is committed to transparency, in
general, and in particular with respect to records related to the Biological License Application
(‘BLA’) for the Comirnaty vaccine”). FDA expressed concern, however, about its ability to
adequately review the volume of requested information in the timeframe that Plaintiff proposed in
order to protect against the inadvertent disclosure of trade secrets, sensitive commercial and
financial information, and confidential personal information about clinical trial test subjects. See,
e.g., First Joint Report 7 (“To ensure protection of this information, and other information subject
to withholding under the FOIA exemptions, FDA must carefully review and, if necessary, redact
exempt information on a line-by-line basis. . . . [I]t is not feasible for FDA to review and produce
the substantial volume of records that Plaintiff seeks to obtain on a short timeframe.”); Second
Joint Report 5 (Nov. 15, 2021), ECF No. 20 (“This type of review for more than 329,000 pages
will necessarily require time if the agency is going to be able to perform the careful analysis
necessary to protect sensitive information.”). At the Scheduling Conference, the Court suggested
that intervention by Pfizer would be advisable given these concerns. Pfizer was not aware of
Plaintiff’s FOIA request or this litigation prior to reading news reports about this Scheduling
Conference in December 2021.
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 4
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 1100 ooff 1166 PPaaggeeIIDD 11777744
On January 6, 2022, the Court issued an Order requiring disclosure of more than 12,000
pages of information responsive to Plaintiff’s FOIA request by January 31, 2022, and subsequently
at a rate of 55,000 pages every 30 days, including production of redacted versions of any
documents for which FDA claims a privilege, exemption, or exclusion. See Order, ECF No. 35.
In light of FDA’s statements regarding its capacity to review the requested information at
an increased pace, and this Court’s order to produce this information on an expedited basis, Pfizer
seeks leave to intervene in this action for the limited purpose of ensuring that information exempt
from disclosure under FOIA is adequately protected as FDA complies with this Court’s order.
ARGUMENT
I. PFIZER IS ENTITLED TO INTERVENE AS A MATTER OF RIGHT UNDER
RULE 24(A)
Rule 24(a) of the Federal Rules of Civil Procedure sets forth the requirements for
intervention as a matter of right. See Fed. R. Civ. P. 24(a)(2); Entergy Gulf States Louisiana,
L.L.C. v. U.S. EPA, 817 F.3d 198, 203 (5th Cir. 2016). To intervene pursuant to Rule 24(a), an
applicant must satisfy four requirements:
(1) the application for intervention must be timely; (2) the applicant
must have an interest relating to the property or transaction which is
the subject of the action; (3) the applicant must be so situated that
the disposition of the action may, as a practical matter, impair or
impede his ability to protect that interest; (4) the applicant’s interest
must be inadequately represented by the existing parties to the suit.
Entergy, 817 F.3d at 203 (quoting Haspel & Davis Milling & Planting Co. v. Bd. of Levee Comm’rs
of the Orleans Levee Dist., 493 F.3d 570, 578 (5th Cir. 2007)); see also In re Lease Oil Antitrust
Litig., 570 F.3d 244, 247 (5th Cir. 2009) (same).
Courts in the Fifth Circuit liberally construe Rule 24. Adam Joseph Res. v. CNA Metals
Ltd., 919 F.3d 856, 864 (5th Cir. 2019) (“Although the movant bears the burden of establishing its
right to intervene, Rule 24 is to be liberally construed.”) (internal quotation marks omitted)
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 5
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 1111 ooff 1166 PPaaggeeIIDD 11777755
(quoting Brumfield v. Dodd, 749 F.3d 339, 341 (5th Cir. 2014)); Wal–Mart Stores, Inc. v. Texas
Alcoholic Beverage Comm’n, 834 F.3d 562, 565 (5th Cir. 2016) (same). Intervention should be
allowed “where no one would be hurt and the greater justice could be attained.” John Doe No. 1
v. Glickman, 256 F.3d 371, 375 (5th Cir. 2001); see also Wal–Mart Stores, Inc., 834 F.3d at 565
(same). As set forth below, the requirements for intervention as of right are satisfied here.
A. Pfizer’s Motion to Intervene is Timely
First, Pfizer’s motion to intervene is timely. Pfizer first learned of this litigation just one
month ago. Rule 24 does not provide a specific deadline by which parties should move to
intervene, but courts routinely treat motions filed within several months after an intervenor learns
of its stake in an action as timely. See, e.g., John Doe No. 1, 256 F.3d at 377–78 (finding
intervenor’s motion to intervene timely when filed a month after it became aware of its stake in
the lawsuit); Wal–Mart Stores, Inc., 834 F.3d at 565–66 (holding motion to intervene was timely
when filed three months after defendant filed its answer following denial of motion to dismiss).
Moreover, the Fifth Circuit consistently emphasizes that courts “should discourage
premature intervention because it wastes judicial resources.” John Doe No. 1, 256 F.3d at 376
(quoting Sierra Club v. Espy, 18 F.3d 1202, 1206 (5th Cir. 1994) (internal quotation marks and
alterations omitted)). “Thus, the timeliness clock runs either from the time the applicant knew or
reasonably should have known of his stake in the case into which he seeks to intervene or from the
time he became aware that his stake would no longer be protected by the existing parties to the
lawsuit.” Id. (internal quotation marks and citations omitted). Here, Pfizer learned of this action
from news reports in connection with the December 14, 2021 Scheduling Conference, and
reviewed FDA’s statements raising concerns about its ability to review the BLA adequately for
FOIA-exempt material under the Court’s timeline shortly thereafter. In light of the above, Pfizer
filed its limited motion to intervene on January 21, 2022. Accordingly, Pfizer’s motion is timely.
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 6
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 1122 ooff 1166 PPaaggeeIIDD 11777766
B. Pfizer Has a Direct Interest Relating to the Action
Pfizer satisfies Rule 24(a)’s second element, which requires that it have a “direct,
substantial, [and] legally protectable” interest in the property or transaction that forms the basis of
the controversy.” Espy, 18 F.3d at 1207. Pfizer’s interest in protecting its proprietary trade secret
and confidential commercial information meets this standard. A “property interest . . . is the most
elementary type of right that Rule 24(a) is designed to protect.” Texas v. United States, 805 F.3d
653, 658 (5th Cir. 2015) (internal quotation marks and citation omitted). Courts routinely grant
motions to intervene in FOIA cases involving FDA where a manufacturer seeks to protect its
confidential business information. See, e.g., Pub. Citizen Health Rsch. Grp. v. FDA, 185 F.3d 898,
900 (D.C. Cir. 1999) (noting that a drug manufacturer intervened to protect confidential
information from disclosure under FOIA); Appleton v. FDA, 310 F. Supp. 2d 194, 196–97 (D.D.C.
2004) (permitting New Drug Application (“NDA”) holders to intervene as a matter of right in
FOIA lawsuit seeking release of materials from the FDA’s review of NDAs).
C. Disposition of this Action May Impair Pfizer’s Ability to Protect Its Interests
Based on FDA’s recent statements about its ability to review the BLA adequately for
Pfizer’s confidential information under the required timeline, there is a risk that this matter could
result in inadvertent disclosure of FOIA-protected material. Pfizer’s ability to protect its interests
would be directly impaired if its trade secrets and other proprietary information were disclosed as
a result of this action. See, e.g., Appleton, 310 F. Supp. 2d at 197 (“[D]isclosure[] resulting from
the disposition of this action could impair the applicants’ ability to protect their trade secrets or
confidential information.”). While much of the information sought by Plaintiff relates to the safety
and efficacy of the vaccine, and Pfizer supports the disclosure of that information to promote
confidence in the vaccine, certain other information in the BLA reflects Pfizer’s trade secrets and
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 7
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 1133 ooff 1166 PPaaggeeIIDD 11777777
confidential commercial information, the disclosure of which would cause substantial harm to
Pfizer’s business interests. As such, Pfizer satisfies Rule 24(a)’s third element.
D. Pfizer’s Interests Are Not Adequately Represented by Existing Parties
The final requirement for intervention under Rule 24(a) is that the “applicant’s interest
must be inadequately represented by the existing parties to the suit.” Entergy, 817 F.3d at 203.
“The applicant has the burden of demonstrating inadequate representation, but this burden is
‘minimal.’” Id. (quoting Brumfield, 749 F.3d at 345); see also Trbovich v. United Mine Workers,
404 U.S. 528, 538 n.10 (1972) (same). Courts in the Fifth Circuit have held that the mere
possibility that representation may be inadequate satisfies this requirement for intervention.
Entergy, 817 F.3d at 203 (The applicant need only “show[] that representation . . . ‘may be’
inadequate.”) (quoting Haspel, 493 F.3d at 578); see also Espy, 18 F.3d at 1207 (same); see also
Trbovich, 404 U.S. at 538 n.10 (same).
FDA’s general interest in avoiding the disclosure of proprietary and private information
does not ensure that FDA will adequately protect Pfizer’s business interests. Indeed, it is well-
established in this Circuit that Government entities generally cannot adequately represent the
interests of aspiring intervenors, especially where the government “must represent the broad public
interest,” while the intervenor seeks to protect specific concerns, such as an individual company’s
proprietary or economic rights. Espy, 18 F.3d at 1208 (“Given the minimal burden on the movants
to satisfy this requirement, we conclude that the government’s representation of the intervenors’
interest is inadequate.”); see also John Doe No. 1, 256 F.3d at 381 (same). Likewise, although
Pfizer and Plaintiff share an interest in transparency regarding the vaccine, that commonality does
not extend to Pfizer’s trade secrets or confidential commercial information. Moreover, Pfizer is
uniquely positioned to evaluate the potential commercial sensitivities associated with the
production of its regulatory submissions and identify trade secrets and other protected confidential
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 8
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 1144 ooff 1166 PPaaggeeIIDD 11777788
information. Thus, while Pfizer shares some interests with the existing Parties, Pfizer ultimately
must intervene to protect its unique business interests and is best positioned to do so.
E. Pfizer Has Standing in This Action
The Supreme Court has held that “an intervenor of right must have Article III standing in
order to pursue relief that is different from that which is sought by a party with standing.” See
DeOtte v. Azar, 332 F.R.D. 173, 179 (N.D. Tex. 2019) (citing Town of Chester, N.Y. v. Laroe Ests.,
Inc., 137 S. Ct. 1645, 1648 (2017)). This Court has found, however, that this standing requirement
is limited to instances where a plaintiff-intervenor is affirmatively seeking relief. See Franciscan
All., Inc. v. Azar, 414 F. Supp. 3d 928, 938 n.3 (N.D. Tex. 2019) (concluding when defendant-
intervenors did not “seek relief” and “as long as they do not also intend to add an affirmative claim
for relief during the district court proceedings, Putative Intervenors need not establish standing to
intervene.”). Because Pfizer is not seeking affirmative relief and is intervening for the limited
purpose of protecting its business interest by ensuring compliance with FOIA’s statutory
exemptions, the standing requirement should not apply here.
Nonetheless, to the extent the standing requirement applies, Pfizer has standing to
intervene. To establish standing under Article III, a prospective intervenor must show: (1) injury-
in-fact, (2) causation, and (3) redressability. DeOtte, 332 F.R.D. at 179 (citing Lujan v. Defs. of
Wildlife, 504 U.S. 555, 560 (1992)). Here, Pfizer’s injury-in-fact is the potential disclosure of its
trade secrets and confidential commercial information and the associated economic harm to Pfizer.
As to causation, the relief requested by Plaintiff could deprive Pfizer of its intellectual property
rights if Pfizer is not afforded the opportunity to advocate for protection of certain confidential
commercial information within the larger set of information to be disclosed. Redressability,
likewise, is satisfied, as the risk of injury to Pfizer likely will be minimized by its intervention and
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 9
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 1155 ooff 1166 PPaaggeeIIDD 11777799
the implementation of a production protocol that safeguards against the disclosure of trade secrets
and other confidential commercial information.
Because it satisfies the requirements for intervention under Rule 24(a), Pfizer respectfully
asks that this Court permit it to intervene in this action as a matter of right.
II. IN THE ALTERNATIVE, THIS COURT SHOULD PERMIT PFIZER TO
INTERVENE UNDER RULE 24(B)
Alternatively, if the Court finds that Pfizer does not have the right to intervene under Rule
24(a), Pfizer respectfully requests that this Court grant it permission to intervene under Rule 24(b).
Courts have discretion to permit intervention where the movant “has a claim or defense that shares
with the main action a common question of law or fact.” Fed. R. Civ. P. 24(b)(1)(B). In
considering a motion for permissive intervention, the Court considers whether the motion is timely
and whether the proposed intervention will “unduly delay or prejudice the adjudication of the
rights of the original parties.” Fed. R. Civ. P. 24(b)(3); see also United States v. Colvin, 203 B.R.
930, 941 (N.D. Tex. 1996).
Pfizer’s interest in protecting its trade secrets and confidential commercial information
shares questions of both law and fact in common with the present case. As shown above, Pfizer’s
motion also is timely. Moreover, Pfizer’s intervention will not prejudice the Parties because Pfizer
does not dispute that Plaintiff is entitled to non-exempt information from the BLA under its FOIA
request and Pfizer does not seek any delay in the production of that information. Rather, Pfizer’s
intervention will facilitate production of the information Plaintiff seeks since Pfizer can assist the
Parties in efficiently segregating and redacting any data and information that are subject to FOIA
statutory exemptions.
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 10
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4411 FFiilleedd 0011//2211//2222 PPaaggee 1166 ooff 1166 PPaaggeeIIDD 11778800
CONCLUSION
For the foregoing reasons, Pfizer respectfully requests that this Court grant its Motion for
Leave to Intervene.
Dated: January 21, 2022 Respectfully submitted,
/s/ Daniel L. Tobey
Daniel L. Tobey
State Bar No. 24048842
DLA PIPER LLP (US)
1900 N. Pearl St, Suite 2200
Dallas, Texas 75201
Telephone: (214) 743-4500
Facsimile: (214) 743-4545
Ashley Allen Carr
State Bar No. 24082619
DLA PIPER LLP (US)
303 Colorado Street, Suite 3000
Austin, Texas 78701
Telephone: (512) 457-7000
Facsimile: (512) 457-7001
Matthew A. Holian (pro hac vice forthcoming)
DLA PIPER LLP (US)
33 Arch Street, 26th Floor
Boston, Massachusetts 02110-1447
Telephone: (617) 406-6009
Facsimile: (617) 406-6109
Counsel for Proposed Intervenor Pfizer Inc.
MEMORANDUM IN SUPPORT OF PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE 11",,16
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/038-Appendix-in-Support-filed-by-FDA-re-36-MOTION-To-Partially-Modify-Scheduling-Order.pdf,19.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 11 ooff 1199 PPaaggeeIIDD 11773355
EXHIBIT A
APPX001
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 22 ooff 1199 PPaaggeeIIDD 11773366
IN THE UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF TEXAS
PUBLIC HEALTH AND MEDICAL
PROFESSIONALS FOR TRANSPARENCY,
Plaintiff, Civil Action No. 4:21-cv-01058-P
-against-
FOOD AND DRUG ADMINISTRATION,
Defendant.
SECOND DECLARATION OF SUZANN BURK
I,Suzann Burk, hereby declare as follows:
1. I am the Director of the Division of Disclosure and Oversight Management
(“DDOM”), Office of Communication Outreach and Development(“OCOD”), Center for
Biologics Evaluation and Research (“CBER”), United States Food and Drug Administration
(“FDA”), in Silver Spring, Maryland. A summary of my work experience and current job
responsibilities is included in my December 6, 2021, declaration (ECF No. 23).
2. FDA is committed to transparency both in general and specifically with respect to
records related to the Comirnaty biologicslicense application (“BLA”). As explained in more
detail in the Declaration of Sarah B. Kotler(“Kotler Decl.”) (ECF No. 30), from the time the
Comirnaty BLA was approved, FDA endeavored to publish on its website information relevant
to the public’s interest in the Comirnaty vaccine. Kotler Decl. ¶¶11-14. FDA’s transparency
efforts began the day after the BLA was approved when it posted the “Summary Basis for
Regulatory Action” on its website. Id.¶13. Those efforts continued when FDA posted
numerous FDA discipline review memos, including clinical, statistical, and toxicology reviews
1
APPX002
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 33 ooff 1199 PPaaggeeIIDD 11773377
as part of the “Action Package” 25 days after approval. Id.(cid:32)That information, along with the
other information on FDA’s website, provides the public with substantial information that it can
use to evaluate FDA’s determination approving the Comirnaty vaccine for use in individuals 16
years and older.
3. FDA has reaffirmed its commitment to transparency by providing copious
information to Plaintiff in response to its FOIA request, number 2021-5683 (Plaintiff’s “FOIA
Request”). FDA has already produced to Plaintiff over 7,000 pages of responsive records plus
several unpaginated data files, and expects—and is on track—to have produced over 12,000
pages of responsive records by January 31, 2022. Declaration of Suzann Burk (“First Burk
Decl.”), ECF No. 23, ¶¶ 27-28.
4. As discussed in more detail below, FDA has begun to take dramatic, and indeed
unprecedented, actions in an effort to comply with this Court’s January 6, 2022, order requiring
production of 55,000 pages every thirty days beginning on March 1, 2022. These efforts include
working to hire at least fifteen outside contract staff to help process these records; creating
“details” to allow current FDA staff from other parts of the agency to work on matters related to
this case; obtaining help from staff members from other parts of OCOD and CBER; temporarily
receiving assistance from other FDA disclosure offices to meet production deadlines in other
FOIA litigation; and reaching out to the vaccine sponsors for assistance identifying information
that they consider confidential. Once fully implemented, these steps will dramatically increase the
agency’s ability to produce records to Plaintiff at a greatly accelerated rate, but they come at
significant cost (estimated to be at least $4 to 5 million) to FDA’s other disclosure work—and to
its public health mission. The agency hopes that these efforts will allow it to achieve the
2
APPX003
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 44 ooff 1199 PPaaggeeIIDD 11773388
production rate required by the Court’sorder, but even with these maximal and unprecedented
efforts, it is not possible to guarantee that FDA will be able to fully comply.
Actions Taken Following January 6, 2022, Order
5. After receiving this Court’s January 6, 2022, Order (ECF No. 35) requiring FDA
to produce 55,000 pages of records every thirty days beginning on March 1, 2022, FDA has
taken extraordinary and unprecedented measures to increase its capacity to review and produce
responsive records.
Hiring of Contractors
6. FDA has initiated the process of hiring at least fifteen full-time contract staff to
help process records responsive to Plaintiff’s FOIA Request. FDA anticipates that eleven of those
contract staff will be able to assist with processing records that do not require review for trade
secret or confidential commercial information; the remaining four contract staff would have the
background necessary (with training and oversight from the current FOIA staff at CBER) to help
process more complex records. In addition to reviewing and redacting responsive records, these
contract staff members would assist with administrative steps required to prepare records for
production (finalizing redactions, applying Bates numbers, etc.).
7. Although FDA anticipates that these contract staff will help expand FDA’s
processing capacity significantly once they are in place, it will take time to advertise for these
positions, select appropriate contract staff members, and train selected workers so that they can
meaningfully contribute to the review and production process. Notably, this would likely slow, at
least initially, the efficiency of the current ALFOI staff working on the litigation as they will need
to spend time partnering with the new contract staff to provide training and oversight.
See(cid:32)Declaration of Sarah B. Kotler (“Kotler Decl.”), Dec. 13, 2021, ECF No. 30, ¶ 22.
3
APPX004
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 55 ooff 1199 PPaaggeeIIDD 11773399
Details for Agency Staff
8. CBER is going to publish an agency-wide advertisement for eight “detail”
positions to work on reviewing and producing materials responsive to Plaintiff’s FOIA Request.
These details would allow agency staff who work in other parts of FDA to be selected for the
opportunity to temporarily work on this matter in CBER.
9. As with the contract staff described above, there will be some lag before these
detailees are able to begin working on this project. CBER plans to start publishing advertisements
for these details by approximately February 1, 2022. Once the detail opportunities are posted,
CBER will need to allow a period of time for submitting applications, and then CBER will need to
select candidates from the applications received. Once detailees are selected, they will need to be
trained to perform work on these files. CBER does not expect that agency staff selected for these
details will have the requisite experience and training to immediately begin working at full
strength. Notably, this would likely slow, at least initially, the efficiency of the current ALFOI
staff working on the litigation as they will need to spend time partnering with the new detailed
staff to provide training and oversight. SeKeo(cid:32)tler Decl. ¶ 22.
Reassignment of Staff within CBER’s OCOD
10. Recognizing that efforts to bring on contractors and detailees will take time, CBER
has already reallocated center resources and staff to prioritize the processing of this FOIA request
to attempt to address this matter as quickly as possible. Prior to entry of this Court’s January 6
order, CBER’s Access Litigation and Freedom of Information Branch (“ALFOI”) had dedicated
approximately three “full time equivalents” to the processing of this request. Now, approximately
five and a half of ALFOI’s ten “full-time equivalents” are being dedicated to reviewing and
redacting records related to this litigation.
4
APPX005
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 66 ooff 1199 PPaaggeeIIDD 11774400
11. Further, CBER has also already temporarily reassigned five additional staff
members from other divisions of OCOD to assist ALFOI with processing this request for the
interim in which some of the other efforts described in this declaration are being ramped up.
These reassigned staff members will require training in order to complete the tasks necessary to
accelerate production in this matter.
Receiving Assistance with Other Litigation Deadlines
12. FDA has disclosure obligations in several other FOIA litigations that involve
CBER. In at least one case, where CBER had agreed to contribute 450 pages toward FDA’s
overall monthly production quota, CBER has asked other agency components to take on extra work
to allow CBER to devote more resources to this matter. Under such an arrangement, CBER would
temporarily reduce its production rate to zero in that case, while other agency components would
take on the work that CBER is not able to do. Doing so would allow CBER ALFOI staff that
would otherwise have been working on that production to devote more time to this production,
while CBER ramps up its production capacity.
Working with Vaccine Sponsors to Identify Records that Do Not Contain Exemption 4 Material
13. FDA has also contacted Comirnaty sponsors Pfizer-BioNTech to seek their
assistance, initially, in identifying sections of the BLA that do not contain any trade secret or
confidential commercial information subject to FOIA Exemption 4. FDA has requested the
sponsors to provide this information to it by February 1, 2022.
14. By knowing which records the sponsors believe do not contain information
protected by FOIA Exemption 4, FDA will be able to streamline its disclosure review. Although
FDA will still need to review these records for other types of information protected by the FOIA
Exemptions (most notably, Exemption 6, which protects the privacy interests of clinical
5
APPX006
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 77 ooff 1199 PPaaggeeIIDD 11774411
participants) it will be able to move more quickly through the records if it does not need to search
for Exemption 4 material. Further, it would allow FDA to assign less experienced staff or staff
from other parts of the agency to work on these records. As discussed in the Kotler Declaration,
reviewing files like BLAs requires specialized training and experience – especially for identifying
trade secret and confidential commercial information. See(cid:32)Kotler Decl. ¶ 24. By eliminating the
need to search these records for information protected under Exemption 4, less training will be
required for staff outside of ALFOI to review the affected subset of documents.
15. In addition, FDA is actively assessing other potential ways in which it may properly
enlist Pfizer-BioNTech to assist with streamlining the processing of the records at issue in this suit.
Overall Increase in Production Capacity
16. Once fully implemented, these dramatic efforts will greatly increase FDA’s
capacity for responding to Plaintiff’s FOIA Request. Between contract staff and detailees, CBER
will be adding approximately 23 new individuals to help ALFOI’s efforts. See, supra,
¶¶ 6, 8. When those 23 individuals are fully added to CBER’s existing efforts (see, supra, ¶ 10,
11), ALFOI expects that its capacity will be approximately tripled from the time the new
individuals are fully trained through the end of this production.
17. Other actions – temporarily reassigning staff from other parts of OCOD and CBER
and asking other FDA components to take on CBER’s other litigation obligations in the short term
– will provide additional resources in the short term that will help CBER bridge the gap while it
awaits the contractors and detailees to arrive and be trained. And, as described above, efforts to
work with the vaccine sponsors may help to streamline CBER’s review by
6
APPX007
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 88 ooff 1199 PPaaggeeIIDD 11774422
limiting the amount of time it needs to spend searching for trade secret and confidential
commercial information.
18. But even with these efforts, it is impossible to guarantee that FDA will be able to
produce 55,000 pages every thirty days beginning March 1, 2022, as required by this Court’s
January 6, 2022, Order. In my first declaration, I estimated that if each of ALFOI’s 10 staff
members devoted all of their working hours to this production, they would be expected to be able to
produce 25,410 pages in 11 weeks (or approximately 10,000 pages per month). See(cid:32)First Burk
Decl. ¶ 31.
19. As discussed above, FDA’s most far-reaching efforts to increase production
capacity – hiring contractors and bringing on detailees – necessarily take time to implement. The
agency has to advertise the positions, select qualified candidates, bring the selected candidates on
board, and train them so that they can contribute to CBER’s production efforts. As a result, very
few, if any, of those additional individuals will be in place before the March 1, 2022 deadline.
The temporary measures CBER has implemented will increase production capacity, but it is not
certain that the combination of the temporary additional staffing and current staff’s tireless
efforts will be sufficient to more than quintuple ALFOI’s estimated maximum production
capacity in the time before the new hiring is completed.
20. Even once the new hires fully take effect, meeting the production burden of
55,000 pages per month will pose a challenge to the agency. As discussed above, FDA is
making every effort to comply with this Court’s order in good faith. But in months where the
agency is processing especially challenging records or may be dealing with staff reductions due
to illness, attrition, or other reasons beyond FDA’s control, the enormity of a 55,000 page per
month obligation could still prove to be too much.
7
APPX008
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 99 ooff 1199 PPaaggeeIIDD 11774433
Adverse Impact of Actions on FDA’s Disclosure and Public Health Work
21. The actions described above exceed what the agency considers feasible for
processing a single FOIA request and, in fact, represent the maximum efforts FDA can apply to
this matter. FDA cannot expand its efforts beyond what it has already committed to do. The
dramatic efforts FDA has undertaken to attempt to comply with the Order have already severely
impacted agency functions, and they will continue to do so for the foreseeable future.
22. First, FDA’s plan to hire at least fifteen contract staff to assist with the review
requires a significant financial commitment from the agency. Although exact figures are not yet
available, FDA expects that the expense of hiring these contractors will cost at least three million
dollars. Money spent on contractors to review Plaintiff’s FOIA Request is then unavailable to
fund other important public health priorities, such as hiring staff to review applications for new
medical products or to inspect FDA-regulated establishments, purchasing laboratory equipment to
run analytical testing, or training staff on new scientific advances and technologies.
23. Further, within ALFOI, the fact that about 55 percent of the branch’s full-time
equivalents are devoted to this matter means that other ALFOI disclosure work, including
hundreds of other FOIA requests, many of which also seek information related to COVID-19, are,
of necessity created by the Court’s Order, being sidelined. In my December 6, 2021, declaration, I
showed the dramatic increase in FOIA backlog that CBER had suffered in recent years. First Burk
Decl., ¶ 21. I copy that chart again here.
8
APPX009
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1100 ooff 1199 PPaaggeeIIDD 11774444
CBER Number of Pending FOIA Requests by Year
500
450
400
350
300
250
200
150
100
50
0
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Figure 1: Number of pending FOIA requests pending in CBER at the end of each calendar year.
(2018 value was taken from end of January 2019 because December 2018 data were unavailable
due to government shutdown. 2021 value was current as of November 26, 2021.)
Further, FDA has no control over the number of new FOIA requests that it may receive, and that
number can be expected to be substantial, especially if new vaccines or other biological products
related to COVID-19 are approved. With the resourcesthat FDA isallocating to fulfilling
Plaintiff’s request, I expect that CBER’s backlog will continue to increase –likely dramatically –
including for requests seeking information from CBERrelated to COVID-19.
24. Borrowing resources from other agency components also comes with tradeoffsfor
the agency. As CBER requests assistance from other parts of OCOD and CBER, as well as
other FDA disclosure offices in an effort to satisfy this Court’s order, those offices will have
fewer staff members available to perform their work. Many of those offices are already
constrained by a lack of resources, and in the case of other FDA disclosure offices, many are
experiencing their own FOIA backlogs. SeeKotler Decl. ¶¶24-38. Any resources diverted from
those offices to support CBER’s effortsin this matterwill inevitably exacerbate their own
resource constraints, likely leading to longer backlogs –and greater exposure to costly litigation
9
APPX010
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1111 ooff 1199 PPaaggeeIIDD 11774455
– in those agency components as well. Further, although FDA does not yet know from which
offices the eight proposed detailees will come, the detailees’ home offices will lose the
productive capacity of a staff member, likely leading to reduced output.
25. For these reasons, and as expressed in the Kotler Declaration, FDA simply cannot
take these same measures in response to every FOIA request or every FOIA litigation. The steps
FDA has taken in this case have already placed an extraordinarily heavy burden on the agency’s
disclosure capability and its public health mission. Extending this type of response beyond this
case would dramatically compound the harm. Thus, the agency’s efforts in this case should not be
viewed as precedent for what may be possible in future situations, including for FOIA requests for
other records related to COVID-19. Indeed, as outlined above (see, supra, ¶¶ 20-23), and in the
Kotler Declaration, the agency’s processing of this request is diverting resources from other
agency priorities. It is also reducing the agency’s capacity to process other FOIA requests, thereby
extending wait times of other FOIA requesters – including other requesters seeking records related
to the COVID-19 pandemic.
BENEFIT OF MODIFYING ORDER
26. Modifying the current order to reduce FDA’s March 1 and March 31, 2022,
productions to 10,000 pages and making FDA’s first 55,000-page production due on May 2,
2022,1 would increase FDA’s likelihood of being able to comply with the Court’s Order. First,
and most importantly, it would allow many of the unprecedented measures described above to
take effect. It would allow time for many, if not all, of the contingent of contract and detail staff
to be brought on board before requiring FDA to produce 55,000 pages every thirty days.
1Under the Court’s current order, FDA’s first 55,000-page production would be due on March 1, 2022; the second
would be due on March 31, 2022. The deadline for the third production would then fall on Saturday, April 30, 2022.
FDA interprets deadlines that would fall on weekends or holidays to be due on the next business day –in this case,
Monday, May 2, 2022.
10
APPX011
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1122 ooff 1199 PPaaggeeIIDD 11774466
27. Second, it would allow FDA more time to work with the vaccine sponsors to
accurately locateany trade secret or confidential commercial information that may be protected
from disclosure by statute. As noted above, FDA sent a letter to the vaccine sponsors on January
14, 2022,requesting that they identify any sections of the Comirnaty BLA that they knew did not
contain any trade secret orconfidential commercial information. FDA continues to look for
opportunities to work with Pfizer-BioNTechto create efficiencies in the review process, and it
expects to make additional requests in the future. Extending the date for the first55,000-page
production to May 2, 2022, will allow more time for the initial phase of the agency’s work with
the vaccine sponsorsto occur.
28. Although it cannot be guaranteed, I expect that reducing the size of FDA’s March
1 and 31, 2022 productions to 10,000 pageswould significantly increase the likelihood that FDA
will be able to comply with the Court’s order.
CONCLUSION
29. FDA is committed to transparency and is doing everything possible to achieve
compliance with this Court’s January 6, 2022, Order. The efforts FDA has begun to undertake
will significantly enhance its ability to review and produce records in this litigation, but many of
them will take time to be fully implemented. Extending the deadline for FDA’s first 55,000-
page production to May 2, 2022,would reduce the chances that FDA will be unable to comply
with the Order.
11
APPX012
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1133 ooff 1199 PPaaggeeIIDD 11774477
Pursuant to 28 U.S.C. §1746, I declare under the penalty of perjury that the foregoing is
true and correct.
Executed on January 18, 2022, in Silver Spring, Maryland.
_________________________________
Suzann Burk
Director
Division of Disclosure and Oversight Management,
Office of Communication, Outreach and
Development
Center for Biologics Evaluation and Research
Food and Drug Administration
U.S. Department of Health and Human Resources
12
APPX013
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1144 ooff 1199 PPaaggeeIIDD 11774488
EXHIBIT B
APPX014
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1155 ooff 1199 PPaaggeeIIDD 11774499
IN THE UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF TEXAS
PUBLIC HEALTH AND MEDICAL
PROFESSIONALS FOR TRANSPARENCY,
Plaintiff, Civil Action No. 4:21-cv-01058-P
-against-
FOOD AND DRUG ADMINISTRATION,
Defendant.
DECLARATION OF DOUGLAS WEINFIELD
I, Douglas Weinfield, do hereby declare and state:
1. I have served as the Associate Chief Counsel for Discovery within the Office of
the Chief Counsel (“OCC”), United States Food and Drug Administration (“FDA”) since July of
2018. As Associate Chief Counsel for Discovery, I am responsible for case-related discovery
issues, including electronic discovery on behalf of FDA. My duties include, among other things,
developing discovery-related policies; training FDA employees regarding discovery; assisting
FDA in responding to discovery requests; advising FDA regarding discovery software and
implementation relating to electronic discovery; and coordinating with other government entities,
includingthe U.S. Department of Justice (“DOJ”), regarding electronic discovery.
2. Prior to joiningFDA, I was at the law firm of Williams & Connolly, LLC,for
more than 13 years, where I directedsingle and multiple teams of attorneys in complex
document review projects, and performed document review myself. In all, I have more than 18
years of experience performing and directingelectronic discovery reviews, ranging from basic,
short review, to complex reviews spanning millions of documents and multiple years, including
APPX015
1
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1166 ooff 1199 PPaaggeeIIDD 11775500
international matters. This experience includes document review related to sensitive criminal and
civil litigation. I have directed and/or performed document review in more than 125 matters and
cases.
3. The statements made in this declaration are based upon my personal knowledge
and expertise in litigation and eDiscovery both in private practice and at FDA. Hereafter,
references to “documents” include electronic documents and references to “document review”
include electronic document review.
4. In my experience, there are significant differences between document review
conducted by a private law firm with commercial clients and that conducted by the federal
government. Those differences preclude a simple apples-to-apples comparison, primarily due to
the differences in the nature of the material reviewed, and the nature of the review and redaction
process.
5. During my time in private practice, a review speed of 50 documents per hour was
within the normal range for document review in a complex matter, with different document
reviews going at a slower or faster rate depending on the nature of the material. Variables that
might shift that number up or down in private practice included the length of the documents, the
complexity of the issues, the complexity of the law, and the relative prevalence of privileged
material.
6. In my experience in private practice reviews, it was commonplace that a notable
number of documents were promptly identifiable as non-responsive, which allowed each
document to be reviewed in less than a minute. Moreover, in private practice reviews, frequently
most of the documents in a review were emails, often short emails of one to three pages, which
usually could be reviewed in a minute or less.
APPX016
2
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1177 ooff 1199 PPaaggeeIIDD 11775511
7. In comparison, the documents under review in the present matter, explicitly
requested under the Freedom of Information Act, contain limitednon-responsive documents.
This also largely moots the use of Artificial Intelligence (“A.I.”) or technology assisted review
(“TAR”) approaches to reviewing these documents. Further, theycontain relatively few or no
emails. Therefore, these documents cannot be reviewed at such a rapid pace.
8. In private practice, the review of documents was relatively straightforward.
Identifying relevance, responsiveness, privilege, hot documents, confidentiality, attorney-eyes
only designation, and coding categories were usually simple tasks.Issues such as privilegewere
typically readily discernable via a scan for readily identifiable terms such as “attorney-client” or
the names of attorneys or paralegals, or in the case of confidentiality or coding categories, via a
scan for otherreadily identifiableterms.
9. In private practice, the bases for redaction in the overwhelming majority of
reviews were attorney-client privilegeand/or the work-product doctrine, which are usually easily
identifiable by the reviewing attorney. These reviews rarely required consultation with subject
matter or programmatic staff or experts, if at all. Additionally, there were infrequent redactions
of material as confidential or as containing personally identifiable information, again depending
on the nature of material under review.
10. In contrast, at FDA, redactions are made for a broader range of reasons than is the
case for private law firms, and an FDA document review typically contains much more redacted
or withheld material than is true in a private practice review. Relevant to the present case, FDA
redactions are made to protect trade secret information, confidential business information, and
personally identifiable information. Many of these redactions or withholdings implicate the
commercial and privacy interests of third parties, as well as FDA’s statutory and/or regulatory
APPX017
3
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1188 ooff 1199 PPaaggeeIIDD 11775522
duty to protect such information, which is often provided to FDA by a third party with the
expectation that the information will not be further disseminated. Identifying the material to be
redacted is usually more difficult and time-consuming than identifying the attorney-client or
work product material to be redacted in private practice reviews.
11. Based on my experience in private practice, for efficiency’s sake it is the usual
practice there to conduct a two-pass review. The first, quicker, pass usually identifies relevance,
privilege, and specific issues of particular importance for that matter, as well as documents that
need redaction or further review or are unreadable. The second, slower, pass usually redacts the
relatively smaller number of documents which contain privileged material, which, generally, was
readily identifiable. In addition, it is common for an attorney substantively involved with the
matter to conduct a third review of some or all of the documents, for quality control.
12. Document reviews in private practice rarely require significant specific subject
matter expertise; rather, the document reviews are highly similar from review to review. A small
degree of training regarding the specific content at the beginning of a new review is common,
usually lasting a day or two at most, and often less, with further learning over the course of the
review.
13. At FDA, document review and redaction are usually performed by reviewers with
subject matter experience, usually with years or decades of experience reviewing documents in a
particular area, such as drugs, devices, food, biologics, tobacco, or veterinary medicine. This
knowledge is important to identify often subtle issues which arise in the course of document
review and identifying material which needs to be redacted. Identification of commercially
sensitive information in a biologics license application, for example, is usually significantly
harder (and requires more specialized expertise) than identification of redactions based on
APPX018
4
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3388 FFiilleedd 0011//1188//2222 PPaaggee 1199 ooff 1199 PPaaggeeIIDD 11775533
attorney-client privilege or work-product doctrine, which comprise the vast majority of
redactions in private practice document reviews. Due to the challenges in identifying these issues,
and the relatively high number of redactions to be made, it is FDA’s practice to conduct a single
pass review which includes redacting protected material at the time it is identified, because a
second pass would require a re-identification of these subtle issues, and nearly double the effort
and time to find them. In addition to this single pass review, FDA often conducts a quality
control review, similar to reviews in private practice. This intermittent process of identifying
issues, pausing the review to redact, and continuing the review, is intrinsically slower than the
comparatively simple two-pass reviews usually conducted by private law firms, which require no
such pausing, and which typically have much less material to redact.
14. Even in the unusual circumstance that the third party that submitted documents is
involved in helping the agency identify trade secrets or confidential commercial information in
them, FDA will still have a role in reviewing records prior to release.
Pursuant to 28 U.S.C. § 1746, I declare under the penalty of perjury that the foregoing is true and
correct.
Executed on this 18th day of January 2022 in Washington, District of Columbia.
_____________________________________
Douglas Weinfield
Associate Chief Counsel for Discovery
US Food and Drug Administration
APPX019
5","[[['', '', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', ''], ['', '', '', '', '', '', '', '', '']]]",19
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/022-FDA-Brief-in-Advance-of-Scheduling-Conference.pdf,19.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 11 ooff 1199 PPaaggeeIIDD 222211
IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF TEXAS
____________________________________
)
PUBLIC HEALTH AND MEDICAL )
PROFESSIONALS FOR )
TRANSPARENCY, )
)
Plaintiff, )
)
v. ) Civil Action No. 4:21-cv-01058-P
)
UNITED STATES FOOD AND DRUG )
ADMINISTRATION, )
)
Defendant. )
___________________________________ )
DEFENDANT’S BRIEF IN ADVANCE OF SCHEDULING CONFERENCE
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 22 ooff 1199 PPaaggeeIIDD 222222
TABLE OF CONTENTS
LEGAL BACKGROUND………………………………………………………………………...1
FACTUAL BACKGROUND…...……………………………………………………….…...…...3
I. Plaintiff’s FOIA Request………………………………………………………….3
II. The Parties’ Negotiations Concerning a Processing Schedule……………………4
III. Plaintiff’s Priority List…………………………………………………………….4
IV. FDA’s Productions of Records to Plaintiff………………………………………..5
V. FDA’s Upcoming Production of Records to Plaintiff……………………………...7
FDA’S UPDATED PROPOSAL FOR A PROCESSING SCHEDULE………………………….8
ARGUMENT……………………………………………………………………………………...9
CONCLUSION…………………………………………………………………………………..13
i
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 33 ooff 1199 PPaaggeeIIDD 222233
TABLE OF AUTHORITIES
Cases
Blakeney v. FBI, No. 17-cv-2288 (BAH), 2019 WL 450678 (D.D.C. Feb. 5, 2019)……………13
Citizens for Responsibility & Ethics in Wash. v. FEC, 711 F.3d 180 (D.C. Cir. 2013)…………..1
Colbert v. FBI, No. 16-CV-1790 (DLF), 2018 WL 6299966 (D.D.C. Sept. 3, 2018)…………...13
Color of Change v. Dep’t of Homeland Sec., 325 F. Supp. 3d 447 (S.D.N.Y. 2018)…………...13
Cooper Cameron Corp. v. U.S. Dep’t of Labor, 280 F.3d 539, 543 (5th Cir. 2002)……………...1
Daily Caller v. Dep’t of State, 152 F. Supp. 3d 1 (D.D.C. 2015)…………………………2, 10, 12
Davis v. Dep’t of Homeland Sec., No. 11-cv-203 (ARR) (VMS),
2013 WL 3288418 (E.D.N.Y. June 27, 2013)…………………………………………...13
Dep't of Air Force v. Rose, 425 U.S. 352 (1976)………………………………………………….1
Elec. Privacy Info. Ctr. v. Dep’t of Justice, 15 F. Supp. 3d 32 (D.D.C. 2014)…………………..12
F.B.I. v. Abramson, 456 U.S. 615 (1982)……………………………………………………..…10
Food Mktg. Inst. v. Argus Leader Media, 139 S. Ct. 2356 (2019)……….……………………….2
Nat’l Sec. Counselors v. Dep’t of Justice, 848 F.3d 467 (D.C. Cir. 2017)………………………12
Republican Nat’l Comm. v. Dep’t of State, No. 16-cv-486,
2016 WL 9244625 (D.D.C. Sept. 16, 2016)……………………………………………..13
Statutes and Regulations
5 U.S.C. § 552……………………………………………………………………………….passim
18 U.S.C. § 1905…………………………………………………………………………………..2
21 U.S.C. § 331(j)…………………………………………………………………………………2
21 C.F.R. § 20.61………………………………………………………………………………….2
i
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 44 ooff 1199 PPaaggeeIIDD 222244
21 C.F.R. § 20.63………………………………………………………………………………….2
21 C.F.R. § 601.51………………………………………………………………………………...3
ii
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 55 ooff 1199 PPaaggeeIIDD 222255
Pursuant to the Court’s Order of November 18, 2021, ECF No. 21, Defendant, the U.S.
Food and Drug Administration (“FDA”), respectfully submits this brief and attached appendix to
assist the Court in setting a schedule for the processing of records responsive to Plaintiff’s
Freedom of Information Act (“FOIA”) request.
LEGAL BACKGROUND
The Freedom of Information Act provides that any person has a right to obtain access to
federal agency records subject to the Act, except to the extent that any portions of such records
are protected from public disclosure by one or more of nine exemptions listed in the Act. See 5
U.S.C. § 552 (a)(3), (a)(4)(B), (b), (c); see also Dep't of Air Force v. Rose, 425 U.S. 352, 362–65
(1976) (stating that FOIA “assure[s] public access to all governmental records whose disclosure
would not significantly harm specific governmental interests”). Under FOIA, a person may
submit a request to a federal agency “reasonably decrib[ing]” records that s/he seeks to obtain. 5
U.S.C. § 552(a)(3)(A). An agency that has received a FOIA request is required, as relevant here,
to “determine within 20 days (excepting Saturdays, Sundays, and legal public holidays) after the
receipt of any such request whether to comply with such request.” Id. § 552(a)(6)(A)(i). FOIA
further provides that a requester “shall be deemed to have exhausted his administrative remedies
with respect to such request if the agency fails to comply with the applicable time limit
provisions.” Id. § 552(a)(6)(C)(i).
FOIA’s 20-working-day time period does not create a deadline for production. Citizens
for Responsibility & Ethics in Wash. v. FEC, 711 F.3d 180, 189–90 (D.C. Cir. 2013).1 Rather,
“if the agency does not adhere to FOIA’s explicit timelines, the ‘penalty’ is that the agency
cannot rely on the administrative exhaustion requirement to keep cases from getting into court.”
1 Courts often rely on case law concerning FOIA from the D.C. Circuit, as it is “the federal appellate court with the
most experience in this field.” Cooper Cameron Corp. v. U.S. Dep’t of Labor, 280 F.3d 539, 543 (5th Cir. 2002).
1
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 66 ooff 1199 PPaaggeeIIDD 222266
Id. No other provision in FOIA creates a specific timeframe for the release of records. See 5
U.S.C. §§ 552(a)(3)(A) (an agency shall make records responsive to a proper request “promptly
available”), (a)(6)(C)(i) (same for litigated cases).
Indeed, the time required to process a FOIA request will inherently depend on the scope
of the request and the nature of the information the requested records contain. Federal law
generally prohibits the release of certain types of information, such as trade secrets and personal
medical information. See 21 U.S.C. § 331(j); 18 U.S.C. § 1905; 21 C.F.R. §§ 20.61, 20.63.
Consistent with these obligations to protect sensitive information, FOIA exempts several types of
information from its production requirements. 5 U.S.C. § 552(b); see Food Mktg. Inst. v. Argus
Leader Media, 139 S. Ct. 2356, 2366 (2019) (“FOIA expressly recognizes that ‘important
interests [are] served by [its] exemptions,’ and ‘[t]hose exemptions are as much a part of
[FOIA’s] purpose[s and policies] as the [statute’s disclosure] requirement.’” (brackets in
original) (quoting FBI v. Abramson, 456 U.S. 615, 630–631 (1982); Encino Motorcars, LLC v.
Navarro, 138 S. Ct. 1134, 1142 (2018))). As particularly relevant to this case, FOIA Exemption
4 permits withholding of “trade secrets and commercial or financial information obtained from a
person and [that are] privileged or confidential.’” 5 U.S.C. § 552(b)(4). And Exemption 6
permits agencies to withhold or redact “personnel and medical files and similar files the
disclosure of which would constitute a clearly unwarranted invasion of personal privacy.” 5
U.S.C. § 552(b)(6). To ensure protection of this information and other information that is
exempt from disclosure under FOIA, government agencies must carefully review all records and
redact exempt information before the records are released to the FOIA requester. See Daily
Caller v. Dep’t of State, 152 F. Supp. 3d 1, 14 (D.D.C. 2015) (stating that the government has a
2
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 77 ooff 1199 PPaaggeeIIDD 222277
“responsibility” when processing FOIA requests to “safeguard[] potentially sensitive
information”).
FACTUAL BACKGROUND
I. Plaintiff’s FOIA Request
On August 27, 2021, FDA received a FOIA request from Plaintiff seeking “all data and
information for the Pfizer Vaccine enumerated in 21 C.F.R. § 601.51(e) with the exception of
publicly available reports on the Vaccine Adverse Events Reporting System.” Ex. A (Decl. of
Suzann Burk) ¶ 24 (hereinafter “Burk Decl.”) (App011).2 Because the regulation cited by
Plaintiff, 21 C.F.R. § 601.51, addresses “data and information in applications for biologics
licenses,” FDA interpreted Plaintiff’s FOIA request as a request for all publicly releasable
information in the original biologics license application (“BLA”) submitted by BioNTech-Pfizer
for the Comirnaty vaccine with internal file number STN 125742/0/0 (“original Comirnaty
BLA”). Id. ¶ 25 (App011–12).
Based on FDA’s initial assessment of the number of records potentially responsive to
Plaintiff’s FOIA request, FDA determined that the original Comirnaty BLA requested by
Plaintiff comprises more than 329,000 pages of records. Id. (App012). In addition to those
329,000 pages, the original Comirnaty BLA includes data files in a format similar to a
spreadsheet for which a page count cannot readily be determined. Id. (App012). FDA has
assessed that the original Comirnaty BLA contains at least 126 of these data files. Id. (App012).
Many of those data files themselves are very large, containing dozens of columns and over ten
thousand rows of data. Id. (App012).
2 Pursuant to this Court’s Motion Practice standard II.C., the portions of the appendix relied upon are underlined.
3
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 88 ooff 1199 PPaaggeeIIDD 222288
II. The Parties’ Negotiations Concerning a Processing Schedule
After Plaintiff filed its Complaint, ECF No. 1, and FDA filed its answer, ECF No. 14, the
parties engaged in negotiations concerning a schedule for the processing and production of the
non-exempt portions of records responsive to Plaintiff’s FOIA request.3
To assist in negotiations and to assist Plaintiff in prioritizing certain records for
processing and production, FDA provided two lists to Plaintiff revealing the (non-confidential)
titles of sections of the original Comirnaty BLA. Burk Decl. ¶ 26 (App013). Those two lists,
which served as something analogous to an index to certain sections of the original biological
license application, totaled nearly 90 pages. Id. (App013). Where feasible and as a courtesy,
FDA also annotated portions of the longer list (hereinafter, the “Index”) with approximate page
counts per section of the original Comirnaty BLA to assist Plaintiff in identifying documents for
priority processing. See Ex. B (Index) (App022–108).
Once subsequent discussions revealed that Plaintiff was most interested in Section 5.2 of
the original Comirnaty BLA and the raw data contained in Section 5.3 of the original Comirnaty
BLA, FDA searched its system for those sections to evaluate their size and scope. Burk Decl.
¶ 26 (App013). FDA assessed that Sections 5.2 and 5.3 comprise more than 321,000 pages of
records (plus additional data files) and requested that Plaintiff use the provided Index to
prioritize the production of certain records. Id. (App013).
III. Plaintiff’s Priority List
On November 4, 2021, Plaintiff provided FDA with the below list of records they
requested FDA prioritize for processing (“Plaintiff’s Priority List”) in order of priority:
1. CRFs for site 1055 (from page 27 of the provided Index)
3 These negotiations were described in detail in the parties’ two joint reports. See ECF Nos. 18, 20. Only the
negotiations relevant to FDA’s current processing proposal are repeated in this filing.
4
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 99 ooff 1199 PPaaggeeIIDD 222299
2. CRFs for site 1081 (from page 31 of the provided Index)
3. CRFs for site 1096 (from page 38 of the provided Index)
4. CRFs for site 1128 (from page 46 of the provided Index)
5. Program Files/SAS files. Plaintiff requested 3 to 4 SAS files as a sample, in the
first instance, so that it could assess whether it would like to prioritize the complete universe of
SAS files. (from page 10 of the provided Index)
6. Section 5.2 of the original Comirnaty BLA – Tabular Listing of all Clinical
Studies (from page 1 of the provided Index)
7. Section 4 of the original Comirnaty BLA – Nonclinical Study Reports (from page
1 of the provided Index)
8. Section 5.3.6 of the original Comirnaty BLA – Reports of Postmarketing
Experience (from page 2 of the provided Index)
9. Section 16.1.1 of the original Comirnaty BLA – Protocol and/or Amendment, and
specifically, Final Analysis Interim Independent Oversight Committees (from page 3 of the
provided Index)
10. In the Analysis Datasets (ADaM) Section -- the Analysis Data Reviewers Guide,
Analysis Dataset Definition, and Analysis Dataset Definition Stylesheet (from page 6 of the
provided Index)
11. Tabulation Datasets (from page 11 of the provided Index)
12. CRFs for site 1085 (from page 33 of the provided Index)
Ex. C (Emails from Aaron Siri to Courtney Enlow) (Nov. 4, 2021)) (App122). Government
counsel proposed that FDA process certain documents on Plaintiff’s priority list by November 17
and December 1, 2021, with the parties to confer after December 1 regarding future productions.
Plaintiff rejected that proposal.
IV. FDA’s Productions of Records to Plaintiff
Although Plaintiff rejected FDA’s production proposal, FDA nevertheless has been
working to process and produce the non-exempt portions of records from Plaintiff’s Priority List.
FDA completed its proposed November 17 and December 1 productions. Burk Decl. ¶ 27
(App013–14). Specifically, on November 17, 2021, FDA produced all publicly releasable
5
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1100 ooff 1199 PPaaggeeIIDD 223300
information from the following:
• A portion of Plaintiff’s priority item #5:
One .txt file; and
o
One SAS (data) file;4
o
• A portion of Plaintiff’s priority item #6:
From Section 5.2 of the original Comirnaty BLA: The Tabular Listing;
o
From Section 5.2 of the original Comirnaty BLA: The Listing of Clinical Sites;
o
• Plaintiff’s priority item #8:
From Section 5.3.6 of the original Comirnaty BLA: The Reports of Postmarketing
o
Experience.
Id. (App013–14). This production amounted to 91 pages of records, as well as the two data files
(the .txt and SAS files). FDA redacted material from the 91 pages under FOIA Exemptions 4
and 6 to protect the disclosure of trade secrets and commercial or financial information that was
obtained from a person outside the government and that is privileged or confidential and to
protect personal privacy. Because FDA assessed that there was no exempt material in the data
files included in this production, FDA made no deletions or redactions to those files.
On December 1, 2021, FDA made a second release. Burk Decl. ¶ 27 (App014–15).
Specifically, FDA produced publicly releasable information from the remainder of Section 5.2 of
the original Comirnaty BLA to Plaintiff, making redactions under FOIA Exemption 6 to protect
personal privacy. With this 248-page production, FDA completed processing and production of
item 6 on Plaintiff’s Priority List. Thus, as of the time of this filing, FDA has produced to
4 In communications between FDA and Plaintiff, Plaintiff indicated that it was interested in obtaining “sample” SAS
files, but none of the files Plaintiff identified in its priority list was an SAS file. Instead, Plaintiff identified .txt files
that included “SAS” in their file names. In an attempt to provide Plaintiff with the information it requested, FDA
produced one of the .txt files Plaintiff requested, as well as one xpt (SAS) file even though Plaintiff did not
specifically prioritize any SAS files in its priority list. As a result, FDA’s November 17, 2021, production included
more records than FDA initially proposed. Burk Decl. ¶ 27 n.5 (App013).
6
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1111 ooff 1199 PPaaggeeIIDD 223311
Plaintiff the non-exempt portions of 339 pages, as well as two data files, and has completed
processing and production of two items on Plaintiff’s Priority List (items 6 and 8).
V. FDA’s Upcoming Production of Records to Plaintiff
Since the time the parties filed their Second Joint Report, ECF No. 20, FDA has had an
opportunity to assess the amount of time it will take to review additional records on Plaintiff’s
Priority List and has determined that it can complete processing of certain records at a pace faster
than the previously proposed 500-pages-per-month rate.5 See Burk Decl. ¶¶ 27–29 (App014–
16). Accordingly, by December 13, 2021, FDA anticipates producing publicly releasable
information from the following:
• All documents related to Plaintiff’s priority item #1 – CRF files for site 1055
(approximately 2,030 pages);
• All remaining documents related to Plaintiff’s priority item #5 –
Four additional .txt files that were listed on page 10 of the Index;
o
Four additional SAS files (not specifically listed on Plaintiff’s priority list, but
o
Plaintiff has expressed interest in these files during the course of negotiations).
• Publicly releasable information from the following additional sections of the original
Comirnaty BLA:
Section 2.5 – Clinical Overview (approximately 333 pages)
o
Section 2.7.3 – Summary of Clinical Efficacy (approximately 182 pages)
o
Section 2.7.4 – Summary of Clinical Safety (approximately 344 pages)
o
Id. ¶ 27 (App014–15).
Thus, by the time of the Court’s status conference on December 14, 2021, FDA
anticipates that it will have produced to Plaintiff more than 3,000 pages of responsive materials,
5 In light of FDA’s assessment, on December 1, 2021, undersigned counsel informed Plaintiff’s counsel of FDA’s
updated proposed processing schedule (as set forth here and below) and asked if Plaintiff would be amenable to the
proposed schedule. As of the time of this filing, Plaintiff has not indicated whether it would accept this proposal.
7
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1122 ooff 1199 PPaaggeeIIDD 223322
most of which were listed on Plaintiff’s Priority List. Id. (App015). Moreover, FDA will have
completed processing and production of four items on Plaintiff’s Priority List (items 1, 5, 6, and
8). Id. (App013–15).
FDA’S UPDATED PROPOSAL FOR A PROCESSING SCHEDULE
In addition to the December 13 production, FDA expects to be able to produce the next
three items on Plaintiff’s Priority List (items 2, 3, and 4) before the end of January 2022. Burk
Decl. ¶ 28 (App015–16). FDA proposes to produce the below records to Plaintiffs according to
the following schedule:
• Thursday, December 30, 2021: FDA proposes to produce publicly releasable information
from Plaintiff’s priority item #2 – CRF files for site 1081 (approximately 3,380 pages);
• Tuesday, January 18, 2022: FDA proposes to produce publicly releasable information
from Plaintiff’s priority item #3 – CRF files for site 1096 (approximately 2,937 pages); and
• Monday, January 31, 2022: FDA proposes to produce publicly releasable information
from Plaintiff’s priority item #4 – CRF files for site 1128 (approximately 3,452 pages).
Id. (App015).
If the Court adopts this schedule, by the end of January 2022, FDA will have produced
publicly releasable information from more than 12,000 pages of records and 10 unpaginated .txt
or SAS data files. Id. (App015). Moreover, FDA will have completed production of seven of
the first eight items on Plaintiff’s Priority List (items 1, 2, 3, 4, 5, 6, and 8). Id. (App015–16).
Because FDA has not yet had an opportunity to assess the amount of time it will take to
process other records responsive to Plaintiff’s FOIA request, following the January 31, 2022
production, FDA proposes to make one production at the end of each subsequent month totaling
8
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1133 ooff 1199 PPaaggeeIIDD 223333
a minimum of 500 pages.6 Id. ¶ 29 (App016). FDA’s general estimate is that it takes
approximately 8 minutes per page to review records for a FOIA production. Id. ¶¶ 18, 29
(App007, App016). It is difficult for FDA to know whether records will take more or less than
the estimated eight minutes per page until reviewers have had an opportunity to perform at least
a preliminary review of those records. Id. ¶¶ 18, 29 (App007–08, App016). Certain records will
likely include more confidential information, and thus more corresponding redactions, which
will require more research and production time. Id. ¶¶ 18, 29 (App007, App016). Once FDA
has an opportunity to assess processing times for other records responsive to Plaintiff’s FOIA
request, FDA may be able to process and produce the non-exempt portions of records to Plaintiff
at a rate faster than 500 pages per month. Id. ¶ 29 (App016). Thus, although FDA proposes a
minimum rate of 500 pages a month after the January 31, 2022 production, FDA will produce
records at a faster rate where feasible. Id. (App016).
ARGUMENT
FDA’s Processing Schedule is Reasonable and Fair to All Requesters
As demonstrated below, the Court should adopt FDA’s proposed schedule because it
properly balances the interest of Plaintiff in receiving records responsive to its FOIA request
with the interests of the vaccine sponsor in the protection of its confidential information, the
interests of clinical trial participants in the protection of their personal privacy information, and
the interests of other FOIA requesters whose requests are being processed alongside Plaintiff’s.
The proposed schedule is also feasible for FDA to complete with its limited processing resources
and is not only consistent with processing schedules entered by other courts, but would in fact
6 For purposes of calculating a “page count” of data records that are not paginated, FDA proposes considering
twenty lines of spreadsheet data the equivalent of one page. For example, production of a spreadsheet containing
2,000 lines of data would be counted the equivalent of a 100-page PDF record.
9
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1144 ooff 1199 PPaaggeeIIDD 223344
result in the FDA producing records to Plaintiff at a rate much faster than most courts order.
First, FDA’s proposed schedule properly addresses the interest of Plaintiff in receiving
records because the schedule would result in production of the non-exempt portions of more than
12,000 pages of records and 10 unpaginated .txt or SAS data files to Plaintiff in less than two
months from the date of the scheduling conference. Burk Decl. ¶ 28 (App015). Moreover, this
schedule would result in the expedited production of seven of the twelve items on Plaintiff’s
Priority List (items 1, 2, 3, 4, 5, 6, and 8). Id. (App015–16).
In addition, FDA’s proposed schedule provides FDA adequate time to assess whether
records contain material that is exempt from production under FOIA and redact that exempt
information. Plaintiff has requested records that comprise information submitted by the vaccine
sponsor (Pfizer-BioNTech) to FDA. Id. ¶ 24 (App011). From FDA’s experience with other
similar FOIA requests, such records can be expected to contain both confidential business and
trade secret information of Pfizer or BioNTech and personal privacy information of patients who
participated in clinical trials. Id. ¶ 36 (App019–20). FDA is required to protect certain
information under the law and this type of information is exempt from production under the
FOIA. See 5 U.S.C. § 552(b)(4), (b)(6); F.B.I. v. Abramson, 456 U.S. 615, 621 (1982)
(“Congress realized that legitimate governmental and private interests could be harmed by
release of certain types of information and provided nine specific exemptions under which
disclosure could be refused.”); see also Burk Decl. ¶ 9 (App004). To ensure protection of this
information, and other information subject to withholding under the FOIA exemptions, FDA
must carefully review and, if necessary, redact exempt information on a line-by-line basis. See
Burk Decl. ¶¶ 11, 13, 34 (App005, App006, App0018–19); see also Daily Caller, 152 F. Supp.
3d at 14. Moreover, if FDA determines not to withhold information that might be confidential
10
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1155 ooff 1199 PPaaggeeIIDD 223355
commercial information, it is sometimes required by regulation to provide notice to the company
that submitted the information and an opportunity to file a claim for injunctive relief (a “reverse
FOIA” claim). See, e.g., 21 C.F.R. §§ 20.47, 20.48, 20.61(e).
FDA has assessed it can conduct this necessary review at a faster rate than normal for the
12,000 pages and 10 data files that comprise FDA’s proposed productions through January 31,
2022. Burk Decl. ¶ 28 (App015). But FDA has not yet had a chance to make an assessment
concerning the time it will take to review records after the proposed January 31, 2022
production. Id. ¶ 29 (App016). FDA is therefore relying on its standard rate of 8 minutes per
page for review to propose a processing rate of 500 pages per month for subsequent productions.
Id. (App016).
Furthermore, FDA’s proposed schedule adequately protects the interests of other FOIA
requesters. FDA, and specifically, the Center for Biologics Evaluation and Research (“CBER”),
which maintains the records requested by Plaintiff, has 459 pending FOIA requests. Id. ¶ 22
(App010). Of the 459 requests pending before CBER, approximately 329 were received before
Plaintiff’s. Id. ¶ 22 (App010). Many of these new requests, including the request at issue in this
case, have sought large amounts of data that require significant resources to process. Id. ¶ 21
(App009). The branch responsible for processing FOIA requests for CBER-maintained
documents, CBER’s Access Litigation and Freedom of Information Branch, has ten staff
members – one branch chief and nine full-time staff members.7 Id. ¶¶ 4, 31, 35 (App003,
App007, App019). Two of those members began working for the office within the last four
months and, because they are new staff members, they are not yet able to review records at the
same rate as more experienced staff members. Id. ¶ 31 n.7 (App017).
7 Along with processing FOIA requests, these ten staff members are also responsible for helping to address non-
FOIA litigation-related document requests.
11
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1166 ooff 1199 PPaaggeeIIDD 223366
FDA is not able to commit to processing Plaintiff’s request at a faster rate than the 12,000
pages and 10 data files by January 31, 2022, and 500 pages per month thereafter, without
diverting significant resources away from the processing of other FOIA requests that are also in
litigation, requests that are ahead of Plaintiff’s in CBER’s processing queues, as well as other
non-FOIA record requests (such as, for example, document review to respond to discovery
requests and third-party subpoenas). Id. ¶¶ 5, 8, 17, 36 (App003, App004, App007, App019–
20). Such diversion would adversely impact FDA’s ability to meet stipulated document
processing deadlines and would be fundamentally unfair to other FOIA requesters, the majority
of whom submitted their FOIA requests before Plaintiff and who likely believe, as Plaintiff does,
that their FOIA request is important and needs to be processed expeditiously. See id. ¶ 22
(App010–11); see also Elec. Privacy Info. Ctr. v. Dep’t of Justice, 15 F. Supp. 3d 32, 47 (D.D.C.
2014) (denying motion for preliminary injunction requesting immediate production of documents
pursuant to FOIA request and noting that allowing the plaintiff “to jump to the head of the line
would upset the agency’s processes and be detrimental to the other expedited requesters”); Daily
Caller, 152 F. Supp. 3d at 14 (stating that “the plaintiff’s effort to jump to the head of the FOIA
processing line would work a significant burden on both the agency and numerous interested
parties”).
Finally, FDA’s proposed schedule that will result in production of the non-exempt
portions of more than 12,000 pages and 10 data files by January 31, 2022, and 500 pages per
month thereafter, Burk Decl. ¶ 28 (App015–16), is a processing rate that is much faster than
other courts have ordered. As the D.C. Circuit has recognized, an agency’s policy of processing
500 pages per request per month “serves to promote efficient responses to a larger number of
requesters.” Nat’l Sec. Counselors v. Dep’t of Justice, 848 F.3d 467, 471–72 (D.C. Cir. 2017).
12
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1177 ooff 1199 PPaaggeeIIDD 223377
Numerous other courts have entered processing schedules requiring production of the non-
exempt portions of 500 pages per month. See, e.g., Blakeney v. FBI, No. 17-cv-2288 (BAH),
2019 WL 450678, at *2 (D.D.C. Feb. 5, 2019); Republican Nat’l Comm. v. Dep’t of State, No.
16-cv-486, 2016 WL 9244625, at *1 (D.D.C. Sept. 16, 2016); Color of Change v. Dep’t of
Homeland Sec., 325 F. Supp. 3d 447, 451 (S.D.N.Y. 2018); Davis v. Dep’t of Homeland Sec.,
No. 11-cv-203 (ARR) (VMS), 2013 WL 3288418, at *1 (E.D.N.Y. June 27, 2013). Courts do
not waiver from the standard 500 page per month processing rate even when a FOIA request
would take significant time to process. See, e.g., Colbert v. FBI, No. 16-CV-1790 (DLF), 2018
WL 6299966, at *3 (D.D.C. Sept. 3, 2018) (permitting a processing rate of 500 pages per month
for 71,000 responsive records).
In sum, FDA’s proposed processing schedule is fair to Plaintiff. It results in the non-
exempt portions of 12,000 pages and 10 data files produced to Plaintiff in less than 60 days and
accommodates Plaintiff’s request to prioritize production of numerous records. Burk Decl. ¶ 28
(App015–16). It is fair to the vaccine sponsor and individuals who participated in clinical trials,
as the schedule allows FDA adequate time to review the records for confidential commercial
information and information that would result in an unwarranted invasion of personal privacy.
Id. ¶ 36 (App019–20). And it is fair to other FOIA requesters, who should not be prejudiced
merely because Plaintiff has the resources to file a lawsuit in an attempt to obtain a faster
processing schedule. Id. (App019–20).
CONCLUSION
For the foregoing reasons, Defendant respectfully requests that the Court enter FDA’s
proposed processing schedule.
13
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1188 ooff 1199 PPaaggeeIIDD 223388
Dated: December 6, 2021 Respectfully submitted,
BRIAN M. BOYNTON
Acting Assistant Attorney General
Civil Division
ELIZABETH J. SHAPIRO
Deputy Director
Federal Programs Branch
/s/ Courtney D. Enlow
ANTONIA KONKOLY
Senior Counsel
COURTNEY D. ENLOW (NC Bar No. 46578)
Trial Attorney
United States Department of Justice
Civil Division, Federal Programs Branch
1100 L Street, N.W.
Room 12102
Washington, D.C. 20005
Tel: (202) 616-8467
Email: courtney.d.enlow@usdoj.gov
Counsel for Defendant
14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2222 FFiilleedd 1122//0066//2211 PPaaggee 1199 ooff 1199 PPaaggeeIIDD 223399
CERTIFICATE OF SERVICE
I hereby certify that on December 6, 2021, I electronically transmitted the foregoing to the
parties and the clerk of court for the United States District Court for the Northern District of Texas
using the CM/ECF filing system.
/s/ Courtney D. Enlow
COURTNEY D. ENLOW
Trial Attorney
United States Department of Justice
Civil Division, Federal Programs Branch
1100 L Street, N.W.
Room 12102
Washington, D.C. 20005
Tel: (202) 616-8467
Email: courtney.d.enlow@usdoj.gov
15",,19
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/Order-February-7-2022.pdf,2.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 5577 FFiilleedd 0022//0077//2222 PPaaggee 11 ooff 22 PPaaggeeIIDD 22115511
UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF TEXAS
FORT WORTH DIVISION
PUBLIC HEALTH AND MEDICAL
PROFESSIONALS FOR TRANSPARENCY,
Plaintiff,
v.
FOOD AND DRUG ADMINISTRATION, No. 4:21-cv-1058-P
Defendant.
v.
PFIZER, INC.,
Movant.
ORDER
Before the Court is Movant Pfizer, Inc.’s Motion to Intervene for a
Limited Purpose (“Motion”). ECF No. 40. On January 28, 2022, the
Court held a hearing on the Motion, where Pfizer represented that their
interests in the litigation are currently aligned with Plaintiff and
Defendant. To that end, Pfizer seeks, like Plaintiff and Defendant, the
expeditious production of the requested documents.
Pfizer also (correctly) recognizes that the Parties’ currently aligned
interests could potentially diverge. For instance, the Parties could
disagree about which documents, or portions of documents, should or
should not be redacted prior to production. Accordingly, Pfizer seeks to
intervene because their interests might not be adequately represented
by either Plaintiff or Defendant in the future. See, e.g., Wal-Mart Stores,
Inc. v. Tex. Alcoholic Beverage Comm’n, 834 F.3d 562 (5th Cir. 2016);
Entergy Gulf States La., L.L.C. v. EPA, 817 F.3d 198 (5th Cir. 2016);
Texas v. United States, 805 F.3d 653 (5th Cir. 2015).
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 5577 FFiilleedd 0022//0077//2222 PPaaggee 22 ooff 22 PPaaggeeIIDD 22115522
The Court, however, concludes that it will defer ruling on the Motion
until a conflict is imminent or has, in fact, manifested. The Court will
therefore hold Pfizer’s Motion in ABEYANCE. Pfizer is INSTRUCTED
to file a concise Notice with the Court if a conflict is imminent or has, in
fact, manifested.
SO ORDERED on this 7th day of February, 2022.
Mark T. Pittman
UNITED STATES DISTRICT JUDGE
2","[[['PUBLIC HEALTH AND MEDICAL'], ['PROFESSIONALS FOR TRANSPARENCY,']]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/044-PL-PHPMTS-MOL-IN-OPPOSITION-TO-DEFENDANTS-MOTION-TO-MODIFY-THE-SCHEDULING-ORDER-OF-THE-COURT.pdf,20.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 11 ooff 2200 PPaaggeeIIDD 11778877
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF TEXAS
PUBLIC HEALTH AND MEDICAL
PROFESSIONALS FOR TRANSPARENCY,
Plaintiff, Civil Action No. 4:21-cv-01058-P
-against-
FOOD AND DRUG ADMINISTRATION,
Defendant.
PLAINTIFF’S MEMORANDUM OF LAW IN OPPOSITION TO DEFENDANT’S
MOTION TO MODIFY THE SCHEDULING ORDER OF THE COURT
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 22 ooff 2200 PPaaggeeIIDD 11778888
TABLE OF CONTENTS
INTRODUCTION........................................................................................................................ 1
ARGUMENT ................................................................................................................................ 4
I. The FDA’s Claim That it Cannot Produce 55,000 Pages on March 1st and March
31st is False ......................................................................................................................... 4
II. The FDA’s Delay Tactics Should Not be Countenanced ................................................ 12
III. Holding the FDA to its Representations, Plaintiff Requests the Monthly Rate
Increase to 180,000 Pages Per Month .............................................................................. 14
IV. The FDA’s Comments Regarding the Cost of the Review or the Need to Reallocate
Resources Cannot Serve to Alter the Court’s Ruling ...................................................... 15
CONCLUSION .......................................................................................................................... 18
ii
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 33 ooff 2200 PPaaggeeIIDD 11778899
INTRODUCTION
It is understandable that the FDA does not want independent scientists to review the
documents it relied upon to license Pfizer’s vaccine given that it is not as effective as the FDA
originally claimed, does not prevent transmission, does not prevent against certain emerging
variants, can cause serious heart inflammation in younger individuals, and has numerous other
undisputed safety issues.1 However, the FDA’s potential embarrassment over its decision to
license this product must take a back seat to the transparency demanded by FOIA and the urgent
need and interests of the American people to review that licensure data. The Court already
recognized this unprecedented urgent need in its January 6th order directing the FDA to produce
55,000 pages per month.2
The FDA now insists it must delay its first 55,000-page production until May 1, 2022 –
four months after the Court entered its order. However, the FDA’s own papers seeking this delay
make plain it can produce at a rate of 55,000 pages per month in February and March. The FDA
affirms it has already “allocated the equivalent of nearly 11 full-time staff to this project” and that
“a review speed of 50 documents per hour was within the normal range for document review in a
complex matter” in private practice; and here the 50 document per hour rate would be faster since
there is only a need to review for personally identifying information (“PII”) for most pages.
Hence, if the FDA’s 11 full-time reviewers work only 7.5 hours per day and review 50 pages (not
1 Reflecting the issues with this product, the FDA failed to send a representative to a federal court
hearing in this matter on December 14th because of the “FDA’s protocols” regarding COVID-19.
Meaning, despite the FDA’s claim the vaccine is “effective,” the FDA is apparently still scared to
send a representative to the hearing. Its actions speak volumes and cast serious doubt on its words.
2 While the FDA asserts in its motion that Plaintiff “opposes the requested relief and stated that it
will explain the reasons why in a written response to this Motion,” Plaintiff clearly set forth within
an email to FDA’s counsel its reasoning for opposing the reduction in the monthly rate and the
FDA chose to not respond and address any concern raised therein. See App000935-App000938.
1
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 44 ooff 2200 PPaaggeeIIDD 11779900
documents) per hour, the FDA could review over 88,000 pages per month in February and March.
That is more than sufficient to produce the 55,000 pages per month currently ordered for these two
months.
Instead of complying with this Court’s reasoned order, the FDA claims these 11 reviewers
can only review a total of 10,000 pages per month. What the FDA does not say, and what basic
math shows, is that a rate of 10,000 pages a month for 11 full-time reviewers amounts to only 5
pages per hour! This rate is made even more absurd because most of the pages the FDA will be
reviewing during this period are repetitive data files that only require second level review to redact
minimal amounts of PII that Pfizer may have left in the documents. FDA’s reality defying claim
and contemptuous approach to its production obligations should not be countenanced. (Infra § I.)
It is also apparent that the instant demand is just the start of a campaign to delay the
production ordered by the Court. In this first salvo, the FDA is not really asking the Court. It is
instead expressly telling the Court it does not intend to produce more than 10,000 pages per month
for February and March, and despite claiming it is making “unprecedented” efforts, the FDA
repeatedly tells the Court: “It is not possible to guarantee that FDA will be able to fully comply”
with the 55,000-page production rate thereafter. (Dkt. No. 38 at APPX004, APPX008.)
Americans must follow the law and the FDA, a multi-billion-dollar agency, should similarly be
given no safe harbor from complying with the orders of this Court. (Infra § II.)
The FDA should also be held to what it attests. The FDA, with over 18,000 employees
and an over $3 billion discretionary budget, repeatedly assures the Court that it is taking steps to
“marshal every possible resource available to it,” “acting with maximal urgency to assemble every
possible resource available to it” and “putting every available resource at its disposal into its efforts
to achieve compliance.” (Dkt. No. 37 at 10, 3, 10.) The FDA also attests that over the coming
2
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 55 ooff 2200 PPaaggeeIIDD 11779911
weeks, it will have 28.5 full-time people reviewing the documents. Working 7.5 hours per day for
20 business days per month, 28.5 people reviewing 50 pages per hour can review a total of
approximately 213,750 pages per month. Putting aside that most of this production can be
reviewed far faster than the rate of 50 pages per hour, Plaintiff asks that the FDA be held to its
representations and be directed to produce at the rate of 180,000 pages per month starting in April.
(Infra § III.)
The Court is, other than Congress, the only check on the FDA. In a free country,
transparency is paramount, and the FDA has chosen to thwart transparency and the requirements
of FOIA by anemically understaffing the office it maintains to respond to FOIA requests. It is
akin to the boy that kills his parents and asks for sympathy for being an orphan. Decrying that this
Court is now making it comply with the law – by actually producing documents in a timely manner
– is ridiculous. It is also incredible for the FDA to claim that compliance here would harm its
health policy objectives. Even if the FDA really does need to spend $4 to $5 million which, as
shown below, is an absurd overestimate, that is an inconsequential amount of its overall $3.41
billion discretionary budget. Moreover, the issues with the Pfizer vaccine – including waning
immunity, variants evading immunity, the failure to prevent transmission, myocarditis, and
pericarditis – show that the FDA’s priority should be to address this product before rushing off to
engage in other activities. (Infra § IV.)
For these reasons, as explained below, the Court should refuse to reduce the rate of
production in February and March and should increase the rate of production for April and
thereafter to 180,000 pages per month consistent with the FDA employing 28.5 full-time reviewers
in the coming weeks to conduct the review and the fact that most of the pages need only be
reviewed for PII.
3
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 66 ooff 2200 PPaaggeeIIDD 11779922
ARGUMENT
I. The FDA’s Claim That it Cannot Produce 55,000 Pages on March 1st and March
31st is False
Plaintiff submitted the instant FOIA request in late August 2021 and filed this action in
September 2021. (Dkt. No. 1.) Nearly four months later, on January 6, 2022, the Court rejected
the FDA’s patently unreasonable request to produce just 500 pages per month and instead ordered
the FDA to produce 55,000 pages every 30 days starting on March 1, 2022. (Dkt. No. 35.) Now,
the FDA wants to have that deadline pushed to May 1, 2022, which would be nearly four months
after the Court entered its order and nine months after Plaintiff submitted its FOIA request.
However, the FDA’s excuses for seeking to further delay the production do not withstand even the
most basic scrutiny.
Even more egregious, its excuses are plainly not tethered to the truth. The FDA is clearly
dissembling when it claims it is taking steps to “marshal every possible resource available to it,”
that the “FDA is doing everything within its ability to comply with the January 6 Order,” that it is
“acting with maximal urgency to assemble every possible resource available to it,” or that the
“FDA is putting every available resource at its disposal into its efforts to achieve compliance with
the Court’s Order.” (Dkt. No. 37 at 10, 2, 3, 10.) It requires suspending reality to accept that the
FDA, with over 18,000 employees and its multi-billion-dollar discretionary budget, could not
comply with the Court’s deadlines if it were truly marshaling every possible resource available to
it. If it was doing so, it could complete the entire production in even less than the originally
requested 108 days.
After making the false claim that it is marshaling every possible resource, which it
apparently defines as assigning “nearly 11 full-time staff to this project” (out of its over 18,000
employees), it then makes the outrageous claim to this Court that these nearly 11 full-time staff
4
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 77 ooff 2200 PPaaggeeIIDD 11779933
can only produce 10,000 pages per month in February and March. Some simple math reveals just
how absurd this claim is and how it stretches reason to accept that the FDA itself believes this
claim. There are a total of 43 business days during this period, and assuming the 11 reviewers
work 7.5 hours per day, 10,000 pages per month amounts to an average review pace of just 5 pages
per hour!
Bringing the absurdity of the FDA’s position into even sharper focus is the straight-forward
nature of this production. There is no dispute as to the universe of responsive documents. The
FDA has never needed to conduct elaborate searches for documents or engage in a long collection
process. The agency just needs to review the documents already in the Pfizer vaccine’s biologics
license file. The FDA does not need to review those documents for relevance because if a
document is in the file, then it is relevant and responsive.
As for reviewing the unquestioned universe of documents, the FDA admits it needs to
review these documents for only two exemptions: trade secrets and PII. That is it.
In its prior briefing, the FDA never contested that almost all the information requested is
clinical trial data that does not contain trade secrets. Making its job even easier, the FDA has now
asked Pfizer to confirm the portions of the requested documents that do not contain trade secrets
by February 1, 2022. These non-trade secret documents almost certainly represent the vast
majority of the production. This is obvious from the fact the FDA claims it will allocate 11 of the
15 contractors it is hiring to review “those records that do not require review for trade secret or
confidential information.” (Dkt. No. 37 at 3.)
As for the FDA’s need to review for PII, the FDA never contested that Pfizer already
redacted the PII before submitting its documents to the FDA (as it was required to do by FDA
regulations). See 21 C.F.R. § 20.63(b). The FDA now just wants to do a second review, which is
5
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 88 ooff 2200 PPaaggeeIIDD 11779944
fair enough. However, there is absolutely no reason why a trained reviewer can only review 5
pages per hour if all they are doing is a second level review for PII. Furthermore, for the new
reviewers the FDA is hiring, beyond its 11 current experienced reviewers, training to review for
PII cannot seriously take more than a few hours.
The production the FDA already delivered to Plaintiffs further evidences the absurdity of
the FDA’s claims concerning the complexity of the instant review. The index provided by the
FDA for the Pfizer vaccine biologics file is 87 pages long. (App000939-App1026.) Out of those
87 pages, 68 pages contain just a long list of 1,035 case report forms (“CRF”) files. Each CRF
file contains only data from a clinical trial site. The FDA, based on Plaintiff’s initial sampling
request, produced 37 of the 1,035 listed CRF files. These 37 CRF files contained a total of 8,347
pages. Assuming this sampling is representative, the 1,035 CRF files in the total production will
amount to around 250,000 pages, or more than half of the 450,000 pages that the FDA has indicated
are responsive to the request at issue.
Taking a closer look at the sample 8,347 pages of CRF files produced to-date, the only
redactions the FDA made were for a single type of PII data: date of birth and death. Nothing more.
Moreover, all of the 8,347 pages are similar, most of them looking like one of the following two
examples:
6
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 99 ooff 2200 PPaaggeeIIDD 11779955
7
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1100 ooff 2200 PPaaggeeIIDD 11779966
8
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1111 ooff 2200 PPaaggeeIIDD 11779977
Claiming it will take a full hour to review 5 pages of the foregoing repetitive documents for only
PII is absurd at best and, at worst, knowingly deceptive.
Included in Plaintiff’s Appendix are the first 50 pages of each of the three CRF files
produced to date, for a total of 150 combined pages. (App000785-App000934.) According to the
FDA, a review of those pages should take approximately 30 hours. To test this claim, a paralegal
at our firm replaced the redactions from these pages with made-up data. Attorney of record in this
matter, Elizabeth Brehm, carefully reviewed this version of these 150 pages and redacted the
relevant PII in just 14 minutes and 15 seconds. (App000781-App000782.) Ms. Brehm caught all
three of the original redactions – which were birthdates. (Id.) This test shows that the FDA’s time
estimates are patently absurd. It also establishes that the instant request is far from evidence of the
agency “doing everything within its ability to comply with the January 6 Order” as it claims, but
rather is just another example of the agency trying to avoid or delay its FOIA obligations. (Dkt.
No. 37 at 2.)
The Declaration of Douglas Weinfield, Associate Chief Counsel for Discovery within the
Office of the Chief Counsel of the FDA, makes clear that during his “time in private practice, a
review speed of 50 documents per hour was within the normal range for document review in a
complex matter.” (Dkt. No. 38 Appx016 ¶ 5); see also David Degnan, Accounting for the Costs
of Electronic Discovery, 12 Minn. J.L. Sci. & Tech. 151, 165 (Winter 2011) (“Industry standards
suggest that document reviewers can read, understand, and mark 50 documents per hour.”). As
Mr. Weinfield explains, within these “private practice” reviews, reviewers search for “relevance,
responsiveness, privilege, hot documents, confidentiality, attorney-eyes only designation, and
coding categories.” (Dkt. No. 38 Appx016 ¶ 8). Obviously, just reviewing for PII is far less
burdensome than reviewing for all these other categories. Here, not only is the review only for PII
9
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1122 ooff 2200 PPaaggeeIIDD 11779988
for a majority of the responsive documents but, as shown, most of the documents are also repetitive
clinical trial data documents. Thus, this review is not even a “complex” matter requiring a reduced
review speed of 50 documents per hour, but rather a simple review that can be accomplished at an
even faster rate. Nonetheless, the FDA expects this Court to believe that its reviewers can only
review 5 pages per hour.
With just the 11 full time reviewers working 7.5 hours per day and reviewing 50 pages per
hour (rather than the absurd claim of just 5 pages per hour), the FDA could review over 88,000
pages per month in February and in March 2022. That is more than sufficient to produce the
55,000 pages per month currently ordered by the Court for these two months, and 8 times greater
than the 10,000 per month the FDA requests.
To further confirm these numbers, and the reasonableness of the Court’s existing Order,
Plaintiff contacted a professional document review company, BIA, is a highly regarded and
established document review company that has been performing document review services for law
firms for over 17 years. (App000782.) Plaintiff provided BIA with copies of the 8,347 pages of
sample CRF data the FDA already produced (after removing redactions and inserting made-up
data). BIA estimated it could provide project management, and review and redact those documents
for both trade secrets and PII within 50-70 hours, and for a budget of just $3,700. (Id.) That is a
rate of between 119 and 166 pages per hour.
The FDA could easily retain BIA (or any similar company) for the entire portion of the
production that only involves PII. In fact, as noted in Plaintiff’s prior papers, BIA estimated it
could complete the whole review of all 450,000 pages for PII and trade secrets within 6-8 weeks
with 10 reviewers and 1 team lead, for approximately $132,000 (Dkt. No. 31 p. 3), a tiny fraction
10
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1133 ooff 2200 PPaaggeeIIDD 11779999
of the purported $4 to $5 million the FDA claims it will cost to review these documents (Dkt. No.
37 at 9).
Mr. Weinfield attempts to persuade the Court that the instant FOIA review will be much
harder and more time consuming than a typical private practice review. (Dkt. No. 38 at APPX012-
19.) In this manner he seeks to defend the indefensible: that the FDA’s 11 reviewers can only
review around 5 pages per hour. His arguments are irrelevant and/or ridiculous:
• Mr. Weinfield never claims that he has specific knowledge of the documents at
issue here. (Id. at APPX016 ¶ 3 (attesting that the declaration is merely based on
his general “knowledge and expertise in litigation and eDiscovery”).) As a result,
his conclusions are all just generalizations, and lack any specificity whatsoever, and
should therefore be given little if any weight. On the other hand, BIA based its
estimation on a sample of the actual documents at issue here.
• Mr. Weinfield does not even try to claim that PII is in any way complicated to
identify, and since the majority of the records only require review of PII, his
arguments, therefore, have no relevance to the majority of documents at issue.
(Dkt. No. 38 at APPX006 ¶ 14 (“By knowing which records the sponsors believe
do not contain information protected by FOIA Exemption 4, FDA will be able to
… move more quickly through the records if it does not need to search for
Exemption 4 material”).)
• As for the subset of pages that may contain trade secrets and confidential business
information, Mr. Weinfield provides little support for his claim that reviewing for
this information here requires more specific knowledge than is required in a private
practice review. Take, for example, an antitrust lawsuit involving a Pfizer drug. In
11
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1144 ooff 2200 PPaaggeeIIDD 11880000
any event, to the extent that a subset of the responsive documents here could contain
trade secrets or confidential business information, the FDA has already involved
Pfizer to identify such documents, further undermining any claim of burden. (See
Dkt No. 38 APPX007 ¶ 15 (“FDA is actively assessing other potential ways in
which it may properly enlist Pfizer-BioNTech to assist with streamlining the
processing of the records at issue in this suit”).) In fact, the FDA has a whole set
of regulations specifically addressing how a company submitting documents to the
FDA can and should “designate part or all of the information” that it has submitted
to the FDA “as exempt from disclosure under exemption 4 of” FOIA, “either at the
time the records are submitted to the Government or within a reasonable time
thereafter.” 21 C.F.R. 20.61(d).
For all these reasons, the FDA’s claim that its current 11 full-time reviewers can only
review 10,000 pages per month for February and March is simply untrue. On the other hand, if
this claim were true, then it raises to a fever pitch questions regarding the competency of the FDA,
and it screams the need to get the documents it relied upon to license the Pfizer vaccine into the
hands of independent scientists forthwith.
II. The FDA’s Delay Tactics Should Not be Countenanced
All Americans must comply with the law. The FDA again asks this Court for special
dispensation to avoid what Congress, and this Court, required. Everyday Americans do not get
such reprieve. The law is the law. At the current ordered rate, the FDA is already being given
leeway with regard to the purpose and intent of FOIA, i.e., timely production. It has been more
12
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1155 ooff 2200 PPaaggeeIIDD 11880011
than four months since Plaintiff commenced this lawsuit and the documents at issue, to be timely
put to good use by independent scientists, are needed forthwith.
That the FDA wants to stall production as long as possible is plain from the fact that during
the parties’ negotiations and briefing, and during the court hearing, it would not agree to be
obligated to produce more than 500 pages per month. The agency made no secret of this goal,
even after its counsel was pressed by the Court. And after being ordered to produce at a faster
rate, the FDA has no issue with making plainly ludicrous claims to obtain additional delay.
The FDA also makes clear that this latest maneuver will no doubt be only the first in a
series of delay tactics. In the FDA’s supporting Declaration of Suzann Burk (Dkt. No 38 at
APPX002 -APPX013), the agency makes clear its future intentions. First, the FDA is not really
asking the Court to produce only 10,000 pages per month for February and March 2022; it is telling
the Court it will not comply with the Court’s order as it exists today. The FDA explicitly states it
may not even meet the dramatically reduced page count of 10,000 pages per month, claiming that
even this amount “cannot be guaranteed,” rather the agency only states that if the productions were
reduced to 10,000 pages for these months, that “would significantly increase the likelihood that
FDA will be able to comply with the Court’s order.” (Dkt. No 38 at APPX012 (emphasis added).)
Hence, the FDA is saying that it does not intend to comply unless the Court bends to its demand
of 10,000 pages for the next two productions and, even then, it may not comply with that amount.
Incredibly, the FDA then goes on to say that it may not comply with the 55,000 pages per
month obligation thereafter. Indeed, after claiming the agency will assign 28.5 full time reviewers
to the project,3 the Declaration of Suzann Burk says that:
3 The FDA is attested to the Court that it plans to hire 15 contractors (Dkt. No. 38 at APPX009 ¶
22), “detail” 8 agency employees (Id. at APPX005 ¶ 8), and assign 5.5 of its normal review staff
to the project (Id. at ¶ 10), for a total of 28.5 reviewers.
13
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1166 ooff 2200 PPaaggeeIIDD 11880022
Even once the new hires fully take effect, meeting the production
burden of 55,000 pages per month will pose a challenge to the
agency. As discussed above, FDA is making every effort to comply
with this Court’s order in good faith. But in months where the
agency is processing especially challenging records or may be
dealing with staff reductions due to illness, attrition, or other reasons
beyond FDA’s control, the enormity of a 55,000 page per month
obligation could still prove too much.
(Dkt. No 38 at APPX008.) In establishing the 55,000 pages per month rate, the Court already took
into account “the FDA’s concerns regarding the burdens of production” and balanced those against
the “need for unprecedented urgency.” (Dkt. No. 35 at 3.) As such, the agency cannot simply tell
the Court that because of the burden on it, the agency may choose to not comply.
That the FDA does not intent to comply with the Order is further foreshadowed by its
harping on its claimed “good faith.” It is plainly laying the foundation for not being held in
contempt when it later fails to comply with the Order. Judging the FDA by its actions, not its
words, it is clear why the FDA filed this motion: it is setting up for delay and more delay later with
the cover of supposed good faith attempts at compliance, none of which is actually made in good
faith. Thus, should the Court grant the agency its requested inch (a 90,000-page reduction for
February and March) in this motion, it has made clear it will subsequently take many miles.
If the FDA is willing to dissemble in this motion by claiming that its current 11 employees
assigned to the project can only review on average 5 pages per hour, then there is no reason to
think anything it says regarding its intentions are true.
III. Holding the FDA to its Representations, Plaintiff Requests the Monthly Rate
Increase to 180,000 Pages Per Month
Since the FDA has affirmed to this Court that it is taking steps to “marshal every possible
resource available to it,” is “acting with maximal urgency to assemble every possible resource
14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1177 ooff 2200 PPaaggeeIIDD 11880033
available to it” and “is putting every available resource at its disposal into its efforts to achieve
compliance,” the Plaintiff asks that the Court hold the FDA to its representations.
The FDA asserts that over the coming weeks, it will have 28.5 full-time people to conduct
a review of the documents. Working 7.5 hours per day for 20 business days in a month, 28.5
people reviewing 50 pages per hour can review a total of approximately 213,750 pages per month.
Reducing this monthly rate by another 15% to allow for different types of documents, and
potential delays caused by unforeseen issues – such as “staff reductions due to illness, attrition, or
other reasons” referenced by Ms. Burk (Dkt. No 38 at APPX008) – results in an exceedingly
reasonable rate of 180,000 pages per month. Meaning, putting aside that a document review
company could review these documents within weeks with far less people and for a tiny fraction
of the budget claimed by the FDA, and that most of the documents (which only involve PII) can
be reviewed far quicker than 50 pages per hour, with 28.5 full time reviewers the agency should
be able to easily review 180,000 pages per month.
As for the FDA’s claim that the rate in this case is unprecedented, the FDA, as noted in
prior argument, fails to identify the relevant metric. The rate is the tail, and the dog is FOIA’s
requirement that the documents be timely produced. Here, the minimum rate of 55,000 pages per
month still means the documents will not be produced until at least the end of September which,
given the current issues with the pandemic, is respectfully still not timely for the current needs.
Independent scientists need these documents today.
IV. The FDA’s Comments Regarding the Cost of the Review or the Need to Reallocate
Resources Cannot Serve to Alter the Court’s Ruling
The FDA repeatedly makes hyperbolic comments in its papers about the cost of the review
and the resources it needs to transfer to comply with the Court’s order. However, the FDA never
15
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1188 ooff 2200 PPaaggeeIIDD 11880044
makes explicit its reasons for making these comments, and it appears the FDA is merely trying to
make the Court feel guilty for ordering the production in the first place.4
The Court is, other than Congress, the only check on the FDA. In a free country,
transparency is paramount, and the FDA has chosen to thwart transparency and the requirements
of FOIA by anemically understaffing the office it maintains to respond to FOIA requests. The
FDA’s understaffing of its FOIA office is in itself a violation of the obligation of FOIA. Decrying
that this Court is now making it comply with the law – by making the agency actually produce
documents in a timely manner – is incredible. Trying to make the Court feel it is doing something
wrong by making the FDA comply with the law is the height of absurdity. That the FDA is not
sufficiently staffed to timely respond to all the transparency requests from the American people is
not the fault of the Court but rather falls squarely upon the FDA itself for understaffing the
personnel available to respond to these requests.
The FDA additionally wants to ensure that the Court’s effort to make it come close to
complying with the law is a one-time affair for this case and this case only. By the way the FDA
describes its supposedly “unprecedented’ actions to comply, the agency makes it sound like it is
attempting to land a man on the moon, rather than simply produce documents it has in its
possession and is statutorily obligated to produce. It is shameful for the agency to continue to
4 The FDA also attempts to minimize the unprecedented importance that the Court already found
regarding the instant FOIA production. In her declaration, Ms. Burk reiterates the FDA’s earlier
claims that the agency supposedly published information that “provides the public with substantial
information that it can use to evaluate FDA’s determination approving the” Pfizer vaccine. (Dkt.
No. 38 APPX003 ¶ 2.) When it directed that the FDA produce 55,000 pages per month, the Court
already dismissed this claim and concluded that the public requires the underlying data so that
independent scientists can review the FDA’s claims, and not just items created by FDA that were
sanitized for public review.
16
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 1199 ooff 2200 PPaaggeeIIDD 11880055
conduct itself in this manner instead of simply doing what it is required to do by statute and now
by Court order: timely respond to all FOIA requests.
It is also remarkable for the FDA to claim, with its over $3.41 billion discretionary budget,
that compliance here would harm its health policy objectives. Even if the FDA really does need
to spend $4 to $5 million, which as shown above is an absurd overestimate, that is an
inconsequential amount of its overall discretionary budget. Moreover, the issues with the Pfizer
vaccine – including waning immunity, variants evading immunity, the failure to prevent
transmission, myocarditis, and pericarditis – show that the FDA’s priority should be to address
this product before rushing off to engage in other activities.
Instead, the FDA gripes about the fact that it must now purportedly spend $4 to $5 million
from its discretionary budget of over $3.41 billion and allocate a few employees when it has over
18,000 of them. The FDA claims the COVID-19 vaccine is the most important thing it is doing to
fight COVID-19, yet now when it needs to be transparent with the American public it tries to claim
that every single other expense it has is more important.
Among the list of its complaints, the agency gripes that it needs to review new product
applications and responding to this FOIA at the Court-ordered rate of production adversely affects
that. Putting aside that the resources for the instant document review are not material to its 18,000
employees and over $3.41 billion discretionary budget, it fails to advise the Court that
pharmaceutical companies pay user fees directly to the FDA in order to carry out these new product
application reviews – the user fees are not part of the discretionary budget and amounted to $2.8
billion last year and are expected to exceed that amount this year.5
5 See https://www.fda.gov/about-fda/budgets/2021-budget-summary.
17
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4444 FFiilleedd 0011//2244//2222 PPaaggee 2200 ooff 2200 PPaaggeeIIDD 11880066
If a multi-billion-dollar company’s counsel advised the Court that it could not comply with
a document demand within even 60 or 90 days for lack of resources, the company would find no
safe harbor before almost any federal judge. The FDA shouldn’t either.
CONCLUSION
Plaintiff respectfully asks that the FDA’s request to reduce the monthly rate for February
and March be denied and that, irrespective of whether that request is granted or denied, that the
FDA be ordered to produce 180,000 pages on April 30, 2022 and every 30 days thereafter.
Dated: January 24, 2022
SIRI & GLIMSTAD LLP
/s/ Aaron Siri
Aaron Siri, NY Bar No. 4321790
Elizabeth A. Brehm, NY Bar No. 4660353
Gabrielle G. Palmer, CO Bar No. 48948
200 Park Avenue
17th Floor
New York, New York 10166
Tel: (212) 532-1091
Fax: (646) 417-5967
aaron@sirillp.com
ebrehm@sirillp.com
gpalmer@sirillp.com
HOWIE LAW, PC
John Howie
Texas Bar Number: 24027239
2608 Hibernia Street
Dallas, Texas 75204
Tel: (214) 622-6340
jhowie@howielaw.net
Attorneys for Plaintiff
18",,20
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/111521-Second-Joint-Status-Report.pdf,14.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 11 ooff 1144 PPaaggeeIIDD 220055
IN THE UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF TEXAS
PUBLIC HEALTH AND MEDICAL
PROFESSIONALS FOR TRANSPARENCY,
Plaintiff, Civil Action No. 4:21-cv-01058-P
-against-
FOOD AND DRUG ADMINISTRATION,
Defendant.
SECOND JOINT REPORT
Plaintiff, Public Health and Medical Professionals for Transparency (“Plaintiff”), by and
through its attorneys, and Defendant, the U.S. Food and Drug Administration (“Defendant or
“FDA”), by and through its attorney, hereby submit this Joint Report in compliance with the
Court’s Order of November 10, 2021, ECF No. 19 (the “Order”):
1. The Order asked the parties to “appraise the Court of whether a scheduling
conference is needed” and if not to “propose[] deadlines for an expedited briefing schedule, if
necessary.”
2. Defendant’s Position: A scheduling conference is needed with the Court in order
to set a schedule for the processing of records in response to Plaintiff’s Freedom of Information
Act (“FOIA”) request. Setting a processing schedule does not go to the merits of the case, but
instead sets the schedule for the necessary deadlines to govern a FOIA case. The processing
schedule serves as an important precursor to future deadlines in the case, including scheduling for
dispositive motions.
In FOIA cases, a FOIA requestor typically files suit after it has submitted a FOIA request
to an agency and the agency has not yet processed and produced all responsive records to the
Page 1 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 22 ooff 1144 PPaaggeeIIDD 220066
requestor. 5 U.S.C. § 552(a)(4)(B). Once a case is filed and the government has answered the
complaint, the parties usually negotiate a schedule by which the government will search for,
process, and produce records responsive to the plaintiff’s FOIA request. If the parties are unable
to agree upon a schedule, courts typically enter a processing schedule after considering arguments
for each party’s proposed schedule that were presented in a status report or at a scheduling
conference.
A processing schedule is necessary because many different types of information are exempt
from the FOIA, such that the government must redact that information before providing responsive
records to the plaintiff. See 5 U.S.C. § 552(b)(1)–(b)(9). Reviewing and redacting records for
exempt information is a time-consuming process that often requires government information
specialists to review each page line-by-line. When a party requests a large amount of records, like
Plaintiff did here, courts typically set a schedule whereby the processing and production of the
non-exempt portions of records is made on a rolling basis.
After the government has completed processing and producing the non-exempt portions of
responsive records to the plaintiff, the parties typically confer as to whether the plaintiff intends to
challenge the adequacy of the government’s search for records or any of the redactions taken to
protect the disclosure of exempt material. If the parties have a dispute over the search or the
exemptions, the parties typically confer and propose a schedule for summary judgment briefing.
Setting a summary judgment schedule before the completion of the production of records is
inefficient for the parties and the Court, as it results in piecemeal briefing and consideration of the
Page 2 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 33 ooff 1144 PPaaggeeIIDD 220077
merits of the case. Summary judgment briefing in a FOIA case is not the appropriate vehicle to
set a schedule for the release of records.1
In this case, FDA has assessed that there are more than 329,000 pages potentially
responsive to Plaintiff’s FOIA request. (This page count is under-inclusive of the material
responsive to the request, as it does not include certain types of records that cannot be meaningfully
paginated, such as data captured in spreadsheets that contain thousands of rows of data.) The
parties have conferred in good faith concerning a processing schedule, but have been unable to
reach agreement for the reasons set forth in the parties’ Joint Report. See ECF No. 18.
Defendant respectfully requests a scheduling conference with the Court for the Court to set
a schedule for the processing of documents. Defendant proposed a processing schedule in the
Joint Report and resubmits it here for ease of reference. FDA proposes to process and produce the
non-exempt portions of the following records by the following dates:
• November 17:
o From Section 5.2 of the Biologics License Application (“BLA”) file:
▪ The Tabular Listing
▪ The Listing of Clinical Sites
o The Reports of Postmarketing Experience from Section 5.3.6 of the BLA
file
o One SAS file.2
1 Nor is establishing a briefing schedule for “expedited production” necessary. Any production schedule established
as part of a scheduling conference with the Court will inherently resolve any questions related to the rate of the
agency’s production.
2 Plaintiff has requested to receive the SAS files in their native format. FDA customarily converts SAS files to PDF
files because PDFs can be redacted to prevent the release of non-exempt information. However, FDA is willing to
produce SAS files to Plaintiff (if it is feasible for FDA to do so) with the parties’ understanding that FDA may have
to delete, rather than redact, exempt information from those files to prevent disclosure of exempted information.
Page 3 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 44 ooff 1144 PPaaggeeIIDD 220088
• December 1: remainder of section 5.2 of the BLA file.
After the December 1 production, FDA proposes to work through the list of documents that
Plaintiff requested FDA prioritize for production in order of priority and process and release the
non-exempt portions of those records to Plaintiff on a rolling basis. FDA proposes to process and
produce the non-exempt portions of responsive records at a rate of 500 pages per month. This rate
is consistent with processing schedules entered by courts across the country in FOIA cases.3
Plaintiff’s request (as set forth below) that FDA process and produce the non-exempt
portions of more than 329,000 pages in four months would force FDA to process more than 80,000
pages per month. Undersigned counsel is not aware of any court ever granting such a request. The
Court should decline to enter Plaintiff’s schedule for numerous reasons.
First, “[r]equiring the agency to process and produce these materials under an abbreviated
deadline raises a significant risk of inadvertent disclosure of records properly subject to exemption
under FOIA.” Daily Caller v. Dep’t of State, 152 F. Supp. 3d 1, 14 (D.D.C. 2015). Plaintiff has
requested records that comprise information submitted by the vaccine sponsor (Pfizer-BioNTech).
From FDA’s experience with other FOIA requests, such records can be expected to contain both
3 See, e.g., Documented NY v. U.S. Dep’t of State, No. 20 Civ. 1946 (AJN) (S.D.N.Y.) Dkt. 26 p.2 (denying plaintiff’s
processing rate demand of 2,500 pages per month and adopting Department of State’s proposed 300 pages per month);
NYCLU v. Admin. for Children & Families, No. 20 Civ. 183 (MKV), Dkt. No. 30 (S.D.N.Y. May 5, 2020) (400 pages
per month); Color of Change v. U.S. Dep’t of Homeland Sec., 325 F. Supp. 3d 447, 451 (S.D.N.Y. 2018) (500 pages
per month); Davis v. U.S. Dep’t of Homeland Sec., No. 11-cv-203 (ARR) (VMS), 2013 WL 3288418, at *1 (E.D.N.Y.
June 27, 2013) (500 pages per month); Blakeney v. FBI, No. 17-cv-2288 (BAH), 2019 WL 450678, at *2 (D.D.C. Feb.
5, 2019) (500 pages per month); Colbert v. FBI, No. 16 Civ. 1790 (DLF), 2018 WL 6299966, at *3 (D.D.C. Sept. 3,
2018) (500 pages per month); Republican Nat’l Comm. v. U.S. Dep’t of State, No. 16 Civ. 486 (JEB), 2016 WL
9244625, at *1 (D.D.C. Sept. 16, 2016) (500 pages per month); Energy & Env’t Legal Inst. v. U.S. Dep’t of State, No.
17 Civ. 340 (D.D.C.), Minute Order of August 22, 2017 (300 pages per month); Judicial Watch, Inc. v. U.S. Dep’t of
State, No. 17 Civ. 205 (D.D.C.), Minute Order of June 30, 2017 (300 pages every four weeks); Am. Ctr. for Law &
Justice v. U.S. Dep’t of State, No. 16 Civ. 2516 (D.D.C.), Minute Order of June 27, 2017 (process 400 pages per
month); Citizens United v. U.S. Dep’t of State, No. 16 Civ. 67 (D.D.C.), Dkt. 17 at 3 (declining “to adopt Plaintiff’s
proposed production order of 2000 pages per month” and instead holding State “to its 300-page commitment”);
Freedom Watch v. Bureau of Land Mgmt., No. 16 Civ. 2320 (D.D.C.), Minute Order of June 13, 2017 (500 pages
every 30 days); Citizens United v. U.S. Dep’t of State, No. 15 Civ. 1720 (D.D.C.), Dkt. 11 ¶ 10 (500 pages every four
weeks); Judicial Watch, Inc. v. U.S. Dep’t of State, No. 15 Civ. 687 (D.D.C.), Minute Order of April 4, 2017 (500
pages per month).
Page 4 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 55 ooff 1144 PPaaggeeIIDD 220099
confidential business and trade secret information of Pfizer or BioNTech and personal privacy
information of patients who participated in clinical trials. FDA is required to protect certain
information under the law and this type of information is exempt from production under the FOIA.
See 5 U.S.C. § 552(b)(4), (b)(6); F.B.I. v. Abramson, 456 U.S. 615, 621 (1982) (“Congress realized
that legitimate governmental and private interests could be harmed by release of certain types of
information and provided nine specific exemptions under which disclosure could be refused.”).
To ensure protection of this information, and other information subject to withholding under the
FOIA exemptions, FDA must carefully review and, if necessary, redact exempt information on a
line-by-line basis. See Daily Caller, 152 F. Supp. 3d at 14 (stating that the government has a
“responsibility” when processing FOIA requests to “safeguard[] potentially sensitive
information”). This type of review for more than 329,000 pages will necessarily require time if
the agency is going to be able to perform the careful analysis necessary to protect sensitive
information.
Second, the FDA does not have the personnel or resources in its FOIA office to process
Plaintiff’s FOIA request at a rate of more than 80,000 pages per month. Plaintiff’s FOIA request
is being processed by the Access Litigation and Freedom of Information Branch (the “Branch”) in
FDA’s Center for Biologics Evaluation and Research (“CBER”). The Branch has a total of ten
employees, including the director and two trainees. It is currently responsible for processing a
total of approximately 400 currently pending FOIA requests, including Plaintiff’s. CBER is
currently involved in 6 active FOIA litigation matters. By processing and making interim
responses based on 500-page increments, FDA will be able to provide more pages to more
requesters, thus avoiding a system where a few large requests monopolize finite processing
resources and where fewer requesters’ requests are being fulfilled. Simply put, processing
Page 5 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 66 ooff 1144 PPaaggeeIIDD 221100
resources are finite. Increasing the volume to more than 80,000 pages per month (if such rate is
even possible – and it likely is not), as Plaintiff requests, would result in Plaintiff monopolizing
essentially all of FDA’s resources and leaving little resources to process other FOIA requests.
Indeed, the D.C. Circuit has recognized that another agency’s policy of processing 500 pages per
request per month “serves to promote efficient responses to a larger number of requesters.” Nat’l
Sec. Counselors v. Dep’t of Justice, 848 F.3d 467, 471–72 (D.C. Cir. 2017); see also Elec. Privacy
Info. Ctr. v. Dep’t of Justice, 15 F. Supp. 3d 32, 47 (D.D.C. 2014) (denying motion for preliminary
injunction requesting immediate production of documents pursuant to FOIA request and noting
that allowing the plaintiff “to jump to the head of the line would upset the agency’s processes and
be detrimental to the other expedited requesters”); Daily Caller, 152 F. Supp. 3d at 14 (stating that
“the plaintiff’s effort to jump to the head of the FOIA processing line would work a significant
burden on both the agency and numerous interested parties”).
Third, the Court should flatly reject Plaintiff’s specious argument that because the scientists
reviewing Pfizer’s Biologics License Application could do so on an expedited timeframe, the
government information specialists should be able to do so in the same period of time. As should
be apparent, the review conducted by FDA scientists when considering to approve a product is
entirely different from the review conducted by FDA government information specialists when
considering whether FDA must keep certain information confidential. Moreover, FDA’s FOIA
office does not have nearly the same level of personnel or resources dedicated to process FOIA
requests as FDA has marshaled to review license applications for live-saving products in the
middle of a pandemic.
Fourth, contrary to Plaintiff’s argument, FDA’s regulations do not require or suggest that
FDA will release all publicly releasable data immediately after a biologics license application is
Page 6 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 77 ooff 1144 PPaaggeeIIDD 221111
approved. When read in context, it is clear that FDA’s regulations establish when information in
a biological product file is held in strict confidence by the agency and when certain data can be
released to the public, for instance in response to standard processing of a request submitted under
the Freedom of Information Act. See generally 21 C.F.R. § 601.51. Put another way, the
regulations establish the point in time when records that may previously have been unavailable for
public disclosure lose their status as confidential and thus become available for public release
“immediately” upon occurrence of the triggering event. Specifically, under 21 C.F.R. § 601.51,
the existence of a biological product file will not be disclosed by FDA prior to BLA approval
unless it has been previously disclosed or acknowledged, and no data or information in that file is
available for public disclosure. 21 C.F.R. § 601.51(b, c). If the existence of the biological product
file has been acknowledged before a license has been issued, FDA generally still will not make
information and data in the file available for public disclosure prior to issuance of a BLA
license. 21 C.F.R. § 601.51(d). Once a license has been issued, however, certain data and
information in the biological product file become “immediately” available for public
disclosure. 21 C.F.R. § 601.51(e). That means that if a properly submitted FOIA request is
received for data and information listed in 21 C.F.R. § 601.51(e), FDA may publicly release such
information in response to such request, without need for additional agency action to reclassify as
publicly releasable data and information that had previously been deemed confidential under this
regulation.
Fifth, although Plaintiff takes issue with the amount of time it will take to process 329,000
pages at a rate of 500 pages per month, such a result is due to its own broad FOIA request. Courts
do not waiver from the standard 500 page per month processing rate even when a FOIA request
would take years to process. See, e.g., Colbert v. F.B.I., No. 16-CV-1790 (DLF), 2018 WL
Page 7 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 88 ooff 1144 PPaaggeeIIDD 221122
6299966, at *3 (D.D.C. Sept. 3, 2018) (permitting a processing rate of 500 pages per month for
71,000 responsive records). FDA has invited Plaintiff to narrow its request by specifying records
it no longer wants FDA to process and release, and Plaintiff has declined to do so. If Plaintiff
decides to request fewer records, then FDA will be able to complete its processing at an earlier
date.
Finally, this case is not about a vaccine mandate or whether Pfizer can be held liable. This
is a FOIA case where the only relevant issue at this stage in the litigation is setting a reasonable
processing schedule. FDA’s proposed schedule of 500 pages per month is consistent with
schedules set by courts across the country, including in cases where the underlying records were
of national significance. It adequately balances the interests of the Plaintiff in responsive records
with the interests of the vaccine sponsor in the protection of its confidential information, the
interests of clinical trial participants in the protection of their personal privacy information, and
the interests of other FOIA requesters whose requests are being processed alongside Plaintiff’s.
3. Plaintiff’s Position: Plaintiff agrees with the Defendant’s position that the Court
may enter a production schedule based on the arguments in this Joint Report or do so at a
conference. Plaintiff seeks the records submitted to the FDA by Pfizer to license its COVID-19
vaccine (the “FOIA request”)4 and requests an order requiring the FDA to produce all documents
4 The FOIA request requested: “All data and information for the Pfizer Vaccine enumerated in 21 C.F.R. § 601.51(e)4
with the exception of publicly available reports on the Vaccine Adverse Events Reporting System.4” The CFR provision
referenced in the FOIA request provides, in relevant part, as follows: “After a license has been issued, the following data
and information in the biological product file are immediately available for public disclosure unless extraordinary
circumstances are shown: (1) All safety and effectiveness data and information. (2) A protocol for a test or study . . . (3)
Adverse reaction reports. . . (4) A list of all active ingredients and any inactive ingredients . . . (5) An assay method or
other analytical method . . . (6) All correspondence and written summaries of oral discussions relating to the biological
product file . . . (7) All records showing the manufacturer’s testing of a particular lot . . . (8) All records showing the
testing of and action on a particular lot by the [FDA].” The FOIA request also explained that “For the avoidance of
doubt, the FOIA Request includes but is not limited to all of the data and information in the biological product file, as
defined in 21 C.F.R. § 601.51(a), for the Pfizer Vaccine enumerated in 21 C.F.R. § 601.51(e) with the exception of
publicly available reports on the Vaccine Adverse Events Reporting System.”
Page 8 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 99 ooff 1144 PPaaggeeIIDD 221133
responsive to its FOIA request no later than March 3, 2022. This 108-day period is the same
amount of time it took the FDA to review the responsive documents for the far more intricate task
of licensing Pfizer’s Covid-19 vaccine (the “Pfizer vaccine”).
Plaintiff is an organization comprised of over 30 accomplished academics, professors, and
scientists from the medical schools and related departments of our most prestigious universities,
including Yale, Harvard, UCLA, and Brown. These academics and scientists represent a cross
section of every discipline relevant to the licensure of the Pfizer vaccine and include many of the
best our country has to offer when it comes to reviewing and assessing the appropriateness and
validity of the FDA’s decision-making in licensing this product.
The ability of a majority of Americans to participate in civil society, and even exercise
basic liberty rights, are now contingent on receiving this product. For example, the White House’s
recent Covid-19 Action Plan5 and executive orders6 have made receipt of this product a condition
of employment7 for more than 6 million federal workers and contractors,8 22 million healthcare
professionals,9 84 million private sector employees,10 and the enlisted and reserve members of our
5 https://www.whitehouse.gov/covidplan/#testing-masking (last visited November 15, 2021).
6 See https://www.whitehouse.gov/briefing-room/presidential-actions/2021/09/09/executive-order-on-ensuring-
adequate-covid-safety-protocols-for-federal-contractors/ (Executive Order of Ensuring Adequate COVID Safety
Protocols for Federal Contractors) (last visited November 15, 2021); https://www.whitehouse.gov/briefing-
room/presidential-actions/2021/09/09/executive-order-on-requiring-coronavirus-disease-2019-vaccination-for-
federal-employees/ (Executive Order on Requiring Coronavirus Disease 2019 Vaccination for Federal Employees)
(last visited November 15, 2021).
7 See, e.g., https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.501 (Emergency Temporary
Standard requiring employers with 100 or more employees to implement vaccination mandates) (last visited
November 12, 2021); https://www.whitehouse.gov/briefing-room/presidential-actions/2021/09/09/executive-order-
on-requiring-coronavirus-disease-2019-vaccination-for-federal-employees/ (Executive Order on Requiring
Coronavirus Disease 2019 Vaccination for Federal Employees) (last visited November 12, 2021).
8 https://thehill.com/opinion/finance/438242-the-federal-government-is-the-largest-employer-in-the-nation (last
visited November 12, 2021).
9 https://www.census.gov/library/stories/2021/04/who-are-our-health-care-workers.html#:~:text=There%20were%
2022%20million%20workers,American%20Community%20Survey%20(ACS) (last visited November 12, 2021).
10 https://www.cnbc.com/2021/11/04/osha-federal-vaccine-mandate-covers-84-million-workerswhat-to-know.html
(last visited November 12, 2021).
Page 9 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 1100 ooff 1144 PPaaggeeIIDD 221144
armed forces.11 There are few whose livelihood, education, service, and participation in civil society
are not contingent on a government requirement to receive this product. On this basis alone, basic
liberty and government transparency demand that the documents and data submitted by Pfizer to
license this product be made available to Plaintiff and the public forthwith, precisely as contemplated
by federal regulations.12
The acute need for transparency regarding this product is heightened by the fact that the
secretary of Health and Human Services (“HHS”), the FDA’s parent department, has granted
Pfizer complete immunity from financial liability for any injury caused by its product. If injured
-- including suffering one of the injuries even federal health authorities admit occur from Pfizer’s
product -- the injured individual effectively has no recourse. Pursuant to the declaration from the
secretary of HHS, Pfizer cannot be sued by anyone receiving this product for any injury. 42 U.S.C.
§ 247d-6d. Pfizer also cannot be sued for willful misconduct regarding this product unless HHS,
which has been promoting this product, agrees to bring such a claim. 42 U.S.C. § 247d-6d(c)(5).13
It should not be that the public is deprived accessing the documents and data submitted by Pfizer
to license this product when at the same time the public are being mandated to receive this product
with no ability to sue Pfizer for compensation if they suffer any adverse reaction.
The FDA has proposed to produce 500 pages per month which, based on its calculated
number of pages, would mean it would complete its production in nearly 55 years – the year 2076.
Until the entire body of documents provided by Pfizer to the FDA are made available, an
11 https://www.americaspromise.org/us-military-demographics#:~:text=Military%20Service%20Member%20Data
,were%202.1%20active%20duty%20members (last visited November 12, 2021).
12 See 21 CFR § 601.51(e).
13 Reports have recently surfaced that the FDA was aware of concerns about unsound practices in connection with
clinical trials for the Pfizer Vaccine, but that FDA failed to properly investigate these claims.
https://www.bmj.com/content/375/bmj.n2635 (last visited November 12, 2021).
Page 10 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 1111 ooff 1144 PPaaggeeIIDD 221155
appropriate analysis by the independent scientists that are members of Plaintiff is not possible.
Would the FDA agree to review and license this product without all the documents? Of course
not. These independent, world-renowned scientists should be provided the same forthwith.
The entire purpose of the FOIA is to assure government transparency. It is difficult to
imagine a greater need for transparency than immediate disclosure of the documents relied upon
by the FDA to license a product that is now being mandated to over 100 million Americans under
penalty of losing their careers, their income, their military service status, and far worse.
It took the FDA precisely 108 days from when Pfizer started producing the records for
licensure on May 7, 2021,14 to when the product was licensed on August 23, 2021.15 We assume,
as the FDA has stated, that it conducted an intense, robust, thorough and complete review and
analysis of those documents in order to assure that the Pfizer vaccine was safe and effective for
licensure. The FDA now has an equally important task of making those documents available to
the Plaintiff in this case and the public at large in at least the same timeframe.
The FDA’s own regulations envision and reflect upon the importance of making this
information public as soon as a vaccine is licensed. Its regulations provide that it is to make
“immediately available” all documents underlying licensure of a vaccine. 21 C.F.R. § 601.51(e).
The FDA knew the intense public interest in that data and information. It should have been
preparing to release it simultaneously with the licensure. Instead, it has done the opposite. Despite
the passage of 84 days since licensure and 192 days since Pfizer started producing the records for
14 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-
biologics (Pfizer announces that it initiated rolling submission of its biologics license application on May 7, 2021)
(last visited November 12, 2021).
15 https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine (FDA announces that
it approved Pfizer’s COVID-19 vaccine on August 23, 2021) (last visited November 12, 2021).
Page 11 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 1122 ooff 1144 PPaaggeeIIDD 221166
licensure, the FDA has not released a single document submitted by Pfizer for the licensure of its
Covid-19 vaccine. Not one page.
Mandates of this liability-free product are ongoing and expanding as we debate in this Joint
Report. School-age children are now being mandated to take this product.16 Even 108 days from
today to produce is far too long, hence Plaintiff respectfully urges that March 3, 2022 be set as the
absolute outside date by which the FDA be compelled to produce these documents. The FDA is
an organization comprised of more than 18,000 people17 with a budget of $6 billion.18 It has itself
said that there is nothing more important than the licensure of this vaccine and being transparent
about this vaccine. This request is precisely why the need for transparency is so critical and why
Congress enacted FOIA. If the FDA claims its obligations under FOIA are too burdensome, it
should take its complaints to Congress – not this Court.
For the Americans that will lose their job, income, career, military status, education, or
worse, for refusing a federal mandate requiring this product, they do not get to argue that it is too
burdensome to comply with federal law. That is not an excuse that individuals get to make when
a federal law requires them to do something. The FDA should similarly be afforded no such safe
harbor. Certainly not on an issue this important. Again, if the FDA finds complying with federal
law burdensome, its recourse is with Congress.
In any event, the FDA should welcome making these documents available to the Plaintiff
if it is confident in the analysis and review it conducted. The fact that it has fought tooth and nail
16 See, e.g., https://www.nbcsandiego.com/news/local/san-diego-unified-school-district-vaccine-mandate/2729909/.
17 https://www.fda.gov/about-fda/fda-basics/how-many-people-are-employed-fda-and-what-areas-do-they-work (last
visited November 12, 2021).
18 https://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance (last visited November 12, 2021).
Page 12 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 1133 ooff 1144 PPaaggeeIIDD 221177
and taken such an absurd and unconscionable position of waiting until the year 2076 to complete
the production further heightens the grave need to have these documents produced forthwith.
Plaintiff respectfully requests that the Court enter an order requiring the FDA to produce
all documents and data submitted by Pfizer on a rolling basis such that all of it shall be produced
on or before March 3, 2022, which is 108 days from today. To require less is to render FOIA
meaningless, the FDA’s promise of transparency a lie, and to send a signal to every American that
while the federal executive branch is shielding Pfizer from any liability for injuries from its product
and requiring employers, schools, hospitals and the military to expel those that don’t receive this
product, it is protecting the very documents Pfizer provided to our taxpayer-funded health agency
to obtain licensure to be able to sell this product. That simply should not be and highlights why
FOIA and equity demand the relief Plaintiff requests herein.
Dated: November 15, 2021
SIRI & GLIMSTAD LLP
/s/ Aaron Siri
Aaron Siri, NY Bar No. 4321790
Elizabeth A. Brehm, NY Bar No. 4660353
Gabrielle G. Palmer, CO Bar No. 48948
200 Park Avenue
17th Floor
New York, New York 10166
Tel: (212) 532-1091
Fax: (646) 417-5967
aaron@sirillp.com
ebrehm@sirillp.com
gpalmer@sirillp.com
Page 13 of 14
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 2200 FFiilleedd 1111//1155//2211 PPaaggee 1144 ooff 1144 PPaaggeeIIDD 221188
HOWIE LAW, PC
/s/ John Howie
John Howie
Texas Bar Number: 24027239
2608 Hibernia Street
Dallas, Texas 75204
Tel: (214) 622-6340
jhowie@howielaw.net
Attorneys for Plaintiff
BRIAN M. BOYNTON
Acting Assistant Attorney General
Civil Division
ELIZABETH J. SHAPIRO
Deputy Director
Federal Programs Branch
/s/ Courtney D. Enlow
COURTNEY D. ENLOW
Trial Attorney
United States Department of Justice
Civil Division, Federal Programs Branch
1100 L Street, N.W.
Room 12102
Washington, D.C. 20005
Tel: (202) 616-8467
Email: courtney.d.enlow@usdoj.gov
Counsel for Defendant
Page 14 of 14",,14
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/ORDER_2022_01_06.pdf,4.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3355 FFiilleedd 0011//0066//2222 PPaaggee 11 ooff 44 PPaaggeeIIDD 11771155
UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF TEXAS
FORT WORTH DIVISION
PUBLIC HEALTH AND MEDICAL
PROFESSIONALS FOR TRANSPARENCY,
Plaintiff,
v. No. 4:21-cv-1058-P
FOOD AND DRUG ADMINISTRATION,
Defendant.
ORDER
This case involves the Freedom of Information Act (“FOIA”).
Specifically, at issue is Plaintiff’s FOIA request seeking “[a]ll data and
information for the Pfizer Vaccine enumerated in 21 C.F.R. § 601.51(e)
with the exception of publicly available reports on the Vaccine Adverse
Events Reporting System” from the Food and Drug Administration
(“FDA”). See ECF No. 1. As has become standard, the Parties failed to
agree to a mutually acceptable production schedule; instead, they
submitted dueling production schedules for this Court’s consideration.
Accordingly, the Court held a conference with the Parties to determine
an appropriate production schedule.1 See ECF Nos. 21, 34.
“Open government is fundamentally an American issue”—it is
neither a Republican nor a Democrat issue.2 As James Madison wrote,
“[a] popular Government, without popular information, or the means of
acquiring it, is but a Prologue to a Farce or a Tragedy; or, perhaps, both.
Knowledge will forever govern ignorance: And a people who mean to be
their own Governors, must arm themselves with the power which
1Surprisingly, the FDA did not send an agency representative to the scheduling
conference.
2151 CONG. REC. S1521 (daily ed. Feb. 16, 2005) (statement of Sen. John Cornyn).
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3355 FFiilleedd 0011//0066//2222 PPaaggee 22 ooff 44 PPaaggeeIIDD 11771166
knowledge gives.”3 John F. Kennedy likewise recognized that “a nation
that is afraid to let its people judge the truth and falsehood in an open
market is a nation that is afraid of its people.”4 And, particularly
appropriate in this case, John McCain (correctly) noted that “[e]xcessive
administrative secrecy . . . feeds conspiracy theories and reduces the
public’s confidence in the government.”5
Echoing these sentiments, “[t]he basic purpose of FOIA is to ensure
an informed citizenry, [which is] vital to the functioning of a democratic
society.” NLRB v. Robbins Tire & Rubber Co., 437 U.S. 214, 242 (1977).
“FOIA was [therefore] enacted to ‘pierce the veil of administrative
secrecy and to open agency action to the light of public scrutiny.’” Batton
v. Evers, 598 F.3d 169, 175 (5th Cir. 2010) (quoting Dep’t of the Air Force
v. Rose, 425 U.S. 352, 361 (1976)). And “Congress has long recognized
that ‘information is often useful only if it is timely’ and that, therefore
‘excessive delay by the agency in its response is often tantamount to
denial.’” Open Soc’y Just. Initiative v. CIA, 399 F. Supp. 3d 161, 165
(S.D.N.Y. 2019) (quoting H.R. REP. NO. 93-876, at 6271 (1974)). When
needed, a court “may use its equitable powers to require an agency to
process documents according to a court-imposed timeline.” Clemente v.
FBI, 71 F. Supp. 3d 262, 269 (D.D.C. 2014).
Here, the Court recognizes the “unduly burdensome” challenges that
this FOIA request may present to the FDA. See generally ECF Nos. 23,
30, 34. But, as expressed at the scheduling conference, there may not be
a “more important issue at the Food and Drug Administration . . . than
the pandemic, the Pfizer vaccine, getting every American vaccinated,
[and] making sure that the American public is assured that this was not
[] rush[ed] on behalf of the United States . . . .” ECF No. 34 at 46.
3Letter from James Madison to W.T. Barry (August 4, 1822), in 9 WRITINGS OF
JAMES MADISON 103 (S. Hunt ed., 1910).
4John F. Kennedy, Remarks on the 20th Anniversary of the Voice of America (Feb.
26, 1962).
5America After 9/11: Freedom Preserved or Freedom Lost?: Hearing Before the S.
Comm. on the Judiciary, 108th Cong. 302 (2003).
2
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3355 FFiilleedd 0011//0066//2222 PPaaggee 33 ooff 44 PPaaggeeIIDD 11771177
Accordingly, the Court concludes that this FOIA request is of paramount
public importance.
“[S]tale information is of little value.” Payne Enters., Inc. v. United
States, 837 F.2d 486, 494 (D.C. Cir. 1988). The Court, agreeing with this
truism, therefore concludes that the expeditious completion of Plaintiff’s
request is not only practicable, but necessary. See Bloomberg, L.P. v.
FDA, 500 F. Supp. 2d 371, 378 (S.D.N.Y. Aug. 15, 2007) (“[I]t is the
compelling need for such public understanding that drives the urgency
of the request.”). To that end, the Court further concludes that the
production rate, as detailed below, appropriately balances the need for
unprecedented urgency in processing this request with the FDA’s
concerns regarding the burdens of production. See Halpern v. FBI, 181
F.3d 279, 284–85 (2nd Cir. 1991) (“[FOIA] emphasizes a preference for
the fullest possible agency disclosure of such information consistent
with a responsible balancing of competing concerns . . . .”).
Accordingly, having considered the Parties’ arguments, filings in
support, and the applicable law, the Court ORDERS that:
1. The FDA shall produce the “more than 12,000 pages” articulated
in its own proposal, see ECF No. 29 at 24, on or before January
31, 2022.
2. The FDA shall produce the remaining documents at a rate of
55,000 pages every 30 days, with the first production being due
on or before March 1, 2022, until production is complete.
3. To the extent the FDA asserts any privilege, exemption, or
exclusion as to any responsive record or portion thereof, FDA
shall, concurrent with each production required by this Order,
produce a redacted version of the record, redacting only those
portions as to which privilege, exemption, or exclusion is asserted.
3
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 3355 FFiilleedd 0011//0066//2222 PPaaggee 44 ooff 44 PPaaggeeIIDD 11771188
4. The Parties shall submit a Joint Status Report detailing the
progress of the rolling production by April 1, 2022, and every
90 days thereafter.6
SO ORDERED on this 6th day of January, 2022.
Mark T. Pittman
UNITED STATES DISTRICT JUDGE
6Although the Court does not decide whether the FDA correctly denied Plaintiff’s
request for expedited processing, the issue is not moot. Should the Parties seek to file
motions for summary judgment, the Court will take up the issue then.
4","[[['PUBLIC HEALTH AND MEDICAL'], ['PROFESSIONALS FOR TRANSPARENCY,']]]",4
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/047-PLAINTIFFS-RESPONSE-TO-PFIZER-INC.S-MOTION-FOR-LEAVE-TO-INTERVENE-FOR-A-LIMITED-PURPOSE.pdf,15.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 11 ooff 1155 PPaaggeeIIDD 22006611
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF TEXAS
PUBLIC HEALTH AND MEDICAL
PROFESSIONALS FOR TRANSPARENCY,
Plaintiff, Civil Action No. 4:21-cv-01058-P
-against-
FOOD AND DRUG ADMINISTRATION,
Defendant.
PLAINTIFF’S RESPONSE TO PFIZER INC.’S MOTION FOR LEAVE TO
INTERVENE FOR A LIMITED PURPOSE
i
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 22 ooff 1155 PPaaggeeIIDD 22006622
TABLE OF CONTENTS
TABLE OF AUTHORITIES ..................................................................................................... iii
INTRODUCTION........................................................................................................................ 1
ARGUMENT ................................................................................................................................ 2
I. STANDARD FOR TIMELINESS UNDER RULE 24 ....................................................... 3
II. PFIZER’S MOTION IS UNTIMELY IF THE COMPANY SEEKS TO ALTER THE
EXISTING SCHEDULE ..................................................................................................... 4
A. Consideration 1: Pfizer’s Delay is Unreasonable if it Hopes to Alter the
Production Schedule ................................................................................................... 5
B. Consideration 2: A Motion to Delay Production Would Prejudice the Existing
Parties…………………………………………………………………………... ...... 6
C. Consideration 3: Pfizer’s Motion Fails to Establish What, if Any, Prejudice the
Company Will Suffer if it’s Current Motion is Denied .............................................. 6
D. Consideration 4: The Unprecedented Urgency of this Matter Calls for Even
Greater Caution when Evaluating the Timeliness of Intervention ............................. 9
CONCLUSION .......................................................................................................................... 10
ii
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 33 ooff 1155 PPaaggeeIIDD 22006633
TABLE OF AUTHORITIES
Cases
Effjohn Int’l Cruise Hldgs., Inc. v. A&L Sales, Inc.,
346 F.3d 552 (5th Cir. 2003) ...................................................................................................... 3
New Orleans Pub. Serv., Inc. v. United Gas Pipe Line Co.,
732 F.2d 452 (5th Cir. 1984) ..................................................................................................... 4
Nikon Corp. v. ASM,
222 F.R.D. 647 (N.D. Cal. 2004) ................................................................................................ 4
Payne Enters., Inc. v. United States,
837 F.2d 486 (D.C. Cir. 1988) ................................................................................................. 10
Script Sec. Sols. LLC v. Logitech Inc.,
No. 216CV01400JRGRSP, 2017 WL 10242574 (E.D. Tex. Nov. 8, 2017)…………….passim
Sierra Club v. Espy,
18 F.3d 1202 (5th Cir. 1994) .................................................................................................. 3, 5
Wal–Mart Stores, Inc. v. Texas Alcoholic Beverage Commn.,
834 F.3d 562 (5th Cir. 2016) ..................................................................................................... 5
Statutes
21 C.F.R. 20.61 ............................................................................................................................... 7
iii
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 44 ooff 1155 PPaaggeeIIDD 22006644
INTRODUCTION
The motion filed by Pfizer Inc. (“Pfizer”) seeks leave for Pfizer to intervene for the limited
purpose of ensuring “expeditious action” and to remain “informed of relevant developments.”
(Dkt. No. 40 at 2.) Plaintiff welcomes Pfizer’s participation in this matter to the extent it will in
fact expedite the release of the requested documents. However, it is what Pfizer has refused to say
that concerns Plaintiff in consenting to the company’s intervention without the Court providing, at
the least, appropriate limitations to assure Pfizer does not cause delay or prejudice to Plaintiff.
Even though the FDA has more than sufficient resources to expeditiously produce the
requested documents, and the agency has repeatedly stated its commitment to protecting Pfizer’s
interests, Pfizer could still assist the FDA with expediting release of the requested documents.
Pfizer, however, provides no reason why it needs to intervene in this matter to render that purported
assistance. Nor can Plaintiff discern why Pfizer needs to intervene in this matter to assist the FDA
with expediting release of the requested documents – it can render this assistance without
intervening. Indeed, Pfizer, for over a year now, has been “working closely with the FDA”
regarding its Covid-19 vaccine and is already working with the FDA to identify, on or before
February 1, 2022, all documents in its application that do not include trade secrets. Nor does Pfizer
have any need now to intervene to protect any trade secrets because Plaintiff has not sought to
challenge any redactions. If the Court has uncertainty as to whether Pfizer has stated an extant
basis for intervening, Plaintiff respectfully requests that the Court ask Pfizer to clarify how
intervening would assist in expediting release of the documents beyond what it could do to assist
the FDA without intervening in this action.
Separately, in conferring with Pfizer’s counsel prior to moving to intervene, Plaintiff
sought confirmation that Pfizer would not seek to challenge the Court’s January 6th order (Dkt.
1
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 55 ooff 1155 PPaaggeeIIDD 22006655
No. 35) requiring the FDA to produce at a rate of 55,000 pages every 30 days. Nevertheless, even
though Pfizer said it “does not presently intend to move the Court to reconsider its January 6, 2022
order,” it refused to rule out such a challenge to the rate of production ordered by the Court, stating
that it “is not in a position at this time to waive its ability to do so if circumstances change such
that there is good cause at a later time to do so.” (Dkt. No. 40 at 3.) The position taken by Pfizer
on this issue casts doubt as to its claimed limited purpose to intervene to seek to expedite release
of the underlying documents. Plaintiff is therefore concerned that its involvement will serve as
another way for the FDA, now with assistance from Pfizer, to continue its campaign to delay
production. Hence, to the extent Pfizer is permitted to intervene without limitation, such that it
may seek to challenge orders entered in this action prior to its intervening, or to otherwise delay
the Court-ordered production schedule, Plaintiff opposes Pfizer’s motion as untimely.
On the other hand, if the Court concludes Pfizer intervening in this action will increase the
rate of production beyond what the FDA could do if Pfizer were not granted leave to intervene,
and Pfizer’s involvement is limited to prevent delay or prejudice as set forth below, Plaintiff does
not object to Pfizer intervening.
ARGUMENT
On January 21, 2022, Pfizer moved to intervene in this action pursuant to either Rule 24(a)
or Rule 24(b). It claims that it made this motion for the stated “limited purpose of helping FDA
and the Court ensure expeditious action as ordered by this Court and ensuring that Pfizer is
informed of relevant developments in relation to the case.” (Dkt. No. 40 at 2.) In doing so, the
company explains that it “hopes that engaging in a dialogue with the Government where it has
questions about Pfizer’s view regarding certain portions of the BLA will make it easier for the
2
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 66 ooff 1155 PPaaggeeIIDD 22006666
Government to meet the production schedule ordered by the Court.” (Id.) However, Pfizer never
explained why it needs to intervene in this action at this time in order to conduct that dialogue.
I. STANDARD FOR TIMELINESS UNDER RULE 24
One of the primary cases Pfizer relies on, Sierra Club v. Espy, 18 F.3d 1202 (5th Cir. 1994),
warns that “[c]ourts should discourage premature intervention that wastes judicial resources.” Id.
at 1206. Rather, “[a] better gauge of promptness is the speed with which the would-be intervenor
acted when it became aware that its interests would no longer be protected by the original parties.”
Id. In evaluating the timeliness of a motion to intervene, courts in the Fifth Circuit examine four
considerations: “‘(1) how long the putative intervenor knew, or reasonably should have known, of
its stake in the action; (2) the prejudice, if any, the existing parties may suffer because the putative
intervenor failed to intervene when it knew, or reasonably should have known, of its stake; (3) the
prejudice, if any, the putative intervenor may suffer if intervention is not allowed; and (4) any
unusual circumstances weighing in favor of, or against, finding timeliness.’” Script Sec. Sols. LLC
v. Logitech Inc., No. 216CV01400JRGRSP, 2017 WL 10242574, at *2 (E.D. Tex. Nov. 8, 2017)
(quoting Effjohn Int’l Cruise Hldgs., Inc. v. A&L Sales, Inc., 346 F.3d 552, 560–61 (5th Cir. 2003)).
The Script Sec. Sols. decision provides a relevant example where the court evaluated these
four considerations. 2017 WL 10242574. There, by the time of the motion to intervene, the
existing parties had established a schedule for evaluating the patent claims and the date to move
to invalidate any claims had already passed. Id. at *2. Likewise, the parties had already
commenced claims discovery, and a claims construction proceeding was planned for just a few
months after the motion to intervene. Id. Under those circumstances, the court denied the motion
to intervene. Id. at *1. It was concerned that the intervenor would seek to invalidate some of the
patent claims and seek changes to the existing scheduling order, both of which would prejudice
3
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 77 ooff 1155 PPaaggeeIIDD 22006677
the plaintiff. Id. at *2. Nevertheless, recognizing the intervenor’s legitimate interest in the action,
the court encouraged it to move for discretionary intervention pursuant to Rule 24(b), under which
“the court may limit the scope of a movant’s intervention to avoid undue delay and prejudice to
the parties.” Id. at *3. The court suggested that, in any such motion, the intervenor would have to
agree “not … to move any … deadlines without the agreement of the parties, and … to be bound
by all existing orders in this action.” Id. (citing Nikon Corp. v. ASM, 222 F.R.D. 647, 651-52 (N.D.
Cal. 2004) (permitting intervention under Rule 24(b) with certain limitations “so as to minimize
delay and burdens to the parties and keep this case on track”)); see also New Orleans Pub. Serv.,
Inc. v. United Gas Pipe Line Co., 732 F.2d 452, 470-71 (5th Cir. 1984) (“Permissive intervention is
wholly discretionary with the [district] court ... even though there is a common question of law or
fact, or the requirements of Rule 24(b) are otherwise satisfied.” (internal quotations omitted)).
II. PFIZER’S MOTION IS UNTIMELY IF THE COMPANY SEEKS TO ALTER
THE EXISTING SCHEDULE
Like in Script Sec. Sols., here, Plaintiff is concerned that Pfizer’s intervention will unduly
prejudice Plaintiff if the company seeks reconsideration of the production schedule established by
the Court’s order entered on January 6, 2022, or otherwise seeks to delay production by the FDA.
With this in mind, Plaintiff advised Pfizer’s counsel as part of their meet-and-confer
process that it “does not object to Pfizer moving to intervene, so long as Pfizer intends to only
address decisions going forward and not to ask the Court to reconsider decisions it has already
reached since any motion to intervene as to already adjudicated matters is untimely.” (Dkt. No.
40 at 3.) Pfizer’s refusal to agree to this limitation raised concerns for Plaintiff because it calls
into question the company’s alleged limited purpose for intervening in this action, which is
purportedly to expedite release of the documents. (Id.)
4
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 88 ooff 1155 PPaaggeeIIDD 22006688
As such, because Pfizer itself will not rule out the possibility, the Court should analyze the
timeliness of the instant motion assuming there is at least the possibility that Pfizer will move to
amend or delay the Court’s existing schedule. Applying the four considerations noted above, it
would be untimely for Pfizer to intervene in order to alter the Court’s January 6th production
schedule, and therefore, if the company is permitted to intervene, it must be limited by restrictions
similar to those in Script Sec. Sols.
A. Consideration 1: Pfizer’s Delay is Unreasonable if it Hopes to Alter the
Production Schedule
Under the first consideration, Pfizer claims that it learned about this action “from news
reports in connection with the December 14, 2021 Scheduling Conference.” (Dkt. No. 41 p. 11.)
Even though Pfizer is correct that only a little over five weeks elapsed between this supposed
discovery and the instant motion, “[t]he timeliness inquiry ‘is contextual; absolute measures of
timelines should be ignored.’” Wal–Mart Stores, Inc. v. Texas Alcoholic Beverage Commn., 834
F.3d 562, 565 (5th Cir. 2016) (cited by Pfizer) (quoting Espy, 18 F.3d at 1205). For instance, in
Wal–Mart Stores, the Fifth Circuit did not look to the exact number of days in order to determine
whether the motion was timely. Id. Rather, the Circuit found that the motion was timely because
the intervenor “sought intervention before discovery progressed and because it did not seek to
delay or reconsider phases of the litigation that had already concluded.” Id.
In contrast to Wal-Mart Stores, Pfizer knew or should have known that Plaintiff was
seeking an expedited production schedule, and that the Court intended to rule on that schedule
quickly. In such circumstances, if Pfizer wanted to have input into the production schedule, it had
more than 3 weeks between its purported discovery of the action and the Court’s order on January
6, 2022, making its delay in filing this motion unreasonable if it hoped to have input into the
production schedule.
5
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 99 ooff 1155 PPaaggeeIIDD 22006699
B. Consideration 2: A Motion to Delay Production Would Prejudice the Existing
Parties
The analysis of the second timeliness consideration plays out much as it did in Script Sec.
Sols. If Pfizer wants to slow the production schedule in any way, that will be prejudicial to
Plaintiff. As described in detail in Plaintiff’s brief to the Court regarding the production schedule,
there is an urgent need to have these documents produced in a quick and timely manner. Likewise,
the FDA claims that since the January 6th order, it has moved heaven and earth to try to meet the
deadlines set by that order. Setting aside whether this claim is true (a point called into serious
question by Plaintiff’s opposition papers regarding the FDA’s motion to modify the schedule, Dkt.
Nos. 44-45), a motion even in the next few weeks by Pfizer to further reconsider the production
schedule will mean that much of the FDA’s work in trying to meet the existing schedule may need
to be changed. Thus, any effort by Pfizer to change the existing schedule will serve to prejudice
both existing parties.
C. Consideration 3: Pfizer’s Motion Fails to Establish What, if Any, Prejudice the
Company Will Suffer if it’s Current Motion is Denied
Pfizer’s motion also fails to identify an extant reason to support the third consideration,
i.e., “the prejudice, if any, the putative intervenor may suffer.” Script Sec. Sols., 2017 WL
10242574, at *2.
As confirmed during the meet and confer, and as evidenced by the fact the FDA has already
requested that Pfizer identify documents not containing trade secrets by February 1st, the agency
and the company have already entered into a dialogue. Indeed, the FDA’s regulations include
provisions that specifically permit companies to engage with the FDA with regard to identifying
trade secrets. 21 C.F.R. 20.61(d). Those regulations are particularly enlightening here because
they include a timeline companies must meet in order to ensure that those companies’ involvement
6
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 1100 ooff 1155 PPaaggeeIIDD 22007700
does not slow down the government’s response to the FOIA request.1 Thus, contrary to Pfizer’s
claims, even if it is not a party to this action, it is not prejudiced in its ability to engage with the
FDA in order to expedite production and relay to the FDA what portions of the documents it
believes require redaction.
Of course, if down the road Plaintiff chooses to challenge any redactions, Pfizer may have
an interest then and could be prejudiced if not permitted to intervene. However, that has not
happened yet, may never happen, and if it happens, will likely not happen for at least several
months, and hence raises the question of why Pfizer needs to intervene at this stage of the litigation
with regard to trade secrets. At the least, there should be some claim made in this action seeking
to lift redactions for trade secrets before Pfizer’s participation is necessary.
Pfizer vaguely claims “that Government entities generally cannot adequately represent the
interests of aspiring intervenors[,]” thereby trying to justify its involvement by appearing to argue
that the FDA will not protect its interests. (Dkt. No. 41 p. 13.) However, this argument contrasts
sharply with the FDA’s repeated attestations throughout this action that it takes very seriously its
obligation to protect private citizen’s data and Pfizer’s trade secrets. If anything, the FDA put
Pfizer’s interests well ahead of the American public’s interest when it originally sought to produce
just 500 pages per month, in large measure to ensure it was protecting Pfizer’s trade secrets and
1 “A person who submits records to the Government may designate part or all of the information
in such records as exempt from disclosure under exemption 4 … The person may make this
designation either at the time the records are submitted to the Government or within a
reasonable time thereafter. 21 C.F.R. 20.61(d) (emphasis added). “When the [FDA] receives a
request for such records and determines that disclosure may be required, the [FDA] will make
reasonable efforts to notify the submitter … The notice will include a copy of the request, and it
will inform the submitter about the procedures and time limits for submission and consideration
of objections to disclosure…The submitter has 5 working days from receipt of the notice to
object to disclosure of any part of the records and to state all bases for its objections.” 21 C.F.R.
20.61(e) (emphasis added).
7
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 1111 ooff 1155 PPaaggeeIIDD 22007711
confidential business information. (E.g., Dkt. No. 22 p. 10 (“To ensure protection of this
[confidential business and trade secret information of Pfizer], … FDA must carefully review and,
if necessary, redact exempt information on a line-by-line basis.”).) The FDA then reiterated that
same strong desire to protect Pfizer’s interests in its current motion to modify the production
schedule. (E.g., Dkt. No. 37 p. 10 (“while the agency recognizes the public interest in the public
disclosure of the records here at issue, FDA must also ensure that the personal information of
clinical trial participants, as well any trade secret or commercially confidential information
contained within the records, is protected from disclosure”).) Thus, especially with Pfizer now
assisting the FDA, the interest Pfizer has in protecting its trade secrets does not require
intervention.
The lack of a need for Pfizer to intervene, at least at this time before Plaintiff has moved to
challenge any redactions, raises questions for Plaintiff, especially in light of Pfizer’s refusal to rule
out a challenge to the current schedule. Of course, in addition to Pfizer seeking to cause delay,
there is another reason why Pfizer may be seeking to intervene, but which the company did not
discuss outright because it does not support intervention. Pfizer may be seeking to intervene to
protect its public relations image.
As Pfizer states in its brief, this action has received significant media attention. (Dkt. No.
41 p. 15 (referencing “news reports about this Scheduling Conference in December 2021”).) Not
all of that attention has been positive given the FDA’s repeated attempts to delay production in
order to avoid transparency. (Dkt. No. 44.) Therefore, it comes as no surprise that Pfizer’s instant
brief is littered with comments like: “Pfizer supports the public disclosure of the vast majority of
this information, to promote transparency and the public’s confidence in the vaccine” (Dkt. No.
40 at 1.) The company then spends a full page and a half of its brief citing documents to support
8
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 1122 ooff 1155 PPaaggeeIIDD 22007722
its claim that, “Pfizer, FDA, and others already have made public extensive data and information
about the vaccine,” all of which is otherwise irrelevant to its motion. (Dkt. No. 40 at 1.) In doing
so, the company even includes a highly misleading header for another irrelevant list of studies,
“Preprints of safety and efficacy data as they became available,” which falsely indicates that these
preprints include the underlying safety and efficacy data. (Dkt. No. 41 at 7.) Of course, none of
these documents contain the raw data relied upon to license Pfizer’s vaccine that is sought in this
action, i.e., the underlying data that would permit verifying any of the company’s claims, but rather
they contain only sanitized summaries of information. Pfizer may just be hoping that the next
reporter does not look any closer than the headlines. At any rate, a company’s desire to protect its
public image is not the type of interest that the drafters of Rule 24 had in mind when they permitted
third parties to intervene in court actions, especially because, as the page-and-a-half in Pfizer’s
brief shows, that desire conflicts with the very real need for judicial efficiency.
D. Consideration 4: The Unprecedented Urgency of this Matter Calls for Even
Greater Caution when Evaluating the Timeliness of Intervention
The fourth timeliness consideration, “any unusual circumstances weighing in favor of, or
against, finding timeliness” also plays an important role in this action. Script Sec. Sols., 2017 WL
10242574, at *2. This Court recognized the unusual circumstances in its order when it
acknowledged “the need for unprecedented urgency in processing this request[.]” (Dkt. No. 35 p.
3.) This matter concerns an issue of national importance, where “stale information is of little
value.” Payne Enters., Inc. v. United States, 837 F.2d 486, 494 (D.C. Cir. 1988). Thus, any delays
now not only prejudice the parties as discussed above, but also prejudice the American public and
its right to transparency when it comes to the unprecedented actions its government has taken
during this pandemic, and in particular with regard to the product at issue – a product which has
9
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 1133 ooff 1155 PPaaggeeIIDD 22007733
been mandated while Pfizer has been given complete financial immunity by the government for
any safety or efficacy issues with its product.
Nonetheless, Pfizer ends it brief by stating that, it “does not dispute that Plaintiff is entitled
to non-exempt information from the BLA under its FOIA request and Pfizer does not seek any
delay in the production of that information. Rather, Pfizer’s intervention will facilitate production
of the information Plaintiff seeks since Pfizer can assist the Parties in efficiently segregating and
redacting any data and information that are subject to FOIA statutory exemptions.” (Dkt. No. 41
at 15.) If that is all Pfizer truly seeks, then Plaintiff welcomes Pfizer’s intervention for that limited
specific purpose. However, for the reasons discussed above, Pfizer’s refusal to rule out a request
to change the production schedule, and its failure to articulate a convincing reason why it needs to
intervene right now (rather than later if any redactions are challenged), concern Plaintiff.
CONCLUSION
For the foregoing reasons, Plaintiff respectfully asks that the Court deny Pfizer’s motion
under Rule 24(a) as untimely under the circumstances and because its interests are already
adequately represented by the FDA, but that it grant the motion under Rule 24(b) for the limited
purpose of helping FDA and the Court ensure expeditious action as ordered by this Court with the
following limitations similar to those imposed in the Script Sec. Sols. matter:
1. Pfizer is bound by all existing orders in this action;
2. Pfizer is prohibited from seeking to alter the January 6th order, or an amended schedule
set forth in any order regarding FDA’s pending motion to amend the January 6th order;
3. Pfizer is prohibited from engaging in conduct that is intended to delay production of
the documents as ordered by the Court; and
10
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 1144 ooff 1155 PPaaggeeIIDD 22007744
4. Pfizer is directed to comply with the FDA’s request for it to identify all documents that
do not include trade secrets and confidential information by or before February 1, 2022.
Dated: January 25, 2022
SIRI & GLIMSTAD LLP
/s/ Aaron Siri
Aaron Siri, NY Bar No. 4321790
Elizabeth A. Brehm, NY Bar No. 4660353
Gabrielle G. Palmer, CO Bar No. 48948
200 Park Avenue
17th Floor
New York, New York 10166
Tel: (212) 532-1091
Fax: (646) 417-5967
aaron@sirillp.com
ebrehm@sirillp.com
gpalmer@sirillp.com
HOWIE LAW, PC
John Howie
Texas Bar Number: 24027239
2608 Hibernia Street
Dallas, Texas 75204
Tel: (214) 622-6340
jhowie@howielaw.net
Attorneys for Plaintiff
11
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4477 FFiilleedd 0011//2255//2222 PPaaggee 1155 ooff 1155 PPaaggeeIIDD 22007755
CERTIFICATE OF SERVICE
On January 25, 2022, I electronically submitted the foregoing document with the clerk of
court for the U.S. District Court, Northern District of Texas, using the electronic case filing system
of the court. I hereby certify that I have served all counsel and/or pro se parties of record
electronically or by another manner authorized by Federal Rule of Civil Procedure 5(b)(2).
DATED: January 25, 2022 /s/ Aaron Siri_____________
Aaron Siri
200 Park Avenue, 17th Floor
New York, New York 10166
Tel: (212) 532-1091
Fax: (646) 417-5967
aaron@sirillp.com
12","[[[None, 'A person who submits records to the Government may designate part or all of the information', None, None], ['in such records as exempt from disclosure under exemption 4 … The person may make this', None, None, None], ['designation either at the time the records are submitted to the Government or within a', None, None, None], ['reasonable time thereafter.', None, '21 C.F.R. 20.61(d) (emphasis added)', '. “When the [FDA] receives a'], ['request for such records and determines that disclosure may be required, the [FDA] will make', None, None, None], ['reasonable efforts to notify the submitter … The notice will include a copy of the request, and it', None, None, None], ['will inform the submitter about the procedures and time limits for submission and consideration', None, None, None], ['of objections to disclosure…The submitter has 5 working days from receipt of the notice to', None, None, None], ['object to disclosure of any part of the records and to state all bases for its objections.”', None, None, None]]]",15
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/046-RESPONSE-filed-by-Food-and-Drug-Administration-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf,4.0,"CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4466 FFiilleedd 0011//2255//2222 PPaaggee 11 ooff 44 PPaaggeeIIDD 22005577
IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF TEXAS
____________________________________
)
PUBLIC HEALTH AND MEDICAL )
PROFESSIONALS FOR )
TRANSPARENCY, )
)
Plaintiff, )
)
v. ) Civil Action No. 4:21-cv-01058-P
)
UNITED STATES FOOD AND DRUG )
ADMINISTRATION, )
)
Defendant. )
___________________________________ )
DEFENDANT FOOD AND DRUG ADMINISTRATION’S RESPONSE TO PFIZER
INC’S MOTION FOR LEAVE TO INTERVENE FOR A LIMITED PURPOSE
Pursuant to the Court’s Order of January 21, 2022, Dkt. No. 43, Defendant Food and
Drug Administration (“FDA”) reports that it consents to Pfizer Inc.’s Motion for Leave to
Intervene for a Limited Purpose (“Pfizer’s Motion to Intervene” or “Motion”), Dkt. Nos. 40-41,
insofar as Pfizer moves for permissive intervention under Federal Rule of Civil Procedure 24(b).
As Pfizer noted in its Motion, “it is the Government’s province to make the relevant
determinations under FOIA.” Dkt. No. 40 at 2. However, due to the unprecedented speed with
which the Court has ordered FDA to process the records at issue, FDA anticipates that
coordination with Pfizer to obtain the company’s views as to which portions of the records are
subject to Exemption 4, the Trade Secrets Act (“TSA”), 18 U.S.C. § 1905, or other statutory
protections will be a necessary component of the agency’s endeavors to meet the extraordinary
exigencies of this case. See Defendant’s Motion to Partially Modify Scheduling Order, Dkt. No.
1
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4466 FFiilleedd 0011//2255//2222 PPaaggee 22 ooff 44 PPaaggeeIIDD 22005588
37, at 6 (explaining that these efforts are already underway, and anticipated to evolve). Pfizer’s
participation in this matter will facilitate these necessary communications.
Additionally, as FDA previously explained, if the agency determines not to withhold
information that might be confidential commercial information, it is required under some
circumstances to provide notice to the company that submitted the information. See, e.g., 21
C.F.R. §§ 20.47, 20.48, 20.61(e). The submitter in that circumstance may challenge the
disclosure under the Administrative Procedure Act (a “reverse FOIA” claim), and may assert a
violation of another statute such as the TSA . See Doe, 1 v. Federal Election Comm’n, 920 F.3d
866, 872 (D.C. Cir. 2019) (holding that, because “FOIA is a disclosure statute,” “the agency
cannot possibly violate FOIA” in disclosing information (citing Chrysler v. Brown, 441 U.S. 281,
292 (1979)); see also Northrop Grumman Sys. Corp. v. NASA, 346 F. Supp. 3d 109, 116 (D.D.C.
2018) (holding that in “reverse-FOIA cases” “an aggrieved party may bring an action under the
APA to enjoin an agency from releasing proprietary information under FOIA in violation of the
Trade Secrets Act” or on the basis that disclosure is otherwise “unlawful or arbitrary and
capricious ‘agency action.’”). Thus, this case may require expedited judicial resolution of any
“reverse FOIA” issues that may arise. It would further judicial efficiency to resolve in the same
case the FOIA claim and any related “reverse FOIA” claims cognizable under the APA, and
Pfizer’s participation in these proceedings will further this interest.
Accordingly, FDA shares Pfizer’s view that, in the unusual and indeed extraordinary
circumstances here presented, Pfizer’s intervention would facilitate an orderly resolution of this
matter, and consents to Pfizer’s intervention pursuant to Rule 24(b).
Dated: January 25, 2022 Respectfully submitted,
2
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4466 FFiilleedd 0011//2255//2222 PPaaggee 33 ooff 44 PPaaggeeIIDD 22005599
BRIAN M. BOYNTON
Acting Assistant Attorney General
Civil Division
ELIZABETH J. SHAPIRO
Deputy Director
Federal Programs Branch
/s/ Antonia Konkoly
ANTONIA KONKOLY
Trial Attorney
United States Department of Justice
Civil Division, Federal Programs Branch
1100 L Street, N.W.
Room 11110
Washington, D.C. 20005
Tel: (202) 514-2395
Email: antonia.konkoly@usdoj.gov
Counsel for Defendant
3
CCaassee 44::2211--ccvv--0011005588--PP DDooccuummeenntt 4466 FFiilleedd 0011//2255//2222 PPaaggee 44 ooff 44 PPaaggeeIIDD 22006600
CERTIFICATE OF SERVICE
I hereby certify that on January 25, 2022, I electronically transmitted the foregoing to the
parties and the clerk of court for the United States District Court for the Northern District of
Texas using the CM/ECF filing system.
/s/ Antonia Konkoly
ANTONIA KONKOLY
Trial Attorney
United States Department of Justice
Civil Division, Federal Programs Branch
1100 L Street, N.W.
Room 11110
Washington, D.C. 20005
Tel: (202) 514-2395
Email: antonia.konkoly@usdoj.gov
4",,4
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-interim-mth6-adverse-events-sensitive.pdf,3.0,"16.2.7.2.3 Listing of Severe and Grade 4 Local Reactions – Subjects With Indeterminate Vaccine –
All Subjects ≥16 Years of Age
Rel Daya
Age Group (Years) Subject Dose No. Dose Date Local Reactionb 1 2 3 4 5 6 7 Stop Datec Dur (Days)d
No subject meets the reporting criteria.
Abbreviation: Dur = duration.
a. Relative day (Rel Day) = date of reaction - date of last vaccination + 1.
b. The maximum measurable size for redness and swelling in the electronic diary (e-diary) was 21 caliper units. Redness and swelling exceeding 21
caliper units are reported as >21. Study sites recorded injection site redness or swelling in centimeters. These were converted to caliper units (1 caliper
unit = 0.5 centimeters).
c. Stop date is the date the reaction was last reported.
d. Duration (days) was calculated as the difference from the start of the first reported reaction to resolution of the last reported reaction, inclusive. If the
reaction continued beyond Day 7, the calculation includes all days from the last e-diary day until the date of resolution collected on the case report form. If
the reaction was ongoing at the time of the subsequent vaccination, the end date/day for the reaction is the date/day that the next vaccine was administered,
which was used for the duration calculation.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 27MAR2021 (01:47)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adce l004 sevlr iv all
)TMG(
65:31
1202-rpA-10
:nO
laniF\laniF\3237fa691e771090
FDA-CBER-2021-5683-0035322
Page 1
16.2.7.3.3 Listing of Severe and Grade 4 Systemic Events – Subjects With Indeterminate Vaccine –
All Subjects ≥16 Years of Age
Rel Daya
Age Group (Years) Subject Dose No. Dose Date Systemic Event 1 2 3 4 5 6 7 Stop Dateb Dur (Days)c
No subject meets the reporting criteria.
Abbreviation: Dur = duration.
a. Relative day (Rel Day) = date of event - date of last vaccination + 1.
b. Stop date is the date the event was last reported.
c. Duration (days) was calculated as the difference from the start of the first reported event to resolution of the last reported event, inclusive. If the event
continued beyond Day 7, the calculation includes all days from the last electronic diary (e-diary) day until the date of resolution collected on the case
report form. If the event is ongoing at the time of the subsequent vaccination, the end date/day for the event is the date/day that the next vaccine was
administered, which was used for the duration calculation.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 27MAR2021 (01:53)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA/adce_l004_sevse_iv_all
)TMG(
65:31
1202-rpA-10
:nO
laniF\laniF\4237fa691e771090
FDA-CBER-2021-5683-0035323
Page 2
16.2.7.4.3 Listing of Adverse Events – Subjects With Indeterminate Vaccine – All Subjects ≥16 Years of Age
Rel Action:
Age Group System Preferred Term/ Daya/ Cause Investigational SAE/Imm
(Years)/ Organ AE Investigator Dose Onset Dur Toxicity Vax of Vaccine Dose/ Outcome AE
Subject Class Text No. Date (Days)b Grade Relc AE Subject (End Date) (Yes/No)
>55/ PSYCH Anxiety/ 1 03NOV2020 96/C 1 No O NA/TC N N/N
C4591001 1163 ANXIETY
11631008
Abbreviations: C = continuing; Dur = duration; Imm = immediate. Refer to the AE legend page (Listing 16.2.7.1) for additional definitions.
Note: MedDRA (v23.1) coding dictionary applied.
a. Relative day (Rel Day) = date of AE - date of last vaccination + 1. For an AE that occurred before the date of the first study vaccination, + 1 was not
added to compute relative day.
b. Duration (days) was calculated as the difference from the start of the first reported event to resolution of the last reported event, inclusive.
c. Vaccine related (Vax Rel): relationship to investigational vaccine as assessed by the investigator.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (20:15) Source Data: adae Table Generation: 27MAR2021 (01:53)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adae l002 iv all
)TMG(
65:31
1202-rpA-10
:nO
laniF\laniF\5237fa691e771090
FDA-CBER-2021-5683-0035324
Page 3","[[['', None, None, None, None, None, None, None, None, None, None, None, None, None, None, None], ['16.2.7.2.3 Listing of Severe and Grade 4 Local Reactions – Subjects With Indeterminate Vaccine –\nAll Subjects ≥16 Years of Age', None, None, None, None, None, None, None, None, None, None, None, None, None, None, None], ['', '', None, None, None, None, 'Rel Daya', None, None, None, None, None, None, '', None, ''], ['Age Group (Years)', None, 'Subject', 'Dose No.', 'Dose Date', 'Local Reactionb', '1', '2', '3', '4', '5', '6', '7', 'Stop Datec', 'Dur (Days)d', None], ['No subject meets the reporting criteria.', None, '', '', '', '', '', '', '', '', '', '', '', '', '', None], [None, '', '', '', '', '', '', '', '', '', '', '', '', '', '', None], ['Abbreviation: Dur = duration.\na. Relative day (Rel Day) = date of reaction - date of last vaccination + 1.\nb. The maximum measurable size for redness and swelling in the electronic diary (e-diary) was 21 caliper units. Redness and swelling exceeding 21\ncaliper units are reported as >21. Study sites recorded injection site redness or swelling in centimeters. These were converted to caliper units (1 caliper\nunit = 0.5 centimeters).\nc. Stop date is the date the reaction was last reported.\nd. Duration (days) was calculated as the difference from the start of the first reported reaction to resolution of the last reported reaction, inclusive. If the\nreaction continued beyond Day 7, the calculation includes all days from the last e-diary day until the date of resolution collected on the case report form. If\nthe reaction was ongoing at the time of the subsequent vaccination, the end date/day for the reaction is the date/day that the next vaccine was administered,\nwhich was used for the duration calculation.\nPFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 27MAR2021 (01:47)\n(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adce l004 sevlr iv all', None, None, None, None, None, None, None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]], [['a. Relative day (Rel Day) = date of reaction - date of last vaccination + 1.'], ['b. The maximum measurable size for redness and swelling in the electronic diary (e-diary) was 21 caliper units. Redness and swelling exceeding 21'], ['caliper units are reported as >21. Study sites recorded injection site redness or swelling in centimeters. These were converted to caliper units (1 caliper'], ['unit = 0.5 centimeters).'], ['c. Stop date is the date the reaction was last reported.'], ['d. Duration (days) was calculated as the difference from the start of the first reported reaction to resolution of the last reported reaction, inclusive. If the'], ['reaction continued beyond Day 7, the calculation includes all days from the last e-diary day until the date of resolution collected on the case report form. If'], ['the reaction was ongoing at the time of the subsequent vaccination, the end date/day for the reaction is the date/day that the next vaccine was administered,'], ['which was used for the duration calculation.'], ['PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 27MAR2021 (01:47)'], ['(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adce l004 sevlr iv all']], [['', None, None, None, None, None, None, None, None, None, None, None, None, None, None, None], ['16.2.7.3.3 Listing of Severe and Grade 4 Systemic Events – Subjects With Indeterminate Vaccine –\nAll Subjects ≥16 Years of Age', None, None, None, None, None, None, None, None, None, None, None, None, None, None, None], ['', '', None, None, None, None, 'Rel Daya', None, None, None, None, None, None, '', None, ''], ['Age Group (Years)', None, 'Subject', 'Dose No.', 'Dose Date', 'Systemic Event', '1', '2', '3', '4', '5', '6', '7', 'Stop Dateb', 'Dur (Days)c', None], ['No subject meets the reporting criteria.', None, '', '', '', '', '', '', '', '', '', '', '', '', '', None], [None, '', '', '', '', '', '', '', '', '', '', '', '', '', '', None], ['Abbreviation: Dur = duration.\na. Relative day (Rel Day) = date of event - date of last vaccination + 1.\nb. Stop date is the date the event was last reported.\nc. Duration (days) was calculated as the difference from the start of the first reported event to resolution of the last reported event, inclusive. If the event\ncontinued beyond Day 7, the calculation includes all days from the last electronic diary (e-diary) day until the date of resolution collected on the case\nreport form. If the event is ongoing at the time of the subsequent vaccination, the end date/day for the event is the date/day that the next vaccine was\nadministered, which was used for the duration calculation.\nPFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 27MAR2021 (01:53)\n(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA/adce_l004_sevse_iv_all', None, None, None, None, None, None, None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None, None, None, None, None, None, None]], [['a. Relative day (Rel Day) = date of event - date of last vaccination + 1.'], ['b. Stop date is the date the event was last reported.'], ['c. Duration (days) was calculated as the difference from the start of the first reported event to resolution of the last reported event, inclusive. If the event'], ['continued beyond Day 7, the calculation includes all days from the last electronic diary (e-diary) day until the date of resolution collected on the case'], ['report form. If the event is ongoing at the time of the subsequent vaccination, the end date/day for the event is the date/day that the next vaccine was'], ['administered, which was used for the duration calculation.'], ['PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:22) Source Data: adfacevd Table Generation: 27MAR2021 (01:53)'], ['(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA/adce_l004_sevse_iv_all']], [['', None, None, None, None, None, None, None, None, None, None, None, None], ['16.2.7.4.3 Listing of Adverse Events – Subjects With Indeterminate Vaccine – All Subjects ≥16 Years of Age', None, None, None, None, None, None, None, None, None, None, None, None], ['Age Group\n(Years)/\nSubject', '', '', '', '', '', 'Rel', '', '', '', 'Action:', '', ''], [None, 'Age Group', 'System', 'Preferred Term/', None, None, 'Daya/', None, None, 'Cause', 'Investigational', None, 'SAE/Imm'], [None, '(Years)/', 'Organ', 'AE Investigator', 'Dose', 'Onset', 'Dur', 'Toxicity', 'Vax', 'of', 'Vaccine Dose/', 'Outcome', 'AE'], [None, None, 'Class', 'Text', 'No.', 'Date', '(Days)b', 'Grade', 'Relc', 'AE', 'Subject', '(End Date)', None], ['>55/\nC4591001 1163\n11631008', None, 'PSYCH', 'Anxiety/', '1', '03NOV2020', '96/C', '1', 'No', 'O', 'NA/TC', 'N', 'N/N'], [None, 'C4591001 1163', '', 'ANXIETY', '', '', '', '', '', '', '', '', ''], [None, '11631008', None, '', None, None, None, None, None, None, None, None, ''], ['Abbreviations: C = continuing; Dur = duration; Imm = immediate. Refer to the AE legend page (Listing 16.2.7.1) for additional definitions.\nNote: MedDRA (v23.1) coding dictionary applied.\na. Relative day (Rel Day) = date of AE - date of last vaccination + 1. For an AE that occurred before the date of the first study vaccination, + 1 was not\nadded to compute relative day.\nb. Duration (days) was calculated as the difference from the start of the first reported event to resolution of the last reported event, inclusive.\nc. Vaccine related (Vax Rel): relationship to investigational vaccine as assessed by the investigator.\nPFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (20:15) Source Data: adae Table Generation: 27MAR2021 (01:53)\n(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adae l002 iv all', None, None, None, None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None, None, None, None]], [['Note: MedDRA (v23.1) coding dictionary applied.'], ['a. Relative day (Rel Day) = date of AE - date of last vaccination + 1. For an AE that occurred before the date of the first study vaccination, + 1 was not'], ['added to compute relative day.'], ['b. Duration (days) was calculated as the difference from the start of the first reported event to resolution of the last reported event, inclusive.'], ['c. Vaccine related (Vax Rel): relationship to investigational vaccine as assessed by the investigator.'], ['PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (20:15) Source Data: adae Table Generation: 27MAR2021 (01:53)'], ['(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adae l002 iv all']]]",3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-invest-signature.pdf,1.0,FDA-CBER-2021-5683-0024762,,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-interim-mth6-audit-certificates.pdf,5.0,"Pfizer Regulatory Quality Assurance
Audit Certificate
I, the undersigned, confirm and certifythat the following investigator site audit activities were performed.
Study C4591001
Twenty-Four(24)investigator site audits wereperformed between29-Apr-2020and13-Mar-2021for Study
C4591001 Phase 2/3*.
Center Type of
Investigator Name Country Dates of Audit Name of Auditor
Number Audit
Mulligan,Mark Joseph 1001 United States 27 Jul 2020 to 30 Jul 2020 Routine Jefferies, Maria
Neuzil,Kathleen
1002 United States 10 Aug 2020 to 13 Aug 2020 Routine Cutler, Robert
Maletic
Seger,William
1042 United States 10 Aug 2020 to 13 Aug 2020 Routine Popelca, Bogdan
Michael
Rankin,BruceGlenn 1109 United States 18 Aug 2020 to 21 Aug 2020 Routine Patel, Frederic
Zerbini,Cristiano
1226 Brazil 24 Aug 2020 to 27 Aug 2020 Routine Tewes, Elisabeth
Augusto de Freitas
Polack,Fernando
1231 Argentina 27 Aug 2020 to 03 Sep 2020 Routine Mohr, Andrea
Pedro
Raad,George Louis 1079 United States 01 Sep 2020 to 04 Sep 2020 Routine Jefferies, Maria
Arora,Samir 1091 United States 14 Sep 2020 to 17 Sep 2020 Routine Samuels, Marilyn
Patel,Suchet R. 1077 United States 29 Sep 2020 to 02 Oct 2020 Routine Tewes, Elisabeth
Non-
Fried, David L. 1124 United States 05 Oct 2020 to 07 Oct 2020 Cutler, Robert
Routine
Non-
Winkle, Peter John 1135 United States 12 Oct 2020 to 14 Oct 2020 Cutler, Robert
Routine
Polack, Fernando Non-
1231 Argentina 13 Oct 2020 to 20 Oct 2020 Mohr, Andrea
Pedro Routine
Non-
Reynolds, Steven H. 1149 United States 16 Oct 2020 to 20 Oct 2020 Cutler, Robert
Routine
Non-
Rankin, Bruce Glenn 1109 United States 19 Oct 2020 to 22 Oct 2020 Oprisko, Cheryl
Routine
Nell,Haylene 1247 South Africa 26 Oct 2020 to 29 Oct 2020 Routine Tewes, Elisabeth
Non-
Koch, Mark 1128 United States 03 Nov 2020 to 06 Nov 2020 Cutler, Robert
Routine
Schaefer,Axel 1195 Germany 16 Nov 2020 to 18 Nov 2020 Routine Auner, Dagmar
Template Version: January2021 Confidential Page 1of 3
1Facsimile of Original Digital Signature
)TMG(
21:20
1202-raM-71
:nO
devorppA\devorppA\1d0998691e771090
FDA-CBER-2021-5683-0029225
Page 1
Williams,Hayes
1251 United States 16 Nov 2020 to 18 Nov 2020 Routine Oprisko, Cheryl
Taylor
MoreiraJr.,Edson
1241 Brazil 24 Nov 2020 to 26 Nov 2020 Routine Mohr, Andrea
Duarte
Riesenberg,Robert Non-
1162 United States 30 Nov 2020 to 04 Dec 2020 Tafurth, Maria
Alan Routine
Finn,Daniel John 1016 United States 01 Dec 2020 to 03 Dec 2020 Routine Jefferies, Maria
Akhan,Sila 1217 Turkey 01 Dec 2020 to 03 Dec 2020 Routine Clayton, Simon
Jennings,Timothy
1008 United States 07 Dec 2020 to 10 Dec 2020 Routine Samuels, Marilyn
William
Christensen,Shane
1009 United States 01 Mar 2021 to 04 Mar 2021 Routine Jilla, Abilash
Glade
*Site 1001 and 1002 audited as part of Phase 1
Approver:
Cecilia Gabarain
Senior Director, Regulatory Quality Assurance
Template Version: January2021 Confidential Page 2of 3
DocUUID : 8ae50323-55c7-44d4-9a99-886930c6e127
)TMG(
21:20
1202-raM-71
:nO
devorppA\devorppA\1d0998691e771090
FDA-CBER-2021-5683-0029226
Page 2
7997eefb-6feb-4dbc-a232-c15936633467
REASON: I attest to the
accuracy and integrity of
this document.
16 Mar 2021
08:30:041-0400
6809829b-f9ec-4ac9-bc23-e28cfba721dc
REASON: I approve
this document.
16 Mar 2021
11:17:012-0400
Template Version: January2021 Confidential Page 3of 3
DocUUID : 8ae50323-55c7-44d4-9a99-886930c6e127
)TMG(
21:20
1202-raM-71
:nO
devorppA\devorppA\1d0998691e771090
FDA-CBER-2021-5683-0029227
Page 3
MSB
Validation Report as of: 16 Mar 2021 11:20:016-0400
1
Subject CN TAIGLE LLC
Subject DN EMAILADDRESS=operations@msbdocs.com,CN=TAIGLE LLC,OU=MSB,O=TAIGLE LLC,L=Irvine,ST=California,C=US
Email operations@msbdocs.com
Serial # 19482482486555712400772614192179934953
Issuer DN CN=Entrust Class 3 Client CA - SHA256,OU=(c) 2015 Entrust, Inc. - for authorized use only,OU=See www.entrust.net/legal-
terms,O=Entrust, Inc.,C=US
Signing Time 16 Mar 2021 11:17:012-0400
The Certificate chain was successfully built to a Trusted Root Certificate.
The Signer's identity is valid.
The Document has not been modified since the signature was applied.
This page was added to the original document by the MSB Validation Service (SVS) as part of the process to convert
active signature block content into inactive text. A full validation report of each signature is generated and cross-
referenced using a numeric footnote annotation.
DocUUID : 8ae50323-55c7-44d4-9a99-886930c6e127
)TMG(
21:20
1202-raM-71
:nO
devorppA\devorppA\1d0998691e771090
FDA-CBER-2021-5683-0029228
Page 4
Audit Trail Report
Date User Document Action Details
(cid:20)(cid:24)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:28)(cid:29)(cid:19)(cid:21)(cid:29)(cid:19)(cid:21)(cid:24)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:38)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:48)(cid:76)(cid:81)(cid:68) (cid:54)(cid:87)(cid:68)(cid:85)(cid:87)(cid:72)(cid:71) (cid:55)(cid:75)(cid:72)(cid:70)(cid:88)(cid:86)(cid:87)(cid:82)(cid:71)(cid:76)(cid:68)(cid:81)(cid:70)(cid:82)(cid:80)(cid:83)(cid:82)(cid:86)(cid:72)(cid:71)(cid:87)(cid:75)(cid:72)(cid:72)(cid:51)(cid:68)(cid:78)(cid:86)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:73)(cid:88)(cid:79)(cid:79)(cid:92)(cid:17)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:68)(cid:22)(cid:69)(cid:21)(cid:72)(cid:20)(cid:27)(cid:20)(cid:16)(cid:22)(cid:68)(cid:72)(cid:72)(cid:16)(cid:23)(cid:68)(cid:72)(cid:68)(cid:16)(cid:69)(cid:20)(cid:19)(cid:20)(cid:16)(cid:72)(cid:70)(cid:22)(cid:20)(cid:27)(cid:24)(cid:22)(cid:71)(cid:19)(cid:19)(cid:22)(cid:22)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:17)(cid:80)(cid:76)(cid:81)(cid:68)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:20)(cid:24)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:28)(cid:29)(cid:19)(cid:21)(cid:29)(cid:19)(cid:21)(cid:24)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:53)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:49)(cid:38)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85) (cid:53)(cid:72)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:54)(cid:72)(cid:81)(cid:87) (cid:54)(cid:76)(cid:74)(cid:81)(cid:85)(cid:72)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:86)(cid:72)(cid:81)(cid:87)(cid:87)(cid:82)(cid:72)(cid:51)(cid:68)(cid:78)(cid:85)(cid:72)(cid:70)(cid:76)(cid:83)(cid:76)(cid:72)(cid:81)(cid:87)(cid:17)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:26)(cid:28)(cid:28)(cid:26)(cid:72)(cid:72)(cid:73)(cid:69)(cid:16)(cid:25)(cid:73)(cid:72)(cid:69)(cid:16)(cid:23)(cid:71)(cid:69)(cid:70)(cid:16)(cid:68)(cid:21)(cid:22)(cid:21)(cid:16)(cid:70)(cid:20)(cid:24)(cid:28)(cid:22)(cid:25)(cid:25)(cid:22)(cid:22)(cid:23)(cid:25)(cid:26)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:85)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:20)(cid:23)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:53)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:49)(cid:38)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85) (cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16) (cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:57)(cid:76)(cid:72)(cid:90)(cid:72)(cid:71) (cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:89)(cid:76)(cid:72)(cid:90)(cid:72)(cid:71)(cid:69)(cid:92)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:17)
(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73) (cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:26)(cid:28)(cid:28)(cid:26)(cid:72)(cid:72)(cid:73)(cid:69)(cid:16)(cid:25)(cid:73)(cid:72)(cid:69)(cid:16)(cid:23)(cid:71)(cid:69)(cid:70)(cid:16)(cid:68)(cid:21)(cid:22)(cid:21)(cid:16)(cid:70)(cid:20)(cid:24)(cid:28)(cid:22)(cid:25)(cid:25)(cid:22)(cid:22)(cid:23)(cid:25)(cid:26)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:85)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)
(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)
(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:53)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:49)(cid:38)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85) (cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16) (cid:54)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:55)(cid:68)(cid:74)(cid:41)(cid:76)(cid:79)(cid:79)(cid:72)(cid:71) (cid:55)(cid:75)(cid:72)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:73)(cid:76)(cid:79)(cid:79)(cid:72)(cid:71)(cid:55)(cid:76)(cid:80)(cid:72)(cid:54)(cid:87)(cid:68)(cid:80)(cid:83)(cid:17)
(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73) (cid:57)(cid:68)(cid:79)(cid:88)(cid:72)(cid:29)(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:20)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:26)(cid:28)(cid:28)(cid:26)(cid:72)(cid:72)(cid:73)(cid:69)(cid:16)(cid:25)(cid:73)(cid:72)(cid:69)(cid:16)(cid:23)(cid:71)(cid:69)(cid:70)(cid:16)(cid:68)(cid:21)(cid:22)(cid:21)(cid:16)(cid:70)(cid:20)(cid:24)(cid:28)(cid:22)(cid:25)(cid:25)(cid:22)(cid:22)(cid:23)(cid:25)(cid:26)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:85)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)
(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)
(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:53)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:49)(cid:38)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85) (cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16) (cid:54)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71) (cid:55)(cid:75)(cid:72)(cid:85)(cid:72)(cid:70)(cid:76)(cid:83)(cid:76)(cid:72)(cid:81)(cid:87)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71)(cid:87)(cid:75)(cid:72)(cid:71)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:90)(cid:76)(cid:87)(cid:75)(cid:81)(cid:82)(cid:70)(cid:82)(cid:80)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:17)
(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73) (cid:38)(cid:82)(cid:80)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:29)(cid:49)(cid:82)(cid:81)(cid:72)
(cid:53)(cid:72)(cid:68)(cid:86)(cid:82)(cid:81)(cid:29)(cid:49)(cid:82)(cid:81)(cid:72)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:26)(cid:28)(cid:28)(cid:26)(cid:72)(cid:72)(cid:73)(cid:69)(cid:16)(cid:25)(cid:73)(cid:72)(cid:69)(cid:16)(cid:23)(cid:71)(cid:69)(cid:70)(cid:16)(cid:68)(cid:21)(cid:22)(cid:21)(cid:16)(cid:70)(cid:20)(cid:24)(cid:28)(cid:22)(cid:25)(cid:25)(cid:22)(cid:22)(cid:23)(cid:25)(cid:26)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:85)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)
(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)
(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:38)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:48)(cid:76)(cid:81)(cid:68) (cid:40)(cid:51)(cid:68)(cid:78)(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:38)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:71) (cid:55)(cid:75)(cid:72)(cid:72)(cid:51)(cid:68)(cid:78)(cid:83)(cid:85)(cid:82)(cid:74)(cid:85)(cid:72)(cid:86)(cid:86)(cid:72)(cid:71)(cid:87)(cid:82)(cid:87)(cid:75)(cid:72)(cid:81)(cid:72)(cid:91)(cid:87)(cid:90)(cid:82)(cid:85)(cid:78)(cid:73)(cid:79)(cid:82)(cid:90)(cid:86)(cid:87)(cid:68)(cid:87)(cid:72)(cid:17)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:68)(cid:22)(cid:69)(cid:21)(cid:72)(cid:20)(cid:27)(cid:20)(cid:16)(cid:22)(cid:68)(cid:72)(cid:72)(cid:16)(cid:23)(cid:68)(cid:72)(cid:68)(cid:16)(cid:69)(cid:20)(cid:19)(cid:20)(cid:16)(cid:72)(cid:70)(cid:22)(cid:20)(cid:27)(cid:24)(cid:22)(cid:71)(cid:19)(cid:19)(cid:22)(cid:22)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:17)(cid:80)(cid:76)(cid:81)(cid:68)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:38)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:48)(cid:76)(cid:81)(cid:68) (cid:53)(cid:72)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:54)(cid:72)(cid:81)(cid:87) (cid:54)(cid:76)(cid:74)(cid:81)(cid:85)(cid:72)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:86)(cid:72)(cid:81)(cid:87)(cid:87)(cid:82)(cid:72)(cid:51)(cid:68)(cid:78)(cid:85)(cid:72)(cid:70)(cid:76)(cid:83)(cid:76)(cid:72)(cid:81)(cid:87)(cid:17)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:68)(cid:22)(cid:69)(cid:21)(cid:72)(cid:20)(cid:27)(cid:20)(cid:16)(cid:22)(cid:68)(cid:72)(cid:72)(cid:16)(cid:23)(cid:68)(cid:72)(cid:68)(cid:16)(cid:69)(cid:20)(cid:19)(cid:20)(cid:16)(cid:72)(cid:70)(cid:22)(cid:20)(cid:27)(cid:24)(cid:22)(cid:71)(cid:19)(cid:19)(cid:22)(cid:22)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:17)(cid:80)(cid:76)(cid:81)(cid:68)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:24)(cid:29)(cid:19)(cid:24)(cid:25)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:38)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:37)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:42)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81) (cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16) (cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:57)(cid:76)(cid:72)(cid:90)(cid:72)(cid:71) (cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:89)(cid:76)(cid:72)(cid:90)(cid:72)(cid:71)(cid:69)(cid:92)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:17)
(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73) (cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:25)(cid:27)(cid:19)(cid:28)(cid:27)(cid:21)(cid:28)(cid:69)(cid:16)(cid:73)(cid:28)(cid:72)(cid:70)(cid:16)(cid:23)(cid:68)(cid:70)(cid:28)(cid:16)(cid:69)(cid:70)(cid:21)(cid:22)(cid:16)(cid:72)(cid:21)(cid:27)(cid:70)(cid:73)(cid:69)(cid:68)(cid:26)(cid:21)(cid:20)(cid:71)(cid:70)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:69)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:17)(cid:74)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)
(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)
(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:26)(cid:29)(cid:19)(cid:20)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:38)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:37)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:42)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81) (cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16) (cid:54)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:55)(cid:68)(cid:74)(cid:41)(cid:76)(cid:79)(cid:79)(cid:72)(cid:71) (cid:55)(cid:75)(cid:72)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:73)(cid:76)(cid:79)(cid:79)(cid:72)(cid:71)(cid:55)(cid:76)(cid:80)(cid:72)(cid:54)(cid:87)(cid:68)(cid:80)(cid:83)(cid:17)
(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73) (cid:57)(cid:68)(cid:79)(cid:88)(cid:72)(cid:29)(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:26)(cid:29)(cid:19)(cid:20)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:25)(cid:27)(cid:19)(cid:28)(cid:27)(cid:21)(cid:28)(cid:69)(cid:16)(cid:73)(cid:28)(cid:72)(cid:70)(cid:16)(cid:23)(cid:68)(cid:70)(cid:28)(cid:16)(cid:69)(cid:70)(cid:21)(cid:22)(cid:16)(cid:72)(cid:21)(cid:27)(cid:70)(cid:73)(cid:69)(cid:68)(cid:26)(cid:21)(cid:20)(cid:71)(cid:70)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:69)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:17)(cid:74)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)
(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)
(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:26)(cid:29)(cid:19)(cid:20)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:38)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:37)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:42)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81) (cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16) (cid:54)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71) (cid:55)(cid:75)(cid:72)(cid:85)(cid:72)(cid:70)(cid:76)(cid:83)(cid:76)(cid:72)(cid:81)(cid:87)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71)(cid:87)(cid:75)(cid:72)(cid:71)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:90)(cid:76)(cid:87)(cid:75)(cid:81)(cid:82)(cid:70)(cid:82)(cid:80)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:17)
(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73) (cid:38)(cid:82)(cid:80)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:29)(cid:49)(cid:82)(cid:81)(cid:72)
(cid:53)(cid:72)(cid:68)(cid:86)(cid:82)(cid:81)(cid:29)(cid:49)(cid:82)(cid:81)(cid:72)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:25)(cid:27)(cid:19)(cid:28)(cid:27)(cid:21)(cid:28)(cid:69)(cid:16)(cid:73)(cid:28)(cid:72)(cid:70)(cid:16)(cid:23)(cid:68)(cid:70)(cid:28)(cid:16)(cid:69)(cid:70)(cid:21)(cid:22)(cid:16)(cid:72)(cid:21)(cid:27)(cid:70)(cid:73)(cid:69)(cid:68)(cid:26)(cid:21)(cid:20)(cid:71)(cid:70)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:69)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:17)(cid:74)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)
(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)
(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:26)(cid:29)(cid:19)(cid:20)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19) (cid:38)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:48)(cid:76)(cid:81)(cid:68) (cid:38)(cid:82)(cid:80)(cid:83)(cid:79)(cid:72)(cid:87)(cid:72)(cid:71) (cid:55)(cid:75)(cid:72)(cid:72)(cid:51)(cid:68)(cid:78)(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:72)(cid:87)(cid:72)(cid:71)(cid:87)(cid:75)(cid:72)(cid:90)(cid:82)(cid:85)(cid:78)(cid:73)(cid:79)(cid:82)(cid:90)(cid:86)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:86)(cid:73)(cid:88)(cid:79)(cid:79)(cid:92)(cid:70)(cid:88)(cid:86)(cid:87)(cid:82)(cid:71)(cid:76)(cid:68)(cid:81)(cid:17)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:68)(cid:22)(cid:69)(cid:21)(cid:72)(cid:20)(cid:27)(cid:20)(cid:16)(cid:22)(cid:68)(cid:72)(cid:72)(cid:16)(cid:23)(cid:68)(cid:72)(cid:68)(cid:16)(cid:69)(cid:20)(cid:19)(cid:20)(cid:16)(cid:72)(cid:70)(cid:22)(cid:20)(cid:27)(cid:24)(cid:22)(cid:71)(cid:19)(cid:19)(cid:22)(cid:22)
(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:17)(cid:80)(cid:76)(cid:81)(cid:68)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)
DocUUID : 8ae50323-55c7-44d4-9a99-886930c6e127
)TMG(
21:20
1202-raM-71
:nO
devorppA\devorppA\1d0998691e771090
FDA-CBER-2021-5683-0029229
Page 5","[[['Twenty-Four(24)investigator site audits wereperformed between29-Apr-2020and13-Mar-2021for Study\nC4591001 Phase 2/3*.', None, None, None, None, None], ['Investigator Name', 'Center\nNumber', 'Country', 'Dates of Audit', 'Type of\nAudit', 'Name of Auditor'], ['Mulligan,Mark Joseph', '1001', 'United States', '27 Jul 2020 to 30 Jul 2020', 'Routine', 'Jefferies, Maria'], ['Neuzil,Kathleen\nMaletic', '1002', 'United States', '10 Aug 2020 to 13 Aug 2020', 'Routine', 'Cutler, Robert'], ['Seger,William\nMichael', '1042', 'United States', '10 Aug 2020 to 13 Aug 2020', 'Routine', 'Popelca, Bogdan'], ['Rankin,BruceGlenn', '1109', 'United States', '18 Aug 2020 to 21 Aug 2020', 'Routine', 'Patel, Frederic'], ['Zerbini,Cristiano\nAugusto de Freitas', '1226', 'Brazil', '24 Aug 2020 to 27 Aug 2020', 'Routine', 'Tewes, Elisabeth'], ['Polack,Fernando\nPedro', '1231', 'Argentina', '27 Aug 2020 to 03 Sep 2020', 'Routine', 'Mohr, Andrea'], ['Raad,George Louis', '1079', 'United States', '01 Sep 2020 to 04 Sep 2020', 'Routine', 'Jefferies, Maria'], ['Arora,Samir', '1091', 'United States', '14 Sep 2020 to 17 Sep 2020', 'Routine', 'Samuels, Marilyn'], ['Patel,Suchet R.', '1077', 'United States', '29 Sep 2020 to 02 Oct 2020', 'Routine', 'Tewes, Elisabeth'], ['Fried, David L.', '1124', 'United States', '05 Oct 2020 to 07 Oct 2020', 'Non-\nRoutine', 'Cutler, Robert'], ['Winkle, Peter John', '1135', 'United States', '12 Oct 2020 to 14 Oct 2020', 'Non-\nRoutine', 'Cutler, Robert'], ['Polack, Fernando\nPedro', '1231', 'Argentina', '13 Oct 2020 to 20 Oct 2020', 'Non-\nRoutine', 'Mohr, Andrea'], ['Reynolds, Steven H.', '1149', 'United States', '16 Oct 2020 to 20 Oct 2020', 'Non-\nRoutine', 'Cutler, Robert'], ['Rankin, Bruce Glenn', '1109', 'United States', '19 Oct 2020 to 22 Oct 2020', 'Non-\nRoutine', 'Oprisko, Cheryl'], ['Nell,Haylene', '1247', 'South Africa', '26 Oct 2020 to 29 Oct 2020', 'Routine', 'Tewes, Elisabeth'], ['Koch, Mark', '1128', 'United States', '03 Nov 2020 to 06 Nov 2020', 'Non-\nRoutine', 'Cutler, Robert'], ['Schaefer,Axel', '1195', 'Germany', '16 Nov 2020 to 18 Nov 2020', 'Routine', 'Auner, Dagmar']], [['Williams,Hayes\nTaylor', '1251', 'United States', '16 Nov 2020 to 18 Nov 2020', 'Routine', 'Oprisko, Cheryl'], ['MoreiraJr.,Edson\nDuarte', '1241', 'Brazil', '24 Nov 2020 to 26 Nov 2020', 'Routine', 'Mohr, Andrea'], ['Riesenberg,Robert\nAlan', '1162', 'United States', '30 Nov 2020 to 04 Dec 2020', 'Non-\nRoutine', 'Tafurth, Maria'], ['Finn,Daniel John', '1016', 'United States', '01 Dec 2020 to 03 Dec 2020', 'Routine', 'Jefferies, Maria'], ['Akhan,Sila', '1217', 'Turkey', '01 Dec 2020 to 03 Dec 2020', 'Routine', 'Clayton, Simon'], ['Jennings,Timothy\nWilliam', '1008', 'United States', '07 Dec 2020 to 10 Dec 2020', 'Routine', 'Samuels, Marilyn'], ['Christensen,Shane\nGlade', '1009', 'United States', '01 Mar 2021 to 04 Mar 2021', 'Routine', 'Jilla, Abilash']], [['Date', 'User', 'Document', 'Action', 'Details'], ['(cid:20)(cid:24)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:28)(cid:29)(cid:19)(cid:21)(cid:29)(cid:19)(cid:21)(cid:24)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:38)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:48)(cid:76)(cid:81)(cid:68)', '', '(cid:54)(cid:87)(cid:68)(cid:85)(cid:87)(cid:72)(cid:71)', '(cid:55)(cid:75)(cid:72)(cid:70)(cid:88)(cid:86)(cid:87)(cid:82)(cid:71)(cid:76)(cid:68)(cid:81)(cid:70)(cid:82)(cid:80)(cid:83)(cid:82)(cid:86)(cid:72)(cid:71)(cid:87)(cid:75)(cid:72)(cid:72)(cid:51)(cid:68)(cid:78)(cid:86)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:73)(cid:88)(cid:79)(cid:79)(cid:92)(cid:17)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:68)(cid:22)(cid:69)(cid:21)(cid:72)(cid:20)(cid:27)(cid:20)(cid:16)(cid:22)(cid:68)(cid:72)(cid:72)(cid:16)(cid:23)(cid:68)(cid:72)(cid:68)(cid:16)(cid:69)(cid:20)(cid:19)(cid:20)(cid:16)(cid:72)(cid:70)(cid:22)(cid:20)(cid:27)(cid:24)(cid:22)(cid:71)(cid:19)(cid:19)(cid:22)(cid:22)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:17)(cid:80)(cid:76)(cid:81)(cid:68)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)'], ['(cid:20)(cid:24)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:28)(cid:29)(cid:19)(cid:21)(cid:29)(cid:19)(cid:21)(cid:24)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:53)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:49)(cid:38)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)', '', '(cid:53)(cid:72)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:54)(cid:72)(cid:81)(cid:87)', '(cid:54)(cid:76)(cid:74)(cid:81)(cid:85)(cid:72)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:86)(cid:72)(cid:81)(cid:87)(cid:87)(cid:82)(cid:72)(cid:51)(cid:68)(cid:78)(cid:85)(cid:72)(cid:70)(cid:76)(cid:83)(cid:76)(cid:72)(cid:81)(cid:87)(cid:17)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:26)(cid:28)(cid:28)(cid:26)(cid:72)(cid:72)(cid:73)(cid:69)(cid:16)(cid:25)(cid:73)(cid:72)(cid:69)(cid:16)(cid:23)(cid:71)(cid:69)(cid:70)(cid:16)(cid:68)(cid:21)(cid:22)(cid:21)(cid:16)(cid:70)(cid:20)(cid:24)(cid:28)(cid:22)(cid:25)(cid:25)(cid:22)(cid:22)(cid:23)(cid:25)(cid:26)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:85)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)'], ['(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:20)(cid:23)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:53)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:49)(cid:38)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)', '(cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16)\n(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73)', '(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:57)(cid:76)(cid:72)(cid:90)(cid:72)(cid:71)', '(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:89)(cid:76)(cid:72)(cid:90)(cid:72)(cid:71)(cid:69)(cid:92)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:17)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:26)(cid:28)(cid:28)(cid:26)(cid:72)(cid:72)(cid:73)(cid:69)(cid:16)(cid:25)(cid:73)(cid:72)(cid:69)(cid:16)(cid:23)(cid:71)(cid:69)(cid:70)(cid:16)(cid:68)(cid:21)(cid:22)(cid:21)(cid:16)(cid:70)(cid:20)(cid:24)(cid:28)(cid:22)(cid:25)(cid:25)(cid:22)(cid:22)(cid:23)(cid:25)(cid:26)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:85)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)\n(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)\n(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)'], ['(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:53)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:49)(cid:38)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)', '(cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16)\n(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73)', '(cid:54)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:55)(cid:68)(cid:74)(cid:41)(cid:76)(cid:79)(cid:79)(cid:72)(cid:71)', '(cid:55)(cid:75)(cid:72)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:73)(cid:76)(cid:79)(cid:79)(cid:72)(cid:71)(cid:55)(cid:76)(cid:80)(cid:72)(cid:54)(cid:87)(cid:68)(cid:80)(cid:83)(cid:17)\n(cid:57)(cid:68)(cid:79)(cid:88)(cid:72)(cid:29)(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:20)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:26)(cid:28)(cid:28)(cid:26)(cid:72)(cid:72)(cid:73)(cid:69)(cid:16)(cid:25)(cid:73)(cid:72)(cid:69)(cid:16)(cid:23)(cid:71)(cid:69)(cid:70)(cid:16)(cid:68)(cid:21)(cid:22)(cid:21)(cid:16)(cid:70)(cid:20)(cid:24)(cid:28)(cid:22)(cid:25)(cid:25)(cid:22)(cid:22)(cid:23)(cid:25)(cid:26)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:85)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)\n(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)\n(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)'], ['(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:53)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:49)(cid:38)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)', '(cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16)\n(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73)', '(cid:54)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71)', '(cid:55)(cid:75)(cid:72)(cid:85)(cid:72)(cid:70)(cid:76)(cid:83)(cid:76)(cid:72)(cid:81)(cid:87)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71)(cid:87)(cid:75)(cid:72)(cid:71)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:90)(cid:76)(cid:87)(cid:75)(cid:81)(cid:82)(cid:70)(cid:82)(cid:80)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:17)\n(cid:38)(cid:82)(cid:80)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:29)(cid:49)(cid:82)(cid:81)(cid:72)\n(cid:53)(cid:72)(cid:68)(cid:86)(cid:82)(cid:81)(cid:29)(cid:49)(cid:82)(cid:81)(cid:72)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:26)(cid:28)(cid:28)(cid:26)(cid:72)(cid:72)(cid:73)(cid:69)(cid:16)(cid:25)(cid:73)(cid:72)(cid:69)(cid:16)(cid:23)(cid:71)(cid:69)(cid:70)(cid:16)(cid:68)(cid:21)(cid:22)(cid:21)(cid:16)(cid:70)(cid:20)(cid:24)(cid:28)(cid:22)(cid:25)(cid:25)(cid:22)(cid:22)(cid:23)(cid:25)(cid:26)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:85)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:88)(cid:87)(cid:79)(cid:72)(cid:85)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)\n(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)\n(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)'], ['(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:38)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:48)(cid:76)(cid:81)(cid:68)', '', '(cid:40)(cid:51)(cid:68)(cid:78)(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:38)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:71)', '(cid:55)(cid:75)(cid:72)(cid:72)(cid:51)(cid:68)(cid:78)(cid:83)(cid:85)(cid:82)(cid:74)(cid:85)(cid:72)(cid:86)(cid:86)(cid:72)(cid:71)(cid:87)(cid:82)(cid:87)(cid:75)(cid:72)(cid:81)(cid:72)(cid:91)(cid:87)(cid:90)(cid:82)(cid:85)(cid:78)(cid:73)(cid:79)(cid:82)(cid:90)(cid:86)(cid:87)(cid:68)(cid:87)(cid:72)(cid:17)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:68)(cid:22)(cid:69)(cid:21)(cid:72)(cid:20)(cid:27)(cid:20)(cid:16)(cid:22)(cid:68)(cid:72)(cid:72)(cid:16)(cid:23)(cid:68)(cid:72)(cid:68)(cid:16)(cid:69)(cid:20)(cid:19)(cid:20)(cid:16)(cid:72)(cid:70)(cid:22)(cid:20)(cid:27)(cid:24)(cid:22)(cid:71)(cid:19)(cid:19)(cid:22)(cid:22)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:17)(cid:80)(cid:76)(cid:81)(cid:68)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)'], ['(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:19)(cid:27)(cid:29)(cid:22)(cid:19)(cid:29)(cid:19)(cid:23)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:38)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:48)(cid:76)(cid:81)(cid:68)', '', '(cid:53)(cid:72)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:54)(cid:72)(cid:81)(cid:87)', '(cid:54)(cid:76)(cid:74)(cid:81)(cid:85)(cid:72)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:86)(cid:72)(cid:81)(cid:87)(cid:87)(cid:82)(cid:72)(cid:51)(cid:68)(cid:78)(cid:85)(cid:72)(cid:70)(cid:76)(cid:83)(cid:76)(cid:72)(cid:81)(cid:87)(cid:17)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:68)(cid:22)(cid:69)(cid:21)(cid:72)(cid:20)(cid:27)(cid:20)(cid:16)(cid:22)(cid:68)(cid:72)(cid:72)(cid:16)(cid:23)(cid:68)(cid:72)(cid:68)(cid:16)(cid:69)(cid:20)(cid:19)(cid:20)(cid:16)(cid:72)(cid:70)(cid:22)(cid:20)(cid:27)(cid:24)(cid:22)(cid:71)(cid:19)(cid:19)(cid:22)(cid:22)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:17)(cid:80)(cid:76)(cid:81)(cid:68)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)'], ['(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:24)(cid:29)(cid:19)(cid:24)(cid:25)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:38)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:37)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:42)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81)', '(cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16)\n(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73)', '(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:57)(cid:76)(cid:72)(cid:90)(cid:72)(cid:71)', '(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:89)(cid:76)(cid:72)(cid:90)(cid:72)(cid:71)(cid:69)(cid:92)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:17)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:25)(cid:27)(cid:19)(cid:28)(cid:27)(cid:21)(cid:28)(cid:69)(cid:16)(cid:73)(cid:28)(cid:72)(cid:70)(cid:16)(cid:23)(cid:68)(cid:70)(cid:28)(cid:16)(cid:69)(cid:70)(cid:21)(cid:22)(cid:16)(cid:72)(cid:21)(cid:27)(cid:70)(cid:73)(cid:69)(cid:68)(cid:26)(cid:21)(cid:20)(cid:71)(cid:70)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:69)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:17)(cid:74)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)\n(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)\n(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)'], ['(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:26)(cid:29)(cid:19)(cid:20)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:38)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:37)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:42)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81)', '(cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16)\n(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73)', '(cid:54)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:55)(cid:68)(cid:74)(cid:41)(cid:76)(cid:79)(cid:79)(cid:72)(cid:71)', '(cid:55)(cid:75)(cid:72)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:85)(cid:73)(cid:76)(cid:79)(cid:79)(cid:72)(cid:71)(cid:55)(cid:76)(cid:80)(cid:72)(cid:54)(cid:87)(cid:68)(cid:80)(cid:83)(cid:17)\n(cid:57)(cid:68)(cid:79)(cid:88)(cid:72)(cid:29)(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:26)(cid:29)(cid:19)(cid:20)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:25)(cid:27)(cid:19)(cid:28)(cid:27)(cid:21)(cid:28)(cid:69)(cid:16)(cid:73)(cid:28)(cid:72)(cid:70)(cid:16)(cid:23)(cid:68)(cid:70)(cid:28)(cid:16)(cid:69)(cid:70)(cid:21)(cid:22)(cid:16)(cid:72)(cid:21)(cid:27)(cid:70)(cid:73)(cid:69)(cid:68)(cid:26)(cid:21)(cid:20)(cid:71)(cid:70)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:69)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:17)(cid:74)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)\n(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)\n(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)'], ['(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:26)(cid:29)(cid:19)(cid:20)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:38)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:37)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:42)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81)', '(cid:38)(cid:23)(cid:24)(cid:28)(cid:20)(cid:19)(cid:19)(cid:20)(cid:36)(cid:88)(cid:71)(cid:76)(cid:87)(cid:38)(cid:72)(cid:85)(cid:87)(cid:20)(cid:24)(cid:16)(cid:48)(cid:68)(cid:85)(cid:16)\n(cid:21)(cid:19)(cid:21)(cid:20)(cid:17)(cid:83)(cid:71)(cid:73)', '(cid:54)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71)', '(cid:55)(cid:75)(cid:72)(cid:85)(cid:72)(cid:70)(cid:76)(cid:83)(cid:76)(cid:72)(cid:81)(cid:87)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71)(cid:87)(cid:75)(cid:72)(cid:71)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:90)(cid:76)(cid:87)(cid:75)(cid:81)(cid:82)(cid:70)(cid:82)(cid:80)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:17)\n(cid:38)(cid:82)(cid:80)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:29)(cid:49)(cid:82)(cid:81)(cid:72)\n(cid:53)(cid:72)(cid:68)(cid:86)(cid:82)(cid:81)(cid:29)(cid:49)(cid:82)(cid:81)(cid:72)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:25)(cid:27)(cid:19)(cid:28)(cid:27)(cid:21)(cid:28)(cid:69)(cid:16)(cid:73)(cid:28)(cid:72)(cid:70)(cid:16)(cid:23)(cid:68)(cid:70)(cid:28)(cid:16)(cid:69)(cid:70)(cid:21)(cid:22)(cid:16)(cid:72)(cid:21)(cid:27)(cid:70)(cid:73)(cid:69)(cid:68)(cid:26)(cid:21)(cid:20)(cid:71)(cid:70)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:72)(cid:70)(cid:76)(cid:79)(cid:76)(cid:68)(cid:69)(cid:72)(cid:68)(cid:87)(cid:85)(cid:76)(cid:93)(cid:17)(cid:74)(cid:68)(cid:69)(cid:68)(cid:85)(cid:68)(cid:76)(cid:81)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)\n(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:27)(cid:68)(cid:72)(cid:24)(cid:19)(cid:22)(cid:21)(cid:22)(cid:16)(cid:24)(cid:24)(cid:70)(cid:26)(cid:16)(cid:23)(cid:23)(cid:71)(cid:23)(cid:16)(cid:28)(cid:68)(cid:28)(cid:28)(cid:16)\n(cid:27)(cid:27)(cid:25)(cid:28)(cid:22)(cid:19)(cid:70)(cid:25)(cid:72)(cid:20)(cid:21)(cid:26)'], ['(cid:20)(cid:25)(cid:48)(cid:68)(cid:85)(cid:21)(cid:19)(cid:21)(cid:20)(cid:20)(cid:20)(cid:29)(cid:20)(cid:26)(cid:29)(cid:19)(cid:20)(cid:21)(cid:16)(cid:19)(cid:23)(cid:19)(cid:19)', '(cid:38)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:48)(cid:76)(cid:81)(cid:68)', '', '(cid:38)(cid:82)(cid:80)(cid:83)(cid:79)(cid:72)(cid:87)(cid:72)(cid:71)', '(cid:55)(cid:75)(cid:72)(cid:72)(cid:51)(cid:68)(cid:78)(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:72)(cid:87)(cid:72)(cid:71)(cid:87)(cid:75)(cid:72)(cid:90)(cid:82)(cid:85)(cid:78)(cid:73)(cid:79)(cid:82)(cid:90)(cid:86)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:86)(cid:73)(cid:88)(cid:79)(cid:79)(cid:92)(cid:70)(cid:88)(cid:86)(cid:87)(cid:82)(cid:71)(cid:76)(cid:68)(cid:81)(cid:17)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:56)(cid:56)(cid:44)(cid:39)(cid:29)(cid:68)(cid:22)(cid:69)(cid:21)(cid:72)(cid:20)(cid:27)(cid:20)(cid:16)(cid:22)(cid:68)(cid:72)(cid:72)(cid:16)(cid:23)(cid:68)(cid:72)(cid:68)(cid:16)(cid:69)(cid:20)(cid:19)(cid:20)(cid:16)(cid:72)(cid:70)(cid:22)(cid:20)(cid:27)(cid:24)(cid:22)(cid:71)(cid:19)(cid:19)(cid:22)(cid:22)\n(cid:56)(cid:86)(cid:72)(cid:85)(cid:40)(cid:80)(cid:68)(cid:76)(cid:79)(cid:29)(cid:70)(cid:75)(cid:85)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:72)(cid:17)(cid:80)(cid:76)(cid:81)(cid:68)(cid:35)(cid:83)(cid:73)(cid:76)(cid:93)(cid:72)(cid:85)(cid:17)(cid:70)(cid:82)(cid:80)']]]",5
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-sponsor-signature.pdf,3.0,"Interim Clinical Study Report
Protocol C4591001
16.1.5.1 SPONSOR
CLINICAL STUDY REPORT APPROVAL FORM
PROTOCOL NUMBER: C4591001
REPORT TITLE: Final Analysis Interim Report: A Phase 1/2/3,
Placebo-Controlled, Randomized, Observer-Blind,
Dose-Finding Study to Evaluate the Safety, Tolerability,
Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine
Candidates Against COVID-19 in Healthy Individuals
AUTHOR: Dzung Nguyen
I have reviewed this clinical study report, which is from its definitive source and final in
content. I confirm that it is a complete and accurate representation of the relevant data and
statistical analyses for this report.
Known deviations in the study did not impact overall compliance with Good Clinical Practice
and local regulations.
Organization/Institution: BioNTech
Name/Position: Uggur Sahin, MD, Chief Executive Officer
Signature:_____________________________________________________________________________ Date:_________________________________________________________________________________________________________________________
CONFIDENTIAL
Template date: 01-July-2020
Page 1
)TMG(
41:51
0202-ceD-30
:nO
devorppA\devorppA\9bddfa591e771090
FDA-CBER-2021-5683-0024759
Page 1
InterimClinical Study Report
Protocol C4591001
16.1.5.1SPONSOR AGENT
CLINICAL STUDY REPORT APPROVAL FORM
PROTOCOL NUMBER: C4591001
REPORT TITLE: Final Analysis Interim Report: A Phase 1/2/3,
Placebo-Controlled, Randomized,Observer-Blind,
Dose-Finding Study to Evaluate the Safety, Tolerability,
Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine
Candidates Against COVID-19 in Healthy Individuals
AUTHOR: Dzung Nguyen
I have reviewedthis clinical study report, which is from its definitive source and final in
content. I confirm that it is a complete and accurate representation of the relevant data and
statistical analyses forthis report.
Known deviations in the study did not impact overall compliance withGood Clinical Practice
and local regulations.
STATISTICS LINE HEAD: Kenneth Koury, PhD
CLINICAL LEAD: John L. Perez, MD, MBA, MA
CONFIDENTIAL
Template date: 01-July-2020
Page 1
)TMG(
21:41
0202-ceD-30
:nO
devorppA\devorppA\c6f78a591e771090
FDA-CBER-2021-5683-0024760
Page 2
Document Approval Record
DocumentName:
(cid:5)(cid:6)(cid:7)(cid:5)(cid:7)(cid:8)(cid:7)(cid:5)(cid:9)(cid:10)(cid:11)(cid:12)(cid:13)(cid:14)(cid:12)(cid:15)(cid:16)(cid:17)(cid:18)(cid:13)(cid:19)
DocumentTitle:
(cid:20)(cid:21)(cid:8)(cid:22)(cid:5)(cid:23)(cid:23)(cid:5)(cid:24)(cid:16)
SignedBy: Date(GMT) SigningCapacity
(cid:25)(cid:18)(cid:15)(cid:18)(cid:26)(cid:27)(cid:28)(cid:12)(cid:29)(cid:13) (cid:23)(cid:30)(cid:9)(cid:31)(cid:18)(cid:32)(cid:9)(cid:33)(cid:23)(cid:33)(cid:23)(cid:5)(cid:33)(cid:34)(cid:21)(cid:6)(cid:34)(cid:8)(cid:23) (cid:24)(cid:35)(cid:13)(cid:36)(cid:37)(cid:16)(cid:11)(cid:11)(cid:15)(cid:12)(cid:38)(cid:36)(cid:37)
(cid:39)(cid:12)(cid:40)(cid:15)(cid:41)(cid:27)(cid:39)(cid:18)(cid:13)(cid:13)(cid:18)(cid:19)(cid:29) (cid:23)(cid:30)(cid:9)(cid:31)(cid:18)(cid:32)(cid:9)(cid:33)(cid:23)(cid:33)(cid:23)(cid:5)(cid:21)(cid:34)(cid:5)(cid:33)(cid:34)(cid:33)(cid:23) (cid:24)(cid:35)(cid:13)(cid:36)(cid:37)(cid:16)(cid:11)(cid:11)(cid:15)(cid:12)(cid:38)(cid:36)(cid:37)
)TMG(
21:41
0202-ceD-30
:nO
devorppA\devorppA\c6f78a591e771090
FDA-CBER-2021-5683-0024761
Page 3","[[['DocumentName:'], ['DocumentTitle:']]]",3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations.pdf,2.0,"16.2.2.1 Listing of Important Protocol Deviations – Phase 1, 2 Doses, 21 Days Apart
Protocol Number Subject
Deviation of (Number of
Category Protocol Deviation Subcategory Subjects Deviations if >1)
Inclusion/Exclusion Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood 1 C4591001 1002
chemistry laboratory value that meets the definition of a >=grade 1 abnormality) 10021053
Inclusion/Exclusion Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood 1 C4591001 1003
chemistry laboratory value that meets the definition of a >=grade 1 abnormality) 10031021
Inclusion/Exclusion Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood 1 C4591001 1003
chemistry laboratory value that meets the definition of a >=grade 1 abnormality) 10031047
Inclusion/Exclusion Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood 2 C4591001 1003
chemistry laboratory value that meets the definition of a >=grade 1 abnormality) 10031017
C4591001 1003
10031070
PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: addv Table Generation: 31AUG2020 (09:18)
(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: (CDISC)/C4591001_IA_P1/adsl_l005_pd_p1
)TMG(
25:30
0202-peS-70
:nO
laniF\laniF\f4587d491e771090
FDA-CBER-2021-5683-0029230
Page 1
16.2.2.1.1 Listing of Important Protocol Deviations – Phase 1 – BNT162b1 (100 μg)
Protocol Subject
Deviation Number of (Number of
Category Protocol Deviation Subcategory Subjects Deviations if >1)
No subject meets the reporting criteria.
PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: addv Table Generation: 19SEP2020 (10:20)
(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: ./nda3/C4591001_IA_P1_100/adsl_l005_pd_100_p1
)TMG(
42:41
0202-peS-22
:nO
laniF\laniF\805cbf491e771090
FDA-CBER-2021-5683-0029231
Page 2","[[['', None, None, None], ['16.2.2.1 Listing of Important Protocol Deviations – Phase 1, 2 Doses, 21 Days Apart', None, None, None], ['Protocol', '', 'Number', 'Subject'], ['Deviation', None, 'of', '(Number of'], ['Category', 'Protocol Deviation Subcategory', 'Subjects', 'Deviations if >1)'], ['Inclusion/Exclusion', 'Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood', '1', 'C4591001 1002'], [None, 'chemistry laboratory value that meets the definition of a >=grade 1 abnormality)', None, '10021053'], ['', None, '', None], ['Inclusion/Exclusion', 'Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood', '1', 'C4591001 1003'], [None, 'chemistry laboratory value that meets the definition of a >=grade 1 abnormality)', None, '10031021'], ['', None, '', None], ['Inclusion/Exclusion', 'Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood', '1', 'C4591001 1003'], [None, 'chemistry laboratory value that meets the definition of a >=grade 1 abnormality)', None, '10031047'], ['', None, '', None], ['Inclusion/Exclusion', 'Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood', '2', 'C4591001 1003'], [None, 'chemistry laboratory value that meets the definition of a >=grade 1 abnormality)', None, '10031017'], ['', None, '', None], ['', '', '', 'C4591001 1003'], [None, None, None, '10031070'], ['', '', '', None], [None, None, None, ''], ['PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: addv Table Generation: 31AUG2020 (09:18)', None, None, None], ['(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: (CDISC)/C4591001_IA_P1/adsl_l005_pd_p1', None, None, None], ['', None, None, None]], [['', None, None, None], ['16.2.2.1.1 Listing of Important Protocol Deviations – Phase 1 – BNT162b1 (100 μg)', None, None, None], ['Protocol', '', '', 'Subject'], ['Deviation', None, 'Number of', '(Number of'], ['Category', 'Protocol Deviation Subcategory', 'Subjects', 'Deviations if >1)'], ['No subject meets the reporting criteria.', '', '', ''], ['', None, None, ''], ['PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: addv Table Generation: 19SEP2020 (10:20)', None, None, None], ['(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: ./nda3/C4591001_IA_P1_100/adsl_l005_pd_100_p1', None, None, None], ['', None, None, None]]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-audit-certificates.pdf,4.0,"Pfizer Regulatory Quality Assurance
Audit Certificate
I, the undersigned, confirm and certifythat the following investigator site audit activities were performed.
Study C4591001
Sixteen(16)investigator site audits wereperformed between29-Apr-2020 and14-Nov-2020 for Study C4591001
Phase 2/3*.
Center Type of
Investigator Name Country Dates of Audit Name of Auditor
Number Audit
Mulligan,Mark Joseph 1001 United States 27 Jul 2020 to 30 Jul 2020 Routine Jefferies, Maria
Neuzil,Kathleen
1002 United States 10 Aug 2020 to 13 Aug 2020 Routine Cutler, Robert
Maletic
Seger,William
1042 United States 10 Aug 2020 to 13 Aug 2020 Routine Popelca, Bogdan
Michael
Rankin,BruceGlenn 1109 United States 18 Aug 2020 to 21 Aug 2020 Routine Patel, Frederic
Zerbini,Cristiano
1226 Brazil 24 Aug 2020 to 27 Aug 2020 Routine Tewes, Elisabeth
Augusto de Freitas
Polack,Fernando
1231 Argentina 27 Aug 2020 to 03 Sep 2020 Routine Mohr, Andrea
Pedro
Raad,George Louis 1079 United States 01 Sep 2020 to 04 Sep 2020 Routine Jefferies, Maria
Arora,Samir 1091 United States 14 Sep 2020 to 17 Sep 2020 Routine Samuels, Marilyn
Patel,Suchet R. 1077 United States 29 Sep 2020 to 02 Oct 2020 Routine Tewes, Elisabeth
Non-
Fried, David L. 1124 United States 05 Oct 2020 to 07 Oct 2020 Cutler, Robert
Routine
Non-
Winkle, Peter John 1135 United States 12 Oct 2020 to 14 Oct 2020 Cutler, Robert
Routine
Polack, Fernando Non-
1231 Argentina 13 Oct 2020 to 20 Oct 2020 Mohr, Andrea
Pedro Routine
Non-
Reynolds, Steven H. 1149 United States 16 Oct 2020 to 20 Oct 2020 Cutler, Robert
Routine
Non-
Rankin, Bruce Glenn 1109 United States 19 Oct 2020 to 22 Oct 2020 Oprisko, Cheryl
Routine
Nell,Haylene 1247 South Africa 26 Oct 2020 to 29 Oct 2020 Routine Tewes, Elisabeth
Non-
Koch, Mark 1128 United States 03 Nov 2020 to 06 Nov 2020 Cutler, Robert
Routine
Template Version: 26-Sep-2014 Confidential Page 1of 2
Page 1
1Facsimile of Original Digital Signature DocUUID : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
)TMG(
30:70
0202-ceD-30
:nO
devorppA\devorppA\6bb22a591e771090
FDA-CBER-2021-5683-0029190
*Site 1001 and 1002 audited as part of Phase 1
Approver:
Cecilia Gabarain
Senior Director, Regulatory Quality Assurance
7997eefb-6feb-4dbc-a232-c15936633467
REASON: I attest to the
accuracy and integrity of
this document.
19 Nov 2020
13:28:049-0500
6809829b-f9ec-4ac9-bc23-e28cfba721dc
REASON: I approve
this document.
20 Nov 2020
10:12:039-0500
Template Version: 26-Sep-2014 Confidential Page 2of 2
Page 2
DocUUID : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
)TMG(
30:70
0202-ceD-30
:nO
devorppA\devorppA\6bb22a591e771090
FDA-CBER-2021-5683-0029191
MSB
Validation Report as of: 20 Nov 2020 10:14:010-0500
1
Subject CN MSB
Subject DN EMAILADDRESS=operations@msbdocs.com,CN=MSB,OU=MSB,O=TAIGLE LLC,L=Irvine,ST=California,C=US
Email operations@msbdocs.com
Serial # 103155442024134641897105422308128156249
Issuer DN CN=Entrust Class 3 Client CA - SHA256,OU=(c) 2015 Entrust, Inc. - for authorized use only,OU=See www.entrust.net/legal-
terms,O=Entrust, Inc.,C=US
Signing Time 20 Nov 2020 10:12:039-0500
The Certificate chain was successfully built to a Trusted Root Certificate.
The Signer's identity is valid.
The Document has not been modified since the signature was applied.
This page was added to the original document by the MSB Validation Service (SVS) as part of the process to convert
active signature block content into inactive text. A full validation report of each signature is generated and cross-
referenced using a numeric footnote annotation.
Page 3
DocUUID : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
)TMG(
30:70
0202-ceD-30
:nO
devorppA\devorppA\6bb22a591e771090
FDA-CBER-2021-5683-0029192
Audit Trail Report
Date User Document Action Details
19 Nov 2020 1309:007-0500 Christine Mina Started The custodian composed the ePak succesfully.
User UUD : a3b2e181-3aee-4aea-b101-ec31853d0033
User Email : christinemina@pfizer.com
19 Nov 2020 1309:007-0500 Robert N Cutler RequestSent Sign request sent to ePak recipient.
User UUID : 7997eefb-6feb-4dbc-a232-c15936633467
User Email : robertcutler@pfizercom
19 Nov 2020 1327:054-0500 Robert N Cutler C4591001 Phase 2_3 Audit DocumentViewed Document viewed by signer.
Cert 19-Nov-2020.pdf User UUID : 7997eefb-6feb-4dbc-a232-c15936633467
User Email : robertcutler@pfizercom
Document UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
19 Nov 2020 1328:050-0500 Robert N Cutler C4591001 Phase 2_3 Audit SignerTagFilled The signer filled Time Stamp.
Cert 19-Nov-2020.pdf Value: 19 Nov 2020 1328:049-0500
User UUID : 7997eefb-6feb-4dbc-a232-c15936633467
User Email : robertcutler@pfizercom
Document UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
19 Nov 2020 1328:050-0500 Robert N Cutler C4591001 Phase 2_3 Audit Signed The recipient signed the document with no comments.
Cert 19-Nov-2020.pdf Comments: None
Reason: None
User UUID : 7997eefb-6feb-4dbc-a232-c15936633467
User Email : robertcutler@pfizercom
Document UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
19 Nov 2020 1328:050-0500 Christine Mina EPakStateChanged The ePak progressed to the next workflow state .
User UUD : a3b2e181-3aee-4aea-b101-ec31853d0033
User Email : christinemina@pfizer.com
19 Nov 2020 1328:050-0500 Christine Mina RequestSent Sign request sent to ePak recipient.
User UUD : a3b2e181-3aee-4aea-b101-ec31853d0033
User Email : christinemina@pfizer.com
20 Nov 2020 10:11:005-0500 Cecilia Gabarain C4591001 Phase 2_3 Audit DocumentViewed Document viewed by signer.
Cert 19-Nov-2020.pdf User UUID : 6809829b-f9ec-4ac9-bc23-e28cfba721dc
User Email : ceciliabeatrizgabarain@pfizercom
Document UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
20 Nov 2020 10:12:040-0500 Cecilia Gabarain C4591001 Phase 2_3 Audit SignerTagFilled The signer filled Time Stamp.
Cert 19-Nov-2020.pdf Value: 20 Nov 2020 10:12:039-0500
User UUID : 6809829b-f9ec-4ac9-bc23-e28cfba721dc
User Email : ceciliabeatrizgabarain@pfizercom
Document UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
20 Nov 2020 10:12:040-0500 Cecilia Gabarain C4591001 Phase 2_3 Audit Signed The recipient signed the document with no comments.
Cert 19-Nov-2020.pdf Comments: None
Reason: None
User UUID : 6809829b-f9ec-4ac9-bc23-e28cfba721dc
User Email : ceciliabeatrizgabarain@pfizercom
Document UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
20 Nov 2020 10:12:040-0500 Christine Mina Completed The ePak completed the workflow successfully custodian.
User UUD : a3b2e181-3aee-4aea-b101-ec31853d0033
User Email : christinemina@pfizer.com
Page 4
DocUUID : dd1d3c42-4215-4faf-843f-b1d1d2d5c436
)TMG(
30:70
0202-ceD-30
:nO
devorppA\devorppA\6bb22a591e771090
FDA-CBER-2021-5683-0029193","[[['Sixteen(16)investigator site audits wereperformed between29-Apr-2020 and14-Nov-2020 for Study C4591001\nPhase 2/3*.', None, None, None, None, None], ['Investigator Name', 'Center\nNumber', 'Country', 'Dates of Audit', 'Type of\nAudit', 'Name of Auditor'], ['Mulligan,Mark Joseph', '1001', 'United States', '27 Jul 2020 to 30 Jul 2020', 'Routine', 'Jefferies, Maria'], ['Neuzil,Kathleen\nMaletic', '1002', 'United States', '10 Aug 2020 to 13 Aug 2020', 'Routine', 'Cutler, Robert'], ['Seger,William\n)TM\nMichael', '1042', 'United States', '10 Aug 2020 to 13 Aug 2020', 'Routine', 'Popelca, Bogdan'], ['G(\nRankin,BruceGlenn\n3', '1109', 'United States', '18 Aug 2020 to 21 Aug 2020', 'Routine', 'Patel, Frederic'], ['Zerbini,Cristiano 0:70\nAugusto de Freitas', '1226', 'Brazil', '24 Aug 2020 to 27 Aug 2020', 'Routine', 'Tewes, Elisabeth'], ['Polack,Fernando 0202\nPedro', '1231', 'Argentina', '27 Aug 2020 to 03 Sep 2020', 'Routine', 'Mohr, Andrea'], ['-ce\nRaad,George Louis', '1079', 'United States', '01 Sep 2020 to 04 Sep 2020', 'Routine', 'Jefferies, Maria'], ['D-3\nArora,Samir', '1091', 'United States', '14 Sep 2020 to 17 Sep 2020', 'Routine', 'Samuels, Marilyn'], ['0\nPatel,Suchet R.\n:n', '1077', 'United States', '29 Sep 2020 to 02 Oct 2020', 'Routine', 'Tewes, Elisabeth'], ['O\nFried, David L.\nde', '1124', 'United States', '05 Oct 2020 to 07 Oct 2020', 'Non-\nRoutine', 'Cutler, Robert'], ['vorpp\nWinkle, Peter John', '1135', 'United States', '12 Oct 2020 to 14 Oct 2020', 'Non-\nRoutine', 'Cutler, Robert'], ['Polack, Fernando A\\de\nPedro', '1231', 'Argentina', '13 Oct 2020 to 20 Oct 2020', 'Non-\nRoutine', 'Mohr, Andrea'], ['vorpp\nReynolds, Steven H.', '1149', 'United States', '16 Oct 2020 to 20 Oct 2020', 'Non-\nRoutine', 'Cutler, Robert'], ['A\\6bb\nRankin, Bruce Glenn', '1109', 'United States', '19 Oct 2020 to 22 Oct 2020', 'Non-\nRoutine', 'Oprisko, Cheryl'], ['Nell,Haylene 22', '1247', 'South Africa', '26 Oct 2020 to 29 Oct 2020', 'Routine', 'Tewes, Elisabeth'], ['a591e\nKoch, Mark', '1128', 'United States', '03 Nov 2020 to 06 Nov 2020', 'Non-\nRoutine', 'Cutler, Robert']], [['Date', 'User', 'Document', 'Action', 'Details'], ['19 Nov 2020 1309:007-0500', 'Christine Mina', '', 'Started', 'The custodian composed the ePak succesfully.\nUser UUD : a3b2e181-3aee-4aea-b101-ec31853d0033\nUser Email : christinemina@pfizer.com'], ['19 Nov 2020 1309:007-0500', 'Robert N Cutler', '', 'RequestSent', 'Sign request sent to ePak recipient.\nUser UUID : 7997eefb-6feb-4dbc-a232-c15936633467\nUser Email : robertcutler@pfizercom'], ['19 Nov 2020 1327:054-0500', 'Robert N Cutler', 'C4591001 Phase 2_3 Audit\nCert 19-Nov-2020.pdf', 'DocumentViewed', 'Document viewed by signer.\nUser UUID : 7997eefb-6feb-4dbc-a232-c15936633467\nUser Email : robertcutler@pfizercom\nDocument UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436'], ['19 Nov 2020 1328:050-0500', 'Robert N Cutler', 'C4591001 Phase 2_3 Audit\nCert 19-Nov-2020.pdf', 'SignerTagFilled', 'The signer filled Time Stamp.\nValue: 19 Nov 2020 1328:049-0500\nUser UUID : 7997eefb-6feb-4dbc-a232-c15936633467\nUser Email : robertcutler@pfizercom\nDocument UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436'], ['19 Nov 2020 1328:050-0500', 'Robert N Cutler', 'C4591001 Phase 2_3 Audit\nCert 19-Nov-2020.pdf', 'Signed', 'The recipient signed the document with no comments.\nComments: None\nReason: None\nUser UUID : 7997eefb-6feb-4dbc-a232-c15936633467\nUser Email : robertcutler@pfizercom\nDocument UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436'], ['19 Nov 2020 1328:050-0500', 'Christine Mina', '', 'EPakStateChanged', 'The ePak progressed to the next workflow state .\nUser UUD : a3b2e181-3aee-4aea-b101-ec31853d0033\nUser Email : christinemina@pfizer.com'], ['19 Nov 2020 1328:050-0500', 'Christine Mina', '', 'RequestSent', 'Sign request sent to ePak recipient.\nUser UUD : a3b2e181-3aee-4aea-b101-ec31853d0033\nUser Email : christinemina@pfizer.com'], ['20 Nov 2020 10:11:005-0500', 'Cecilia Gabarain', 'C4591001 Phase 2_3 Audit\nCert 19-Nov-2020.pdf', 'DocumentViewed', 'Document viewed by signer.\nUser UUID : 6809829b-f9ec-4ac9-bc23-e28cfba721dc\nUser Email : ceciliabeatrizgabarain@pfizercom\nDocument UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436'], ['20 Nov 2020 10:12:040-0500', 'Cecilia Gabarain', 'C4591001 Phase 2_3 Audit\nCert 19-Nov-2020.pdf', 'SignerTagFilled', 'The signer filled Time Stamp.\nValue: 20 Nov 2020 10:12:039-0500\nUser UUID : 6809829b-f9ec-4ac9-bc23-e28cfba721dc\nUser Email : ceciliabeatrizgabarain@pfizercom\nDocument UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436'], ['20 Nov 2020 10:12:040-0500', 'Cecilia Gabarain', 'C4591001 Phase 2_3 Audit\nCert 19-Nov-2020.pdf', 'Signed', 'The recipient signed the document with no comments.\nComments: None\nReason: None\nUser UUID : 6809829b-f9ec-4ac9-bc23-e28cfba721dc\nUser Email : ceciliabeatrizgabarain@pfizercom\nDocument UUD : dd1d3c42-4215-4faf-843f-b1d1d2d5c436'], [')TM\n20 Nov 2020 10:12:040-0500', 'Christine Mina', '', 'Completed', 'The ePak completed the workflow successfully custodian.\nUser UUD : a3b2e181-3aee-4aea-b101-ec31853d0033\nUser Email : christinemina@pfizer.com']]]",4
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-interim-mth6-invest-signature.pdf,1.0,"Infectious Diseases Division
INVESTIGATOR DECLARATION
Clinical Study Report
Protocol Number: C4591001
Report Title: Interim Report – 6 Month Update: A Phase 1/2/3, Placebo-Controlled,
Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability,
Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19
in Healthy Individuals
Clinical Lead: John L. Perez, MD, MBA, MA
Date of the Report: 29 April 2021
I, Dr. Stephen J. Thomas, the undersigned, have read the above-referenced clinical study report
for study C4591001, which I have undertaken with Pfizer.
I confirm that to the best of my knowledge, it accurately describes the conduct and results of the
study.
Signed:
Stephen J. Thomas, MD
State University of New York
Upstate Medical University
Date: 29 April 2021
The above lead investigator is acting as coordinator and signing on behalf of all centers involved
in the above study.
Page 1
)TMG(
14:70
1202-rpA-03
:nO
devorppA\devorppA\e42cbe691e771090
FDA-CBER-2021-5683-0029224","[[['', None], [None, '']]]",1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-randomization.pdf,15.0,"16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10011004 C4591001 1001 18-55 04MAY2020 1084 BNT162b1 04MAY2020 BNT162b1 26MAY2020 BNT162b1
10011004 (10 μg) (10 μg) (10 μg)
10011005 C4591001 1001 18-55 06MAY2020 1093 Placebo 06MAY2020 Placebo 26MAY2020 Placebo
10011005
10011006 C4591001 1001 18-55 06MAY2020 1090 BNT162b1 06MAY2020 BNT162b1 27MAY2020 BNT162b1
10011006 (10 μg) (10 μg) (10 μg)
10011007 C4591001 1001 18-55 06MAY2020 1092 BNT162b1 06MAY2020 BNT162b1 28MAY2020 BNT162b1
10011007 (10 μg) (10 μg) (10 μg)
10011008 C4591001 1001 18-55 06MAY2020 1094 BNT162b1 06MAY2020 BNT162b1 27MAY2020 BNT162b1
10011008 (10 μg) (10 μg) (10 μg)
10011009 C4591001 1001 18-55 06MAY2020 1095 BNT162b1 06MAY2020 BNT162b1 27MAY2020 BNT162b1
10011009 (10 μg) (10 μg) (10 μg)
10011011 C4591001 1001 18-55 11MAY2020 1220 BNT162b1 11MAY2020 BNT162b1 01JUN2020 BNT162b1
10011011 (30 μg) (30 μg) (30 μg)
10011012 C4591001 1001 18-55 13MAY2020 1230 BNT162b1 13MAY2020 BNT162b1 03JUN2020 BNT162b1
10011012 (30 μg) (30 μg) (30 μg)
10011015 C4591001 1001 18-55 11MAY2020 1219 BNT162b1 11MAY2020 BNT162b1 01JUN2020 BNT162b1
10011015 (30 μg) (30 μg) (30 μg)
10011017 C4591001 1001 18-55 13MAY2020 1228 BNT162b1 13MAY2020 BNT162b1 03JUN2020 BNT162b1
10011017 (30 μg) (30 μg) (30 μg)
10011019 C4591001 1001 18-55 13MAY2020 1229 BNT162b1 13MAY2020 BNT162b1 03JUN2020 BNT162b1
10011019 (30 μg) (30 μg) (30 μg)
10011020 C4591001 1001 18-55 13MAY2020 1226 BNT162b1 13MAY2020 BNT162b1 03JUN2020 BNT162b1
10011020 (30 μg) (30 μg) (30 μg)
10011024 C4591001 1001 18-55 13MAY2020 1225 BNT162b1 13MAY2020 BNT162b1 03JUN2020 BNT162b1
10011024 (30 μg) (30 μg) (30 μg)
10011037 C4591001 1001 65-85 11JUN2020 1631 BNT162b1 11JUN2020 BNT162b1 30JUN2020 BNT162b1
10011037 (10 μg) (10 μg) (10 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024763
Page 1
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10011039 C4591001 1001 65-85 09JUN2020 1624 BNT162b1 09JUN2020 BNT162b1 29JUN2020 BNT162b1
10011039 (10 μg) (10 μg) (10 μg)
10011040 C4591001 1001 65-85 11JUN2020 1635 BNT162b1 11JUN2020 BNT162b1 02JUL2020 BNT162b1
10011040 (10 μg) (10 μg) (10 μg)
10011041 C4591001 1001 65-85 11JUN2020 1632 BNT162b1 11JUN2020 BNT162b1 02JUL2020 BNT162b1
10011041 (10 μg) (10 μg) (10 μg)
10011042 C4591001 1001 65-85 11JUN2020 1634 Placebo 11JUN2020 Placebo 30JUN2020 Placebo
10011042
10011043 C4591001 1001 65-85 15JUN2020 2029 BNT162b1 15JUN2020 BNT162b1 08JUL2020 BNT162b1
10011043 (20 μg) (20 μg) (20 μg)
10011044 C4591001 1001 65-85 09JUN2020 1625 BNT162b1 09JUN2020 BNT162b1 29JUN2020 BNT162b1
10011044 (10 μg) (10 μg) (10 μg)
10011045 C4591001 1001 65-85 11JUN2020 1633 BNT162b1 11JUN2020 BNT162b1 02JUL2020 BNT162b1
10011045 (10 μg) (10 μg) (10 μg)
10011046 C4591001 1001 65-85 18JUN2020 1767 BNT162b1 18JUN2020 BNT162b1 09JUL2020 BNT162b1
10011046 (30 μg) (30 μg) (30 μg)
10011048 C4591001 1001 65-85 16JUN2020 1759 BNT162b1 16JUN2020 BNT162b1 08JUL2020 BNT162b1
10011048 (30 μg) (30 μg) (30 μg)
10011049 C4591001 1001 65-85 15JUN2020 2030 BNT162b1 15JUN2020 BNT162b1 06JUL2020 BNT162b1
10011049 (20 μg) (20 μg) (20 μg)
10011050 C4591001 1001 65-85 17JUN2020 2031 BNT162b1 17JUN2020 BNT162b1 07JUL2020 BNT162b1
10011050 (20 μg) (20 μg) (20 μg)
10011052 C4591001 1001 65-85 17JUN2020 2037 BNT162b1 17JUN2020 BNT162b1 08JUL2020 BNT162b1
10011052 (20 μg) (20 μg) (20 μg)
10011053 C4591001 1001 65-85 16JUN2020 1760 Placebo 16JUN2020 Placebo 09JUL2020 Placebo
10011053
10011055 C4591001 1001 65-85 17JUN2020 2039 BNT162b1 17JUN2020 BNT162b1 08JUL2020 BNT162b1
10011055 (20 μg) (20 μg) (20 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024764
Page 2
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10011057 C4591001 1001 65-85 17JUN2020 2038 Placebo 17JUN2020 Placebo 08JUL2020 Placebo
10011057
10011058 C4591001 1001 65-85 18JUN2020 1768 BNT162b1 18JUN2020 BNT162b1 09JUL2020 BNT162b1
10011058 (30 μg) (30 μg) (30 μg)
10011059 C4591001 1001 65-85 17JUN2020 2040 BNT162b1 17JUN2020 BNT162b1 08JUL2020 BNT162b1
10011059 (20 μg) (20 μg) (20 μg)
10011061 C4591001 1001 65-85 18JUN2020 1765 BNT162b1 18JUN2020 BNT162b1 09JUL2020 BNT162b1
10011061 (30 μg) (30 μg) (30 μg)
10011063 C4591001 1001 65-85 18JUN2020 1769 BNT162b1 18JUN2020 BNT162b1 07JUL2020 BNT162b1
10011063 (30 μg) (30 μg) (30 μg)
10011064 C4591001 1001 65-85 18JUN2020 1770 Placebo 18JUN2020 Placebo 07JUL2020 Placebo
10011064
10011066 C4591001 1001 18-55 29JUN2020 1489 Placebo 29JUN2020 Placebo 20JUL2020 Placebo
10011066
10011067 C4591001 1001 18-55 01JUL2020 1499 BNT162b1 01JUL2020 BNT162b1 22JUL2020 BNT162b1
10011067 (20 μg) (20 μg) (20 μg)
10011068 C4591001 1001 18-55 29JUN2020 1490 BNT162b1 29JUN2020 BNT162b1 20JUL2020 BNT162b1
10011068 (20 μg) (20 μg) (20 μg)
10011069 C4591001 1001 18-55 01JUL2020 1496 Placebo 01JUL2020 Placebo 22JUL2020 Placebo
10011069
10011070 C4591001 1001 18-55 01JUL2020 1500 BNT162b1 01JUL2020 BNT162b1 22JUL2020 BNT162b1
10011070 (20 μg) (20 μg) (20 μg)
10011071 C4591001 1001 18-55 01JUL2020 1497 BNT162b1 01JUL2020 BNT162b1 22JUL2020 BNT162b1
10011071 (20 μg) (20 μg) (20 μg)
10011076 C4591001 1001 18-55 01JUL2020 1498 BNT162b1 01JUL2020 BNT162b1 21JUL2020 BNT162b1
10011076 (20 μg) (20 μg) (20 μg)
10021003 C4591001 1002 18-55 04MAY2020 1081 BNT162b1 04MAY2020 BNT162b1 26MAY2020 BNT162b1
10021003 (10 μg) (10 μg) (10 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024765
Page 3
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10021004 C4591001 1002 18-55 04MAY2020 1082 BNT162b1 04MAY2020 BNT162b1 26MAY2020 BNT162b1
10021004 (10 μg) (10 μg) (10 μg)
10021005 C4591001 1002 18-55 04MAY2020 1083 Placebo 04MAY2020 Placebo 26MAY2020 Placebo
10021005
10021006 C4591001 1002 18-55 11MAY2020 1218 BNT162b1 11MAY2020 BNT162b1 02JUN2020 BNT162b1
10021006 (30 μg) (30 μg) (30 μg)
10021007 C4591001 1002 18-55 06MAY2020 1089 BNT162b1 06MAY2020 BNT162b1 26MAY2020 BNT162b1
10021007 (10 μg) (10 μg) (10 μg)
10021008 C4591001 1002 18-55 06MAY2020 1088 Placebo 06MAY2020 Placebo 26MAY2020 Placebo
10021008
10021009 C4591001 1002 18-55 06MAY2020 1091 BNT162b1 06MAY2020 BNT162b1 26MAY2020 BNT162b1
10021009 (10 μg) (10 μg) (10 μg)
10021011 C4591001 1002 18-55 06MAY2020 1086 BNT162b1 06MAY2020 BNT162b1 26MAY2020 BNT162b1
10021011 (10 μg) (10 μg) (10 μg)
10021012 C4591001 1002 18-55 05MAY2020 1085 BNT162b1 05MAY2020 BNT162b1 26MAY2020 BNT162b1
10021012 (10 μg) (10 μg) (10 μg)
10021013 C4591001 1002 18-55 06MAY2020 1087 BNT162b1 06MAY2020 BNT162b1 26MAY2020 BNT162b1
10021013 (10 μg) (10 μg) (10 μg)
10021014 C4591001 1002 18-55 13MAY2020 1224 BNT162b1 13MAY2020 BNT162b1 02JUN2020 BNT162b1
10021014 (30 μg) (30 μg) (30 μg)
10021015 C4591001 1002 18-55 11MAY2020 1216 BNT162b1 11MAY2020 BNT162b1 02JUN2020 BNT162b1
10021015 (30 μg) (30 μg) (30 μg)
10021017 C4591001 1002 18-55 13MAY2020 1221 BNT162b1 13MAY2020 BNT162b1 02JUN2020 BNT162b1
10021017 (30 μg) (30 μg) (30 μg)
10021018 C4591001 1002 18-55 11MAY2020 1217 Placebo 11MAY2020 Placebo 02JUN2020 Placebo
10021018
10021020 C4591001 1002 18-55 13MAY2020 1222 BNT162b1 13MAY2020 BNT162b1 02JUN2020 BNT162b1
10021020 (30 μg) (30 μg) (30 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024766
Page 4
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10021021 C4591001 1002 18-55 13MAY2020 1223 Placebo 13MAY2020 Placebo 02JUN2020 Placebo
10021021
10021022 C4591001 1002 18-55 13MAY2020 1227 Placebo 13MAY2020 Placebo 02JUN2020 Placebo
10021022
10021042 C4591001 1002 65-85 09JUN2020 1623 Placebo 09JUN2020 Placebo 30JUN2020 Placebo
10021042
10021043 C4591001 1002 65-85 09JUN2020 1621 BNT162b1 09JUN2020 BNT162b1 30JUN2020 BNT162b1
10021043 (10 μg) (10 μg) (10 μg)
10021044 C4591001 1002 65-85 09JUN2020 1622 BNT162b1 09JUN2020 BNT162b1 30JUN2020 BNT162b1
10021044 (10 μg) (10 μg) (10 μg)
10021045 C4591001 1002 65-85 11JUN2020 1629 BNT162b1 11JUN2020 BNT162b1 30JUN2020 BNT162b1
10021045 (10 μg) (10 μg) (10 μg)
10021047 C4591001 1002 65-85 11JUN2020 1626 Placebo 11JUN2020 Placebo 30JUN2020 Placebo
10021047
10021049 C4591001 1002 65-85 11JUN2020 1630 BNT162b1 11JUN2020 BNT162b1 30JUN2020 BNT162b1
10021049 (10 μg) (10 μg) (10 μg)
10021050 C4591001 1002 65-85 15JUN2020 2026 Placebo 15JUN2020 Placebo 07JUL2020 Placebo
10021050
10021052 C4591001 1002 65-85 11JUN2020 1628 BNT162b1 11JUN2020 BNT162b1 30JUN2020 BNT162b1
10021052 (10 μg) (10 μg) (10 μg)
10021053 C4591001 1002 65-85 11JUN2020 1627 BNT162b1 11JUN2020 BNT162b1 30JUN2020 BNT162b1
10021053 (10 μg) (10 μg) (10 μg)
10021054 C4591001 1002 65-85 15JUN2020 2028 BNT162b1 15JUN2020 BNT162b1 07JUL2020 BNT162b1
10021054 (20 μg) (20 μg) (20 μg)
10021059 C4591001 1002 65-85 15JUN2020 1757 BNT162b1 15JUN2020 BNT162b1 07JUL2020 BNT162b1
10021059 (30 μg) (30 μg) (30 μg)
10021060 C4591001 1002 65-85 15JUN2020 2027 BNT162b1 15JUN2020 BNT162b1 07JUL2020 BNT162b1
10021060 (20 μg) (20 μg) (20 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024767
Page 5
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10021062 C4591001 1002 65-85 15JUN2020 1756 BNT162b1 15JUN2020 BNT162b1 07JUL2020 BNT162b1
10021062 (30 μg) (30 μg) (30 μg)
10021063 C4591001 1002 65-85 15JUN2020 1758 BNT162b1 15JUN2020 BNT162b1 07JUL2020 BNT162b1
10021063 (30 μg) (30 μg) (30 μg)
10021064 C4591001 1002 65-85 17JUN2020 2034 BNT162b1 17JUN2020 BNT162b1 08JUL2020 BNT162b1
10021064 (20 μg) (20 μg) (20 μg)
10021067 C4591001 1002 65-85 17JUN2020 2032 BNT162b1 17JUN2020 BNT162b1 08JUL2020 BNT162b1
10021067 (20 μg) (20 μg) (20 μg)
10021068 C4591001 1002 65-85 17JUN2020 2035 BNT162b1 17JUN2020 BNT162b1 08JUL2020 BNT162b1
10021068 (20 μg) (20 μg) (20 μg)
10021069 C4591001 1002 65-85 18JUN2020 1764 BNT162b1 18JUN2020 BNT162b1 08JUL2020 BNT162b1
10021069 (30 μg) (30 μg) (30 μg)
10021071 C4591001 1002 65-85 17JUN2020 2036 BNT162b1 17JUN2020 BNT162b1 08JUL2020 BNT162b1
10021071 (20 μg) (20 μg) (20 μg)
10021072 C4591001 1002 65-85 18JUN2020 1761 Placebo 18JUN2020 Placebo 08JUL2020 Placebo
10021072
10021073 C4591001 1002 65-85 17JUN2020 2033 Placebo 17JUN2020 Placebo 08JUL2020 Placebo
10021073
10021074 C4591001 1002 65-85 18JUN2020 1762 BNT162b1 18JUN2020 BNT162b1 08JUL2020 BNT162b1
10021074 (30 μg) (30 μg) (30 μg)
10021075 C4591001 1002 65-85 18JUN2020 1766 BNT162b1 18JUN2020 BNT162b1 08JUL2020 BNT162b1
10021075 (30 μg) (30 μg) (30 μg)
10021077 C4591001 1002 65-85 18JUN2020 1763 BNT162b1 18JUN2020 BNT162b1 08JUL2020 BNT162b1
10021077 (30 μg) (30 μg) (30 μg)
10021079 C4591001 1002 18-55 29JUN2020 1487 BNT162b1 29JUN2020 BNT162b1 21JUL2020 BNT162b1
10021079 (20 μg) (20 μg) (20 μg)
10021080 C4591001 1002 18-55 01JUL2020 1491 BNT162b1 01JUL2020 BNT162b1 21JUL2020 BNT162b1
10021080 (20 μg) (20 μg) (20 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024768
Page 6
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10021081 C4591001 1002 18-55 01JUL2020 1492 BNT162b1 01JUL2020 BNT162b1 21JUL2020 BNT162b1
10021081 (20 μg) (20 μg) (20 μg)
10021082 C4591001 1002 18-55 01JUL2020 1494 BNT162b1 01JUL2020 BNT162b1 21JUL2020 BNT162b1
10021082 (20 μg) (20 μg) (20 μg)
10021083 C4591001 1002 18-55 01JUL2020 1495 Placebo 01JUL2020 Placebo 21JUL2020 Placebo
10021083
10021084 C4591001 1002 18-55 29JUN2020 1488 BNT162b1 29JUN2020 BNT162b1 21JUL2020 BNT162b1
10021084 (20 μg) (20 μg) (20 μg)
10021085 C4591001 1002 18-55 29JUN2020 1486 BNT162b1 29JUN2020 BNT162b1 21JUL2020 BNT162b1
10021085 (20 μg) (20 μg) (20 μg)
10021087 C4591001 1002 18-55 01JUL2020 1493 BNT162b1 01JUL2020 BNT162b1 21JUL2020 BNT162b1
10021087 (20 μg) (20 μg) (20 μg)
10031016 C4591001 1003 18-55 09JUN2020 2164 Placebo 09JUN2020 Placebo 30JUN2020 Placebo
10031016
10031017 C4591001 1003 18-55 11JUN2020 2172 Placebo 11JUN2020 Placebo 02JUL2020 Placebo
10031017
10031018 C4591001 1003 18-55 09JUN2020 2163 BNT162b2 09JUN2020 BNT162b2 30JUN2020 BNT162b2
10031018 (10 μg) (10 μg) (10 μg)
10031019 C4591001 1003 18-55 11JUN2020 2170 BNT162b2 11JUN2020 BNT162b2 02JUL2020 BNT162b2
10031019 (10 μg) (10 μg) (10 μg)
10031020 C4591001 1003 18-55 11JUN2020 2174 BNT162b2 11JUN2020 BNT162b2 02JUL2020 BNT162b2
10031020 (10 μg) (10 μg) (10 μg)
10031021 C4591001 1003 18-55 09JUN2020 2165 BNT162b2 09JUN2020 BNT162b2 30JUN2020 BNT162b2
10031021 (10 μg) (10 μg) (10 μg)
10031022 C4591001 1003 18-55 11JUN2020 2171 BNT162b2 11JUN2020 BNT162b2 02JUL2020 BNT162b2
10031022 (10 μg) (10 μg) (10 μg)
10031024 C4591001 1003 18-55 11JUN2020 2173 BNT162b2 11JUN2020 BNT162b2 02JUL2020 BNT162b2
10031024 (10 μg) (10 μg) (10 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024769
Page 7
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10031026 C4591001 1003 18-55 17JUN2020 2573 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10031026 (20 μg) (20 μg) (20 μg)
10031027 C4591001 1003 18-55 15JUN2020 2567 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10031027 (20 μg) (20 μg) (20 μg)
10031028 C4591001 1003 18-55 15JUN2020 2566 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10031028 (20 μg) (20 μg) (20 μg)
10031029 C4591001 1003 18-55 15JUN2020 2568 Placebo 15JUN2020 Placebo 06JUL2020 Placebo
10031029
10031030 C4591001 1003 18-55 17JUN2020 2575 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10031030 (20 μg) (20 μg) (20 μg)
10031031 C4591001 1003 65-85 15JUN2020 3109 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10031031 (20 μg) (20 μg) (20 μg)
10031032 C4591001 1003 18-55 17JUN2020 2572 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10031032 (20 μg) (20 μg) (20 μg)
10031034 C4591001 1003 18-55 17JUN2020 2571 Placebo 17JUN2020 Placebo 08JUL2020 Placebo
10031034
10031035 C4591001 1003 65-85 15JUN2020 3108 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10031035 (20 μg) (20 μg) (20 μg)
10031036 C4591001 1003 65-85 15JUN2020 3110 Placebo 15JUN2020 Placebo 06JUL2020 Placebo
10031036
10031037 C4591001 1003 65-85 16JUN2020 2840 BNT162b2 16JUN2020 BNT162b2 07JUL2020 BNT162b2
10031037 (30 μg) (30 μg) (30 μg)
10031038 C4591001 1003 18-55 17JUN2020 2574 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10031038 (20 μg) (20 μg) (20 μg)
10031043 C4591001 1003 65-85 16JUN2020 2838 Placebo 16JUN2020 Placebo 07JUL2020 Placebo
10031043
10031046 C4591001 1003 65-85 18JUN2020 2847 Placebo 18JUN2020 Placebo 09JUL2020 Placebo
10031046
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024770
Page 8
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10031047 C4591001 1003 65-85 16JUN2020 2839 BNT162b2 16JUN2020 BNT162b2 07JUL2020 BNT162b2
10031047 (30 μg) (30 μg) (30 μg)
10031050 C4591001 1003 18-55 22JUN2020 2297 Placebo 22JUN2020 Placebo 13JUL2020 Placebo
10031050
10031051 C4591001 1003 65-85 18JUN2020 2848 BNT162b2 18JUN2020 BNT162b2 09JUL2020 BNT162b2
10031051 (30 μg) (30 μg) (30 μg)
10031053 C4591001 1003 65-85 17JUN2020 3111 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10031053 (20 μg) (20 μg) (20 μg)
10031054 C4591001 1003 65-85 17JUN2020 3115 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10031054 (20 μg) (20 μg) (20 μg)
10031055 C4591001 1003 65-85 17JUN2020 3112 BNT162b2 17JUN2020 BNT162b2 06JUL2020 BNT162b2
10031055 (20 μg) (20 μg) (20 μg)
10031056 C4591001 1003 65-85 18JUN2020 2844 Placebo 18JUN2020 Placebo 09JUL2020 Placebo
10031056
10031057 C4591001 1003 18-55 24JUN2020 2301 BNT162b2 24JUN2020 BNT162b2 15JUL2020 BNT162b2
10031057 (30 μg) (30 μg) (30 μg)
10031058 C4591001 1003 65-85 18JUN2020 2846 BNT162b2 18JUN2020 BNT162b2 09JUL2020 BNT162b2
10031058 (30 μg) (30 μg) (30 μg)
10031059 C4591001 1003 18-55 24JUN2020 2305 BNT162b2 24JUN2020 BNT162b2 15JUL2020 BNT162b2
10031059 (30 μg) (30 μg) (30 μg)
10031061 C4591001 1003 18-55 22JUN2020 2298 BNT162b2 22JUN2020 BNT162b2 13JUL2020 BNT162b2
10031061 (30 μg) (30 μg) (30 μg)
10031063 C4591001 1003 65-85 17JUN2020 3113 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10031063 (20 μg) (20 μg) (20 μg)
10031065 C4591001 1003 18-55 24JUN2020 2303 BNT162b2 24JUN2020 BNT162b2 15JUL2020 BNT162b2
10031065 (30 μg) (30 μg) (30 μg)
10031066 C4591001 1003 18-55 22JUN2020 2296 BNT162b2 22JUN2020 BNT162b2 13JUL2020 BNT162b2
10031066 (30 μg) (30 μg) (30 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024771
Page 9
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10031067 C4591001 1003 65-85 17JUN2020 3114 Placebo 17JUN2020 Placebo 08JUL2020 Placebo
10031067
10031069 C4591001 1003 65-85 18JUN2020 2845 BNT162b2 18JUN2020 BNT162b2 09JUL2020 BNT162b2
10031069 (30 μg) (30 μg) (30 μg)
10031070 C4591001 1003 18-55 24JUN2020 2304 Placebo 24JUN2020 Placebo 15JUL2020 Placebo
10031070
10031072 C4591001 1003 18-55 24JUN2020 2302 BNT162b2 24JUN2020 BNT162b2 16JUL2020 BNT162b2
10031072 (30 μg) (30 μg) (30 μg)
10031076 C4591001 1003 65-85 29JUN2020 2702 BNT162b2 29JUN2020 BNT162b2 20JUL2020 BNT162b2
10031076 (10 μg) (10 μg) (10 μg)
10031077 C4591001 1003 65-85 01JUL2020 2711 BNT162b2 01JUL2020 BNT162b2 22JUL2020 BNT162b2
10031077 (10 μg) (10 μg) (10 μg)
10031078 C4591001 1003 65-85 01JUL2020 2712 BNT162b2 01JUL2020 BNT162b2 22JUL2020 BNT162b2
10031078 (10 μg) (10 μg) (10 μg)
10031079 C4591001 1003 65-85 01JUL2020 2715 BNT162b2 01JUL2020 BNT162b2 22JUL2020 BNT162b2
10031079 (10 μg) (10 μg) (10 μg)
10031080 C4591001 1003 65-85 29JUN2020 2703 BNT162b2 29JUN2020 BNT162b2 20JUL2020 BNT162b2
10031080 (10 μg) (10 μg) (10 μg)
10031083 C4591001 1003 65-85 01JUL2020 2714 Placebo 01JUL2020 Placebo 22JUL2020 Placebo
10031083
10031087 C4591001 1003 65-85 01JUL2020 2713 BNT162b2 01JUL2020 BNT162b2 22JUL2020 BNT162b2
10031087 (10 μg) (10 μg) (10 μg)
10071014 C4591001 1007 18-55 11JUN2020 2175 BNT162b2 11JUN2020 BNT162b2 01JUL2020 BNT162b2
10071014 (10 μg) (10 μg) (10 μg)
10071015 C4591001 1007 18-55 08JUN2020 2161 BNT162b2 08JUN2020 BNT162b2 29JUN2020 BNT162b2
10071015 (10 μg) (10 μg) (10 μg)
10071016 C4591001 1007 18-55 10JUN2020 2166 BNT162b2 10JUN2020 BNT162b2 01JUL2020 BNT162b2
10071016 (10 μg) (10 μg) (10 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024772
Page 10
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10071017 C4591001 1007 18-55 15JUN2020 2569 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10071017 (20 μg) (20 μg) (20 μg)
10071019 C4591001 1007 18-55 08JUN2020 2162 BNT162b2 08JUN2020 BNT162b2 29JUN2020 BNT162b2
10071019 (10 μg) (10 μg) (10 μg)
10071020 C4591001 1007 18-55 10JUN2020 2167 Placebo 10JUN2020 Placebo 01JUL2020 Placebo
10071020
10071021 C4591001 1007 18-55 10JUN2020 2168 BNT162b2 10JUN2020 BNT162b2 01JUL2020 BNT162b2
10071021 (10 μg) (10 μg) (10 μg)
10071022 C4591001 1007 18-55 10JUN2020 2169 BNT162b2 10JUN2020 BNT162b2 01JUL2020 BNT162b2
10071022 (10 μg) (10 μg) (10 μg)
10071023 C4591001 1007 18-55 17JUN2020 2577 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10071023 (20 μg) (20 μg) (20 μg)
10071025 C4591001 1007 18-55 17JUN2020 2580 Placebo 17JUN2020 Placebo 08JUL2020 Placebo
10071025
10071026 C4591001 1007 18-55 15JUN2020 2570 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10071026 (20 μg) (20 μg) (20 μg)
10071027 C4591001 1007 18-55 17JUN2020 2576 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10071027 (20 μg) (20 μg) (20 μg)
10071029 C4591001 1007 18-55 17JUN2020 2578 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10071029 (20 μg) (20 μg) (20 μg)
10071031 C4591001 1007 65-85 17JUN2020 3117 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10071031 (20 μg) (20 μg) (20 μg)
10071032 C4591001 1007 65-85 15JUN2020 3106 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10071032 (20 μg) (20 μg) (20 μg)
10071034 C4591001 1007 65-85 15JUN2020 2836 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10071034 (30 μg) (30 μg) (30 μg)
10071035 C4591001 1007 65-85 15JUN2020 3107 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10071035 (20 μg) (20 μg) (20 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024773
Page 11
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10071037 C4591001 1007 65-85 15JUN2020 2837 BNT162b2 15JUN2020 BNT162b2 06JUL2020 BNT162b2
10071037 (30 μg) (30 μg) (30 μg)
10071038 C4591001 1007 65-85 17JUN2020 3120 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10071038 (20 μg) (20 μg) (20 μg)
10071039 C4591001 1007 65-85 17JUN2020 3118 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10071039 (20 μg) (20 μg) (20 μg)
10071040 C4591001 1007 18-55 17JUN2020 2579 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10071040 (20 μg) (20 μg) (20 μg)
10071042 C4591001 1007 65-85 17JUN2020 3119 Placebo 17JUN2020 Placebo 08JUL2020 Placebo
10071042
10071043 C4591001 1007 65-85 18JUN2020 2843 BNT162b2 18JUN2020 BNT162b2 09JUL2020 BNT162b2
10071043 (30 μg) (30 μg) (30 μg)
10071044 C4591001 1007 65-85 18JUN2020 2841 BNT162b2 18JUN2020 BNT162b2 09JUL2020 BNT162b2
10071044 (30 μg) (30 μg) (30 μg)
10071045 C4591001 1007 65-85 18JUN2020 2842 BNT162b2 18JUN2020 BNT162b2 09JUL2020 BNT162b2
10071045 (30 μg) (30 μg) (30 μg)
10071046 C4591001 1007 18-55 22JUN2020 2299 BNT162b2 22JUN2020 BNT162b2 15JUL2020 BNT162b2
10071046 (30 μg) (30 μg) (30 μg)
10071049 C4591001 1007 65-85 18JUN2020 2849 BNT162b2 18JUN2020 BNT162b2 09JUL2020 BNT162b2
10071049 (30 μg) (30 μg) (30 μg)
10071050 C4591001 1007 18-55 22JUN2020 2300 BNT162b2 22JUN2020 BNT162b2 13JUL2020 BNT162b2
10071050 (30 μg) (30 μg) (30 μg)
10071051 C4591001 1007 65-85 29JUN2020 2701 BNT162b2 29JUN2020 BNT162b2 20JUL2020 BNT162b2
10071051 (10 μg) (10 μg) (10 μg)
10071052 C4591001 1007 65-85 17JUN2020 3116 BNT162b2 17JUN2020 BNT162b2 08JUL2020 BNT162b2
10071052 (20 μg) (20 μg) (20 μg)
10071053 C4591001 1007 65-85 18JUN2020 2850 BNT162b2 18JUN2020 BNT162b2 09JUL2020 BNT162b2
10071053 (30 μg) (30 μg) (30 μg)
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024774
Page 12
16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart
Vaccine Received
Subject Age
Study Group Randomization Randomization Randomization
Identifiera Subject (Years) Date Number Vaccine Group Date Dose 1 Date Dose 2
10071056 C4591001 1007 65-85 29JUN2020 2704 Placebo 29JUN2020 Placebo 20JUL2020 Placebo
10071056
10071057 C4591001 1007 65-85 30JUN2020 2706 BNT162b2 30JUN2020 BNT162b2 22JUL2020 BNT162b2
10071057 (10 μg) (10 μg) (10 μg)
10071058 C4591001 1007 18-55 24JUN2020 2309 BNT162b2 24JUN2020 BNT162b2 15JUL2020 BNT162b2
10071058 (30 μg) (30 μg) (30 μg)
10071063 C4591001 1007 18-55 24JUN2020 2306 BNT162b2 24JUN2020 BNT162b2 15JUL2020 BNT162b2
10071063 (30 μg) (30 μg) (30 μg)
10071064 C4591001 1007 18-55 24JUN2020 2307 BNT162b2 24JUN2020 BNT162b2 15JUL2020 BNT162b2
10071064 (30 μg) (30 μg) (30 μg)
10071065 C4591001 1007 18-55 24JUN2020 2308 Placebo 24JUN2020 Placebo 15JUL2020 Placebo
10071065
10071066 C4591001 1007 18-55 24JUN2020 2310 BNT162b2 24JUN2020 BNT162b2 15JUL2020 BNT162b2
10071066 (30 μg) (30 μg) (30 μg)
10071071 C4591001 1007 65-85 29JUN2020 2705 BNT162b2 29JUN2020 BNT162b2 20JUL2020 BNT162b2
10071071 (10 μg) (10 μg) (10 μg)
10071073 C4591001 1007 65-85 30JUN2020 2707 BNT162b2 30JUN2020 BNT162b2 22JUL2020 BNT162b2
10071073 (10 μg) (10 μg) (10 μg)
10071074 C4591001 1007 65-85 30JUN2020 2708 BNT162b2 30JUN2020 BNT162b2 20JUL2020 BNT162b2
10071074 (10 μg) (10 μg) (10 μg)
10071075 C4591001 1007 65-85 30JUN2020 2710 Placebo 30JUN2020 Placebo 22JUL2020 Placebo
10071075
10071077 C4591001 1007 65-85 30JUN2020 2709 BNT162b2 30JUN2020 BNT162b2 22JUL2020 BNT162b2
10071077 (10 μg) (10 μg) (10 μg)
a. Subject Study Identifier = the subject number is the current study 4-digit site number followed by unique 4-digit subject identifier.
PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 02SEP2020 (17:24)
(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: (CDISC)/C4591001_IA_P1/adsl_l003_p1
)TMG(
15:30
0202-peS-70
:nO
laniF\laniF\d4587d491e771090
FDA-CBER-2021-5683-0024775
Page 13
16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1 – BNT162b1 (100 μg)
Vaccine Received
Study
Subject Age Group Randomization Randomization
Identifiera Subject (Years) Randomization Date Number Vaccine Group Date Dose 1
10011013 C4591001 1001 10011013 18-55 18MAY2020 1355 Placebo 18MAY2020 Placebo
10011021 C4591001 1001 10011021 18-55 20MAY2020 1356 Placebo 20MAY2020 Placebo
10011026 C4591001 1001 10011026 18-55 18MAY2020 1354 BNT162b1 18MAY2020 BNT162b1
(100 μg) (100 μg)
10011028 C4591001 1001 10011028 18-55 20MAY2020 1359 BNT162b1 20MAY2020 BNT162b1
(100 μg) (100 μg)
10011030 C4591001 1001 10011030 18-55 20MAY2020 1357 BNT162b1 20MAY2020 BNT162b1
(100 μg) (100 μg)
10011032 C4591001 1001 10011032 18-55 20MAY2020 1360 BNT162b1 20MAY2020 BNT162b1
(100 μg) (100 μg)
10011034 C4591001 1001 10011034 18-55 20MAY2020 1358 BNT162b1 20MAY2020 BNT162b1
(100 μg) (100 μg)
10021023 C4591001 1002 10021023 18-55 18MAY2020 1352 BNT162b1 18MAY2020 BNT162b1
(100 μg) (100 μg)
10021024 C4591001 1002 10021024 18-55 18MAY2020 1353 BNT162b1 18MAY2020 BNT162b1
(100 μg) (100 μg)
10021027 C4591001 1002 10021027 18-55 18MAY2020 1351 BNT162b1 18MAY2020 BNT162b1
(100 μg) (100 μg)
10021034 C4591001 1002 10021034 18-55 21MAY2020 1363 BNT162b1 21MAY2020 BNT162b1
(100 μg) (100 μg)
)TMG(
42:41
0202-peS-22
:nO
laniF\laniF\705cbf491e771090
FDA-CBER-2021-5683-0024776
Page 14
16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1 – BNT162b1 (100 μg)
Vaccine Received
Study
Subject Age Group Randomization Randomization
Identifiera Subject (Years) Randomization Date Number Vaccine Group Date Dose 1
10021035 C4591001 1002 10021035 18-55 21MAY2020 1361 BNT162b1 21MAY2020 BNT162b1
(100 μg) (100 μg)
10021036 C4591001 1002 10021036 18-55 21MAY2020 1364 BNT162b1 21MAY2020 BNT162b1
(100 μg) (100 μg)
10021038 C4591001 1002 10021038 18-55 21MAY2020 1365 BNT162b1 21MAY2020 BNT162b1
(100 μg) (100 μg)
10021041 C4591001 1002 10021041 18-55 21MAY2020 1362 Placebo 21MAY2020 Placebo
a. Subject Study Identifier = the subject number is the current study 4-digit site number followed by unique 4-digit subject identifier.
PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 19SEP2020 (10:20)
(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: ./nda3/C4591001 IA P1 100/adsl l003 100 p1
)TMG(
42:41
0202-peS-22
:nO
laniF\laniF\705cbf491e771090
FDA-CBER-2021-5683-0024777
Page 15","[[['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10011004', None, 'C4591001 1001', '18-55', '04MAY2020', '1084', 'BNT162b1', '04MAY2020', 'BNT162b1', '26MAY2020', 'BNT162b1\n(10 μg)', None], [None, '', '10011004', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011005', 'C4591001 1001', '18-55', '06MAY2020', '1093', 'Placebo', '06MAY2020', 'Placebo', '26MAY2020', 'Placebo', ''], [None, '', '10011005', '', '', '', '', '', '', '', '', None], ['', '10011006', 'C4591001 1001', '18-55', '06MAY2020', '1090', 'BNT162b1', '06MAY2020', 'BNT162b1', '27MAY2020', 'BNT162b1', ''], [None, '', '10011006', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011007', 'C4591001 1001', '18-55', '06MAY2020', '1092', 'BNT162b1', '06MAY2020', 'BNT162b1', '28MAY2020', 'BNT162b1', ''], [None, '', '10011007', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011008', 'C4591001 1001', '18-55', '06MAY2020', '1094', 'BNT162b1', '06MAY2020', 'BNT162b1', '27MAY2020', 'BNT162b1', ''], [None, '', '10011008', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011009', 'C4591001 1001', '18-55', '06MAY2020', '1095', 'BNT162b1', '06MAY2020', 'BNT162b1', '27MAY2020', 'BNT162b1', ''], [None, '', '10011009', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011011', 'C4591001 1001', '18-55', '11MAY2020', '1220', 'BNT162b1', '11MAY2020', 'BNT162b1', '01JUN2020', 'BNT162b1', ''], [None, '', '10011011', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011012', 'C4591001 1001', '18-55', '13MAY2020', '1230', 'BNT162b1', '13MAY2020', 'BNT162b1', '03JUN2020', 'BNT162b1', ''], [None, '', '10011012', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011015', 'C4591001 1001', '18-55', '11MAY2020', '1219', 'BNT162b1', '11MAY2020', 'BNT162b1', '01JUN2020', 'BNT162b1', ''], [None, '', '10011015', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011017', 'C4591001 1001', '18-55', '13MAY2020', '1228', 'BNT162b1', '13MAY2020', 'BNT162b1', '03JUN2020', 'BNT162b1', ''], [None, '', '10011017', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011019', 'C4591001 1001', '18-55', '13MAY2020', '1229', 'BNT162b1', '13MAY2020', 'BNT162b1', '03JUN2020', 'BNT162b1', ''], [None, '', '10011019', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011020', 'C4591001 1001', '18-55', '13MAY2020', '1226', 'BNT162b1', '13MAY2020', 'BNT162b1', '03JUN2020', 'BNT162b1', ''], [None, '', '10011020', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011024', 'C4591001 1001', '18-55', '13MAY2020', '1225', 'BNT162b1', '13MAY2020', 'BNT162b1', '03JUN2020', 'BNT162b1', ''], [None, '', '10011024', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011037', 'C4591001 1001', '65-85', '11JUN2020', '1631', 'BNT162b1', '11JUN2020', 'BNT162b1', '30JUN2020', 'BNT162b1', ''], [None, '', '10011037', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10011039', None, 'C4591001 1001', '65-85', '09JUN2020', '1624', 'BNT162b1', '09JUN2020', 'BNT162b1', '29JUN2020', 'BNT162b1\n(10 μg)', None], [None, '', '10011039', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011040', 'C4591001 1001', '65-85', '11JUN2020', '1635', 'BNT162b1', '11JUN2020', 'BNT162b1', '02JUL2020', 'BNT162b1', ''], [None, '', '10011040', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011041', 'C4591001 1001', '65-85', '11JUN2020', '1632', 'BNT162b1', '11JUN2020', 'BNT162b1', '02JUL2020', 'BNT162b1', ''], [None, '', '10011041', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011042', 'C4591001 1001', '65-85', '11JUN2020', '1634', 'Placebo', '11JUN2020', 'Placebo', '30JUN2020', 'Placebo', ''], [None, '', '10011042', '', '', '', '', '', '', '', '', None], ['', '10011043', 'C4591001 1001', '65-85', '15JUN2020', '2029', 'BNT162b1', '15JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10011043', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10011044', 'C4591001 1001', '65-85', '09JUN2020', '1625', 'BNT162b1', '09JUN2020', 'BNT162b1', '29JUN2020', 'BNT162b1', ''], [None, '', '10011044', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011045', 'C4591001 1001', '65-85', '11JUN2020', '1633', 'BNT162b1', '11JUN2020', 'BNT162b1', '02JUL2020', 'BNT162b1', ''], [None, '', '10011045', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10011046', 'C4591001 1001', '65-85', '18JUN2020', '1767', 'BNT162b1', '18JUN2020', 'BNT162b1', '09JUL2020', 'BNT162b1', ''], [None, '', '10011046', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011048', 'C4591001 1001', '65-85', '16JUN2020', '1759', 'BNT162b1', '16JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10011048', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011049', 'C4591001 1001', '65-85', '15JUN2020', '2030', 'BNT162b1', '15JUN2020', 'BNT162b1', '06JUL2020', 'BNT162b1', ''], [None, '', '10011049', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10011050', 'C4591001 1001', '65-85', '17JUN2020', '2031', 'BNT162b1', '17JUN2020', 'BNT162b1', '07JUL2020', 'BNT162b1', ''], [None, '', '10011050', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10011052', 'C4591001 1001', '65-85', '17JUN2020', '2037', 'BNT162b1', '17JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10011052', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10011053', 'C4591001 1001', '65-85', '16JUN2020', '1760', 'Placebo', '16JUN2020', 'Placebo', '09JUL2020', 'Placebo', ''], [None, '', '10011053', '', '', '', '', '', '', '', '', None], ['', '10011055', 'C4591001 1001', '65-85', '17JUN2020', '2039', 'BNT162b1', '17JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10011055', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10011057', None, 'C4591001 1001', '65-85', '17JUN2020', '2038', 'Placebo', '17JUN2020', 'Placebo', '08JUL2020', 'Placebo', None], [None, '', '10011057', '', '', '', '', '', '', '', '', None], ['', '10011058', 'C4591001 1001', '65-85', '18JUN2020', '1768', 'BNT162b1', '18JUN2020', 'BNT162b1', '09JUL2020', 'BNT162b1', ''], [None, '', '10011058', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011059', 'C4591001 1001', '65-85', '17JUN2020', '2040', 'BNT162b1', '17JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10011059', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10011061', 'C4591001 1001', '65-85', '18JUN2020', '1765', 'BNT162b1', '18JUN2020', 'BNT162b1', '09JUL2020', 'BNT162b1', ''], [None, '', '10011061', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011063', 'C4591001 1001', '65-85', '18JUN2020', '1769', 'BNT162b1', '18JUN2020', 'BNT162b1', '07JUL2020', 'BNT162b1', ''], [None, '', '10011063', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10011064', 'C4591001 1001', '65-85', '18JUN2020', '1770', 'Placebo', '18JUN2020', 'Placebo', '07JUL2020', 'Placebo', ''], [None, '', '10011064', '', '', '', '', '', '', '', '', None], ['', '10011066', 'C4591001 1001', '18-55', '29JUN2020', '1489', 'Placebo', '29JUN2020', 'Placebo', '20JUL2020', 'Placebo', ''], [None, '', '10011066', '', '', '', '', '', '', '', '', None], ['', '10011067', 'C4591001 1001', '18-55', '01JUL2020', '1499', 'BNT162b1', '01JUL2020', 'BNT162b1', '22JUL2020', 'BNT162b1', ''], [None, '', '10011067', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10011068', 'C4591001 1001', '18-55', '29JUN2020', '1490', 'BNT162b1', '29JUN2020', 'BNT162b1', '20JUL2020', 'BNT162b1', ''], [None, '', '10011068', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10011069', 'C4591001 1001', '18-55', '01JUL2020', '1496', 'Placebo', '01JUL2020', 'Placebo', '22JUL2020', 'Placebo', ''], [None, '', '10011069', '', '', '', '', '', '', '', '', None], ['', '10011070', 'C4591001 1001', '18-55', '01JUL2020', '1500', 'BNT162b1', '01JUL2020', 'BNT162b1', '22JUL2020', 'BNT162b1', ''], [None, '', '10011070', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10011071', 'C4591001 1001', '18-55', '01JUL2020', '1497', 'BNT162b1', '01JUL2020', 'BNT162b1', '22JUL2020', 'BNT162b1', ''], [None, '', '10011071', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10011076', 'C4591001 1001', '18-55', '01JUL2020', '1498', 'BNT162b1', '01JUL2020', 'BNT162b1', '21JUL2020', 'BNT162b1', ''], [None, '', '10011076', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021003', 'C4591001 1002', '18-55', '04MAY2020', '1081', 'BNT162b1', '04MAY2020', 'BNT162b1', '26MAY2020', 'BNT162b1', ''], [None, '', '10021003', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10021004', None, 'C4591001 1002', '18-55', '04MAY2020', '1082', 'BNT162b1', '04MAY2020', 'BNT162b1', '26MAY2020', 'BNT162b1\n(10 μg)', None], [None, '', '10021004', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021005', 'C4591001 1002', '18-55', '04MAY2020', '1083', 'Placebo', '04MAY2020', 'Placebo', '26MAY2020', 'Placebo', ''], [None, '', '10021005', '', '', '', '', '', '', '', '', None], ['', '10021006', 'C4591001 1002', '18-55', '11MAY2020', '1218', 'BNT162b1', '11MAY2020', 'BNT162b1', '02JUN2020', 'BNT162b1', ''], [None, '', '10021006', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021007', 'C4591001 1002', '18-55', '06MAY2020', '1089', 'BNT162b1', '06MAY2020', 'BNT162b1', '26MAY2020', 'BNT162b1', ''], [None, '', '10021007', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021008', 'C4591001 1002', '18-55', '06MAY2020', '1088', 'Placebo', '06MAY2020', 'Placebo', '26MAY2020', 'Placebo', ''], [None, '', '10021008', '', '', '', '', '', '', '', '', None], ['', '10021009', 'C4591001 1002', '18-55', '06MAY2020', '1091', 'BNT162b1', '06MAY2020', 'BNT162b1', '26MAY2020', 'BNT162b1', ''], [None, '', '10021009', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021011', 'C4591001 1002', '18-55', '06MAY2020', '1086', 'BNT162b1', '06MAY2020', 'BNT162b1', '26MAY2020', 'BNT162b1', ''], [None, '', '10021011', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021012', 'C4591001 1002', '18-55', '05MAY2020', '1085', 'BNT162b1', '05MAY2020', 'BNT162b1', '26MAY2020', 'BNT162b1', ''], [None, '', '10021012', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021013', 'C4591001 1002', '18-55', '06MAY2020', '1087', 'BNT162b1', '06MAY2020', 'BNT162b1', '26MAY2020', 'BNT162b1', ''], [None, '', '10021013', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021014', 'C4591001 1002', '18-55', '13MAY2020', '1224', 'BNT162b1', '13MAY2020', 'BNT162b1', '02JUN2020', 'BNT162b1', ''], [None, '', '10021014', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021015', 'C4591001 1002', '18-55', '11MAY2020', '1216', 'BNT162b1', '11MAY2020', 'BNT162b1', '02JUN2020', 'BNT162b1', ''], [None, '', '10021015', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021017', 'C4591001 1002', '18-55', '13MAY2020', '1221', 'BNT162b1', '13MAY2020', 'BNT162b1', '02JUN2020', 'BNT162b1', ''], [None, '', '10021017', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021018', 'C4591001 1002', '18-55', '11MAY2020', '1217', 'Placebo', '11MAY2020', 'Placebo', '02JUN2020', 'Placebo', ''], [None, '', '10021018', '', '', '', '', '', '', '', '', None], ['', '10021020', 'C4591001 1002', '18-55', '13MAY2020', '1222', 'BNT162b1', '13MAY2020', 'BNT162b1', '02JUN2020', 'BNT162b1', ''], [None, '', '10021020', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10021021', None, 'C4591001 1002', '18-55', '13MAY2020', '1223', 'Placebo', '13MAY2020', 'Placebo', '02JUN2020', 'Placebo', None], [None, '', '10021021', '', '', '', '', '', '', '', '', None], ['', '10021022', 'C4591001 1002', '18-55', '13MAY2020', '1227', 'Placebo', '13MAY2020', 'Placebo', '02JUN2020', 'Placebo', ''], [None, '', '10021022', '', '', '', '', '', '', '', '', None], ['', '10021042', 'C4591001 1002', '65-85', '09JUN2020', '1623', 'Placebo', '09JUN2020', 'Placebo', '30JUN2020', 'Placebo', ''], [None, '', '10021042', '', '', '', '', '', '', '', '', None], ['', '10021043', 'C4591001 1002', '65-85', '09JUN2020', '1621', 'BNT162b1', '09JUN2020', 'BNT162b1', '30JUN2020', 'BNT162b1', ''], [None, '', '10021043', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021044', 'C4591001 1002', '65-85', '09JUN2020', '1622', 'BNT162b1', '09JUN2020', 'BNT162b1', '30JUN2020', 'BNT162b1', ''], [None, '', '10021044', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021045', 'C4591001 1002', '65-85', '11JUN2020', '1629', 'BNT162b1', '11JUN2020', 'BNT162b1', '30JUN2020', 'BNT162b1', ''], [None, '', '10021045', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021047', 'C4591001 1002', '65-85', '11JUN2020', '1626', 'Placebo', '11JUN2020', 'Placebo', '30JUN2020', 'Placebo', ''], [None, '', '10021047', '', '', '', '', '', '', '', '', None], ['', '10021049', 'C4591001 1002', '65-85', '11JUN2020', '1630', 'BNT162b1', '11JUN2020', 'BNT162b1', '30JUN2020', 'BNT162b1', ''], [None, '', '10021049', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021050', 'C4591001 1002', '65-85', '15JUN2020', '2026', 'Placebo', '15JUN2020', 'Placebo', '07JUL2020', 'Placebo', ''], [None, '', '10021050', '', '', '', '', '', '', '', '', None], ['', '10021052', 'C4591001 1002', '65-85', '11JUN2020', '1628', 'BNT162b1', '11JUN2020', 'BNT162b1', '30JUN2020', 'BNT162b1', ''], [None, '', '10021052', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021053', 'C4591001 1002', '65-85', '11JUN2020', '1627', 'BNT162b1', '11JUN2020', 'BNT162b1', '30JUN2020', 'BNT162b1', ''], [None, '', '10021053', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10021054', 'C4591001 1002', '65-85', '15JUN2020', '2028', 'BNT162b1', '15JUN2020', 'BNT162b1', '07JUL2020', 'BNT162b1', ''], [None, '', '10021054', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021059', 'C4591001 1002', '65-85', '15JUN2020', '1757', 'BNT162b1', '15JUN2020', 'BNT162b1', '07JUL2020', 'BNT162b1', ''], [None, '', '10021059', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021060', 'C4591001 1002', '65-85', '15JUN2020', '2027', 'BNT162b1', '15JUN2020', 'BNT162b1', '07JUL2020', 'BNT162b1', ''], [None, '', '10021060', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10021062', None, 'C4591001 1002', '65-85', '15JUN2020', '1756', 'BNT162b1', '15JUN2020', 'BNT162b1', '07JUL2020', 'BNT162b1\n(30 μg)', None], [None, '', '10021062', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021063', 'C4591001 1002', '65-85', '15JUN2020', '1758', 'BNT162b1', '15JUN2020', 'BNT162b1', '07JUL2020', 'BNT162b1', ''], [None, '', '10021063', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021064', 'C4591001 1002', '65-85', '17JUN2020', '2034', 'BNT162b1', '17JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10021064', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021067', 'C4591001 1002', '65-85', '17JUN2020', '2032', 'BNT162b1', '17JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10021067', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021068', 'C4591001 1002', '65-85', '17JUN2020', '2035', 'BNT162b1', '17JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10021068', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021069', 'C4591001 1002', '65-85', '18JUN2020', '1764', 'BNT162b1', '18JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10021069', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021071', 'C4591001 1002', '65-85', '17JUN2020', '2036', 'BNT162b1', '17JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10021071', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021072', 'C4591001 1002', '65-85', '18JUN2020', '1761', 'Placebo', '18JUN2020', 'Placebo', '08JUL2020', 'Placebo', ''], [None, '', '10021072', '', '', '', '', '', '', '', '', None], ['', '10021073', 'C4591001 1002', '65-85', '17JUN2020', '2033', 'Placebo', '17JUN2020', 'Placebo', '08JUL2020', 'Placebo', ''], [None, '', '10021073', '', '', '', '', '', '', '', '', None], ['', '10021074', 'C4591001 1002', '65-85', '18JUN2020', '1762', 'BNT162b1', '18JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10021074', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021075', 'C4591001 1002', '65-85', '18JUN2020', '1766', 'BNT162b1', '18JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10021075', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021077', 'C4591001 1002', '65-85', '18JUN2020', '1763', 'BNT162b1', '18JUN2020', 'BNT162b1', '08JUL2020', 'BNT162b1', ''], [None, '', '10021077', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10021079', 'C4591001 1002', '18-55', '29JUN2020', '1487', 'BNT162b1', '29JUN2020', 'BNT162b1', '21JUL2020', 'BNT162b1', ''], [None, '', '10021079', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021080', 'C4591001 1002', '18-55', '01JUL2020', '1491', 'BNT162b1', '01JUL2020', 'BNT162b1', '21JUL2020', 'BNT162b1', ''], [None, '', '10021080', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10021081', None, 'C4591001 1002', '18-55', '01JUL2020', '1492', 'BNT162b1', '01JUL2020', 'BNT162b1', '21JUL2020', 'BNT162b1\n(20 μg)', None], [None, '', '10021081', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021082', 'C4591001 1002', '18-55', '01JUL2020', '1494', 'BNT162b1', '01JUL2020', 'BNT162b1', '21JUL2020', 'BNT162b1', ''], [None, '', '10021082', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021083', 'C4591001 1002', '18-55', '01JUL2020', '1495', 'Placebo', '01JUL2020', 'Placebo', '21JUL2020', 'Placebo', ''], [None, '', '10021083', '', '', '', '', '', '', '', '', None], ['', '10021084', 'C4591001 1002', '18-55', '29JUN2020', '1488', 'BNT162b1', '29JUN2020', 'BNT162b1', '21JUL2020', 'BNT162b1', ''], [None, '', '10021084', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021085', 'C4591001 1002', '18-55', '29JUN2020', '1486', 'BNT162b1', '29JUN2020', 'BNT162b1', '21JUL2020', 'BNT162b1', ''], [None, '', '10021085', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10021087', 'C4591001 1002', '18-55', '01JUL2020', '1493', 'BNT162b1', '01JUL2020', 'BNT162b1', '21JUL2020', 'BNT162b1', ''], [None, '', '10021087', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031016', 'C4591001 1003', '18-55', '09JUN2020', '2164', 'Placebo', '09JUN2020', 'Placebo', '30JUN2020', 'Placebo', ''], [None, '', '10031016', '', '', '', '', '', '', '', '', None], ['', '10031017', 'C4591001 1003', '18-55', '11JUN2020', '2172', 'Placebo', '11JUN2020', 'Placebo', '02JUL2020', 'Placebo', ''], [None, '', '10031017', '', '', '', '', '', '', '', '', None], ['', '10031018', 'C4591001 1003', '18-55', '09JUN2020', '2163', 'BNT162b2', '09JUN2020', 'BNT162b2', '30JUN2020', 'BNT162b2', ''], [None, '', '10031018', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031019', 'C4591001 1003', '18-55', '11JUN2020', '2170', 'BNT162b2', '11JUN2020', 'BNT162b2', '02JUL2020', 'BNT162b2', ''], [None, '', '10031019', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031020', 'C4591001 1003', '18-55', '11JUN2020', '2174', 'BNT162b2', '11JUN2020', 'BNT162b2', '02JUL2020', 'BNT162b2', ''], [None, '', '10031020', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031021', 'C4591001 1003', '18-55', '09JUN2020', '2165', 'BNT162b2', '09JUN2020', 'BNT162b2', '30JUN2020', 'BNT162b2', ''], [None, '', '10031021', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031022', 'C4591001 1003', '18-55', '11JUN2020', '2171', 'BNT162b2', '11JUN2020', 'BNT162b2', '02JUL2020', 'BNT162b2', ''], [None, '', '10031022', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031024', 'C4591001 1003', '18-55', '11JUN2020', '2173', 'BNT162b2', '11JUN2020', 'BNT162b2', '02JUL2020', 'BNT162b2', ''], [None, '', '10031024', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10031026', None, 'C4591001 1003', '18-55', '17JUN2020', '2573', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2\n(20 μg)', None], [None, '', '10031026', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031027', 'C4591001 1003', '18-55', '15JUN2020', '2567', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2', ''], [None, '', '10031027', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031028', 'C4591001 1003', '18-55', '15JUN2020', '2566', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2', ''], [None, '', '10031028', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031029', 'C4591001 1003', '18-55', '15JUN2020', '2568', 'Placebo', '15JUN2020', 'Placebo', '06JUL2020', 'Placebo', ''], [None, '', '10031029', '', '', '', '', '', '', '', '', None], ['', '10031030', 'C4591001 1003', '18-55', '17JUN2020', '2575', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10031030', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031031', 'C4591001 1003', '65-85', '15JUN2020', '3109', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2', ''], [None, '', '10031031', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031032', 'C4591001 1003', '18-55', '17JUN2020', '2572', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10031032', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031034', 'C4591001 1003', '18-55', '17JUN2020', '2571', 'Placebo', '17JUN2020', 'Placebo', '08JUL2020', 'Placebo', ''], [None, '', '10031034', '', '', '', '', '', '', '', '', None], ['', '10031035', 'C4591001 1003', '65-85', '15JUN2020', '3108', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2', ''], [None, '', '10031035', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031036', 'C4591001 1003', '65-85', '15JUN2020', '3110', 'Placebo', '15JUN2020', 'Placebo', '06JUL2020', 'Placebo', ''], [None, '', '10031036', '', '', '', '', '', '', '', '', None], ['', '10031037', 'C4591001 1003', '65-85', '16JUN2020', '2840', 'BNT162b2', '16JUN2020', 'BNT162b2', '07JUL2020', 'BNT162b2', ''], [None, '', '10031037', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031038', 'C4591001 1003', '18-55', '17JUN2020', '2574', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10031038', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031043', 'C4591001 1003', '65-85', '16JUN2020', '2838', 'Placebo', '16JUN2020', 'Placebo', '07JUL2020', 'Placebo', ''], [None, '', '10031043', '', '', '', '', '', '', '', '', None], ['', '10031046', 'C4591001 1003', '65-85', '18JUN2020', '2847', 'Placebo', '18JUN2020', 'Placebo', '09JUL2020', 'Placebo', ''], [None, '', '10031046', '', '', '', '', '', '', '', '', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10031047', None, 'C4591001 1003', '65-85', '16JUN2020', '2839', 'BNT162b2', '16JUN2020', 'BNT162b2', '07JUL2020', 'BNT162b2\n(30 μg)', None], [None, '', '10031047', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031050', 'C4591001 1003', '18-55', '22JUN2020', '2297', 'Placebo', '22JUN2020', 'Placebo', '13JUL2020', 'Placebo', ''], [None, '', '10031050', '', '', '', '', '', '', '', '', None], ['', '10031051', 'C4591001 1003', '65-85', '18JUN2020', '2848', 'BNT162b2', '18JUN2020', 'BNT162b2', '09JUL2020', 'BNT162b2', ''], [None, '', '10031051', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031053', 'C4591001 1003', '65-85', '17JUN2020', '3111', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10031053', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031054', 'C4591001 1003', '65-85', '17JUN2020', '3115', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10031054', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031055', 'C4591001 1003', '65-85', '17JUN2020', '3112', 'BNT162b2', '17JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2', ''], [None, '', '10031055', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031056', 'C4591001 1003', '65-85', '18JUN2020', '2844', 'Placebo', '18JUN2020', 'Placebo', '09JUL2020', 'Placebo', ''], [None, '', '10031056', '', '', '', '', '', '', '', '', None], ['', '10031057', 'C4591001 1003', '18-55', '24JUN2020', '2301', 'BNT162b2', '24JUN2020', 'BNT162b2', '15JUL2020', 'BNT162b2', ''], [None, '', '10031057', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031058', 'C4591001 1003', '65-85', '18JUN2020', '2846', 'BNT162b2', '18JUN2020', 'BNT162b2', '09JUL2020', 'BNT162b2', ''], [None, '', '10031058', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031059', 'C4591001 1003', '18-55', '24JUN2020', '2305', 'BNT162b2', '24JUN2020', 'BNT162b2', '15JUL2020', 'BNT162b2', ''], [None, '', '10031059', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031061', 'C4591001 1003', '18-55', '22JUN2020', '2298', 'BNT162b2', '22JUN2020', 'BNT162b2', '13JUL2020', 'BNT162b2', ''], [None, '', '10031061', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031063', 'C4591001 1003', '65-85', '17JUN2020', '3113', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10031063', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10031065', 'C4591001 1003', '18-55', '24JUN2020', '2303', 'BNT162b2', '24JUN2020', 'BNT162b2', '15JUL2020', 'BNT162b2', ''], [None, '', '10031065', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031066', 'C4591001 1003', '18-55', '22JUN2020', '2296', 'BNT162b2', '22JUN2020', 'BNT162b2', '13JUL2020', 'BNT162b2', ''], [None, '', '10031066', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10031067', None, 'C4591001 1003', '65-85', '17JUN2020', '3114', 'Placebo', '17JUN2020', 'Placebo', '08JUL2020', 'Placebo', None], [None, '', '10031067', '', '', '', '', '', '', '', '', None], ['', '10031069', 'C4591001 1003', '65-85', '18JUN2020', '2845', 'BNT162b2', '18JUN2020', 'BNT162b2', '09JUL2020', 'BNT162b2', ''], [None, '', '10031069', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031070', 'C4591001 1003', '18-55', '24JUN2020', '2304', 'Placebo', '24JUN2020', 'Placebo', '15JUL2020', 'Placebo', ''], [None, '', '10031070', '', '', '', '', '', '', '', '', None], ['', '10031072', 'C4591001 1003', '18-55', '24JUN2020', '2302', 'BNT162b2', '24JUN2020', 'BNT162b2', '16JUL2020', 'BNT162b2', ''], [None, '', '10031072', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10031076', 'C4591001 1003', '65-85', '29JUN2020', '2702', 'BNT162b2', '29JUN2020', 'BNT162b2', '20JUL2020', 'BNT162b2', ''], [None, '', '10031076', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031077', 'C4591001 1003', '65-85', '01JUL2020', '2711', 'BNT162b2', '01JUL2020', 'BNT162b2', '22JUL2020', 'BNT162b2', ''], [None, '', '10031077', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031078', 'C4591001 1003', '65-85', '01JUL2020', '2712', 'BNT162b2', '01JUL2020', 'BNT162b2', '22JUL2020', 'BNT162b2', ''], [None, '', '10031078', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031079', 'C4591001 1003', '65-85', '01JUL2020', '2715', 'BNT162b2', '01JUL2020', 'BNT162b2', '22JUL2020', 'BNT162b2', ''], [None, '', '10031079', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031080', 'C4591001 1003', '65-85', '29JUN2020', '2703', 'BNT162b2', '29JUN2020', 'BNT162b2', '20JUL2020', 'BNT162b2', ''], [None, '', '10031080', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10031083', 'C4591001 1003', '65-85', '01JUL2020', '2714', 'Placebo', '01JUL2020', 'Placebo', '22JUL2020', 'Placebo', ''], [None, '', '10031083', '', '', '', '', '', '', '', '', None], ['', '10031087', 'C4591001 1003', '65-85', '01JUL2020', '2713', 'BNT162b2', '01JUL2020', 'BNT162b2', '22JUL2020', 'BNT162b2', ''], [None, '', '10031087', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071014', 'C4591001 1007', '18-55', '11JUN2020', '2175', 'BNT162b2', '11JUN2020', 'BNT162b2', '01JUL2020', 'BNT162b2', ''], [None, '', '10071014', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071015', 'C4591001 1007', '18-55', '08JUN2020', '2161', 'BNT162b2', '08JUN2020', 'BNT162b2', '29JUN2020', 'BNT162b2', ''], [None, '', '10071015', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071016', 'C4591001 1007', '18-55', '10JUN2020', '2166', 'BNT162b2', '10JUN2020', 'BNT162b2', '01JUL2020', 'BNT162b2', ''], [None, '', '10071016', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10071017', None, 'C4591001 1007', '18-55', '15JUN2020', '2569', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2\n(20 μg)', None], [None, '', '10071017', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071019', 'C4591001 1007', '18-55', '08JUN2020', '2162', 'BNT162b2', '08JUN2020', 'BNT162b2', '29JUN2020', 'BNT162b2', ''], [None, '', '10071019', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071020', 'C4591001 1007', '18-55', '10JUN2020', '2167', 'Placebo', '10JUN2020', 'Placebo', '01JUL2020', 'Placebo', ''], [None, '', '10071020', '', '', '', '', '', '', '', '', None], ['', '10071021', 'C4591001 1007', '18-55', '10JUN2020', '2168', 'BNT162b2', '10JUN2020', 'BNT162b2', '01JUL2020', 'BNT162b2', ''], [None, '', '10071021', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071022', 'C4591001 1007', '18-55', '10JUN2020', '2169', 'BNT162b2', '10JUN2020', 'BNT162b2', '01JUL2020', 'BNT162b2', ''], [None, '', '10071022', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071023', 'C4591001 1007', '18-55', '17JUN2020', '2577', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10071023', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071025', 'C4591001 1007', '18-55', '17JUN2020', '2580', 'Placebo', '17JUN2020', 'Placebo', '08JUL2020', 'Placebo', ''], [None, '', '10071025', '', '', '', '', '', '', '', '', None], ['', '10071026', 'C4591001 1007', '18-55', '15JUN2020', '2570', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2', ''], [None, '', '10071026', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071027', 'C4591001 1007', '18-55', '17JUN2020', '2576', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10071027', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071029', 'C4591001 1007', '18-55', '17JUN2020', '2578', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10071029', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071031', 'C4591001 1007', '65-85', '17JUN2020', '3117', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10071031', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071032', 'C4591001 1007', '65-85', '15JUN2020', '3106', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2', ''], [None, '', '10071032', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071034', 'C4591001 1007', '65-85', '15JUN2020', '2836', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2', ''], [None, '', '10071034', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071035', 'C4591001 1007', '65-85', '15JUN2020', '3107', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2', ''], [None, '', '10071035', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10071037', None, 'C4591001 1007', '65-85', '15JUN2020', '2837', 'BNT162b2', '15JUN2020', 'BNT162b2', '06JUL2020', 'BNT162b2\n(30 μg)', None], [None, '', '10071037', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071038', 'C4591001 1007', '65-85', '17JUN2020', '3120', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10071038', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071039', 'C4591001 1007', '65-85', '17JUN2020', '3118', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10071039', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071040', 'C4591001 1007', '18-55', '17JUN2020', '2579', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10071040', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071042', 'C4591001 1007', '65-85', '17JUN2020', '3119', 'Placebo', '17JUN2020', 'Placebo', '08JUL2020', 'Placebo', ''], [None, '', '10071042', '', '', '', '', '', '', '', '', None], ['', '10071043', 'C4591001 1007', '65-85', '18JUN2020', '2843', 'BNT162b2', '18JUN2020', 'BNT162b2', '09JUL2020', 'BNT162b2', ''], [None, '', '10071043', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071044', 'C4591001 1007', '65-85', '18JUN2020', '2841', 'BNT162b2', '18JUN2020', 'BNT162b2', '09JUL2020', 'BNT162b2', ''], [None, '', '10071044', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071045', 'C4591001 1007', '65-85', '18JUN2020', '2842', 'BNT162b2', '18JUN2020', 'BNT162b2', '09JUL2020', 'BNT162b2', ''], [None, '', '10071045', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071046', 'C4591001 1007', '18-55', '22JUN2020', '2299', 'BNT162b2', '22JUN2020', 'BNT162b2', '15JUL2020', 'BNT162b2', ''], [None, '', '10071046', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071049', 'C4591001 1007', '65-85', '18JUN2020', '2849', 'BNT162b2', '18JUN2020', 'BNT162b2', '09JUL2020', 'BNT162b2', ''], [None, '', '10071049', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071050', 'C4591001 1007', '18-55', '22JUN2020', '2300', 'BNT162b2', '22JUN2020', 'BNT162b2', '13JUL2020', 'BNT162b2', ''], [None, '', '10071050', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071051', 'C4591001 1007', '65-85', '29JUN2020', '2701', 'BNT162b2', '29JUN2020', 'BNT162b2', '20JUL2020', 'BNT162b2', ''], [None, '', '10071051', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071052', 'C4591001 1007', '65-85', '17JUN2020', '3116', 'BNT162b2', '17JUN2020', 'BNT162b2', '08JUL2020', 'BNT162b2', ''], [None, '', '10071052', '', '', '', '(20 μg)', '', '(20 μg)', '', '(20 μg)', None], ['', '10071053', 'C4591001 1007', '65-85', '18JUN2020', '2850', 'BNT162b2', '18JUN2020', 'BNT162b2', '09JUL2020', 'BNT162b2', ''], [None, '', '10071053', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None]], [['', None, None, None, None, None, None, None, None, None, None, None], ['', '16.1.7.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart', None, None, None, None, None, None, None, None, None, ''], ['', '', None, None, None, None, None, 'Vaccine Received', None, None, None, ''], ['Subject\nStudy\nIdentifiera', 'Subject', '', 'Age', '', '', '', '', '', '', '', None], [None, 'Study', None, 'Group', 'Randomization', 'Randomization', 'Randomization', None, None, None, None, None], [None, None, 'Subject', '(Years)', 'Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1', 'Date', None, None], ['10071056', None, 'C4591001 1007', '65-85', '29JUN2020', '2704', 'Placebo', '29JUN2020', 'Placebo', '20JUL2020', 'Placebo', None], [None, '', '10071056', '', '', '', '', '', '', '', '', None], ['', '10071057', 'C4591001 1007', '65-85', '30JUN2020', '2706', 'BNT162b2', '30JUN2020', 'BNT162b2', '22JUL2020', 'BNT162b2', ''], [None, '', '10071057', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071058', 'C4591001 1007', '18-55', '24JUN2020', '2309', 'BNT162b2', '24JUN2020', 'BNT162b2', '15JUL2020', 'BNT162b2', ''], [None, '', '10071058', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071063', 'C4591001 1007', '18-55', '24JUN2020', '2306', 'BNT162b2', '24JUN2020', 'BNT162b2', '15JUL2020', 'BNT162b2', ''], [None, '', '10071063', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071064', 'C4591001 1007', '18-55', '24JUN2020', '2307', 'BNT162b2', '24JUN2020', 'BNT162b2', '15JUL2020', 'BNT162b2', ''], [None, '', '10071064', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071065', 'C4591001 1007', '18-55', '24JUN2020', '2308', 'Placebo', '24JUN2020', 'Placebo', '15JUL2020', 'Placebo', ''], [None, '', '10071065', '', '', '', '', '', '', '', '', None], ['', '10071066', 'C4591001 1007', '18-55', '24JUN2020', '2310', 'BNT162b2', '24JUN2020', 'BNT162b2', '15JUL2020', 'BNT162b2', ''], [None, '', '10071066', '', '', '', '(30 μg)', '', '(30 μg)', '', '(30 μg)', None], ['', '10071071', 'C4591001 1007', '65-85', '29JUN2020', '2705', 'BNT162b2', '29JUN2020', 'BNT162b2', '20JUL2020', 'BNT162b2', ''], [None, '', '10071071', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071073', 'C4591001 1007', '65-85', '30JUN2020', '2707', 'BNT162b2', '30JUN2020', 'BNT162b2', '22JUL2020', 'BNT162b2', ''], [None, '', '10071073', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071074', 'C4591001 1007', '65-85', '30JUN2020', '2708', 'BNT162b2', '30JUN2020', 'BNT162b2', '20JUL2020', 'BNT162b2', ''], [None, '', '10071074', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], ['', '10071075', 'C4591001 1007', '65-85', '30JUN2020', '2710', 'Placebo', '30JUN2020', 'Placebo', '22JUL2020', 'Placebo', ''], [None, '', '10071075', '', '', '', '', '', '', '', '', None], ['', '10071077', 'C4591001 1007', '65-85', '30JUN2020', '2709', 'BNT162b2', '30JUN2020', 'BNT162b2', '22JUL2020', 'BNT162b2', ''], [None, '', '10071077', '', '', '', '(10 μg)', '', '(10 μg)', '', '(10 μg)', None], [None, None, '', None, None, None, '', None, '', None, '', None], ['a. Subject Study Identifier = the subject number is the current study 4-digit site number followed by unique 4-digit subject identifier.\nPFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 02SEP2020 (17:24)\n(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: (CDISC)/C4591001_IA_P1/adsl_l003_p1', None, None, None, None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None, None, None, None]], [['PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 02SEP2020 (17:24)'], ['(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: (CDISC)/C4591001_IA_P1/adsl_l003_p1']], [['', None, None, None, None, None, None, None], ['16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1 – BNT162b1 (100 μg)', None, None, None, None, None, None, None], ['', None, None, None, None, None, 'Vaccine Received', None], ['Study', '', '', '', '', '', '', ''], ['Subject', None, 'Age Group', None, 'Randomization', 'Randomization', None, None], ['Identifiera', 'Subject', '(Years)', 'Randomization Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1'], ['10011013', 'C4591001 1001 10011013', '18-55', '18MAY2020', '1355', 'Placebo', '18MAY2020', 'Placebo'], ['10011021', 'C4591001 1001 10011021', '18-55', '20MAY2020', '1356', 'Placebo', '20MAY2020', 'Placebo'], ['10011026', 'C4591001 1001 10011026', '18-55', '18MAY2020', '1354', 'BNT162b1', '18MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10011028', 'C4591001 1001 10011028', '18-55', '20MAY2020', '1359', 'BNT162b1', '20MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10011030', 'C4591001 1001 10011030', '18-55', '20MAY2020', '1357', 'BNT162b1', '20MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10011032', 'C4591001 1001 10011032', '18-55', '20MAY2020', '1360', 'BNT162b1', '20MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10011034', 'C4591001 1001 10011034', '18-55', '20MAY2020', '1358', 'BNT162b1', '20MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10021023', 'C4591001 1002 10021023', '18-55', '18MAY2020', '1352', 'BNT162b1', '18MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10021024', 'C4591001 1002 10021024', '18-55', '18MAY2020', '1353', 'BNT162b1', '18MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10021027', 'C4591001 1002 10021027', '18-55', '18MAY2020', '1351', 'BNT162b1', '18MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10021034', 'C4591001 1002 10021034', '18-55', '21MAY2020', '1363', 'BNT162b1', '21MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None]], [['', None, None, None, None, None, None, None], ['16.1.7.1.1 Listing of Randomization Scheme and Actual Vaccine Received – Phase 1 – BNT162b1 (100 μg)', None, None, None, None, None, None, None], ['', None, None, None, None, None, 'Vaccine Received', None], ['Study', '', '', '', '', '', '', ''], ['Subject', None, 'Age Group', None, 'Randomization', 'Randomization', None, None], ['Identifiera', 'Subject', '(Years)', 'Randomization Date', 'Number', 'Vaccine Group', 'Date', 'Dose 1'], ['10021035', 'C4591001 1002 10021035', '18-55', '21MAY2020', '1361', 'BNT162b1', '21MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10021036', 'C4591001 1002 10021036', '18-55', '21MAY2020', '1364', 'BNT162b1', '21MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10021038', 'C4591001 1002 10021038', '18-55', '21MAY2020', '1365', 'BNT162b1', '21MAY2020', 'BNT162b1'], [None, None, None, None, None, '(100 μg)', None, '(100 μg)'], ['', '', '', '', '', None, '', None], ['10021041', 'C4591001 1002 10021041', '18-55', '21MAY2020', '1362', 'Placebo', '21MAY2020', 'Placebo'], ['', '', '', '', '', '', '', ''], ['a. Subject Study Identifier = the subject number is the current study 4-digit site number followed by unique 4-digit subject identifier.', None, None, None, None, None, None, None], ['PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: adsl Table Generation: 19SEP2020 (10:20)', None, None, None, None, None, None, None], ['(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: ./nda3/C4591001 IA P1 100/adsl l003 100 p1', None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None]]]",15
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_com195lpus-carton-puurs.pdf,1.0,"LOT/EXP:
LOT/EXP:
NOTE:
Area around QR Code is a required
quiet zone.
Nothing is to print within this space.
Code to scan as:
https://www.pfi.sr/comirnaty
SUPL591MOC
SUPL591MOC
NDC 0069-1000-02
Suspension for Intramuscular Injection
195 Multiple Dose Vials
(after dilution each vial contains 6 doses of 0.3 mL)
STORAGE: Prior to dilution, store at -90°C to -60°C (-130°F to -76°F).
Store in this carton to protect from light.
DOSAGE AND ADMINISTRATION:
After dilution, each vial contains 6 doses of 0.3 mL.
See prescribing information or scan QR code.
MUST BE DILUTED BEFORE USE with sterile 0.9% Sodium Chloride Injection,
USP (supplied separately).
After dilution, store the vaccine at 2°C to 25°C (35°F to 77°F). Discard after 6 hours.
Contains no preservative. Rx only
Manufactured for
BioNTech
Manufacturing GmbH
An der Goldgrube 12
55131 Mainz, Germany Manufactured by
Pfizer Inc.
New York, NY 10017
US License No. XXXX
MUST BE DILUTED
BEFORE USE with sterile 0.9% Sodium
Suspension for Intramuscular Injection Chloride Injection,
195 Multiple Dose Vials USP (supplied (after dilution each vial contains 6 doses of 0.3 mL) separately).
STORAGE: Prior to dilution, store at A stf ote rer d thil eu t vio an c, c ine
-90°C to -60°C (-130°F to -76°F). at 2°C to 25°C
Store in this carton to protect from light. (35°F to 77°F).
DOSAGE AND ADMINISTRATION: Discard after 6 hours.
After dilution, each vial contains 6 doses of 0.3 mL. Contains no
See prescribing information or scan QR code. preservative.
120000196003
Comirnaty Carton Label COM195LPUS - Puurs 14P April 23, 2021 am
Black PMS 7671 PMS 2162 PMS 7597
BOTCHFZRINECPIEBONEHPZRBNTCHFERONECPIEBOTEHFZRBNTCHFER
M
A-CPU
OPF
Comirnaty Carton Label COM195LPUS - Puurs_14.pdf 1 4/23/21 1:44 PM
FPO
)TMG(
90:30
1202-yaM-11
:nO
devorppA\devorppA\dc9200791e771090
FDA-CBER-2021-5683-0225025","[[['000-02\n120000196003\nsion for Intramuscular Injection A-CPU\nultiple Dose Vials\nution each vial contains 6 doses of 0.3 mL) OPF\nE: Prior to dilution, store at -90°C to -60°C (-130°F to -76°F).\nis carton to protect from light.\nAND ADMINISTRATION:\nion, each vial contains 6 doses of 0.3 mL.\nribing information or scan QR code.\nDILUTED BEFORE USE with sterile 0.9% Sodium Chloride Injection,\nplied separately).\nion, store the vaccine at 2°C to 25°C (35°F to 77°F). Discard after 6 hours.\nno preservative. Rx only\nLOT/EXP:\nSUPL591MOC Manufactured for\nBioNTech\nManufacturing GmbH\nAn der Goldgrube 12\n55131 Mainz, Germany O\nManufactured by\nPfizer Inc.\nNew York, NY 10017\nUS License No. XXXX\nBOTCHFZRINECPIEBONEHPZRBNTCHFERONECPIEBOTEHFZRBNTCHFER', None, None], ['MUST BE DILUTED LOT/EXP:\nBEFORE USE with', None, None], ['M sterile 0.9% Sodium\nIntramuscular Injection Chloride Injection,\nose Vials USP (supplied\nch vial contains 6 doses of 0.3 mL) separately).\no dilution, store at A stf ote rer d thil eu t vio an c, c ine\n130°F to -76°F). at 2°C to 25°C\nn to protect from light. (35°F to 77°F).\nMINISTRATION: Discard after 6 hours\nh vial contains 6 doses of 0.3 mL. Contains no\nformation or scan QR code. preservative.', 'SUPL591MOC\n.', '']], [['SUPL591MOC', 'LOT/EXP:'], [None, '']]]",1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-compliance-sensitive.pdf,2.0,"16.2.5.1 Listing of Subjects Who Received Vaccine Not as Randomized – All Subjects ≥16 Years of Age
Vaccine Group Age Group Randomization Vaccination Dose
(as Randomized) (Years) Subject Date Date No. Vaccine Received
BNT162b2 (30 μg) 16-55 C4591001 1012 10121103 01SEP2020 22SEP2020 2 Placebo
16-55 C4591001 1088 10881077 21AUG2020 11SEP2020 2 Placebo
16-55 C4591001 1116 11161226 11SEP2020 11SEP2020 1 Placebo
16-55 C4591001 1116 11161226 11SEP2020 02OCT2020 2 Placebo
16-55 C4591001 1163 11631006 31JUL2020 31JUL2020 1
>55 C4591001 1081 10811053 17AUG2020 09SEP2020 2 Placebo
>55 C4591001 1121 11211071 22SEP2020 03SEP2020 1 Placebo
>55 C4591001 1121 11211071 22SEP2020 22SEP2020 2 Placebo
>55 C4591001 1129 11291091 11AUG2020 01SEP2020 2
>55 C4591001 1163 11631005 31JUL2020 31JUL2020 1
Placebo 16-55 C4591001 1079 10791130 17AUG2020 17AUG2020 1 BNT162b2 (30 μg)
16-55 C4591001 1090 10901334 03SEP2020 03SEP2020 1 BNT162b2 (30 μg)
16-55 C4591001 1090 10901334 03SEP2020 24SEP2020 2 BNT162b2 (30 μg)
>55 C4591001 1054 10541024 21AUG2020 10OCT2020 2 BNT162b2 (30 μg)
>55 C4591001 1163 11631008 31JUL2020 31JUL2020 1
>55 C4591001 1177 11771089 19AUG2020 09SEP2020 2 BNT162b2 (30 μg)
>55 C4591001 1231 12311057 11AUG2020 11AUG2020 1 BNT162b2 (30 μg)
>55 C4591001 1265 12651026 31AUG2020 31AUG2020 1 BNT162b2 (30 μg)
>55 C4591001 1265 12651026 31AUG2020 21SEP2020 2 BNT162b2 (30 μg)
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:45)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adsl l001 p3 rand notvax
)TMG(
65:31
1202-rpA-10
:nO
laniF\laniF\8037fa691e771090
FDA-CBER-2021-5683-0220371
Page 1
16.2.5.2 Listing of Subjects With Indeterminate Vaccine – All Subjects ≥16 Years of Age
Age Group
(Years) Subject Comments
16-55 C4591001 1163 11631006 Vaccinated per CRF but actual treatment not confirmed in IRT.
>55 C4591001 1163 11631005 Vaccinated per CRF but actual treatment not confirmed in IRT.
C4591001 1163 11631008 Vaccinated per CRF but actual treatment not confirmed in IRT.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:45)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA/adsl_l001_iv
)TMG(
65:31
1202-rpA-10
:nO
laniF\laniF\2237fa691e771090
FDA-CBER-2021-5683-0220372
Page 2","[[['', None, None, None, None, None, None, None, None], ['16.2.5.1 Listing of Subjects Who Received Vaccine Not as Randomized – All Subjects ≥16 Years of Age', None, None, None, None, None, None, None, None], ['Vaccine Group\n(as Randomized)', 'Vaccine Group', 'Age Group', '', 'Randomization', 'Vaccination', 'Dose', '', None], [None, None, '(Years)', 'Subject', 'Date', 'Date', 'No.', None, None], ['BNT162b2 (30 μg)', None, '16-55', 'C4591001 1012 10121103', '01SEP2020', '22SEP2020', '2', 'Placebo', None], ['', '', '16-55', 'C4591001 1088 10881077', '21AUG2020', '11SEP2020', '2', 'Placebo', ''], ['', '', '16-55', 'C4591001 1116 11161226', '11SEP2020', '11SEP2020', '1', 'Placebo', ''], ['', '', '16-55', 'C4591001 1116 11161226', '11SEP2020', '02OCT2020', '2', 'Placebo', ''], ['', '', '16-55', 'C4591001 1163 11631006', '31JUL2020', '31JUL2020', '1', '', ''], ['', '', '>55', 'C4591001 1081 10811053', '17AUG2020', '09SEP2020', '2', 'Placebo', ''], ['', '', '>55', 'C4591001 1121 11211071', '22SEP2020', '03SEP2020', '1', 'Placebo', ''], ['', '', '>55', 'C4591001 1121 11211071', '22SEP2020', '22SEP2020', '2', 'Placebo', ''], ['', '', '>55', 'C4591001 1129 11291091', '11AUG2020', '01SEP2020', '2', '', ''], ['', '', '>55', 'C4591001 1163 11631005', '31JUL2020', '31JUL2020', '1', '', ''], ['', 'Placebo', '16-55', 'C4591001 1079 10791130', '17AUG2020', '17AUG2020', '1', 'BNT162b2 (30 μg)', ''], ['', '', '16-55', 'C4591001 1090 10901334', '03SEP2020', '03SEP2020', '1', 'BNT162b2 (30 μg)', ''], ['', '', '16-55', 'C4591001 1090 10901334', '03SEP2020', '24SEP2020', '2', 'BNT162b2 (30 μg)', ''], ['', '', '>55', 'C4591001 1054 10541024', '21AUG2020', '10OCT2020', '2', 'BNT162b2 (30 μg)', ''], ['', '', '>55', 'C4591001 1163 11631008', '31JUL2020', '31JUL2020', '1', '', ''], ['', '', '>55', 'C4591001 1177 11771089', '19AUG2020', '09SEP2020', '2', 'BNT162b2 (30 μg)', ''], ['', '', '>55', 'C4591001 1231 12311057', '11AUG2020', '11AUG2020', '1', 'BNT162b2 (30 μg)', ''], ['', '', '>55', 'C4591001 1265 12651026', '31AUG2020', '31AUG2020', '1', 'BNT162b2 (30 μg)', ''], ['', '', '>55', 'C4591001 1265 12651026', '31AUG2020', '21SEP2020', '2', 'BNT162b2 (30 μg)', ''], [None, '', '', '', '', '', '', '', None], ['PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:45)\n(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adsl l001 p3 rand notvax', None, None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None, None]], [['', None, None, None, None], ['', '16.2.5.2 Listing of Subjects With Indeterminate Vaccine – All Subjects ≥16 Years of Age', None, None, ''], ['Age Group\n(Years)', 'Age Group', '', '', None], [None, None, 'Subject', None, None], ['16-55', None, 'C4591001 1163 11631006', 'Vaccinated per CRF but actual treatment not confirmed in IRT.', None], ['', '>55', 'C4591001 1163 11631005', 'Vaccinated per CRF but actual treatment not confirmed in IRT.', ''], ['', '', 'C4591001 1163 11631008', 'Vaccinated per CRF but actual treatment not confirmed in IRT.', ''], [None, '', '', '', None], ['', 'PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:45)', None, None, ''], [None, '(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA/adsl_l001_iv', None, None, None], ['', None, None, None, None]]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_comvlabkz-vial-kzoo.pdf,1.0,"LOT/EXP COMVLABKZ
GS1 DataBar Code Scans as:
(01)10300691000011
10-0001-9600
CDN
raB ataD 1SG
OPF
Comirnaty Label COMVLABKZ - Kzoo_14.pdf 1 3/22/21 9:38 AM
Comirnaty Label - Kzoo COMVLABKZ 14P March 22, 2021 am
Black PMS 7671
Body text point size - 3.3pt.
TM Rx only
Afer dlution, vial contains 6 doses of 03 mL For inramuscular use Conains no preservaive DLUTE BEFORE USE Discard 6 hours after dilution when sored at 2 to 25ºC (35 o 77ºF)
Dlution date and time:
US License No XXXX BioNTech Manufacturing GmbH & Pfizer Inc
)TMG(
33:30
1202-yaM-01
:nO
devorppA\devorppA\c182df691e771090
FDA-CBER-2021-5683-0225026",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_comvlabp-vial-puurs.pdf,1.0,"After dilution, vial contains 6 doses of 0.3 mL
GS1 DataBar Code Scans as:
(01)10300691000011
raB ataD 1SG
OPF
For ntramuscular use Contains no preservative DILUTE BEFORE USE Dscard 6 hours after dluion when stored at 2 to 25ºC (35 to 77ºF)
Diuton date and ime:
US Lcense No XXXX BoNTech Manufacturing GmbH & Pfizer Inc
10-0001-9600
CDN
TM Rx only LOT/EXP: COMVLABP
Comirnaty Label COMVLABP - Puurs_14.pdf 1 3/22/21 9:36 AM
Comirnaty Label COMVLABP - Puurs 14P March 22, 2021 am
Black PMS 7671
Body text point size - 3.3pt.
)TMG(
04:30
1202-yaM-01
:nO
devorppA\devorppA\c183df691e771090
FDA-CBER-2021-5683-0225027",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-interlab-standard.pdf,1.0,"Protocol C4591001
16.1.10 List of Laboratories Under Vaccine Research & Development Oversight
List of Laboratories – Interim – 6Month Update
Organization Address Service(s)Provided
Pfizer Vaccine Research & 401 NorthMiddletown Road S1-binding IgG level assay;
Development Pearl River, NY 10965 RBD-binding IgG level assay;
USA N-binding antibodyassay; and
RT-PCRon nasal swabsfor
SARS-CoV-2
Pfizer Vaccine Research & 111 Ideation Way SARS-CoV-2 neutralization
Developmenta Nutley, NJ 07110 assay -NT50
USA
University of Texas Medical Department of Biochemistry & SARS-CoV-2 neutralization
Branchb Molecular Biology assay -NT50
Universityof Texas Medical
Branch
5.136 Medical Research
Building (L15532)
Galveston, TX 77555-1055
USA
Abbreviations: IgG = immunoglobulin G; N= SARS-CoV-2nucleoprotein;NT50= 50%neutralizing
titer;RBD= receptor-binding domain;RT-PCR=reverse transcription–polymerasechain reaction;
S1=spikeproteinS1subunit;SARS-CoV-2= severe acute respiratory syndromecoronavirus 2.
Note: The laboratories listed are those under Pfizer Vaccine Research & Developmentoversight. See
Appendix 16.1.4.2.List of Contract Research Organizations,Vendors,and Service Providers,for all
other external laboratories.
a. Pfizer Vaccine Research & Development, Nutley, NJ,performed theneutralization assays for
Phase2/3.
b. The University of Texas Medical Branch, Galveston,TX,performedthe neutralization assays for
Phase1.
Protocol C4591001 List of Laboratories–Interim –6 MonthUpdate, Final, Version2.0,18Mar2021.
Page1
CONFIDENTIAL
)TMG(
52:31
1202-raM-81
:nO
laniF\laniF\2866e8691e771090
FDA-CBER-2021-5683-0220584",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_right-of-reference.pdf,1.0,"BNT162b2
1.4.2. Statement of Right to Reference
1.4.2. STATEMENT OF RIGHT TO REFERENCE
The following Drug Master File (DMF)/ Master File (MF) Letters of Authorization are
provided herein as presented in Table1.4.2-1.
Table1.4.2-1.DMF Letters of Authorization
DMF/MF Holder DMF/MF DMF/MFSubject Reference Information
Number
Gerresheimer Buende DMF 9543 Type I Tubular Containers 2 mL Type I borosilicate glass
GmbH vial, 13 mm finish
Gerresheimer Buende DMF 15209 Containers made from tubular 2 mL Type I borosilicate glass
GmbH glass as ampoules, bulk vial, 13 mm finish
syringes, cartridges, and vials
up to 100mlto be used as
primary packaging containers
for pharmaceutical and
medicinal products
Schott Hungary Kft. DMF 011793 Primary packaging material 2 mL Type I borosilicate glass
vial, 13 mm finish
Schott AG DMF 011820 Glass vials manufactured in 2 mL Type I borosilicate glass
Mullheim, Germany vial, 13 mm finish
Schott North America, DMF 012683 Glass products manufactured in 2 mL Type I borosilicate glass
Inc. Lebanon, Pennsylvania vial, 13 mm finish
SchottKaisha Private DMF 031786 Glass ampoules, glass vials, 2 mL Type I borosilicate glass
Limited glass cartridges and glass vial, 13 mm finish
syringes
Stevanato Group S.p.A. DMF 011321 0612090.5636 –VIAL VB 2 mL Type I borosilicate glass
2mL 16.25x0.85x31 vial, 13 mm finish
Datwyler Pharma DMF 10953 Rubber compounds FM457/0
Packaging Belgium NV
PFIZER CONFIDENTIAL
Page 1
)TMG(
55:20
1202-yaM-21
:nO
devorppA\devorppA\8fba00791e771090
FDA-CBER-2021-5683-0225039","[[['DMF/MF Holder', 'DMF/MF\nNumber', 'DMF/MFSubject', 'Reference Information'], ['Gerresheimer Buende\nGmbH', 'DMF 9543', 'Type I Tubular Containers', '2 mL Type I borosilicate glass\nvial, 13 mm finish'], ['Gerresheimer Buende\nGmbH', 'DMF 15209', 'Containers made from tubular\nglass as ampoules, bulk\nsyringes, cartridges, and vials\nup to 100mlto be used as\nprimary packaging containers\nfor pharmaceutical and\nmedicinal products', '2 mL Type I borosilicate glass\nvial, 13 mm finish'], ['Schott Hungary Kft.', 'DMF 011793', 'Primary packaging material', '2 mL Type I borosilicate glass\nvial, 13 mm finish'], ['Schott AG', 'DMF 011820', 'Glass vials manufactured in\nMullheim, Germany', '2 mL Type I borosilicate glass\nvial, 13 mm finish'], ['Schott North America,\nInc.', 'DMF 012683', 'Glass products manufactured in\nLebanon, Pennsylvania', '2 mL Type I borosilicate glass\nvial, 13 mm finish'], ['SchottKaisha Private\nLimited', 'DMF 031786', 'Glass ampoules, glass vials,\nglass cartridges and glass\nsyringes', '2 mL Type I borosilicate glass\nvial, 13 mm finish'], ['Stevanato Group S.p.A.', 'DMF 011321', '0612090.5636 –VIAL VB\n2mL 16.25x0.85x31', '2 mL Type I borosilicate glass\nvial, 13 mm finish'], ['Datwyler Pharma\nPackaging Belgium NV', 'DMF 10953', 'Rubber compounds', 'FM457/0']]]",1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-031786-vials.pdf,1.0,")TMG(
54:80
1202-yaM-01
:nO
devorppA\devorppA\369edf691e771090
FDA-CBER-2021-5683-0225038",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_fk-diluent-carton.pdf,1.0,FDA-CBER-2021-5683-0225028,,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_hospira-diluent-label.pdf,1.0,"Comirnaty Diluent Label_2.pdf 1 5/10/21 4:41 PM
Comirnaty Diluent Label 2P May 10, 2021 am
Black
1.25” x 2.75”
Diluent For Use with
[COVID-19 mRNA Vaccine
(nucleoside modified)]
COMIRNATYTM
COMDILRM
)TMG(
25:02
1202-yaM-11
:nO
devorppA\devorppA\4fd820791e771090
FDA-CBER-2021-5683-0225031",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-011321-vials.pdf,1.0,"To: Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
Building 71, Room G112
Silver Spring, MD 20993-0002
Copy to Pfizer Inc. as US Agent for BioNTech RNA
Pharmaceuticals GmbH
500 Arcola Road
Collegeville, PA 19436
USA
Piombino Dese (Italy), August 25,2020
DMF Type III no. #011321
Submission date: Submitted on January 15, 1995 revised on May 22, 2015
DMF Holder: Stevanato Group S.p.A.
Letter of authorization for: 0612090.5636 VIAL VB 2mL 16.25x0.85x31
Dear DMF Staff,
Stevanato Group S.p.A. hereby authorizes Pfizer Inc. to incorporate by reference
information 0612090.5636 VIAL VB 2mL 16.25x0.85x31in DMF Type III #011321
into any application filed by Pfizer Inc. We also authorize the FDA to review the
aforementioned specific information in DMF Type III #011321 when considering any
application filed by Pfizer Inc.
Item:0612090.5636 VIAL VB 2mL
Drug product:SARS-COV-2-mRNA Vaccine
Drawing:5636/05-02
Referenced Section: Module 3, Section 3.2.P.1 List of products ANNEX A Attachment 530
Stevanato Group S.p.A states that DMF Type III #011321 is current and Stevanato Group
S.p.A will comply with the statements made within it. Stevanato Group S.p.A will notify
FDA through an amendment to DMF#011321 of any addition, change, or deletion of
information in the DMF. Stevanato Group S.p.A will also notify in writing Pfizer Inc. that
an addition, change, or deletion of information has been made to the DMF.
Sincerely,
Andrea Salmaso
Regulatory and Scientific Affairs Manager
Stevanato Group S.p.A.
Via Molinella 17, 35017- Piombino Dese - Padova - Italy
Ph. +390499318008 F. +39 049 9366151
andrea.salmaso@stevanatogroup.com
FDA-CBER-2021-5683-0225034",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-012683-vials.pdf,1.0,")TMG(
82:60
1202-raM-62
:nO
devorppA\devorppA\a7831a691e771090
FDA-CBER-2021-5683-0225037",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_fk-diluent-stamp.pdf,1.0,FDA-CBER-2021-5683-0225029,,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-efficacy-response.pdf,5.0,"16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo
Assay
Dose/ S1-Binding
Age Group Vaccine Group Sampling Date of Rel NT50 IgG Level
(Years) (as Randomized) Subject Time Point Sample Daya (Titer) (U/mL)
18-55 BNT162b2 (30 μg) C4591001 1003 10031057 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 22 127.84 530.363
2/1 Month 14AUG2020 31 135.45 2786.473
2/6 Months 13JAN2021 183 28.02 463.85
C4591001 1003 10031059 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 22 82.25 1848.867
2/1 Month 12AUG2020 29 257.68 5829.146
2/6 Months 08JAN2021 178 33.20 771.147
C4591001 1003 10031061 1/Prevax 22JUN2020 1 10.00 BLQ
1/Day 21 13JUL2020 22 72.74 427.932
2/1 Month 10AUG2020 29 175.85 5660.364
2/6 Months 08JAN2021 180 75.30 1046.509
C4591001 1003 10031065 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 22 10.00 925.76
2/1 Month 19AUG2020 36 962.68 13393.623
2/6 Months 08JAN2021 178 114.16 1724.284
C4591001 1003 10031066 1/Prevax 22JUN2020 1 10.00 BLQ
1/Day 21 13JUL2020 22 78.30 399.817
2/1 Month 13AUG2020 32 122.66 9897.22
2/6 Months 04JAN2021 176 44.01 538.771
C4591001 1003 10031072 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 16JUL2020 23 10.00 553.482
2/1 Month 19AUG2020 35 92.04 5257.297
2/6 Months 07JAN2021 176 69.39 934.959
C4591001 1007 10071046 1/Prevax 22JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 24 10.00 475.638
2/1 Month 10AUG2020 27 75.78 7642.997
2/6 Months 04JAN2021 174 10.00 395.017
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\0027fa691e771090
FDA-CBER-2021-5683-0220373
Page 1
16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo
Assay
Dose/ S1-Binding
Age Group Vaccine Group Sampling Date of Rel NT50 IgG Level
(Years) (as Randomized) Subject Time Point Sample Daya (Titer) (U/mL)
C4591001 1007 10071050 1/Prevax 22JUN2020 1 10.00 BLQ
1/Day 21 13JUL2020 22 88.61 1295.29
2/1 Month 10AUG2020 29 191.17 8857.72
2/6 Months 04JAN2021 176 36.53 710.176
C4591001 1007 10071058 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 22 70.08 646.145
2/1 Month 12AUG2020 29 642.09 6451.389
C4591001 1007 10071063 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 22 10.00 573.795
2/1 Month 19AUG2020 36 128.62 4024.352
2/6 Months 07JAN2021 177 24.77 481.076
C4591001 1007 10071064 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 22 10.00 135.052
2/1 Month 12AUG2020 29 204.04 5119.635
2/6 Months 06JAN2021 176 60.46 1028.15
C4591001 1007 10071066 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 22 10.00 403.233
2/1 Month 12AUG2020 29 71.74 4858.413
2/6 Months 06JAN2021 176 653.46 10552.95
Placebo C4591001 1003 10031050 1/Prevax 22JUN2020 1 10.00 BLQ
1/Day 21 13JUL2020 22 10.00 BLQ
2/1 Month 13AUG2020 32 10.00 BLQ
C4591001 1003 10031070 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 22 10.00 BLQ
2/1 Month 12AUG2020 29 10.00 BLQ
C4591001 1007 10071065 1/Prevax 24JUN2020 1 10.00 BLQ
1/Day 21 15JUL2020 22 10.00 BLQ
2/1 Month 12AUG2020 29 10.00 BLQ
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\0027fa691e771090
FDA-CBER-2021-5683-0220374
Page 2
16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo
Assay
Dose/ S1-Binding
Age Group Vaccine Group Sampling Date of Rel NT50 IgG Level
(Years) (as Randomized) Subject Time Point Sample Daya (Titer) (U/mL)
65-85 BNT162b2 (30 μg) C4591001 1003 10031037 1/Prevax 16JUN2020 1 10.00 BLQ
1/Day 21 07JUL2020 22 31.46 2141.783
2/1 Month 07AUG2020 32 403.35 22091.375
2/6 Months 08JAN2021 186 30.70 556.288
C4591001 1003 10031047 1/Prevax 16JUN2020 1 10.00 BLQ
1/Day 21 07JUL2020 22 10.00 1751.532
2/1 Month 07AUG2020 32 89.05 9349.196
2/6 Months 04JAN2021 182 23.08 1328.069
C4591001 1003 10031051 1/Prevax 18JUN2020 1 10.00 BLQ
1/Day 21 09JUL2020 22 10.00 687.383
2/1 Month 12AUG2020 35 390.56 5523.432
2/6 Months 29DEC2020 174 36.83 687.657
C4591001 1003 10031058 1/Prevax 18JUN2020 1 10.00 BLQ
1/Day 21 09JUL2020 22 10.00 34.257
2/1 Month 06AUG2020 29 10.00 2330.549
2/6 Months 31DEC2020 176 27.80 594.548
C4591001 1003 10031069 1/Prevax 18JUN2020 1 10.00 BLQ
1/Day 21 09JUL2020 22 10.00 115.815
2/1 Month 10AUG2020 33 48.51 1525.019
2/6 Months 31DEC2020 176 21.11 269.535
C4591001 1007 10071034 1/Prevax 15JUN2020 1 10.00 BLQ
1/Day 21 06JUL2020 22 36.29 151.88
2/1 Month 03AUG2020 29 207.03 2728.832
2/6 Months 28DEC2020 176 10.00 205.531
C4591001 1007 10071037 1/Prevax 15JUN2020 1 10.00 BLQ
1/Day 21 06JUL2020 22 10.00 362.55
2/1 Month 05AUG2020 31 293.34 5440.505
2/6 Months 04JAN2021 183 57.76 990.531
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\0027fa691e771090
FDA-CBER-2021-5683-0220375
Page 3
16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo
Assay
Dose/ S1-Binding
Age Group Vaccine Group Sampling Date of Rel NT50 IgG Level
(Years) (as Randomized) Subject Time Point Sample Daya (Titer) (U/mL)
C4591001 1007 10071043 1/Prevax 18JUN2020 1 10.00 BLQ
1/Day 21 09JUL2020 22 24.18 339.124
2/1 Month 06AUG2020 29 433.37 7277.572
2/6 Months 04JAN2021 180 33.81 527.782
C4591001 1007 10071044 1/Prevax 18JUN2020 1 10.00 BLQ
1/Day 21 09JUL2020 22 52.38 1307.168
2/1 Month 06AUG2020 29 1457.45 16973.01
2/6 Months 04JAN2021 180 55.92 1524.031
C4591001 1007 10071045 1/Prevax 18JUN2020 1 10.00 BLQ
1/Day 21 09JUL2020 22 10.00 497.692
2/1 Month 06AUG2020 29 123.99 5663.073
2/6 Months 04JAN2021 180 39.94 1243.902
C4591001 1007 10071049 1/Prevax 18JUN2020 1 10.00 BLQ
1/Day 21 09JUL2020 22 20.93 198.941
2/1 Month 06AUG2020 29 33.98 2318.744
2/6 Months 04JAN2021 180 10.00 259.008
C4591001 1007 10071053 1/Prevax 18JUN2020 1 10.00 BLQ
1/Day 21 09JUL2020 22 10.00 733.863
2/1 Month 06AUG2020 29 78.63 3235.365
2/6 Months 04JAN2021 180 42.58 521.125
Placebo C4591001 1003 10031043 1/Prevax 16JUN2020 1 10.00 BLQ
1/Day 21 07JUL2020 22 10.00 BLQ
C4591001 1003 10031046 1/Prevax 18JUN2020 1 10.00 BLQ
1/Day 21 09JUL2020 22 10.00 BLQ
2/1 Month 10AUG2020 33 10.00 BLQ
C4591001 1003 10031056 1/Prevax 18JUN2020 1 10.00 2.015
1/Day 21 09JUL2020 22 10.00 2.451
2/1 Month 06AUG2020 29 10.00 3.258
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\0027fa691e771090
FDA-CBER-2021-5683-0220376
Page 4
16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo
Assay
Dose/ S1-Binding
Age Group Vaccine Group Sampling Date of Rel NT50 IgG Level
(Years) (as Randomized) Subject Time Point Sample Daya (Titer) (U/mL)
Abbreviations: BLQ = below the limit of quantitation; IgG = immunoglobulin G; NT50 = 50% neutralizing titer; S1 = spike protein S1 subunit.
Note: Blood samples from the Day 7 and Day 14 post–Dose 2 visits are not included since these samples were not retested with the 6-month post–Dose 2
samples.
a. Relative day (Rel Day) = date of blood draw - date of last vaccination + 1.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:25) Source Data: adva Table Generation: 27MAR2021 (05:00)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adva l001 p1
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\0027fa691e771090
FDA-CBER-2021-5683-0220377
Page 5","[[['', None, None, None, None, None, None, None], ['16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo', None, None, None, None, None, None, None], ['', None, None, None, None, None, 'Assay', None], ['', '', '', 'Dose/', '', '', '', 'S1-Binding'], ['Age Group', 'Vaccine Group', None, 'Sampling', 'Date of', 'Rel', 'NT50', 'IgG Level'], ['(Years)', '(as Randomized)', 'Subject', 'Time Point', 'Sample', 'Daya', '(Titer)', '(U/mL)'], ['18-55', 'BNT162b2 (30 μg)', 'C4591001 1003 10031057', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '22', '127.84', '530.363'], ['', '', '', '2/1 Month', '14AUG2020', '31', '135.45', '2786.473'], ['', '', '', '2/6 Months', '13JAN2021', '183', '28.02', '463.85'], ['', '', 'C4591001 1003 10031059', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '22', '82.25', '1848.867'], ['', '', '', '2/1 Month', '12AUG2020', '29', '257.68', '5829.146'], ['', '', '', '2/6 Months', '08JAN2021', '178', '33.20', '771.147'], ['', '', 'C4591001 1003 10031061', '1/Prevax', '22JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '13JUL2020', '22', '72.74', '427.932'], ['', '', '', '2/1 Month', '10AUG2020', '29', '175.85', '5660.364'], ['', '', '', '2/6 Months', '08JAN2021', '180', '75.30', '1046.509'], ['', '', 'C4591001 1003 10031065', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '22', '10.00', '925.76'], ['', '', '', '2/1 Month', '19AUG2020', '36', '962.68', '13393.623'], ['', '', '', '2/6 Months', '08JAN2021', '178', '114.16', '1724.284'], ['', '', 'C4591001 1003 10031066', '1/Prevax', '22JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '13JUL2020', '22', '78.30', '399.817'], ['', '', '', '2/1 Month', '13AUG2020', '32', '122.66', '9897.22'], ['', '', '', '2/6 Months', '04JAN2021', '176', '44.01', '538.771'], ['', '', 'C4591001 1003 10031072', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '16JUL2020', '23', '10.00', '553.482'], ['', '', '', '2/1 Month', '19AUG2020', '35', '92.04', '5257.297'], ['', '', '', '2/6 Months', '07JAN2021', '176', '69.39', '934.959'], ['', '', 'C4591001 1007 10071046', '1/Prevax', '22JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '24', '10.00', '475.638'], ['', '', '', '2/1 Month', '10AUG2020', '27', '75.78', '7642.997'], ['', '', '', '2/6 Months', '04JAN2021', '174', '10.00', '395.017']], [['', None, None, None, None, None, None, None], ['16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo', None, None, None, None, None, None, None], ['', None, None, None, None, None, 'Assay', None], ['', '', '', 'Dose/', '', '', '', 'S1-Binding'], ['Age Group', 'Vaccine Group', None, 'Sampling', 'Date of', 'Rel', 'NT50', 'IgG Level'], ['(Years)', '(as Randomized)', 'Subject', 'Time Point', 'Sample', 'Daya', '(Titer)', '(U/mL)'], ['', '', 'C4591001 1007 10071050', '1/Prevax', '22JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '13JUL2020', '22', '88.61', '1295.29'], ['', '', '', '2/1 Month', '10AUG2020', '29', '191.17', '8857.72'], ['', '', '', '2/6 Months', '04JAN2021', '176', '36.53', '710.176'], ['', '', 'C4591001 1007 10071058', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '22', '70.08', '646.145'], ['', '', '', '2/1 Month', '12AUG2020', '29', '642.09', '6451.389'], ['', '', 'C4591001 1007 10071063', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '22', '10.00', '573.795'], ['', '', '', '2/1 Month', '19AUG2020', '36', '128.62', '4024.352'], ['', '', '', '2/6 Months', '07JAN2021', '177', '24.77', '481.076'], ['', '', 'C4591001 1007 10071064', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '22', '10.00', '135.052'], ['', '', '', '2/1 Month', '12AUG2020', '29', '204.04', '5119.635'], ['', '', '', '2/6 Months', '06JAN2021', '176', '60.46', '1028.15'], ['', '', 'C4591001 1007 10071066', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '22', '10.00', '403.233'], ['', '', '', '2/1 Month', '12AUG2020', '29', '71.74', '4858.413'], ['', '', '', '2/6 Months', '06JAN2021', '176', '653.46', '10552.95'], ['', 'Placebo', 'C4591001 1003 10031050', '1/Prevax', '22JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '13JUL2020', '22', '10.00', 'BLQ'], ['', '', '', '2/1 Month', '13AUG2020', '32', '10.00', 'BLQ'], ['', '', 'C4591001 1003 10031070', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '22', '10.00', 'BLQ'], ['', '', '', '2/1 Month', '12AUG2020', '29', '10.00', 'BLQ'], ['', '', 'C4591001 1007 10071065', '1/Prevax', '24JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '15JUL2020', '22', '10.00', 'BLQ'], ['', '', '', '2/1 Month', '12AUG2020', '29', '10.00', 'BLQ']], [['', None, None, None, None, None, None, None], ['16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo', None, None, None, None, None, None, None], ['', None, None, None, None, None, 'Assay', None], ['', '', '', 'Dose/', '', '', '', 'S1-Binding'], ['Age Group', 'Vaccine Group', None, 'Sampling', 'Date of', 'Rel', 'NT50', 'IgG Level'], ['(Years)', '(as Randomized)', 'Subject', 'Time Point', 'Sample', 'Daya', '(Titer)', '(U/mL)'], ['65-85', 'BNT162b2 (30 μg)', 'C4591001 1003 10031037', '1/Prevax', '16JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '07JUL2020', '22', '31.46', '2141.783'], ['', '', '', '2/1 Month', '07AUG2020', '32', '403.35', '22091.375'], ['', '', '', '2/6 Months', '08JAN2021', '186', '30.70', '556.288'], ['', '', 'C4591001 1003 10031047', '1/Prevax', '16JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '07JUL2020', '22', '10.00', '1751.532'], ['', '', '', '2/1 Month', '07AUG2020', '32', '89.05', '9349.196'], ['', '', '', '2/6 Months', '04JAN2021', '182', '23.08', '1328.069'], ['', '', 'C4591001 1003 10031051', '1/Prevax', '18JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '09JUL2020', '22', '10.00', '687.383'], ['', '', '', '2/1 Month', '12AUG2020', '35', '390.56', '5523.432'], ['', '', '', '2/6 Months', '29DEC2020', '174', '36.83', '687.657'], ['', '', 'C4591001 1003 10031058', '1/Prevax', '18JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '09JUL2020', '22', '10.00', '34.257'], ['', '', '', '2/1 Month', '06AUG2020', '29', '10.00', '2330.549'], ['', '', '', '2/6 Months', '31DEC2020', '176', '27.80', '594.548'], ['', '', 'C4591001 1003 10031069', '1/Prevax', '18JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '09JUL2020', '22', '10.00', '115.815'], ['', '', '', '2/1 Month', '10AUG2020', '33', '48.51', '1525.019'], ['', '', '', '2/6 Months', '31DEC2020', '176', '21.11', '269.535'], ['', '', 'C4591001 1007 10071034', '1/Prevax', '15JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '06JUL2020', '22', '36.29', '151.88'], ['', '', '', '2/1 Month', '03AUG2020', '29', '207.03', '2728.832'], ['', '', '', '2/6 Months', '28DEC2020', '176', '10.00', '205.531'], ['', '', 'C4591001 1007 10071037', '1/Prevax', '15JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '06JUL2020', '22', '10.00', '362.55'], ['', '', '', '2/1 Month', '05AUG2020', '31', '293.34', '5440.505'], ['', '', '', '2/6 Months', '04JAN2021', '183', '57.76', '990.531']], [['', None, None, None, None, None, None, None], ['16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo', None, None, None, None, None, None, None], ['', None, None, None, None, None, 'Assay', None], ['', '', '', 'Dose/', '', '', '', 'S1-Binding'], ['Age Group', 'Vaccine Group', None, 'Sampling', 'Date of', 'Rel', 'NT50', 'IgG Level'], ['(Years)', '(as Randomized)', 'Subject', 'Time Point', 'Sample', 'Daya', '(Titer)', '(U/mL)'], ['', '', 'C4591001 1007 10071043', '1/Prevax', '18JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '09JUL2020', '22', '24.18', '339.124'], ['', '', '', '2/1 Month', '06AUG2020', '29', '433.37', '7277.572'], ['', '', '', '2/6 Months', '04JAN2021', '180', '33.81', '527.782'], ['', '', 'C4591001 1007 10071044', '1/Prevax', '18JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '09JUL2020', '22', '52.38', '1307.168'], ['', '', '', '2/1 Month', '06AUG2020', '29', '1457.45', '16973.01'], ['', '', '', '2/6 Months', '04JAN2021', '180', '55.92', '1524.031'], ['', '', 'C4591001 1007 10071045', '1/Prevax', '18JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '09JUL2020', '22', '10.00', '497.692'], ['', '', '', '2/1 Month', '06AUG2020', '29', '123.99', '5663.073'], ['', '', '', '2/6 Months', '04JAN2021', '180', '39.94', '1243.902'], ['', '', 'C4591001 1007 10071049', '1/Prevax', '18JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '09JUL2020', '22', '20.93', '198.941'], ['', '', '', '2/1 Month', '06AUG2020', '29', '33.98', '2318.744'], ['', '', '', '2/6 Months', '04JAN2021', '180', '10.00', '259.008'], ['', '', 'C4591001 1007 10071053', '1/Prevax', '18JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '09JUL2020', '22', '10.00', '733.863'], ['', '', '', '2/1 Month', '06AUG2020', '29', '78.63', '3235.365'], ['', '', '', '2/6 Months', '04JAN2021', '180', '42.58', '521.125'], ['', 'Placebo', 'C4591001 1003 10031043', '1/Prevax', '16JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '07JUL2020', '22', '10.00', 'BLQ'], ['', '', 'C4591001 1003 10031046', '1/Prevax', '18JUN2020', '1', '10.00', 'BLQ'], ['', '', '', '1/Day 21', '09JUL2020', '22', '10.00', 'BLQ'], ['', '', '', '2/1 Month', '10AUG2020', '33', '10.00', 'BLQ'], ['', '', 'C4591001 1003 10031056', '1/Prevax', '18JUN2020', '1', '10.00', '2.015'], ['', '', '', '1/Day 21', '09JUL2020', '22', '10.00', '2.451'], ['', '', '', '2/1 Month', '06AUG2020', '29', '10.00', '3.258']], [['', None, None, None, None, None, None, None], ['16.2.6 Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo', None, None, None, None, None, None, None], ['', None, None, None, None, None, 'Assay', None], ['', '', '', 'Dose/', '', '', '', 'S1-Binding'], ['Age Group', 'Vaccine Group', None, 'Sampling', 'Date of', 'Rel', 'NT50', 'IgG Level'], ['(Years)', '(as Randomized)', 'Subject', 'Time Point', 'Sample', 'Daya', '(Titer)', '(U/mL)'], ['', '', '', '', '', '', '', ''], ['Abbreviations: BLQ = below the limit of quantitation; IgG = immunoglobulin G; NT50 = 50% neutralizing titer; S1 = spike protein S1 subunit.', None, None, None, None, None, None, None], ['Note: Blood samples from the Day 7 and Day 14 post–Dose 2 visits are not included since these samples were not retested with the 6-month post–Dose 2', None, None, None, None, None, None, None], ['samples.', None, None, None, None, None, None, None], ['a. Relative day (Rel Day) = date of blood draw - date of last vaccination + 1.', None, None, None, None, None, None, None], ['PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:25) Source Data: adva Table Generation: 27MAR2021 (05:00)', None, None, None, None, None, None, None], ['(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adva l001 p1', None, None, None, None, None, None, None], ['', None, None, None, None, None, None, None]]]",5
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-011793-vials.pdf,1.0,")TMG(
21:60
1202-raM-62
:nO
devorppA\devorppA\71ee0a691e771090
FDA-CBER-2021-5683-0225035",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_hospira-diluent-carton.pdf,1.0,FDA-CBER-2021-5683-0225030,,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-errata.pdf,2.0,"CLINICAL STUDY REPORT ERRATA
Protocol Number: C4591001
Study Report Title: Interim Report –6 Month Update: A Phase 1/2/3,
Placebo-Controlled, Randomized, Observer-Blind,
Dose-Finding Study to Evaluate the Safety,
Tolerability, Immunogenicity, and Efficacy of
SARS-COV-2 RNA Vaccine Candidates Against
COVID-19 in Healthy Individuals
Minor errors were identified in the Clinical Study Report. Those errors are listed below.
Although these errors do not affect the conclusions of the study, they have been included in
this Erratato ensure the accuracy of the report.
Section Description of Error
Sections 10.1.2, 12.2.3, 12.2.4, and After the data cutoff date of 13Mar2021 (with
14 database snapshot taken on 25Mar2021), it was
determined that:
Section 16.2.7 Narratives(contain
corrected information)  Participants C4591001 1044 10441163 and
C4591001 1090 10901140 did not withdraw from
Appendix 16.2.7.4.1 Listing of
the study because of the injection site pain and
Adverse Events –All Subjects
remain in the study
≥16Years of Age
 Participants C4591001 1090 10901492 and
Appendix 16.2.7.5 Listing of
C4591001 1091 10911297did not withdraw from
Serious Adverse Events –All
Subjects ≥16 Years of Agea the study because of the fatigue and remain in the
study
Appendix 16.2.7.6 Listing of
 Participant C4591001 1091 10911247 did not
Adverse Events Leading to
withdraw from the study because of the dermatitis
Discontinuation –All Subjects
and remains in the study
≥16Years of Age
 Participant C4591001 1092 10921021 did not
withdraw from thestudy because of the pain and
remains in the study
 Participant C4591001 1254 12541006 did not
withdraw from the study because of the chills and
remains in the study
 Participant C4591001 1254 12541189 did not
withdraw from the study because of the headache
and remains in the study
 Participant C4591001 1096 10961036 did not
discontinue from the study interventionbecause of
the suicidal depression but discontinued from the
study because she no longer met the eligibility
criteria
CONFIDENTIAL
Page 1
)TMG(
44:51
1202-rpA-92
:nO
devorppA\devorppA\27607e691e771090
FDA-CBER-2021-5683-0220378
CLINICAL STUDY REPORT ERRATA
Protocol Number: C4591001
 Participant C4591001 1232 12321299was not
withdrawn from the study for safety reasons
(hypertension) but was lost to follow-up
 Participant C4591001 1037 10371141 was not
pregnant and remains in the study
a. Participant C4591001 1096 10961036only.
CONFIDENTIAL
Page 2
)TMG(
44:51
1202-rpA-92
:nO
devorppA\devorppA\27607e691e771090
FDA-CBER-2021-5683-0220379","[[['Study Report Title:', 'Interim Report –6 Month Update: A Phase 1/2/3,\nPlacebo-Controlled, Randomized, Observer-Blind,\nDose-Finding Study to Evaluate the Safety,\nTolerability, Immunogenicity, and Efficacy of\nSARS-COV-2 RNA Vaccine Candidates Against\nCOVID-19 in Healthy Individuals']], [['Section', 'Description of Error'], ['Sections 10.1.2, 12.2.3, 12.2.4, and\n14\nSection 16.2.7 Narratives(contain\ncorrected information)\nAppendix 16.2.7.4.1 Listing of\nAdverse Events –All Subjects\n≥16Years of Age\nAppendix 16.2.7.5 Listing of\nSerious Adverse Events –All\nSubjects ≥16 Years of Agea\nAppendix 16.2.7.6 Listing of\nAdverse Events Leading to\nDiscontinuation –All Subjects\n≥16Years of Age', 'After the data cutoff date of 13Mar2021 (with\ndatabase snapshot taken on 25Mar2021), it was\ndetermined that:\n\uf0b7 Participants C4591001 1044 10441163 and\nC4591001 1090 10901140 did not withdraw from\nthe study because of the injection site pain and\nremain in the study\n\uf0b7 Participants C4591001 1090 10901492 and\nC4591001 1091 10911297did not withdraw from\nthe study because of the fatigue and remain in the\nstudy\n\uf0b7 Participant C4591001 1091 10911247 did not\nwithdraw from the study because of the dermatitis\nand remains in the study\n\uf0b7 Participant C4591001 1092 10921021 did not\nwithdraw from thestudy because of the pain and\nremains in the study\n\uf0b7 Participant C4591001 1254 12541006 did not\nwithdraw from the study because of the chills and\nremains in the study\n\uf0b7 Participant C4591001 1254 12541189 did not\nwithdraw from the study because of the headache\nand remains in the study\n\uf0b7 Participant C4591001 1096 10961036 did not\ndiscontinue from the study interventionbecause of\nthe suicidal depression but discontinued from the\nstudy because she no longer met the eligibility\ncriteria']], [['', '\uf0b7 Participant C4591001 1232 12321299was not\nwithdrawn from the study for safety reasons\n(hypertension) but was lost to follow-up\n\uf0b7 Participant C4591001 1037 10371141 was not\npregnant and remains in the study']]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_com195lkz-carton-kzoo.pdf,1.0,"NO COPY
NDC 0069-1000-02
Suspension for Intramuscular Injection
195 Multiple Dose Vials
(after dilution each vial contains
NOTE: 6 doses of 0.3 mL)
Area around QR Code is a required
quiet zone. STORAGE: Prior to dilution, store at
-90°C to -60°C (-130°F to -76°F).
Nothing is to print within this space. Store in this carton to protect from light.
DOSAGE AND ADMINISTRATION: After
Code to scan as: dilution, each vial contains 6 doses of 0.3 mL.
See prescribing information or scan QR code. GS1 Data XXXXXX
https://www.pfi.sr/comirnaty MUST BE DILUTED BEFORE USE with sterile LOT: M (Ga Tt Ir Nix , MM/YYYY
0.9% Sodium Chloride Injection, USP (supplied separately). EXP: Lot, Exp)
After dilution, store the vaccine at 2°C to 25°C (35°F to 77°F).
Discard after 6 hours.
Contains no preservative. Rx only
NO COPY
NO COPY
Suspension for Intramuscular Injection
195 Multiple Dose Vials
(after dilution each vial contains 6 doses of 0.3 mL) GS1 Data XXXXXX
S (-T 1O 30R °A FG toE : - 7P 6ri °o Fr ) .t o S td oi rl eu t ii no n th, iss t co are rt oa nt t- o9 0 pr° oC te t co t - fr6 o0 m° C light. LOT: M (Ga Tt Ir Nix , MM/YYYY
DOSAGE AND ADMINISTRATION: Lot, Exp)
After dilution, each vial contains 6 doses of 0.3 mL. EXP:
See prescribing information or scan QR code.
NO COPY
120000196003
Comirnaty Carton Label - Kzoo COM195LKZ 16P April 23, 2021 am
Black PMS 7671 PMS 2162 PMS 7597
Minimum point size - 5pt.
Manufactured for
BioNTech
Manufacturing GmbH
An der Goldgrube 12
55131 Mainz, Germany
Manufactured by
Pfizer Inc.
New York, NY 10017
US License No. XXXX
BOTEHFZRBNTCPFERONEHPZEBOTCHFZRINTCPFERONEHPZEBOTCHFZR
COM195LKZ
MUST BE DILUTED BEFORE
USE with sterile 0.9% Sodium COM195LKZ
Chloride Injection, USP
(supplied separately).
After dilution, store
the vaccine at
2°C to 25°C (35°F to 77°F).
Discard after 6 hours.
Contains no
preservative.
A-CPU
OPF
Comirnaty Carton Label COM195LKZ - Kzoo_16.pdf 1 4/23/21 1:34 PM
FPO
)TMG(
53:30
1202-yaM-01
:nO
devorppA\devorppA\d182df691e771090
FDA-CBER-2021-5683-0225024","[[['NDC 0069-1000-02\n120000196003\nSuspension for Intramuscular Injection\nManufactured for A-CPU\n195 Multiple Dose Vials BioNTech\nManufacturing GmbH\n(after dilution each vial contains An der Goldgrube 12 OPF\n6 doses of 0.3 mL) 55131 Mainz, Germany\nManufactured by\nPfizer Inc.\nSTORAGE: Prior to dilution, store at New York, NY 10017 FPO\n-90°C to -60°C (-130°F to -76°F). US License No. XXXX\nStore in this carton to protect from light. BOTEHFZRBNTCPFERONEHPZEBOTCHFZRINTCPFERONEHPZEBOTCHFZR\nCOM195LKZ\nDOSAGE AND ADMINISTRATION: After\ndilution, each vial contains 6 doses of 0.3 mL.\nSee prescribing information or scan QR code. GS1 Data XXXXXX\nMUST BE DILUTED BEFORE USE with sterile LOT: M (Ga Tt Ir Nix , MM/YYYY\n0.9% Sodium Chloride Injection, USP (supplied separately). EXP: Lot, Exp)\nAfter dilution, store the vaccine at 2°C to 25°C (35°F to 77°F).\nDiscard after 6 hours.\nContains no preservative. Rx only\nNO COPY', None, None, None, None], [None, None, None, 'New York, NY 10017\nUS License No. XXXX\nBOTEHFZRBNTCPFERONEHPZEBOTCHFZRINTCPFERONEHPZEBOTCHFZR\nCOM195LKZ', ''], [None, None, 'GS1 Data XXXXXX\nMatrix\n(GTIN, MM/YYYY\nLot, Exp)', None, ''], [None, None, None, None, ''], ['NO COPY\nMUST BE DILUTED BEFORE\nUSE with sterile 0.9% Sodium', None, None, None, ''], ['Chloride Injection, USP\nSuspension for Intramuscular Injection (supplied separately).\n195 Multiple Dose Vials After dilution, store\n(after dilution each vial contains 6 doses of 0.3 mL) the vaccine at\nSTORAGE: Prior to dilution, store at -90°C to -60°C 2°C to 25°C LOT:\n(-130°F to -76°F). Store in this carton to protect from light. (35°F to 77°F).\nDOSAGE AND ADMINISTRATION: Discard after 6 hours.\nAfter dilution, each vial contains 6 doses of 0.3 mL. Contains no EXP:\nSee prescribing information or scan QR code. preservative.', None, 'COM195LKZ', None, ''], [None, None, 'GS1 Data XXXXXX\nMatrix\n(GTIN, MM/YYYY\nLot, Exp)', None, None], [None, '', None, None, None]]]",1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-10953-stopper.pdf,2.0,"Food and Drug Administration Contact
Center for Biologics Evaluation and Research Renaud Janssen, Ph.D.
Document Control Center Head of Regulatory Affairs and
10903 New Hampshire Ave. Chemical Compliance
Building 71, Room G112
T +32 (0)11 59 08 11
Silver Spring, MD 20993-002
renaud.janssen@datwyler.com
USA
September 17, 2020
Our internal reference : B4013 update 1
DMF#: 10953
Holder: Datwyler Pharma Packaging Belgium NV
Subject : Rubber Compounds
Letter of Authorization for:
compound FM457/0, located in record # 026, Update 3, pages 1-7, dated April 21,
2020.
Dear DMF Staff:
Datwyler Pharma Packaging Belgium NV hereby authorizes Pfizer Inc. as US Agent for
BioNTech RNA Pharmaceuticals GmbH to incorporate by reference information regarding
compound FM457/0 in DMF 10953 into a BLA application filed by Pfizer Inc. as US Agent for
BioNTech RNA Pharmaceuticals GmbH, 500 Arcola Road, Collegeville, PA, 19436, USA, for
their product SARS-COV-2-mRNA Vaccine. We also authorize the FDA to review the
aforementioned specific information in DMF 10953 when considering a BLA application filed
by Pfizer Inc. as US Agent for BioNTech RNA Pharmaceuticals GmbH.
Datwyler Pharma Packaging Belgium NV states that DMF 10953 is current and Datwyler
Pharma Packaging Belgium NV will comply with the statements made within it. Datwyler
Pharma Packaging Belgium NV will notify FDA through an amendment to DMF 10953 of any
addition, change, or deletion of information in the DMF. Datwyler Pharma Packaging Belgium
NV will also notify in writing Pfizer Inc. as US Agent for BioNTech RNA Pharmaceuticals GmbH
that an addition, change, or deletion of information has been made to the DMF.
Sincerely,
September 17, 2020
Drug Master File # 10953 - Letter of Authorization
Our internal reference: B4013 update 1
Page 1 of 2
)TMG(
01:60
1202-raM-62
:nO
devorppA\devorppA\b6ee0a691e771090
FDA-CBER-2021-5683-0225032
Tabassam Sharif
Manager Regulatory Affairs
Datwyler Pharma Packaging Belgium NV
Phone : +32 11 59 08 11
Fax : +32 11 31 40 86
tabassam.sharif@datwyler.com
September 17, 2020
Drug Master File # 10953 - Letter of Authorization
Our internal reference: B4013 update 1
Page 2 of 2
)TMG(
01:60
1202-raM-62
:nO
devorppA\devorppA\b6ee0a691e771090
FDA-CBER-2021-5683-0225033",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_com25ctkz-carton-kzoo.pdf,1.0,"ylno xR
.sruoh 6 retfa dracsiD
.)F°77 ot F°53( C°52 ot C°2
ta eniccav eht erots ,noitulid retfA
.)yletarapes deilppus( PSU
,noitcejnI edirolhC muidoS %9.0 elirets
htiw ESU EROFEB DETULID EB TSUM
)Lm 3.0 fo sesod 6
sniatnoc laiv hcae noitulid retfa(
slaiV esoD elpitluM 52
noitcejnI ralucsumartnI rof noisnepsuS
NDC 0069-1000-03
STORAGE: Prior to dilution, store at
-90°C to -60°C (-130°F to -76°F).
Store in this carton to protect from light.
Suspension for Intramuscular Injection
DOSAGE AND ADMINISTRATION:
25 Multiple Dose Vials After dilution, each vial contains 6 doses of 0.3 mL.
(after dilution each vial contains 6 doses of 0.3 mL)
Contains no preservative. MUST BE DILUTED BEFORE USE with sterile
0.9% Sodium Chloride Injection, USP (supplied separately).
After dilution, store the vaccine at 2°C to 25°C (35°F to 77°F). See prescribing information
Discard after 6 hours. or scan QR code.
830000196003
XXXXXXAAP
lim 01 821 OPF
Comirnaty 25ct Carton - Kzoo COM25CTKZ 16P April 23, 2021 am
Black PMS 7671 PMS 2162 PMS 7597
:PXE/TOL
Minimum point size - 7pt.
COM25CTKZ
Manufactured for
BioNTech
Manufacturing GmbH
An der Goldgrube 12 55131 Mainz, Germany FPO
Manufactured by
Pfizer Inc.
New York, NY 10017
US License No. XXXX
NOTE:
Area around QR Code is a required
quiet zone.
Nothing is to print within this space.
Code to scan as:
https://www.pfi.sr/comirnaty
)TMG(
63:30
1202-yaM-01
:nO
devorppA\devorppA\e182df691e771090
BNTCPZBONTHPZRBOTCHPZRBNTCPZBONTHPZRBOTCHPZRBNTCPZBONTHPZRBOTCHPZRBNTCPZBONTHPZR
A-CPU
OPF
FDA-CBER-2021-5683-0225022","[[['', '', '', None, ''], [None, '', None, '', None]]]",1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_com25ctpus-carton-puurs.pdf,1.0,".evitavreserp on sniatnoC
.Lm 3.0 fo sesod 6
sniatnoc laiv hcae ,noitulid retfA
:NOITARTSINIMDA DNA EGASOD
.thgil morf tcetorp ot notrac siht ni erotS
.)F°67- ot F°031-( C°06- ot C°09-
ta erots ,noitulid ot roirP :EGAROTS
NDC 0069-1000-03
Suspension for Intramuscular Injection
25 Multiple Dose Vials
(after dilution each vial contains
6 doses of 0.3 mL)
MUST BE DILUTED BEFORE USE with
sterile 0.9% Sodium Chloride Injection,
USP (supplied separately).
After dilution, store the vaccine at
2°C to 25°C (35°F to 77°F).
Discard after 6 hours.
Rx only
300691000038
rof
derutcafunaM
hceTNoiB
HbmG
gnirutcafunaM
21
eburgdloG
red
nA
ynamreG
,zniaM
13155
yb
derutcafunaM
.cnI
rezifP
71001
YN
,kroY
weN
XXXX
.oN
esneciL
SU
gnibircserp
eeS
ro
noitamrofni
.edoc
RQ
nacs
Comirnaty 25ct Carton COM25CTPUS - Puurs 15P April 23, 2021 am
Black PMS 7671 PMS 2162 PMS 7597
Minimum point size - 7pt.
SUPTC52MOC
NOTE:
Suspension for Intramuscular Injection Area around QR Code is a required
25 Multiple Dose Vials quiet zone.
(after dilution each vial contains
Nothing is to print within this space.
6 doses of 0.3 mL)
Code to scan as:
https://www.pfi.sr/comirnaty
FPO
UPC-A
OPF
RZPHTNORZPHCTOBZPCTNBRZPHTNOBZPHCTOBZPHTNBRZPHTNOBZPCTNBRZPHTNBRZPHCTOB
Comirnaty 25ct Carton COM25CTPUS - Puurs_15.pdf 1 4/23/21 1:24 PM
)TMG(
14:30
1202-yaM-01
:nO
devorppA\devorppA\d183df691e771090
FDA-CBER-2021-5683-0225023","[[['', None, None], ['SUPTC52MOC', None, None], ['.evitavreserp on sniatnoC 300691000038\n.Lm 3.0 fo sesod 6 FPO\nsniatnoc laiv hcae ,noitulid retfA\nUPC-A\n:NOITARTSINIMDA DNA EGASOD\n.thgil morf tcetorp ot notrac siht ni erotS\n.)F°67- ot F°031-( C°06- ot C°09-\nta erots ,noitulid ot roirP :EGAROTS', None, None], ['', 'NDC 0069-1000-03\nSuspension for Intramuscular Injection\n25 Multiple Dose Vials\n(after dilution each vial contains\n6 doses of 0.3 mL)\nMUST BE DILUTED BEFORE USE with\nsterile 0.9% Sodium Chloride Injection,\nUSP (supplied separately).\nAfter dilution, store the vaccine at\n2°C to 25°C (35°F to 77°F).\nDiscard after 6 hours.\nRx only', ''], ['Suspension for Intramuscular Injection\n25 Multiple Dose Vials\n(after dilution each vial contains\n6 doses of 0.3 mL)', None, None]]]",1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-excluded-patients.pdf,6.0,"16.2.3.2 Listing of Subjects Excluded From Immunogenicity Populations – Phase 1, 2 Doses, 21 Days Apart –
BNT162b2 (30 μg)/Placebo
Age Vaccine Group
Group (as
(Years) Randomized) Subject Population Reason for Exclusion
18-55 BNT162b2 (30 C4591001 1007 Dose 2 evaluable Did not have blood collection within 6-8 days after Dose 2.
μg) 10071050
Placebo C4591001 1003 Dose 1 evaluable Not eligible for the study at randomization; had important protocol deviation(s) as
10031070 determined by the clinician.
Dose 2 evaluable Not eligible for the study at randomization; had important protocol deviation(s) as
determined by the clinician.
65-85 BNT162b2 (30 C4591001 1003 Dose 1 evaluable Not eligible for the study at randomization; had important protocol deviation(s) as
μg) 10031047 determined by the clinician.
Dose 2 evaluable Not eligible for the study at randomization; had important protocol deviation(s) as
determined by the clinician.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 28MAR2021 (15:28)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adsl l001 excl eval p1
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\cf17fa691e771090
FDA-CBER-2021-5683-0220380
Page 1
16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age
Age Group (Years) Subject Reason for Exclusion
16-55 C4591001 1003 10031140 Subject did not receive study vaccine.
C4591001 1003 10031143 Subject did not receive study vaccine.
C4591001 1005 10051381 Subject did not receive study vaccine.
C4591001 1013 10131017 Subject did not receive study vaccine.
C4591001 1013 10131740 Subject did not receive study vaccine.
C4591001 1036 10361050 Subject did not receive study vaccine.
C4591001 1057 10571031 Subject did not receive study vaccine.
C4591001 1057 10571211 Subject did not receive study vaccine.
C4591001 1057 10571212 Subject did not receive study vaccine.
C4591001 1057 10571215 Subject did not receive study vaccine.
C4591001 1057 10571268 Subject did not receive study vaccine.
C4591001 1066 10661335 Subject did not receive study vaccine.
C4591001 1071 10711162 Subject did not receive study vaccine.
C4591001 1081 10811105 Subject did not receive study vaccine.
C4591001 1082 10821013 Subject did not receive study vaccine.
C4591001 1089 10891346 Subject did not receive study vaccine.
C4591001 1089 10891351 Subject did not receive study vaccine.
C4591001 1092 10921128 Subject did not receive study vaccine.
C4591001 1093 10931055 Subject did not receive study vaccine.
C4591001 1109 11091349 Subject did not receive study vaccine.
C4591001 1112 11121229 Subject did not receive study vaccine.
C4591001 1116 11161015 Subject did not receive study vaccine.
C4591001 1120 11201038 Subject did not receive study vaccine.
C4591001 1120 11201252 Subject did not receive study vaccine.
C4591001 1122 11221006 Subject did not receive study vaccine.
C4591001 1122 11221026 Subject did not receive study vaccine.
C4591001 1123 11231027 Subject did not receive study vaccine.
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\df17fa691e771090
FDA-CBER-2021-5683-0220381
Page 2
16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age
Age Group (Years) Subject Reason for Exclusion
C4591001 1123 11231301 Subject did not receive study vaccine.
C4591001 1126 11261074 Subject did not receive study vaccine.
C4591001 1129 11291048 Subject did not receive study vaccine.
C4591001 1133 11331162 Subject did not receive study vaccine.
C4591001 1135 11351389 Subject did not receive study vaccine.
C4591001 1149 11491108 Subject did not receive study vaccine.
C4591001 1161 11611002 Unreliable data due to lack of PI oversight.
C4591001 1161 11611005 Unreliable data due to lack of PI oversight.
C4591001 1161 11611006 Unreliable data due to lack of PI oversight.
C4591001 1161 11611011 Unreliable data due to lack of PI oversight.
C4591001 1161 11611015 Unreliable data due to lack of PI oversight.
C4591001 1161 11611016 Unreliable data due to lack of PI oversight.
C4591001 1161 11611018 Unreliable data due to lack of PI oversight.
C4591001 1161 11611019 Unreliable data due to lack of PI oversight.
C4591001 1162 11621024 Subject did not receive study vaccine.
C4591001 1162 11621477 Subject did not receive study vaccine.
C4591001 1167 11671003 Subject did not receive study vaccine.
C4591001 1168 11681030 Subject did not receive study vaccine.
C4591001 1205 12051028 Subject did not receive study vaccine.
C4591001 1212 12121023 Subject did not receive study vaccine.
C4591001 1223 12231200 Subject did not receive study vaccine.
C4591001 1223 12231234 Subject did not receive study vaccine.
C4591001 1224 12241170 Subject did not receive study vaccine.
C4591001 1231 12311409 Subject did not receive study vaccine.
C4591001 1231 12311516 Subject did not receive study vaccine.
C4591001 1231 12311926 Subject did not receive study vaccine.
C4591001 1231 12312176 Subject did not receive study vaccine.
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\df17fa691e771090
FDA-CBER-2021-5683-0220382
Page 3
16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age
Age Group (Years) Subject Reason for Exclusion
C4591001 1231 12312483 Subject did not receive study vaccine.
C4591001 1231 12313443 Subject did not receive study vaccine.
C4591001 1231 12313527 Subject did not receive study vaccine.
C4591001 1231 12313869 Subject did not receive study vaccine.
C4591001 1231 12314738 Subject did not receive study vaccine.
C4591001 1231 12315308 Subject did not receive study vaccine.
C4591001 1232 12321037 Subject did not receive study vaccine.
C4591001 1235 12351167 Subject did not receive study vaccine.
C4591001 1248 12481018 Subject did not receive study vaccine.
C4591001 1248 12481025 Subject did not receive study vaccine.
C4591001 1248 12481060 Subject did not receive study vaccine.
C4591001 1248 12481218 Subject did not receive study vaccine.
C4591001 1251 12511204 Subject did not receive study vaccine.
C4591001 1260 12601049 Subject did not receive study vaccine.
C4591001 1260 12601070 Subject did not receive study vaccine.
C4591001 1264 12641018 Subject did not receive study vaccine.
C4591001 4444 44441135 Subject did not receive study vaccine.
>55 C4591001 1013 10131097 Subject did not receive study vaccine.
C4591001 1019 10191033 Subject did not receive study vaccine.
C4591001 1019 10191300 Subject did not receive study vaccine.
C4591001 1022 10221015 Subject did not receive study vaccine.
C4591001 1022 10221057 Subject did not receive study vaccine.
C4591001 1022 10221150 Subject did not receive study vaccine.
C4591001 1037 10371057 Subject did not receive study vaccine.
C4591001 1037 10371117 Subject did not receive study vaccine.
C4591001 1044 10441113 Subject did not receive study vaccine.
C4591001 1054 10541071 Subject did not receive study vaccine.
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\df17fa691e771090
FDA-CBER-2021-5683-0220383
Page 4
16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age
Age Group (Years) Subject Reason for Exclusion
C4591001 1054 10541175 Subject did not receive study vaccine.
C4591001 1056 10561078 Subject did not receive study vaccine.
C4591001 1080 10801222 Subject did not receive study vaccine.
C4591001 1082 10821062 Subject did not receive study vaccine.
C4591001 1084 10841366 Subject did not receive study vaccine.
C4591001 1084 10841446 Subject did not receive study vaccine.
C4591001 1087 10871434 Subject did not receive study vaccine.
C4591001 1087 10871512 Subject did not receive study vaccine.
C4591001 1091 10911092 Subject did not receive study vaccine.
C4591001 1097 10971003 Subject did not receive study vaccine.
C4591001 1098 10981092 Subject did not receive study vaccine.
C4591001 1098 10981109 Subject did not receive study vaccine.
C4591001 1109 11091259 Subject did not receive study vaccine.
C4591001 1116 11161117 Subject did not receive study vaccine.
C4591001 1116 11161118 Subject did not receive study vaccine.
C4591001 1120 11201436 Subject did not receive study vaccine.
C4591001 1128 11281023 Subject did not receive study vaccine.
C4591001 1128 11281109 Subject did not receive study vaccine.
C4591001 1129 11291082 Subject did not receive study vaccine.
C4591001 1129 11291117 Subject did not receive study vaccine.
C4591001 1133 11331197 Subject did not receive study vaccine.
C4591001 1134 11341130 Subject did not receive study vaccine.
C4591001 1149 11491100 Subject did not receive study vaccine.
C4591001 1157 11571028 Subject did not receive study vaccine.
C4591001 1161 11611012 Unreliable data due to lack of PI oversight.
C4591001 1161 11611013 Unreliable data due to lack of PI oversight.
C4591001 1178 11781056 Subject did not receive study vaccine.
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\df17fa691e771090
FDA-CBER-2021-5683-0220384
Page 5
16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age
Age Group (Years) Subject Reason for Exclusion
C4591001 1185 11851006 Subject did not receive study vaccine.
C4591001 1223 12231215 Subject did not receive study vaccine.
C4591001 1223 12231250 Subject did not receive study vaccine.
C4591001 1224 12241157 Subject did not receive study vaccine.
C4591001 1231 12312222 Subject did not receive study vaccine.
C4591001 1232 12321432 Subject did not receive study vaccine.
C4591001 1248 12481182 Subject did not receive study vaccine.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:45)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adsl l001 excl p3 saf all
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\df17fa691e771090
FDA-CBER-2021-5683-0220385
Page 6","[[['', None, None, None, None], ['16.2.3.2 Listing of Subjects Excluded From Immunogenicity Populations – Phase 1, 2 Doses, 21 Days Apart –', None, None, None, None], ['BNT162b2 (30 μg)/Placebo', None, None, None, None], ['Age', 'Vaccine Group', '', '', ''], ['Group', '(as', None, None, None], ['(Years)', 'Randomized)', 'Subject', 'Population', 'Reason for Exclusion'], ['18-55', 'BNT162b2 (30', 'C4591001 1007', 'Dose 2 evaluable', 'Did not have blood collection within 6-8 days after Dose 2.'], ['', 'μg)', '10071050', '', ''], ['', 'Placebo', 'C4591001 1003', 'Dose 1 evaluable', 'Not eligible for the study at randomization; had important protocol deviation(s) as'], ['', '', '10031070', '', 'determined by the clinician.'], ['', '', '', 'Dose 2 evaluable', 'Not eligible for the study at randomization; had important protocol deviation(s) as'], ['', '', '', '', 'determined by the clinician.'], ['65-85', 'BNT162b2 (30', 'C4591001 1003', 'Dose 1 evaluable', 'Not eligible for the study at randomization; had important protocol deviation(s) as'], ['', 'μg)', '10031047', '', 'determined by the clinician.'], ['', '', '', 'Dose 2 evaluable', 'Not eligible for the study at randomization; had important protocol deviation(s) as'], ['', '', '', '', 'determined by the clinician.'], [None, None, None, None, ''], ['PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 28MAR2021 (15:28)', None, None, None, None], ['(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adsl l001 excl eval p1', None, None, None, None], ['', None, None, None, None]], [['', None, None, None, None], ['16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age', None, None, None, None], ['Age Group (Years)', None, 'Subject', 'Reason for Exclusion', None], ['16-55', None, 'C4591001 1003 10031140', 'Subject did not receive study vaccine.', None], ['', '', 'C4591001 1003 10031143', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1005 10051381', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1013 10131017', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1013 10131740', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1036 10361050', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571031', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571211', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571212', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571215', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1057 10571268', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1066 10661335', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1071 10711162', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1081 10811105', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1082 10821013', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1089 10891346', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1089 10891351', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1092 10921128', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1093 10931055', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1109 11091349', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1112 11121229', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1116 11161015', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1120 11201038', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1120 11201252', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1122 11221006', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1122 11221026', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1123 11231027', 'Subject did not receive study vaccine.', '']], [['', None, None, None, None], ['16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age', None, None, None, None], ['Age Group (Years)', None, 'Subject', 'Reason for Exclusion', None], ['', None, 'C4591001 1123 11231301', 'Subject did not receive study vaccine.', None], ['', '', 'C4591001 1126 11261074', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1129 11291048', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1133 11331162', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1135 11351389', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1149 11491108', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1161 11611002', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1161 11611005', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1161 11611006', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1161 11611011', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1161 11611015', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1161 11611016', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1161 11611018', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1161 11611019', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1162 11621024', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1162 11621477', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1167 11671003', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1168 11681030', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1205 12051028', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1212 12121023', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1223 12231200', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1223 12231234', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1224 12241170', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12311409', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12311516', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12311926', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12312176', 'Subject did not receive study vaccine.', '']], [['', None, None, None, None], ['16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age', None, None, None, None], ['Age Group (Years)', None, 'Subject', 'Reason for Exclusion', None], ['', None, 'C4591001 1231 12312483', 'Subject did not receive study vaccine.', None], ['', '', 'C4591001 1231 12313443', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12313527', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12313869', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12314738', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12315308', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1232 12321037', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1235 12351167', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1248 12481018', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1248 12481025', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1248 12481060', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1248 12481218', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1251 12511204', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1260 12601049', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1260 12601070', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1264 12641018', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 4444 44441135', 'Subject did not receive study vaccine.', ''], ['', '>55', 'C4591001 1013 10131097', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1019 10191033', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1019 10191300', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1022 10221015', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1022 10221057', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1022 10221150', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1037 10371057', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1037 10371117', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1044 10441113', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1054 10541071', 'Subject did not receive study vaccine.', '']], [['', None, None, None, None], ['16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age', None, None, None, None], ['Age Group (Years)', None, 'Subject', 'Reason for Exclusion', None], ['', None, 'C4591001 1054 10541175', 'Subject did not receive study vaccine.', None], ['', '', 'C4591001 1056 10561078', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1080 10801222', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1082 10821062', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1084 10841366', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1084 10841446', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1087 10871434', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1087 10871512', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1091 10911092', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1097 10971003', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1098 10981092', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1098 10981109', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1109 11091259', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1116 11161117', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1116 11161118', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1120 11201436', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1128 11281023', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1128 11281109', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1129 11291082', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1129 11291117', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1133 11331197', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1134 11341130', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1149 11491100', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1157 11571028', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1161 11611012', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1161 11611013', 'Unreliable data due to lack of PI oversight.', ''], ['', '', 'C4591001 1178 11781056', 'Subject did not receive study vaccine.', '']], [['', None, None, None, None], ['16.2.3.3 Listing of Subjects Excluded From Safety Population – All Subjects ≥16 Years of Age', None, None, None, None], ['Age Group (Years)', None, 'Subject', 'Reason for Exclusion', None], ['', None, 'C4591001 1185 11851006', 'Subject did not receive study vaccine.', None], ['', '', 'C4591001 1223 12231215', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1223 12231250', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1224 12241157', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1231 12312222', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1232 12321432', 'Subject did not receive study vaccine.', ''], ['', '', 'C4591001 1248 12481182', 'Subject did not receive study vaccine.', ''], [None, '', '', '', None], ['', 'PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:45)', None, None, ''], [None, '(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA/adsl l001 excl p3 saf all', None, None, None], ['', None, None, None, None]]]",6
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-011820-vials.pdf,1.0,"Food and Drug Administration SCHOTT AG
Center for Drug Evaluation and Research
Central Document Room Industriestrasse 3
5901-B Ammendale Road D-79379 Muellheim-Baden
Germany
Drug Master File Staff
Beltsville MD 20705-1266
USA
Phone +49 (0) 7631 36 85 0
Fax +49 (0) 7631 36 85 95
www.schott.com/pharmaceutical_systems
Date: September 22, 2020
DMF#: 011820
Holder: SCHOTT AG
Subject: GLASS VIALS MANUFACTURED IN MULLHEIM, GERMANY.
Letter of Authorization for: Entire DMF 011820
SCHOTT AG hereby authorizes the following company to incorporate by reference information regarding packag-
ing material in DMF 011820 into any application filed by this company for their product. We also authorize the
FDA to review all information in DMF 011820 when considering any application filed by this company.
Information to be referenced: Entire Type III DMF 011820,
Date of Submission: December 22, 1995
Company: Pfizer Agent for BioNTech RNA Pharmaceuticals GmbH
500 Arcola Road
19436 Collegeville, PA
USA
The DMF holder states that DMF 011820 is current and will comply with the statements made within it.
We request that all information in this file be treated as confidential within the meaning of 21 CFR 314.420.
Sincerely,
SCHOTT AG
Stefanie Stühmer
Customer Service
SCHOTT AG, Müllheim
)TMG(
21:60
1202-raM-62
:nO
devorppA\devorppA\dc1f0a691e771090
FDA-CBER-2021-5683-0225036",,1
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/signed-F21-5683-CBER-Dec-13-2021-Response-Letter.pdf,2.0,"DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration
Rockville, MD 20857
December 13, 2021
Mr. Aaron Siri
Siri & Glimstad LLP
200 Park Avenue
Seventeenth Floor
New York, NY 10166
Sent via email: aaron@sirillp.com
Re: FDA FOIA Request 2021-5683; Public Health and Medical Professionals for Transparency
v. FDA, 21-cv-01058-P
Dear Mr. Siri,
This is a partial response to the Freedom of Information Act (FOIA) request number 2021-5683 that is the
subject of the Complaint filed in Public Health and Medical Professionals for Transparency v. FDA, 21-cv-
01058, now pending in the U.S. District Court for the Northern District of Texas.
Enclosed are 2,890 pages of records, some of which contain redaction to prevent the disclosure of material
exempt from the FOIA.
In addition to those 2,890 pages, please find enclosed three txt files from page 10 and one txt file from page
11 of the provided Index as you requested in prioritized item number 5.1 We have also enclosed one xpt
(SAS) file from page 13 and four xpt (SAS) files from page 14 of the Index.2 Because we have assessed that
there is no exempt material in these txt and xpt files, there have been no deletions to the txt or xpt files. Per
your request, we have provided data files in their native format.
We have withheld portions of pages under FOIA Exemption (b)(4), 5 U.S.C. § 552(b)(4). That exemption
permits the withholding of trade secrets and commercial or financial information that was obtained from a
person outside the government and that is privileged or confidential.
1 Plaintiff provided its priority list of records via two emails from you to Courtney Enlow at the Department of Justice
on November 4, 2021.
2 In your request for records listed on page 10 of the Index, you indicated that you were interested in obtaining
“sample” SAS files. Although the files listed on page 10 and 11 all may appear to be SAS files, we have determined
that none of the files listed on page 10 and 11 are SAS files. As indicated above, we processed three files from page
10 and one file from page 11 for this production because you requested a record from page 10. To accommodate your
request for sample SAS files, we also processed one xpt (SAS) file that was listed on page 13 and four xpt (SAS) files
that were listed on page 14 of the Index, even though you did not prioritize files from pages 13 and 14 of the Index.
We have withheld portions of pages under FOIA Exemption (b)(6), 5 U.S.C. § 552(b)(6). That exemption
protects information from disclosure when its release would cause a clearly unwarranted invasion of personal
privacy. FOIA Exemption 6 is available to protect information in personnel or medical files and similar files.
This requires a balancing of the public’s right to disclosure against the individual’s right to privacy.
Please direct any questions regarding this response to Courtney Enlow of the Department of Justice, at
(202) 616-8467 or Courtney.D.Enlow@usdoj.gov.
Sincerely,
Beth Brockner Ryan
Chief, Access Litigation and Freedom of Information Branch
Division of Disclosure and Oversight Management
Office of Communication Outreach and Development
Center for Biologics Evaluation and Research
Enclosure(s)",,2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M2_summary-biopharm.pdf,3.0,"BNT162b2
2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
2.7.1 SUMMARY OF BIOPHARMACEUTIC STUDIES AND ASSOCIATED
ANALYTICAL METHODS
CONFIDENTIAL
Page 1
)TMG(
80:41
1202-raM-71
:nO
devorppA\devorppA\073a17691e771090
FDA-CBER-2021-5683-0142288
BNT162b2
2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
SUMMARY OF BIOPHARMACEUTIC STUDIES AND ASSOCIATED
ANALYTICAL METHODS
COVID-19 diagnostic and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
human serological assays were utilized in support of the Phase 1 and 2/3 clinical evaluation
of BNT162b2 (BioNTech code number BNT162, Pfizer code number PF-07302048),an
investigational vaccine intended to prevent COVID-19, which is caused by SARS-CoV-2.
Assay descriptions and summaries of the qualification or validation studies performed for
each assay method are included in Section 5.3.1.4 Reports of Bioanalytical and Analytical
Methods for Human Studies or Section 5.3.5.1 Study Reports and Related Information of
Controlled Clinical Studies Pertinent to the Claimed Indication. Per communications with the
Center for Biologics Evaluation and Research, primary endpoint assays used in the Phase 2/3
studies are validated; whereas assays used for exploratory endpoints are qualified.
Table1lists each bioanalytical method, the location of its corresponding assay summary, and
the assay parameters, including limit of detection (LOD), the lower and upper range, and/or
the assay’s lower limit of quantitation (LLOQ).
Table1. Summary of Bioanalytical Methods for Human Studies
Bioanalytical Method Title and Assay Parameters
Section
Location
LOD Lower Upper LLOQ
Range Range
Cepheid Xpert® 5.3.1.4 0.01
Xpress SARS-CoV-2a VR-MVR-10080 FFU/mL N/A N/A N/A
Roche Elecsys 5.3.1.4 N/A N/A N/A N/A
SARS-CoV-2 VR-MVR-10081
N-Binding Antibody
Assaya
Single-plex Direct 5.3.1.4 N/A 0.002533 0.128000 1.2665
Luminex Assay for VR-MQR-10211 U/mL well U/mL well Dilution adjusted
Quantitation of SARS- concentration concentration U/mL
CoV-2 S1-binding IgG
in Human Serumb
Single-plex Direct 5.3.1.4 N/A 0.002301 0.128000 1.1505
Luminex Assay for VR-MQR-10212 U/mL well U/mL well Dilution adjusted
Quantitation of SARS- concentration concentration U/mL
CoV-2
RBD-binding IgG in
Human Serumb
CONFIDENTIAL
Page 2
)TMG(
80:41
1202-raM-71
:nO
devorppA\devorppA\073a17691e771090
FDA-CBER-2021-5683-0142289
BNT162b2
2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
Table1. Summary of Bioanalytical Methods for Human Studies
Bioanalytical Method Title and Assay Parameters
Section
Location
LOD Lower Upper LLOQ
Range Range
mNeonGreen 5.3.1.4 20 N/A N/A N/A
SARS-CoV-2 VR-MQR-10214
Microneutralization
Assayb
mNeonGreen SARS- 5.3.1.4 20 41 3187 41
CoV-2 VR-MVR-10083
Microneutralization
Assaya,c
ELISpot Assayb 5.3.5.1 N/A N/A N/A N/A
BNT 162-01,
Appendix
16.1.14
R-20-0244
5.3.5.1 N/A N/A N/A N/A
BNT 162-01,
Appendix
16.1.14
GA-RB-022-
01A
Intracellular Cytokine 5.3.5.1 N/A N/A N/A N/A
Staining (ICS) for BNT 162-01,
BNT162b1b Appendix
16.1.14
R-20-0235
Intracellular Cytokine 5.3.5.1 N/A N/A N/A N/A
Staining (ICS) for BNT 162-01,
BNT162b2b Appendix
16.1.14
R-20-0241
a. Validation performed on method
b. Qualification performed on method
c.NT50 ranges shown.
Abbreviations: FFU = focus forming units; ICS = intracellular cytokine staining; LOD = limit of detection;
LLOQ = lower limit of quantitation; N/A = not applicable; NT = neutralizing titer; U = units
CONFIDENTIAL
Page 3
)TMG(
80:41
1202-raM-71
:nO
devorppA\devorppA\073a17691e771090
FDA-CBER-2021-5683-0142290",,3
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5351_c4591001-interim-mth6-randomization.pdf,2.0,"16.1.7.2 Listing of Subjects Who Transferred to a Different Site – All Subjects ≥16 Years of Age
Age Group
(Years) Subject Transferred to Site Reason for Transfer
16-55 C4591001 1013 10131005 1117 Subject moving to another site
16-55 C4591001 1013 10131498 1015 Subject is moving
16-55 C4591001 1013 10131518 1044 CTM request
16-55 C4591001 1022 10221179 1015 Subject change of address
16-55 C4591001 1055 10551061 1261 Subject moving to new site.
16-55 C4591001 1055 10551071 1224 Subject request
16-55 C4591001 1055 10551104 1269 Subject transfer to new site
16-55 C4591001 1068 10681100 1146 Subject request
16-55 C4591001 1080 10801135 1057 Subject transfer to new site.
16-55 C4591001 1081 10811012 1110 subject transfer to new site
16-55 C4591001 1081 10811023 1015 Subject request
16-55 C4591001 1081 10811042 1091 Subject transfer to new site
16-55 C4591001 1082 10821107 1156 Subject request
16-55 C4591001 1090 10901291 1260 CTM requested subject transfer
16-55 C4591001 1117 11171190 1114 subject moving to another site.
16-55 C4591001 1126 11261082 1270 Study team request
16-55 C4591001 1126 11261101 1270 Study team request
16-55 C4591001 1126 11261196 1130 Study team request
16-55 C4591001 1134 11341314 1156 Subject transfer based on request
16-55 C4591001 1135 11351099 1126 CTM requested subject transfer
16-55 C4591001 1135 11351100 1126 CTM requested subject transfer
16-55 C4591001 1135 11351480 1133 Subject moved to another site based on subject's request
16-55 C4591001 1140 11401176 1169 Subject change of address
16-55 C4591001 1141 11411046 1009 Subject request
16-55 C4591001 1162 11621304 1224 subject transfer to other site.
16-55 C4591001 1170 11701364 1117 Subject transfers from site 1170 to site 1117
16-55 C4591001 1170 11701365 1117 Subject transfers from site 1170 to site 1117
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\6f17fa691e771090
FDA-CBER-2021-5683-0128988
Page 1
16.1.7.2 Listing of Subjects Who Transferred to a Different Site – All Subjects ≥16 Years of Age
Age Group
(Years) Subject Transferred to Site Reason for Transfer
16-55 C4591001 1177 11771047 1152 Subject request
16-55 C4591001 1204 12041107 1226 Subject 12041107 transferred to 1226 site.
16-55 C4591001 1204 12041128 1091 Subject moving to another site
16-55 C4591001 1204 12041129 1091 Subject moving to another site
16-55 C4591001 1241 12412418 1226 Subject request
>55 C4591001 1001 10011098 1223 Subject moving to another site
>55 C4591001 1015 10151036 1260 Subject transferring to site 1260
>55 C4591001 1015 10151037 1260 Subject transferring to site 1260
>55 C4591001 1015 10151140 1083 Subject transfer to new site
>55 C4591001 1015 10151141 1083 Subject transfer to new site
>55 C4591001 1015 10151178 1260 CTM requested subject transfer
>55 C4591001 1015 10151244 1013 Subject moving to another site
>55 C4591001 1090 10901483 1027 subject transferring to new site
>55 C4591001 1204 12041119 1091 Subject moving to another site
>55 C4591001 1224 12241046 1168 Subject transfer to another site
>55 C4591001 1235 12351111 1171 Subject request
>55 C4591001 1260 12601113 1015 Subject transfer to new site
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:37)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA/adsl_l003_site
)TMG(
33:31
1202-rpA-10
:nO
laniF\laniF\6f17fa691e771090
FDA-CBER-2021-5683-0128989
Page 2","[[['', None, None, None, None, None], ['16.1.7.2 Listing of Subjects Who Transferred to a Different Site – All Subjects ≥16 Years of Age', None, None, None, None, None], ['Age Group\n(Years)', 'Age Group', '', '', '', None], [None, None, 'Subject', 'Transferred to Site', None, None], ['16-55', None, 'C4591001 1013 10131005', '1117', 'Subject moving to another site', None], ['', '16-55', 'C4591001 1013 10131498', '1015', 'Subject is moving', ''], ['', '16-55', 'C4591001 1013 10131518', '1044', 'CTM request', ''], ['', '16-55', 'C4591001 1022 10221179', '1015', 'Subject change of address', ''], ['', '16-55', 'C4591001 1055 10551061', '1261', 'Subject moving to new site.', ''], ['', '16-55', 'C4591001 1055 10551071', '1224', 'Subject request', ''], ['', '16-55', 'C4591001 1055 10551104', '1269', 'Subject transfer to new site', ''], ['', '16-55', 'C4591001 1068 10681100', '1146', 'Subject request', ''], ['', '16-55', 'C4591001 1080 10801135', '1057', 'Subject transfer to new site.', ''], ['', '16-55', 'C4591001 1081 10811012', '1110', 'subject transfer to new site', ''], ['', '16-55', 'C4591001 1081 10811023', '1015', 'Subject request', ''], ['', '16-55', 'C4591001 1081 10811042', '1091', 'Subject transfer to new site', ''], ['', '16-55', 'C4591001 1082 10821107', '1156', 'Subject request', ''], ['', '16-55', 'C4591001 1090 10901291', '1260', 'CTM requested subject transfer', ''], ['', '16-55', 'C4591001 1117 11171190', '1114', 'subject moving to another site.', ''], ['', '16-55', 'C4591001 1126 11261082', '1270', 'Study team request', ''], ['', '16-55', 'C4591001 1126 11261101', '1270', 'Study team request', ''], ['', '16-55', 'C4591001 1126 11261196', '1130', 'Study team request', ''], ['', '16-55', 'C4591001 1134 11341314', '1156', 'Subject transfer based on request', ''], ['', '16-55', 'C4591001 1135 11351099', '1126', 'CTM requested subject transfer', ''], ['', '16-55', 'C4591001 1135 11351100', '1126', 'CTM requested subject transfer', ''], ['', '16-55', 'C4591001 1135 11351480', '1133', ""Subject moved to another site based on subject's request"", ''], ['', '16-55', 'C4591001 1140 11401176', '1169', 'Subject change of address', ''], ['', '16-55', 'C4591001 1141 11411046', '1009', 'Subject request', ''], ['', '16-55', 'C4591001 1162 11621304', '1224', 'subject transfer to other site.', ''], ['', '16-55', 'C4591001 1170 11701364', '1117', 'Subject transfers from site 1170 to site 1117', ''], ['', '16-55', 'C4591001 1170 11701365', '1117', 'Subject transfers from site 1170 to site 1117', '']], [['', None, None, None, None, None], ['16.1.7.2 Listing of Subjects Who Transferred to a Different Site – All Subjects ≥16 Years of Age', None, None, None, None, None], ['Age Group\n(Years)', 'Age Group', '', '', '', None], [None, None, 'Subject', 'Transferred to Site', None, None], ['16-55', None, 'C4591001 1177 11771047', '1152', 'Subject request', None], ['', '16-55', 'C4591001 1204 12041107', '1226', 'Subject 12041107 transferred to 1226 site.', ''], ['', '16-55', 'C4591001 1204 12041128', '1091', 'Subject moving to another site', ''], ['', '16-55', 'C4591001 1204 12041129', '1091', 'Subject moving to another site', ''], ['', '16-55', 'C4591001 1241 12412418', '1226', 'Subject request', ''], ['', '>55', 'C4591001 1001 10011098', '1223', 'Subject moving to another site', ''], ['', '>55', 'C4591001 1015 10151036', '1260', 'Subject transferring to site 1260', ''], ['', '>55', 'C4591001 1015 10151037', '1260', 'Subject transferring to site 1260', ''], ['', '>55', 'C4591001 1015 10151140', '1083', 'Subject transfer to new site', ''], ['', '>55', 'C4591001 1015 10151141', '1083', 'Subject transfer to new site', ''], ['', '>55', 'C4591001 1015 10151178', '1260', 'CTM requested subject transfer', ''], ['', '>55', 'C4591001 1015 10151244', '1013', 'Subject moving to another site', ''], ['', '>55', 'C4591001 1090 10901483', '1027', 'subject transferring to new site', ''], ['', '>55', 'C4591001 1204 12041119', '1091', 'Subject moving to another site', ''], ['', '>55', 'C4591001 1224 12241046', '1168', 'Subject transfer to another site', ''], ['', '>55', 'C4591001 1235 12351111', '1171', 'Subject request', ''], ['', '>55', 'C4591001 1260 12601113', '1015', 'Subject transfer to new site', ''], [None, '', '', '', '', None], ['PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:37)\n(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA/adsl_l003_site', None, None, None, None, None], ['', None, None, None, None, None]]]",2
/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5314_shi-sop-10011.pdf,16.0,"UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
TABLE OF CONTENTS
1. HISTORICAL REVISION SUMMARY...............................................................................2
Table 1. Chronological Summary of Previous Versions........................................................2
2. PURPOSE.............................................................................................................................2
3. SCOPE...................................................................................................................................2
4. GLOSSARY...........................................................................................................................2
Table 2. Terms and Definitions..................................................................................................2
5. GENERAL.............................................................................................................................3
6. RESPONSABILITIES..........................................................................................................4
Table 3. Roles and Responsibilities..........................................................................................4
7. SAFETY.................................................................................................................................5
8. MATERIALS AND EQUIPMENT.......................................................................................5
9. PROCEDURE.......................................................................................................................6
9.1. Day 0: Preparation of ROPs............................................................................................... 6
9.1.1. Seeding Cells.................................................................................................................6
9.2. Day 1: Preparation of SAPs................................................................................................ 8
9.2.1. Sera Dilution/Infection...................................................................................................9
9.2.2. Processing of SAPs....................................................................................................10
9.2.3. Preparation of Viral Stock Solution...........................................................................11
9.2.4. Addition of Viral Stock Solution to SAPs and Neutralization of Virus..................11
9.2.5. TransferNeutralization Reaction onto ROPs and Decontamination of SAPs....11
9.3. Day 2: Acquire images......................................................................................................12
9.3.1. Preparation and Addition of Hoechst 33342 Solution to ROPs............................13
9.3.2. Image Acquisition and Counting on the Cytation 7................................................13
9.4. Analysis of Data and Calculation of SARS-CoV-2_NT Titers.....................................13
9.5. SARS-CoV-2_NT Data and Document Review............................................................13
10. REFERENCES...................................................................................................................14
Table 6. Form References........................................................................................................14
11. DOCUMENT VERSION MODIFICATIONS...................................................................14
Table 7. Detailed Changes......................................................................................................14
UTMB-Shi Lab CONFIDENTIAL
Page 1
FDA-CBER-2021-5683-0142291
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
Document Approval Record.....................................................................................................15
1. HISTORICAL REVISION SUMMARY
Table 1. Chronological Summary of Previous Versions
Version # Effective Date Originator Summary
2.0 Current Pei-Yong Shi Approved.
1.1 20200614 Xuping Xie Revised…
1.0 20200529 Camila Fontes New Document
2. PURPOSE
This document describes the procedure for a manual 96-well SARS-CoV-2-mNG
reporter virus neutralization assay (SARS-CoV-2_NT) designed to measure functional,
neutralizing antibodies specific for SARS-CoV-2 in test serum using Cytation 5 Image
Reader.
3. SCOPE
The scope applies to all personnel in the Shi Lab at UTMB responsible to support Pfizer
clinical study.
NOTE: Procedures for other UTMB and Pfizer groups may vary in format, content,
numbering, and approval procedures.
4. GLOSSARY
Table 2. Terms and Definitions
TERM DEFINITION
Ab Antibody
Batch A sample list for an assay. One batch contains all samples tested in
a single assay run.
BSC Biological Safety Cabinet
Cytation 7 Cell imaging multi-mode reader manufactured by Biotek
FBS Fetal Bovine Serum
FFU Focus Forming Units
Gen5 Software associated with the Cytation 7
UTMB-Shi Lab CONFIDENTIAL
Page 2
FDA-CBER-2021-5683-0142292
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
GMT Geometric Mean Titer
HBSS Hanks' Balanced Salt Solution
Hoechst 33342 Cell-permeant nuclear counterstain that emits blue fluorescence
when bound to dsDNA
Monolayer Cell culture in which cells are grown in a single homogenous layer
PPE Personal Protective Equipment
PBS Phosphate Buffered Saline
ROP Read Out Plate
SARS-CoV- Manual 96-well neutralization assay for the detection of functional
2_NT antibodies to SARS-CoV-2
SARS-CoV-2 SARS-CoV-2_NT reference document that contains clinical or
Critical Reagent developmental study-specific information, eg, viral bank number,
Reference Form viral bank date, viral stock solution dilution, and staining antibody
information. One critical reagent form is created prior to the start of
each clinical study or assay development activity.
QCS Quality Control Sample
QNS Quantity Not Sufficient
SAP Sample Assay Plate
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
SARS-CoV-2- SARS-CoV-2-mNeonGreen reporter virus
mNG
SOP Standard Operating Procedure
Titer The reciprocal of the dilution of a test serum required to neutralize
virus at a specified percentage of the viral input in a neutralization
assay
VSS Viral Stock Solution
Vero African green monkey kidney epithelial cells
5. GENERAL
The SARS-CoV-2_NT is a biofunctional assay designed to measure total serum
antibody levels capable of neutralizing SARS-CoV-2 infection of cells in culture.
The SARS-CoV-2-NT is a three-day assay, performed manually. On Day 0, African
green monkey kidney epithelial cells (Vero) are seeded into 96-well tissue-culture
treated plates. On Day 1, serial dilutions of heat-inactivated immune sera in sample
assay plates (SAPs) are incubated with SARS-CoV-2-mNG reporter virus for 60
minutes to allow antigen specific antibodies to bind to the virus. The reaction is then
transferred onto the Vero cell monolayer read-out plates (ROPs) and allowed to
incubate overnight; only non-neutralized virus is able to infect the cells. On Day 2,
productive viral infection is detected in live cells using the mNeonGreen expressed by
UTMB-Shi Lab CONFIDENTIAL
Page 3
FDA-CBER-2021-5683-0142293
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
the reporter virus. Live cells are stained with Hoechst 33342. Both viral foci and live
cells are enumerated from the ROPs on a Cytation 7 reader.
A sample titer is calculated as the reciprocal serum dilution at which a specific
percentage of the virus is neutralized (eg, 50% or 90% of the virus). This value is
referred to as the titer determining value (TDV). To calculate this percentage, an
infection rate must first be determined by dividing the number of viral foci by live cells in
any given well. The percent neutralization is then determined by comparing the
infection rates of the serum containing wells to that of the control wells without serum
samples. A titer is calculated for each of the two replicates of a sample and the
geometric mean titer (GMT) of the two is reported as the final sample titer.
The initial serum dilution for the SARS-CoV-2_NT is 1:20, which, along with a 9-point 2-
fold serum dilution series, enables a potential plate titer range of 20 to 5,120. Samples
that receive titers greater than 5,120 are retested after pre-dilution in assay buffer.
Samples that fail to neutralize at the TDV when tested at the lowest serum dilution of
1:20 are reported to have a neutralizing titer of 10, one half of the LOD of 20.
A quality control sample (QCS) is run on each assay plate to assess plate and run
suitability. Plating of Vero onto the ROPs occurs at least 20 hours prior to the infection
of the monolayer. This incubation time allows the cells to adhere to the plate surface
and grow to a confluent monolayer to allow for consistent measurement of infection.
6. RESPONSABILITIES
 All personnel must be trained and knowledgeable with theprocess. Personnel can
have multiple roles within the process but may only sign once withthe most
appropriate approval code.
Table 3. Roles and Responsibilities
Roles Responsibilities
SARS-CoV-2_NT  Read, understand, and complete training and qualification on
-Analyst this test method.
-Coordinator  Read, understand, and complete training on applicable
-Data Analyst equipment operating manuals, procedures and test methods
CF that are required to execute the procedure described in this
document.
 Execute this test method and complete SHI-TM-10011-FM01
and SHI-TM-10011-FM02.
 Consult with the PI if there are any questions related to the
procedure itself or serum samples, if an atypical event is
UTMB-Shi Lab CONFIDENTIAL
Page 4
FDA-CBER-2021-5683-0142294
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
observed or if a protocol deviation occurs.
 Provides detailed scheduling of all SARS-CoV-2_NT runs.
 Creates assay run batches and corrects run information with
QNS information from the annotated SHI-TM-10011-FM01.
 Prepare SARS-CoV-2_NT assay plates
 Maintain and grow Vero cells.
 Plate the appropriate concentration of Vero cells
Reviewer XP  Review SARS-CoV-2_NT documentation to ensure
completeness of data entry and compliance with Shi Lab
policies. Direct the SARS-CoV-2_NT Analyst to correct
documentation errors.
 Verify that documentation is complete and compliant.
Supervisor PY  Read and understand this test method.
 Review and approve this test method.
 Ensure that SARS-CoV-2_NT analysts executing this test
method are trained in the appropriate procedures and test
methods.
 Provide guidance to SARS-CoV-2_NT analysts and reviewers
and answer any questions that arise during the execution of this
procedure.
7. SAFETY
 Biosafety level 3 (BSL-3) precautions are required for any work with SARS-CoV-2
virus and has to be handled in accordance with BSL-3 procedures.
o Prior to starting work at BSL3:
o Register as BSL3 worker and complete the training and access requirements
for BSL3 facilities:
 UTMB BSL3 training course
 BSL3 facility specific training and access checklist form
 BSL3 check off
 BSL3 mentorship
 All laboratory work is to be carried out in compliance with UTMB safety policies and
generally accepted laboratory safety guidelines.
 Refer to Laboratory Safety Reference Manual found on UTMB Website at
https://liveutmb.sharepoint.com/:b:/r/sites/collaboration/webfiles/Shared%20Docume
nts/EHS/Website_Files/UTMB%20Safety%20Manual%202019_3-5-
20.pdf?csf=1&web=1&e=lKehru
8. MATERIALS AND EQUIPMENT
UTMB-Shi Lab CONFIDENTIAL
Page 5
FDA-CBER-2021-5683-0142295
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
 Cell bank of Vero African green monkey kidney epithelial cells (ATCC CCL81). Each
vial is used from p1 to p35.
 Viral stock of SARS-CoV-2 mNeonGreen, prepared in individual use aliquots (virus
construction described in Xie et al 2020). Viral stock is at ~2x107 PFU/mL.
 Black µCLEAR flat-bottom 96-well plates (Greiner Bio-one™ 655090)
 Corning™ Clear Polystyrene 96-Well Microplates, round bottom (Corning Cat. No:
3799)
 DMEM (Gibco Cat. No: 11965-092)
 Fetal Bovine Serum (Hyclone Cat. No.: SH30071.03)
 Penicillium-Streptomycin (P/S) (10,000 U/ml) (Gibco Cat. No: 15140-122)
 Gibco™ Trysin-EDTA (0.25%), phenol red (Gibco Cat. No.: 25200072)
 Phosphate Buffered Saline (PBS) solution, pH 7.4 (Gibco Cat. No.: 10010-023)
 Gilson™ Accessory for PIPETMAN Complete Pipetting System
 Reagent Reservoirs 25 ml (Gilson Cat. No.: F267660) & 50 ml (Gilson Cat. No.:
F267670)
 Cell Counting slides for TC10™/TC20™ Cell Counter, dual-chamber (Bio-Rad Cat.
No.: 1450011)
 Corning™ Cell Culture Treated flasks .2µM Vent Cap T175cm2 (Corning™ Cat. No.:
431080)
 VACUBOY Hand Operator (INTEGRA Biosciences)
 Eppendorf Xplorer pipette, electronic 12 channel pipette 15-300 µL (Eppendorf Cat.
No.: 4861000031)
 TC20™ Automated Cell Counter (Bio-Rad)
 Dualfilter 200ul (filtered tips) (Eppendorf Cat. No.:0030077.555)
 Hank’s Balanced Salt Solution (HBSS) (1X) (Gibco Cat. No:14025-092)
 Breath-Easy sealing membrane. (Diversified Biotech Cat No.: BEM-1)
 Tissue culture CO incubator
2
 Cell Imager or inverted microscope
 Microplate Reader (BioTek) (Cytation 7 Cell Imaging Multi-Mode Reader)
 Hoechst 33342 (20mM) (Thermo Scientific Prod # 62249)
 DMEM (1X) (Phenol Red Free) (Gibco Cat. No: 31053-028)
 GlutaMAXTM-1 (100X) (Gibco Cat. No: 35050-061)
9. PROCEDURE
9.1. Day 0: Preparation of ROPs
o Note: Refer to Tables 3-9 of SHI-TM-10011-FM01.
o Ensure the incubators are reading at 37°C/5% CO 2. Confirm that water
reservoir is full.
9.1.1. Seeding Cells
o Seed cells into 96-well plate Black Microplates.
UTMB-Shi Lab CONFIDENTIAL
Page 6
FDA-CBER-2021-5683-0142296
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
o Remove the cotton filter from 2ml serological pipette and assembly on the
hand operator of the VACUBOY
o Remove the medium from the cells using the VACUBOY.
o Briefly rinse the cell layer with 25ml PBS (same volume as the growth
medium) to remove all traces of serum that contains trypsin inhibitor. Remove
PBS using the VACUBOY. Repeat, wash twice.
o Note: make sure rinse every corner of the flask to get rid of any trypsin
inhibitor.
o Add 3ml Trypsin-EDTA solution. Observe cells under an inverted microscope
until cell layer is dispersed (usually within 2 minutes at RT).
o Note: The activity of trypsin decreases when stored at 4°C. Do not store
trypsin at 4°C for > 1 week.
o Hit/tap the flask to detach cells, add 10 mL of complete growth medium and
shake the flask to let the medium cover all the trypsinazed cells in order to
inhibit the trypsin. Aspirate the cell suspension by gently pipetting and
transfer the cell suspension into 50ml falcon tube.
o Centrifuge, RT, 3min, 1200rpm (300g)
o Remove media carefully don’t get too close to the cells.
o Resuspend cells in phenol red free media (DMEM phenol red free, 2% FBS,
1% P/S, 2% GlutaMAX). Disperse cells by tapping the tube with finger gently,
this is critical steps make sure cells are evenly dispersed. Add 5ml of media,
keep tapping and swirling to resuspend, add more media (10-20 ml mix by
pipetting up/down). Note: Using phenol red free media reduces the
background when reading the plate.
o Count using the cell counter (C-Chip DHC-N01-5). Count live cells. Get a
microcentrifuge tube and mix 50ul of trypan blue with 50ul of cell suspension.
Add mixture to both sides of counting slide, count both sides to get the
average of live cells.
o Dilute to 2.4×105 cells/ml. Add 50 µl of the diluted cell suspension to each
well in the 96-well plate (ROP) to reach 1.2×104 cells/well. Note: to make
sure the cells are evenly distributed in the 96-well plate. Leave the plate on
the bench after seeding about 5-10min, then hit/tap the plate gently to make
cells evenly distribute in the wells.
 Example: 1-96W plate 50ul/well, live cell count= 1.0×106
UTMB-Shi Lab CONFIDENTIAL
Page 7
FDA-CBER-2021-5683-0142297
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
o Add 1-5 ml of the remaining cell suspension to new culture flask to continue
to grow cells depending on your needs.
o Incubate cell plates at 37°C. 6. Ensure ROPs have incubated at least 20
hours prior to execution of Transfer of Neutralization Reaction onto ROPs
9.2. Day 1: Preparation of SAPs
o Note: Refer to Tables 3-9 of SHI-TM-10011-FM01.
o Ensure the incubators are reading at 37°C/5% CO 2. Confirm that water
reservoir is full.
o Inspect 6 wells at random of 2 ROPs per run under the light microscope to
ensure the monolayer is healthy with no microbial contamination and has
≥80% confluency. A healthy Vero monolayer is evenly dispersed squamous
cells adhered to the bottom of the ROP well. Record abnormalities in Table
13 of SHI-TM-10011-FM01.
o ROP. Label and number each plate appropriately (typically 1-12) in the
Biosafety hood with marker and store in 37 °C/5% CO until transfer.
2
ROP lid labeling
UTMB-Shi Lab CONFIDENTIAL
Page 8
FDA-CBER-2021-5683-0142298
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
ROPside labeling
o Heat inactive all the sera at 56C, 30mins (If needed)
9.2.1. Sera Dilution/Infection
o SAP. Take a new 96-well plate with lid (clear plate, for dilutions). Label and
number each plate appropriately (typically 1-12) in the Biosafety hood with
marker.
SAP lid labeling
SAP side labeling
o
o Prepare serial dilutions of serum. Refer to SHI-SOP-10002 to process
samples.
o Prepare 10 serials of 2-fold dilutions. The highest dilution is 10 folds. Prepare
duplicates. See step 5
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10
10 20 40 80 160 320 640 1280 2560 0
D1: 6μl + 56 μl2% FBSmedium.
D2-D9: 30μl dilutedsamples + 30μlmedium.
o Transfer proper medium (according to cell type, phenol red free
DMEM+2%FBS+1%P/S) to the 50ml reservoir to facilitate the use of a
multichannel pipette (each plate needs 3.3ml, aliquot 4ml for each plate)
o Skip the first column. The outer wells are not used.
o Columns #3-11 add 30 µl DMEM+2%FBS+1%P/S.
o Notes: Columns 3-10, add 30 µl DMEM+2%FBS+1%P/S for 2-fold serial
dilution from column 3. Column #11 on the 96W plate is control without any
antibody.
o Columns #3-10, add 30 µl DMEM+2%FBS+1%P/S for 2-fold serial dilution
from column 3
o Column #1 and 12, add 60 µl DMEM+2%FBS+1%P/S.
UTMB-Shi Lab CONFIDENTIAL
Page 9
FDA-CBER-2021-5683-0142299
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
o Column #2 add 54 µl DMEM+2%FBS+1%P/S, then mix with 6 µl serum. Mix
without creating bubbles. Note: the starting dilution is 1:10, then followed
with 10, 20, 40, 80, 160, 320, 640, 1280, 2560 dilutions (refer to step 4).
Overall dilution will be 1:20 once virus is added.
o Column #2, mix using an electronic 12-channel pipette (settings, P/M, 30/50,
speed 6/4, 5X), discard the tips
o Load new tips, transfer 30 µl from column #2 to column #3 (settings, P/M,
30/50, speed 6/4, 5X), discard the tips
o Repeat step 12 for column #4 to #10
o Attention: remember to take 30 µl from column #10 after dilution and discard.
The total volume of the dilute serum should be 30µl/well
o Sera dilution plate set-up (SAP). Samples are run in duplicates. The outer
wells are not used for dilutions, just add media. Column 11 is reserved for
viral input (wells B11-G11). Column 12 is reserved for cell control to monitor
cell contamination (wells B12-G12). Row H is reserved for a QCS (wells H2
H10). The QCS is used to assess plate and run suitability.
Well 1 2 3 4 5 6 7 8 9 10 11 12
Reciprocal N/A 20 40 80 160 320 640 1,280 2,560 5,120 N/A N/A
Serum
Dilution
A
UTMB-Shi Lab CONFIDENTIAL
Page 10
suriV
+
aideM
Media + Virus
B Test Sample 1 (Virus+Serum)
lortnoc
tupni
suriV
lortnoc
lleC
C Test Sample 1 replicate (Virus+Serum)
D Test Sample 2 (Virus+Serum)
E Test Sample 2 replicate (Virus+Serum)
F Test Sample 3 (Virus+Serum)
G Test Sample 3 replicate (Virus+Serum)
H Quality Control Sample (Virus+Serum) Media + Virus
9.2.2. Processing of SAPs
o Transfer SAPs and ROPs to BSL3.
o Note: Refer to Tables 3-9 of SHI-TM-10011-FM01.
o Ensure the incubators are reading at 37°C/5% CO 2. Confirm that water
reservoir is full.
o Confirm a correct set of assay plates.
o Inspect plates to confirm that all wells of each SAP contain approximately 30
µL liquid and that volumes are consistent from well to well. Use the Atypical
Event(s) box (Table 13 of SHI-TM-10011-FM01) to record the location of any
wells that have no liquid or appear to have a volume other than 30 µL. Do not
use a pipette to measure well volumes; this step is a visual inspection only.
FDA-CBER-2021-5683-0142300
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
o Number each SAP with a marker. The hand-written number dictates the
order in which the SAPs will receive a reagent and corresponds to its
respective ROP.
o Place ROPs in incubator.
9.2.3. Preparation of Viral Stock Solution
o Note: Refer to Table 7 of SHI-TM-10011-FM01.
o Perform all manipulations of reagents and active virus in a Level II biosafety
cabinet within the BSL-3 laboratory using sterile techniques.
o In BSC add 30 μl diluted SARS-CoV2-mNG virus. 1µl reporter virus + 29µl
media/well (phenol red free). Any new batch of virus should be tested before
use. Use the volume of virus that can cause about 30% infection rate at 24 h
post-infection.
o Complete Viral Stock Solution (VSS) Table; verify with another analyst.
o Remove the appropriate number of frozen viral stock vials from -80 °C
freezer.
o Thaw virus in distilled water at room temperature.
o If multiple vials are needed, pool all vials into a larger tube and pipette up and
down 3 times to ensure proper mixing.
o Label a sterile bottle “VSS”. Add the appropriate volume of Assay Media.
o Add the appropriate volume of SARS-CoV-2-mNG into VSS bottle and gently
swirl to mix.
9.2.4. Addition of Viral Stock Solution to SAPs and Neutralization of Virus
o Transfer diluted virus to the 25ml reservoir to facilitate the use of a
multichannel pipette (each plate needs ~2ml, 60 wellsx30µl=1800µ, always
make 1ml extra to the total volume to avoid running out)
o Add 30μl of diluted virus to each well of the plate which containing diluted
sera (SAP). Mix using an electronic 12-channel pipette (settings, P/M, 30/50,
speed 6/4, 5X), after each column discard the tips
o Incubate at 37°C/5% CO 2 for 1 hour.
o Record the start and end times for this incubation in Table 8 in SHI-TM-
10011-FM01.
9.2.5. Transfer Neutralization Reaction onto ROPs and Decontamination of
SAPs
o Note: Refer to Table 9 of SHI-TM-10011-FM01.
o Remove ROPs from incubator.
o Transfer 50μl virus-Ab diluted plate (SAP) to 96-well plate seeded on day 0
(ROP) (plates containing cells 1.2x104 in 50 μl/well, after adding the diluted
reporter virus the total volume of each well will be 100µl). Mix using an
electronic 12-channel pipette (settings, P, 50/80, speed 3/3, 3X), after each
column discard the tips. Note: do not touch the bottom of the plate, add the
mixture on the side of the well, make sure the pipette tip is touching the media
to avoid making bubbles when mixing. It is very important to avoid bubbles,
mix well, and do not disturb the cells to get an even infection.
UTMB-Shi Lab CONFIDENTIAL
Page 11
FDA-CBER-2021-5683-0142301
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
o ROP. Cells+Ab+reporter plate set up (black plate)
1 2 3 4 5 6 7 8 9 10 11 12
A
Sample 1 B +V +V +V +V +V +V +V +V +V +V No virus
Sample 1 C +V +V +V +V +V +V +V +V +V +V No virus
Sample 2 D +V +V +V +V +V +V +V +V +V +V No virus
Sample 2 E +V +V +V +V +V +V +V +V +V +V No virus
Sample 3 F +V +V +V +V +V +V +V +V +V +V No virus
Sample 3 G +V +V +V +V +V +V +V +V +V +V No virus
H
o Incubate ROPs at 37°C5% CO 2 for 16-24HR.
o Record the time the ROPs were placed in incubator in Table 9 of SHI-TM-
10011-FM01.
9.3. Day 2: Acquire images
o Note: Refer to Tables 10-12 of SHI-TM-10011-FM01.
o At 16-24 h post-infection, read the plate using Cytation 7 Cell Imaging Multi-
Mode Reader
o Prior to imaging, carefully examine the instrument CytationTM 7, bioStackTM
4 robotor and the workplace. Please ensure no used plates or any boxes
blocking the plate carrier.
o Power on the instrument, wait about 5 minutes to warm up the instrument.
Green light will show on the machine if instrument if it is ready. Open the
Gen5 software from the instrument attached computer and make sure the
software communicates with the instrument. Choose the right program for
reading (Since all the reading will be performed with plate lid-on, please make
sure the lid has been selected in your program).
o If the bioStackTM 4 is going to be used for your experiment, place test-plates
(set of empty plates dedicated for testing only) on the bioStackTM 4 robotor
UTMB-Shi Lab CONFIDENTIAL
Page 12
FDA-CBER-2021-5683-0142302
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
and run a quick test to verify the system and protocol. Ensure the
bioStackTM 4 robotor transfers the plates smoothly.
o If the instrument is under any abnormal conditions, do not use the instrument.
Notify the lab manager or PI immediately.
o Weekly System Checks and Calibration plate instructions are described in
SHI-SHOP-10006
9.3.1. Preparation and Addition of Hoechst 33342 Solution to ROPs
o Carefully transfer the plates in a secondary container from the incubator to
the biosafety cabinet.
o Add 25 μl diluted Hoechst 33342 Solution (500-fold in HBSS) to each well of
the 96-well plates.
o Seal the plates carefully with films.
o Incubate plate at 37°C for about 20 minutes.
9.3.2. Image Acquisition and Counting on the Cytation 7
o After surface decontamination with calvicide, carefully transfer the plate with a
secondary container to CytationTM 7 or BioStackTM 4 to acquire images by
following the operation manual attached to the instrument.
o The individual who performed scanning and counting completes the “Cytation
7 Analyst” section of Table 1 of SHI-TM-10011-FM01 and enters the date that
these steps were completed.
o At the end of the experiment, remove the plate from the carrier and transfer it
to the biosafety cabinet. Use 70% ethanol to wipe out the plate carrier. And
power off the instrument. Disinfect and dispose all the plates and liquid
properly according to the laboratory waste disposal procedures.
9.4. Analysis of Data and Calculation of SARS-CoV-2_NT Titers
o The individual who performs data analysis completes the “SAS Operator/Data
Analyst” section on Table 1 of SHI-TM-10011-FM01 and enters the date the
steps were completed.
o SARS-CoV-2_NT serum titers are calculated, and data is interpreted
according to the instructions outlined in SHI-SOP-10011
o Complete Table 14 of SHI-TM-10011-FM01.
9.5. SARS-CoV-2_NT Data and Document Review
o The individual who performs data and document review completes the
“Reviewer” section on Table 1 of SHI-TM-10011-FM01 and enters the date
the steps were completed.
o Assembly of SARS-CoV-2_NT data packages, review of worksheets to
confirm that proper documentation practices are followed, and review and
processing of data are described in SHI-SOP-10012. Checklists and
comments for the documentation reviews are provided in SHI-TM-10011-
FM01 Tables 15 and 16.
UTMB-Shi Lab CONFIDENTIAL
Page 13
FDA-CBER-2021-5683-0142303
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to
SARS-CoV-2 in Test Serumusing Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
10.REFERENCES
Xie X, Muruato M, Lokugamage KG et al, An Infectious cDNA Clone of SARS-CoV-2. Cell
Host & Microbe 2020, 27 (5): 841-848.
Table 6. Form References
Document Title
SHI-SOP-10011 NT50 and NT90 calculations for SARS-CoV-2
Neutralization Assay
SHI-SOP-10012 Data transferring between UTMB and Pfizer
SHI-SOP-10006 Equipment Management
SHI-TM-10011-FM01 Manual 96-well SARS-CoV-2 Neutralization Assay
Worksheet
SHI-TM-10011-FM02 Manual Sample Preparation for the 96-well SARS-
CoV-2 Neutralization Assay Worksheet
11.DOCUMENT VERSION MODIFICATIONS
Table 7. Detailed Changes
List detailed changes for documents List rationale for each change
N/A N/A
UTMB-Shi Lab CONFIDENTIAL
Page 14
FDA-CBER-2021-5683-0142304
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies
to SARS-CoV-2 in Test Serum using Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
Document Approval Record
Document Name:
SHI-SOP-10011
Document Title:
Manual 96-well Neutralization Assay for the Detection of
Functional Antibodies to SARS-CoV-2 in Test Serum using
Cytation 7 Image Reader
Signed By: Date Signing Capacity
Fontes, Camila 20200614 Author Approval
Shi, Pei-Yong Final Approval
UTMB-Shi Lab CONFIDENTIAL
Page 15
FDA-CBER-2021-5683-0142305
UTMB-Shi Lab SOP
TITLE: Manual 96-well Neutralization Assay for the Detection of Functional Antibodies
to SARS-CoV-2 in Test Serum using Cytation 7 Image Reader
Doc.Number: SHI-SOP-10011 Version: 2.0
PERSONS TRAINED IN THIS PROTOCOL:
The following persons state that they have read and understood the protocol and the risk
assessment and have been properly trained in the procedures.
Name: Date: Signature: Name andSignature of
Trainer:
UTMB-Shi Lab CONFIDENTIAL
Page 16
FDA-CBER-2021-5683-0142306","[[['Version #', 'Effective Date', 'Originator'], ['2.0', 'Current', 'Pei-Yong Shi'], ['1.1', '20200614', 'Xuping Xie'], ['1.0', '20200529', 'Camila Fontes']], [['TERM', 'DEFINITION'], ['Ab', 'Antibody'], ['Batch', 'A sample list for an assay. One batch contains all samples tested in\na single assay run.'], ['BSC', 'Biological Safety Cabinet'], ['Cytation 7', 'Cell imaging multi-mode reader manufactured by Biotek'], ['FBS', 'Fetal Bovine Serum'], ['FFU', 'Focus Forming Units'], ['Gen5', 'Software associated with the Cytation 7']], [['GMT', 'Geometric Mean Titer'], ['HBSS', ""Hanks' Balanced Salt Solution""], ['Hoechst 33342', 'Cell-permeant nuclear counterstain that emits blue fluorescence\nwhen bound to dsDNA'], ['Monolayer', 'Cell culture in which cells are grown in a single homogenous layer'], ['PPE', 'Personal Protective Equipment'], ['PBS', 'Phosphate Buffered Saline'], ['ROP', 'Read Out Plate'], ['SARS-CoV-\n2_NT', 'Manual 96-well neutralization assay for the detection of functional\nantibodies to SARS-CoV-2'], ['SARS-CoV-2\nCritical Reagent\nReference Form', 'SARS-CoV-2_NT reference document that contains clinical or\ndevelopmental study-specific information, eg, viral bank number,\nviral bank date, viral stock solution dilution, and staining antibody\ninformation. One critical reagent form is created prior to the start of\neach clinical study or assay development activity.'], ['QCS', 'Quality Control Sample'], ['QNS', 'Quantity Not Sufficient'], ['SAP', 'Sample Assay Plate'], ['SARS-CoV-2', 'Severe acute respiratory syndrome coronavirus 2'], ['SARS-CoV-2-\nmNG', 'SARS-CoV-2-mNeonGreen reporter virus'], ['SOP', 'Standard Operating Procedure'], ['Titer', 'The reciprocal of the dilution of a test serum required to neutralize\nvirus at a specified percentage of the viral input in a neutralization\nassay'], ['VSS', 'Viral Stock Solution'], ['Vero', 'African green monkey kidney epithelial cells']], [['Roles', 'Responsibilities'], ['SARS-CoV-2_NT\n-Analyst\n-Coordinator\n-Data Analyst\nCF', '\uf0b7 Read, understand, and complete training and qualification on\nthis test method.\n\uf0b7 Read, understand, and complete training on applicable\nequipment operating manuals, procedures and test methods\nthat are required to execute the procedure described in this\ndocument.\n\uf0b7 Execute this test method and complete SHI-TM-10011-FM01\nand SHI-TM-10011-FM02.\n\uf0b7 Consult with the PI if there are any questions related to the\nprocedure itself or serum samples, if an atypical event is']], [['', 'observed or if a protocol deviation occurs.\n\uf0b7 Provides detailed scheduling of all SARS-CoV-2_NT runs.\n\uf0b7 Creates assay run batches and corrects run information with\nQNS information from the annotated SHI-TM-10011-FM01.\n\uf0b7 Prepare SARS-CoV-2_NT assay plates\n\uf0b7 Maintain and grow Vero cells.\n\uf0b7 Plate the appropriate concentration of Vero cells'], ['Reviewer XP', '\uf0b7 Review SARS-CoV-2_NT documentation to ensure\ncompleteness of data entry and compliance with Shi Lab\npolicies. Direct the SARS-CoV-2_NT Analyst to correct\ndocumentation errors.\n\uf0b7 Verify that documentation is complete and compliant.'], ['Supervisor PY', '\uf0b7 Read and understand this test method.\n\uf0b7 Review and approve this test method.\n\uf0b7 Ensure that SARS-CoV-2_NT analysts executing this test\nmethod are trained in the appropriate procedures and test\nmethods.\n\uf0b7 Provide guidance to SARS-CoV-2_NT analysts and reviewers\nand answer any questions that arise during the execution of this\nprocedure.']], [['ROP lid labeling', '']], [['ROPside labeling', '']], [['SAP lid labeling', ''], ['SAP side labeling', '']], [['D1', 'D2', 'D3', 'D4', 'D5', 'D6', 'D7', 'D8', 'D9', 'D10'], ['10', '20', '40', '80', '160', '320', '640', '1280', '2560', '0']], [['Well', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12'], ['Reciprocal\nSerum\nDilution', 'N/A', '20', '40', '80', '160', '320', '640', '1,280', '2,560', '5,120', 'N/A', 'N/A'], ['A', 'suriV\n+\naideM', 'Media + Virus', None, None, None, None, None, None, None, None, None, None], ['B', None, 'Test Sample 1 (Virus+Serum)', None, None, None, None, None, None, None, None, 'lortnoc\ntupni\nsuriV', 'lortnoc\nlleC'], ['C', None, 'Test Sample 1 replicate (Virus+Serum)', None, None, None, None, None, None, None, None, None, None], ['D', None, 'Test Sample 2 (Virus+Serum)', None, None, None, None, None, None, None, None, None, None], ['E', None, 'Test Sample 2 replicate (Virus+Serum)', None, None, None, None, None, None, None, None, None, None], ['F', None, 'Test Sample 3 (Virus+Serum)', None, None, None, None, None, None, None, None, None, None], ['G', None, 'Test Sample 3 replicate (Virus+Serum)', None, None, None, None, None, None, None, None, None, None], ['H', None, 'Quality Control Sample (Virus+Serum)', None, None, None, None, None, None, None, None, 'Media + Virus', None]], [['', '', '1', '2', None, None, '3', None, None, '4', None, None, '5', None, None, '6', None, None, '7', None, None, '8', None, None, '9', None, None, '10', None, None, '11', None, None, '12', None, None], ['', 'A', '', '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None], ['Sample 1', 'B', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', 'No virus', ''], ['Sample 1', 'C', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', 'No virus', ''], ['Sample 2', 'D', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', 'No virus', ''], ['Sample 2', 'E', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', 'No virus', ''], ['Sample 3', 'F', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', 'No virus', ''], ['Sample 3', 'G', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', '+V', '', '', 'No virus', ''], ['', 'H', '', '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', None, None, '', '', '']], [['Document', 'Title'], ['SHI-SOP-10011', 'NT50 and NT90 calculations for SARS-CoV-2\nNeutralization Assay'], ['SHI-SOP-10012', 'Data transferring between UTMB and Pfizer'], ['SHI-SOP-10006', 'Equipment Management'], ['SHI-TM-10011-FM01', 'Manual 96-well SARS-CoV-2 Neutralization Assay\nWorksheet'], ['SHI-TM-10011-FM02', 'Manual Sample Preparation for the 96-well SARS-\nCoV-2 Neutralization Assay Worksheet']], [['List detailed changes for documents', 'List rationale for each change'], ['N/A', 'N/A']], [['Signed By:', 'Date', 'Signing Capacity'], ['', '', '']], [['Name:', 'Date:', 'Signature:', 'Name andSignature of\nTrainer:'], ['', '', '', ''], ['', '', '', ''], ['', '', '', ''], ['', '', '', ''], ['', '', '', ''], ['', '', '', ''], ['', '', '', ''], ['', '', '', ''], ['', '', '', ''], ['', '', '', ''], ['', '', '', '']]]",16
